PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	PADDOCK, CD; SUCHARD, DP; GRUMBACH, KL; HADLEY, WK; KERSCHMANN, RL; ABBEY, NW; DAWSON, JE; ANDERSON, BE; SIMS, KG; DUMLER, JS; HERNDIER, BG				PADDOCK, CD; SUCHARD, DP; GRUMBACH, KL; HADLEY, WK; KERSCHMANN, RL; ABBEY, NW; DAWSON, JE; ANDERSON, BE; SIMS, KG; DUMLER, JS; HERNDIER, BG			FATAL SERONEGATIVE EHRLICHIOSIS IN A PATIENT WITH HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CHAFFEENSIS; IDENTIFICATION; PANCYTOPENIA; RISTICII; HUMANS; AGENT; CANIS		SAN FRANCISCO GEN HOSP,DEPT PATHOL,BLDG 3,RM 106,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,DEPT LAB MED,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; CTR DIS CONTROL & PREVENT,CTR INFECT DIS,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA; UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201	San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; University System of Maryland; University of Maryland Baltimore			Grumbach, Kevin/L-9222-2016; Anderson, Burt/H-4449-2011					ABBOTT KC, 1991, AM J HEMATOL, V38, P230, DOI 10.1002/ajh.2830380315; ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BROUQUI P, 1992, ANTIMICROB AGENTS CH, V36, P2799, DOI 10.1128/AAC.36.12.2799; DAWSON JE, 1990, J INFECT DIS, V162, P91, DOI 10.1093/infdis/162.1.91; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DORAN TI, 1989, J PEDIATR-US, V114, P809, DOI 10.1016/S0022-3476(89)80143-X; DUMLER JS, 1993, HUM PATHOL, V24, P391; DUMLER JS, 1991, NEW ENGL J MED, V325, P1109, DOI 10.1056/NEJM199110103251517; DUMLER JS, 1991, MODERN PATHOL, V4, pA87; DUNN BE, 1992, J CLIN MICROBIOL, V30, P2207, DOI 10.1128/JCM.30.8.2207-2210.1992; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; FRICKHOFEN N, 1990, ANN INTERN MED, V113, P926, DOI 10.7326/0003-4819-113-12-926; GALGIANI JN, 1990, J INFECT DIS, V162, P1165, DOI 10.1093/infdis/162.5.1165; Harkess J R, 1991, Infect Dis Clin North Am, V5, P37; HILDEBRANDT PK, 1973, AM J VET RES, V34, P1309; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MANDELL W, 1986, AM J MED, V81, P974, DOI 10.1016/0002-9343(86)90390-6; MCDADE JE, 1990, J INFECT DIS, V161, P609, DOI 10.1093/infdis/161.4.609; PARK J, 1991, INFECT IMMUN, V59, P3418, DOI 10.1128/IAI.59.10.3418-3423.1991; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; RIKIHISA Y, 1987, INFECT IMMUN, V55, P2215, DOI 10.1128/IAI.55.9.2215-2222.1987; RIKIHISA Y, 1991, CLIN MICROBIOL REV, V4, P286, DOI 10.1128/CMR.4.3.286-308.1991; WALKER DH, 1988, BIOL RICKETTSIAL DIS, V1, P115	24	76	78	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1164	1167		10.1056/NEJM199310143291605	http://dx.doi.org/10.1056/NEJM199310143291605			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377780	Bronze			2022-12-28	WOS:A1993MA66700005
J	FLETCHER, SW; BURING, JE; GOODMAN, SN; GOODRIDGE, AG; GUTHRIE, HA; HAGAN, DW; KAFKA, B; LEEVY, CM; NUCKOLLS, JG; SCHNEIDER, AB; WAGNER, EH; WEINER, H; WILLIAMS, OD				FLETCHER, SW; BURING, JE; GOODMAN, SN; GOODRIDGE, AG; GUTHRIE, HA; HAGAN, DW; KAFKA, B; LEEVY, CM; NUCKOLLS, JG; SCHNEIDER, AB; WAGNER, EH; WEINER, H; WILLIAMS, OD			METHODS FOR VOLUNTARY WEIGHT-LOSS AND CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article								One quarter to one third of Americans are over-weight; as many as 40% of women and 24% of men are trying to lose weight at any given time; many have tried a variety of methods, such as diets, exercise, behavior modification, and drugs. In controlled settings, participants who remain in weight loss programs usually lose approximately 10% of their weight. However, one third to two thirds of the weight is regained within 1 year, and almost all is regained within 5 years. For many overweight persons, achieving and maintaining a healthy weight is a lifelong challenge. Successful weight loss improves several cardiovascular risk factors and diabetic control; effects on mortality are not clear. Several epidemiologic studies have found that weight loss is associated with increased mortality but the reasons for weight loss were not known. Survey data also confirm that many Americans who are not overweight, particularly young women, are trying to lose weight, which may have adverse physical and psychological consequences. Because of the importance of these issues, research on weight and on weight loss and control should assume a high priority on the nation's health agenda.	HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, BOSTON, MA 02115 USA; JOHNS HOPKINS UNIV, CTR ONCOL, DIV BIOSTAT, BALTIMORE, MD 21218 USA; UNIV IOWA, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; PENN STATE UNIV, COLL HUMAN DEV, UNIV PK, PA 16802 USA; OREGON HLTH SCI UNIV, DIETET INTERNSHIP PROGRAM, PORTLAND, OR 97201 USA; BARBARA KAFKA ASSOCIATES, NEW YORK, NY USA; UNIV HOSP NEWARK, SAMMY DAVIS JR NATL LIVER INST, NEWARK, NJ USA; UNIV MED & DENT NEW JERSEY, NEWARK, NJ 07103 USA; BLUE RIDGE HLTH ASSOCIATES INC, INTERNAL MED, GALAX, VA USA; UNIV ILLINOIS, HUMANA HOSP,COLL MED,MICHAEL REESE ROTHSCHILD CTR, ENDOCRINOL SECT, CHICAGO, IL 60680 USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV ALABAMA, SCH PUBL HLTH, BIRMINGHAM, AL 35294 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Johns Hopkins University; Johns Hopkins Medicine; University of Iowa; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Oregon Health & Science University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Michael Reese Hospital & Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Group Health Cooperative; University of California System; University of California Los Angeles; University of Alabama System; University of Alabama Birmingham	FLETCHER, SW (corresponding author), AMER COLL PHYSICIANS, PHILADELPHIA, PA USA.								0	162	162	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				764	770		10.7326/0003-4819-119-7_Part_2-199310011-00026	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00026			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363212				2022-12-28	WOS:A1993MA33000026
J	SERDULA, MK; COLLINS, ME; WILLIAMSON, DF; ANDA, RF; PAMUK, E; BYERS, TE				SERDULA, MK; COLLINS, ME; WILLIAMSON, DF; ANDA, RF; PAMUK, E; BYERS, TE			WEIGHT CONTROL PRACTICES OF UNITED-STATES ADOLESCENTS AND ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article							PREVALENCE; POPULATION; OVERWEIGHT	Objective: To estimate the prevalence of various weight-loss practices in U.S. adolescents and adults. Design: The Youth Risk Behavior Survey, a self-administered survey of a random sample of high school students in 1990 and the Behavioral Risk Factor Surveillance System, a random-digit dial survey in 1989. Setting: Thirty-eight states and the District of Columbia. Participants: High school students (n = 11 467) and adults 18 years and older (n = 60 861). Results: Among high school students, 44% of female students and 15% of male students reported that they were trying to lose weight. An additional 26% of female students and 15% of male students reported that they were trying to keep from gaining more weight. Students reported that they had used the following weight control methods in the 7 days preceding the survey: exercise (51% of female students and 30% of male students); skipping meals (49% and 18%, respectively); taking diet pills (4% and 2%, respectively); and vomiting (3% and 1%, respectively). Among adults, 38% of women and 24% of men reported that they were trying to lose weight, whereas 28% of each sex reported that they were trying to maintain their weight. Conclusions: Attempts to lose or maintain weight are very prevalent among both adolescents and adults, especially among females.			SERDULA, MK (corresponding author), CTR DIS CONTROL & PREVENT, 4770 BUFORD HIGHWAY NE, MAILSTOP K26, ATLANTA, GA 30341 USA.							DAWSON DA, 1988, AM J PUBLIC HEALTH, V78, P1326, DOI 10.2105/AJPH.78.10.1326; DESMOND SM, 1989, J SCHOOL HEALTH, V59, P353, DOI 10.1111/j.1746-1561.1989.tb04743.x; DREWNOWSKI A, 1988, AM J PUBLIC HEALTH, V78, P1322, DOI 10.2105/AJPH.78.10.1322; HERZOG DB, 1985, NEW ENGL J MED, V313, P295, DOI 10.1056/NEJM198508013130505; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P349, DOI 10.2105/AJPH.74.4.349; KOLBE LJ, 1990, HLTH ED, V21, P44; REMINGTON PL, 1988, PUBLIC HEALTH REP, V103, P366; STEPHENSON MG, 1987, PUBLIC HEALTH REP, V102, P61; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; 1989, NATIONAL ADOLESCENT; [No title captured]; 1991, MMWR, V40, P747	13	212	214	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				667	671		10.7326/0003-4819-119-7_Part_2-199310011-00008	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00008			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363194				2022-12-28	WOS:A1993MA33000008
J	MORELL, V				MORELL, V			JOBS IN SOCIAL-SCIENCE .2. ANTHROPOLOGY - NATURE-CULTURE BATTLEGROUND	SCIENCE			English	Article																		WILSON EO, SOCIOBIOLOGY	1	11	11	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1798	&		10.1126/science.8378782	http://dx.doi.org/10.1126/science.8378782			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LY584	8378782				2022-12-28	WOS:A1993LY58400044
J	OSTEEN, AM				OSTEEN, AM			25 YEARS IN CONTINUING MEDICAL-EDUCATION - THE SILVER ANNIVERSARY OF THE AMA-PRA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											OSTEEN, AM (corresponding author), AMER MED ASSOC,DIV CONTINUING MED EDUC,OFF PHYSICIAN CREDENTIALS & QUALIFICAT,CHICAGO,IL 60610, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1092	1092		10.1001/jama.270.9.1092	http://dx.doi.org/10.1001/jama.270.9.1092			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU512	8350454				2022-12-28	WOS:A1993LU51200012
J	BARBET, NC; CARR, AM				BARBET, NC; CARR, AM			FISSION YEAST WEE1 PROTEIN-KINASE IS NOT REQUIRED FOR DNA DAMAGE-DEPENDENT MITOTIC ARREST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; CELL-CYCLE; M-PHASE; MITOSIS; REPLICATION; DIVISION; MUTANTS	CHECKPOINTS maintain the dependency relationships between discrete events in the cell cycle (for example, ensuring mitosis does not occur before DNA replication is complete)1,2. In Schizosaccharomyces pombe, mitotic checkpoints monitor DNA synthesis3 and the presence of DNA damage4,5. The replication-dependent mitotic checkpoint prevents mitosis by inactivating p34cdc2 kinase3. The mechanism by which the DNA damage checkpoint interacts with the mitotic machinery is distinct from that used by the replication checkpoint4,5. The activity of p34cdc is controlled, in part, by the wee 1 protein kinase6, which inactivates cdc2 through phosphorylation at tyrosine-15 (ref. 7). Here we report normal mitotic arrest after DNA damage in S. pombe cells in which the wee 1 gene is defective or missing. We suggest why these findings contradict a recent report8 which suggested that the wee1 gene product was required for DNA damage-dependent mitotic arrest.	SUSSEX UNIV,MRC,CELL MUTAT UNIT,FALMER,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HAGAN IM, 1988, THESIS U LONDON; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Mitchison J M, 1975, Methods Cell Biol, V11, P201, DOI 10.1016/S0091-679X(08)60324-6; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2	14	89	97	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					824	827		10.1038/364824a0	http://dx.doi.org/10.1038/364824a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355807				2022-12-28	WOS:A1993LU58100062
J	DAY, S; WARD, H; PERROTTA, L				DAY, S; WARD, H; PERROTTA, L			PROSTITUTION AND RISK OF HIV - MALE PARTNERS OF FEMALE PROSTITUTES	BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe risk behaviours for infection with HIV in male sexual partners of female prostitutes. Design-A cross sectional study. Setting-Genitourinary medicine clinic, St Mary's Hospital, London. Subjects-112 self identified male sexual partners of female prostitutes: 101 who reported commerical sexual relationships only, five who reported noncommercial relationships only, and six who reported both commercial and non-commercial relationships. Main outcome measures-Reported risk behaviours for infection with HIV. Results-Of the 40 men who had had previous HIV tests or were tested during the study, two (5%) were infected with HIV. Of the men who would answer the questions, 34/94 reported having sex with other men, 2/105 reported using injected drugs, 8/105 had a history of blood transfusion, 14/108 reported a past history of gonorrhoea, 44/102 reported paying for sex abroad, and 8/92 said that they had also been paid for sex. Of the 55 men who reported paying for vaginal intercourse in the past year, 45 (82%) said that they had always used a condom. In contrast, of the 11 non-paying partners of prostitutes, only two (18%) reported ever using a condom with their partners. Conclusions-Men who have sex with female prostitutes cannot be assumed to be at risk of infection with HIV only by this route: homosexual contact may place them at greater risk. Despite the heterogeneity among male sexual partners of prostitutes, patterns of use of condoms were uniform when they were considered as a reflection of the type of relationship a man had with a female prostitute rather than a consequence of an individual's level of risk.			DAY, S (corresponding author), ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND.		Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036; Day, Sophie/0000-0002-9822-9094				ALEXANDER P, 1990, SEX WORK WRITINGS WO, P15; CHIASSON NA, 1988, 4 P INT C AIDS STOCK, P273; DAY S, 1990, ANTE PUBLIQUE MALADI, P88; KINNELL H, 1989, PROSTITUES THEIR CLI; MCLEOD E, 1982, WOMEN WORKING PROSTI; MELBYE M, 1992, AM J EPIDEMIOL, V135, P593, DOI 10.1093/oxfordjournals.aje.a116338; PLUMMER FA, 1991, AIDS, V5, pS169; WALLACE J, 1988, 4 P INT C AIDS STOCH, P273; WARD H, 1993, BRIT MED J, V307, P356, DOI 10.1136/bmj.307.6900.356; WARD H, 1990, RECENT ADV STD AIDS, V4, P183	10	59	59	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					359	361		10.1136/bmj.307.6900.359	http://dx.doi.org/10.1136/bmj.307.6900.359			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374418	Green Published, Bronze			2022-12-28	WOS:A1993LR76800019
J	VEEKEN, H				VEEKEN, H			HOPE FOR HAITI	BRITISH MEDICAL JOURNAL			English	Article								Haiti, one of the world's five poorest nations, gets international attention because of the number of refugees who leave by boat in search of a better future. The 80 000 inhabitants of Ile de la Gonave are neglected, even in Haiti-there is no government medical post, and facilities in the health posts run by missions are minimal. Typhoid and cholera epidemics threaten the island. Medecins Sans Frontieres plans to send staff and supplies and train local health workers.			VEEKEN, H (corresponding author), MED SANS FRONTIERES,POB 10014,1001 EA AMSTERDAM,NETHERLANDS.								0	4	4	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					312	313		10.1136/bmj.307.6899.312	http://dx.doi.org/10.1136/bmj.307.6899.312			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374383	Bronze, Green Published			2022-12-28	WOS:A1993LQ51600028
J	SHINTON, R; SAGAR, G				SHINTON, R; SAGAR, G			LIFELONG EXERCISE AND STROKE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; MIDDLE-AGED MEN; PHYSICAL-ACTIVITY; RISK-FACTORS; BLOOD-PRESSURE; HEART-DISEASE; DEATH; WOMEN; HYPERTENSION; HEALTH	Objectives-To examine the potential of lifelong patterns of increased physical activity to prevent stroke. Design-Case-control study. Setting-11 general practices in west Birmingham. Subjects-125 men and women who had just had their first stroke and were aged 35-74 and 198 controls frequency matched for age and sex recruited over 24 months during 1988-90. Exclusion criteria were a previous history of stroke, mitral valvular heart disease combined with atrial fibrillation, primary or metastatic cerebral neoplasm, or coagulation disorder or myeloproliferative disease. Main outcome measures-Odds ratios for stroke related to lifetime history of exercise after 15 years of age. Results-A history of vigorous exercise during the ages 15-25 appeared to protect from stroke: odds ratio adjusted for age and sex 0.33 (95% confidence interval 0.2 to 0.6). This effect was independent of other potential risk factors. Increasing years of participation in vigorous exercise between the ages of 15 and 55 produced an increasing protection from stroke (p<0.001). In the 65 cases and 169 controls who were free of cardiac ischaemia, peripheral vascular disease, and poor health recent vigorous exercise and walking were protective against stroke: odds ratios of 0.41 (0.2 to 1.0) for recent vigorous exercise and 0.30 (0.1 to 0.7) for recent walking. Conclusions-Appreciable protection from stroke in later life is conferred by vigorous exercise in early adulthood. This increased level of physical activity should, if possible, be continued lifelong.	UNIV BIRMINGHAM, DUDLEY RD HOSP, DEPT MED, BIRMINGHAM B18 7QH, ENGLAND; DUDLEY RD GEN HOSP, DEPT RADIOL, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND	University of Birmingham					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BLAIR SN, 1991, AM J EPIDEMIOL, V133, P266, DOI 10.1093/oxfordjournals.aje.a115871; Breslow N, 1980, STATISTICAL METHODS, V32; DYKEN ML, 1984, STROKE, V15, P1105; FOLSOM AR, 1990, STROKE, V21, P701, DOI 10.1161/01.STR.21.5.701; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HERMAN B, 1983, AM J EPIDEMIOL, V118, P514, DOI 10.1093/oxfordjournals.aje.a113657; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; NELSON L, 1986, LANCET, V2, P473, DOI 10.1016/S0140-6736(86)90354-5; PAFFENBA.RS, 1967, LANCET, V1, P753, DOI 10.1016/S0140-6736(67)91367-0; PAFFENBARGER RS, 1984, JAMA-J AM MED ASSOC, V252, P491, DOI 10.1001/jama.252.4.491; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P12; PAFFENBARGER RS, 1971, AM J EPIDEMIOL, V94, P524, DOI 10.1093/oxfordjournals.aje.a121351; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHINTON R, 1993, J NEUROL NEUROSUR PS, V56, P458, DOI 10.1136/jnnp.56.5.458; SHINTON RA, 1992, LIFESTYLE RISK STROK; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; Weiner J. S., 1969, IBP HDB, V9; 1989, STROKE BETTER MANAGE; 1990, REFERENCE MANUAL; 1971, WHO TECHNICAL REPORT, V469; 1992, LANCET, V340, P19; 1991, MED ASPECTS EXERCISE	27	84	85	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					231	234		10.1136/bmj.307.6898.231	http://dx.doi.org/10.1136/bmj.307.6898.231			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369683	Bronze, Green Published			2022-12-28	WOS:A1993LP31400021
J	BIESECKER, BB; BOEHNKE, M; CALZONE, K; MARKEL, DS; GARBER, JE; COLLINS, FS; WEBER, BL				BIESECKER, BB; BOEHNKE, M; CALZONE, K; MARKEL, DS; GARBER, JE; COLLINS, FS; WEBER, BL			GENETIC-COUNSELING FOR FAMILIES WITH INHERITED SUSCEPTIBILITY TO BREAST AND OVARIAN-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUNTINGTON DISEASE; LINKAGE	Efforts are under way to isolate a gene (BRCA1) on chromosome 17q12-21. Mutations in this gene predispose women to breast and ovarian cancer. Women with germline mutations in BRCA1 are estimated to have an 85% lifetime risk of developing breast cancer and an increased but as yet undetermined risk of ovarian cancer. It is estimated that one in 200 to 400 American women may be carriers of BRCA1 mutations. We have identified several families that show linkage between breast and/or ovarian cancer and genetic markers that flank BRCA1. It is now possible, within these linked families, to prospectively identify family members likely to be carrying BRCA1 mutations. Because of profound and immediate clinical ramifications, we offered to provide this information to one such extended family. To provide information to this family, we developed a protocol to address the many issues that arise in the delivery of these services. Although testing for BRCA1 mutation carriers is currently limited to very rare families being analyzed for research purposes, this experience presages the complexities of the much larger scale availability of population screening for BRCA1 mutations, which is likely to become a reality in the next few years.	UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV HEMATOL ONCOL,ROOM 5510,MSRB 1,1150 W MED CTR DR,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,CTR HUMAN GENOME,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH PUBL HLTH,DEPT BIOSTAT,ANN ARBOR,MI 48109; HOWARD HUGHES MED INST,ANN ARBOR,MI; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School				Biesecker, Barbara/0000-0001-9665-8963; Markel, Dorene/0000-0002-3382-6779; Calzone, Kathleen/0000-0002-2354-6810	NATIONAL CANCER INSTITUTE [R01CA057601] Funding Source: NIH RePORTER; NCI NIH HHS [CA57601] Funding Source: Medline; NHGRI NIH HHS [HG00209] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ARASON A, IN PRESS AM J HUM GE; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BLOCH M, 1990, AM J HUM GENET, V46, P1; CHAMBERLAIN JS, IN PRESS AM J HUM GE; CHAPMAN MA, 1990, AM J HUM GENET, V47, P1; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Collins F S, 1991, J Clin Ethics, V2, P260; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CROPP CS, 1990, P NATL ACAD SCI USA, V87, P7737, DOI 10.1073/pnas.87.19.7737; EASTON DF, IN PRESS AM J HUM GE; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HANNIG VL, 1991, AM J MED GENET, V40, P425, DOI 10.1002/ajmg.1320400409; HUGGINS M, 1990, AM J HUM GENET, V47, P4; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; LEONE A, 1991, CANCER RES, V51, P2490; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; LI FP, 1992, J CLIN ONCOL, V10, P1203, DOI 10.1200/JCO.1992.10.8.1203; LYNCH HT, 1992, LANCET, V339, P1181, DOI 10.1016/0140-6736(92)90787-4; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; MORTON NE, 1955, AM J HUM GENET, V7, P277; NAROD SA, 1991, LANCET, V338, P82; Quaid K A, 1992, J Genet Couns, V1, P277, DOI 10.1007/BF00962825; ROSEN P, 1992, FEB INT C RISK AD AD; SATO T, 1991, CANCER RES, V51, P5794; WHITE R, 1992, 17 CHROM WORKSH PARK; WIGGINS S, 1992, NEW ENGL J MED, V327, P1401, DOI 10.1056/NEJM199211123272001; 1989, AM J KIDNEY DIS, V13, P85; 1989, GUIDELINES PREDICTIV	28	256	258	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1970	1974		10.1001/jama.269.15.1970	http://dx.doi.org/10.1001/jama.269.15.1970			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX215	8352830				2022-12-28	WOS:A1993KX21500028
J	EDDY, DM				EDDY, DM			BROADENING THE RESPONSIBILITIES OF PRACTITIONERS - THE TEAM-APPROACH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									DUKE UNIV,DURHAM,NC 27706	Duke University								Eddy D, 1990, JAMA-J AM MED ASSOC, V263, P389; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P2575, DOI 10.1001/jama.268.18.2575; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P132, DOI 10.1001/jama.268.1.132	3	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1849	1855		10.1001/jama.269.14.1849	http://dx.doi.org/10.1001/jama.269.14.1849			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8379979				2022-12-28	WOS:A1993KW25000045
J	KAPIKIAN, AZ				KAPIKIAN, AZ			VIRAL GASTROENTERITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTIOUS NONBACTERIAL GASTROENTERITIS; NON-BACTERIAL GASTROENTERITIS; NORWALK VIRUS; ACUTE DIARRHEA; UNITED-STATES; OUTBREAKS; ROTAVIRUS; CHILDREN; THERAPY; AGENT				KAPIKIAN, AZ (corresponding author), NIAID,EPIDEMIOL SECT,INFECT DIS LAB,BLDG 7,ROOM 103,BETHESDA,MD 20892, USA.							AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; BISHOP RF, 1973, LANCET, V2, P1281, DOI 10.1016/s0140-6736(73)92867-5; BLACKLOW NR, 1991, NEW ENGL J MED, V325, P252, DOI 10.1056/NEJM199107253250406; BLACKLOW NR, 1972, ANN INTERN MED, V76, P993, DOI 10.7326/0003-4819-76-6-993; Daum R S, 1991, Adv Pediatr Infect Dis, V6, P1; DOLIN R, 1971, J INFECT DIS, V123, P307, DOI 10.1093/infdis/123.3.307; GREENBERG HB, 1979, J INFECT DIS, V139, P564, DOI 10.1093/infdis/139.5.564; HO MS, 1988, J INFECT DIS, V158, P1112, DOI 10.1093/infdis/158.5.1112; JIANG X, 1990, Science (Washington D C), V250, P1580; Kapikian A Z, 1991, Adv Exp Med Biol, V310, P255; KAPIKIAN AZ, 1986, J INFECT DIS, V153, P815, DOI 10.1093/infdis/153.5.815; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; KAPIKIAN AZ, 1974, SCIENCE, V185, P1049, DOI 10.1126/science.185.4156.1049; KAPIKIAN AZ, 1988, MODERN APPROACHES NE, P151; KAPIKIAN AZ, 1990, VIROLOGY, P1353; Kapikian AZ, 1990, VIROLOGY, P671; KAPIKIAN AZ, IN PRESS ADV EXP MED; KAPLAN JE, 1982, AM J PUBLIC HEALTH, V72, P1329, DOI 10.2105/AJPH.72.12.1329; KAPLAN JE, 1982, ANN INTERN MED, V96, P756, DOI 10.7326/0003-4819-96-6-756; KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519; LANATA CF, 1992, VACCINE, V10, P273; LANATA CF, 1992, VACCINE, V10, P272; MADORE HP, 1992, J INFECT DIS, V166, P235, DOI 10.1093/infdis/166.2.235; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; MIDTHUN K, 1986, J CLIN MICROBIOL, V24, P822, DOI 10.1128/JCM.24.5.822-826.1986; MIDTHUN K, 1985, J VIROL, V53, P99; RODRIGUEZ WJ, 1977, J PEDIATR-US, V91, P188, DOI 10.1016/S0022-3476(77)80810-X; SACK DA, 1992, 32ND ANN M INT C ANT; SACK RB, 1982, VIRUS INFECTIONS GAS, P239; SANTOSHAM M, 1985, PEDIATRICS, V76, P159; STEINHOFF MC, 1980, GASTROENTEROLOGY, V78, P1495; VESIKARI T, 1988, Southeast Asian Journal of Tropical Medicine and Public Health, V19, P437; VESIKARI T, 1992, PEDIATR INFECT DIS J, V11, P535, DOI 10.1097/00006454-199207000-00006; 1986, NEW VACCINE DEV ESTA, V2, P308; 1985, NEW VACCINE DEV ESTA, V1, P410	35	58	63	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 3	1993	269	5					627	630		10.1001/jama.269.5.627	http://dx.doi.org/10.1001/jama.269.5.627			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ444	8380619				2022-12-28	WOS:A1993KJ44400031
J	KLAUSNER, RD; ROUAULT, TA; HARFORD, JB				KLAUSNER, RD; ROUAULT, TA; HARFORD, JB			REGULATING THE FATE OF MESSENGER-RNA - THE CONTROL OF CELLULAR IRON-METABOLISM	CELL			English	Review							PAIRED FLANKING REGIONS; ELEMENT-BINDING-PROTEIN; RESPONSIVE ELEMENT; TRANSFERRIN RECEPTOR; UNTRANSLATED REGION; 5-AMINOLEVULINATE SYNTHASE; TRANSLATIONAL REGULATION; SECONDARY STRUCTURE; CHELATABLE IRON; HEAVY-SUBUNIT				KLAUSNER, RD (corresponding author), NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA.							AISEN P, 1980, ANNU REV BIOCHEM, V49, P357, DOI 10.1146/annurev.bi.49.070180.002041; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; BETTANY AJE, 1992, J BIOL CHEM, V267, P16531; BOMFORD AB, 1992, PATHOBIOLOGY, V60, P10, DOI 10.1159/000163691; BOTTOMLEY SS, 1988, SEMIN HEMATOL, V25, P282; BRAUN V, 1991, BIOL MET, V4, P14, DOI 10.1007/BF01135552; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CASEY JL, 1988, P NATL ACAD SCI USA, V85, P1787, DOI 10.1073/pnas.85.6.1787; CAUGHMAN SW, 1988, J BIOL CHEM, V263, P19048; CHEN R, 1988, EUR J BIOCHEM, V175, P565, DOI 10.1111/j.1432-1033.1988.tb14229.x; CONSTABLE A, 1992, P NATL ACAD SCI USA, V89, P4554, DOI 10.1073/pnas.89.10.4554; COX TC, 1991, EMBO J, V10, P1891, DOI 10.1002/j.1460-2075.1991.tb07715.x; Crichton R. R., 1991, INORGANIC BIOCH IRON; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANDEKAR T, 1991, EMBO J, V10, P1903, DOI 10.1002/j.1460-2075.1991.tb07716.x; Dierks P, 1990, BIOSYNTHESIS HEME CH, P201; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; DIX DJ, 1992, BIOCHEMISTRY-US, V31, P2818, DOI 10.1021/bi00125a024; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; ELFERINK CJ, 1988, J BIOL CHEM, V263, P13012; GARDNER LC, 1988, J BIOL CHEM, V263, P6676; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; GOESSLING LS, 1992, SCIENCE, V256, P670, DOI 10.1126/science.1316633; GOOSSEN B, 1992, MOL CELL BIOL, V12, P1959, DOI 10.1128/MCB.12.5.1959; GUTTERIDGE JMC, 1989, ACTA PAEDIATR SCAND, P78; HAILE DJ, 1990, J BIOL CHEM, V265, P12786; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; HAILE DJ, 1992, IN PRESS P NATL ACAD; HARFORD JB, 1990, ENZYME, V44, P28, DOI 10.1159/000468745; HARFORD JB, 1990, INTRACELLULAR TRAFFI, P302; HARRELL CM, 1991, P NATL ACAD SCI USA, V88, P4166, DOI 10.1073/pnas.88.10.4166; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HENTZE MW, 1987, SCIENCE, V238, P1570, DOI 10.1126/science.3685996; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIRLING H, 1992, NUCLEIC ACIDS RES, V20, P33, DOI 10.1093/nar/20.1.33; HOROWITZ JA, 1992, NEW BIOL, V4, P330; KAPTAIN S, 1991, P NATL ACAD SCI USA, V88, P10109, DOI 10.1073/pnas.88.22.10109; KENNEDY MC, 1992, IN PRESS P NATL ACAD; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LAUBLE H, 1992, BIOCHEMISTRY-US, V31, P2735, DOI 10.1021/bi00125a014; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; LIN JJ, 1991, P NATL ACAD SCI USA, V88, P6068, DOI 10.1073/pnas.88.14.6068; LIN JJ, 1990, SCIENCE, V247, P74, DOI 10.1126/science.2294594; LIN JJ, 1990, BIOCHIM BIOPHYS ACTA, V1050, P146, DOI 10.1016/0167-4781(90)90156-V; MARTIN JH, 1990, NATURE, V345, P156, DOI 10.1038/345156a0; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; MULLNER EW, 1992, EUR J BIOCHEM, V208, P597, DOI 10.1111/j.1432-1033.1992.tb17224.x; MUNRO HN, 1990, J CELL BIOCHEM, V44, P107, DOI 10.1002/jcb.240440205; Neilands J.B., 1974, MICROBIAL IRON METAB, P3; NEILANDS JB, 1985, NUTR REV, V43, P193, DOI 10.1111/j.1753-4887.1985.tb02419.x; NUNEZ MT, 1990, J BIOL CHEM, V265, P6688; OWEN D, 1987, EMBO J, V6, P1287, DOI 10.1002/j.1460-2075.1987.tb02366.x; PATINO MM, 1992, J BIOL CHEM, V267, P19011; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PHILPOTT CC, 1991, NUCLEIC ACIDS RES, V19, P6333, DOI 10.1093/nar/19.22.6333; PONKA P, 1988, BIOCHEM J, V251, P105, DOI 10.1042/bj2510105; Ponka P, 1990, BIOSYNTHESIS HEME CH, P393; PRODROMOU C, 1992, EUR J BIOCHEM, V204, P599, DOI 10.1111/j.1432-1033.1992.tb16673.x; ROGERS J, 1987, P NATL ACAD SCI USA, V84, P2277, DOI 10.1073/pnas.84.8.2277; ROUAULT T, 1985, J BIOL CHEM, V260, P4862; ROUAULT TA, 1988, SCIENCE, V241, P1207, DOI 10.1126/science.3413484; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SCRIMSHAW NS, 1991, SCI AM, V265, P46, DOI 10.1038/scientificamerican1091-46; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SETOYAMA C, 1990, J BIOL CHEM, V265, P1293; STUBBE J, 1990, ADV ENZYMOL RAMB, V63, P349; SUZUKI T, 1989, J BIOL CHEM, V264, P2581; TANG CK, 1992, INP RESS J BIOL CHEM; WALDEN WE, 1988, P NATL ACAD SCI USA, V85, P9503, DOI 10.1073/pnas.85.24.9503; WANG YH, 1991, BIOL MET, V4, P56, DOI 10.1007/BF01135558; WARD JH, 1984, J BIOL CHEM, V259, P3235; YU Y, 1992, J BIOL CHEM, V267, P19005; ZHENG L, 1992, J BIOL CHEM, V267, P7895	74	1145	1172	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 15	1993	72	1					19	28		10.1016/0092-8674(93)90046-S	http://dx.doi.org/10.1016/0092-8674(93)90046-S			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8380757				2022-12-28	WOS:A1993KG95500006
J	LARSSON, LG; BAUM, J; MUDHOLKAR, GS; KOLLIA, GD				LARSSON, LG; BAUM, J; MUDHOLKAR, GS; KOLLIA, GD			BENEFITS AND DISADVANTAGES OF JOINT HYPERMOBILITY AMONG MUSICIANS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOBILITY; STUDENTS; PAIN	Background. Joint hypermobility is considered to be both an advantage and a disadvantage. However, the degree of hypermobility in members of particular occupations requiring intense physical activity and the nature of the association between symptoms referable to specific joints and their hypermobility are unknown. Methods. We interviewed 660 musicians (300 women and 360 men) about work-related symptoms such as joint pain and swelling and examined them for joint hypermobility according to a standard protocol. We then determined the relation between the mobility of their fingers, thumbs, elbows, knees, and spine and any symptoms referable to these regions. Results. Five of the 96 musicians (5 percent) with hypermobility of the wrists, mostly instrumentalists who played the flute, violin, or piano, had pain and stiffness in this region, whereas 100 of the 564 musicians (18 percent) Hypermobility of the elbow was associated with symptoms in only 1 of 208 musicians (<1 percent), whereas 7 of 452 (2 percent) without this hypermobility had symptoms (P = 0.45). Among the 132 musicians who had hypermobile knees, 6 (5 percent) had symptoms, whereas only 1 of 528 (<1 percent) with normal knees had symptoms (P<0.001). Of the 462 musicians who had normal mobility of the spine, 50 (11 percent) had symptoms involving the back, as compared with 46 of the 198 musicians (23 percent) who had hypermobility of the spine (P<0.001). Conclusions. Among musicians who play instruments requiring repetitive motion, hypermobility of joints such as the wrists and elbows may be an asset, whereas hypermobility of less frequently moved joints such as the knees and spine may be a liability.	UNIV ROCHESTER, MONROE COMMUNITY HOSP, SCH MED & DENT, ARTHRIT & CLIN IMMUNOL UNIT, ROCHESTER, NY 14620 USA; HOSP RHEUMAT DIS, OSTERSUND, SWEDEN; UNIV ROCHESTER, DEPT STAT, DIV BIOSTAT, ROCHESTER, NY 14627 USA	University of Rochester; University of Rochester								Adams F, 1849, HIPPOCRATES GENUINE; ALRAWI ZS, 1985, BRIT J RHEUMATOL, V24, P326; BEIGHTON P, 1973, ANN RHEUM DIS, V32, P413, DOI 10.1136/ard.32.5.413; BENNATI F, 1831, REV PARIS, V11, P52; BIRO F, 1983, PEDIATRICS, V72, P701; BROOKS P, 1989, BRIT J RHEUMATOL, V28, P180; CARTER C, 1964, J BONE JOINT SURG BR, V46, P40, DOI 10.1302/0301-620X.46B1.40; DAWSON WJ, 1988, MED PROBL PERFORM AR, V3, P19; FRY HJH, 1986, MED J AUSTRALIA, V145, P620, DOI 10.5694/j.1326-5377.1986.tb139514.x; FRY HJH, 1989, ANN RHEUM DIS, V48, P998, DOI 10.1136/ard.48.12.998; GEDALIA A, 1985, J PEDIATR-US, V107, P873, DOI 10.1016/S0022-3476(85)80178-5; GRAHAME R, 1972, ANN RHEUM DIS, V31, P109, DOI 10.1136/ard.31.2.109; HOCHBERG F H, 1983, Journal of the American Medical Association, V249, P1869, DOI 10.1001/jama.249.14.1869; HORAN F T, 1973, Rheumatology and Rehabilitation, V12, P47, DOI 10.1093/rheumatology/12.1.47; LARSSON LG, 1993, BRIT J RHEUMATOL, V32, P116; LARSSON LG, 1987, ARTHRITIS RHEUM, V30, P1426, DOI 10.1002/art.1780301216; Lichtor J, 1972, J Sports Med, V1, P22; MANCHESTER RA, 1988, MED PROBL PERFORM AR, V3, P15; RISHER RA, 1934, STATISTICAL METHODS; SMITH RD, 1967, J AMER MED ASSOC, V199, P820, DOI 10.1001/jama.199.11.820; SUTRO CJ, 1947, SURGERY, V21, P67; WYNNEDAVIES R, 1971, P ROY SOC MED, V64, P689, DOI 10.1177/003591577106400649; Zelen M, 1972, 6 BERK S MATH STAT P, P737	23	98	101	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1079	1082		10.1056/NEJM199310073291504	http://dx.doi.org/10.1056/NEJM199310073291504			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371729				2022-12-28	WOS:A1993LZ64000004
J	KUMANYIKA, SK				KUMANYIKA, SK			SPECIAL ISSUES REGARDING OBESITY IN MINORITY POPULATIONS	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; BODY-FAT DISTRIBUTION; MEXICAN-AMERICANS; ETHNIC-DIFFERENCES; NAVAJO COMMUNITY; BLACK-WOMEN; MASS INDEX; WEIGHT; RISK	Special attention must be given to obesity as it occurs in and affects ethnic minorities (that is, black Americans, Hispanic Americans, Asian and Pacific Islander Americans, American Indians and Alaska Natives, and Native Hawaiians) in the United States. In most of these groups, the prevalence of obesity is substantially higher than in whites, especially among women. Poverty and lower educational attainment, which are associated with higher than average rates of female obesity (independent of ethnicity), affect proportionately more persons in these minority populations than in white populations. Diabetes mellitus and certain other obesity-related conditions occur to a markedly greater than average extent in many minority populations. A high-risk body fat distribution (upper body or central obesity) occurs to a greater extent in some minority populations than in whites. Because of situational and cultural factors, effective obesity prevention and treatment approaches may need to be defined on an ethnicity-specific basis. Increased attention to obesity as it occurs in and affects diverse ethnic groups can help to address critical minority health issues. Such efforts can also broaden and enrich aspects of obesity research for which models based on white populations are inappropriate or limited.			KUMANYIKA, SK (corresponding author), PENN STATE UNIV, MILTON S HERSHEY MED CTR, COLL MED, DEPT BIOSTAT & EPIDEMIOL, HERSHEY, PA 17033 USA.							ALULI NE, 1991, AM J CLIN NUTR, V53, pS1556, DOI 10.1093/ajcn/53.6.1556S; [Anonymous], 1991, CARDIOVASCULAR DIS B; BROUSSARD BA, 1991, AM J CLIN NUTR, V53, pS1535, DOI 10.1093/ajcn/53.6.1535S; BROWN PJ, 1987, ANN NY ACAD SCI, V499, P29, DOI 10.1111/j.1749-6632.1987.tb36195.x; BURKE GL, 1990, PREV MED, V19, P476, DOI 10.1016/0091-7435(90)90045-L; BURKITT DP, 1981, W DISEASES THEIR EME; CURB JD, 1991, AM J CLIN NUTR, V53, pS1612, DOI 10.1093/ajcn/53.6.1612S; DAWSON DA, 1988, AM J PUBLIC HEALTH, V78, P1326, DOI 10.2105/AJPH.78.10.1326; DESMOND SM, 1989, J SCHOOL HEALTH, V59, P353, DOI 10.1111/j.1746-1561.1989.tb04743.x; FARRELL SW, 1987, HUM BIOL, V59, P657; FOREYT JP, 1991, AM J CLIN NUTR, V53, pS1639, DOI 10.1093/ajcn/53.6.1639S; FUJIMOTO WY, 1991, INT J OBESITY, V15, P41; GOLDBLATT PB, 1965, J AMER MED ASSOC, V192, P1039, DOI 10.1001/jama.1965.03080250017004; GRAY JJ, 1987, INT J EAT DISORDER, V6, P733, DOI 10.1002/1098-108X(198711)6:6<733::AID-EAT2260060606>3.0.CO;2-U; HAFFNER SM, 1990, DIABETES, V39, P283, DOI 10.2337/diabetes.39.3.283; HAFFNER SM, 1986, INT J OBESITY, V10, P493; HALL TR, 1991, AM J HUM BIOL, V3, P119, DOI 10.1002/ajhb.1310030207; HALL TR, 1992, AM J HUM BIOL, V4, P547, DOI 10.1002/ajhb.1310040414; HAZUDA HP, 1983, AM J EPIDEMIOL, V117, P717, DOI 10.1093/aje/117.6.717; JONES DJ, 1980, PSYCHOSOM MED, V42, P551, DOI 10.1097/00006842-198011000-00003; KAHN HS, 1991, AM J PUBLIC HEALTH, V81, P319, DOI 10.2105/AJPH.81.3.319; KNOWLER WC, 1991, AM J CLIN NUTR, V53, pS1543, DOI 10.1093/ajcn/53.6.1543S; KUMANYAKA SK, 1991, AM J CLIN NUTR, V53, pS1631, DOI 10.1093/ajcn/53.6.1631S; KUMANYIKA S, 1993, J AM DIET ASSOC, V93, P416, DOI 10.1016/0002-8223(93)92287-8; KUMANYIKA S, 1987, EPIDEMIOL REV, V9, P31, DOI 10.1093/oxfordjournals.epirev.a036307; KUMANYIKA S, 1990, J NUTR EDUC, V22, P89; KUMANYIKA S K, 1992, Ethnicity and Disease, V2, P166; KUMANYIKA S K, 1991, Ethnicity and Disease, V1, P50; KUMANYIKA SK, 1992, PATIENT EDUC COUNS, V19, P19, DOI 10.1016/0738-3991(92)90099-5; Leininger M M, 1991, NLN Publ, P345; MCGARVEY ST, 1991, AM J CLIN NUTR, V53, pS1586, DOI 10.1093/ajcn/53.6.1586S; MITHUN JS, 1983, CULTURE ETHNICITY ID, P209; OBRIEN TR, 1989, JAMA-J AM MED ASSOC, V262, P1485, DOI 10.1001/jama.262.11.1485; RAND CSW, 1990, INT J EAT DISORDER, V9, P329, DOI 10.1002/1098-108X(199005)9:3&lt;329::AID-EAT2260090311&gt;3.0.CO;2-B; REICHLEY KB, 1987, AM J EPIDEMIOL, V125, P373, DOI 10.1093/oxfordjournals.aje.a114544; RIMM AA, 1988, J CLIN EPIDEMIOL, V41, P459, DOI 10.1016/0895-4356(88)90047-9; RITENBAUGH C, 1982, CULT MED PSYCHIAT, V6, P347, DOI 10.1007/BF00118882; SCHOENBORN CA, 1985, VITAL HLTH STATIS 10, V163; Seidell J C, 1987, World Rev Nutr Diet, V50, P57; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; STERN MP, 1990, INT J OBESITY, V14, P623; TERRY RD, 1984, ECOL FOOD NUTR, V14, P117, DOI 10.1080/03670244.1984.9990779; WIENPAHL J, 1990, J CLIN EPIDEMIOL, V43, P949, DOI 10.1016/0895-4356(90)90078-4; WING RR, 1989, INT J OBESITY, V13, P511; 1991, AM J CLIN NUTR S, V53, pS1507; [No title captured]; 1985, REPORT SECRETARYS TA, V1; 1991, DHHS PHS911232 US DE; 1989, DHHS PHS891255 US DE	49	169	170	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				650	654		10.7326/0003-4819-119-7_Part_2-199310011-00005	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363191				2022-12-28	WOS:A1993MA33000005
J	KUMPF, RA; DOUGHERTY, DA				KUMPF, RA; DOUGHERTY, DA			A MECHANISM FOR ION SELECTIVITY IN POTASSIUM CHANNELS - COMPUTATIONAL STUDIES OF CATION-PI INTERACTIONS	SCIENCE			English	Article							ENERGY PERTURBATION SIMULATIONS; ACETYLCHOLINE-RECEPTOR; AROMATIC INTERACTIONS; TEA BLOCKADE; K+ CHANNEL; BINDING; WATER; PERMEATION; RESIDUES; PROTEINS	A combination of computational methods has been used to evaluate the interaction between the pi face of a benzene molecule and the monovalent cations of lithium, sodium, potassium, and rubidium. In the gas phase, the ions are strongly bound, and the affinity for benzene follows the expected electrostatic trend (lithium, largest; rubidium, smallest). However, in an aqueous environment, a reordering occurs such that the potassium ion is preferred over all the other ions for 2:1 benzene:ion complexes. The selectivity sequence parallels that seen in voltage-gated potassium channels. Given that several conserved aromatic residues are present in the pore region of such channels, these results suggest that the cation-pi interaction may be responsible for the ion selectivity in potassium channels.	CALTECH,DIV CHEM & CHEM ENGN,ARNOLD & MABEL BECKMAN LABS CHEM SYNTH,PASADENA,CA 91125	California Institute of Technology								AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; BEVERIDGE DL, 1989, ANNU REV BIOPHYS BIO, V18, P431, DOI 10.1146/annurev.bb.18.060189.002243; BOGUSZ S, 1992, PROTEIN ENG, V5, P285, DOI 10.1093/protein/5.4.285; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; BUTLER A, 1993, SCIENCE, V261, P221, DOI 10.1126/science.7687074; CHANGEUX JP, 1992, TRENDS PHARMACOL SCI, V13, P299, DOI 10.1016/0165-6147(92)90094-M; CHATURVEDI V, 1992, BIOCHEMISTRY-US, V31, P1370, DOI 10.1021/bi00120a012; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; EISENMAN G, 1990, PROG CELL R, V1, P195; EISENMAN G, 1983, J MEMBRANE BIOL, V76, P197, DOI 10.1007/BF01870364; EISENMAN G, 1992, J INCLUS PHENOM MOL, V12, P23, DOI 10.1007/BF01053854; EISENMAN G, 1975, BIOCH SERIES, V2, P27; Eisenman G., 1961, S MEMBRANE TRANSPORT, P163; Frisch M. J, 1992, GAUSSIAN 92; FRISCH MJ, 1990, GAUSSIAN 90; Hehre W. J., 1986, AB INITIO MOL ORBITA; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; JORGENSEN WL, 1989, J AM CHEM SOC, V111, P3770, DOI 10.1021/ja00192a057; JORGENSEN WL, 1989, ACCOUNTS CHEM RES, V22, P184, DOI 10.1021/ar00161a004; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; JORGENSEN WL, 1990, J AM CHEM SOC, V112, P4768, DOI 10.1021/ja00168a022; JORGENSEN WL, 1989, BOSS VERSION 27; KAVANAUGH MP, 1991, J BIOL CHEM, V266, P7583; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LEDU MH, 1992, J BIOL CHEM, V267, P22122; LENTZ TL, 1991, BIOCHEMISTRY-US, V30, P10949, DOI 10.1021/bi00109a020; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1982, BIOPHYS J, V38, P227, DOI 10.1016/S0006-3495(82)84552-9; MILLER C, 1991, SCIENCE, V252, P1092, DOI 10.1126/science.252.5009.1092; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PETTI MA, 1988, J AM CHEM SOC, V110, P682; SUNNER J, 1981, J PHYS CHEM-US, V85, P1814, DOI 10.1021/j150613a011; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAFT RW, 1990, PURE APPL CHEM, V62, P17, DOI 10.1351/pac199062010017; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; WU J, 1991, BIOPHYS J, V60, P238, DOI 10.1016/S0006-3495(91)82046-X; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YOOL AJ, 1991, NATURE, V349, P700, DOI 10.1038/349700a0; ZWANZIG RW, 1954, J CHEM PHYS, V22, P1420, DOI 10.1063/1.1740409	43	597	602	3	104	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1708	1710		10.1126/science.8378771	http://dx.doi.org/10.1126/science.8378771			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378771				2022-12-28	WOS:A1993LY58400018
J	MOFFAT, AS				MOFFAT, AS			MOLECULAR MEDICINE - A CALLING FOR THE DUAL-DEGREED	SCIENCE			English	Editorial Material																		WEICHSELBAUM, 1989, P NATIONAL ACADEMY S	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1786	1786		10.1126/science.8378778	http://dx.doi.org/10.1126/science.8378778			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378778				2022-12-28	WOS:A1993LY58400040
J	STONE, R				STONE, R			JOBS IN BIO-MED .2. PHARMACEUTICALS - GOOD OPPORTUNITIES IN SMALL PACKAGES	SCIENCE			English	Article																		1993, SCIENCE, V260, P908	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1788	&		10.1126/science.8378779	http://dx.doi.org/10.1126/science.8378779			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378779				2022-12-28	WOS:A1993LY58400041
J	SPACH, DH; LILES, WC; CAMPBELL, GL; QUICK, RE; ANDERSON, DE; FRITSCHE, TR				SPACH, DH; LILES, WC; CAMPBELL, GL; QUICK, RE; ANDERSON, DE; FRITSCHE, TR			TICK-BORNE DISEASES IN THE UNITED-STATES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							MOUNTAIN-SPOTTED-FEVER; JARISCH-HERXHEIMER REACTION; POLYMERASE CHAIN-REACTION; EARLY LYME-DISEASE; HUMAN EHRLICHIOSIS; HUMAN BABESIOSIS; RELAPSING FEVER; NANTUCKET-ISLAND; RICKETTSIA-RICKETTSII; FRANCISELLA-TULARENSIS		CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VECTOR BORNE INFECT, FT COLLINS, CO USA; CTR DIS CONTROL & PREVENT, DIV FIELD EPIDEMIOL, EPIDEMIOL PROGRAM OFF, ATLANTA, GA USA; UNIV WASHINGTON, DEPT MED, DIV INFECT DIS, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DIV CLIN MICROBIOL, SEATTLE, WA 98195 USA; SACRED HEART MED CTR, DIV LAB MED, SPOKANE, WA 99204 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								ANDERSEN RD, 1985, J INFECT DIS, V151, P449, DOI 10.1093/infdis/151.3.449; ANDERSON BE, 1992, J CLIN MICROBIOL, V30, P775, DOI 10.1128/JCM.30.4.775-780.1992; ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BARBOUR AG, 1990, ANNU REV MICROBIOL, V44, P155, DOI 10.1146/annurev.mi.44.100190.001103; BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BARTON LL, 1992, J PEDIATR-US, V120, P998, DOI 10.1016/S0022-3476(05)81978-X; BENACH JL, 1981, J INFECT DIS, V144, P481, DOI 10.1093/infdis/144.5.481; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; Bowersock G. W., 1989, ARBOVIRUSES EPIDEMIO, P159; Boyce J. M., 1990, Principles and practice of infectious diseases., P1742; BOYCE JM, 1975, J INFECT DIS, V131, P197, DOI 10.1093/infdis/131.2.197; BOYER KM, 1977, AM J EPIDEMIOL, V105, P469, DOI 10.1093/oxfordjournals.aje.a112406; BRADFORD WD, 1977, AM J DIS CHILD, V131, P1228, DOI 10.1001/archpedi.1977.02120240046010; BREDT AB, 1981, JAMA-J AM MED ASSOC, V245, P1938, DOI 10.1001/jama.245.19.1938; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Burgdorfer W., 1991, MANUAL CLIN MICROBIO, P560; BURKE DS, 1977, J INFECT DIS, V135, P55, DOI 10.1093/infdis/135.1.55; BUTLER T, 1985, ANN INTERN MED, V102, P397, DOI 10.7326/0003-4819-102-3-397; BUTLER TC, 1992, INFECT DIS, P1302; Centers for Disease Control (CDC), 1983, MMWR Morb Mortal Wkly Rep, V32, P65; CHERINGTON M, 1968, NEW ENGL J MED, V278, P95, DOI 10.1056/NEJM196801112780207; CHISHOLM ES, 1986, AM J TROP MED HYG, V35, P921, DOI 10.4269/ajtmh.1986.35.921; CUPP EW, 1991, VET CLIN N AM-SMALL, V21, P1, DOI 10.1016/S0195-5616(91)50001-2; DAMMIN GJ, 1981, HUM PATHOL, V12, P398, DOI 10.1016/S0046-8177(81)80020-2; DAVIS AE, 1982, JAMA-J AM MED ASSOC, V247, P2811, DOI 10.1001/jama.247.20.2811; DAWSON JE, 1990, J INFECT DIS, V162, P91, DOI 10.1093/infdis/162.1.91; DAWSON JE, 1991, J INFECT DIS, V163, P564, DOI 10.1093/infdis/163.3.564; DAWSON JE, 1991, J CLIN MICROBIOL, V29, P2741, DOI 10.1128/JCM.29.12.2741-2745.1991; DIMMITT DC, 1989, AM J MED, V87, P677, DOI 10.1016/S0002-9343(89)80404-8; DONAT JR, 1981, ARCH NEUROL-CHICAGO, V38, P59, DOI 10.1001/archneur.1981.00510010085020; DONOHUE JF, 1980, ARCH INTERN MED, V140, P223, DOI 10.1001/archinte.140.2.223; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; DUNN BE, 1992, J CLIN MICROBIOL, V30, P2207, DOI 10.1128/JCM.30.8.2207-2210.1992; EARNEST M P, 1971, Rocky Mountain Medical Journal, V68, P60; EKLUND C M, 1961, Rocky Mt Med J, V58, P21; Emmons R.W., 1985, Progress in Clinical and Biological Research, V178, P47; ENG TR, 1990, JAMA-J AM MED ASSOC, V264, P2251, DOI 10.1001/jama.264.17.2251; EVANS ME, 1985, MEDICINE, V64, P251, DOI 10.1097/00005792-198507000-00006; Felsenfeld O., 1971, BORRELIA STRAINS VEC; FIHN S, 1980, WESTERN J MED, V133, P203; FLANIGAN TP, 1991, J INFECT DIS, V163, P1391, DOI 10.1093/infdis/163.6.1391; Francis E, 1925, J AMER MED ASSOC, V84, P1243, DOI 10.1001/jama.1925.02660430001001; GOMBERT ME, 1982, JAMA-J AM MED ASSOC, V248, P3005, DOI 10.1001/jama.248.22.3005; GOODPASTURE HC, 1978, ANN INTERN MED, V88, P303, DOI 10.7326/0003-4819-88-3-303; GORMAN RJ, 1978, CLIN PEDIATR, V17, P249, DOI 10.1177/000992287801700306; GOTHE R, 1979, J MED ENTOMOL, V16, P357, DOI 10.1093/jmedent/16.5.357; GUERRANT RL, 1976, ARCH INTERN MED, V136, P811, DOI 10.1001/archinte.136.7.811; Harkess J R, 1991, Infect Dis Clin North Am, V5, P37; HATTWICK MAW, 1976, ANN INTERN MED, V84, P732, DOI 10.7326/0003-4819-84-6-732; Healy G., 1989, Transactions of the Royal Society of Tropical Medicine and Hygiene, V83, P35, DOI 10.1016/0035-9203(89)90601-9; HEALY GR, 1976, AM J TROP MED HYG, V25, P376, DOI 10.4269/ajtmh.1976.25.376; HEALY GR, 1980, AM J CLIN PATHOL, V73, P107; HELMICK CG, 1984, J INFECT DIS, V150, P480, DOI 10.1093/infdis/150.4.480; HIERHOLZER WJ, 1971, J AMER MED ASSOC, V217, P825, DOI 10.1001/jama.1971.03190060063019; HORTON JM, 1985, ARCH INTERN MED, V145, P871, DOI 10.1001/archinte.145.5.871; HOSKINS JD, 1991, VET CLIN N AM-SMALL, V21, P185, DOI 10.1016/S0195-5616(91)50018-8; IACOPINO V, 1990, ARCH INTERN MED, V150, P1527, DOI 10.1001/archinte.150.7.1527; Jellison W.L., 1974, TULAREMIA N AM 1930; KAIRE GH, 1966, TOXICON, V4, P91, DOI 10.1016/0041-0101(66)90003-1; KIRK JL, 1990, MEDICINE, V69, P35, DOI 10.1097/00005792-199001000-00003; KRAUSE PJ, 1991, J CLIN MICROBIOL, V29, P1; LAGOS JC, 1969, ARCH NEUROL-CHICAGO, V21, P471, DOI 10.1001/archneur.1969.00480170043004; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; LILES WC, 1993, WESTERN J MED, V158, P200; LOGE RV, 1985, WESTERN J MED, V142, P91; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MAEDA K, 1987, NEW ENGL J MED, V317, P899, DOI 10.1056/NEJM198710013171412; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MARKOWITZ LE, 1985, JAMA-J AM MED ASSOC, V254, P2922, DOI 10.1001/jama.254.20.2922; MASON WL, 1980, AM REV RESPIR DIS, V121, P39; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; McCoy G, 1912, J INFECT DIS, V10, P61, DOI 10.1093/infdis/10.1.61; MCDADE JE, 1986, ANNU REV MICROBIOL, V40, P287, DOI 10.1146/annurev.mi.40.100186.001443; MCDADE JE, 1990, J INFECT DIS, V161, P609, DOI 10.1093/infdis/161.4.609; Meader C.N., 1915, COLO MED, V12, P365; MELDRUM SC, 1992, CLIN INFECT DIS, V15, P1019, DOI 10.1093/clind/15.6.1019; MINTZ ED, 1991, TRANSFUSION, V31, P365, DOI 10.1046/j.1537-2995.1991.31491213305.x; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; NEEDHAM GR, 1985, PEDIATRICS, V75, P997; NEGUSSIE Y, 1992, J EXP MED, V175, P1207, DOI 10.1084/jem.175.5.1207; OLIVER JH, 1993, J MED ENTOMOL, V30, P54, DOI 10.1093/jmedent/30.1.54; Parker RR, 1924, PUBLIC HEALTH REP, V39, P1057, DOI 10.2307/4577151; PETERSEN LR, 1989, J INFECT DIS, V159, P562, DOI 10.1093/infdis/159.3.562; PIESMAN J, 1991, J INFECT DIS, V163, P895, DOI 10.1093/infdis/163.4.895; PIKE RM, 1976, HEALTH LAB SCI, V13, P105; POPOVSKY MA, 1988, TRANSFUSION, V28, P59, DOI 10.1046/j.1537-2995.1988.28188127955.x; QUICK RE, 1993, ANN INTERN MED, V119, P284, DOI 10.7326/0003-4819-119-4-199308150-00006; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; RAMPHAL R, 1978, ARCH INTERN MED, V138, P260, DOI 10.1001/archinte.138.2.260; RAMSEY PG, 1984, WESTERN J MED, V140, P94; RAOULT D, 1991, ANTIMICROB AGENTS CH, V35, P2457, DOI 10.1128/AAC.35.12.2457; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; RICKETTS HJ, 1991, REV INFECT DIS, V13, P1227; RIKIHISA Y, 1991, CLIN MICROBIOL REV, V4, P286, DOI 10.1128/CMR.4.3.286-308.1991; ROSNER F, 1984, AM J MED, V76, P696, DOI 10.1016/0002-9343(84)90298-5; RUEBUSH TK, 1977, ANN INTERN MED, V86, P6, DOI 10.7326/0003-4819-86-1-6; RUEBUSH TK, 1981, AM J TROP MED HYG, V30, P291, DOI 10.4269/ajtmh.1981.30.291; RUEBUSH TK, 1977, NEW ENGL J MED, V297, P825, DOI 10.1056/NEJM197710132971511; SACKS HS, 1981, AM REV RESPIR DIS, V123, P547; SALGO MP, 1988, NEW ENGL J MED, V318, P1345, DOI 10.1056/NEJM198805263182101; SCHMID GP, 1983, J INFECT DIS, V148, P63, DOI 10.1093/infdis/148.1.63; SCHMITT N, 1969, CAN MED ASSOC J, V100, P417; SCHOLTENS RG, 1968, AM J TROP MED HYG, V17, P810, DOI 10.4269/ajtmh.1968.17.810; SCIOTTO CG, 1983, ARCH PATHOL LAB MED, V107, P384; Scofield R H, 1992, J Okla State Med Assoc, V85, P165; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; SIGAL LH, 1992, DRUGS, V43, P683, DOI 10.2165/00003495-199243050-00005; Skrabalo Z., 1957, Documenta de Medicina Geographica et Tropica, V9, P11; Sonenshine D.E., 1992, BIOL TICKS, VI; SONENSHINE DE, 1991, HUNTERS TROPICAL MED, P971; SOUTHERN PM, 1969, MEDICINE, V48, P129, DOI 10.1097/00005792-196903000-00002; SPACH DH, 1993, INFECT DIS CLIN PRAC, V2, P276, DOI 10.1097/00019048-199307000-00008; SPIELMAN A, 1979, J MED ENTOMOL, V15, P218, DOI 10.1093/jmedent/15.3.218; SPIELMAN A, 1981, AM J TROP MED HYG, V30, P560, DOI 10.4269/ajtmh.1981.30.560; SPRUANCE SL, 1973, ARCH INTERN MED, V131, P288, DOI 10.1001/archinte.1973.00320080124018; Stafford K C 3rd, 1989, Conn Med, V53, P347; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1978, AM J EPIDEMIOL, V108, P312, DOI 10.1093/oxfordjournals.aje.a112625; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; TAYLOR JP, 1991, AM J EPIDEMIOL, V133, P1032, DOI 10.1093/oxfordjournals.aje.a115812; TEKLU B, 1983, LANCET, V1, P835; THOMPSON RS, 1969, J AMER MED ASSOC, V210, P1045, DOI 10.1001/jama.210.6.1045; Todd JL, 1912, CAN MED ASSOC J, V2, P1118; TZIANABOS T, 1989, J CLIN MICROBIOL, V27, P2866, DOI 10.1128/JCM.27.12.2866-2868.1989; WALKER DH, 1979, ARCH INTERN MED, V139, P443, DOI 10.1001/archinte.139.4.443; Weber D J, 1991, Infect Dis Clin North Am, V5, P19; WISSEMAN CL, 1986, J INFECT DIS, V153, P626, DOI 10.1093/infdis/153.3.626; WOODWARD TE, 1976, J INFECT DIS, V134, P297, DOI 10.1093/infdis/134.3.297; WORMSER GP, 1992, JAMA-J AM MED ASSOC, V268, P1311, DOI 10.1001/jama.268.10.1311; 1975, MMWR MORB MORTAL WKL, V24, P422; 1985, MED LETT DRUGS THER, V27, P62; 1989, MMWR MORB MORTAL WKL, V38, P668; 1992, MED LETT DRUGS THER, V34, P95; 1993, MMWR MORB MORTAL WKL, V42, P345; 1981, MMWR MORB MORTAL WKL, V30, P217; 1991, MMWR MORB MORTAL WKL, V40, P296; 1991, MMWR MORB MORTAL WKL, V39, P55; 1991, MMWR MORB MORTAL WKL, V40, P451; 1983, MMWR MORB MORTAL WKL, V32, P72; 1975, MMWR MORB MORTAL WKL, V24, P427	147	164	169	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					936	947		10.1056/NEJM199309233291308	http://dx.doi.org/10.1056/NEJM199309233291308			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361509				2022-12-28	WOS:A1993LX75100008
J	GASTER, B				GASTER, B			THE LEARNING-CURVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1280	1280		10.1001/jama.270.11.1280	http://dx.doi.org/10.1001/jama.270.11.1280			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360952				2022-12-28	WOS:A1993LW34500001
J	ISEMAN, MD				ISEMAN, MD			DRUG-THERAPY - TREATMENT OF MULTIDRUG-RESISTANT TUBERCULOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; HIV-INFECTION; TRANSMISSION; PULMONARY; OFLOXACIN; OUTBREAK; BACILLI; CIPROFLOXACIN; DISEASE				ISEMAN, MD (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DIV INFECT DIS, 1400 JACKSON ST, J 201 ANNEX BLDG, DENVER, CO 80206 USA.							[Anonymous], 1991, Am Rev Respir Dis, V143, P707; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BENDOV I, 1987, AM REV RESPIR DIS, V135, P1307; BERNING SE, 1992, NEW ENGL J MED, V327, P1817, DOI 10.1056/NEJM199212173272514; BUSILLO CP, 1992, CHEST, V102, P797, DOI 10.1378/chest.102.3.797; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; CARPENTER JL, 1983, AM REV RESPIR DIS, V128, P1055; CHEN CH, 1989, AM REV RESPIR DIS, V140, P987, DOI 10.1164/ajrccm/140.4.987; CLEMENS JD, 1983, JAMA-J AM MED ASSOC, V249, P2362, DOI 10.1001/jama.249.17.2362; COHN DL, 1990, ANN INTERN MED, V112, P407, DOI 10.7326/0003-4819-76-3-112-6-407; COSTELLO HD, 1980, AM REV RESPIR DIS, V121, P313; DAVID HL, 1980, CLIN CHEST MED, V1, P227; DIPERRI G, 1992, LANCET, V340, P682; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOSTER B, 1976, AM REV RESPIR DIS, V113, P419; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28; FISCHL MA, 1992, ANN INTERN MED, V117, P184, DOI 10.7326/0003-4819-117-3-184; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GALALGHER CT, 1992, AM REV RESPIR DIS S, V145, pA812; GIRLING DJ, 1992, TUBERCLE LUNG DIS, V73, P59; GOBLE M, 1993, NEW ENGL J MED, V328, P527, DOI 10.1056/NEJM199302253280802; GREENBERG PD, 1991, AM REV RESPIR DIS, V143, P490, DOI 10.1164/ajrccm/143.3.490; HEIFETS L, 1988, AM REV RESPIR DIS, V137, P1217, DOI 10.1164/ajrccm/137.5.1217; HEIFETS LB, 1987, TUBERCLE, V68, P267, DOI 10.1016/0041-3879(87)90067-5; Heifets LB., 1991, DRUG SUSCEPTIBILITY; HOBBY GL, 1963, AM REV RESPIR DIS, V87, P29; HOBBY GL, 1962, AM REV RESPIR DIS, V86, P839; Iseman M D, 1992, Curr Clin Top Infect Dis, V12, P188; ISEMAN MD, 1990, AM REV RESPIR DIS, V141, P623, DOI 10.1164/ajrccm/141.3.623; ISEMAN MD, 1993, NEW ENGL J MED, V328, P576, DOI 10.1056/NEJM199302253280811; ISEMAN MD, 1992, ANN INTERN MED, V117, P251, DOI 10.7326/0003-4819-117-3-251; ISEMAN MD, 1985, CHEST S, V87; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; MAHMOUDI A, 1992, American Review of Respiratory Disease, V145, pA816; MITCHISON DA, 1950, THORAX, V5, P144, DOI 10.1136/thx.5.2.144; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; NADLER JP, 1991, CHEST, V99, P1025, DOI 10.1378/chest.99.4.1025; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302, DOI 10.1164/ajrccm/144.2.302; NUNN P, 1991, LANCET, V337, P627; OTTEN J, 1992, NOV P WORLD C TUB BE; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; PITCHENIK AE, 1990, LANCET, V336, P440, DOI 10.1016/0140-6736(90)91987-L; PONNIGHAUS JM, 1992, LANCET, V339, P636, DOI 10.1016/0140-6736(92)90794-4; REVES R, 1981, AM J EPIDEMIOL, V113, P423, DOI 10.1093/oxfordjournals.aje.a113110; Riley R.L., 1961, MOL MED MICROBIOLOGY, P1; SBARBARO JA, 1979, CHEST, V76, P750, DOI 10.1378/chest.76.6.750; SNIDER DE, 1985, AM REV RESPIR DIS, V132, P125; SNIDER DE, 1991, AM REV RESPIR DIS, V144, P732, DOI 10.1164/ajrccm/144.3_Pt_1.732; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; TSUKAMURA M, 1985, AM REV RESPIR DIS, V131, P352; TSUKAMURA M, 1985, American Review of Respiratory Disease, V132, P915; 1990, MMWR MORB MORTAL WKL, V39, P369; 1991, MMWR MORB MORTAL WKL, V40, P585; 1991, MMWR MORB MORTAL WKL, V40, P129; [No title captured]; 1980, B INT UNION TUBERC, V55, P14; 1992, MMWR MORB MORTAL WKL, V41, P61; 1993, MMWR MORB MORTAL WKL, V42, P1	62	548	564	1	54	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					784	791						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350889				2022-12-28	WOS:A1993LV64200008
J	WOOD, SA; ALLEN, ND; ROSSANT, J; AUERBACH, A; NAGY, A				WOOD, SA; ALLEN, ND; ROSSANT, J; AUERBACH, A; NAGY, A			NON-INJECTION METHODS FOR THE PRODUCTION OF EMBRYONIC STEM CELL-EMBRYO CHIMERAS	NATURE			English	Article							MOUSE EMBRYO		MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO M5G 1X5, ONTARIO, CANADA; AFRC, BABRAHAM INST, CAMBRIDGE CB2 4AT, ENGLAND	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	WOOD, SA (corresponding author), MAX PLANCK INST IMMUNBIOL, DEPT MOLEC EMBRYOL, W-7800 FREIBURG, GERMANY.		allen, nick d/A-4336-2010; Nagy, Andras/G-6465-2013; Wood, Stephen A/E-8357-2011	Nagy, Andras/0000-0003-4311-0413; Wood, Stephen A/0000-0002-2576-7457; Allen, Nicholas/0000-0003-4009-186X				BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; FRIEDRICH G, 1991, GENE DEV, V6, P1; FUJII JT, 1983, J EMBRYOL EXP MORPH, V74, P79; FUJII JT, 1980, DEV BIOL, V74, P239, DOI 10.1016/0012-1606(80)90066-4; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9605; LALLEMAND Y, 1990, DEVELOPMENT, V110, P1241; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, PRACTICAL APPROACH S; NAGY A, IN PRESS P NATN ACAD; PASCOE WS, 1992, BIOCHIM BIOPHYS ACTA, V114, P209; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; STEWART C, 1980, J EMBRYOL EXP MORPH, V58, P289; TOKUNAGA T, 1992, DEV GROWTH DIFFER, V34, P561; WOOD SA, 1993, P NATL ACAD SCI USA, V90, P4582, DOI 10.1073/pnas.90.10.4582	16	194	210	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1993	365	6441					87	89		10.1038/365087a0	http://dx.doi.org/10.1038/365087a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361547				2022-12-28	WOS:A1993LV64600062
J	CLARK, MM; KARPIUK, P; GALEF, BG				CLARK, MM; KARPIUK, P; GALEF, BG			HORMONALLY MEDIATED INHERITANCE OF ACQUIRED CHARACTERISTICS IN MONGOLIAN GERBILS	NATURE			English	Article							ADULT FEMALE MICE; INTRAUTERINE POSITION; UTERINE POSITION; SEXUAL-BEHAVIOR; FETUSES; RATS; MORPHOLOGY; CONTIGUITY; ANDROGEN; UTERUS	THE intrauterine position relative to members of the same or opposite sex that a rodent fetus occupies affects both its morphology and behaviour when adult1-14. Female fetuses that mature between males are androgenized by testosterone crossing fetal membranes15,16, and their phenotypes as adults differ significantly from those of sisters that received less intrauterine exposure to exogenous testosterone17-20. We report here that adult female Mongolian gerbils that gestated between male fetuses produce litters containing a significantly greater proportion of sons than the litters produced by those that gestated between female fetuses. Consequently, daughters delivered by dams that gestated between male fetuses are more likely to have gestated between male fetuses and be androgenized in utero than are daughters of dams that gestated between female fetuses. Female gerbils thus tend to inherit the phenotype (either androgenized or not androgenized) of their respective mothers.			CLARK, MM (corresponding author), MCMASTER UNIV,DEPT PSYCHOL,HAMILTON L8S 4K1,ONTARIO,CANADA.		Galef, Bennett G/A-5678-2008					BROWN MJ, 1984, ENDOCRINOLOGY, V115, P2318, DOI 10.1210/endo-115-6-2318; CLARK MM, 1991, PHYSIOL BEHAV, V49, P239, DOI 10.1016/0031-9384(91)90038-P; CLARK MM, 1993, DEV PSYCHOBIOL, V26, P185, DOI 10.1002/dev.420260402; CLARK MM, 1990, DEV PSYCHOBIOL, V23, P29, DOI 10.1002/dev.420230104; CLARK MM, 1991, DEV PSYCHOBIOL, V24, P81, DOI 10.1002/dev.420240202; CLARK MM, 1986, ANIM BEHAV, V34, P551, DOI 10.1016/S0003-3472(86)80124-5; CLARK MM, 1988, PHYSIOL BEHAV, V42, P15, DOI 10.1016/0031-9384(88)90253-3; CLARK MM, 1990, PHYSIOL BEHAV, V47, P301, DOI 10.1016/0031-9384(90)90146-U; CLEMENS LG, 1978, HORM BEHAV, V10, P40, DOI 10.1016/0018-506X(78)90023-5; CLEMENS LG, 1974, REPRODUCTIVE BEHAVIO, P25; EVEN MD, 1992, J REPROD FERTIL, V96, P709, DOI 10.1530/jrf.0.0960709; GANDELMAN R, 1977, NATURE, V266, P722, DOI 10.1038/266722a0; KINSLEY C, 1986, HORM BEHAV, V20, P7, DOI 10.1016/0018-506X(86)90025-5; KINSLEY C, 1986, HORM BEHAV, V20, P201, DOI 10.1016/0018-506X(86)90018-8; KINSLEY CH, 1986, PHYSIOL BEHAV, V36, P793, DOI 10.1016/0031-9384(86)90434-8; MEISEL RL, 1981, SCIENCE, V213, P239, DOI 10.1126/science.7244634; SAAL FSV, 1980, SCIENCE, V208, P597, DOI 10.1126/science.7367881; SAAL FSV, 1992, PHYSIOL BEHAV, V52, P163, DOI 10.1016/0031-9384(92)90447-A; SAAL FSV, 1983, SCIENCE, V220, P1306, DOI 10.1126/science.6857252; SAAL FSV, 1978, BIOL REPROD, V19, P842; TOBET SA, 1982, HORM BEHAV, V16, P251, DOI 10.1016/0018-506X(82)90025-3; VOMACHKA AJ, 1986, HORM BEHAV, V20, P181, DOI 10.1016/0018-506X(86)90016-4; VONSAAL FS, 1991, J ANIM SCI, V67, P1824; WECHMAN R, 1985, BIOL REPROD, V33, P803, DOI 10.1095/biolreprod33.4.803; ZIELINSKI WJ, 1992, BEHAV ECOL SOCIOBIOL, V30, P185, DOI 10.1007/BF00166702	25	99	102	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					712	712		10.1038/364712a0	http://dx.doi.org/10.1038/364712a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355782	Bronze			2022-12-28	WOS:A1993LT67700055
J	REINER, O; CARROZZO, R; SHEN, Y; WEHNERT, M; FAUSTINELLA, F; DOBYNS, WB; CASKEY, CT; LEDBETTER, DH				REINER, O; CARROZZO, R; SHEN, Y; WEHNERT, M; FAUSTINELLA, F; DOBYNS, WB; CASKEY, CT; LEDBETTER, DH			ISOLATION OF A MILLER-DIEKER LISSENCEPHALY GENE CONTAINING G-PROTEIN BETA-SUBUNIT-LIKE REPEATS	NATURE			English	Article							MOLECULAR DISSECTION; SEQUENCE; YEAST; DELETIONS; CLONING; REGION	LISSENCEPHALY (agyria-pachygyria) is a human brain malformation manifested by a smooth cerebral surface and abnormal neuronal migration1,2. Identification of the gene(s) involved in this disorder would facilitate molecular dissection of normal events in brain development3. Type 1 lissencephaly occurs either as an isolated abnormality or in association with dysmorphic facial appearance in patients with Miller-Dieker syndrome4,5. About 15% of patients with isolated lissencephaly and more than 90% of patients with Miller-Dieker syndrome have microdeletions in a critical 350-kilobase region in chromosome 17p13.3 (ref. 6). These deletions are hemizygous, so haplo-insufficiency for a gene in this interval is implicated. Here we report the cloning of a gene (LIS-1, lissencephaly-1) in 17p13.3 that is deleted in Miller-Dieker patients. Non-overlapping deletions involving either the 5' or 3' end of the gene were found in two patients, identifying LIS-1 as the disease gene. The deduced amino-acid sequence shows significant homology to beta-subunits of heterotrimeric G proteins, suggesting that it could possibly be involved in a signal transduction pathway crucial for cerebral development.	BAYLOR COLL MED,INST MOLEC GENET,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; UNIV MINNESOTA,SCH MED,DEPT NEUROL,DIV PEDIAT NEUROL,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH MED,DEPT PEDIAT,MINNEAPOLIS,MN 55455	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities			Dobyns, William/AAI-2768-2020; Dobyns, William Brian/ABC-6525-2021; Reiner, Orly/E-9455-2010	Dobyns, William/0000-0002-7681-2844; Reiner, Orly/0000-0001-7560-9599				AICARDI J, 1989, INT PEDIATR, V4, P118; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARTH PG, 1987, CAN J NEUROL SCI, V14, P1; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; DIEKER H, 1969, CLIN DELINEATION BIR, V2, P1; DOBYNS WB, 1991, AM J HUM GENET, V48, P584; DOBYNS WB, 1989, NEUROL CLIN, V7, P89, DOI 10.1016/S0733-8619(18)30830-2; DURONIO RJ, 1992, PROTEINS, V13, P41, DOI 10.1002/prot.340130105; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUILLEMOT F, 1989, P NATL ACAD SCI USA, V86, P4594, DOI 10.1073/pnas.86.12.4594; GUZZETTA V, 1992, GENOMICS, V13, P551, DOI 10.1016/0888-7543(92)90124-B; IGARASHI M, 1993, SCIENCE, V259, P77, DOI 10.1126/science.8418498; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KLEUSS C, 1993, SCIENCE, V259, P832, DOI 10.1126/science.8094261; KUWANO A, 1991, AM J HUM GENET, V49, P707; Kuwano Akira, 1992, Human Molecular Genetics, V1, P417, DOI 10.1093/hmg/1.6.417; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; LEDBETTER DH, 1989, P NATL ACAD SCI USA, V86, P5136, DOI 10.1073/pnas.86.13.5136; LEDBETTER SA, 1992, AM J HUM GENET, V50, P182; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; MILLER JQ, 1963, NEUROLOGY, V13, P841, DOI 10.1212/WNL.13.10.841; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; ORIKIN SH, 1976, NEW ENGL J MED, V295, P710; SAMBROOK S, 1989, MOL CLONING LABORATO; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; van Tuinen P, 1987, Genomics, V1, P374, DOI 10.1016/0888-7543(87)90042-5	29	867	888	0	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					717	721		10.1038/364717a0	http://dx.doi.org/10.1038/364717a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355785				2022-12-28	WOS:A1993LT67700058
J	ROEHL, H; KIMBLE, J				ROEHL, H; KIMBLE, J			CONTROL OF CELL FATE IN C-ELEGANS BY A GLP-1 PEPTIDE CONSISTING PRIMARILY OF ANKYRIN REPEATS	NATURE			English	Article							OF-FUNCTION MUTATIONS; CAENORHABDITIS-ELEGANS; NOTCH-GENE; LIN-12; DROSOPHILA; SEQUENCES; LINEAGES; LOCUS	THE homologous proteins GLP-1 and LIN-12 are required for cell interactions during nematode development1-5. glp-1 and lin-12 are members of a gene family that includes Drosophila Notch and several vertebrate homologues6. The members of this family have a single transmembrane domain and a similar arrangement of repeated amino-acid motifs (see Fig. 1). The mechanism by which proteins in this family function is not understood. One hypothesis is that these proteins are receptors, each with an extracellular domain that binds a ligand and an intracellular domain that influences the activity of downstream cell fate regulators. Here we report that a region of the GLP-1 intracellular domain, consisting primarily of six ankyrin repeats, is sufficient to direct cell fate. The cell fate transformations seen are similar to transformations caused by gain-of-function mutations in either glp-1 or lin-12 and do not rely on endogenous lin-12 or glp-1 activity. We propose that the ankyrin repeat region of GLP-1 is responsible for controlling downstream regulators of cell fate.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	ROEHL, H (corresponding author), UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706, USA.							ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BRENNER S, 1974, GENETICS, V77, P71; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FERGUSON EL, 1987, NATURE, V326, P259, DOI 10.1038/326259a0; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KODOYIANNI V, 1992, MOL BIOL CELL, V3, P1199, DOI 10.1091/mbc.3.11.1199; LAMBIE EJ, 1991, DEVELOPMENT, V112, P231; LISSEMORE J, IN PRESS GENETICS; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; PRIESS JR, 1987, CELL, V51, P610; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4	26	101	112	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					632	635		10.1038/364632a0	http://dx.doi.org/10.1038/364632a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350921				2022-12-28	WOS:A1993LR77100054
J	TZOURIO, C; IGLESIAS, S; HUBERT, JB; VISY, JM; ALPEROVITCH, A; TEHINDRAZANARIVELO, A; BIOUSSE, V; WOIMANT, F; BOUSSER, MG				TZOURIO, C; IGLESIAS, S; HUBERT, JB; VISY, JM; ALPEROVITCH, A; TEHINDRAZANARIVELO, A; BIOUSSE, V; WOIMANT, F; BOUSSER, MG			MIGRAINE AND RISK OF ISCHEMIC STROKE - A CASE-CONTROL STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PLATELET AGGREGABILITY; BLOOD-PRESSURE; HEADACHE; SYMPTOMS; SMOKING; WOMEN	Objectives-To determine whether migraine is a risk factor for ischaemic stroke. Design-A case-control study. Setting-Two hospitals in Paris. Subjects-212 patients with stroke (137 men and 75 women) and 212 controls matched for sex, age (to within five years), and history of hypertension. Main outcome measures-Ischaemic stroke, confirmed by brain computed tomography or magnetic resonance imaging, and history of headache, recorded with structured questionnaire during interview. Results-Prevalence of migraine did not differ between patients with stroke and controls: 18/137 v 17/137 for men (odds ratio 1.1 (95% confidence interval 0.5 to 2.2), p=0.86); 23/75 v 17/75 for women (odds ratio 1.6 (0.7 to 3.5), p=0.24); and 41/212 v 34/212 for both sexes (odds ratio 1.3 (0.8 to 2.3), p=0.33). When subjects were split into two age groups, however, prevalence of migraine was significantly higher among younger women (aged <45) with stroke compared with their controls (13/20 v 6/20, odds ratio 4.3 (1.2 to 16.3), p=0.03). Furthermore, the risk of ischaemic stroke was higher among younger women who smoked (7/20 v 1/20, odds ratio 10.2 (1.1 to 93.3)). Conclusions-Prevalence of migraine was not different between patients with stroke and matched controls except among women aged <45, when migraine and stroke were significantly associated.	HOP ST ANTOINE, SERV NEUROL, F-75571 PARIS 12, FRANCE; HOP LARIBOISIERE, SERV NEUROL, F-75475 PARIS 10, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	TZOURIO, C (corresponding author), INSERM, U360, 16 AV PAUL VAILLANT COUTURIER, F-94807 VILLEJUIF, FRANCE.		Tzourio, christophe/L-6344-2019; Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/B-4015-2009	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984				[Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P718; [Anonymous], 1989, STROKE, V20, P1407; Breslow N, 1980, STATISTICAL METHODS, V32; CHEN TC, 1987, ARCH NEUROL-CHICAGO, V44, P1024, DOI 10.1001/archneur.1987.00520220030011; COUCH JR, 1977, NEUROLOGY, V27, P843, DOI 10.1212/WNL.27.9.843; DIXON WJ, 1983, BMDP STATISTICAL SOF; GILL JS, 1989, ARCH INTERN MED, V149, P2053, DOI 10.1001/archinte.149.9.2053; HENRICH JB, 1989, J CLIN EPIDEMIOL, V42, P773, DOI 10.1016/0895-4356(89)90075-9; KALENDOVSKY Z, 1975, ARCH NEUROL-CHICAGO, V32, P13, DOI 10.1001/archneur.1975.00490430035004; MARKUSH RE, 1975, NEUROLOGY, V25, P430, DOI 10.1212/WNL.25.5.430; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; TATEMICHI TK, 1986, STROKE PATHOPHYSIOLO, V2, P845; WATERS WE, 1971, BMJ-BRIT MED J, V1, P142, DOI 10.1136/bmj.1.5741.142; WEISS NS, 1972, NEW ENGL J MED, V287, P631, DOI 10.1056/NEJM197209282871303; ZIEGLER DK, 1977, NEUROLOGY, V27, P265, DOI 10.1212/WNL.27.3.265; 1990, SAS USERS GUIDE STAT, V1	17	177	178	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	1993	307	6899					289	292		10.1136/bmj.307.6899.289	http://dx.doi.org/10.1136/bmj.307.6899.289			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374374	Bronze, Green Published			2022-12-28	WOS:A1993LQ51600016
J	THOMAS, HE; STUNNENBERG, HG; STEWART, AF				THOMAS, HE; STUNNENBERG, HG; STEWART, AF			HETERODIMERIZATION OF THE DROSOPHILA ECDYSONE RECEPTOR WITH RETINOID-X RECEPTOR AND ULTRASPIRACLE	NATURE			English	Article							RESPONSE ELEMENT; MAMMALIAN-CELLS; ACID; SUPERFAMILY; EXPRESSION; PROTEINS; PRODUCT; MEMBER; FAMILY; GENES	ECDYSONE in Drosophila has been a paradigm for steroid hormones since its ability to induce gene activity directly was demonstrated by its effects on moulting and polytene chromosome puffing1-3. The ecdysone receptor (EcR) was recently confirmed as a member of the nuclear receptor superfamily by cloning and characterization in a Drosophila cell line4. Here we show that EcR needs to heterodimerize with either the retinoid X receptor (RXR)5 or its Drosophila homologue, ultraspiracle (USP)6, for DNA binding and transactivation. These results place the ecdysone receptor in the heterodimerizing class of the nuclear receptor superfamily and demonstrate that the role of RXR/USP as a central and promiscuous partner in mediating the activity of these receptors7-12 is highly conserved. Whereas EcR-USP DNA-binding activity is unaffected by hormone, EcR-RXR DNA-binding activity is stimulated by either ecdysteroid or 9-cis-retinoic acid, demonstrating that hormone can play a role in heterodimer stabilization.	EMBL,GENE EXPRESS PROGRAMME,MEYERHOFSTR 1,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Stewart, A. Francis/E-7789-2010; Stunnenberg, Hendrik G./D-6875-2012	Stunnenberg, Hendrik G./0000-0002-0066-1576				AMIN J, 1991, MOL CELL BIOL, V11, P5937, DOI 10.1128/MCB.11.12.5937; ANDERSSON ML, 1992, NUCLEIC ACIDS RES, V20, P4803, DOI 10.1093/nar/20.18.4803; ASHBURNER M, 1990, CELL, V61, P1, DOI 10.1016/0092-8674(90)90205-S; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; CLEVER U, 1964, SCIENCE, V146, P794, DOI 10.1126/science.146.3645.794; CLEVER U, 1960, EXP CELL RES, V20, P623, DOI 10.1016/0014-4827(60)90141-5; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1992, DEVELOPMENT, V115, P449; PERRIMON N, 1985, GENETICS, V111, P23; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; WANG LH, 1989, NATURE, V340, P163, DOI 10.1038/340163a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	29	441	454	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					471	475		10.1038/362471a0	http://dx.doi.org/10.1038/362471a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8385270				2022-12-28	WOS:A1993KV42400091
J	GRESSENS, P; HILL, JM; GOZES, I; FRIDKIN, M; BRENNEMAN, DE				GRESSENS, P; HILL, JM; GOZES, I; FRIDKIN, M; BRENNEMAN, DE			GROWTH-FACTOR FUNCTION OF VASOACTIVE-INTESTINAL-PEPTIDE IN WHOLE CULTURED MOUSE EMBRYOS	NATURE			English	Article							SYMPATHETIC NEUROBLASTS; NEUROTROPHIC ACTION; REGULATES MITOSIS; RAT-BRAIN; POLYPEPTIDE; ANTAGONIST; SURVIVAL; VIP; DIFFERENTIATION; QUANTITATION	FACTORS controlling central nervous system (CNS) growth immediately after neurulation are mostly unknown. Vasoactive intestinal peptide (VIP) receptors are widely distributed in the embryonic nervous system1,2, and VIP has trophic and mitogenic properties3,4 on embryonic neural tissues but inhibits growth5 and mitosis in certain tumours6. To address the potential effects of VIP on embryonic growth, we used whole postimplantation embryo cultures7,8. After a 4-h incubation, VIP stimulated growth, increasing somite number, embryonic volume, DNA and protein content, and number of cells in S-phase. A VIP antagonist9,10 substantially inhibited these VIP-mediated increments in growth. The VIP antagonist completely suppressed VIP-stimulated mitosis in the CNS while decreasing the same. in non-neuronal tissues by 38%. In vitro autoradiography revealed GTP-sensitive and GTP-insensitive VIP receptors which were differentially regulated in VIP antagonist-treated embryos. The present study suggests that VIP acts as a growth factor on early postimplantation embryos through multiple VIP receptors that exhibit tissue-specific responses.	NICHHD, DEV NEUROBIOL LAB, BETHESDA, MD 20892 USA; TEL AVIV UNIV, DEPT CHEM PATHOL, IL-69978 TEL AVIV, ISRAEL; WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Weizmann Institute of Science	GRESSENS, P (corresponding author), NINCDS, EXPTL NEUROPATHOL LAB, BETHESDA, MD 20892 USA.		gressens, pierre/M-7557-2017	gressens, pierre/0000-0002-0909-4221				ALLEN JM, 1985, J NEURO-ONCOL, V3, P197, DOI 10.1007/BF00165179; AUDIGIER S, 1986, BRAIN RES, V376, P363, DOI 10.1016/0006-8993(86)90200-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; BRENNEMAN DE, 1985, PEPTIDES, V6, P35, DOI 10.1016/0196-9781(85)90132-9; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; BRENNEMAN DE, 1987, J CELL BIOL, V104, P1603, DOI 10.1083/jcb.104.6.1603; BROWN NA, 1981, TERATOLOGY, V24, P65, DOI 10.1002/tera.1420240108; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; EMSON PC, 1979, BRAIN RES, V177, P437, DOI 10.1016/0006-8993(79)90462-1; GOZES I, 1988, NEUROENDOCRINOLOGY, V47, P27, DOI 10.1159/000124886; GOZES I, 1989, ENDOCRINOLOGY, V125, P2945, DOI 10.1210/endo-125-6-2945; GOZES I, 1991, J PHARMACOL EXP THER, V257, P959; GOZES Y, 1991, BRAIN RES, V540, P319, DOI 10.1016/0006-8993(91)90528-4; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; GRESSENS P, 1992, J NEUROPATH EXP NEUR, V51, P206, DOI 10.1097/00005072-199203000-00010; HAEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993, DOI 10.1073/pnas.86.15.5993; Heyner S., 1990, Current Topics in Developmental Biology, V24, P137, DOI 10.1016/S0070-2153(08)60086-1; Hill J. M., 1992, Society for Neuroscience Abstracts, V18, P1294; HILL J M, 1991, Society for Neuroscience Abstracts, V17, P1126; HILL JM, 1992, NEUROSCIENCE, V48, P925, DOI 10.1016/0306-4522(92)90280-F; MASUO Y, 1992, BRAIN RES, V575, P113, DOI 10.1016/0006-8993(92)90430-H; MCGREGOR GP, 1982, NEUROSCI LETT, V28, P21, DOI 10.1016/0304-3940(82)90202-6; MUNRO H. N., 1966, METHOD BIOCHEM ANAL, V14, P113; New D.A., 1971, METHODS MAMMALIAN EM, P305; PINCUS DW, 1990, NATURE, V343, P564, DOI 10.1038/343564a0; POSTON GJ, 1988, PANCREAS, V3, P439, DOI 10.1097/00006676-198808000-00012; RUSSELL JT, 1990, SOC NEUR ABSTR, V16, P194; SCHOLAR EM, 1991, CANCER, V67, P1561, DOI 10.1002/1097-0142(19910315)67:6<1561::AID-CNCR2820670617>3.0.CO;2-Z; TAKAHASHI T, 1992, J NEUROCYTOL, V21, P185, DOI 10.1007/BF01194977; THEILER K, 1975, HOUSE MOUSE; TSUTSUI Y, 1987, AM J PATHOL, V127, P262; VANMAELEFABRY G, 1988, ARCH BIOL, V99, P431	33	263	278	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 11	1993	362	6416					155	158		10.1038/362155a0	http://dx.doi.org/10.1038/362155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8383805				2022-12-28	WOS:A1993KR02800059
J	PEARCE, D; YAMAMOTO, KR				PEARCE, D; YAMAMOTO, KR			MINERALOCORTICOID AND GLUCOCORTICOID RECEPTOR ACTIVITIES DISTINGUISHED BY NONRECEPTOR FACTORS AT A COMPOSITE RESPONSE ELEMENT	SCIENCE			English	Article							C-JUN; DNA-BINDING; FOS-JUN; TRANSCRIPTION FACTORS; SIGNAL TRANSDUCTION; NEGATIVE REGULATOR; COMPLEMENTARY-DNA; GENE-EXPRESSION; RETINOIC ACID; HORMONE	Mineralocorticoid and glucocorticoid hormones elicit distinct physiologic responses, yet the mineralocorticoid receptor (MR) and glucocorticoid receptor (GR) bind to and activate transcription similarly from a consensus simple hormone response element (HRE). The activities of GR and MR at plfG, a 25-base pair composite response element to which both the steroid receptors and transcription factor AP1 can bind, are analyzed here. Under conditions in which GR represses AP1-stimulated transcription from plfG, MR was inactive. With the use of MR-GR chimeras, a segment of the NH2-terminal region of GR (amino acids 105 to 440) was shown to be required for this repression. Thus, the distinct physiologic effects mediated by MR and GR may be determined by differential interactions of nonreceptor factors with specific receptor domains at composite response elements.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV NEPHROL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ADLER AA, IN PRESS P NATL ACAD; AMERO SA, 1992, MOL ENDOCRINOL, V6, P3, DOI 10.1210/me.6.1.3; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BASTL CP, 1989, AM J PHYSIOL, V257, pF1027, DOI 10.1152/ajprenal.1989.257.6.F1027; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1990, ONCOGENE, V5, P929; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GODOWSKI PJ, 1988, SCIENCE, V241, P812, DOI 10.1126/science.3043662; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; JACOBSEN MD, 1991, THESIS U CALIFORNIA; JOELS M, 1990, P NATL ACAD SCI USA, V87, P4495, DOI 10.1073/pnas.87.12.4495; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KONIG H, 1992, EMBO J, V11, P2241, DOI 10.1002/j.1460-2075.1992.tb05283.x; LAPLACE JR, 1992, J CLIN INVEST, V90, P1370, DOI 10.1172/JCI116003; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MIESFELD R, 1987, SCIENCE, V236, P423, DOI 10.1126/science.3563519; MINER JN, 1991, TRENDS BIOCHEM SCI, V16, P423, DOI 10.1016/0968-0004(91)90168-U; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; PATEL PD, 1989, MOL ENDOCRINOL, V3, P1877, DOI 10.1210/mend-3-11-1877; PAYVAR F, 1983, CELL, V35, P381, DOI 10.1016/0092-8674(83)90171-X; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; SAKAI DD, 1988, GENE DEV, V2, P1144, DOI 10.1101/gad.2.9.1144; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SHEMSHEDINI L, 1991, EMBO J, V10, P3839, DOI 10.1002/j.1460-2075.1991.tb04953.x; STRAHLE U, 1989, NATURE, V339, P629, DOI 10.1038/339629a0; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TURNAMIAN SG, 1989, J CLIN INVEST, V84, P1924, DOI 10.1172/JCI114380; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016; ZHANG XK, 1991, J BIOL CHEM, V266, P8248	42	406	408	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 19	1993	259	5098					1161	1165		10.1126/science.8382376	http://dx.doi.org/10.1126/science.8382376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8382376				2022-12-28	WOS:A1993KM91700039
J	WINSTON, DJ; HO, WG; BARTONI, K; DUMOND, C; EBELING, DF; BUHLES, WC; CHAMPLIN, RE				WINSTON, DJ; HO, WG; BARTONI, K; DUMOND, C; EBELING, DF; BUHLES, WC; CHAMPLIN, RE			GANCICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS-INFECTION AND DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS - RESULTS OF A PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUSES; CYTOMEGALIC INCLUSION DISEASE; TRANSPLANTATION, HOMOLOGOUS; GANCICLOVIR	INTRAVENOUS IMMUNE GLOBULIN; VIRUS INFECTION; RESISTANT CYTOMEGALOVIRUS; INTERSTITIAL PNEUMONIA; FOSCARNET THERAPY; RISK-FACTORS; IMMUNOGLOBULIN; PREVENTION; RETINITIS; AIDS	Objective: To evaluate the efficacy and safety of ganciclovir for prevention of cytomegalovirus (CMV) infection and disease. Design: A randomized, placebo-controlled, double-blind trial. Setting: University-affiliated bone marrow transplant center. Patients: Cytomegalovirus-seropositive allogeneic bone marrow transplant recipients. Interventions: Random assignment to receive either a placebo or ganciclovir at a dose of 2.5 mg/kg body weight every 8 hours for 1 week before transplant and then at a dose of 6 mg/kg once per day, Monday through Friday, after transplant when the post-transplant neutrophil count reached 1.0 x 10(9)/L. Measurements: Cytomegalovirus infection (positive culture, seroconversion, positive histologic findings), CMV disease (pneumonia, gastroenteritis, the wasting syndrome), and study-drug toxicity. Results: Cytomegalovirus infection developed in 25 of 45 placebo patients (56%) but in only 8 of 40 ganciclovir patients (20%) (P < 0.001). Cytomegalovirus disease may also have occurred less often in the ganciclovir patients (4 of 40 patients [10%] versus 11 of 45 patients [24%]; P = 0.09). The probability of CMV disease occurring within the first 120 days after transplantation was 0.29 among the placebo patients but only 0.12 among ganciclovir patients (P = 0.06). Reversible neutropenia was the only appreciable toxicity related to ganciclovir and required interruption of the study drug after transplant in 25 of 43 ganciclovir patients (58%) and in 13 of 47 placebo patients (28%) (P = 0.005). Overall survival was similar in both the placebo patients (29 of 45 [64%]) and ganciclovir patients (28 of 40 [70%]; P > 0.2). Conclusions: Prophylactic ganciclovir, started before transplant and continued after recovery of the post-transplant neutrophil count, reduces the incidence and severity of CMV infection in CMV-seropositive bone marrow transplant recipients but is frequently associated with neutropenia.	SYNTEX INC, INST CLIN MED, PALO ALTO, CA 94304 USA	Syntex Corporation	WINSTON, DJ (corresponding author), UCLA LOS ANGELES MED CTR, DEPT MED, ROOM 42-121 CHS, LOS ANGELES, CA 90024 USA.				NCI NIH HHS [CA-23175] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOWDEN RA, 1986, NEW ENGL J MED, V314, P1006, DOI 10.1056/NEJM198604173141602; BUHLES WC, 1988, REV INFECT DIS, V10, pS495; CHAMPLIN R, 1990, BLOOD, V76, P418; CHAMPLIN RE, 1990, TRANSPLANTATION, V49, P720, DOI 10.1097/00007890-199004000-00013; DREW WL, 1991, J INFECT DIS, V163, P716, DOI 10.1093/infdis/163.4.716; DROBYSKI WR, 1991, TRANSPLANTATION, V52, P155; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; ERICE A, 1989, NEW ENGL J MED, V320, P289, DOI 10.1056/NEJM198902023200505; GAJEWSKI JL, 1990, TRANSPLANTATION, V50, P244, DOI 10.1097/00007890-199008000-00015; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; GROSSBERG HS, 1989, NEW ENGL J MED, V320, P1560; HARDY WD, 1991, J ACQ IMMUN DEF SYND, V4, pS22; JACOBSON MA, 1991, J INFECT DIS, V163, P1348, DOI 10.1093/infdis/163.6.1348; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; MEYERS JD, 1983, RECENT ADV BONE MARR, P405; MILLS J, 1988, REV INFECT DIS, V10, pS522; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; RINGDEN O, 1987, BONE MARROW TRANSPL, V2, P299; RUBIN RH, 1989, ANTIMICROB AGENTS CH, V33, P1975, DOI 10.1128/AAC.33.11.1975; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; SULLIVAN KM, 1990, NEW ENGL J MED, V323, P705, DOI 10.1056/NEJM199009133231103; TYMS AS, 1984, LANCET, V2, P924; WEINER RS, 1986, ANN INTERN MED, V104, P168, DOI 10.7326/0003-4819-104-2-168; WINSTON DJ, 1990, REV INFECT DIS, V12, pS776; WINSTON DJ, 1987, ANN INTERN MED, V106, P12, DOI 10.7326/0003-4819-106-1-12; WINSTON DJ, 1982, ANN INTERN MED, V97, P11, DOI 10.7326/0003-4819-97-1-11	28	351	362	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					179	184		10.7326/0003-4819-118-3-199302010-00004	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8380243				2022-12-28	WOS:A1993KJ43900004
J	PAUKER, SG; KOPELMAN, RI				PAUKER, SG; KOPELMAN, RI			A REWARDING PURSUIT OF CERTAINTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							BRAIN-ABSCESS; BIOPSY; EXPERIENCE; ACTINOMYCOSIS		TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DIV GEN INTERNAL MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University	PAUKER, SG (corresponding author), TUFTS UNIV, NEW ENGLAND MED CTR, SCH MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA.				NATIONAL LIBRARY OF MEDICINE [R01LM004493] Funding Source: NIH RePORTER; NLM NIH HHS [LM 4493] Funding Source: Medline	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		AMINOFF MJ, 1980, AM J MED, V69, P657, DOI 10.1016/0002-9343(80)90415-5; APUZZO MLJ, 1987, NEUROSURGERY, V20, P930, DOI 10.1227/00006123-198706000-00019; BELL BA, 1991, INFECTIONS CENTRAL N, P361; BOLTON CF, 1964, CAN MED ASSOC J, V90, P922; BREWER NS, 1975, ANN INTERN MED, V82, P571, DOI 10.7326/0003-4819-82-4-571; BULLOCK WE, 1992, CECIL TXB MED, P1723; CHUN CH, 1986, MEDICINE, V65, P415, DOI 10.1097/00005792-198611000-00006; COULAM CM, 1980, INVEST RADIOL, V15, P103, DOI 10.1097/00004424-198003000-00003; DICHTER MA, 1991, HARRISONS PRINCIPLES, V2, P1968; EDELMAN RR, 1993, NEW ENGL J MED, V328, P708, DOI 10.1056/NEJM199303113281008; EINHORN LH, 1989, CANC PRINCIPLES PRAC, V1, P1071; EPSTEIN CM, 1992, MED PRACTITING PHYSI, P1696; GARFIELD J, 1969, BRIT MED J, V2, P7, DOI 10.1136/bmj.2.5648.7; HARTER DH, 1991, HARRISONS PRINCIPLES, V2, P2023; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; HUTTON RM, 1979, J INFECTION, V1, P195, DOI 10.1016/S0163-4453(79)80014-6; JUNGREIS CA, 1991, MR CT IMAGING HEAD N, V1, P303; KAPLAN K, 1985, MED CLIN N AM, V69, P345; KASSIRER JP, 1989, NEW ENGL J MED, V320, P1489, DOI 10.1056/NEJM198906013202211; KASSIRER JP, 1991, LEARNING CLIN REASON, P187; KAUFMAN HH, 1979, NEUROSURGERY, V4, P129, DOI 10.1227/00006123-197902000-00004; Lerner P. I., 1990, Principles and practice of infectious diseases., P1932; MARKS PV, 1992, NEW ZEAL MED J, V105, P85; OSTERTAG CB, 1980, SURG NEUROL, V14, P275; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; SAMSON DS, 1973, AM J MED, V54, P201, DOI 10.1016/0002-9343(73)90224-6; SAWYER J, 1988, MED DECIS MAKING, V8, P95, DOI 10.1177/0272989X8800800205; SHORVON SD, 1992, DIS NERV SYST, V2, P896; SIMON RP, 1992, CECIL TXB MED, P2170; SMEGO RA, 1987, REV INFECT DIS, V9, P855; SOKOLOV RT, 1990, INFECTIONS NERVOUS S, P93; TUNKEL AR, 1992, DIS NERVOUS SYSTEM C, P1340; WISPELWEY B, 1990, PRINCIPLES PRACTICE, P777; YANG SY, 1981, J NEUROSURG, V55, P794, DOI 10.3171/jns.1981.55.5.0794; YEAGER BA, 1986, ARCH OTOLARYNGOL, V112, P1293	35	12	13	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1103	1107		10.1056/NEJM199310073291508	http://dx.doi.org/10.1056/NEJM199310073291508			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371733				2022-12-28	WOS:A1993LZ64000008
J	BENNETT, HJ				BENNETT, HJ			THE INS AND OUTS OF OUTIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1508	1508		10.1001/jama.270.13.1508	http://dx.doi.org/10.1001/jama.270.13.1508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371451				2022-12-28	WOS:A1993LZ33400001
J	BOROW, W				BOROW, W			MEDICAL TELEVISION - PRESCRIPTION FOR PROGRESS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											BOROW, W (corresponding author), AMER MED TELEVIS,1515 N STATE ST,CHICAGO,IL 60610, USA.							DAVIS RM, 1988, JAMA-J AM MED ASSOC, V259, P1036, DOI 10.1001/jama.259.7.1036; GUNBY P, 1993, JAMA-J AM MED ASSOC, V269, P1606, DOI 10.1001/jama.269.13.1606; 1990, VIEWERSHIP STUDY; 1990, PHYSICIAN VIEWERSHIP; 1992, TRENDS TELEVISION AN, P551	5	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1601	1602		10.1001/jama.270.13.1601	http://dx.doi.org/10.1001/jama.270.13.1601			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371473				2022-12-28	WOS:A1993LZ33400036
J	BROWN, WT; HOUCK, GE; JEZIOROWSKA, A; LEVINSON, FN; DING, XH; DOBKIN, C; ZHONG, N; HENDERSON, J; BROOKS, SS; JENKINS, EC				BROWN, WT; HOUCK, GE; JEZIOROWSKA, A; LEVINSON, FN; DING, XH; DOBKIN, C; ZHONG, N; HENDERSON, J; BROOKS, SS; JENKINS, EC			RAPID FRAGILE-X CARRIER SCREENING AND PRENATAL-DIAGNOSIS USING A NONRADIOACTIVE PCR TEST	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; DNA-SEQUENCE; GENE; MUTATION; REPEAT; AMPLIFICATION; REGION; FREQUENCY; PROGRAM	Objective.-To develop a rapid, nonradioactive test using the polymerase chain reaction (PCR) capable of detecting full fragile X mutations, premutations, and resolving normal alleles and to apply this to prenatal diagnosis and carrier screening of pregnant women at risk for fragile X carrier status. Design.-Prenatal and blood sample PCR analysis with confirmation by direct Southern blotting and cytogenetic techniques. Setting.-Samples sent to a DNA diagnostic research laboratory at a tertiary referral center. Participants.-Pregnant women with a family history of undiagnosed mental retardation or known fragile X syndrome and controls. Results.-A rapid, nonradioactive PCR screening protocol for the fragile X mental retardation-1 gene for both normal and mutant alleles was developed. Analysis of 570 control X chromosomes showed a modal number of 30 CGG repeats (range, 12 to 52 repeats) and a calculated heterozygosity of approximately 80%. No excess of homozygosity was found, indicating the test was accurate for normal allele resolution. In addition, 150 unrelated pregnant women were screened. Within known fragile X families, five of 20 pregnant women were diagnosed as carriers. Two new fragile X families were diagnosed among relatives of 130 females with family histories of undiagnosed mental retardation, although no carriers were identified. Prenatal PCR testing of 28 carriers accurately detected nine fetuses with full mutations. Conclusions.-This rapid, nonradioactive PCR protocol allows accurate resolution of normal alleles as well as simultaneous detection of carrier alleles and full mutations. With this approach, efficient screening of pregnant women at risk for fragile X carrier status, subsequent genetic counseling of identified carriers, and reliable prenatal diagnosis can be offered.			BROWN, WT (corresponding author), NEW YORK STATE INST BASIC RES DEV DISABIL, DEPT HUMAN GENET, 1050 FOREST HILL RD, STATEN ISL, NY 10314 USA.		Brown, William/GXN-2777-2022		PHS HHS [MCJ360587] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELL DA, 1991, NUCLEIC ACIDS RES, V19, P5079, DOI 10.1093/nar/19.18.5079; BLOMQUIST HK, 1983, CLIN GENET, V24, P393; Brown W T, 1992, Mol Genet Med, V2, P39; BROWN WT, 1992, AM J MED GENET, V43, P96, DOI 10.1002/ajmg.1320430114; BROWN WT, 1991, AM J MED GENET, V38, P292, DOI 10.1002/ajmg.1320380226; BROWN WT, 1988, NUCLEIC ACID PROBES, P11; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; DAQUILA RT, 1991, NUCLEIC ACIDS RES, V19, P3749, DOI 10.1093/nar/19.13.3749; DEKA R, 1992, AM J HUM GENET, V51, P1325; DOBKIN CS, 1991, LANCET, V338, P957; ERSTER SH, 1992, HUM GENET, V90, P55; FORNAGE M, 1992, GENOMICS, V12, P63, DOI 10.1016/0888-7543(92)90407-J; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; HAGERMAN RJ, 1991, FRAGILE X SYNDROME; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HIRST M, 1991, LANCET, V338, P956, DOI 10.1016/0140-6736(91)91831-E; INNIS MA, 1990, PCR PROTOCOLS, P54; JENKINS EC, 1992, 1992 INTERNATIONAL FRAGILE X CONFERENCE PROCEEDINGS, P349; JENKINS EC, 1992, GENETIC DISORDERS FE, P241; KRAWCZUN MS, 1992, AM J MED GENET, V43, P149, DOI 10.1002/ajmg.1320430123; LASPADA AR, 1992, NAT GENET, V2, P301, DOI 10.1038/ng1292-301; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MACPHERSON JN, 1992, J MED GENET, V29, P802, DOI 10.1136/jmg.29.11.802; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MANDEL JL, 1992, AM J MED GENET, V43, P5, DOI 10.1002/ajmg.1320430104; MARKHAM AF, 1993, BMJ-BRIT MED J, V306, P441, DOI 10.1136/bmj.306.6875.441; McCabe E R, 1991, PCR Methods Appl, V1, P99; MOSER HW, 1989, PRINCIPLES PRACTICE, V1, P495; NOLIN SL, 1991, AM J MED GENET, V38, P251, DOI 10.1002/ajmg.1320380218; OOSTRA BA, 1993, J MED GENET, V30, P410, DOI 10.1136/jmg.30.5.410; OUDET C, 1993, AM J HUM GENET, V52, P297; PATTEN JL, 1990, NEW ENGL J MED, V322, P1412, DOI 10.1056/NEJM199005173222002; PERGOLIZZI RG, 1992, LANCET, V339, P271, DOI 10.1016/0140-6736(92)91334-5; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; POLLARDKNIGHT D, 1990, ANAL BIOCHEM, V185, P353, DOI 10.1016/0003-2697(90)90307-U; RICHARDS RI, 1992, NAT GENET, V1, P257, DOI 10.1038/ng0792-257; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; RYCHLIK W, 1989, NUCLEIC ACIDS RES, V17, P8543, DOI 10.1093/nar/17.21.8543; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHELBOURNE P, 1993, NEW ENGL J MED, V328, P471, DOI 10.1056/NEJM199302183280704; SHERMAN SL, 1985, HUM GENET, V69, P289, DOI 10.1007/BF00291644; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SMITS APT, 1993, J MED GENET, V30, P94, DOI 10.1136/jmg.30.2.94; STRAUSS WM, 1988, CURRENT PROTOCOLS MO; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; SUTHERLAND GR, 1991, NEW ENGL J MED, V325, P1720, DOI 10.1056/NEJM199112123252407; TRNOVSKY J, 1992, BIOTECHNIQUES, V13, P800; TURNER G, 1992, LANCET, V339, P1210, DOI 10.1016/0140-6736(92)91142-U; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Walsh P S, 1992, PCR Methods Appl, V1, P241, DOI 10.1101/gr.1.4.241; WEBB TP, 1986, J MED GENET, V23, P396, DOI 10.1136/jmg.23.5.396; WITT M, 1989, HUM GENET, V82, P271, DOI 10.1007/BF00291168; YAMAGATA H, 1992, LANCET, V339, P692, DOI 10.1016/0140-6736(92)90862-W; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179	55	234	239	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1569	1575		10.1001/jama.270.13.1569	http://dx.doi.org/10.1001/jama.270.13.1569			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371467				2022-12-28	WOS:A1993LZ33400030
J	FANG, GD; KEYS, TF; GENTRY, LO; HARRIS, AA; RIVERA, N; GETZ, K; FUCHS, PC; GUSTAFSON, M; WONG, ES; GOETZ, A; WAGENER, MM; YU, VL				FANG, GD; KEYS, TF; GENTRY, LO; HARRIS, AA; RIVERA, N; GETZ, K; FUCHS, PC; GUSTAFSON, M; WONG, ES; GOETZ, A; WAGENER, MM; YU, VL			PROSTHETIC VALVE ENDOCARDITIS RESULTING FROM NOSOCOMIAL BACTEREMIA - A PROSPECTIVE, MULTICENTER STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						ENDOCARDITIS, BACTERIAL; CROSS INFECTION; PROSTHESIS-RELATED INFECTIONS; HEART VALVE PROSTHESIS; BACTEREMIA	HEART-VALVES; THERAPY; PROPHYLAXIS	Objective: To determine the incidence of endocarditis in bacteremic patients with prosthetic heart valves and the risk factors for and the effect of duration of antibiotic therapy on development of endocarditis in such patients. Design: Multicenter, prospective observational study. Setting: Six university teaching hospitals with high-volume cardiothoracic surgery. Participants: One hundred seventy-one consecutive patients with prosthetic heart valves who developed bacteremia during hospitalization. . Measurements and Main Results: Patients were evaluated when they were identified as having bacteremia and 1, 2, 6, and 12 months after its occurrence. Of 171 patients, 74 (43%) developed endocarditis: Fifty-six (33%) had prosthetic valve endocarditis at the time bacteremia was discovered (''endocarditis at outset''), whereas 18 (11%) developed endocarditis a mean of 45 days after bacteremia was discovered (''new endocarditis''). Mitral valve location and staphylococcal bacteremia (Staphylococcus aureus or S. epidermidis) were significantly associated with the development of ''new'' endocarditis. All 18 cases of new endocarditis were nosocomial, and in 6 of these cases (33%) bacteremia was acquired via intravascular devices. Twenty-one patients without evidence of endocarditis at the time of bacteremia received short-term antibiotic therapy (< 14 days); 1 patient (5%) developed endocarditis. Eleven of 70 patients (16%) who received long-term antibiotic therapy (> 14 days) developed endocarditis (P > 0.2). M Conclusions: Bacteremic patients with prosthetic heart valves were at notable risk for developing endocarditis, even when they received antibiotic therapy before endocarditis developed and regardless of the duration of such therapy. Intravascular devices were a common portal of entry.	UNIV PITTSBURGH, MED CTR, DIV INFECT DIS, MONTEFIORE BLDG W931, PITTSBURGH, PA 15213 USA; VET AFFAIRS MED CTR, PITTSBURGH, PA USA; CLEVELAND CLIN, DEPT INFECT DIS, CLEVELAND, OH 44106 USA; BAYLOR UNIV, HOUSTON, TX USA; RUSH PRESBYTERIAN ST LUKES MED CTR, HOSP EPIDEMIOL, CHICAGO, IL 60612 USA; ST VINCENT HOSP & MED CTR, PORTLAND, OR USA; HUNTER MCGUIRE VET AFFAIRS MED CTR, RICHMOND, VA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cleveland Clinic Foundation; Baylor University; Rush University; Saint Vincents Hospital Manhattan; Hunter Holmes McGuire Veterinary Affairs Medical Center								ALVAREZELCORO S, 1985, SOUTHERN MED J, V78, P1431, DOI 10.1097/00007611-198512000-00008; BROOKS RG, 1988, AM J MED, V84, P617, DOI 10.1016/0002-9343(88)90145-3; CALDERWOOD SB, 1986, J THORAC CARDIOV SUR, V92, P776; CALDERWOOD SB, 1985, CIRCULATION, V72, P31, DOI 10.1161/01.CIR.72.1.31; CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; DISMUKES WE, 1973, CIRCULATION, V48, P365, DOI 10.1161/01.CIR.48.2.365; FRIEDLAND G, 1984, INFECT CONT HOSP EP, V5, P284, DOI 10.1017/S0195941700060343; Heimberger T S, 1989, Infect Dis Clin North Am, V3, P221; HORSTKOTTE D, 1986, Z KARDIOL, V75, P8; INVERT TS, 1984, CIRCULATION, V69, P223; KARCHMER AW, 1989, INFECTIONS ASS INDWE; KORVICK JA, 1992, ANTIMICROB AGENTS CH, V36, P620, DOI 10.1128/AAC.36.3.620; LAZENBY D, 1991, INFECT MED, V8, P42; LAZENBY D, 1991, INFECT MED, V8, P15; ROCCHICCIOLI C, 1986, J THORAC CARDIOV SUR, V92, P784; ROSSITER SJ, 1978, J THORAC CARDIOV SUR, V76, P795; SANDE MA, 1972, NEW ENGL J MED, V286, P1067, DOI 10.1056/NEJM197205182862001; VONREYN CF, 1981, ANN INTERN MED, V94, P505, DOI 10.7326/0003-4819-94-4-505; WILSON WR, 1975, ANN INTERN MED, V82, P751, DOI 10.7326/0003-4819-82-6-751	19	124	127	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				560	567		10.7326/0003-4819-119-7_Part_1-199310010-00003	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363166				2022-12-28	WOS:A1993MA29100003
J	KARNI, A; SAGI, D				KARNI, A; SAGI, D			THE TIME-COURSE OF LEARNING A VISUAL SKILL	NATURE			English	Article							TEXTURE-DISCRIMINATION; CORTEX; ORIENTATION	SEVERAL examples of experience-dependent perceptual improvement (perceptual learning) suggest that plasticity in specific neuronal loci could underlie the learning process1-6. For a basic visual discrimination task (using an optimal stimulus for 'automatic' pre-attentive texture segregation7-10), discrete retinal input-dependent changes within a very early stage in the stream of visual processing were indicated as the locus of a large and consistent learning effect5. When do these changes occur? Here we report that except for a fast, rapidly saturating improvement early in the first practice session, performance was very stable within sessions. Indeed, observers showed little or no improvement until up to 8 hours after their last training session (latent phase). But large improvements occurred thereafter. Finally, there was almost no forgetting; what was gained was retained for at least 2-3 years. We conjecture that some types of perceptual experience trigger permanent neural changes in early processing stages of the adult visual system. These may take many hours to become functional.	WEIZMANN INST SCI,DEPT NEUROBIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Sagi, Dov/A-5454-2008	Sagi, Dov/0000-0002-8446-9230				BALL K, 1987, VISION RES, V27, P935; BEAR MF, 1990, J NEUROSCI, V10, P909; BECK J, 1982, ORG REPRESENTATION P, P285; BUISSERET P, 1978, NATURE, V272, P816, DOI 10.1038/272816a0; FIORENTINI A, 1981, VISION RES, V21, P1149, DOI 10.1016/0042-6989(81)90017-1; GURNSEY R, 1987, PERCEPT PSYCHOPHYS, V41, P239, DOI 10.3758/BF03208222; HORN G, 1990, J PHYSL, V423, P92; HUBEL DH, 1982, NATURE, V299, P515, DOI 10.1038/299515a0; JULESZ B, 1984, DYNAMIC ASPECTS NEOC, P585; KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966; KARNI A, 1992, NEUR ABSTR, V18, P387; MATTHIES H, 1989, PROG NEUROBIOL, V32, P277, DOI 10.1016/0301-0082(89)90024-5; MCGAUGH JL, 1966, SCIENCE, V153, P1351, DOI 10.1126/science.153.3742.1351; MCKEE SP, 1978, PERCEPT PSYCHOPHYS, V24, P258, DOI 10.3758/BF03206097; NOTHDURFT HC, 1985, VISION RES, V25, P551, DOI 10.1016/0042-6989(85)90159-2; POGGIO T, 1992, SCIENCE, V256, P1018, DOI 10.1126/science.1589770; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, 1993, INVEST OPHTH VIS SCI, V34, P776; RAMACHANDRAN VS, 1973, PERCEPTION, V2, P371, DOI 10.1068/p020371; SAGI D, 1985, SCIENCE, V228, P1217, DOI 10.1126/science.4001937; ULLMAN S, 1984, COGNITION, V18, P97, DOI 10.1016/0010-0277(84)90023-4; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	22	616	632	0	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					250	252		10.1038/365250a0	http://dx.doi.org/10.1038/365250a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LX471	8371779				2022-12-28	WOS:A1993LX47100053
J	ZARET, BL; WACKERS, FJ				ZARET, BL; WACKERS, FJ			MEDICAL PROGRESS - NUCLEAR CARDIOLOGY .2.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY-ARTERY DISEASE; POSITRON EMISSION TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; LEFT-VENTRICULAR FUNCTION; CONGESTIVE-HEART-FAILURE; IN-111 PLATELET SCINTIGRAPHY; PRESSURE-VOLUME RELATIONS; RADIONUCLIDE ANGIOGRAPHY; EJECTION FRACTION; ANTIMYOSIN ANTIBODY		YALE UNIV, SCH MED, DEPT DIAGNOST RADIOL, NUCL MED SECT, NEW HAVEN, CT 06510 USA	Yale University	ZARET, BL (corresponding author), YALE UNIV, SCH MED, DEPT INTERNAL MED, CARDIOVASC MED SECT, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.							ABRAHAM RD, 1987, AM J CARDIOL, V60, P225, DOI 10.1016/0002-9149(87)90218-9; AHNVE, 1987, AM J CARDIOL, V59, pA12; AHNVE S, 1986, AM J CARDIOL, V58, P872, DOI 10.1016/S0002-9149(86)80002-9; ARMBRECHT JJ, 1989, CIRCULATION, V80, P863, DOI 10.1161/01.CIR.80.4.863; BALLESTER M, 1990, CIRCULATION, V82, P2100, DOI 10.1161/01.CIR.82.6.2100; BASHORE TM, 1991, CARDIAC NUCLEAR MED, P195; BERGER HJ, 1984, FREEMAN JOHNSONS CLI, V1, P364; BERGMANN SR, 1989, J AM COLL CARDIOL, V14, P639, DOI 10.1016/0735-1097(89)90105-8; BERGMANN SR, 1991, CARDIAC NUCLEAR MED, P299; BHATTACHARYA S, 1991, AM HEART J, V122, P1583, DOI 10.1016/0002-8703(91)90274-L; BONOW RO, 1981, CIRCULATION, V64, P315, DOI 10.1161/01.CIR.64.2.315; BONOW RO, 1987, J AM COLL CARDIOL, V9, P1108, DOI 10.1016/S0735-1097(87)80315-7; BONOW RO, 1984, NEW ENGL J MED, V311, P1339, DOI 10.1056/NEJM198411223112103; BORGESNETO S, 1990, J NUCL MED, V31, P1128; BOROW KM, 1982, CIRCULATION, V65, P988, DOI 10.1161/01.CIR.65.5.988; BOUCHER CA, 1992, AM J CARDIOL, V69, P22, DOI 10.1016/0002-9149(92)90670-T; BRAAT SH, 1984, J AM COLL CARDIOL, V4, P940, DOI 10.1016/S0735-1097(84)80054-6; BRAUNWALD E, 1989, CIRCULATION, V79, P441, DOI 10.1161/01.CIR.79.2.441; BRENT BN, 1984, AM J CARDIOL, V53, P1349, DOI 10.1016/0002-9149(84)90092-4; BROADHURST P, 1991, J NUCL MED, V32, P37; Burg MM, 1993, J AM COLL CARDIOL, V22, P440, DOI 10.1016/0735-1097(93)90048-6; CALLAHAN RJ, 1982, J NUCL MED, V23, P315; CARRIO I, 1991, EUR J NUCL MED, V18, P806, DOI 10.1007/BF00175059; DAE MW, 1989, CIRCULATION, V79, P634, DOI 10.1161/01.CIR.79.3.634; DEC GW, 1990, J AM COLL CARDIOL, V16, P97, DOI 10.1016/0735-1097(90)90463-Y; DEMER LL, 1989, CIRCULATION, V79, P825, DOI 10.1161/01.CIR.79.4.825; DEUSSEN A, 1990, CIRCULATION, V82, P479; DEYANG L, 1991, J NUCL MED, V32, P796; EZEKOWITZ MD, 1982, NEW ENGL J MED, V306, P1509, DOI 10.1056/NEJM198206243062502; FIRTH BG, 1982, AM J CARDIOL, V50, P954, DOI 10.1016/0002-9149(82)90401-5; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FOUAD FM, 1984, J AM COLL CARDIOL, V3, P1500, DOI 10.1016/S0735-1097(84)80289-2; GROPLER RJ, 1992, J AM COLL CARDIOL, V20, P569, DOI 10.1016/0735-1097(92)90010-K; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; HANLEY PC, 1989, J AM COLL CARDIOL, V13, P624, DOI 10.1016/0735-1097(89)90603-7; HENDERSON EB, 1988, CIRCULATION, V78, P1192, DOI 10.1161/01.CIR.78.5.1192; HOCHREITER C, 1986, CIRCULATION, V73, P900, DOI 10.1161/01.CIR.73.5.900; HUNG J, 1984, AM J CARDIOL, V53, P1221, DOI 10.1016/0002-9149(84)90068-7; HUTCHINS GD, 1990, J AM COLL CARDIOL, V15, P1032, DOI 10.1016/0735-1097(90)90237-J; HUTCHINS GD, 1993, NUCLEAR CARDIOLOGY S, P305; ISKANDRIAN AS, 1986, AM HEART J, V112, P75, DOI 10.1016/0002-8703(86)90681-2; ISKANDRIAN AS, 1989, AM J CARDIOL, V64, P270, DOI 10.1016/0002-9149(89)90518-3; JOHNSON LL, 1990, CIRCULATION, V81, P37, DOI 10.1161/01.CIR.81.1.37; JONES RH, 1983, ANN SURG, V197, P743, DOI 10.1097/00000658-198306000-00014; KAYDEN DS, 1990, J AM COLL CARDIOL, V15, P1500, DOI 10.1016/0735-1097(90)92817-L; KAYDEN DS, 1991, CARDIAC NUCLEAR MED, P219; LAHIRI A, 1993, NUCLEAR CARDIOLOGY S, P331; LEE FA, 1985, IEEE COMPUT SOC, V8, P443; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KL, 1990, CIRCULATION, V82, P1705, DOI 10.1161/01.CIR.82.5.1705; LEVY WC, 1992, J NUCL MED, V33, P763; LINKS JM, 1982, CIRCULATION, V65, P82, DOI 10.1161/01.CIR.65.1.82; MAGORIEN DJ, 1983, CIRCULATION, V67, P844, DOI 10.1161/01.CIR.67.4.844; MARMOR A, 1989, J NUCL MED, V30, P1657; MARMOR A, IN PRESS J NUCL MED; MASSARDO, 1990, J NUCL MED, V31, P1449; MASSARDO T, 1990, J NUCL MED, V31, P450; MCGHIE AI, 1991, AM J CARDIOL, V67, P236, DOI 10.1016/0002-9149(91)90552-V; MEIZLISH JL, 1984, NEW ENGL J MED, V311, P1001, DOI 10.1056/NEJM198410183111601; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; OSTER ZH, 1985, P NATL ACAD SCI USA, V82, P3465, DOI 10.1073/pnas.82.10.3465; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; POPE CF, 1985, AM J CARDIOL, V55, P495, DOI 10.1016/0002-9149(85)90400-X; PRYOR DB, 1984, AM J CARDIOL, V53, P18, DOI 10.1016/0002-9149(84)90677-5; RABINOVITCH MA, 1987, CIRC RES, V61, P797, DOI 10.1161/01.RES.61.6.797; REDUTO LA, 1980, AM J CARDIOL, V45, P1013, DOI 10.1016/0002-9149(80)90170-8; REVENAUGH JR, 1991, CIRCULATION, V84, P424; RIBA AL, 1979, CIRCULATION, V60, P767, DOI 10.1161/01.CIR.60.4.767; RITCHIE JL, 1985, AM J CARDIOL, V55, P645, DOI 10.1016/0002-9149(85)90129-8; ROSAMOND TL, 1987, J NUCL MED, V28, P1322; SCHELBERT HR, 1988, CIRCULATION, V78, P496, DOI 10.1161/01.CIR.78.3.496; SCHELBERT HR, 1993, FRONTIERS IN CARDIOVASCULAR IMAGING, P53; SCHOFER J, 1988, J AM COLL CARDIOL, V12, P1252, DOI 10.1016/0735-1097(88)92608-3; SCHWAIGER M, 1990, CIRCULATION, V82, P457, DOI 10.1161/01.CIR.82.2.457; SCHWARTZ RG, 1987, AM J MED, V82, P1109, DOI 10.1016/0002-9343(87)90212-9; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; SETARO JF, 1992, AM J CARDIOL, V69, P1212, DOI 10.1016/0002-9149(92)90938-U; SOUFER R, 1985, AM J CARDIOL, V55, P1032, DOI 10.1016/0002-9149(85)90741-6; STRATTON JR, 1990, CIRCULATION, V81, P1182, DOI 10.1161/01.CIR.81.4.1182; TAMAKI N, 1989, AM J CARDIOL, V64, P860, DOI 10.1016/0002-9149(89)90832-1; TAMAKI N, 1988, J AM COLL CARDIOL, V12, P669, DOI 10.1016/S0735-1097(88)80054-8; TAMAKI N, 1987, AM J CARDIOL, V59, P1164, DOI 10.1016/0002-9149(87)90868-X; VONMOLL L, 1987, J NUCL MED, V28, P979; VORNE M, 1987, NUCL MED COMMUN, V8, P921, DOI 10.1097/00006231-198711000-00009; WALSH MN, 1988, CIRCULATION, V78, P612, DOI 10.1161/01.CIR.78.3.612; WEINER DA, 1987, AM J CARDIOL, V59, P725, DOI 10.1016/0002-9149(87)91081-2; ZARET B L, 1991, Journal of the American College of Cardiology, V17, p214A; ZARET BL, 1971, NEW ENGL J MED, V284, P1165, DOI 10.1056/NEJM197105272842101; ZARET BL, 1990, SILENT MYOCARDIAL IS, V37, P105; ZARET BL, 1991, CARDIAC NUCLEAR MED, P183	90	70	70	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					855	863		10.1056/NEJM199309163291208	http://dx.doi.org/10.1056/NEJM199309163291208			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355745				2022-12-28	WOS:A1993LW55100008
J	WALLACE, RJ; TANNER, D; BRENNAN, PJ; BROWN, BA				WALLACE, RJ; TANNER, D; BRENNAN, PJ; BROWN, BA			CLINICAL-TRIAL OF CLARITHROMYCIN FOR CUTANEOUS (DISSEMINATED) INFECTION DUE TO MYCOBACTERIUM-CHELONAE	ANNALS OF INTERNAL MEDICINE			English	Article						CLARITHROMYCIN; MYCOBACTERIUM-CHELONAE MYCOBACTERIUM INFECTIONS, ATYPICAL; PREDNISONE; CYCLOPHOSPHAMIDE	RAPIDLY GROWING MYCOBACTERIA; FORTUITUM; COMPLEX; SUSCEPTIBILITY; IDENTIFICATION; CIPROFLOXACIN; RESISTANCE; SUBGROUPS; PATTERNS; THERAPY	Objective: To determine if clarithromycin monotherapy is safe and effective in treating cutaneous disease (especially disseminated disease) due to Mycobacterium chelonae (formerly M. chelonae subspecies chelonae). Design: An open, noncomparative trial of clarithromycin as single-drug therapy. Setting: Nationwide referrals. Patients: Culture-positive patients whose M. chelonae came from a cutaneous source and whose isolate was submitted to a single referral laboratory for susceptibility testing. Intervention: Clarithromycin, 500 mg twice a day by mouth for 6 months. No attempt was made to alter use of immunosuppressive drugs. Main Outcome Measures: Acid-fast bacilli smears and cultures of skin lesions during and after treatment, with monitoring of clinical response, side effects, and development of new lesions. Results: Fourteen patients (10 with disseminated disease) were enrolled in the study and completed at least 3 months of therapy. Underlying diseases included rheumatoid arthritis, other autoimmune disorders, and organ transplantation. All were taking corticosteroids (93%) or cyclophosphamide (7%). All patients had an excellent response to therapy, with only mild side effects from the drug. Two patients died of other diseases after improving clinically but while still taking medication. One noncompliant patient who prematurely discontinued therapy after 3.5 months relapsed 1 month later with an isolate resistant to clarithromycin. The remaining 11 patients have all completed therapy given for a mean of 6.8 months (range, 4.5 to 9 months). Therapy has been discontinued for 9 of the 11 patients for at least 6 months (mean, 7.1 months; range, 6 to 12 months), with no evidence of relapse. No remaining patient had positive acid-fast bacilli smears or cultures of skin lesions after 1 month of therapy. Conclusions: Clarithromycin may be the drug of choice for cutaneous (disseminated) disease due to M. chelonae, although more patients with long-term clinical follow-up need to be studied.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; HOSP UNIV PENN, PHILADELPHIA, PA 19104 USA	Duke University; University of Pennsylvania; Pennsylvania Medicine	WALLACE, RJ (corresponding author), UNIV TEXAS, CTR HLTH, DEPT MICROBIOL, POB 2003, TYLER, TX 75710 USA.							ARROYO J, 1977, ANTIMICROB AGENTS CH, V11, P763, DOI 10.1128/AAC.11.4.763; BROWN BA, 1992, ANTIMICROB AGENTS CH, V36, P180, DOI 10.1128/AAC.36.1.180; BUTLER WR, 1990, J CLIN MICROBIOL, V28, P2094, DOI 10.1128/JCM.28.9.2094-2098.1990; COOPER JF, 1989, AM J MED, V86, P173, DOI 10.1016/0002-9343(89)90264-7; GRIFFITH DE, 1993, AM REV RESPIR DIS, V147, P1271, DOI 10.1164/ajrccm/147.5.1271; GUTKNECHT DR, 1990, J AM ACAD DERMATOL, V23, P1179, DOI 10.1016/S0190-9622(08)80927-9; JACKSON PG, 1981, TUBERCLE, V62, P277, DOI 10.1016/S0041-3879(81)80008-6; KUSUNOKI S, 1992, INT J SYST BACTERIOL, V42, P240, DOI 10.1099/00207713-42-2-240; LEVYFREBAULT X, 1986, INT J SYST BACTERIOL, V36, P458; MERLIN TL, 1989, AM J CLIN PATHOL, V91, P717, DOI 10.1093/ajcp/91.6.717; SILCOX VA, 1981, J CLIN MICROBIOL, V14, P686, DOI 10.1128/JCM.14.6.686-691.1981; SWENSON JM, 1985, ANTIMICROB AGENTS CH, V28, P807, DOI 10.1128/AAC.28.6.807; SWENSON JM, 1982, ANTIMICROB AGENTS CH, V22, P186, DOI 10.1128/AAC.22.2.186; WALLACE RJ, 1983, REV INFECT DIS, V5, P657; WALLACE RJ, 1992, J INFECT DIS, V166, P405, DOI 10.1093/infdis/166.2.405; WALLACE RJ, 1990, ANTIMICROB AGENTS CH, V34, P65, DOI 10.1128/AAC.34.1.65; WALLACE RJ, 1989, J INFECT DIS, V160, P281, DOI 10.1093/infdis/160.2.281; WALLACE RJ, 1989, J INFECT DIS, V159, P708, DOI 10.1093/infdis/159.4.708; WALLACE RJ, 1991, J INFECT DIS, V163, P598, DOI 10.1093/infdis/163.3.598; WALLACE RJ, 1991, ANTIMICROB AGENTS CH, V35, P773, DOI 10.1128/AAC.35.4.773; YOUNG LS, 1991, LANCET, V338, P1107, DOI 10.1016/0140-6736(91)91965-W; 1991, M7A2 NAT COMM CLIN L	22	188	191	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					482	486		10.7326/0003-4819-119-6-199309150-00006	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357113				2022-12-28	WOS:A1993LZ27500006
J	LAMANTIA, ML; LENNARZ, WJ				LAMANTIA, ML; LENNARZ, WJ			THE ESSENTIAL FUNCTION OF YEAST PROTEIN DISULFIDE-ISOMERASE DOES NOT RESIDE IN ITS ISOMERASE ACTIVITY	CELL			English	Article							ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; BOND FORMATION; GENE; GLUTATHIONE; CELL; PURIFICATION; PROCOLLAGEN	Protein disulfide isomerase (PDI) is believed to function in vivo by catalyzing the isomerization of disulfide bonds in proteins and thereby facilitating their folding. In S. cerevisiae PDI is encoded by an essential gene. Deletion of nearly one-third of the C-terminal residues of PDI altered PDI's cellular localization but not cell viability. Further deletions resulted in lethality, but these truncated proteins still exhibited PDI activity in vitro. Cells carrying a variant PDI in which both -CGHC-active sites were disrupted were viable. However, these cells exhibited a delay in the disulfide bond formation and transport of carboxypeptidase Y. In vitro enzyme assays revealed that disruption of both sites abolished catalytic activity. These results indicate that PDI catalyzes disulfide bond formation both in vivo and in vitro and that the integrity of the active sites is required for catalysis. However, this catalytic activity is not essential for yeast viability.	SUNY, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College					NIGMS NIH HHS [GM33184, GM33185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184, R37GM033185, R01GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1974, J MOL BIOL, V87, P563, DOI 10.1016/0022-2836(74)90104-1; EDMAN JC, 1985, NATURE, V317, P267, DOI 10.1038/317267a0; FARQUHAR R, 1991, GENE, V108, P81, DOI 10.1016/0378-1119(91)90490-3; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; GEARING DP, 1989, BIO-TECHNOL, V7, P1157; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIVOL D, 1965, P NATL ACAD SCI USA, V53, P676, DOI 10.1073/pnas.53.3.676; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; GUNTHER R, 1993, J BIOL CHEM, V268, P7728; GUNTHER R, 1991, J BIOL CHEM, V266, P24557; Gurd F R, 1972, Methods Enzymol, V25, P424, DOI 10.1016/S0076-6879(72)25038-8; HARDWICK KG, 1990, EMBO J, V9, P623, DOI 10.1002/j.1460-2075.1990.tb08154.x; HAWKINS HC, 1991, BIOCHEM J, V275, P335, DOI 10.1042/bj2750335; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KOIVU J, 1987, J BIOL CHEM, V262, P6159; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LAMBERT N, 1984, BIOCHEM SOC T, V12, P1024; LU XJ, 1992, BIOCHEMISTRY-US, V31, P4205, DOI 10.1021/bi00132a008; MIZUNAGA T, 1990, J BIOCHEM, V108, P846, DOI 10.1093/oxfordjournals.jbchem.a123291; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1991, J BIOL CHEM, V266, P19645; NOIVA R, 1993, IN PRESS J BIOL CHEM, V268; PERSSON R, 1991, J CELL BIOL, V112, P257, DOI 10.1083/jcb.112.2.257; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; ROTH RA, 1987, BIOCHEMISTRY-US, V26, P4179, DOI 10.1021/bi00388a001; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SCHERENS B, 1991, YEAST, V7, P185, DOI 10.1002/yea.320070212; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TACHIKAWA H, 1991, J BIOCHEM, V110, P306, DOI 10.1093/oxfordjournals.jbchem.a123576; VUORI K, 1992, J BIOL CHEM, V267, P7211; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; WICKERHAM LJ, 1946, J BACTERIOL, V142, P414	50	194	204	0	0	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					899	908		10.1016/0092-8674(93)90469-7	http://dx.doi.org/10.1016/0092-8674(93)90469-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374956				2022-12-28	WOS:A1993LX29200015
J	ZARET, BL; WACKERS, FJ				ZARET, BL; WACKERS, FJ			MEDICAL PROGRESS - NUCLEAR CARDIOLOGY .1.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; EXERCISE TL-201 SCINTIGRAPHY; CHEST PAIN; VASCULAR-SURGERY; PROGNOSTIC VALUE; NONINVASIVE ASSESSMENT; ANGINA-PECTORIS; LEFT MAIN; THALLIUM SCINTIGRAPHY		YALE UNIV,SCH MED,DEPT DIAGNOST RADIOL,NUCL MED SECT,NEW HAVEN,CT 06510	Yale University	ZARET, BL (corresponding author), YALE UNIV,SCH MED,DEPT INTERNAL MED,CARDIOVASC MED SECT,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							ABRAHAM RD, 1986, AM J CARDIOL, V58, P423, DOI 10.1016/0002-9149(86)90008-1; ALBRO PC, 1978, AM J CARDIOL, V42, P751, DOI 10.1016/0002-9149(78)90094-2; BAIREY CN, 1989, AM J CARDIOL, V64, P282, DOI 10.1016/0002-9149(89)90520-1; BEANLANDS R, 1992, J AM COLL CARDIOL, V20, P712, DOI 10.1016/0735-1097(92)90029-M; BELLER GA, 1979, CARDIOVASCULAR NUCLE, P225; BERGER BC, 1979, CIRCULATION, V60, P1114, DOI 10.1161/01.CIR.60.5.1114; BERGER HJ, 1981, NEW ENGL J MED, V305, P799, DOI 10.1056/NEJM198110013051405; BERGER HJ, 1981, NEW ENGL J MED, V305, P855, DOI 10.1056/NEJM198110083051504; BONOW RO, 1991, CIRCULATION, V83, P26, DOI 10.1161/01.CIR.83.1.26; BOUCHER CA, 1980, AM J CARDIOL, V46, P189, DOI 10.1016/0002-9149(80)90057-0; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BROWN KA, 1987, AM J CARDIOL, V60, P15, DOI 10.1016/0002-9149(87)90975-1; BROWN KA, 1983, J AM COLL CARDIOL, V1, P994, DOI 10.1016/S0735-1097(83)80100-4; CHRISTIAN TF, 1991, J AM COLL CARDIOL, V17, P1303, DOI 10.1016/S0735-1097(10)80140-8; CHRISTIAN TF, 1990, J AM COLL CARDIOL, V16, P1632, DOI 10.1016/0735-1097(90)90313-E; CHRISTIAN TF, 1992, AM J CARDIOL, V70, P14, DOI 10.1016/0002-9149(92)91382-E; CHRISTIAN TF, 1992, CIRCULATION, V86, P81, DOI 10.1161/01.CIR.86.1.81; CLONINGER KG, 1988, J AM COLL CARDIOL, V12, P955, DOI 10.1016/0735-1097(88)90461-5; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; EAGLE KA, 1987, JAMA-J AM MED ASSOC, V257, P2185, DOI 10.1001/jama.257.16.2185; EISNER RL, 1988, J NUCL MED, V29, P1901; FINTEL DJ, 1989, J AM COLL CARDIOL, V13, P600, DOI 10.1016/0735-1097(89)90600-1; GARCIA E, 1981, J NUCL MED, V22, P309; GIBBONS RJ, 1989, CIRCULATION, V80, P1277, DOI 10.1161/01.CIR.80.5.1277; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; GIBSON RS, 1983, J AM COLL CARDIOL, V1, P804, DOI 10.1016/S0735-1097(83)80194-6; GILL JB, 1987, NEW ENGL J MED, V317, P1485, DOI 10.1056/NEJM198712103172401; GOULD KL, 1978, AM J CARDIOL, V41, P267, DOI 10.1016/0002-9149(78)90165-0; GREGOIRE J, 1990, AM J CARDIOL, V66, pE42, DOI 10.1016/0002-9149(90)90611-4; HARDOFF R, 1990, J AM COLL CARDIOL, V15, P1486, DOI 10.1016/0735-1097(90)92815-J; HECHT HS, 1991, J AM COLL CARDIOL, V17, P670, DOI 10.1016/S0735-1097(10)80183-4; HECHT HS, 1990, AM J CARDIOL, V66, P1314, DOI 10.1016/0002-9149(90)91160-8; HENDEL RC, 1992, AM J CARDIOL, V70, P1243, DOI 10.1016/0002-9149(92)90756-O; HEO JY, 1992, J NUCL MED, V33, P186; JAIN A, 1988, J AM COLL CARDIOL, V11, P970, DOI 10.1016/S0735-1097(98)90053-5; JAIN D, 1992, Journal of Nuclear Medicine, V33, P874; KAUL S, 1988, J AM COLL CARDIOL, V12, P25, DOI 10.1016/0735-1097(88)90351-8; KAUL S, 1986, J AM COLL CARDIOL, V7, P527, DOI 10.1016/S0735-1097(86)80462-4; KAYDEN DS, 1991, J AM COLL CARDIOL, V18, P1480, DOI 10.1016/0735-1097(91)90678-3; KAYDEN DS, 1991, J AM COLL CARDIOL, V19, P1121; KIAT H, 1988, J AM COLL CARDIOL, V12, P1456, DOI 10.1016/S0735-1097(88)80009-3; KIAT H, 1989, AM HEART J, V117, P1, DOI 10.1016/0002-8703(89)90649-2; KLEIN JL, 1993, J NUCL MED, V31, P1240; KLOCKE FJ, 1993, NUCL CARDIOLOGY STAT, P149; KONG BA, 1992, AM J CARDIOL, V70, P168, DOI 10.1016/0002-9149(92)91270-E; LADENHEIM ML, 1986, J AM COLL CARDIOL, V7, P464, DOI 10.1016/S0735-1097(86)80454-5; LEVINSON JR, 1990, AM J CARDIOL, V66, P406, DOI 10.1016/0002-9149(90)90694-V; MADDAHI J, 1989, J AM COLL CARDIOL, V14, P1689, DOI 10.1016/0735-1097(89)90017-X; MADDAHI J, 1986, J AM COLL CARDIOL, V7, P53, DOI 10.1016/S0735-1097(86)80259-5; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; MANYARI DE, 1988, CIRCULATION, V77, P86, DOI 10.1161/01.CIR.77.1.86; MATZER L, 1992, Journal of the American College of Cardiology, V19, p127A; MILLER DD, 1987, J AM COLL CARDIOL, V10, P275; NISHIMURA S, 1992, J AM COLL CARDIOL, V20, P265, DOI 10.1016/0735-1097(92)90090-A; NISHIMURA S, 1992, J NUCL MED, V33, P1600; NYGAARD TW, 1984, AM J CARDIOL, V53, P462, DOI 10.1016/0002-9149(84)90013-4; PAMELIA FX, 1985, AM J CARDIOL, V55, P920, DOI 10.1016/0002-9149(85)90718-0; PARODI O, 1991, J AM COLL CARDIOL, V18, P1439, DOI 10.1016/0735-1097(91)90672-V; PENNELL DJ, 1991, J AM COLL CARDIOL, V18, P1471, DOI 10.1016/0735-1097(91)90677-2; PIWNICAWORMS D, 1990, J NUCL MED, V31, P464; REHN T, 1981, AM J CARDIOL, V48, P217, DOI 10.1016/0002-9149(81)90599-3; REISMAN S, 1986, J NUCL MED, V27, P1273; ROZANSKI A, 1983, NEW ENGL J MED, V309, P518, DOI 10.1056/NEJM198309013090902; SELDIN DW, 1989, J NUCL MED, V30, P312; SHAW L, 1992, J AM COLL CARDIOL, V19, P1390, DOI 10.1016/0735-1097(92)90592-B; SIGAL SL, 1991, J NUCL MED, V32, P759; SINUSAS AJ, 1992, CIRCULATION, V86, P505; SOCHOR H, 1984, EUR HEART J, V5, P500, DOI 10.1093/oxfordjournals.eurheartj.a061697; STANILOFF HM, 1986, J NUCL MED, V27, P1842; STRAUSS HW, 1975, CIRCULATION, V51, P641, DOI 10.1161/01.CIR.51.4.641; SUTTON JM, 1991, CIRCULATION, V83, P1278, DOI 10.1161/01.CIR.83.4.1278; TAILLEFER R, 1991, J NUCL MED, V32, P1961; TILKEMEIER PL, 1990, AM J CARDIOL, V66, P1203, DOI 10.1016/0002-9149(90)91100-K; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; VARETTO T, 1992, Journal of the American College of Cardiology, V19, p268A; WACKERS F J T, 1992, American Journal of Cardiac Imaging, V6, P42; WACKERS F J T, 1992, Journal of the American College of Cardiology, V19, p22A; WACKERS FJT, 1976, NEW ENGL J MED, V295, P1, DOI 10.1056/NEJM197607012950101; WACKERS FJT, 1989, J AM COLL CARDIOL, V14, P861, DOI 10.1016/0735-1097(89)90456-7; WACKERS FJT, 1985, SEMIN NUCL MED, V15, P46, DOI 10.1016/S0001-2998(85)80043-X; WACKERS FJT, 1978, CIRCULATION, V57, P738, DOI 10.1161/01.CIR.57.4.738; WACKERS FJT, 1977, CIRCULATION, V56, P72, DOI 10.1161/01.CIR.56.1.72; WACKERS FJT, 1985, J AM COLL CARDIOL, V6, P27, DOI 10.1016/S0735-1097(85)80247-3; WACKERS FJT, 1979, BRIT HEART J, V41, P111; WACKERS FJT, 1989, J NUCL MED, V30, P301; WACKERS FJT, 1988, DIAGNOSTIC NUCLEAR M, V1, P291; WAHL JM, 1985, ARCH INTERN MED, V145, P253, DOI 10.1001/archinte.145.2.253; WATSON DD, 1981, J NUCL MED, V22, P577; WEISS AT, 1987, J AM COLL CARDIOL, V9, P752; WEISS AT, 1986, J AM COLL CARDIOL, V7, P61, DOI 10.1016/S0735-1097(86)80260-1; ZARET BL, 1992, HEART DIS TXB CARDIO, V1, P276; ZIJLSTRA F, 1988, AM J CARDIOL, V61, P55, DOI 10.1016/0002-9149(88)91304-5	93	116	117	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					775	783		10.1056/NEJM199309093291107	http://dx.doi.org/10.1056/NEJM199309093291107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350888				2022-12-28	WOS:A1993LV64200007
J	KNAUS, WA; HARRELL, FE; FISHER, CJ; WAGNER, DP; OPAL, SM; SADOFF, JC; DRAPER, EA; WALAWANDER, CA; CONBOY, K; GRASELA, TH				KNAUS, WA; HARRELL, FE; FISHER, CJ; WAGNER, DP; OPAL, SM; SADOFF, JC; DRAPER, EA; WALAWANDER, CA; CONBOY, K; GRASELA, TH			THE CLINICAL-EVALUATION OF NEW DRUGS FOR SEPSIS - A PROSPECTIVE-STUDY DESIGN BASED ON SURVIVAL ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ILL HOSPITALIZED ADULTS; ORGAN-SYSTEM FAILURE; GRAM-NEGATIVE SEPSIS; REGRESSION-MODELS; SEPTIC SHOCK; PROPORTIONAL HAZARDS; MONOCLONAL-ANTIBODY; MORTALITY; TRIAL; DEFINITIONS	Objective.- To develop a survival model and severity assessment method to estimate the 28-day mortality risk for patients with sepsis syndrome entering phase 2 and 3 drug evaluations. Design.- Retrospective analysis of intensive care unit admissions with sepsis syndrome by means of log-normal regression to identify risk factors for 28-day mortality. Prospective application of the model to patients with gram-negative infection meeting sepsis syndrome criteria from separate data collection (validation group). Patients.- A total of 58 737 intensive care unit admissions at 107 hospitals in the United States and Western Europe screened to yield 1195 patients meeting entry criteria for the sepsis syndrome study for the original model; 295 hospitalized patients with gram-negative infection meeting criteria for sepsis syndrome for validation. Main Outcome Measures.- Survival time and mortality at 28 days after fulfillment of the sepsis syndrome criteria. Results.- Acute physiologic abnormalities were the most important prognostic factors influencing outcome (82% of total chi2). Specific disease resulting in intensive care unit admission and the time the patient was in the hospital and intensive care unit before qualification were also independent risks, as were age and a clinical history of cirrhosis. The model's overall classification accuracy was a Somers' Dyx of .52 (rank correlation between predicted risk and 28-day mortality) (receiver operating characteristic area, 0.76), with equal accuracy (Dyx=.59; receiver operating characteristic area, 0.80) in the independent group of patients. Conclusions.- We created an accurate independent estimate for 28-day mortality risk for patients with sepsis syndrome (severe sepsis). This estimate could improve the evaluation of new drugs by investigating whether the drug's benefit varies by patient risk and then determining the amount of benefit for individual patients.	DUKE UNIV, MED CTR, DIV BIOMETRY, DURHAM, NC 27710 USA; CLEVELAND CLIN EDUC FDN, CRIT CARE RES UNIT, CLEVELAND, OH 44106 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA; WALTER REED ARMY INST RES, WASHINGTON, DC 20307 USA; APACHE MED SYST INC, WASHINGTON, DC USA; SUNY Buffalo, CTR PHARMACOEPIDEMIOL RES, BUFFALO, NY 14260 USA	Duke University; Cleveland Clinic Foundation; Brown University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	KNAUS, WA (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, ICU, RES UNIT, 2300 K ST NW, WASHINGTON, DC 20037 USA.		Knaus, William/AAX-2138-2020		AHRQ HHS [HSO 7137] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AUSTRIAN R, 1964, ANN INTERN MED, V60, P759, DOI 10.7326/0003-4819-60-5-759; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BONE RC, 1992, JAMA-J AM MED ASSOC, V268, P3452, DOI 10.1001/jama.268.24.3452; BONE RC, 1991, JAMA-J AM MED ASSOC, V266, P1686, DOI 10.1001/jama.266.12.1686; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CLEMMER TP, 1992, CRIT CARE MED, V20, P1395, DOI 10.1097/00003246-199210000-00006; COX DR, 1972, J R STAT SOC B, V34, P187; DAMIANO AM, 1992, J CLIN EPIDEMIOL, V45, P93, DOI 10.1016/0895-4356(92)90001-4; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Goodman LA, 1979, MEASURES ASS CROSS C; GORE SM, 1984, APPL STAT-J ROY ST C, V33, P176; GRASELA TH, 1987, DRUG INTEL CLIN PHAR, V21, P902, DOI 10.1177/106002808702101112; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; HULSEBOS RG, 1992, 6TH EUR C INT CAR ME; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KNAUS WA, 1992, CHEST, V101, P1656, DOI 10.1378/chest.101.6.1656; KNAUS WA, 1992, S COMPUTER APPLICATI, P987; LAWLESS JF, 1982, STATISTICAL MODELS M; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Meinert CL., 1986, CLIN TRIALS DESIGN C; PARILLO JE, 1989, TXB CRITICAL CARE ME, P111; PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006; SCHEDEL I, 1991, CRIT CARE MED, V19, P1104, DOI 10.1097/00003246-199109000-00003; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SCHULMAN KA, 1991, JAMA-J AM MED ASSOC, V266, P3466, DOI 10.1001/jama.266.24.3466; SIRIO CA, 1993, CLIN RES, V14, pA152; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; WARRE HS, 1992, NEW ENGL J MED, V236, P1153; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	36	158	160	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1233	1241		10.1001/jama.270.10.1233	http://dx.doi.org/10.1001/jama.270.10.1233			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355388				2022-12-28	WOS:A1993LV64900031
J	WACHTEL, TJ; STEIN, MD				WACHTEL, TJ; STEIN, MD			FEE-FOR-TIME SYSTEM - A CONCEPTUAL-FRAMEWORK FOR AN INCENTIVE-NEUTRAL METHOD OF PHYSICIAN-PAYMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RELATIVE-VALUE SCALE; FINANCIAL INCENTIVES; CARE; MEDICINE; SPECIALTIES; OBJECTIONS; MALONEY; REFORM; RBRVS		RHODE ISL HOSP, DIV GERIATR, 593 EDDY ST, PROVIDENCE, RI 02903 USA; BROWN UNIV, DEPT COMMUNITY HLTH, PROVIDENCE, RI 02912 USA; BROWN UNIV, DEPT MED, PROVIDENCE, RI 02912 USA; RHODE ISL HOSP, DIV GEN INTERNAL MED, PROVIDENCE, RI 02902 USA	Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital								BOCK RS, 1983, NEW ENGL J MED, V319, P785; BRAHAM RL, 1990, J GEN INTERN MED, V5, P95, DOI 10.1007/BF02600506; DELOZIER JE, 1991, VITAL HLTH STAT, V203, P7; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; GERETY MB, 1992, J AM GERIATR SOC, V40, P1272, DOI 10.1111/j.1532-5415.1992.tb03655.x; GINZBERG E, 1992, NEW ENGL J MED, V327, P1310, DOI 10.1056/NEJM199210293271812; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; HADLEY J, 1986, MED PHYSICIAN PAYMEN, P29; HADLEY J, 1986, MED PHYSICIAN PAYMEN, P47; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HILLMAN AL, 1987, NEW ENGL J MED, V317, P1743, DOI 10.1056/NEJM198712313172725; HILLMAN AL, 1990, ANN INTERN MED, V112, P891, DOI 10.7326/0003-4819-112-12-891; HSIAO W, 1992, JAMA-J AM MED ASSOC, V267, P1822, DOI 10.1001/jama.267.13.1822; HSIAO WC, 1988, NEW ENGL J MED, V319, P881, DOI 10.1056/NEJM198809293191330; HSIAO WC, 1988, NEW ENGL J MED, V319, P835, DOI 10.1056/NEJM198809293191305; HSIAO WC, 1987, JAMA-J AM MED ASSOC, V258, P799, DOI 10.1001/jama.258.6.799; IGLEHART JK, 1990, NEW ENGL J MED, V322, P1247, DOI 10.1056/NEJM199004263221728; IGLEHART JK, 1991, NEW ENGL J MED, V325, P1820, DOI 10.1056/NEJM199112193252523; JENCKS SF, 1985, NEW ENGL J MED, V312, P1492, DOI 10.1056/NEJM198506063122306; KASSIRER JP, 1993, NEW ENGL J MED, V328, P1268, DOI 10.1056/NEJM199304293281710; KIMMELSTEIN DU, 1986, NEW ENGL J MED, V314, P441; LEAF A, 1984, NEW ENGL J MED, V310, P718, DOI 10.1056/NEJM198403153101111; LEVINSKY NG, 1993, NEW ENGL J MED, V328, P656, DOI 10.1056/NEJM199303043280913; MALONEY JV, 1992, JAMA-J AM MED ASSOC, V268, P3363, DOI 10.1001/jama.268.23.3363; MALONEY JV, 1992, JAMA-J AM MED ASSOC, V267, P2896; MALONEY JV, 1991, JAMA-J AM MED ASSOC, V266, P3453; MECHANIC D, 1985, NEW ENGL J MED, V312, P181, DOI 10.1056/NEJM198501173120312; MENDENHALL RC, 1978, JAMA-J AM MED ASSOC, V240, P1160, DOI 10.1001/jama.240.11.1160; Pauly MV, 1980, DOCTORS THEIR WORKSH, P57; RADECKI SE, 1992, JAMA-J AM MED ASSOC, V267, P1824, DOI 10.1001/jama.267.13.1824; REAGAN MD, 1987, NEW ENGL J MED, V317, P1729; RELMAN AS, 1992, NEW ENGL J MED, V327, P1522, DOI 10.1056/NEJM199211193272112; RELMAN AS, 1987, NEW ENGL J MED, V316, P1150, DOI 10.1056/NEJM198704303161810; ROE BB, 1982, NEW ENGL J MED, V307, P551, DOI 10.1056/NEJM198208263070910; ROPER WL, 1988, NEW ENGL J MED, V319, P865, DOI 10.1056/NEJM198809293191311; SCHWARTZ H, 1978, NEW ENGL J MED, V299, P1071, DOI 10.1056/NEJM197811092991913; SCOVERN H, 1988, NEW ENGL J MED, V319, P787, DOI 10.1056/NEJM198809223191211; Somers A R, 1977, Inquiry, V14, P115; SOMERS AR, 1984, NEW ENGL J MED, V311, P853, DOI 10.1056/NEJM198409273111312; STARR P, 1992, LOGIC HLTH CARE REFO, P65; 1987, ANN INTERN MED, V106, P151	43	7	7	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1226	1229		10.1001/jama.270.10.1226	http://dx.doi.org/10.1001/jama.270.10.1226			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355386				2022-12-28	WOS:A1993LV64900029
J	MOMBAERTS, P; ARNOLDI, J; RUSS, F; TONEGAWA, S; KAUFMANN, SHE				MOMBAERTS, P; ARNOLDI, J; RUSS, F; TONEGAWA, S; KAUFMANN, SHE			DIFFERENT ROLES OF ALPHA-BETA AND GAMMA-DELTA T-CELLS IN IMMUNITY AGAINST AN INTRACELLULAR BACTERIAL PATHOGEN	NATURE			English	Article							DELAYED-TYPE HYPERSENSITIVITY; LISTERIA-MONOCYTOGENES; MEDIATED-IMMUNITY; INFECTION; MICE; PROTECTION; INTERFERON; LYMPHOCYTES; EXPRESSION; RESOLUTION	SEVERAL bacterial pathogens of medical importance are able to persist and replicate inside host mononuclear phagocytes. Protective immunity depends on specific T lymphocytes that induce granulomatous lesions at the sites of bacterial multiplication1,2. Listeria monocytogenes is an intracellular pathogen that replicates inside mononuclear phagocytes and hepatocytes of mice1-4. Invasion from the phagosomal compartment into the cytoplasmic compartment is the principal mechanism of intracellular survival5. Early in infection, resistance against L. monocytogenes is mediated by polymorphonuclear phagocytes which destroy infected liver cells, followed by natural killer cells which activate macrophages by means of interferon-gamma (refs 6, 7). A specific immune response by T cells then develops which leads to sterile eradication of the microbes1,2,8. T cells are also responsible for the highly effective protection in vaccinated mice against secondary infections1,2. Although the role of alphabeta T cells has been demonstrated in these immune responses, that of gammadelta T cells is unclear2,9,10. Here we use mice that selectively lack either alphabeta or gammadelta T cells as a result of targeted germ-line mutations in their T-cell receptor genes11,12 to investigate the relative roles of these T-cell populations during experimental infection with L. monocytogenes. We find that in primary listeriosis, either alphabeta or gammadelta T cells are sufficient for early protection. Resistance to secondary infection is mediated mainly by alphabeta T cells but also involves gammadelta T cells. Thus alphabeta T-cell-deficient mice can be rendered partially resistant by vaccination, and gammadelta T cells are shown to be responsible for this protective effect. In infected gammadelta T-cell-deficient mice we noticed the appearance of unusual liver lesions, indicating that gammadelta T cells have a unique regulatory role in this bacterial infection.	UNIV ULM,DEPT IMMUNOL,ALBERT EINSTEIN ALLEE 11,D-89070 ULM,GERMANY; MIT,DEPT BIOL,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Ulm University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)			Kaufmann, Stefan HE/I-5454-2014	Kaufmann, Stefan HE/0000-0001-9866-8268				BALDRIDGE JR, 1990, INFECT IMMUN, V58, P654, DOI 10.1128/IAI.58.3.654-658.1990; BANCROFT GJ, 1991, IMMUNOL REV, V124, P5, DOI 10.1111/j.1600-065X.1991.tb00613.x; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CONLAN JW, 1991, J EXP MED, V174, P741, DOI 10.1084/jem.174.3.741; DUNN PL, 1991, J INFECT DIS, V164, P869, DOI 10.1093/infdis/164.5.869; EMMERLING P, 1974, J INFECT IMMUN, V12, P437; EMMERLING P, 1974, INFECT IMMUN, V12, P437; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GREGORY SH, 1993, J IMMUNOL, V150, P2901; HAAS W, 1993, REV IMMUNOL, V11, P637; HAHN H, 1981, REV INFECT DIS, V3, P1221; HARTY JT, 1992, P NATL ACAD SCI USA, V89, P11612, DOI 10.1073/pnas.89.23.11612; HIROMATSU K, 1992, J EXP MED, V175, P49, DOI 10.1084/jem.175.1.49; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KAUFMANN SHE, 1986, MICROB PATHOGENESIS, V1, P249, DOI 10.1016/0882-4010(86)90049-5; KAUFMANN SHE, 1982, J EXP MED, V155, P1754, DOI 10.1084/jem.155.6.1754; KAUFMANN SHE, 1985, INFECT IMMUN, V48, P263, DOI 10.1128/IAI.48.1.263-266.1985; KAUFMANN SHE, 1993, REV IMMUNOL, V11, P129; KIDERLEN AF, 1984, EUR J IMMUNOL, V14, P964, DOI 10.1002/eji.1830141019; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NORTH RJ, 1970, J EXP MED, V132, P521, DOI 10.1084/jem.132.3.521; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; ROBERTS AD, 1993, INFECT IMMUN, V61, P1113, DOI 10.1128/IAI.61.3.1113-1116.1993; SINGH IG, 1992, INFECT IMMUN, V60, P257, DOI 10.1128/IAI.60.1.257-263.1992	25	410	410	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					53	56		10.1038/365053a0	http://dx.doi.org/10.1038/365053a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361537				2022-12-28	WOS:A1993LV64600052
J	MORI, K; MA, WZ; GETHING, MJ; SAMBROOK, J				MORI, K; MA, WZ; GETHING, MJ; SAMBROOK, J			A TRANSMEMBRANE PROTEIN WITH A CDC2+/CDC28-RELATED KINASE-ACTIVITY IS REQUIRED FOR SIGNALING FROM THE ER TO THE NUCLEUS	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CONSERVED FEATURES; SECRETORY PROTEINS; SHUTTLE VECTORS; GENE ENCODES; YEAST; SEQUENCE; BIP; TRANSFORMATION	In eukaryotic cells, the accumulation of unfolded proteins in the endoplasmic reticulum (ER) triggers a signaling pathway from the ER to the nucleus. Several yeast mutants defective in this pathway map to the ERN1 gene, which protects cells from lethal consequences of stress by signaling for increased expression of BiP and other ER proteins. ERN1 encodes a 1115 amino acid transmembrane protein (Ern1p) whose glycosylated N-terminal portion is located inside microsomes and whose cytoplasmic C-terminal portion carries an essential protein kinase activity. We postulate that Ern1p is the proximal sensor of events in the ER and that binding of ligand causes transduction of information across the ER membrane, leading to activation of a specific set of transcription factors.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, MCDERMOTT CTR, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	MORI, K (corresponding author), UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA.		Mori, Kazutoshi/K-6106-2015					BECKER DM, 1991, METHOD ENZYMOL, V194, P182; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; FERRONOVICK S, 1984, J CELL BIOL, V98, P44, DOI 10.1083/jcb.98.1.44; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HINDLEY J, 1984, GENE, V31, P129, DOI 10.1016/0378-1119(84)90203-8; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KEPES F, 1988, J BIOL CHEM, V263, P9155; KNIGHTON DR, 1992, SCIENCE, V258, P130, DOI 10.1126/science.1439761; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOZUTSUMI Y, 1989, J CELL SCI, P115; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAWRENCE CW, 1982, ADV GENET, V21, P173, DOI 10.1016/S0065-2660(08)60299-0; LEE AS, 1987, TRENDS BIOCHEM SCI, V12, P20, DOI 10.1016/0968-0004(87)90011-9; LEVY D, 1990, New Biologist, V2, P923; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NONET ML, 1989, GENETICS, V123, P715; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; PARK HO, 1989, MOL CELL BIOL, V9, P2025, DOI 10.1128/MCB.9.5.2025; PFEFFER LM, 1991, TRENDS BIOCHEM SCI, V16, P321, DOI 10.1016/0968-0004(91)90132-F; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHONBERGER O, 1991, MOL MICROBIOL, V5, P2663, DOI 10.1111/j.1365-2958.1991.tb01975.x; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; STODDARD BL, 1992, COLD SPRING HARB SYM, V52, P1; TACHIBANA C, 1992, MOL CELL BIOL, V12, P4601, DOI 10.1128/MCB.12.10.4601; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P433; [No title captured]	53	642	671	0	58	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					743	756						14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358794				2022-12-28	WOS:A1993LU59200017
J	CHAPMAN, S				CHAPMAN, S			UNRAVELING GOSSAMER WITH BOXING GLOVES - PROBLEMS IN EXPLAINING THE DECLINE IN SMOKING	BRITISH MEDICAL JOURNAL			English	Article							PASSIVE SMOKING; RESTAURANTS; WORKPLACE; ATTITUDES	For about three decades countries such as Australia, Great Britain, and the United States have been turning up the heat on tobacco advertising. Encouraging, sometimes dramatic falls in consumption have followed. On any given day in 1993 smokers in such countries are exposed to a welter of news, information, persuasion, and policies designed to turn them off smoking. For a long time explanations and evaluations of the effects of these policies and interventions have been tied to oversimplified causal models when the reality is rather more messy and complicated. Four factors largely explain the reluctance of researchers to move beyond these models: the reductionist tradition of science; the explanatory privileging of recent events and factors; pragmatic concern for policy ''tractable'' factors; and the relation of funding to the evaluative process. Broader research approaches to understanding changes in complex behaviours such as smoking are required-for example, qualitative methods.			CHAPMAN, S (corresponding author), UNIV SYDNEY,WESTMEAD HOSP,DEPT COMMUNITY MED,WESTMEAD,NSW 2145,AUSTRALIA.							BORLAND R, 1991, MED J AUSTRALIA, V154, P292, DOI 10.5694/j.1326-5377.1991.tb121104.x; BORLAND R, 1990, AM J PUBLIC HEALTH, V80, P178, DOI 10.2105/AJPH.80.2.178; Brackenridge R. D. C., 1985, MED SELECTION LIFE R; Brewer J., 1989, MULTIMETHOD RES SYNT, DOI [10.1002/nur.4770140212, DOI 10.1002/NUR.4770140212]; BROWNSON RC, 1991, AM J EPIDEMIOL, V134, P938, DOI 10.1093/oxfordjournals.aje.a116177; CHAPMAN S, 1989, BRIT J ADDICT, V84, P1267; CHAPMAN S, 1989, AM J PUBLIC HEALTH, V79, P1419, DOI 10.2105/AJPH.79.10.1419; CHAPMAN S, 1990, INT J HEALTH SERV, V20, P417, DOI 10.2190/YYKC-PGTC-VUMM-3A5P; CHAPMAN S, 1992, LANCET, V339, P1614, DOI 10.1016/0140-6736(92)91880-H; Chapman S., 1992, TOB CONTROL, V1, P248; CHAPMAN S, 1993, BMJ, V306, P102; Chapman S, 1992, TOBACCO CONTROL S, V1, pS2; CHESTERFIELDEVANS A, 1992, BRIT MED J, V304, P1529; Garfinkel H., 1967, STUDIES ETHNOMETHODO; Geertz Clifford, 1973, INTERPRETATION CULTU; GILPIN E, 1992, TOB CONTROL, V1, P256; Gray N, 1980, GUIDELINES SMOKING C; HILL DJ, 1991, MED J AUSTRALIA, V154, P788; HILL DJ, 1993, MED J AUSTRALIA, P228; JANKOWSKI NW, 1991, HDB QUALITATIVE METH, P44; JICK TD, 1979, ADMIN SCI QUART, V24, P602, DOI 10.2307/2392366; MARLATT GA, 1990, J CONSULT CLIN PSYCH, V58, P310; MULLINS R, 1992, SMOKING RESTRICTIONS; PIERCE JP, 1986, MED J AUSTRALIA, V144, P341, DOI 10.5694/j.1326-5377.1986.tb115915.x; ROBERTS C, 1992, MED J AUSTRALIA, V157, P210, DOI 10.5694/j.1326-5377.1992.tb137096.x; SWEANOR D, 1992, TOBACCO CONTROL S, V1, pS31; Van Dijk T. A., 1985, DISCOURSE COMMUNICAT; WHITE VM, 1990, CIGARETTE ALCOHOL CO; WILSON DH, 1990, MED J AUSTRALIA, V152, P518, DOI 10.5694/j.1326-5377.1990.tb125351.x; 1992, HERALD SUN       MAR, P1; 1992, TOBACCO CONTROL, V1, P50; 1990, TOBACCO AUSTR SUMMAR, P12; 1979, WHO TECH REP SER, V636	33	78	78	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					429	432		10.1136/bmj.307.6901.429	http://dx.doi.org/10.1136/bmj.307.6901.429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR895	8374457	Green Published, Bronze			2022-12-28	WOS:A1993LR89500022
J	SHEPHERD, JC; SCHUMACHER, TNM; ASHTONRICKARDT, PG; IMAEDA, S; PLOEGH, HL; JANEWAY, CA; TONEGAWA, S				SHEPHERD, JC; SCHUMACHER, TNM; ASHTONRICKARDT, PG; IMAEDA, S; PLOEGH, HL; JANEWAY, CA; TONEGAWA, S			TAP1-DEPENDENT PEPTIDE TRANSLOCATION IN-VITRO IS ATP-DEPENDENT AND PEPTIDE SELECTIVE	CELL			English	Article							CLASS-I MOLECULES; MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEASOME-RELATED GENE; MHC-LINKED TRANSPORTER; MULTIDRUG RESISTANCE; MICROSOMAL-MEMBRANES; ANTIGEN PRESENTATION; BACTERIAL TRANSPORT; CYSTIC-FIBROSIS; P-GLYCOPROTEIN	T cells detect infection of cells by recognizing peptide fragments of foreign proteins bound to class I molecules of the major histocompatibility complex (MHC) on the surface of the infected cell. MHC class I molecules bind peptide in the endoplasmic reticulum, and analysis of mutant cells has demonstrated that an adequate supply of peptides requires the presence of two genes in the MHC class II locus that encode proteins called transporters associated with antigen processing (TAP) 1 and 2. TAP1 and TAP2 are members of the ATP-binding cassette family of membrane translocators. In this study, we demonstrate in a cell-free system that TAP1 is part of an ATP-dependent, sequence-specific, peptide translocator.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	SHEPHERD, JC (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DIV IMMUNOBIOL FMB402,NEW HAVEN,CT 06510, USA.		Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804				Aronson N N Jr, 1974, Methods Enzymol, V31, P90; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BIJLMAKERS MKE, 1993, IN PRESS EUR J IMMUN; BLIGHT MA, 1990, MOL MICROBIOL, V4, P873, DOI 10.1111/j.1365-2958.1990.tb00660.x; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DEMARS R, 1984, HUM IMMUNOL, V11, P77, DOI 10.1016/0198-8859(84)90047-8; DERES K, 1992, EUR J IMMUNOL, V22, P1603, DOI 10.1002/eji.1830220638; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HAMMERLING GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4737, DOI 10.1073/pnas.79.15.4737; HILES ID, 1987, J MOL BIOL, V195, P125, DOI 10.1016/0022-2836(87)90332-9; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; LEVY F, 1991, CELL, V67, P265, DOI 10.1016/0092-8674(91)90178-2; LEVY F, 1991, J CELL BIOL, V115, P959, DOI 10.1083/jcb.115.4.959; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOBIGS M, 1993, P NATL ACAD SCI USA, V90, P2676, DOI 10.1073/pnas.90.7.2676; LOKEN MR, 1982, J IMMUNOL METHODS, V50, pR85, DOI 10.1016/0022-1759(82)90161-2; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES J J, 1991, Current Opinion in Cell Biology, V3, P601, DOI 10.1016/0955-0674(91)90029-X; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SCHUMACHER TNM, 1991, NATURE, V350, P703, DOI 10.1038/350703a0; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; WALTER P, 1983, METHOD ENZYMOL, V96, P84; YEWDELL JW, 1993, J EXP MED, V177, P1785, DOI 10.1084/jem.177.6.1785; ZWEERINK HJ, 1993, J IMMUNOL, V150, P1763	49	329	331	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					577	584		10.1016/0092-8674(93)80058-M	http://dx.doi.org/10.1016/0092-8674(93)80058-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348620				2022-12-28	WOS:A1993LT73900018
J	THOMAS, SHL; BATCHELOR, S; ODOHERTY, MJ				THOMAS, SHL; BATCHELOR, S; ODOHERTY, MJ			THERAPEUTIC AEROSOLS IN CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEONATAL VENTILATOR CIRCUITS; DELIVERY; LUNG; NEBULIZERS; DEPOSITION; INSULIN	The use and variety of drugs administered to children as inhaled aerosols is increasing, but little is known about how much drug reaches the lung and how it is distributed there in different age groups. In this article the reasons for measuring aerosol deposition in children are discussed and the potential methods for doing this described. Of the methods available, only the use of radiolabelled aerosols gives accurate information on total lung deposition and distribution. The potential risk of the radiation exposure required for these measurements varies with the age of the child but seems to be small. Properly designed studies are expected to clarify the factors affecting lung deposition in children and identify methods of inhalation associated with efficient and predictable delivery of the drug. Measurements of radioaerosol deposition may therefore be justified in children when this information is expected to lead to improvements in the effectiveness or safety of their treatment.	ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, MED PHYS DIRECTORATE, LONDON SE1 7EH, ENGLAND; ST THOMAS HOSP, GUYS & ST THOMAS HOSP TRUST, DEPT NUCL MED, LONDON SE1 7EH, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	THOMAS, SHL (corresponding author), NEWCASTLE UNIV, WOLFSON DEPT CLIN PHARMACOL, NEWCASTLE UPON TYNE NE1 4LP, ENGLAND.							AHRENS RC, 1986, PEDIATR PULM, V2, P19, DOI 10.1002/ppul.1950020108; ALDERSON PO, 1974, J PEDIATR-US, V84, P479, DOI 10.1016/S0022-3476(74)80664-5; [Anonymous], 1991, Ann ICRP, V21, P1; BLACKHALL MI, 1987, EUR J RESPIR DIS, V71, P96; BORGSTROM L, 1990, PHARMACEUT RES, V7, P1068, DOI 10.1023/A:1015951402799; CAMERON D, 1990, CRIT CARE MED, V18, P866, DOI 10.1097/00003246-199008000-00015; CAMERON D, 1990, PAEDIATRIC PULMONOLO, V10, P208; CHUA HL, 1991, AM REV RESPIR DIS, V43, pA706; COLLIS GG, 1990, LANCET, V336, P341, DOI 10.1016/0140-6736(90)91880-J; COLTHORPE P, 1992, PHARMACEUT RES, V9, P764, DOI 10.1023/A:1015851521551; DAHLBACK M, 1989, J AEROSOL MED, V2, P339; DAVIES DS, 1984, EUR J RESPIR DIS, V65, P141; ELLIOTT RB, 1987, AUST PAEDIATR J, V23, P293; EVERARD ML, 1992, ARCH DIS CHILD, V67, P586, DOI 10.1136/adc.67.5.586; EVERARD ML, 1992, ARCH DIS CHILD-FETAL, V67, P826, DOI 10.1136/adc.67.7_Spec_No.826; HINDLE M, 1992, BRIT J CLIN PHARMACO, V34, P311, DOI 10.1111/j.1365-2125.1992.tb05921.x; HUNG OR, 1993, CLIN PHARMACOL THER, V53, P207; LESOUEF PN, 1992, LANCET, V339, P1282, DOI 10.1016/0140-6736(92)91602-5; ODOHERTY MJ, 1993, THORAX, V48, P220, DOI 10.1136/thx.48.3.220; SALMON B, 1990, ARCH DIS CHILD, V65, P401, DOI 10.1136/adc.65.4.401; SILVERMAN M, 1990, ARCH DIS CHILD, V65, P906, DOI 10.1136/adc.65.8.906; THOMAS SHL, 1991, CLIN SCI, V81, P767, DOI 10.1042/cs0810767; WILKIE RA, 1987, J PEDIATR-US, V111, P278, DOI 10.1016/S0022-3476(87)80087-2; WOLFSDORF J, 1969, PEDIATRICS, V43, P799; 1988, SERIES MBI, V16; 1987, ANN ICRP, V18, P219; 1989, SERIES DH2, V14	27	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					245	247		10.1136/bmj.307.6898.245	http://dx.doi.org/10.1136/bmj.307.6898.245			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369692	Bronze, Green Published			2022-12-28	WOS:A1993LP31400031
J	KOPF, M; LEGROS, G; BACHMANN, M; LAMERS, MC; BLUETHMANN, H; KOHLER, G				KOPF, M; LEGROS, G; BACHMANN, M; LAMERS, MC; BLUETHMANN, H; KOHLER, G			DISRUPTION OF THE MURINE IL-4 GENE BLOCKS TH2 CYTOKINE RESPONSES	NATURE			English	Article							STIMULATORY FACTOR-I; CD4+ T-CELLS; MONOCLONAL-ANTIBODY; IGE RESPONSES; GROWTH-FACTOR; LYMPHOCYTE-T; STEM-CELLS; INVIVO; CLONES; MICE	MURINE T-helper clones are classified into two distinct subsets (Th1 and Th2) on the basis of their patterns of lymphokine secretion. Th1 clones secrete interleukin-2 (IL-2), tumour necrosis factor-beta (TNF-beta) and interferon-gamma (IFN-gamma), whereas Th2 clones secrete IL-4, IL-5 and IL-10 (ref. 1). These subsets are reciprocally regulated by IL-4, IL-10 and IFN-gamma and differentially promote antibody or delayed-type hypersensitivity responses2,3. To evaluate whether IL-4 is required for mounting Th2 responses, we generated IL-4-mutant mice (IL4-/-)4,5 and assessed the cytokine secretion pattern of T cells both from naive and Nippostrongylus brasiliensis infected mice. CD4+ T cells from naive IL-4-/- mice failed to produce Th2-derived cytokines after in vitro stimulation. The levels of Th2 cytokines IL-5, IL-9 and IL-10 from CD4+ T cells obtained after nematode infection were significantly reduced. The reduced IL-5 production in IL-4-/- mice correlated with reduced helminth-induced eosinophilia, which has been shown to be dependent on IL-5 in vivo6. We conclude that IL4 is required for the generation of the Th2-derived cytokines and that immune responses dependent on these cytokines are impaired.	CIBA GEIGY AG,CH-4002 BASEL,SWITZERLAND; UNIV ZURICH,INST EXPTL IMMUNOL,CH-8006 ZURICH,SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD,CH-4002 BASEL,SWITZERLAND	Novartis; University of Zurich; Roche Holding	KOPF, M (corresponding author), MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY.		Le Gros, Graham/C-6725-2011; Kopf, Manfred/B-6907-2009	Kopf, Manfred/0000-0002-0628-7140; Le Gros, Graham/0000-0002-5721-0442				BANIYASH M, 1984, EUR J IMMUNOL, V14, P799, DOI 10.1002/eji.1830140907; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; DEKRUYFF RH, 1990, EUR J IMMUNOL, V20, P2219, DOI 10.1002/eji.1830201010; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOETSCHMANN T, 1987, NATURE, V330, P376; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1991, INT IMMUNOL, V3, P599, DOI 10.1093/intimm/3.6.599; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; JENNINGS FW, 1963, EXP PARASITOL, V13, P367, DOI 10.1016/0014-4894(63)90087-0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MOSKOPHIDIS D, 1989, P NATL ACAD SCI USA, V86, P3291, DOI 10.1073/pnas.86.9.3291; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHMITT E, 1989, EUR J IMMUNOL, V19, P2167, DOI 10.1002/eji.1830191130; SEDER RA, 1991, EUR J IMMUNOL, V21, P1241, DOI 10.1002/eji.1830210522; STREET NE, 1990, J IMMUNOL, V144, P1629; SVETIC A, 1991, J IMMUNOL, V147, P2391; SWAIN SL, 1990, J IMMUNOL, V145, P3796; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5	30	1113	1147	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					245	248		10.1038/362245a0	http://dx.doi.org/10.1038/362245a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8384701				2022-12-28	WOS:A1993KT02600056
J	ONYANGO, FE; STEINHOFF, MC; WAFULA, EM; WARIUA, S; MUSIA, J; KITONYI, J				ONYANGO, FE; STEINHOFF, MC; WAFULA, EM; WARIUA, S; MUSIA, J; KITONYI, J			HYPOXEMIA IN YOUNG KENYAN CHILDREN WITH ACUTE LOWER RESPIRATORY-INFECTION	BRITISH MEDICAL JOURNAL			English	Article							TRACT INFECTIONS; SYNCYTIAL VIRUS; CLINICAL SIGNS; PULSE OXIMETRY; PNEUMONIA; BRONCHIOLITIS; INFANTS; BACTEREMIA; CRITERIA; DEATH	Objectives-To determine the prevalence, clinical correlates, and outcome of hypoxaemia in acutely ill children with respiratory symptoms. Design-Prospective observational study. Setting-Paediatric casualty ward of a referral hospital at 1670 m altitude in Nairobi, Kenya. Subjects-256 Infants and children under 3 years of age with symptoms of respiratory infection. Main outcome measures-Prevalence of hypoxaemia, defined as arterial oxygen saturation <90% determined by pulse oximetry, and condition of patient on the fifth day after admission. Results-Over half (151) of the children were hypoxaemic, and short term mortality was 4.3 times greater in these children. In contrast, the relative risk of a fatal outcome in children with radiographic pneumonia was only 1.03 times that of children without radiographic pneumonia. A logistic regression model showed that in 3-11 month old infants a respiratory rate greater-than-or-equal-to 70/min, grunting, and retractions were the best independent clinical signs for the prediction of hypoxaemia. In the older children a respiratory rate of greater-than-or-equal-to 60/min was the single best clinical predictor of hypoxaemia. The presence of hypoxaemia predicted radiographic pneumonia with a sensitivity of 71% and specificity of 55%. Conclusions-Over half the children presenting to this referral hospital with respiratory symptoms were hypoxaemic. A group of specific clinical signs seem useful in predicting hypoxaemia. The clear association of hypoxaemia with mortality suggests that the detection and effective treatment of hypoxaemia are important aspects of the clinical management of acute infections of the lower respiratory tract in children in hospital in developing regions.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; UNIV NAIROBI,COLL HLTH SCI,DEPT PAEDIAT & CHILD HLTH,NAIROBI,KENYA	Johns Hopkins University; Johns Hopkins University; University of Nairobi								BANKS RA, 1984, BRIT J DIS CHEST, V78, P352; BERMAN S, 1990, Pediatric Emergency Care, V6, P179, DOI 10.1097/00006565-199009000-00003; CAMPBELL H, 1989, LANCET, V1, P297, DOI 10.1016/S0140-6736(89)91308-1; CHERIAN T, 1988, LANCET, V2, P125; CHRETIEN J, 1984, NEW ENGL J MED, V310, P382; FARR BM, 1991, ANN INTERN MED, V115, P428, DOI 10.7326/0003-4819-115-6-428; GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007; HALL CB, 1979, AM J DIS CHILD, V133, P798, DOI 10.1001/archpedi.1979.02130080038006; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; LEMESHOW S., 1989, APPL LOGISTIC REGRES, P10; MULHOLLAND EK, 1990, LANCET, V335, P1259, DOI 10.1016/0140-6736(90)91314-Z; MULHOLLAND EK, 1992, PEDIATR INFECT DIS J, V11, P77, DOI 10.1097/00006454-199202000-00004; NORUSIS MJ, 1990, SPSSPC PLUS ADV STAT; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9; REYNOLDS EO, 1963, J PEDIATR-US, V63, P1135, DOI 10.1016/S0022-3476(63)80196-1; ROSEN LM, 1989, AM J EMERG MED, V7, P567, DOI 10.1016/0735-6757(89)90275-1; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P81; SHANN F, 1989, PEDIATR INFECT DIS J, V8, P852, DOI 10.1097/00006454-198912000-00005; SHANN F, 1984, B WORLD HEALTH ORGAN, V62, P749; SHAW KN, 1991, AM J DIS CHILD, V145, P151, DOI 10.1001/archpedi.1991.02160020041012; Swischuk LE, 1986, EMERGENCY RADIOLOGY; THILO EH, 1991, AM J DIS CHILD, V145, P1137, DOI 10.1001/archpedi.1991.02160100069025; 1990, WHOARI905; 1987, Q J MED, V239, P195	25	119	122	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 6	1993	306	6878					612	615		10.1136/bmj.306.6878.612	http://dx.doi.org/10.1136/bmj.306.6878.612			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ859	8369033	Bronze, Green Published			2022-12-28	WOS:A1993KQ85900018
J	THIEL, DJ; LIVINS, P; STERN, EA; LEWIS, A				THIEL, DJ; LIVINS, P; STERN, EA; LEWIS, A			MICROSECOND-RESOLVED XAFS OF THE TRIPLET EXCITED-STATE OF PT2(P2O5H2)4(4-)	NATURE			English	Article							BINUCLEAR PLATINUM(II); ELECTRONIC SPECTROSCOPY; DIPHOSPHITE COMPLEXES; SPECTRA; RAMAN; ABSORPTION	LITTLE is known about the excited-state structures of most inorganic compounds. Time-resolved resonance Raman and time-resolved infrared spectroscopies can provide only indirect structural information for short-lived excited species in solution at room temperature. Time-resolved X-ray diffraction' has the potential to give more direct information, but no excited-state structures have yet been reported; picosecond gas-phase electron diffraction has been proposed recently2, but not yet demonstrated. Here we report a technique that combines the X-ray absorption fine-structure (XAFS) method3 With rapid-flow laser spectroscopy4 to measure structural changes in a solution-phase excited-state transition-metal complex with microsecond resolution. We find that the triplet excited state of Pt2(P2O5H2)44-, with a lifetime of about 4 mus, undergoes a contraction in the Pt-Pt distance of 0.52 +/- 0.13 angstrom relative to the ground state. We anticipate that time-resolved XAFS will have broad applications in chemistry and biology.	UNIV WASHINGTON,DEPT PHYS,SEATTLE,WA 98195; HEBREW UNIV JERUSALEM,DIV APPL PHYS,JERUSALEM,ISRAEL	University of Washington; University of Washington Seattle; Hebrew University of Jerusalem	THIEL, DJ (corresponding author), CORNELL UNIV,DEPT APPL PHYS,ITHACA,NY 14853, USA.							BOUDREAUX EA, 1986, INT J QUANTUM CHEM Q, V20, P239; CHE CM, 1983, J AM CHEM SOC, V105, P5492, DOI 10.1021/ja00354a059; CHE CM, 1983, J AM CHEM SOC, V105, P4604, DOI 10.1021/ja00352a015; COWMAN CD, 1973, J AM CHEM SOC, V95, P7873, DOI 10.1021/ja00804a057; FORDYCE WA, 1981, J AM CHEM SOC, V103, P7061, DOI 10.1021/ja00414a006; HARVEY EL, 1987, J AM CHEM SOC, V109, P5233, DOI 10.1021/ja00251a031; HIRAGA T, 1989, J AM CHEM SOC, V111, P7466, DOI 10.1021/ja00201a029; MARCUS MA, 1977, SCIENCE, V195, P1328, DOI 10.1126/science.841330; NEWVILLE M, IN PRESS PHYS REV B; PETERSON JR, 1985, J PHYS CHEM-US, V89, P2486, DOI 10.1021/j100258a013; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; RICE SF, 1983, J AM CHEM SOC, V105, P4571, DOI 10.1021/ja00352a011; ROUNDHILL DM, 1989, ACCOUNTS CHEM RES, V22, P55, DOI 10.1021/ar00158a002; ROUNDHILL DM, 1987, J AM CHEM SOC, V109, P6076, DOI 10.1021/ja00254a028; STEIN P, 1983, J AM CHEM SOC, V105, P3489, DOI 10.1021/ja00349a020; Stern E. A., 1983, Handbook on synchrotron radiation, P955; STIEGMAN AE, 1987, INORG CHEM, V26, P1112, DOI 10.1021/ic00254a029; SZEBENYI DME, 1988, T AM CRYSTALLOGR ASS, V24, P167; WILLIAMSON JC, 1991, P NATL ACAD SCI USA, V88, P5021, DOI 10.1073/pnas.88.11.5021; ZIPP AP, 1988, COORDIN CHEM REV, V84, P47, DOI 10.1016/0010-8545(88)80031-6	20	69	69	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					40	43		10.1038/362040a0	http://dx.doi.org/10.1038/362040a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8383295				2022-12-28	WOS:A1993KP97600052
J	CANESSA, CM; HORISBERGER, JD; ROSSIER, BC				CANESSA, CM; HORISBERGER, JD; ROSSIER, BC			EPITHELIAL SODIUM-CHANNEL RELATED TO PROTEINS INVOLVED IN NEURODEGENERATION	NATURE			English	Article							ION CHANNEL; CAENORHABDITIS-ELEGANS; HAIR CELL; CURRENTS; CHICK	THE epithelial amiloride-sensitive sodium channel constitutes the rate limiting step for sodium reabsorbtion by the epithelia lining the distal part of the kidney tubule, the urinary bladder and the distal colon. Reabsorbtion of sodium through this channel, which is regulated by hormones such as aldosterone and vasopressin, is one of the essential mechanisms involved in the regulation of sodium balance, blood volume and blood pressure1-6. Here we isolate a DNA from epithelial cells of rat distal colon and identify it by functional expression of an amiloride-sensitive sodium current in Xenopus oocyte. The deduced polypeptide (698 amino acids) has at least two putative transmembrane segments. Expression of this protein in Xenopus oocytes reconstitutes the functional properties of the highly selective amiloride-sensitive, epithelial sodium channel. The gene encoding this rat sodium channel subunit shares significant sequence similarity with mec-4 and deg-1, members of a family of Caenorhabditis elegans genes involved in sensory touch transduction and, when mutated, neuronal degeneration. We propose that the gene products of these three genes are members of a gene family coding for cation channels.	UNIV LAUSANNE,INST PHARMACOL & TOXICOL,RUE BUGNON 27,CH-1005 LAUSANNE,SWITZERLAND	University of Lausanne			Horisberger, Jean-Daniel/A-2538-2009					AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; DRISCOLL M, 1992, TRENDS NEUROSCI, V15, P15, DOI 10.1016/0166-2236(92)90343-7; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; EATON DC, 1988, ION CHANNELS, P251; GARTY H, 1988, PHYSIOL REV, V68, P309, DOI 10.1152/physrev.1988.68.2.309; GUHARAY F, 1984, J PHYSIOL-LONDON, V352, P685, DOI 10.1113/jphysiol.1984.sp015317; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HORISBERGER JD, 1992, HYPERTENSION, V19, P221, DOI 10.1161/01.HYP.19.3.221; HUDSPETH AJ, 1986, HEARING RES, V22, P21, DOI 10.1016/0378-5955(86)90070-5; MACHEN TE, 1978, AM J PHYSIOL, V234, pE228, DOI 10.1152/ajpendo.1978.234.3.E228; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; OHMORI H, 1984, J PHYSIOL-LONDON, V350, P561, DOI 10.1113/jphysiol.1984.sp015218; PALMER LG, 1990, J GEN PHYSIOL, V96, P23, DOI 10.1085/jgp.96.1.23; PALMER LGA, 1992, REV PHYSL, V54, P51; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; ROSSIER BC, 1992, KIDNEY PHYSL PATHOPH, V2, P1373; SCHAFER JA, 1992, KIDNEY INT, V41, P255, DOI 10.1038/ki.1992.37; SIGURDSON WJ, 1989, J NEUROSCI, V9, P2801; SINGER D, 1991, SCIENCE, V253, P1553, DOI 10.1126/science.1716787; STAUB O, IN PRESS J CELL BIOL	22	831	851	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					467	470		10.1038/361467a0	http://dx.doi.org/10.1038/361467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8381523				2022-12-28	WOS:A1993KK71300066
J	KERR, D; SHERWIN, RS; PAVALKIS, F; FAYAD, PB; SIKORSKI, L; RIFE, F; TAMBORLANE, WV; DURING, MJ				KERR, D; SHERWIN, RS; PAVALKIS, F; FAYAD, PB; SIKORSKI, L; RIFE, F; TAMBORLANE, WV; DURING, MJ			EFFECT OF CAFFEINE ON THE RECOGNITION OF AND RESPONSES TO HYPOGLYCEMIA IN HUMANS	ANNALS OF INTERNAL MEDICINE			English	Article						HYPOGLYCEMIA; CAFFEINE; EPINEPHRINE; NOREPINEPHRINE; CORTISOL	CEREBRAL GLUCOSE-UTILIZATION; CONSCIOUS RAT; BLOOD-FLOW; INSULIN; BRAIN; METHYLXANTHINES; SECRETION; CHILDREN	Objective: To determine whether two effects of acute caffeine ingestion-decrease in cerebral blood flow and increase in brain glucose use-alter the recognition of and physiologic responses to hypoglycemia. Design: On two occasions, a hyperinsulinemic glucose clamp technique (2 mU/kg body weight per minute) was used to maintain plasma glucose at 5 mmol/L for 90 minutes, followed by 60 minutes at 3.8 mmol/L, and then 2.8 mmol/L. After 30 minutes at 5 mmol/L, participants consumed, using a randomized, double-blind design, caffeine-free cola with or without caffeine (400 mg) added. Setting. Yale Clinical Research Center. Participants: Eight healthy, nonobese volunteers (5 men; age range, 20 to 33 years). Measurements: Middle cerebral artery velocity (V MCA), counter-regulatory hormone levels, hypoglycemic symptoms, and cognitive function (P300 evoked potentials). Results: Caffeine caused an immediate and sustained 23% decrease in V(MCA) from 64 to 49 cm/s (point estimate of difference, +15 cm/s [95% CI, 10 to 21 cm/s], P < 0.001). At a glucose level of 3.8 mmol/L, only the participants given caffeine had warning symptoms and ''felt hypoglycemic.'' Moreover, the level of epinephrine was 118% ([CI of point difference, 76% to 158%] [CI, P < 0.001]) higher after caffeine consumption compared with placebo. Similarly, levels of norepinephrine (41% [CI, 26% to 60%], P < 0.002), cortisol (65% [CI, 26% to 78%], P < 0.008), and growth hormone (60% [CI, 16% to 143%], P < 0.05) were higher after caffeine consumption compared with placebo. At 2.8 mmol/L, epinephrine (40% [point estimate of the percentage difference], P < 0.05), norepinephrine (27%, P < 0.05), and cortisol (24%, P < 0.05) levels were higher, participants were more aware (P < 0.02) of hypoglycemia, and P300 latency was prolonged in the group that consumed caffeine (7.2%, P < 0.05). Conclusions: Acute ingestion of caffeine is associated with sympathoadrenal activation and awareness of hypoglycemia at a glucose level not usually considered hypoglycemic. Our data suggest that individuals who ingest moderate amounts of caffeine may develop hypoglycemic symptoms if plasma glucose levels fall into the ''low-normal'' range, as might occur in the late postprandial period after ingestion of a large carbohydrate load.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA	Yale University			During, Matthew/AAC-1388-2020		NCRR NIH HHS [RR 00125, RR 06022] Funding Source: Medline; NIDDK NIH HHS [DK 20495] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020495, R37DK020495] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASLID R, 1984, J NEUROSURG, V57, P739; AMIEL SA, 1987, J PEDIATR-US, V110, P832, DOI 10.1016/S0022-3476(87)80393-1; BIGGERS DW, 1989, DIABETES, V38, P7, DOI 10.2337/diabetes.38.1.7; BUNKER ML, 1979, J AM DIET ASSOC, V74, P28; CAMERON OG, 1990, LIFE SCI, V47, P1141, DOI 10.1016/0024-3205(90)90174-P; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; DIAMOND MP, 1991, J CLIN ENDOCR METAB, V72, P1388, DOI 10.1210/jcem-72-6-1388; DURING MJ, 1991, TECHNIQUES BEHAVIORA, V7, P425; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; GROME JJ, 1986, N-S ARCH PHARMACOL, V333, P172, DOI 10.1007/BF00506522; HOFELDT FD, 1989, ENDOCRIN METAB CLIN, V18, P185, DOI 10.1016/S0889-8529(18)30396-7; JONES TW, 1991, DIABETES, V40, P358, DOI 10.2337/diabetes.40.3.358; JONES TW, 1990, DIABETES, V39, P1550, DOI 10.2337/diabetes.39.12.1550; KERR D, 1991, DIABETES, V40, P1057, DOI 10.2337/diabetes.40.8.1057; KERR D, 1993, DIABETOLOGIA, V36, P73, DOI 10.1007/BF00399097; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KUHR WG, 1988, J CEREBR BLOOD F MET, V8, P130, DOI 10.1038/jcbfm.1988.17; MARKS V, 1986, HORM METABOL RES S, P1; MATHEW RJ, 1985, STROKE, V16, P814, DOI 10.1161/01.STR.16.5.814; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE67, DOI 10.1152/ajpendo.1991.260.1.E67; NEHLIG A, 1984, EUR J PHARMACOL, V101, P91, DOI 10.1016/0014-2999(84)90034-7; NEHLIG A, 1988, EUR J PHARMACOL, V157, P1, DOI 10.1016/0014-2999(88)90464-5; NEHLIG A, 1986, EUR J PHARMACOL, V129, P93, DOI 10.1016/0014-2999(86)90340-7; NEWTON R, 1981, EUR J CLIN PHARMACOL, V21, P45, DOI 10.1007/BF00609587; PALARDY J, 1989, NEW ENGL J MED, V321, P1421, DOI 10.1056/NEJM198911233212101; POLICH J, 1986, ELECTROEN CLIN NEURO, V65, P236, DOI 10.1016/0168-5597(86)90059-6; PRAMMING S, 1990, J INTERN MED, V228, P641, DOI 10.1111/j.1365-2796.1990.tb00292.x; SHENKIN HA, 1951, J APPL PHYSIOL, V3, P465, DOI 10.1152/jappl.1951.3.8.465; SKLARE DA, 1984, ELECTROEN CLIN NEURO, V59, P420, DOI 10.1016/0168-5597(84)90043-1; SNYDER SH, 1981, P NATL ACAD SCI-BIOL, V78, P3260, DOI 10.1073/pnas.78.5.3260; SUTHERLAND GR, 1991, NEUROSCIENCE, V42, P171, DOI 10.1016/0306-4522(91)90157-J; WEIR G, 1976, J CLIN INVEST, V54, P1403	33	51	52	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					799	804		10.7326/0003-4819-119-8-199310150-00005	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379601				2022-12-28	WOS:A1993MB49600005
J	TEO, KK; YUSUF, S; FURBERG, CD				TEO, KK; YUSUF, S; FURBERG, CD			EFFECTS OF PROPHYLACTIC ANTIARRHYTHMIC DRUG-THERAPY IN ACUTE MYOCARDIAL-INFARCTION - AN OVERVIEW OF RESULTS FROM RANDOMIZED CONTROLLED TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PRIMARY VENTRICULAR-FIBRILLATION; PLACEBO-CONTROLLED TRIAL; LOW-DOSE AMIODARONE; DOUBLE-BLIND; SECONDARY PREVENTION; ORAL MEXILETINE; HOSPITAL PHASE; TERM TREATMENT; ARRHYTHMIAS; LIDOCAINE	Objective.-To investigate the effects of prophylactic therapy with antiarrhythmic agents on mortality in patients with myocardial infarction. Data Sources and Study Selection.-Data were obtained from all completed, published or unpublished, randomized, parallel controlled trials of antiarrhythmic agents, regardless of sample size. Investigators were contacted for data on patients excluded after randomization. Data Extraction.-Data on mortality were extracted by one author and confirmed where necessary by the others. Data Synthesis.-Mortality data from 138 trials on 98 000 patients were combined by the Yusuf-Peto adaptation of the Mantel-Haenszel method. There were 660 deaths among 11 712 patients allocated to receive class I agents and 571 deaths among 11 517 corresponding control patients (51 trials: odds ratio [OR], 1.14; 95% confidence interval [CI], 1.01 to 1.28; P=.03). Of 26 973 patients allocated to receive beta-blockers (class II agents), 1464 died compared with 1727 deaths among 26 295 control patients (55 trials: OR, 0.81; 95% CI, 0.75 to 0.87; P=.00001). Of 778 patients allocated to receive amiodarone (a class III agent), 77 died compared with 101 deaths in 779 control patients (eight trials: OR, 0.71; 95% CI, 0.51 to 0.97; P=.03). There were 982 deaths in 10 154 patients allocated to receive a class IV agent (calcium channel blockers) and 949 deaths in 10 188 control patients (24 trials: OR, 1.04; 95% CI, 0.95 to 1.14; P=.41). Conclusions.-The routine use of class I antiarrhythmic agents after myocardial infarction is associated with increased mortality. Beta-blockers have been conclusively demonstrated to reduce mortality. The limited data on amiodarone appear promising. Data on calcium channel blockers remain unpromising.	NHLBI, CLIN TRIALS BRANCH, BETHESDA, MD 20892 USA; MCMASTER UNIV, DIV CARDIOL, HAMILTON L8S 4L8, ONTARIO, CANADA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT PUBL HLTH SCI, WINSTON SALEM, NC 27103 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); McMaster University; Wake Forest University; Wake Forest Baptist Medical Center	TEO, KK (corresponding author), UNIV ALBERTA, DIV CARDIOL, 2C2 WALTER MACKENZIE CTR, EDMONTON T6G 2R7, AB, CANADA.			Yusuf, Salim/0000-0003-4776-5601				ALLENNARKER RAC, 1984, BRIT J CLIN PHARMACO, V18, P725, DOI 10.1111/j.1365-2125.1984.tb02535.x; [Anonymous], 1989, NEW ENGL J MED, V321, P406; [Anonymous], 1988, LANCET, V1, P921; [Anonymous], 1988, AM J CARDIOL, V61, P501; [Anonymous], 1989, NEW ENGL J MED, V320, P618; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; Baker I A, 1971, Guys Hosp Rep, V120, P1; BASTIAN BC, 1980, AM HEART J, V100, P1017, DOI 10.1016/0002-8703(80)90207-0; BELL JA, 1982, BRIT HEART J, V48, P285; BENNETT MA, 1970, LANCET, V2, P909; BIGGER JT, 1977, PROG CARDIOVASC DIS, V19, P255, DOI 10.1016/0033-0620(77)90005-6; BOISSEL JP, 1990, AM J CARDIOL, V66, P251, DOI 10.1016/0002-9149(90)90831-K; BURKART F, 1990, J AM COLL CARDIOL, V16, P1711, DOI 10.1016/0735-1097(90)90324-I; CAIRNS JA, 1991, CIRCULATION, V84, P550, DOI 10.1161/01.CIR.84.2.550; CAMPBELL RWF, 1979, J CARDIOVASC PHARM, V1, P43, DOI 10.1097/00005344-197901000-00005; CAMPBELL RWF, 1983, BRIT HEART J, V49, P557; CAMPBELL RWF, 1975, LANCET, V1, P1257, DOI 10.1016/S0140-6736(75)92548-9; CAMPBELL RWF, 1979, P WORKSHOP TOCAINIDE, P141; CEREMUZYNSKI L, 1991, CIRCULATION, V84, P347; CHAMBERLAIN DA, 1980, LANCET, V2, P1324; CHOPRA MP, 1971, BMJ-BRIT MED J, V2, P668; COPLEN SE, 1990, CIRCULATION, V82, P1106, DOI 10.1161/01.CIR.82.4.1106; COSIN J, 1991, CIRCULATION S2, V84, P348; DARBY S, 1972, LANCET, V1, P817; DENNISS AR, 1988, EUR HEART J, V9, P746, DOI 10.1093/eurheartj/9.7.746; DESILVA RA, 1981, LANCET, V2, P855; DUNN HM, 1985, AM HEART J, V110, P353, DOI 10.1016/0002-8703(85)90156-5; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; GARGUICHEVICH J, 1992, European Heart Journal, V13, P291; GOTTLIEB SH, 1987, CIRCULATION, V75, P792, DOI 10.1161/01.CIR.75.4.792; HALINEN MO, 1984, EUR HEART J, V5, P675, DOI 10.1093/oxfordjournals.eurheartj.a061725; HAMER AWF, 1989, J AM COLL CARDIOL, V14, P1768, DOI 10.1016/0735-1097(89)90030-2; HANSEN JF, 1990, AM J CARDIOL, V66, P779; HARGARTEN KM, 1986, ANN EMERG MED, V15, P881, DOI 10.1016/S0196-0644(86)80667-9; HELD PH, 1989, BMJ-BRIT MED J, V299, P1187, DOI 10.1136/bmj.299.6709.1187; HELD PH, 1991, TXB INTERVENTIONAL C, P49; HINE LK, 1989, JAMA-J AM MED ASSOC, V262, P3037, DOI 10.1001/jama.262.21.3037; HOCKINGS BEF, 1987, AM J CARDIOL, V60, P967, DOI 10.1016/0002-9149(87)90334-1; HOLMBERG S, 1967, ACTA MED SCAND, V181, P297; HUGENHOLTZ PG, 1978, MANAGEMENT VENTRICUL, P572; Impact Research Group, 1984, J AM COLL CARDIOL, V4, P1148; JENNINGS G, 1976, LANCET, V1, P51; JONES DT, 1974, AM J CARDIOL, V33, P655, DOI 10.1016/0002-9149(74)90258-6; KERTES P, 1984, BRIT HEART J, V52, P241; KLINKE WP, 1984, CURR THER RES CLIN E, V35, P840; KOCHWESE.J, 1969, NEW ENGL J MED, V281, P1253, DOI 10.1056/NEJM196912042812301; KOSOWSKY BD, 1973, CIRCULATION, V47, P1204, DOI 10.1161/01.CIR.47.6.1204; KOSTER RW, 1985, NEW ENGL J MED, V313, P1105, DOI 10.1056/NEJM198510313131801; KOSTUK WJ, 1969, CIRCULATION S, V39, P111; LICHTLEN PR, 1990, LANCET, V335, P1109, DOI 10.1016/0140-6736(90)91121-P; LIE KI, 1974, NEW ENGL J MED, V291, P1324, DOI 10.1056/NEJM197412192912504; LIE KI, 1978, AM J CARDIOL, V42, P486, DOI 10.1016/0002-9149(78)90945-1; MACMAHON S, 1988, JAMA-J AM MED ASSOC, V260, P1910, DOI 10.1001/jama.260.13.1910; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; MAY GS, 1983, PROG CARDIOVASC DIS, V25, P335, DOI 10.1016/0033-0620(83)90013-0; MORGANROTH J, 1986, AM J CARDIOL, V57, P769, DOI 10.1016/0002-9149(86)90611-9; MORGANROTH J, 1991, CIRCULATION, V84, P1977, DOI 10.1161/01.CIR.84.5.1977; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; MOSS AJ, 1977, AM J CARDIOL, V39, P635, DOI 10.1016/S0002-9149(77)80122-7; NICHOLLS DP, 1980, LANCET, V2, P936; NICKLAS JM, 1991, AM HEART J, V122, P1016, DOI 10.1016/0002-8703(91)90466-U; NIELSEN BL, 1978, DAN MED BULL, V25, P121; OBRIEN KP, 1973, MED J AUSTRALIA, V2, P36; PETER T, 1978, BRIT HEART J, V40, P1356; PITT A, 1971, LANCET, V1, P612; POULEUR H, 1977, EUR J CARDIOL, V5, P397; REYNELL PC, 1961, BRIT HEART J, V23, P421; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; ROGERS WJ, 1992, NEW ENGL J MED, V327, P227; RYDEN L, 1980, AM HEART J, V100, P1006, DOI 10.1016/0002-8703(80)90205-7; SANDLER G, 1976, CURR THER RES CLIN E, V20, P563; SCHAFFER WA, 1975, NEW ENGL J MED, V293, P259, DOI 10.1056/NEJM197508072930601; SINGH JB, 1976, AM HEART J, V91, P430, DOI 10.1016/S0002-8703(76)80323-7; SMYLLIE HC, 1984, EUR J CLIN PHARMACOL, V26, P537, DOI 10.1007/BF00543481; VALENTINE PA, 1974, NEW ENGL J MED, V291, P1327, DOI 10.1056/NEJM197412192912505; VANDURME JP, 1977, MULTICENTER CONTROLL, P43; VAUGHAN WEM, 1981, CARDIAC ARRHYTHMIAS, P449; VOLPI A, 1988, NEW ENGL J MED, V318, P382; WATERS D, 1990, CIRCULATION, V82, P1940, DOI 10.1161/01.CIR.82.6.1940; WEINBLATT E, 1968, AM J PUBLIC HEALTH N, V58, P1329, DOI 10.2105/AJPH.58.8.1329; WENNERBLOM B, 1982, EUR HEART J, V3, P516, DOI 10.1093/oxfordjournals.eurheartj.a061346; WILCOX RG, 1980, LANCET, V2, P765; WYSE DG, 1988, J AM COLL CARDIOL, V12, P507, DOI 10.1016/0735-1097(88)90427-5; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; YUSUF S, 1991, AM J CARDIOL, V67, P1295, DOI 10.1016/0002-9149(91)90944-G; YUSUF S, 1991, J CARDIOVASC ELECT S, V2, pS233; ZAINAL N, 1977, LANCET, V2, P887; 1984, POSTGRAD MED J, V60, P98; 1971, LANCET, V2, P1055	89	445	458	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1589	1595		10.1001/jama.270.13.1589	http://dx.doi.org/10.1001/jama.270.13.1589			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371471				2022-12-28	WOS:A1993LZ33400034
J	WADDEN, TA				WADDEN, TA			TREATMENT OF OBESITY BY MODERATE AND SEVERE CALORIC RESTRICTION - RESULTS OF CLINICAL RESEARCH TRIALS	ANNALS OF INTERNAL MEDICINE			English	Article							WEIGHT-LOSS; FOLLOW-UP; ENERGY-INTAKE; DIET; EXERCISE; MAINTENANCE; PROGRAM; SAFETY; DEXFENFLURAMINE; DISORDER	Recent studies of the treatment of obesity by moderate and severe caloric restriction show that patients treated in randomized trials using a conventional 1200 kcal/d reducing diet, combined with behavior modification, lose approximately 8.5 kg in 20 weeks. They maintain approximately two thirds of this weight loss 1 year later. Patients treated under medical supervision using a very-low-calorie diet (400 to 800 kcal/d) lose approximately 20 kg in 12 to 16 weeks and maintain one half to two thirds of this loss in the following year. Both dietary interventions are associated with increasing weight regain over time, although regain can be minimized with the recognition that obesity, in many cases, is a chronic condition that requires continuing care. Patients who participate in a formal weight-loss maintenance program, exercise regularly, or both are likely to achieve the best long-term results.			WADDEN, TA (corresponding author), SYRACUSE UNIV, CTR HLTH & BEHAV, 804 UNIV AVE, SYRACUSE, NY 13244 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049451] Funding Source: NIH RePORTER; NIMH NIH HHS [NIMH MH00702-05, NIMH R01-MH49451-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN T, 1984, NEW ENGL J MED, V310, P352, DOI 10.1056/NEJM198402093100604; ANDERSEN T, 1992, INT J OBESITY, V16, P35; ANDERSON JW, 1991, J AM DIET ASSOC, V91, P1582; [Anonymous], 1958, N Y State J Med, V58, P79; BANDINI LG, 1990, AM J CLIN NUTR, V52, P421, DOI 10.1093/ajcn/52.3.421; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; BROWNELL KD, 1987, BEHAV THER, V18, P353, DOI 10.1016/S0005-7894(87)80004-7; BROWNELL KD, 1982, J CONSULT CLIN PSYCH, V50, P820, DOI 10.1037/0022-006X.50.6.820; Brownell KD., 1989, LEARN PROGRAM WEIGHT; DAHLKOETTER JA, 1979, J CONSULT CLIN PSYCH, V47, P898, DOI 10.1037/0022-006X.47.5.898; DOHERTY JU, 1991, AM J CLIN NUTR, V53, P854, DOI 10.1093/ajcn/53.4.854; FINER N, 1989, INT J OBESITY, V13, P91; FOSTER GD, 1992, AM J CLIN NUTR, V55, P811, DOI 10.1093/ajcn/55.4.811; KANDERS BS, 1989, INT J OBESITY, V13, P131; KAYMAN S, 1990, AM J CLIN NUTR, V52, P800, DOI 10.1093/ajcn/52.5.800; KING AC, 1991, SPORTS MED, V11, P331, DOI 10.2165/00007256-199111050-00004; KRAMER FM, 1989, INT J OBESITY, V13, P123; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MIURA J, 1989, INT J OBESITY, V13, P73; ONEILL M, 1990, NY TIMES        0401, P1; PALGI A, 1985, AM J PUBLIC HEALTH, V75, P1190, DOI 10.2105/AJPH.75.10.1190; PAVLOU KN, 1986, ANN SURG, V203, P136, DOI 10.1097/00000658-198602000-00005; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; PERRI MG, 1989, J CONSULT CLIN PSYCH, V57, P450, DOI 10.1037/0022-006X.57.3.450; PERRI MG, 1988, J CONSULT CLIN PSYCH, V56, P529, DOI 10.1037/0022-006X.56.4.529; PERRI MG, 1984, J CONSULT CLIN PSYCH, V52, P404, DOI 10.1037/0022-006X.52.3.404; SIKAND G, 1988, J AM DIET ASSOC, V88, P487; SMITH DE, 1991, HEALTH PSYCHOL, V10, P378, DOI 10.1037/0278-6133.10.6.378; SPITZER RL, 1992, INT J EAT DISORDER, V11, P191, DOI 10.1002/1098-108X(199204)11:3&lt;191::AID-EAT2260110302&gt;3.0.CO;2-S; STEPTOE A, 1988, HEALTH PSYCHOL, V7, P329, DOI 10.1037/0278-6133.7.4.329; STUNKARD A, 1959, ARCH INTERN MED, V103, P79, DOI 10.1001/archinte.1959.00270010085011; TAYLOR CB, 1991, AM J EPIDEMIOL, V134, P235, DOI 10.1093/oxfordjournals.aje.a116077; TREMBLAY A, 1991, AM J CLIN NUTR, V54, P506, DOI 10.1093/ajcn/54.3.506; VERTES V, 1977, JAMA-J AM MED ASSOC, V238, P2151, DOI 10.1001/jama.238.20.2151; VOLKMAR FR, 1981, ARCH INTERN MED, V141, P426, DOI 10.1001/archinte.141.4.426; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961; WADDEN TA, 1989, INT J OBESITY, V13, P39; WADDEN TA, 1983, ANN INTERN MED, V99, P675, DOI 10.7326/0003-4819-99-5-675; WADDEN TA, 1992, TREATMENT SERIOUSLY, P44; WING RR, 1991, ARCH INTERN MED, V151, P1334, DOI 10.1001/archinte.151.7.1334; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; YANG MU, 1992, TREATMENT SERIOUSLY, P83; 1989, EXCHANGE LISTS MEAL; [No title captured]	45	346	359	1	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				688	693		10.7326/0003-4819-119-7_Part_2-199310011-00012	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363198				2022-12-28	WOS:A1993MA33000012
J	TRENTHAM, DE; DYNESIUSTRENTHAM, RA; ORAV, EJ; COMBITCHI, D; LORENZO, C; SEWELL, KL; HAFLER, DA; WEINER, HL				TRENTHAM, DE; DYNESIUSTRENTHAM, RA; ORAV, EJ; COMBITCHI, D; LORENZO, C; SEWELL, KL; HAFLER, DA; WEINER, HL			EFFECTS OF ORAL-ADMINISTRATION OF TYPE-II COLLAGEN ON RHEUMATOID-ARTHRITIS	SCIENCE			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; GROWTH-FACTOR-BETA; IMMUNE-RESPONSES; SUPPRESSION; ANTIGEN; ANTIBODIES; TOLERANCE; INDUCTION; INVITRO	Rheumatoid arthritis is an inflammatory synovial disease thought to involve T cells reacting to an antigen within the joint. Type II collagen is the major protein in articular cartilage and is a potential autoantigen in this disease. Oral tolerization to autoantigens suppresses animal models of T cell-mediated autoimmune disease, including two models of rheumatoid arthritis. In this randomized, double-blind trial involving 60 patients with severe, active rheumatoid arthritis, a decrease in the number of swollen joints and tender joints occurred in subjects fed chicken type II collagen for 3 months but not in those that received a placebo. Four patients in the collagen group had complete remission of the disease. No side effects were evident. These data demonstrate clinical efficacy of an oral tolerization approach for rheumatoid arthritis.	CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV NEUROL,CTR NEUROL DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH PUBL HLTH,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HARVARD THORNDIKE LAB,BOSTON,MA 02115	Harvard University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	TRENTHAM, DE (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV RHEUMATOL,BOSTON,MA 02215, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR01032] Funding Source: Medline; NIA NIH HHS [AG00294] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AL-SABBAGH A, 1992, Neurology, V42, P346; ANDRIOPOULOS NA, 1976, ARTHRITIS RHEUM, V19, P613, DOI 10.1002/art.1780190314; BITAR DM, 1988, CELL IMMUNOL, V112, P364, DOI 10.1016/0008-8749(88)90305-X; BROOKS PM, 1993, LANCET, V341, P286, DOI 10.1016/0140-6736(93)92628-7; CATHCART ES, 1986, LAB INVEST, V54, P26; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; FRIEDMAN A, 1993, J IMMUNOL, V150, pA4; HELFGOTT SM, 1985, J EXP MED, V162, P1531, DOI 10.1084/jem.162.5.1531; HELFGOTT SM, 1991, LANCET, V337, P387, DOI 10.1016/0140-6736(91)91165-Q; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; KAMMER GM, 1984, ARTHRITIS RHEUM, V27, P489, DOI 10.1002/art.1780270502; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; LIDER O, 1989, J IMMUNOL, V142, P748; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; NAGLERANDERSON C, 1986, P NATL ACAD SCI USA, V83, P7443, DOI 10.1073/pnas.83.19.7443; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; NUSSENBLATT RB, COMMUNICATION; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; SEWELL KL, 1993, LANCET, V341, P283, DOI 10.1016/0140-6736(93)92627-6; SEWELL KL, IN PRESS ARTHRITIS R; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; TARKOWSKI A, 1989, ARTHRITIS RHEUM, V32, P1087, DOI 10.1002/anr.1780320906; THOMPSON HSG, 1986, CLIN EXP IMMUNOL, V64, P581; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; TRENTHAM DE, 1978, NEW ENGL J MED, V299, P327, DOI 10.1056/NEJM197808172990703; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, IN PRESS ANN REV IMM; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; ZHANG ZJ, 1991, P NATL ACAD SCI USA, V88, P10252, DOI 10.1073/pnas.88.22.10252; ZHANG ZYJ, 1990, J IMMUNOL, V145, P2489	33	597	665	5	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1727	1730		10.1126/science.8378772	http://dx.doi.org/10.1126/science.8378772			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378772				2022-12-28	WOS:A1993LY58400024
J	ALLISON, DB; HESHKA, S; SEPULVEDA, D; HEYMSFIELD, SB				ALLISON, DB; HESHKA, S; SEPULVEDA, D; HEYMSFIELD, SB			COUNTING CALORIES - CAVEAT-EMPTOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							WEIGHT	Objective.-To determine the accuracy of caloric labeling of ''diet'' and ''health'' foods and whether the accuracy differs for certain categories of food suppliers. Design.-Survey; ''diet'' and ''health'' foods were analyzed via bomb calorimetry and categorized as regionally distributed, nationally advertised, or locally prepared. Setting.-Foods were sampled from retail merchants throughout the borough of Manhattan, New York, NY. Sample.-A convenience sample of 40 food items including regionally distributed (n=12), nationally advertised (n=20), and locally prepared items (n=8). Main Outcome Measures.-Number of kilocalories per item and number of kilocalories per gram. Results.-All locally prepared foods had more actual than labeled kilocalories. The mean percentage of actual kilocalories greater than the labeled kilocalories (mean percentage over label) per item was 85.42% (SD=77.88%; P=.01). Regionally distributed foods had significantly more kilocalories than were reported (P=.001 for kilocalories per item, P=.02 for kilocalories per gram) and mean percentage over label per item was 25.22% (SD=15.58%) and per gram was 14.97% (SD=17.95%). Nationally advertised foods did not have significantly more actual than reported kilocalories (P=.37 for per item, P=.78 for per gram). Mean percentage over label per gram was -0.01% (SD=9.13%) and per item was 2.18% (SD=13.93%). Conclusion.-These findings suggest that food labels may be inadequate sources for caloric monitoring. Health care professionals should consider the accuracy of caloric labeling when advising patients to use food labels to help monitor their caloric intake.			ALLISON, DB (corresponding author), COLUMBIA UNIV,COLL PHYSICIANS & SURGEONS,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10025, USA.		Heymsfield, Steven B/N-1968-2017	Heymsfield, Steven B/0000-0003-1127-9425; Allison, David/0000-0003-3566-9399	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687] Funding Source: NIH RePORTER; NIDDK NIH HHS [DKNY2618, DK26687] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON RG, 1983, PERSPECTIVE APPLICAT, P11; BANDINI LG, 1990, PEDIATR RES, V27, P198, DOI 10.1203/00006450-199002000-00022; BURROS M, 1989, NY TIMES        0809, pC1; EDGINGTON ES, 1987, J COUNS PSYCHOL, V34, P437, DOI 10.1037/0022-0167.34.4.437; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; KLASSEN ML, 1991, J ADVERTISING RES, V30, P32; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; MERTZ W, 1991, AM J CLIN NUTR, V54, P291, DOI 10.1093/ajcn/54.2.291; MILLER DS, 1959, BRIT J NUTR, V13, P501, DOI 10.1079/BJN19590064; STUNKARD AJ, 1992, TREATMENT SERIOUSLY, P33; WADDEN TA, 1992, TREATMENT SERIOUSLY, P44; 1992, CONSUM REP, V59, P483; 1993, FED REGISTER, V58, P2302; 1991, U CALIF BERKELEY NEW, V8, P1	14	15	15	1	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1454	1456		10.1001/jama.270.12.1454	http://dx.doi.org/10.1001/jama.270.12.1454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371446				2022-12-28	WOS:A1993LX17300030
J	CHAN, IT; LIMMER, A; LOUIE, MC; BULLOCK, ED; FUNGLEUNG, WP; MAK, TW; LOH, DY				CHAN, IT; LIMMER, A; LOUIE, MC; BULLOCK, ED; FUNGLEUNG, WP; MAK, TW; LOH, DY			THYMIC SELECTION OF CYTOTOXIC T-CELLS INDEPENDENT OF CD8-ALPHA-LCK ASSOCIATION	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; I ALPHA-3 DOMAIN; TRANSGENIC MICE; LYMPHOCYTES-T; CYTOPLASMIC DOMAINS; POSITIVE SELECTION; NEGATIVE SELECTION; ANTIGEN RECEPTOR; CD4 RECEPTOR; P56LCK	The CD8alpha cytoplasmic domain associates with p56lck, a nonreceptor protein-tyrosine kinase. The biological relevance of CD8alpha-Lck association in T cell development was tested with transgenic mice generated to express a CD8alpha molecule with two amino acid substitutions in its cytoplasmic domain, which abolishes the association of CD8alpha with Lck. The CD8alpha mutant was analyzed in a CD8-/- background and in the context of the transgenic 2C T cell receptor. The development and function of CD8+ T cells in these mice were apparently normal. Thus, CD8alpha-Lck association is not necessary for positive selection, negative selection, or CD8-dependent cytotoxic function.	WASHINGTON UNIV,SCH MED,DEPT MED GENET & MOLEC MICROBIOL,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; ONTARIO CANC INST,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO M4X 1K9,ONTARIO,CANADA; UNIV TORONTO,DEPT IMMUNOL,TORONTO M4X 1K9,ONTARIO,CANADA	Howard Hughes Medical Institute; Washington University (WUSTL); University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto				Fung-Leung, Wai-Ping/0000-0001-7013-8855	NIAID NIH HHS [AI 155322-13] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, J EXP MED, V173, P1421, DOI 10.1084/jem.173.6.1421; ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CHALUPNY NJ, 1991, EMBO J, V10, P1201, DOI 10.1002/j.1460-2075.1991.tb08061.x; CHAN IY, UNPUB; CONNOLLY JM, 1988, J EXP MED, V168, P325, DOI 10.1084/jem.168.1.325; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; FUNGLEUNG WP, 1993, EUR J IMMUNOL, V23, P212, DOI 10.1002/eji.1830230133; GEORGOPOULOS K, 1988, EMBO J, V7, P2401, DOI 10.1002/j.1460-2075.1988.tb03085.x; GORMAN SD, 1988, J IMMUNOL, V140, P3646; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LITTMAN DR, 1987, ANNU REV IMMUNOL, V5, P561, DOI 10.1146/annurev.iy.05.040187.003021; LOH DY, 1991, NEW BIOL, V3, P924; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NAKAUCHI H, 1987, NUCLEIC ACIDS RES, V15, P4337, DOI 10.1093/nar/15.10.4337; NAKAYAMA K, 1992, SCIENCE, V257, P94, DOI 10.1126/science.1621101; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUSSELL JH, 1990, J IMMUNOL, V144, P3318; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; TELFER JC, 1991, SCIENCE, V254, P439, DOI 10.1126/science.1925604; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANDENELSEN P, 1986, P NATL ACAD SCI USA, V83, P2944; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	35	66	66	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1581	1584		10.1126/science.8372352	http://dx.doi.org/10.1126/science.8372352			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372352				2022-12-28	WOS:A1993LX47400031
J	THOMAS, GMH; CUNNINGHAM, E; FENSOME, A; BALL, A; TOTTY, NF; TRUONG, O; HSUAN, JJ; COCKCROFT, S				THOMAS, GMH; CUNNINGHAM, E; FENSOME, A; BALL, A; TOTTY, NF; TRUONG, O; HSUAN, JJ; COCKCROFT, S			AN ESSENTIAL ROLE FOR PHOSPHATIDYLINOSITOL TRANSFER PROTEIN IN PHOSPHOLIPASE C-MEDIATED INOSITOL LIPID SIGNALING	CELL			English	Article							BOVINE BRAIN; STREPTOLYSIN-O; ALPHA-SUBUNITS; BETA-GAMMA; CELLS; RECEPTOR; GQ; ACTIVATION; MEMBRANE; BINDING	Transmembrane signaling by the phospholipase C-beta (PLC-beta) pathway is known to require at least three components: the receptor, the G protein, and the PLC. Recent studies have indicated that if the cytosol is allowed to leak out of HL60 cells, then G protein-stimulated PLC activity is greatly diminished, indicating an essential role for a cytosolic component(s). We now report the complete purification of one component based on its ability to reconstitute GTPgammaS-mediated PLC activity and identify it as the phosphatidylinositol transfer protein (PI-TP). Based on the in vitro effects of PI-TP, we surmise that it is involved in transporting PI from intracellular compartments for conversion to PI bisphosphate (PIP2) prior to hydrolysis by PLC-beta2/PLC-beta3, the endogenous PLC isoforms present in these cells.	UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	THOMAS, GMH (corresponding author), UNIV LONDON UNIV COLL, DEPT PHYSIOL, LONDON WC1E 6JJ, ENGLAND.		Hsuan, Justin/C-8825-2009; Cockcroft, Shamshad/F-9480-2011	Hsuan, Justin/0000-0001-6083-7564; Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AITKEN JF, 1990, J BIOL CHEM, V265, P4711; ALLAN D, 1989, BIOCHIM BIOPHYS ACTA, V987, P199, DOI 10.1016/0005-2736(89)90545-2; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; CAROZZI AJ, 1992, EUR J BIOCHEM, V210, P521, DOI 10.1111/j.1432-1033.1992.tb17450.x; COCKCROFT S, 1988, PHILOS T ROY SOC B, V320, P247, DOI 10.1098/rstb.1988.0075; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COCKCROFT S, 1985, BIOCHIM BIOPHYS ACTA, V845, P163, DOI 10.1016/0167-4889(85)90173-9; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DOWNES CP, 1989, INOSITOL LIPIDS CELL, P3; FAIN JN, 1979, BIOCHEM J, V180, P655, DOI 10.1042/bj1800655; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; IMAI A, 1987, NATURE, V325, P726, DOI 10.1038/325726a0; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOREH K, 1986, J BIOL CHEM, V261, P88; KRITZ R, 1990, CIBA F S, V150, P112; LEE CH, 1992, J BIOL CHEM, V267, P16044; MICHELL RH, 1988, PHILOS T ROY SOC B, V320, P239, DOI 10.1098/rstb.1988.0074; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; MONACO ME, 1992, ENDOCR REV, V13, P707, DOI 10.1210/er.13.4.707; MUNTZ KH, 1992, MOL BIOL CELL, V3, P49, DOI 10.1091/mbc.3.1.49; PARK D, 1992, J BIOL CHEM, V267, P16048; PAYRASTRE B, 1991, J CELL BIOL, V115, P121, DOI 10.1083/jcb.115.1.121; RHEE SG, 1992, J BIOL CHEM, V267, P12393; SANTIAGO OM, 1993, BIOCHEM J, V290, P179, DOI 10.1042/bj2900179; SCHERMOLY MJ, 1983, BRAIN RES, V268, P197, DOI 10.1016/0006-8993(83)90410-9; SNOEK GT, 1992, J CELL BIOCHEM, V49, P339, DOI 10.1002/jcb.240490404; SOMERHARJU P, 1983, BIOCHIM BIOPHYS ACTA, V731, P186, DOI 10.1016/0005-2736(83)90008-1; STUTCHFIELD J, 1988, BIOCHEM J, V250, P375, DOI 10.1042/bj2500375; STUTCHFIELD J, 1991, EUR J BIOCHEM, V197, P119, DOI 10.1111/j.1432-1033.1991.tb15889.x; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMAS GMH, 1991, EMBO J, V10, P2507, DOI 10.1002/j.1460-2075.1991.tb07790.x; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; VAZIRI C, 1992, J BIOL CHEM, V267, P22973; VENUTI SE, 1988, BIOCHIM BIOPHYS ACTA, V946, P119, DOI 10.1016/0005-2736(88)90464-6; WIRTZ KWA, 1991, ANNU REV BIOCHEM, V60, P73, DOI 10.1146/annurev.biochem.60.1.73; WU DQ, 1992, J BIOL CHEM, V267, P1811	43	188	193	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 10	1993	74	5					919	928		10.1016/0092-8674(93)90471-2	http://dx.doi.org/10.1016/0092-8674(93)90471-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374957				2022-12-28	WOS:A1993LX29200017
J	MUELLER, MW; HETZER, M; SCHWEYEN, RJ				MUELLER, MW; HETZER, M; SCHWEYEN, RJ			GROUP-II INTRON RNA CATALYSIS OF PROGRESSIVE NUCLEOTIDE INSERTION - A MODEL FOR RNA EDITING	SCIENCE			English	Article							MESSENGER-RNA; LARIAT FORMATION; INVITRO; TETRAHYMENA; SITES	The self-splicing bl1 intron lariat from mitochondria of Saccharomyces cerevisiae catalyzed the insertion of nucleotidyl monomers derived from the 3' end of a donor RNA into an acceptor RNA in a 3' to 5' direction in vitro. In this catalyzed reaction, the site specificity provided by intermolecular base pair interactions, the formation of chimeric intermediates, the polarity of the nucleotidyl insertion, and its reversibility all resemble such properties in previously proposed models of RNA editing in kinetoplastid mitochondria. These results suggest that RNA editing occurs by way of a concerted, two-step transesterification mechanism and that RNA splicing and RNA editing might be prebiotically related mechanisms; possibly, both evolved from a primordial demand for self-replication.			MUELLER, MW (corresponding author), UNIV VIENNA,INST MICROBIOL & GENET,VIENNA BIOCTR,DR BOHR GASSE 9,A-1030 VIENNA,AUSTRIA.							ATKINSON RJ, 1989, NATURE, V340, P290, DOI 10.1038/340290a0; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BENNE R, 1990, TRENDS GENET, V6, P177, DOI 10.1016/0168-9525(90)90173-4; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; CAMERON V, 1977, BIOCHEMISTRY-US, V16, P5120, DOI 10.1021/bi00642a027; CECH TR, 1986, P NATL ACAD SCI USA, V83, P4360, DOI 10.1073/pnas.83.12.4360; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DOUDNA JA, 1989, NATURE, V339, P519, DOI 10.1038/339519a0; FEAGIN JE, 1990, J BIOL CHEM, V265, P19373; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; MORL M, 1990, NUCLEIC ACIDS RES, V18, P6545, DOI 10.1093/nar/18.22.6545; MORL M, 1990, CELL, V60, P629, DOI 10.1016/0092-8674(90)90666-3; MULLER MW, 1991, J MOL BIOL, V222, P145, DOI 10.1016/0022-2836(91)90201-G; SCHMEIZER C, 1987, CELL, V51, P753, DOI 10.1016/0092-8674(87)90098-5; SCHMELZER C, 1986, CELL, V46, P557, DOI 10.1016/0092-8674(86)90881-0; SIMPSON L, 1989, CELL, V57, P355, DOI 10.1016/0092-8674(89)90911-2; Sollner-Webb B, 1991, CURR OPIN CELL BIOL, V3, P1056, DOI 10.1016/0955-0674(91)90129-M; SOLLNERWEBB B, 1992, NATURE, V356, P743, DOI 10.1038/356743a0; STUART K, 1991, TRENDS BIOCHEM SCI, V16, P68, DOI 10.1016/0968-0004(91)90027-S; WEINER AM, 1990, CELL, V61, P917, DOI 10.1016/0092-8674(90)90053-H; WEISSMANN C, 1990, NATURE, V343, P697, DOI 10.1038/343697a0; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	28	14	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					1035	1038		10.1126/science.8351516	http://dx.doi.org/10.1126/science.8351516			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351516				2022-12-28	WOS:A1993LT74700031
J	KILLEEN, N; LITTMAN, DR				KILLEEN, N; LITTMAN, DR			HELPER T-CELL DEVELOPMENT IN THE ABSENCE OF CD4-P56(LCK) ASSOCIATION	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; TRANSGENIC MICE; PHYSICAL ASSOCIATION; SIGNAL TRANSDUCTION; CYTOPLASMIC DOMAINS; POSITIVE SELECTION; ALPHA-3 DOMAIN; LYMPHOCYTES-T	THE CD4 and CD8 glycoproteins are expressed on helper and cytoxic T lymphocytes, respectively, and have important functions in the differentiation and activation of these cells1-8. These molecules are thought to participate in signal transduction by binding to the same class II or class I major histocompatibility complex molecules that are engaged by the T-cell antigen receptor9-13. The cytoplasmic domains of both CD4 and CD8 interact with the protein tyrosine kinase p56lck (refs 14-17), an essential participant in thymocyte maturation18 and T-cell activation19. This interaction is required for effective in vitro responses to antigen5-8, suggesting that signalling through p56lck is a major function of CD4 and CD8. Here we investigate the role of the CD4-p56lck interaction during T-lymphocyte development by expressing wild-type and truncated products of CD4 transgenes in mice that lack endogenous CD4 and hence have defective helper-cell development3,4. We find that transgenic CD4, which cannot associate with p56lck, can nevertheless rescue the helper-cell lineage when overexpressed. This result indicates that the contribution of CD4 to lineage development need not involve signalling through p56lck, and provides insight into the general function of CD4 and CD8.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	KILLEEN, N (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.							ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BORGULYA P, 1991, EMBO J, V10, P913, DOI 10.1002/j.1460-2075.1991.tb08024.x; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COLLINS TL, 1992, J IMMUNOL, V148, P2159; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HOGAN B, 1986, MANIPULATING MOUSE E; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KIYOSHI M, 1993, SCIENCE, V254, P1788; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; LOCKSLEY R, IN PRESS SCIENCE; MICELI MC, 1991, P NATL ACAD SCI USA, V88, P2623, DOI 10.1073/pnas.88.7.2623; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROBEY E, 1991, P NATL ACAD SCI USA, V88, P608, DOI 10.1073/pnas.88.2.608; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SEONG RH, 1992, NATURE, V356, P718, DOI 10.1038/356718a0; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TEH HS, 1991, NATURE, V349, P241, DOI 10.1038/349241a0; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VANOERS NSC, 1992, EUR J IMMUNOL, V22, P735, DOI 10.1002/eji.1830220317; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; XU H, IN PRESS CELL; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	37	123	123	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					729	732		10.1038/364729a0	http://dx.doi.org/10.1038/364729a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355789				2022-12-28	WOS:A1993LT67700062
J	HAWORTH, EA; BOOY, R; STIRZAKER, L; WILKES, S; BATTERSBY, A				HAWORTH, EA; BOOY, R; STIRZAKER, L; WILKES, S; BATTERSBY, A			IS THE COLD CHAIN FOR VACCINES MAINTAINED IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							STORAGE	Objective-To investigate the cold chain for vaccines and compliance with the local code of practice for storage. Design-In a random sample of general practices orders for live vaccines (oral polio and measles, mumps, and rubella) were accompanied by a cold chain monitor which was activated on leaving the supplying pharmacy. The monitors were read at specified intervals and when all vaccines in the order had been used. Structured interview was used to check compliance with the local code of practice on storage. Setting-West Berkshire and Aylesbury Vale district health authorities. Subjects-16 (25%) general practices in West Berkshire, and 13 (50%) in Aylesbury Vale. Main outcome measures-Compliance with code of practice. Changes in the cold chain monitor. Results-For six key requirements within the code of practice compliance varied from 70% to 0%. Only 16 of 29 practices had a named person responsible for vaccine storage and only four were aware of the local code of practice. Vaccine was stored for longer and more breaks in the cold chain occurred in West Berkshire than in Aylesbury Vale. The potency of some vaccines in 10 of 26 orders became suspect before use. Conclusions-Knowledge of appropriate management of the cold chain in two districts was poor. Breaks in the chain were more frequent and compromised potency more likely when vaccine had been stored for more than eight weeks. Problems in maintaining the cold chain indicate the need for continuing audit, which should become a prerequisite for payments to general practitioners for immunisation.	JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND; AYLESBURY VALE HLTH AUTHOR,AYLESBURY HP19 3DX,ENGLAND; WHO,OPERAT MANAGEMENT,BATH BA3 6RL,ENGLAND	University of Oxford; World Health Organization	HAWORTH, EA (corresponding author), PROSPECT PK HOSP,W BERKSHIRE HLTH AUTHOR,READING RG3 4EJ,ENGLAND.		Booy, Robert/D-4188-2011					BISHAI DM, 1992, PEDIATRICS, V89, P193; HUNTER S, 1989, BRIT MED J, V299, P661, DOI 10.1136/bmj.299.6700.661; KRUGMAN RD, 1974, J PEDIATR-US, V85, P512, DOI 10.1016/S0022-3476(74)80455-5; LERMAN SJ, 1971, J AMER MED ASSOC, V216, P1311, DOI 10.1001/jama.216.8.1311; LUGOSI L, 1990, B WORLD HEALTH ORGAN, V68, P431; NOKES DJ, 1991, LANCET, V338, P1309, DOI 10.1016/0140-6736(91)92601-W; THAKKER Y, 1992, BRIT MED J, V304, P756, DOI 10.1136/bmj.304.6829.756; 1987, WHO EPICCIS83REV1; 1985, WHO EPICCIS851; 1989, MMWR, V38, P863; 1990, GUIDELINES STORAGE V; 1989, GUIDELINES STORAGE V; 1990, IMMUNISATION INFECTI	13	29	29	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					242	244		10.1136/bmj.307.6898.242	http://dx.doi.org/10.1136/bmj.307.6898.242			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369691	Green Published, Bronze			2022-12-28	WOS:A1993LP31400029
J	MANSELL, P; SCOTT, VL; LOGAN, RF; RECKLESS, JPD				MANSELL, P; SCOTT, VL; LOGAN, RF; RECKLESS, JPD			LESSON OF THE WEEK - SECONDARY ADRENOCORTICAL INSUFFICIENCY	BRITISH MEDICAL JOURNAL			English	Article							PITUITARY-FUNCTION; CORTISOL RESPONSE; CORTICOTROPIN		ST MARYS HOSP,DEPT GENET,PORTSMOUTH PO3 6AQ,HANTS,ENGLAND; ROYAL UNITED HOSP,DEPT MED,BATH,AVON,ENGLAND		MANSELL, P (corresponding author), ROYAL S HANTS HOSP,DEPT MED,SOUTHAMPTON SO9 4PE,HANTS,ENGLAND.							BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; BURKE CW, 1985, CLIN ENDOCRINOL META, V14, P947, DOI 10.1016/S0300-595X(85)80084-0; CLAYTON RN, 1989, BRIT MED J, V298, P271, DOI 10.1136/bmj.298.6669.271; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; HARSOULIS P, 1973, BMJ-BRIT MED J, V4, P326, DOI 10.1136/bmj.4.5888.326; LYTRAS N, 1984, CLIN ENDOCRINOL, V20, P71, DOI 10.1111/j.1365-2265.1984.tb00061.x; PARK GR, 1989, BRIT MED J, V298, P669, DOI 10.1136/bmj.298.6674.669-b; PAVORD SR, 1992, CLIN ENDOCRINOL, V36, P135, DOI 10.1111/j.1365-2265.1992.tb00947.x; SHAH A, 1992, BMJ, V304, P193; STEWART PM, 1988, LANCET, V1, P1208	11	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					253	254		10.1136/bmj.307.6898.253	http://dx.doi.org/10.1136/bmj.307.6898.253			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369695	Bronze, Green Published			2022-12-28	WOS:A1993LP31400034
J	SWEDLOW, JR; SEDAT, JW; AGARD, DA				SWEDLOW, JR; SEDAT, JW; AGARD, DA			MULTIPLE CHROMOSOMAL POPULATIONS OF TOPOISOMERASE-II DETECTED INVIVO BY TIME-LAPSE, 3-DIMENSIONAL WIDE-FIELD MICROSCOPY	CELL			English	Article							DNA TOPOISOMERASE; DROSOPHILA-MELANOGASTER; NUCLEAR-ENVELOPE; MITOTIC CHROMOSOMES; SCAFFOLD ATTACHMENT; CONDENSATION; CHROMATIN; INVITRO; EMBRYOS; ORGANIZATION	The localization of topoisomerase II (topo II) in vivo was studied by recording time-lapse, three-dimensional data sets of living Drosophila melanogaster embryos injected with rhodamine-labeled topo II. These images show that topo II is concentrated at specific sites within the interphase nucleus and that this localization is temporally regulated. The enzyme is not restricted to a central chromosome axis, but is distributed uniformly throughout the chromosome. During mitosis, the enzyme present in the early prophase chromosome is lost in two stages, following prophase and following anaphase. Overall, 70% of the enzyme leaves the nucleus and diffuses into the cytoplasm. The localization of the enzyme thus correlates with its role in chromosome condensation and segregation. Rather than being solely a structural protein, topo II appears to localize at the sites on the chromosome where it is required.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	SWEDLOW, JR (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Swedlow, Jason/0000-0002-2198-1958	NIGMS NIH HHS [GM-25101, GM-31627] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031627, R01GM025101] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; AGARD DA, 1989, METHOD CELL BIOL, V30, P353; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BELMONT AS, 1987, J CELL BIOL, V105, P77, DOI 10.1083/jcb.105.1.77; BELMONT AS, 1989, CHROMOSOMA, V98, P129, DOI 10.1007/BF00291049; BERRIOS M, 1985, P NATL ACAD SCI USA, V82, P4142, DOI 10.1073/pnas.82.12.4142; Castleman KR., 1979, DIGITAL IMAGE PROCES; CHEN H, 1989, HANDBOOK OF BIOLOGICAL CONFOCAL MICROSCOPY, REVISED EDITION, P141; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DOWNES CS, 1991, P NATL ACAD SCI USA, V88, P8895, DOI 10.1073/pnas.88.20.8895; EARNSHAW WC, 1985, J CELL BIOL, V100, P1706, DOI 10.1083/jcb.100.5.1706; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; FAIRMAN R, 1988, BIOCHEMISTRY-US, V27, P560, DOI 10.1021/bi00402a009; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOE VE, 1983, J CELL SCI, V61, P31; FUCHS JP, 1983, J CELL SCI, V64, P331; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; GASSER SM, 1986, EMBO J, V5, P511, DOI 10.1002/j.1460-2075.1986.tb04240.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; HIRAOKA Y, 1989, NATURE, V342, P293, DOI 10.1038/342293a0; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; HIRAOKA Y, 1990, J CELL BIOL, V111, P2815, DOI 10.1083/jcb.111.6.2815; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; HSIEH TS, 1983, METHOD ENZYMOL, V100, P161; IZAURRALDE E, 1988, J MOL BIOL, V200, P111, DOI 10.1016/0022-2836(88)90337-3; KAS E, 1992, EMBO J, V11, P705, DOI 10.1002/j.1460-2075.1992.tb05103.x; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; MINDEN JS, 1989, J CELL BIOL, V109, P505, DOI 10.1083/jcb.109.2.505; MIRKOVITCH J, 1988, J MOL BIOL, V200, P101, DOI 10.1016/0022-2836(88)90336-1; MOENS PB, 1989, CHROMOSOMA, V98, P317, DOI 10.1007/BF00292383; NEGRI C, 1992, EXP CELL RES, V200, P452, DOI 10.1016/0014-4827(92)90195-E; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PARHAM P, 1986, HDB EXPT IMMUNOLOGY; SANDER M, 1983, J BIOL CHEM, V258, P8421; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SHELTON ER, 1983, J BIOL CHEM, V258, P9530; Sonnenblick B., 1950, BIOL DROSOPHILA, P62; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; UDVARDY A, 1991, MOL CELL BIOL, V11, P4973, DOI 10.1128/MCB.11.10.4973; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WHALEN AM, 1991, J CELL BIOL, V112, P203, DOI 10.1083/jcb.112.2.203; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; WU CT, 1989, TRENDS GENET, V5, P189, DOI 10.1016/0168-9525(89)90074-7; WYCKOFF E, 1989, J MOL BIOL, V205, P1, DOI 10.1016/0022-2836(89)90361-6; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	59	158	163	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 9	1993	73	1					97	108		10.1016/0092-8674(93)90163-K	http://dx.doi.org/10.1016/0092-8674(93)90163-K			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8384932				2022-12-28	WOS:A1993KW75300011
J	RAMAKRISHNAN, V; FINCH, JT; GRAZIANO, V; LEE, PL; SWEET, RM				RAMAKRISHNAN, V; FINCH, JT; GRAZIANO, V; LEE, PL; SWEET, RM			CRYSTAL-STRUCTURE OF GLOBULAR DOMAIN OF HISTONE H5 AND ITS IMPLICATIONS FOR NUCLEOSOME BINDING	NATURE			English	Article							GENE ACTIVATOR PROTEIN; SYNCHROTRON RADIATION; ANOMALOUS DISPERSION; B-DNA; CHROMATIN; SEQUENCE; RESOLUTION; MODEL; H-5; MOLECULE	The structure of GH5, the globular domain of the linker histone H5, has been solved to 2.5 angstrom resolution by multiwavelength anomalous diffraction on crystals of the selenomethionyl protein. The structure shows a striking similarity to the DNA-binding domain of the catabolite gene activator protein CAP, thereby providing a possible model for the binding of GH5 to DNA.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND	MRC Laboratory Molecular Biology	RAMAKRISHNAN, V (corresponding author), BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973, USA.			Ramakrishnan, V/0000-0002-4699-2194				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; APPELS R, 1972, J MOL BIOL, V70, P425, DOI 10.1016/0022-2836(72)90550-5; AVILES FJ, 1978, EUR J BIOCHEM, V88, P363, DOI 10.1111/j.1432-1033.1978.tb12457.x; BLOW DM, 1961, ACTA CRYSTALLOGR, V14, P1195, DOI 10.1107/S0365110X61003454; BLOW DM, 1959, ACTA CRYSTALLOGR, V12, P794, DOI 10.1107/S0365110X59002274; BRIAND G, 1980, FEBS LETT, V112, P147, DOI 10.1016/0014-5793(80)80167-0; BRICOGNE G, 1991, ISOMORPHOUS REPLACEM, P60; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BUCKLE RS, 1992, J MOL BIOL, V223, P651, DOI 10.1016/0022-2836(92)90981-O; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLORE GM, 1987, EMBO J, V6, P1833, DOI 10.1002/j.1460-2075.1987.tb02438.x; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CRANEROBINSON C, 1989, PROTEIN ENG, V2, P577, DOI 10.1093/protein/2.8.577; DRAVES PH, 1992, J MOL BIOL, V225, P1105, DOI 10.1016/0022-2836(92)90108-V; FINCH JT, 1976, P NATL ACAD SCI USA, V73, P1897, DOI 10.1073/pnas.73.6.1897; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRAZIANO V, 1990, J MOL BIOL, V212, P253, DOI 10.1016/0022-2836(90)90122-3; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HENDRICKSON WA, 1988, PROTEINS, V4, P77, DOI 10.1002/prot.340040202; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MATTHEWS BW, 1966, ACTA CRYSTALLOGR, V20, P82, DOI 10.1107/S0365110X6600015X; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MIRZABEKOV AD, 1989, J MOL BIOL, V211, P479; NORTH ACT, 1965, ACTA CRYSTALLOGR, V18, P212, DOI 10.1107/S0365110X65000488; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PAHLER A, 1990, ACTA CRYSTALLOGR A, V46, P537, DOI 10.1107/S0108767390002379; PEHRSON JR, 1981, BIOCHEMISTRY-US, V20, P2298, DOI 10.1021/bi00511a035; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SEGERS A, 1991, BIOCHEM BIOPH RES CO, V174, P898, DOI 10.1016/0006-291X(91)91502-4; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P61; SUN JM, 1989, SCIENCE, V245, P68, DOI 10.1126/science.2740916; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1986, EMBO J, V5, P3531, DOI 10.1002/j.1460-2075.1986.tb04679.x; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; TURNELL WG, 1988, FEBS LETT, V232, P263, DOI 10.1016/0014-5793(88)80750-6; van Holde KE., 1989, SPRINGER SERIES MOL; WEBER IT, 1984, P NATL ACAD SCI-BIOL, V81, P3973, DOI 10.1073/pnas.81.13.3973; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; YAGUCHI M, 1979, BIOCHEM BIOPH RES CO, V90, P1400, DOI 10.1016/0006-291X(79)91191-4; 1991, CCP4 SERC COLL COMP	47	656	668	2	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					219	223		10.1038/362219a0	http://dx.doi.org/10.1038/362219a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8384699				2022-12-28	WOS:A1993KT02600046
J	MARKOVITZ, DM				MARKOVITZ, DM			INFECTION WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-2	ANNALS OF INTERNAL MEDICINE			English	Review						HUMAN IMMUNODEFICIENCY VIRUS-2; ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN IMMUNODEFICIENCY INFECTIONS; AFRICA, WESTERN; SIMIAN IMMUNODEFICIENCY VIRUS	T-LYMPHOTROPIC RETROVIRUS; LONG TERMINAL REPEAT; HAIRY-CELL LEUKEMIA; VIRAL MESSENGER-RNA; HIV-1 TAT PROTEIN; REV GENE-PRODUCT; WEST-AFRICA; TRANS-ACTIVATOR; HTLV-III; MOLECULAR CHARACTERIZATION	Purpose: To review the clinical, epidemiologic, and biological features of infection with the human immunodeficiency virus type 2 (HIV-2). Data Identification: Studies published since 1981 identified from MEDLINE searches, articles accumulated by the author, bibliographies of identified articles, and discussions with other investigators. Study Selection: Information for review was taken from the author's own studies, data from other investigators that have been submitted for publication, and from 131 of the more than 200 articles examined. Data Extraction: Pertinent studies were selected and the data synthesized into a review format. Results of Data Synthesis: Infection with HIV-2 is prevalent in West Africa and is increasingly being identified elsewhere. The human immunodeficiency virus type 2 is spread through sexual contact and via contaminated blood but, unlike HIV-1, perinatal transmission is limited. Human immunodeficiency virus type 2 is genetically much more closely related to the simian immunodeficiency virus (SIV) than to HIV-1; biological and demographic data suggest that HIV-2 may have originally been transmitted from monkeys to man. Although HIV-2 causes the acquired immunodeficiency syndrome (AIDS), the asymptomatic incubation period after infection with HIV-2 appears to be substantially longer than that following HIV-1 infection. Consistent with these clinical observations, genetic regulation of HIV-2 differs from that of HIV-1. Therapeutic studies of patients infected with HIV-2 are lacking. Conclusions: The human immunodeficiency virus type 2 is prevalent in West Africa and is now recognized on several other continents, including North America. Its epidemiology, biology, and clinical course differ from HIV-1. Therapeutic studies are needed.			MARKOVITZ, DM (corresponding author), UNIV MICHIGAN, MED CTR, 5510 MSRB I, 1150 MED CTR DR, ANN ARBOR, MI 48109 USA.				NATIONAL CANCER INSTITUTE [K08CA001479] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI030924] Funding Source: NIH RePORTER; NCI NIH HHS [CA01479] Funding Source: Medline; NIAID NIH HHS [AI30924] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANCELLE R, 1987, LANCET, V1, P688; ANDREASSON PA, 1989, 4 INT C AIDS AFR MAR; ARYA S K, 1990, New Biologist, V2, P57; AYRES L, 1990, AIDS, V4, P131, DOI 10.1097/00002030-199002000-00006; Barabe P, 1988, Med Trop (Mars), V48, P337; BARIN F, 1985, LANCET, V2, P1387; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BRUNVEZINET F, 1987, LANCET, V1, P128; BRYCESON A, 1988, LANCET, V2, P220; CHANG DD, 1990, SCIENCE, V249, P614, DOI 10.1126/science.2143313; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CLAPHAM PR, 1989, NATURE, V337, P368, DOI 10.1038/337368a0; CLAVEL F, 1987, NEW ENGL J MED, V316, P1180, DOI 10.1056/NEJM198705073161903; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; CLAVEL F, 1986, NATURE, V324, P691, DOI 10.1038/324691a0; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; CORTES E, 1989, NEW ENGL J MED, V320, P953, DOI 10.1056/NEJM198904133201501; COUROUCE AM, 1988, AIDS, V2, P261, DOI 10.1097/00002030-198808000-00004; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; CULLEN BR, 1991, J VIROL, V65, P1053, DOI 10.1128/JVI.65.3.1053-1056.1991; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DIETRICH U, 1989, NATURE, V342, P948, DOI 10.1038/342948a0; DILLON PJ, 1991, J VIROL, V65, P445, DOI 10.1128/JVI.65.1.445-449.1991; EMERMAN M, 1987, EMBO J, V6, P3755, DOI 10.1002/j.1460-2075.1987.tb02710.x; EMERMAN M, 1989, CELL, V57, P1155, DOI 10.1016/0092-8674(89)90053-6; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; FENRICK R, 1989, J VIROL, V63, P5006, DOI 10.1128/JVI.63.12.5006-5012.1989; FISHER AG, 1987, SCIENCE, V237, P888, DOI 10.1126/science.3497453; FULTZ PN, 1986, P NATL ACAD SCI USA, V83, P5286, DOI 10.1073/pnas.83.14.5286; GALLO RC, 1987, NATURE, V326, P435; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GAO F, 1992, NATURE, V358, P495, DOI 10.1038/358495a0; GARRETT ED, 1991, J VIROL, V65, P1653, DOI 10.1128/JVI.65.3.1653-1657.1991; GEORGE JR, 1990, AIDS, V4, P321, DOI 10.1097/00002030-199004000-00006; GEORGE JR, 1992, LANCET, V340, P337, DOI 10.1016/0140-6736(92)91406-X; GESSAIN A, 1985, LANCET, V2, P407; GNANN JW, 1987, SCIENCE, V237, P1346, DOI 10.1126/science.2888192; GUYADER M, 1989, EMBO J, V8, P1169, DOI 10.1002/j.1460-2075.1989.tb03488.x; GUYADER M, 1987, NATURE, V326, P662, DOI 10.1038/326662a0; HAMMARSKJOLD ML, 1989, J VIROL, V63, P1959; HARADA S, 1986, VIROLOGY, V154, P249, DOI 10.1016/0042-6822(86)90451-4; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRSCH VM, 1989, NATURE, V339, P389, DOI 10.1038/339389a0; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HOJIYNG N, 1989, 4 P INT C AIDS AFR M; HORSBURGH CR, 1988, TRANSFUSION, V28, P192, DOI 10.1046/j.1537-2995.1988.28288179031.x; HOXIE JA, 1991, J VIROL, V65, P5096, DOI 10.1128/JVI.65.9.5096-5101.1991; HU SL, 1992, SCIENCE, V255, P456, DOI 10.1126/science.1531159; HUANG ML, 1991, J VIROL, V65, P5073, DOI 10.1128/JVI.65.9.5073-5079.1991; IVEYHOYLE M, 1991, P NATL ACAD SCI USA, V88, P512, DOI 10.1073/pnas.88.2.512; JOHNSON VA, 1989, ANTIMICROB AGENTS CH, V33, P53, DOI 10.1128/AAC.33.1.53; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; Kanki P J, 1989, AIDS Clin Rev, P95; Kanki P J, 1991, AIDS Clin Rev, P17; KANKI PJ, 1985, SCIENCE, V228, P1199, DOI 10.1126/science.3873705; KANKI PJ, 1986, SCIENCE, V232, P238, DOI 10.1126/science.3006256; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KAPPES JC, 1991, VIROLOGY, V184, P197, DOI 10.1016/0042-6822(91)90836-Z; KAWAMURA M, 1989, LANCET, V1, P385; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KJEMS J, 1991, CELL, V67, P169, DOI 10.1016/0092-8674(91)90580-R; KLEMM E, 1988, J NEUROL, V235, P304, DOI 10.1007/BF00314179; KUHNEL H, 1990, NUCLEIC ACIDS RES, V18, P6142, DOI 10.1093/nar/18.20.6142; KUHNEL H, 1989, P NATL ACAD SCI USA, V86, P2383, DOI 10.1073/pnas.86.7.2383; KUMAR P, 1990, J VIROL, V64, P890, DOI 10.1128/JVI.64.2.890-901.1990; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LOVEDAY C, 1989, BRIT MED J, V298, P419, DOI 10.1136/bmj.298.6671.419; LU XB, 1990, P NATL ACAD SCI USA, V87, P7598, DOI 10.1073/pnas.87.19.7598; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MARCON L, 1991, J VIROL, V65, P3938, DOI 10.1128/JVI.65.7.3938-3942.1991; MARKOVITZ DM, 1990, P NATL ACAD SCI USA, V87, P9098, DOI 10.1073/pnas.87.23.9098; MARKOVITZ DM, 1992, J VIROL, V66, P5479, DOI 10.1128/JVI.66.9.5479-5484.1992; MARKOVITZ DM, 1992, J VIROL, V66, P3961, DOI 10.1128/JVI.66.6.3961-3965.1992; MARLINK R, 1991, 7 P INT C AIDS FLOR; MARTIN JA, 1991, BIOCHEM BIOPH RES CO, V176, P180, DOI 10.1016/0006-291X(91)90906-N; MARX PA, 1991, J VIROL, V65, P4480, DOI 10.1128/JVI.65.8.4480-4485.1991; MCCLURE MO, 1987, NATURE, V330, P487, DOI 10.1038/330487a0; MITSUYA H, 1988, SCIENCE, V240, P646, DOI 10.1126/science.2452480; MITSUYA H, 1988, AIDS RES HUM RETROV, V4, P107, DOI 10.1089/aid.1988.4.107; MURPHEYCORB M, 1989, SCIENCE, V246, P1293, DOI 10.1126/science.2555923; MYERS RA, 1992, J ACQ IMMUN DEF SYND, V5, P417; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NELBOCK P, 1990, SCIENCE, V248, P1650, DOI 10.1126/science.2194290; NEUMANN PW, 1989, CAN MED ASSOC J, V140, P125; OBRIEN TR, 1992, JAMA-J AM MED ASSOC, V267, P2775; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; OSAME M, 1986, LANCET, V1, P1031; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OUATTARA SA, 1988, J TROP MED HYG, V91, P212; PAREKH BS, 1991, AIDS, V5, P1009, DOI 10.1097/00002030-199108000-00013; PAU CP, 1991, LANCET, V337, P616, DOI 10.1016/0140-6736(91)91683-L; PEETERS M, 1992, LANCET, V340, P339, DOI 10.1016/0140-6736(92)91407-Y; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PFUTZNER A, 1993, IN PRESS J AIDS; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1982, NATURE, V300, P63, DOI 10.1038/300063a0; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; RAYFIELD M, 1988, J INFECT DIS, V158, P1170, DOI 10.1093/infdis/158.6.1170; RICHARDS AD, 1989, FEBS LETT, V253, P214, DOI 10.1016/0014-5793(89)80961-5; RICHMAN DD, 1987, ANTIMICROB AGENTS CH, V31, P1879, DOI 10.1128/AAC.31.12.1879; ROMIEU I, 1990, J ACQ IMMUN DEF SYND, V3, P220; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; RUBSAMENWAIGMANN H, 1991, LANCET, V337, P550, DOI 10.1016/0140-6736(91)91333-P; RUEF C, 1989, AM J MED, V86, P709, DOI 10.1016/0002-9343(89)90451-8; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHULZ TF, 1990, J VIROL, V64, P5177, DOI 10.1128/JVI.64.10.5177-5182.1990; TERWILLIGER E, 1988, J VIROL, V62, P655, DOI 10.1128/JVI.62.2.655-658.1988; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TONGSTARKSEN SE, 1990, J IMMUNOL, V145, P4348; TRISTEM M, 1989, J GEN VIROL, V70, P479, DOI 10.1099/0022-1317-70-2-479; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; ZAGURY JF, 1988, P NATL ACAD SCI USA, V85, P5941, DOI 10.1073/pnas.85.16.5941; 1989, HIV 2 WORKING GROUP; 1988, MMWR MORBID MORTAL W, V37, P33; 1990, MMWR MORBID MORTAL W, V39, P829	131	76	78	1	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					211	218		10.7326/0003-4819-118-3-199302010-00010	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8380244				2022-12-28	WOS:A1993KJ43900010
J	BERRIDGE, MJ				BERRIDGE, MJ			INOSITOL TRISPHOSPHATE AND CALCIUM SIGNALING	NATURE			English	Review							MUSCLE SARCOPLASMIC-RETICULUM; PROTEIN-KINASE-C; CHANNEL RYANODINE RECEPTOR; LONG-TERM POTENTIATION; RAT-LIVER CELLS; PHOSPHOLIPASE-C; MOLECULAR-CLONING; XENOPUS EMBRYOS; CA-2+ RELEASE; 2ND MESSENGER	Inositol trisphosphate is a second messenger that controls many cellular processes by generating internal calcium signals. It operates through receptors whose molecular and physiological properties closely resemble the calcium-mobilizing ryanodine receptors of muscle. This family of intracellular calcium channels displays the regenerative process of calcium-induced calcium release responsible for the complex spatiotemporal patterns of calcium waves and oscillations. Such a dynamic signalling pathway controls many cellular processes, including fertilization, cell growth, transformation, secretion, smooth muscle contraction, sensory perception and neuronal signalling.			BERRIDGE, MJ (corresponding author), UNIV CAMBRIDGE, DEPT ZOOL, AFRC, MOLEC SIGNALLING LAB, DOWNING ST, CAMBRIDGE CB2 3EJ, ENGLAND.							AGELL N, 1991, BIOCHEM BIOPH RES CO, V177, P973, DOI 10.1016/0006-291X(91)90633-I; ALLEN LF, 1991, P NATL ACAD SCI USA, V88, P11354, DOI 10.1073/pnas.88.24.11354; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; ATTREE O, 1992, NATURE, V358, P239, DOI 10.1038/358239a0; BAIROCH A, 1990, FEBS LETT, V269, P454, DOI 10.1016/0014-5793(90)81214-9; BENNETT CF, 1988, NATURE, V334, P268, DOI 10.1038/334268a0; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIRCH BD, 1992, P NATL ACAD SCI USA, V89, P7978, DOI 10.1073/pnas.89.17.7978; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BLACKSTONE CD, 1989, P NATL ACAD SCI USA, V86, P4316, DOI 10.1073/pnas.86.11.4316; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BOITANO S, 1992, SCIENCE, V258, P292, DOI 10.1126/science.1411526; BOOTMAN MD, 1992, J PHYSIOL-LONDON, V450, P163, DOI 10.1113/jphysiol.1992.sp019121; BOOTMAN MD, 1992, J BIOL CHEM, V267, P25113; BORTOLOTTO ZA, 1992, EUR J PHARMACOL, V214, P297, DOI 10.1016/0014-2999(92)90135-Q; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309; BURGESS GM, 1991, J BIOL CHEM, V266, P4772; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CARROLL J, 1992, J BIOL CHEM, V267, P11196; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CLEMENTI E, 1992, J BIOL CHEM, V267, P2164; COCKCROFT S, 1992, BIOCHEM J, V288, P1; COCKROFT DL, 1992, TERATOLOGY, V45, P223, DOI 10.1002/tera.1420450216; CROSSLEY I, 1991, CELL REGUL, V2, P121, DOI 10.1091/mbc.2.2.121; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DELISLE S, 1992, J BIOL CHEM, V267, P7963; DEVIVO M, 1992, J BIOL CHEM, V267, P18263; DOTTO GP, 1985, NATURE, V318, P472; EHRLICH BE, 1988, NATURE, V336, P583, DOI 10.1038/336583a0; FADOOL DA, 1992, NEURON, V9, P907, DOI 10.1016/0896-6273(92)90243-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1992, NATURE, V356, P350, DOI 10.1038/356350a0; FERRIS CD, 1992, J NEUROSCI, V12, P1567; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; FRIEL DD, 1992, J PHYSIOL-LONDON, V450, P217, DOI 10.1113/jphysiol.1992.sp019125; FUJINAGA M, 1992, DEV BIOL, V150, P419, DOI 10.1016/0012-1606(92)90253-D; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIANNINI G, 1992, SCIENCE, V257, P91, DOI 10.1126/science.1320290; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRANDIN N, 1991, J CELL BIOL, V112, P711, DOI 10.1083/jcb.112.4.711; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HAN JK, 1992, J CELL BIOL, V116, P147, DOI 10.1083/jcb.116.1.147; HENZI V, 1992, NEUROSCIENCE, V46, P251, DOI 10.1016/0306-4522(92)90049-8; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; HOMA ST, 1991, DEV BIOL, V146, P461, DOI 10.1016/0012-1606(91)90247-Z; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HWANG PM, 1990, P NATL ACAD SCI USA, V87, P7395, DOI 10.1073/pnas.87.19.7395; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; ILYIN V, 1992, J PHYSIOL-LONDON, V448, P339, DOI 10.1113/jphysiol.1992.sp019045; Irvine R F, 1992, Semin Cell Biol, V3, P225, DOI 10.1016/1043-4682(92)90024-P; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; ITO I, 1988, NEUROSCI LETT, V90, P181, DOI 10.1016/0304-3940(88)90808-7; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KALINOSKI DL, 1992, BIOCHEM J, V281, P449, DOI 10.1042/bj2810449; KATO H, 1992, J BIOL CHEM, V267, P6483; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LECHLEITER JD, 1992, CELL, V69, P283, DOI 10.1016/0092-8674(92)90409-6; LEE HC, 1989, J BIOL CHEM, V264, P1608; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAEDA N, 1989, DEV BIOL, V133, P67, DOI 10.1016/0012-1606(89)90297-2; MAGNI M, 1991, J BIOL CHEM, V266, P6329; MAKRAM H, 1992, J PHYSL, V447, P513; MARTELLI AM, 1992, NATURE, V358, P242, DOI 10.1038/358242a0; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MCGUINNESS N, 1991, EUR J PHARMACOL, V197, P231, DOI 10.1016/0014-2999(91)90529-Y; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MELDOLESI J, 1990, BIOCHIM BIOPHYS ACTA, V1055, P130, DOI 10.1016/0167-4889(90)90113-R; MEYER T, 1990, BIOCHEMISTRY-US, V29, P32, DOI 10.1021/bi00453a004; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MINKE B, 1991, PROG RETIN RES, V11, P99, DOI 10.1016/0278-4327(91)90026-X; MISSIAEN L, 1991, NATURE, V352, P241, DOI 10.1038/352241a0; MISSIAEN L, 1992, J PHYSIOL-LONDON, V455, P623, DOI 10.1113/jphysiol.1992.sp019319; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MIYAZAKI S, 1992, FEBS LETT, V309, P180, DOI 10.1016/0014-5793(92)81090-9; MIYAZAKI S, 1988, J CELL BIOL, V106, P345, DOI 10.1083/jcb.106.2.345; MIYAZAKI S, 1992, SCIENCE, V257, P251, DOI 10.1126/science.1321497; MUALLEM S, 1989, J BIOL CHEM, V264, P205; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NICHOLSON NB, 1984, J CELL BIOL, V99, P2314, DOI 10.1083/jcb.99.6.2314; NICOTERA P, 1990, P NATL ACAD SCI USA, V87, P6858, DOI 10.1073/pnas.87.17.6858; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; OTSU K, 1990, J BIOL CHEM, V265, P13472; PARKER I, 1991, J PHYSIOL-LONDON, V433, P229, DOI 10.1113/jphysiol.1991.sp018423; PARKER I, 1991, P ROY SOC B-BIOL SCI, V246, P269, DOI 10.1098/rspb.1991.0154; PARYS JB, 1992, J BIOL CHEM, V267, P18776; PAYRASTRE B, 1992, J BIOL CHEM, V267, P5078; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; POUYSSEGUR J, 1992, REV PHYSL, V54, P195; PUJOL MJ, 1989, J BIOL CHEM, V264, P18863; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANA RS, 1990, PHYSIOL REV, V70, P115, DOI 10.1152/physrev.1990.70.1.115; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; REED RR, 1992, NEURON, V8, P205, DOI 10.1016/0896-6273(92)90287-N; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; RENARD DC, 1992, BIOCHEM J, V281, P775, DOI 10.1042/bj2810775; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBINSON IM, 1992, BIOCHEM J, V288, P457, DOI 10.1042/bj2880457; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; ROONEY TA, 1991, J BIOL CHEM, V266, P12272; ROSS CA, 1992, P NATL ACAD SCI USA, V89, P4265, DOI 10.1073/pnas.89.10.4265; ROUXEL FP, 1992, J BIOL CHEM, V267, P20017; SANDBERG K, 1992, J CELL BIOL, V117, P157, DOI 10.1083/jcb.117.1.157; SATOH T, 1990, J CELL BIOL, V111, P615, DOI 10.1083/jcb.111.2.615; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; SMITH MR, 1989, P NATL ACAD SCI USA, V86, P3659, DOI 10.1073/pnas.86.10.3659; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; STRICKER SA, 1992, DEV BIOL, V149, P370, DOI 10.1016/0012-1606(92)90292-O; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SWANN K, 1989, EMBO J, V8, P3711, DOI 10.1002/j.1460-2075.1989.tb08546.x; SWANN K, 1991, FEBS LETT, V278, P175, DOI 10.1016/0014-5793(91)80110-O; SWANN K, 1992, BIOCHEM J, V287, P79, DOI 10.1042/bj2870079; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKUWA N, 1991, J BIOL CHEM, V266, P1403; TAYLOR CW, 1991, PHARMACOL THERAPEUT, V51, P97, DOI 10.1016/0163-7258(91)90043-L; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; TREGEAR RT, 1991, P ROY SOC B-BIOL SCI, V243, P263, DOI 10.1098/rspb.1991.0040; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; VANDENPOL AN, 1992, J NEUROSCI, V12, P2648; VERMA A, 1990, CELL REGUL, V1, P781, DOI 10.1091/mbc.1.10.781; VOLPE P, 1991, EMBO J, V10, P3183, DOI 10.1002/j.1460-2075.1991.tb04880.x; WALTON PD, 1991, J CELL BIOL, V113, P1145, DOI 10.1083/jcb.113.5.1145; WATRAS J, 1991, J NEUROSCI, V11, P3239; WHALLEY T, 1992, MOL BIOL CELL, V3, P373, DOI 10.1091/mbc.3.3.373; WHITAKER M, 1990, DEVELOPMENT, V108, P525; WILSON HA, 1987, J EXP MED, V166, P601, DOI 10.1084/jem.166.2.601; WU D, IN PRESS J BIOL CHEM; YAMADA H, 1991, FEBS LETT, V284, P249, DOI 10.1016/0014-5793(91)80696-Z; ZHENG F, 1992, NEURON, V9, P163, DOI 10.1016/0896-6273(92)90231-2; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	159	6430	6562	12	406	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 28	1993	361	6410					315	325		10.1038/361315a0	http://dx.doi.org/10.1038/361315a0			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8381210				2022-12-28	WOS:A1993KJ59000046
J	JOHNSON, DG; SCHWARZ, JK; CRESS, WD; NEVINS, JR				JOHNSON, DG; SCHWARZ, JK; CRESS, WD; NEVINS, JR			EXPRESSION OF TRANSCRIPTION FACTOR E2F1 INDUCES QUIESCENT CELLS TO ENTER S-PHASE	NATURE			English	Article							RETINOBLASTOMA GENE-PRODUCT; CELLULAR DNA-SYNTHESIS; BINDING PROTEIN; ADENOVIRUS-E1A PREVENTS; CYCLE REGULATION; E1A PROTEINS; DOMAINS; RB; IDENTIFICATION; SUPPRESSOR	SEVERAL lines of evidence implicate the E2F transcription factor as an important component of cell proliferation control. First, E2F binding sites are found in the promoters of genes responsive to proliferation signals and the level of E2F binding activity increases at a time when many of these genes are activated1-3. Second, the tumour suppressor protein Rb, as well as the related p107 protein, complexes with E2F2-7, resulting in an inhibition of E2F transcriptional activity3,8-12. Third, oncogenic products of the DNA tumour viruses can dissociate these E2F complexes4,13. We provide here direct evidence that E2F is involved in cellular proliferation control. Specifically, we demonstrate that overexpression of the E2F1 complementary DNA14,15 can activate DNA synthesis in cells that would otherwise growth-arrest, with an efficiency that is similar to that achieved by the expression of the adenovirus E1A gene. Moreover, microinjection of the E2F1 cDNA into quiescent cells can induce S-phase entry, whereas two E2F1 mutants, which are unable to transactivate the DHFR and TK promoters, are unable to induce S phase. We conclude that the E2F transcription factor plays an important role in progression into S phase and that this probably coincides with its capacity to stimulate transcription.			JOHNSON, DG (corresponding author), DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,GENET SECT,POB 3054,DURHAM,NC 27710, USA.			Johnson, David/0000-0002-6223-1790				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHALLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CROSS WD, IN PRESS MOL CELL BI; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; KACZMAREK L, 1986, VIROLOGY, V152, P1, DOI 10.1016/0042-6822(86)90366-1; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIPSON KE, 1989, P NATL ACAD SCI USA, V86, P9774, DOI 10.1073/pnas.86.24.9774; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; MORAN B, 1988, MOL CELL BIOL, V8, P1756, DOI 10.1128/MCB.8.4.1756; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SPINDLER KR, 1985, J VIROL, V53, P742, DOI 10.1128/JVI.53.3.742-750.1985; STABEL S, 1985, EMBO J, V4, P2329, DOI 10.1002/j.1460-2075.1985.tb03934.x; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; ZAMANIAN M, 1992, EMBO J, V11, P2603, DOI 10.1002/j.1460-2075.1992.tb05325.x	31	762	785	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					349	352		10.1038/365349a0	http://dx.doi.org/10.1038/365349a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377827				2022-12-28	WOS:A1993LY49600055
J	DEHART, DJ				DEHART, DJ			TINEA-CAPITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DEHART, DJ (corresponding author), SAGINAW COOPERAT HOSP,SAGINAW,MI 48602, USA.								0	0	0	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					849	849						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355743				2022-12-28	WOS:A1993LW55100006
J	HALPERIN, HR; TSITLIK, JE; GELFAND, M; WEISFELDT, ML; GRUBEN, KG; LEVIN, HR; RAYBURN, BK; CHANDRA, NC; SCOTT, CJ; KREPS, BJ; SIU, CO; GUERCI, AD				HALPERIN, HR; TSITLIK, JE; GELFAND, M; WEISFELDT, ML; GRUBEN, KG; LEVIN, HR; RAYBURN, BK; CHANDRA, NC; SCOTT, CJ; KREPS, BJ; SIU, CO; GUERCI, AD			A PRELIMINARY-STUDY OF CARDIOPULMONARY-RESUSCITATION BY CIRCUMFERENTIAL COMPRESSION OF THE CHEST WITH USE OF A PNEUMATIC VEST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REGIONAL BLOOD-FLOW; INTRATHORACIC PRESSURE; CARDIAC-ARREST; DOGS; VENTILATION; HUMANS; CPR; AUGMENTATION; EPINEPHRINE; MECHANISMS	Background. More than 300,000 people die each year of cardiac arrest. Studies have shown that raising vascular pressures during cardiopulmonary resuscitation (CPR) can improve survival and that vascular pressures can be raised by increasing intrathoracic pressure. Methods. To produce periodic increases in intrathoracic pressure, we developed a pneumatically cycled circumferential thoracic vest system and compared the results of the use of this system in CPR (vest CPR) with those of manual CPR. In phase 1 of the study, aortic and right-atrial pressures were measured during both vest CPR (60 inflations per minute) and manual CPR in 15 patients in whom a mean (+/-SD) of 42+/-16 minutes of initial manual CPR had been unsuccessful. Vest CPR was also carried out on 14 other patients in whom pressure measurements were not made. In phase 2 of the study, short-term survival was assessed in 34 additional patients randomly assigned to undergo vest CPR (17 patients) or continued manual CPR (17 patients) after initial manual CPR (duration, 11+/-4 minutes) had been unsuccessful. Results. In phase 1 of the study, vest CPR increased the peak aortic pressure from 78+/-26 mm Hg to 138+/-28 mm Hg (P<0.0010 and the coronary perfusion pressure from 15+/-8 mm Hg to 23-11 mm Hg (P<0.003). Despite prolonged unsuccessful manual CPR, spontaneous circulation returned with vest CPR in 4 of the 29 patients. In phase 2 of the study, spontaneous circulation returned in 8 of the 17 patients who underwent vest CPR as compared with only 3 of the 17 patients who received continued manual CPR (P = 0.14). More patients in the vest-CPR group than in the manual-CPR group were alive 6 hours after attempted resuscitation (6 of 17 vs. 1 of 17) and 24 hours after attempted resuscitation (3 of 17 vs. 1 of 17), but none survived to leave the hospital. Conclusions. In this preliminary study, vest CPR, despite its late application, successfully increased aortic pressure and coronary perfusion pressure, and there was an insignificant trend toward a greater likelihood of the return of spontaneous circulation with vest CPR than with continued manual CPR. The effect of vest CPR on survival, however, is currently unknown and will require further study.	JOHNS HOPKINS MED INST,DEPT MED,DIV CARDIOL,PETER BELFER CARDIAC MECH LAB,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT BIOMED ENGN,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT EMERGENCY MED,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine					NHLBI NIH HHS [5P50-HL-17655] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017655] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON NS, 1986, JAMA-J AM MED ASSOC, V255, P2466, DOI 10.1001/jama.255.18.2466; ARMITAGE P, 1987, STATISTICAL METHODS, P104; CHANDRA N, 1981, AM J CARDIOL, V48, P1053, DOI 10.1016/0002-9149(81)90320-9; GONZALEZ ER, 1989, ANN EMERG MED, V18, P920, DOI 10.1016/S0196-0644(89)80453-6; GRUBEN KG, 1990, IEEE T BIO-MED ENG, V37, P204, DOI 10.1109/10.46261; HALPERIN H, 1983, IEEE FRONTIERS ENG C, V5, P483; HALPERIN HR, 1986, CIRCULATION, V73, P539, DOI 10.1161/01.CIR.73.3.539; HALPERIN HR, 1987, IEEE T BIO-MED ENG, V34, P738, DOI 10.1109/TBME.1987.325998; HALPERIN HR, 1989, CIRC RES, V65, P946, DOI 10.1161/01.RES.65.4.946; HALPERIN HR, 1986, CIRCULATION, V74, P1407, DOI 10.1161/01.CIR.74.6.1407; HALPERIN HR, 1987, ANN BIOMED ENG, V15, P385, DOI 10.1007/BF02584292; KOEHLER RC, 1983, CIRCULATION, V67, P266, DOI 10.1161/01.CIR.67.2.266; LIVESAY JJ, 1978, J THORAC CARDIOV SUR, V76, P244; LUCE JM, 1983, CIRCULATION, V67, P258, DOI 10.1161/01.CIR.67.2.258; MAIER GW, 1984, CIRCULATION, V70, P86, DOI 10.1161/01.CIR.70.1.86; NAGEL EL, 1981, CRIT CARE MED, V9, P424, DOI 10.1097/00003246-198105000-00037; NIEMANN JT, 1985, AM J CARDIOL, V55, P199, DOI 10.1016/0002-9149(85)90328-5; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; PARADIS NA, 1989, CIRCULATION, V80, P361, DOI 10.1161/01.CIR.80.2.361; PEARSON JW, 1965, ANESTH ANAL CURR RES, V44, P746; RALSTON SH, 1984, ANN EMERG MED, V13, P79, DOI 10.1016/S0196-0644(84)80566-1; REDDING JS, 1961, ANESTHESIOLOGY, V22, P280, DOI 10.1097/00000542-196103000-00018; RUDIKOFF MT, 1980, CIRCULATION, V61, P345, DOI 10.1161/01.CIR.61.2.345; SILBERBERG B, 1964, SURG GYNECOL OBSTET, V119, P6; SWENSON RD, 1988, CIRCULATION, V78, P630, DOI 10.1161/01.CIR.78.3.630; TORTOLANI AJ, 1990, RESUSCITATION, V20, P115, DOI 10.1016/0300-9572(90)90047-I; WOLFE WG, 1968, ARCH SURG-CHICAGO, V96, P123	27	133	141	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					762	768		10.1056/NEJM199309093291104	http://dx.doi.org/10.1056/NEJM199309093291104			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350885	Bronze			2022-12-28	WOS:A1993LV64200004
J	VANDERHEIDE, JJH; BILO, HJG; DONKER, JM; WILMINK, JM; TEGZESS, AM				VANDERHEIDE, JJH; BILO, HJG; DONKER, JM; WILMINK, JM; TEGZESS, AM			EFFECT OF DIETARY FISH-OIL ON RENAL-FUNCTION AND REJECTION IN CYCLOSPORINE-TREATED RECIPIENTS OF RENAL-TRANSPLANTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYUNSATURATED FATTY-ACIDS; GLOMERULAR-FILTRATION; MONONUCLEAR-CELLS; SUPPLEMENTATION; NEPHROTOXICITY; INHIBITION; IMMUNOSUPPRESSION; ALLOGRAFTS; MODULATION; RATS	Background. Dietary fish oil exerts effects on renal hemodynamics and the immune response that may benefit renal-transplant recipients treated with cyclosporine. To evaluate this possibility, we studied the effect of fish oil on renal function, blood pressure, and the incidence of acute rejection episodes in cyclosporine-treated recipients of renal transplants. Methods. In a randomized, double-blind trial, 33 recipients of first cadaveric kidney transplants who were treated with cyclosporine and prednisolone ingested 6 g of fish oil daily during the first postoperative year (the fish-oil group), whereas another 33 renal-graft recipients treated with cyclosporine and prednisolone ingested 6 g of coconut oil daily for three months, after which time it was stopped (the control group). Results. One year after transplantation, the fish-oil group had higher median values than the controls for glomerular filtration rate (53 vs. 40 ml per minute per 1.73 m2, P = 0.038) and effective renal plasma flow (214 vs. 178 ml per minute per 1.73 m2, P = 0.023) and lower mean arterial pressure (103 vs. 118 mm Hg, P = 0.0011). The cyclosporine doses in the two groups were similar. The cumulative number of rejection episodes was 20 in the controls, as compared with 8 in the fish-oil group (P = 0.029). One-year graft survival also tended to be better in the fish-oil group (97 vs. 84 percent, P = 0.097). Conclusions. The daily administration of 6 g of fish oil during the first postoperative year has a beneficial effect on renal hemodynamics and blood pressure in renal-transplant recipients treated with cyclosporine. Although the fish-oil group had significantly fewer rejection episodes than the control group, graft survival at one year was not significantly better in the fish-oil group.	DE WEEZENLANDEN HOSP,DEPT INTERNAL MED,ZWOLLE,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT INTERNAL MED,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT INTERNAL MED,DIV RENAL TRANSPLANT,1105 AZ AMSTERDAM,NETHERLANDS	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	VANDERHEIDE, JJH (corresponding author), UNIV GRONINGEN HOSP,DEPT INTERNAL MED,DIV RENAL TRANSPLANT,OOSTERSINGEL 59,9713 EZ GRONINGEN,NETHERLANDS.							BILO HJG, 1991, NEPHRON, V57, P385, DOI 10.1159/000186301; CHAPMAN JR, 1987, TRANSPLANTATION, V43, P860, DOI 10.1097/00007890-198743060-00018; COFFMAN TM, 1989, KIDNEY INT, V35, P24, DOI 10.1038/ki.1989.4; DIEPERINK H, 1987, EUR J CLIN INVEST, V17, P493, DOI 10.1111/j.1365-2362.1987.tb01147.x; DONKER AJM, 1977, NETH J MED, V20, P97; DYERBERG J, 1979, LANCET, V2, P433, DOI 10.1016/S0140-6736(79)91490-9; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FEEHALLY J, 1987, BRIT MED J, V295, P310, DOI 10.1136/bmj.295.6593.310; FOEGH ML, 1986, TRANSPLANT P, V18, P20; FOEGH ML, 1981, LANCET, V2, P431; HAMBERG M, 1980, BIOCHIM BIOPHYS ACTA, V618, P389, DOI 10.1016/0005-2760(80)90257-X; JEVNIKAR AM, 1988, TRANSPLANTATION, V46, P722, DOI 10.1097/00007890-198811000-00018; KELLEY VE, 1989, TRANSPLANTATION, V48, P98, DOI 10.1097/00007890-198907000-00023; KINSELLA JE, 1990, NUTRITION, V6, P24; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; MEYDANI S N, 1990, FASEB Journal, V4, pA795; MEYDANI SN, 1990, NUTR REV, V48, P361, DOI 10.1111/j.1753-4887.1990.tb02880.x; MURRAY BM, 1985, KIDNEY INT, V28, P767, DOI 10.1038/ki.1985.196; MYERS BD, 1988, TRANSPLANTATION, V46, P694, DOI 10.1097/00007890-198811000-00014; MYERS BD, 1986, KIDNEY INT, V30, P964, DOI 10.1038/ki.1986.280; MYERS BD, 1984, NEW ENGL J MED, V311, P699, DOI 10.1056/NEJM198409133111103; OTTO DA, 1990, TRANSPLANTATION, V50, P193, DOI 10.1097/00007890-199008000-00004; PERICO N, 1986, AM J PHYSIOL, V251, pF581, DOI 10.1152/ajprenal.1986.251.4.F581; PERICO N, 1991, TRANSPLANTATION, V52, P873, DOI 10.1097/00007890-199111000-00023; SANDERS TAB, 1987, POLYUNSATURATED FATT, P71; SMITH SR, 1992, KIDNEY INT, V41, P199, DOI 10.1038/ki.1992.27; SPURNEY R F, 1991, Journal of the American Society of Nephrology, V2, P432; TEGZESS AM, 1988, CICLOSPORIN PSORIASI, P128; VANDERHEIDE JJH, 1990, TRANSPL INT, V3, P171; VANDERHEIDE JJH, 1990, TRANSPLANTATION, V49, P523, DOI 10.1097/00007890-199003000-00010; VANDERTEMPEL H, 1990, ANN RHEUM DIS, V49, P76, DOI 10.1136/ard.49.2.76; VONSHACKY C, 1985, J CLIN INVEST, V76, P1621; WEIR MR, 1988, TRANSPLANT P, V20, P240; WEIR MR, 1992, J AM SOC NEPHROL, V2, P1285; 1983, NEW ENGL J MED, V309, P809	35	167	169	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					769	773		10.1056/NEJM199309093291105	http://dx.doi.org/10.1056/NEJM199309093291105			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350886				2022-12-28	WOS:A1993LV64200005
J	KRAKOWER, JY; JOLLY, P; BERAN, R				KRAKOWER, JY; JOLLY, P; BERAN, R			UNITED-STATES MEDICAL-SCHOOL FINANCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									ASSOC AMER MED COLL,DIV MED STUDENT & RESIDENT EDUC,WASHINGTON,DC 20037	Association of American Medical Colleges	KRAKOWER, JY (corresponding author), ASSOC AMER MED COLL,OPERAT STUDIES SECT,2450 N ST NW,WASHINGTON,DC 20037, USA.							JOLIN LD, 1992, JAMA-J AM MED ASSOC, V268, P1149, DOI 10.1001/jama.268.9.1149	1	21	21	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1085	1091						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU512	8350453				2022-12-28	WOS:A1993LU51200011
J	SWINBANKS, D				SWINBANKS, D			A NEW TREND FOR JAPAN	NATURE			English	Editorial Material																		1993, NATURE, V361, P762	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					744	744		10.1038/364744a0	http://dx.doi.org/10.1038/364744a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355793	Bronze			2022-12-28	WOS:A1993LT67700071
J	KENDRICK, AH; HIGGS, CMB; WHITFIELD, MJ; LASZLO, G				KENDRICK, AH; HIGGS, CMB; WHITFIELD, MJ; LASZLO, G			ACCURACY OF PERCEPTION OF SEVERITY OF ASTHMA - PATIENTS TREATED IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							PEAK-FLOW; MORTALITY	Objective-To determine the frequency of poor perception of severity of asthma in general practice. Design-Asthmatic patients recorded their perceived severity of asthma, with a visual analogue score, and a coded measurement of their peak expiratory flow up to four times daily for 14 consecutive days. Settings-11 general practices in and around Bristol. Subjects-255 asthmatic patients (139 men and 116 women) aged 17-76 who were recruited by random selection from the general practices' disease registers or when they requested prescriptions for inhaled bronchodilators. Main outcome measures-Correlation between visual analogue scores and peak expiratory flow (as a percentage of predicted peak flow). Results-152 (60%) of the patients showed no significant correlation between visual analogue asthma scores and simultaneous peak flow measurements (p>0.05) and were termed poor discriminators. The distribution of good and poor discriminators within each general practice was similar (chi2=6.11, df=10). The two groups were not characterised by differences in the maximum, minimum, or standard deviation of peak expiratory flow or visual analogue score; in age; or in the proportion of men and women in each group. Conclusion-In general practice a high proportion of asthmatic patients do not reliably detect changes in their lung function. This reinforces the need for careful objective assessment of lung function in the management of asthma.	UNIV BRISTOL,DEPT EPIDEMIOL & PUBL HLTH,GEN PRACTICE UNIT,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol	KENDRICK, AH (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT RESP,BRISTOL BS2 8HW,AVON,ENGLAND.							BARNES PJ, 1992, THORAX, V47, P408, DOI 10.1136/thx.47.6.408; BATES DV, 1952, CLIN SCI, V11, P203; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; CLARK NM, 1992, AM REV RESPIR DIS, V145, P722, DOI 10.1164/ajrccm/145.3.722; FRITZ GK, 1990, J DEV BEHAV PEDIATR, V11, P69; HETZEL MR, 1979, LANCET, V1, P597; HIGGS CMB, 1986, THORAX, V41, P671, DOI 10.1136/thx.41.9.671; HIGGS CMB, 1987, THESIS U CAMBRIDGE C; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; PEIFFER C, 1989, CLIN SCI, V77, P237, DOI 10.1042/cs0770237; QUANJER PLH, 1983, B EUROP PHYSIOPAT S5, V19, P7; RICHARDSON RB, 1984, CLIN PHYS PHYSIOL M, V5, P201, DOI 10.1088/0143-0815/5/3/004; RUBINFELD AR, 1976, LANCET, V1, P882; RUBINFELD AR, 1977, CHEST, V72, P154, DOI 10.1378/chest.72.2.154; RUBINFELD AR, 1977, AM REV RESPIR DIS, V115, P381; SEARS MR, 1986, BRIT MED J, V293, P1342, DOI 10.1136/bmj.293.6558.1342; Siegel S., 1988, NONPARAMETRIC STAT B; STEINER H, 1987, PSYCHOSOM MED, V49, P35, DOI 10.1097/00006842-198701000-00003	20	169	171	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					422	424		10.1136/bmj.307.6901.422	http://dx.doi.org/10.1136/bmj.307.6901.422			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374455	Bronze, Green Published			2022-12-28	WOS:A1993LR89500019
J	LOWY, A; BRAZIER, J; FALL, M; THOMAS, K; JONES, N; WILLIAMS, BT				LOWY, A; BRAZIER, J; FALL, M; THOMAS, K; JONES, N; WILLIAMS, BT			MINOR SURGERY BY GENERAL-PRACTITIONERS UNDER THE 1990 CONTRACT - EFFECTS ON HOSPITAL WORKLOAD	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the extent to which minor surgery undertaken by general practitioners after the introduction of the 1990 contract substituted for hospital outpatient workload. Design-Before and after observational study. Setting-Four English family health services authorities. Subjects-Patients in 22 practice populations who were operated on by their general practitioner or referred to hospital for minor surgery during April to June 1990 or April to June 1991. Main outcome measures-Numbers of minor surgical procedures undertaken in general practice and in hospital, numbers of referrals to hospitals for conditions treatable by a minor surgical procedure, and the mix of diagnoses and procedures undertaken in each setting. Results-General practitioners claimed reimbursement for 600 minor surgical procedures during April to June 1990 and for 847 during April to June 1991, an increase of 41%. Referrals to hospital for comparable conditions showed no compensatory decrease (385 during April to June 1990 and 388 during April to June 1991, 95% confidence interval for change in referrals -51 to 57), and the number of hospital Procedures resulting from those referrals also remained constant (187 in the first period, 189 in the second, 95% confidence interval for change in procedures -36 to 40). The mix of procedures did not change significantly from one study period to the next in either setting: Conclusions-Many or all of the additional patients receiving minor surgery under the terms of the 1990 contract may not have previously been referred to hospital. General practitioners seem not to have systematically shifted towards treating the more trivial cases. The overall increase in minor surgical activity may reflect an improvement in accessibility of care or changes in patients' perceptions and attitudes.	UNIV SHEFFIELD,SCH MED,DEPT PUBL HLTH MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND	University of Sheffield			brazier, john e/B-1936-2008	Brazier, John/0000-0001-8645-4780				BOYLE S, 1992, HLTH CARE UK 1991; BROWN JS, 1979, BRIT MED J, V1, P1609, DOI 10.1136/bmj.1.6178.1609; COID D R, 1990, Health Bulletin (Edinburgh), V48, P132; Dean A. G., 1990, EPI INFO VERSION 5 W; FRY J, 1984, UPDATE, V29, P293; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HUNT JH, 1955, LANCET, V22, P681; MCWILLIAM LJ, 1991, BRIT MED J, V303, P1177, DOI 10.1136/bmj.303.6811.1177; OCATHAIN A, 1992, BRIT J GEN PRACT, V42, P13; SHRANK A, 1992, HOSPITAL DOCTOR 0521, pC12; 1989, GENERAL PRACTICE NAT; 1983, COST EFFECTIVENESS G; 1979, GENERAL MED SERVICES; 1987, CM249	14	35	36	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					413	417		10.1136/bmj.307.6901.413	http://dx.doi.org/10.1136/bmj.307.6901.413			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374452	Green Published, Bronze			2022-12-28	WOS:A1993LR89500015
J	GOODRICK, I				GOODRICK, I			VOLUNTARY HELPERS IN GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY				GOODRICK, I (corresponding author), HLTH CTR,CROWLAND PE6 0AL,LINCS,ENGLAND.							ALLIBONE A, 1977, BMA NEWS REV     FEB, P49; ALLIBONE A, 1986, PUBLICATION UPDA JAN, P432; ALLIBONE A, 1987, BMJ, V283, P1581; Berger John, 1967, 7 UOMO; BLACK N, 1988, BRIT MED J, V296, P82, DOI 10.1136/bmj.296.6615.82; CARPENTER GI, 1990, BMJ-BRIT MED J, V300, P1253, DOI 10.1136/bmj.300.6734.1253; DAVIDSON K, 1981, VOLUNTEERS PRIMARY H; GOODRICK I, 1991, 10 KINGS FUND I RES, P41; GOODRICK I, 1988, GMSC NEWS REV, V14, P6; GREEN PA, 1983, J ROY COLL GEN PRACT, V33, P304; Harrison Brian, 1982, PEACEABLE KINGDOM ST; HAYNES A, 1988, PRACTITIONER, V232, P705; NESBITT M, 1988, PRIMARY HLTH CARE, V4, P32; Pro-chaska Frank, 1988, VOLUNTARY IMPULSE PH; WATT A, 1986, J ROY COLL GEN PRACT, V36, P72	15	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					302	304		10.1136/bmj.307.6899.302	http://dx.doi.org/10.1136/bmj.307.6899.302			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374380	Green Published, Bronze			2022-12-28	WOS:A1993LQ51600022
J	KEW, J; MORRIS, C; AIHIE, A; FYSH, R; JONES, S; BROOKS, D				KEW, J; MORRIS, C; AIHIE, A; FYSH, R; JONES, S; BROOKS, D			LESSON OF THE WEEK - ARSENIC AND MERCURY INTOXICATION DUE TO INDIAN ETHNIC REMEDIES	BRITISH MEDICAL JOURNAL			English	Article									GUYS HOSP,POISONS UNIT,LONDON SE1,ENGLAND; METROPOLITAN POLICE,FORENS SCI LAB,LONDON,ENGLAND; ST ANDREWS HOSP,LONDON,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	KEW, J (corresponding author), HAMMERSMITH HOSP,DEPT NEUROL,LONDON W12 0HS,ENGLAND.		Sayer, Avan Aihie/A-4359-2012	Aihie Sayer, Avan/0000-0003-1283-6457; Brooks, David/0000-0003-2602-2518				CHHUTTANI PN, 1967, ARCH NEUROL-CHICAGO, V17, P269; Healy M., 1990, ASIAN COMMUNITY MED; KARK RAP, 1979, HDB CLIN NEUROLOGY 1, V36, P147; KAYE S, 1977, HDB EMERGENCY TOXICO, P148; MURPHY MJ, 1981, J NEUROL NEUROSUR PS, V44, P896, DOI 10.1136/jnnp.44.10.896; WINDEBANK AJ, 1984, PERIPHERAL NEUROPATH, P2133	6	89	89	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1993	306	6876					506	507		10.1136/bmj.306.6876.506	http://dx.doi.org/10.1136/bmj.306.6876.506			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KN786	8383555	Bronze, Green Published			2022-12-28	WOS:A1993KN78600025
J	HERMAN, J				HERMAN, J			MOTKE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									BEN GURION UNIV NEGEV, IL-84105 BEER SHEVA, ISRAEL	Ben Gurion University									0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					851	852		10.7326/0003-4819-119-8-199310150-00012	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379606				2022-12-28	WOS:A1993MB49600012
J	SLATTERY, ML; KERBER, RA				SLATTERY, ML; KERBER, RA			A COMPREHENSIVE EVALUATION OF FAMILY HISTORY AND BREAST-CANCER RISK - THE UTAH POPULATION DATABASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPRODUCTIVE FACTORS; ATTRIBUTABLE RISK; AGE; DISEASE; ONSET; EPIDEMIOLOGY; ASSOCIATION; INDICATOR; WOMEN	Objective.-The purpose of this study is to assess the impact of family history on the risk of developing breast cancer. Design.-A case-control study design was used. Setting.-To provide a comprehensive assessment of family history risk, we used the Utah Population Database, a linked database compiled of genealogy data of the descendants of Mormon pioneer families, cancer data from the Utah Cancer Registry, and mortality data from the Utah Department of Vital Statistics. Patients.-All women diagnosed with breast cancer who were in the genealogy database and the Utah Cancer Registry were included. Controls were women selected from the genealogy, who like cases had no record of previous cancer. They were matched to the cases by age and place of birth. Outcome.-Several definitions of family history were used. The total familial risk variable, developed to work effectively in the Utah Genealogy Database, accounts for all family members, their degree of relatedness to the case, and the amount of time they were observed for possible cancer diagnosis. Results.-A threefold increase in risk, estimated by the odds ratio (OR), of breast cancer among those with the highest family history score (6% of cases) was observed when compared with those with the lowest family history score. The OR for women with a first-degree relative with breast cancer was 2.45 (95% confidence interval [CI], 1.84 to 3.06). If the nearest relative was a second-degree relative, the OR was 1.82 (95% CI, 1.39 to 2.24); if the nearest relative was a third-degree relative, the OR was 1.35 (95% CI, 1.07 to 1.64). A slightly greater risk was observed if the first-degree relative was a woman's mother (OR, 2.44; 95% CI, 1.77 to 3.42) rather than a sister (OR, 2.01; 95% CI, 1.66 to 2.43). Among subjects diagnosed before the age of 50 years, the disease experience of relatives prior to age 50 was most important, while for older subjects the experience of relatives of all ages was of roughly equal importance. Women who developed contralateral breast cancer within 3 years of initial diagnosis were nearly 10 times as likely as women without breast cancer to have a first-degree relative with breast cancer. Based on the risk estimates in this study, we have estimated that approximately 17% to 19% of breast cancer in the population could be attributed to family history. Women who had a first-degree relative with colon cancer had a 30% increased risk of breast cancer. Conclusions.-In this study population, women with a family history of breast cancer, even if the nearest relative with breast cancer is a third-degree relative, are at increased risk of the disease.			SLATTERY, ML (corresponding author), UNIV UTAH,SCH MED,DEPT FAMILY & PREVENT MED,50 N MED DR,ROOM C26,SALT LAKE CITY,UT 84132, USA.		Kerber, Richard/B-8038-2009		NCI NIH HHS [5-R01-CA48998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON DE, 1989, CANCER, V63, P349, DOI 10.1002/1097-0142(19890115)63:2<349::AID-CNCR2820630225>3.0.CO;2-R; ANDERSON DE, 1971, CANCER, V28, P1500, DOI 10.1002/1097-0142(197112)28:6<1500::AID-CNCR2820280623>3.0.CO;2-D; [Anonymous], 1976, INT CLASSIFICATION D; [Anonymous], 1990, FERTILITY CHANGE AM; BAIN C, 1980, AM J EPIDEMIOL, V111, P301, DOI 10.1093/oxfordjournals.aje.a112901; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Byrne C, 1991, Epidemiology, V2, P276, DOI 10.1097/00001648-199107000-00007; CLAUS EB, 1990, AM J EPIDEMIOL, V131, P961, DOI 10.1093/oxfordjournals.aje.a115616; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; DUPONT WD, 1987, AM J EPIDEMIOL, V125, P769, DOI 10.1093/oxfordjournals.aje.a114594; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HORN PL, 1988, AM J EPIDEMIOL, V128, P309, DOI 10.1093/oxfordjournals.aje.a114971; JANERICH DT, 1980, MED HYPOTHESES, V6, P1149, DOI 10.1016/0306-9877(80)90137-1; JORDE LB, 1982, HUM BIOL, V54, P583; JORDE LB, 1984, MIGRATION MOBILITY, P83; JORDE LB, 1990, ENCY HUMAN BIOL; KELSEY JL, 1988, CANCER RES, V48, P5615; KING MC, 1990, CANCER SURV, V9, P417; LYNCH HT, 1988, BREAST CANCER RES TR, V12, P275, DOI 10.1007/BF01811240; LYNCH HT, 1988, BREAST CANCER RES TR, V11, P263, DOI 10.1007/BF01807285; Malecot G., 1969, MATH HEREDITY; METTLIN C, 1990, AM J EPIDEMIOL, V131, P973, DOI 10.1093/oxfordjournals.aje.a115617; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MOOLGAVKAR SH, 1980, J NATL CANCER I, V65, P559; MURRAY PP, 1989, OBSTET GYNECOL, V73, P977; OTTMAN R, 1986, AM J EPIDEMIOL, V123, P15, DOI 10.1093/oxfordjournals.aje.a114209; PARAZZINI F, 1992, INT J CANCER, V51, P677, DOI 10.1002/ijc.2910510502; PRESTON DL, 1990, EPICURE GENERALIZED; ROSEMAN DL, 1990, ARCH INTERN MED, V150, P191, DOI 10.1001/archinte.150.1.191; SATTIN RW, 1985, JAMA-J AM MED ASSOC, V253, P1908, DOI 10.1001/jama.253.13.1908; SCHILDKRAUT JM, 1989, AM J HUM GENET, V45, P521; SELLERS TA, 1992, NEW ENGL J MED, V326, P1323, DOI 10.1056/NEJM199205143262004; SKOLNICK M, 1980, CANCER INCIDENCE DEF	33	236	244	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1563	1568		10.1001/jama.270.13.1563	http://dx.doi.org/10.1001/jama.270.13.1563			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371466				2022-12-28	WOS:A1993LZ33400029
J	BLAIR, SN				BLAIR, SN			EVIDENCE FOR SUCCESS OF EXERCISE IN WEIGHT-LOSS AND CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article							DEPENDENT DIABETES-MELLITUS; BODY-FAT DISTRIBUTION; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; WOMEN; MEN; OVERWEIGHT; SMOKING	Physically active men and women may be less likely than their sedentary peers to become overweight. Caloric restriction in overweight persons produces larger weight losses than does exercise, although more of the weight loss by dieting is from lean body mass. The addition of exercise to diet intervention produces more weight loss than does dieting alone. Exercise has a favorable effect on body fat distribution, with a reduction in waist-to-hip ratio with increased exercise. Exercise is especially important in maintaining weight loss in overweight persons. Several prospective studies have shown that overweight men and women who are active and fit have lower rates of morbidity and mortality than overweight persons who are sedentary and unfit. Therefore, exercise is of benefit to overweight persons, even if it does not make them lean. Exercise is recommended as an important part bf a weight control program.			BLAIR, SN (corresponding author), COOPER INST AEROB RES, 12330 PRESTON RD, DALLAS, TX 75230 USA.				NATIONAL INSTITUTE ON AGING [R01AG006945, R37AG006945] Funding Source: NIH RePORTER; NIA NIH HHS [AG06945] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLAIR SN, 1981, MED SCI SPORT EXER, V13, P310; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; KING AC, 1991, SPORTS MED, V11, P331, DOI 10.2165/00007256-199111050-00004; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MORRIS JN, 1990, BRIT HEART J, V63, P325; PACY PJ, 1986, SPORTS MED, V3, P89, DOI 10.2165/00007256-198603020-00002; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; RISSANEN AM, 1991, EUR J CLIN NUTR, V45, P419; SEIDELL JC, 1991, AM J EPIDEMIOL, V133, P257, DOI 10.1093/oxfordjournals.aje.a115870; SHAH M, 1991, Annals of Behavioral Medicine, V13, P73; TREMBLAY A, 1990, AM J CLIN NUTR, V51, P153, DOI 10.1093/ajcn/51.2.153; TREMBLAY A A, 1991, Medicine and Science in Sports and Exercise, V23, P1326; TROISI RJ, 1991, AM J CLIN NUTR, V53, P1104, DOI 10.1093/ajcn/53.5.1104; WILLIAMSON DF, 1992, IN PRESS INT J OBESI; WILMORE JH, 1983, RES Q EXERCISE SPORT, V54, P415, DOI 10.1080/02701367.1983.10605328; WING RR, 1991, ARTERIOSCLER THROMB, V11, P1250, DOI 10.1161/01.ATV.11.5.1250; WOOD PD, 1991, NEW ENGL J MED, V325, P461, DOI 10.1056/NEJM199108153250703; WOOD PD, 1984, ENCY BRITANNICA HLTH, P126	20	150	152	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				702	706		10.7326/0003-4819-119-7_Part_2-199310011-00015	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00015			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363201				2022-12-28	WOS:A1993MA33000015
J	RODIN, J				RODIN, J			CULTURAL AND PSYCHOSOCIAL DETERMINANTS OF WEIGHT CONCERNS	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL ATTRACTIVENESS; ANOREXIA-NERVOSA; BODY-IMAGE; SEX-DIFFERENCES; FEMALE; MALES; SHAPE; DISTURBANCES; PERCEPTIONS; POPULATION	Several sociocultural and psychological factors underlie Western society's intense preoccupation with the body. These factors include the social value of attractiveness, the strong correlation between attractiveness and perceived fitness, the interrelation among attractiveness, a good body image, and feelings of self-worth, and the relation between pressures to succeed in both the appearance- and work-related domains. The strong societal emphasis on appearance and slimness has translated to both intense body preoccupation and a willingness to try almost any weight-loss strategy. Thus, dieting occurs across all weight categories in response to these powerful social and psychological motivators.			RODIN, J (corresponding author), YALE UNIV, BOX 11A, YALE STN, NEW HAVEN, CT 06520 USA.							ADAMS GR, 1977, HUM DEV, V20, P217, DOI 10.1159/000271558; ANDERSEN AE, 1992, INT J EAT DISORDER, V11, P283, DOI 10.1002/1098-108X(199204)11:3&lt;283::AID-EAT2260110313&gt;3.0.CO;2-O; Banner L, 1983, AM BEAUTY; BARSKY AJ, 1988, WORRIED SICK OUR TRO; BECK SB, 1976, J PERS SOC PSYCHOL, V34, P1200, DOI 10.1037/0022-3514.34.6.1200; BERSCHEID E, 1973, PSYCHOL TODAY, V7, P119; Berscheid E., 1978, INTERPERSONAL ATTRAC; BROWNELL KD, 1991, BEHAV THER, V22, P1, DOI 10.1016/S0005-7894(05)80239-4; BUTTON EJ, 1977, PSYCHOL MED, V7, P235, DOI 10.1017/S0033291700029317; CANNING H, 1966, NEW ENGL J MED, V275, P1172, DOI 10.1056/NEJM196611242752107; CASH RF, 1990, BODY IMAGES DEV DEVI; CASH TF, 1986, PSYCHOL TODAY, V20, P30; CASH TF, 1990, BODY IMAGES, P96; CASH TF, 1986, PERSONALITY SOCIAL P, V11, P246; CASPER RC, 1979, BRIT J PSYCHIAT, V134, P60, DOI 10.1192/bjp.134.1.60; COHN LD, 1992, PSYCHOL WOMEN QUART, V16, P69, DOI 10.1111/j.1471-6402.1992.tb00240.x; DIBIASE WJ, 1968, PERCEPT MOTOR SKILL, V27, P1143, DOI 10.2466/pms.1968.27.3f.1143; DION K, 1972, J PERS SOC PSYCHOL, V24, P285, DOI 10.1037/h0033731; DREWNOWSKI A, 1987, PSYCHOSOM MED, V49, P626, DOI 10.1097/00006842-198711000-00008; EAGLY AH, 1991, PSYCHOL BULL, V110, P109, DOI 10.1037/0033-2909.110.1.109; Fallon A., 1990, BODY IMAGES DEV DEVI; FALLON AE, 1985, J ABNORM PSYCHOL, V94, P102, DOI 10.1037/0021-843X.94.1.102; Fisher G. J., 1976, PHOTOCHEM PHOTOBIOL, V1, P169; FRANZOI SL, 1984, J PERS ASSESS, V48, P173, DOI 10.1207/s15327752jpa4802_12; FRANZOI SL, 1987, PERS SOC PSYCHOL B, V13, P19, DOI 10.1177/0146167287131002; FRIEZE IH, 1990, J APPL SOC PSYCHOL, V20, P46, DOI 10.1111/j.1559-1816.1990.tb00377.x; Garner D. M., 1985, HDB PSYCHOTHERAPY AN, P513; GARNER DM, 1980, PSYCHOL REP, V47, P483, DOI 10.2466/pr0.1980.47.2.483; GARNER DM, 1976, PSYCHOSOM MED, V38, P327, DOI 10.1097/00006842-197609000-00005; GERZON M, 1982, CHOICE HEROES; Gillen B., 1981, PERSONALITY SOCIAL P, V7, P277, DOI [10.1177/014616728172015, DOI 10.1177/014616728172015]; GLASSNER B, 1988, BODIES WHY WE LOOK W; LERNER RM, 1972, CHILD DEV, V43, P908, DOI 10.2307/1127641; LERNER RM, 1975, J GENET PSYCHOL, V127, P91, DOI 10.1080/00221325.1975.10532359; LERNER RM, 1974, J YOUTH ADOLESCENCE, V3, P307, DOI 10.1007/BF02214744; Mazur Allan, 1986, J SEX RES, V22, P281, DOI 10.1080/00224498609551309; RODIN J, 1985, NEBR SYM MOTIV, V32, P267; RODIN J, 1992, BODY TRAPS; RODIN J, 1985, PSYCHOL GENDER; SCHEIER MF, 1977, J PERS SOC PSYCHOL, V35, P625, DOI 10.1037/0022-3514.35.9.625; SCHEIER MF, 1979, J PERS SOC PSYCHOL, V37, P1576, DOI 10.1037/0022-3514.37.9.1576; SIMMONS RG, 1973, AM SOCIOL REV, V38, P553, DOI 10.2307/2094407; STAKE J, 1987, SEX ROLES, V17, P31, DOI 10.1007/BF00287898; STEIGER H, 1989, CAN J PSYCHIAT, V34, P419, DOI 10.1177/070674378903400510; STORY MD, 1979, J SOC PSYCHOL, V108, P49, DOI 10.1080/00224545.1979.9711960; STRIEGELMOORE RH, 1986, AM PSYCHOL, V41, P246, DOI 10.1037/0003-066X.41.3.246; WRIGHTMAN LS, 1981, SOCIAL PSYCHOL 80S; 1983, METROPOLITAN LIFE IN, V64, P2; [No title captured]; 1991, GLAMOUR          APR, P297	50	87	88	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				643	645		10.7326/0003-4819-119-7_Part_2-199310011-00003	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00003			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363189				2022-12-28	WOS:A1993MA33000003
J	BAKER, DG; SCHUMACHER, HR				BAKER, DG; SCHUMACHER, HR			CURRENT CONCEPTS - ACUTE MONOARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SEPTIC ARTHRITIS; SYNOVIAL-FLUID; GONOCOCCAL-INFECTION; BACTERIAL ARTHRITIS; MYCOBACTERIUM-AVIUM; VIRUS-INFECTION; CRYSTALS; DISEASE; OSTEOMYELITIS		PHILADELPHIA VET AFFAIRS MED CTR, CTR RHEUMATOL IMMUNOL, UNIV & WOODLAND AVE, PHILADELPHIA, PA 19104 USA; MED COLL PENN, PHILADELPHIA, PA 19129 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Drexel University; University of Pennsylvania								ADEBONOJO FO, 1972, CLIN PEDIATR, V11, P549, DOI 10.1177/000992287201100923; ANGFONTE GZ, 1985, ARTHRITIS RHEUM, V28, P210, DOI 10.1002/art.1780280217; ARKFELD D G, 1991, Arthritis and Rheumatism, V34, pS33; BERMAN A, 1988, AM J MED, V85, P59, DOI 10.1016/0002-9343(88)90503-7; BLUMENTHAL DR, 1990, ARTHRITIS RHEUM, V33, P757, DOI 10.1002/art.1780330522; BOMALASKI JS, 1984, B RHEUM DIS, V34, P1; BOULWARE DW, 1985, J RHEUMATOL, V12, P1022; BRITIGAN BE, 1985, NEW ENGL J MED, V312, P1683, DOI 10.1056/NEJM198506273122606; CHRISTENSEN TH, 1989, SCAND J RHEUMATOL, V18, P235, DOI 10.3109/03009748909099935; DAVIDSON PT, 1970, AM J MED, V48, P77, DOI 10.1016/0002-9343(70)90101-4; DILIBERTI JH, 1977, CLIN PEDIATR, V16, P663, DOI 10.1177/000992287701600716; EISENBERG JM, 1984, ARCH INTERN MED, V144, P715, DOI 10.1001/archinte.144.4.715; ESPINOZA LR, 1988, ARTHRITIS RHEUM-US, V31, P1034, DOI 10.1002/art.1780310815; FAM AG, 1992, J RHEUMATOL, V19, P662; FRIEDMAN HM, 1980, AM J MED, V69, P241, DOI 10.1016/0002-9343(80)90384-8; GATTER RA, 1991, PRACTICAL HDB SYNOVI, P14; GOLDENBERG DL, 1985, NEW ENGL J MED, V312, P764, DOI 10.1056/NEJM198503213121206; GOLDENBERG DL, 1976, AM J MED, V60, P369, DOI 10.1016/0002-9343(76)90753-1; GOLDENBERG DL, 1982, J RHEUMATOL, V9, P204; HALL BB, 1984, ORTHOP CLIN N AM, V15, P505; HOFFMAN GS, 1978, J RHEUMATOL, V5, P199; HOFFMAN GS, 1982, ANN INTERN MED, V97, P36, DOI 10.7326/0003-4819-97-1-36; HUGHES RA, 1990, BRIT J RHEUMATOL, V29, P166; IGUCHI T, 1990, CLIN ORTHOP RELAT R, P241; KATZENSTEIN D, 1985, ARTHRITIS RHEUM, V28, P1421, DOI 10.1002/art.1780281216; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; KELLEY WN, 1989, TXB RHEUMATOLOGY, V2, P1395; KLEIN MA, 1991, J COMPUT ASSIST TOMO, V15, P126, DOI 10.1097/00004728-199101000-00020; LANE JG, 1990, CLIN ORTHOP RELAT R, V252, P198; LEE AH, 1992, ARTHRITIS RHEUM, V35, P443, DOI 10.1002/art.1780350414; LIOTE F, 1989, J RHEUMATOL, V16, P1161; LOTKE PA, 1985, ORTHOP CLIN N AM, V16, P797; MCCUTCHAN HJ, 1990, CLIN ORTHOP RELAT R, V257, P226; OBRIEN JP, 1983, MEDICINE, V62, P395, DOI 10.1097/00005792-198311000-00005; OCONNOR CR, 1988, J RHEUMATOL, V15, P1568; PASCUAL E, 1989, ANN RHEUM DIS, V48, P983, DOI 10.1136/ard.48.12.983; PAUL H, 1983, ARTHRITIS RHEUM, V26, P191, DOI 10.1002/art.1780260211; RAHMAN MU, 1992, ARTHRITIS RHEUM, V35, P521, DOI 10.1002/art.1780350506; REGINATO AJ, 1985, ANN RHEUM DIS, V44, P537, DOI 10.1136/ard.44.8.537; REGINATO AJ, 1979, ARTHRITIS RHEUM-US, V22, P170, DOI 10.1002/art.1780220210; RIEGELSNIELSEN P, 1987, ACTA ORTHOP SCAND, V58, P14, DOI 10.3109/17453678709146335; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; ROWE IF, 1989, Q J MED, V73, P1167; SCHUMACHER HR, 1972, ARTHRITIS RHEUM-US, V15, P465, DOI 10.1002/art.1780150502; SCHUMACHER HR, 1972, NEW ENGL J MED, V286, P416, DOI 10.1056/NEJM197202242860807; SCHUMACHER HR, 1975, ARTHRITIS RHEUM, V18, P603, DOI 10.1002/art.1780180611; SCHUMACHER HR, 1977, ANN INTERN MED, V87, P411, DOI 10.7326/0003-4819-87-4-411; SCHUMACHER HR, 1991, ATLAS SYNOVIAL FLUID, P121; SHARP JT, 1979, ARCH INTERN MED, V139, P1125, DOI 10.1001/archinte.139.10.1125; SINGLETON JD, 1991, J RHEUMATOL, V18, P1319; Smith J W, 1990, Infect Dis Clin North Am, V4, P523; SOKOLOFF L, 1990, ARCH PATHOL LAB MED, V114, P1035; STEERE AC, 1991, SCAND J INFECT DIS, P51; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; STORM W, 1989, MONATSSCHR KINDERH, V137, P722; THIERY J A, 1989, Arthroscopy, V5, P65, DOI 10.1016/0749-8063(89)90095-9; VINCENT J, 1980, ARTHRITIS RHEUM, V23, P1399, DOI 10.1002/art.1780231214; WEISSMAN BN, 1991, RHEUM DIS CLIN N AM, V17, P637; WILBUR AC, 1988, MAGN RESON IMAGING, V6, P341, DOI 10.1016/0730-725X(88)90411-0; WILSON MG, 1990, J BONE JOINT SURG AM, V72A, P878, DOI 10.2106/00004623-199072060-00013	60	90	92	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1013	1020						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366902				2022-12-28	WOS:A1993LY58700007
J	SHAMOON, H; DUFFY, H; FLEISCHER, N; ENGEL, S; SAENGER, P; STRELZYN, M; LITWAK, M; WYLIEROSETT, J; FARKASH, A; GEIGER, D; ENGEL, H; FLEISCHMAN, J; POMPI, D; GINSBERG, N; GLOVER, M; BRISMAN, M; WALKER, E; THOMASHUNIS, A; GONZALEZ, J; GENUTH, S; BROWN, E; DAHMS, W; PUGSLEY, P; MAYER, L; KERR, D; LANDAU, B; SINGERMAN, L; RICE, T; NOVAK, M; SMITHBREWER, S; MCCONNELL, J; DROTAR, D; WOODS, D; KATIRGI, B; LITVENE, M; BROWN, C; LUSK, M; CAMPBELL, R; LACKAYE, M; RICHARDSON, M; LEVY, B; CHANG, S; HEINHEINEMANN, M; BARRON, S; ASTOR, L; LEBECK, D; BRILLON, D; DIAMOND, B; VASILASDWOSKIN, A; LAURENZI, B; FOLDI, N; RUBIN, M; FLYNN, T; REPPUCCI, V; HEISE, C; SANCHEZ, A; WHITEHOUSE, F; KRUGER, D; KAHKONEN, D; FACHNIE, J; FISK, J; CAREY, J; COX, M; AHMAD, B; ANGUS, E; CAMPBELL, H; FIELDS, D; CROSWELL, M; BASHA, K; CHUNG, P; SCHOENHERR, A; MOBLEY, M; MARCHIORI, K; FRANCIS, J; KELLY, J; ETZWILER, D; CALLAHAN, P; HOLLANDER, P; CASTLE, G; BERGENSTAL, R; SPENCER, M; NELSON, J; BEZECNY, L; ROETHKE, C; ORBAN, M; ULRICH, C; GILL, L; MORGAN, K; LAECHELT, J; TAYLOR, F; FREKING, D; TOWEY, A; LIEPPMAN, M; RAKES, S; MANGUM, J; COOPER, N; UPHAM, P; JACOBSON, A; CROWELL, S; WOLFSDORF, J; BEASER, R; GANDA, O; ROSENZWEIG, J; STEWART, C; HALFORD, B; FRIEDLANDER, E; TARSY, D; ARRIGG, P; SHARUK, G; SHAH, S; WU, G; CAVALLERANO, J; POOLE, R; SILVER, P; CAVICCHI, R; FLEMING, D; MARCUS, J; GRIFFITHS, C; CAPPELLA, N; NATHAN, D; LARKIN, M; GODINE, J; LYNCH, J; NORMAN, D; MCKITRICK, C; HAGGEN, C; DELAHANTY, L; ANDERSON, E; LOU, P; TAYLOR, C; CROS, D; FOLINO, K; BRINK, S; ABBOTT, K; SICOTTE, K; SERVICE, FJ; SCHMIDT, A; RIZZA, R; ZIMMERMAN, B; SCHWENK, W; MORTENSON, J; ZIEGLER, G; LUCAS, A; HANSON, N; SELLNOW, S; PACH, J; STEIN, D; EICKHOFF, B; WOODWICK, R; TACKMANN, R; TRAUTMANN, J; ROSTVOLD, J; LINK, T; DYCK, P; DAUBE, J; COLLIGAN, R; WINDEBANK, A; KING, J; COLWELL, J; WOOD, D; MAYFIELD, R; PICKET, J; CHITWOOD, M; BILLINGS, D; DABNEY, Y; BUSE, J; KING, L; VALE, S; THOMPSON, T; BOHM, B; LYONS, T; HERMAYER, K; RICE, A; MOLITCH, M; SCHAEFER, B; JOHNSON, C; LYONS, J; METZGER, B; COHEN, B; NISHIDA, T; PARQUE, K; YUSIM, V; MOORE, M; JAMPOL, L; DINEEN, K; STAHL, J; RICHINE, L; WEINBERG, D; LOOSE, I; KUSHNER, M; MORRISON, A; JALBERT, A; TILDESLEY, H; LEUNG, S; BEGG, I; JOHNSON, D; LALANI, S; KENNEDY, T; MEADOWS, G; KOLTERMAN, O; LORENZI, G; JONES, K; GOLDBAUM, M; SWENSON, M; LYON, R; GIOTTA, M; KADLEC, K; REED, R; KIRSCH, L; GOODMAN, J; CAHILL, S; CLARK, T; ABRAM, R; SAYNER, L; OCHABSKI, R; GLORIA, R; BIRCHLER, G; GRANT, J; GRASSE, B; CHRISTLE, L; ABREU, B; GRANT, I; HEATON, R; ZEITLER, R; SIVITZ, W; BAYLESS, M; SCHROTT, H; OLSON, N; TINDAL, B; SNETSELAAR, L; MUELLER, D; DUDLER, A; SWARTZENDRUBER, J; HOFFMAN, R; MACINDOE, J; KRAMER, J; WEINGEIST, T; KIMURA, A; STONE, E; GROUT, T; FOUNTAIN, C; KARAKAS, S; VOGEL, C; MONTAGUE, P; KEYSER, D; MENNEN, S; DOGGETT, C; ROSE, G; DEVET, K; MUHLE, P; KOWARSKI, A; OSTROWSKI, D; LEVIN, P; CHALEW, S; HYLTON, J; YOUNGHYMAN, D; BARLOW, M; MAYER, R; ELMAN, M; LAKHANPAL, V; WEINER, B; MILLAR, M; BLUM, S; BUIE, W; MACE, B; GREENE, D; MARTIN, C; FLOYD, J; DUNN, F; HENRY, D; BENNETT, S; LASICHAK, A; VINE, A; ALBERS, J; SANDFORD, T; LOFTIN, J; STEVENS, M; ELNER, S; MARTONYI, C; MCIVER, F; STANLEY, S; WILLIS, J; RYAN, K; SPIEGELBERG, T; NALEPA, S; GLASGOW, B; CHAN, E; DOTIMAS, P; BANTLE, J; MECH, M; BALLES, M; KENNEDY, W; KHAN, M; KNOBLOCH, W; KWONG, C; MCKENZIE, L; OLSON, J; RAMSAY, R; ROBINER, W; WARHOL, R; GENIA, A; MCDONOUGH, G; MCMICHAEL, B; PHILIPH, D; PONWITH, L; SAHINEN, R; STINSON, E; VERNESS, J; FIMREITE, L; STEIN, J; GOLDSTEIN, D; HALL, M; BURNS, T; KLACHKO, D; GIANGIACOMO, J; RAWLINGS, S; ASTON, L; ENGLAND, J; WIEDMEYER, H; DAUGHERTY, M; LIGHTFOOT, M; WILSON, R; WILSON, R; GRIFFING, G; GARDNER, D; CONWAY, R; BLINDER, K; BROWNLEEDUFFECK, M; PALMER, N; GASH, L; SCHADE, D; JOHANNES, C; REIDY, R; BICKNELL, J; VOGEL, A; DRUMM, D; BOYLE, P; BURGE, M; JONES, N; CANADY, J; NICKELL, D; BAKER, L; ILVESCORRESSEL, P; SCHWARTZ, S; BRAUNSTEIN, S; MCBRIDE, J; BRUCKER, A; RENDLE, L; BROWN, M; SLADKY, J; MASCHAKCAREY, B; LAWLEY, D; NYBERG, W; WEENEY, L; SANDBURG, E; BYRD, S; AGUADO, E; MULHOLLAND, N; CAHN, D; SUSCAVAGE, M; EGLER, J; VAUGHNNORTON, M; COLLINS, C; MAMENISKIS, H; DRASH, A; WESCHE, J; BRATKOWSKI, M; BECKER, D; ARSLANIAN, S; DOFT, B; LOBES, L; RINKOFF, J; WARNICKI, J; CURTIN, D; STEINBERG, D; VAGSTAD, G; RYAN, C; HARRIS, F; STERANCHAK, L; ARCH, J; KELLY, K; OSTROSKA, P; GUILIANI, M; GOOD, M; WILLIAMS, T; OLSEN, K; CAMPBELL, A; SHIPE, C; CONWIT, R; FINEGOLD, D; ZAUCHA, M; MALONE, J; GROVE, N; MCMILLAN, D; BABIONE, L; DECLUE, T; PAVAN, P; KORTHALS, J; SOLC, H; MANGIONE, A; KITABCHI, A; TAYLOR, L; JONES, L; PITTS, K; BERTORINI, T; BITTLE, J; BURGHEN, G; FISHER, J; HUGHES, T; LINN, J; MEYER, D; MURPHY, W; JUSTICE, M; SHERMAN, A; WRIGHT, L; MURPHY, L; RASKIN, P; STROWIG, S; BASCO, M; CERCONE, S; RAMIREZ, L; ANAND, R; WILSON, C; GREENLEE, R; ANDERSON, W; MENDELSON, E; VANACEK, P; HOWARD, J; OUSLEY, C; YATES, B; CONGER, D; MAGUIRE, B; BIGGS, M; NEWTON, B; SHERILL, K; ZINMAN, B; BARNIE, A; EHRLICH, R; DANEMAN, D; PERLMAN, K; LEITER, L; GOTTESMAN, I; DEVENYI, R; MORTIMER, C; MOFFAT, K; GORDON, A; FERGUSON, R; CAMELON, K; SIMKINS, S; LITTLEFIELD, C; RODIN, G; HARTLEY, K; KWAN, J; GNANAPANDITHEN, D; ROGERS, S; HAYE, L; ROSE, J; MEZEI, S; BUNPHY, B; MACLEAN, S; MACKEEN, L; MANDELCORN, M; NELLIS, P; RUTTAN, L; WILSONSMITH, D; PALMER, J; GINSBERG, J; HIRSCH, I; KINYOUN, J; DOERR, H; MAUSETH, R; SWEENEY, K; VANOTTINGHAM, L; THOMSON, L; GREENBAUM, C; SAMESHIMA, L; FARKASHIRSCH, R; ROSENBAUM, G; RUBNER, N; BROWN, T; KRAFT, G; BROECKEL, J; KARLSEN, M; KHAKPOUR, D; RAMIREZ, M; SMIT, B; MIX, L; DUPRE, J; COLBY, P; RODGER, W; HRAMIAK, I; JENNER, M; CANNY, C; BROWN, W; SMITH, T; HARTH, J; BONDY, S; BEATH, S; MCCABE, S; GOUCHIE, C; BLANCHARD, K; MCCALLUM, J; JUNG, S; SUETANG, A; LORENZ, R; LIPPS, J; MCRAE, J; MAY, J; MAY, M; CAMPBELL, P; FEMAN, S; KILROY, A; PULLIAM, C; SCHLUNDT, D; JANNASCH, K; DAVIS, D; CULLEN, N; ADKINS, T; SNELL, M; VIRTS, K; QUESENBERRY, L; SANTIAGO, J; LEVANDOSKI, L; WHITE, N; MCGILL, J; BUBB, J; SCHMIDT, L; STRASBERG, Y; CASSO, M; NOETZEL, M; OLK, R; BONIUK, I; GRAND, M; THOMAS, M; WILLIAMS, D; NOBEL, G; KACIZAK, R; ORT, E; DAHL, J; BREEDING, L; HOFFMEYER, G; BILYEU, P; BLANK, J; WALTERS, C; BODNAR, J; RODRIGUEZ, P; ERICKSON, M; HEDRICK, S; TAMBORLANE, W; AHERN, J; SHERWIN, R; GATCOMB, P; STOESSEL, K; HELD, N; EBERSOLE, J; SCANLON, I; LOUARD, R; WILDSTEIN, C; BILODEAU, D; FONG, K; OTTAVIANO, D; LARSON, C; CROFFORD, OB; LACHIN, J; CLEARY, P; THOMPSON, D; KENNY, D; LAN, S; LAN, G; BRENNEMAN, A; OWEN, W; ADAMS, K; ARNOLD, D; CAMPANELL, R; LORING, N; SCHEIRER, P; BECKER, D; LAMAS, D; DUNEGAN, C; VEERAMACHANENI, H; WILLIAMS, C; ABDULBAAQIY, S; KASSOFF, A; ADAMS, K; GRANT, I; HEATON, R; DORMAN, J; SPIELMAN, R; KLEIN, R; SIEBERT, C; SILVERMAN, R; PFEIFER, M; SCHUMER, M; MORAN, M; FARQUHAR, J; ENGLAND, J; WIEDMEYER, H; ROHLFING, C; DAVIS, M; HUBBARD, L; MAGLI, Y; THOMAS, S; ONOFREY, J; JENSEN, K; BROTHERS, R; ANSAY, S; ARMSTRONG, J; BADAL, D; VANDERHOOFYOUNG, M; ESSER, B; GEITHMAN, P; HURLBURT, D; REIMERS, J; KEWLEY, K; MINER, K; STEFFES, M; BUCKSA, J; RYAN, C; CATANZARO, R; LUKES, A; BAGOVICH, G; WOODFILL, T; CROW, R; HUGHLETT, J; SWANSON, C; BUZZARD, I; STEVENS, M; SIELAFF, B; PICKERING, B; SCHAKEL, S; HERMAN, W; DASBACH, E; SONGER, T; JANES, G; DEEB, L; EWART, R; ORCHARD, T; CLARK, C; CUTTER, G; DAVIS, M; DEMETS, D; FERRIS, F; FURBERG, C; HORTON, E; KEEN, J; LOCKWOOD, D; PALMBERG, P; ROURKE, B; TSIATIS, A; LEVY, R; FRANK, R; GRIZZLE, J; RUBENSTEIN, A; SCHNEIDER, J; SKYLER, J; NATHAN, DM; GENUTH, S; LACHIN, J; CLEARY, P; CROFFORD, O; DAVIS, M; RAND, L; SIEBERT, C				SHAMOON, H; DUFFY, H; FLEISCHER, N; ENGEL, S; SAENGER, P; STRELZYN, M; LITWAK, M; WYLIEROSETT, J; FARKASH, A; GEIGER, D; ENGEL, H; FLEISCHMAN, J; POMPI, D; GINSBERG, N; GLOVER, M; BRISMAN, M; WALKER, E; THOMASHUNIS, A; GONZALEZ, J; GENUTH, S; BROWN, E; DAHMS, W; PUGSLEY, P; MAYER, L; KERR, D; LANDAU, B; SINGERMAN, L; RICE, T; NOVAK, M; SMITHBREWER, S; MCCONNELL, J; DROTAR, D; WOODS, D; KATIRGI, B; LITVENE, M; BROWN, C; LUSK, M; CAMPBELL, R; LACKAYE, M; RICHARDSON, M; LEVY, B; CHANG, S; HEINHEINEMANN, M; BARRON, S; ASTOR, L; LEBECK, D; BRILLON, D; DIAMOND, B; VASILASDWOSKIN, A; LAURENZI, B; FOLDI, N; RUBIN, M; FLYNN, T; REPPUCCI, V; HEISE, C; SANCHEZ, A; WHITEHOUSE, F; KRUGER, D; KAHKONEN, D; FACHNIE, J; FISK, J; CAREY, J; COX, M; AHMAD, B; ANGUS, E; CAMPBELL, H; FIELDS, D; CROSWELL, M; BASHA, K; CHUNG, P; SCHOENHERR, A; MOBLEY, M; MARCHIORI, K; FRANCIS, J; KELLY, J; ETZWILER, D; CALLAHAN, P; HOLLANDER, P; CASTLE, G; BERGENSTAL, R; SPENCER, M; NELSON, J; BEZECNY, L; ROETHKE, C; ORBAN, M; ULRICH, C; GILL, L; MORGAN, K; LAECHELT, J; TAYLOR, F; FREKING, D; TOWEY, A; LIEPPMAN, M; RAKES, S; MANGUM, J; COOPER, N; UPHAM, P; JACOBSON, A; CROWELL, S; WOLFSDORF, J; BEASER, R; GANDA, O; ROSENZWEIG, J; STEWART, C; HALFORD, B; FRIEDLANDER, E; TARSY, D; ARRIGG, P; SHARUK, G; SHAH, S; WU, G; CAVALLERANO, J; POOLE, R; SILVER, P; CAVICCHI, R; FLEMING, D; MARCUS, J; GRIFFITHS, C; CAPPELLA, N; NATHAN, D; LARKIN, M; GODINE, J; LYNCH, J; NORMAN, D; MCKITRICK, C; HAGGEN, C; DELAHANTY, L; ANDERSON, E; LOU, P; TAYLOR, C; CROS, D; FOLINO, K; BRINK, S; ABBOTT, K; SICOTTE, K; SERVICE, FJ; SCHMIDT, A; RIZZA, R; ZIMMERMAN, B; SCHWENK, W; MORTENSON, J; ZIEGLER, G; LUCAS, A; HANSON, N; SELLNOW, S; PACH, J; STEIN, D; EICKHOFF, B; WOODWICK, R; TACKMANN, R; TRAUTMANN, J; ROSTVOLD, J; LINK, T; DYCK, P; DAUBE, J; COLLIGAN, R; WINDEBANK, A; KING, J; COLWELL, J; WOOD, D; MAYFIELD, R; PICKET, J; CHITWOOD, M; BILLINGS, D; DABNEY, Y; BUSE, J; KING, L; VALE, S; THOMPSON, T; BOHM, B; LYONS, T; HERMAYER, K; RICE, A; MOLITCH, M; SCHAEFER, B; JOHNSON, C; LYONS, J; METZGER, B; COHEN, B; NISHIDA, T; PARQUE, K; YUSIM, V; MOORE, M; JAMPOL, L; DINEEN, K; STAHL, J; RICHINE, L; WEINBERG, D; LOOSE, I; KUSHNER, M; MORRISON, A; JALBERT, A; TILDESLEY, H; LEUNG, S; BEGG, I; JOHNSON, D; LALANI, S; KENNEDY, T; MEADOWS, G; KOLTERMAN, O; LORENZI, G; JONES, K; GOLDBAUM, M; SWENSON, M; LYON, R; GIOTTA, M; KADLEC, K; REED, R; KIRSCH, L; GOODMAN, J; CAHILL, S; CLARK, T; ABRAM, R; SAYNER, L; OCHABSKI, R; GLORIA, R; BIRCHLER, G; GRANT, J; GRASSE, B; CHRISTLE, L; ABREU, B; GRANT, I; HEATON, R; ZEITLER, R; SIVITZ, W; BAYLESS, M; SCHROTT, H; OLSON, N; TINDAL, B; SNETSELAAR, L; MUELLER, D; DUDLER, A; SWARTZENDRUBER, J; HOFFMAN, R; MACINDOE, J; KRAMER, J; WEINGEIST, T; KIMURA, A; STONE, E; GROUT, T; FOUNTAIN, C; KARAKAS, S; VOGEL, C; MONTAGUE, P; KEYSER, D; MENNEN, S; DOGGETT, C; ROSE, G; DEVET, K; MUHLE, P; KOWARSKI, A; OSTROWSKI, D; LEVIN, P; CHALEW, S; HYLTON, J; YOUNGHYMAN, D; BARLOW, M; MAYER, R; ELMAN, M; LAKHANPAL, V; WEINER, B; MILLAR, M; BLUM, S; BUIE, W; MACE, B; GREENE, D; MARTIN, C; FLOYD, J; DUNN, F; HENRY, D; BENNETT, S; LASICHAK, A; VINE, A; ALBERS, J; SANDFORD, T; LOFTIN, J; STEVENS, M; ELNER, S; MARTONYI, C; MCIVER, F; STANLEY, S; WILLIS, J; RYAN, K; SPIEGELBERG, T; NALEPA, S; GLASGOW, B; CHAN, E; DOTIMAS, P; BANTLE, J; MECH, M; BALLES, M; KENNEDY, W; KHAN, M; KNOBLOCH, W; KWONG, C; MCKENZIE, L; OLSON, J; RAMSAY, R; ROBINER, W; WARHOL, R; GENIA, A; MCDONOUGH, G; MCMICHAEL, B; PHILIPH, D; PONWITH, L; SAHINEN, R; STINSON, E; VERNESS, J; FIMREITE, L; STEIN, J; GOLDSTEIN, D; HALL, M; BURNS, T; KLACHKO, D; GIANGIACOMO, J; RAWLINGS, S; ASTON, L; ENGLAND, J; WIEDMEYER, H; DAUGHERTY, M; LIGHTFOOT, M; WILSON, R; WILSON, R; GRIFFING, G; GARDNER, D; CONWAY, R; BLINDER, K; BROWNLEEDUFFECK, M; PALMER, N; GASH, L; SCHADE, D; JOHANNES, C; REIDY, R; BICKNELL, J; VOGEL, A; DRUMM, D; BOYLE, P; BURGE, M; JONES, N; CANADY, J; NICKELL, D; BAKER, L; ILVESCORRESSEL, P; SCHWARTZ, S; BRAUNSTEIN, S; MCBRIDE, J; BRUCKER, A; RENDLE, L; BROWN, M; SLADKY, J; MASCHAKCAREY, B; LAWLEY, D; NYBERG, W; WEENEY, L; SANDBURG, E; BYRD, S; AGUADO, E; MULHOLLAND, N; CAHN, D; SUSCAVAGE, M; EGLER, J; VAUGHNNORTON, M; COLLINS, C; MAMENISKIS, H; DRASH, A; WESCHE, J; BRATKOWSKI, M; BECKER, D; ARSLANIAN, S; DOFT, B; LOBES, L; RINKOFF, J; WARNICKI, J; CURTIN, D; STEINBERG, D; VAGSTAD, G; RYAN, C; HARRIS, F; STERANCHAK, L; ARCH, J; KELLY, K; OSTROSKA, P; GUILIANI, M; GOOD, M; WILLIAMS, T; OLSEN, K; CAMPBELL, A; SHIPE, C; CONWIT, R; FINEGOLD, D; ZAUCHA, M; MALONE, J; GROVE, N; MCMILLAN, D; BABIONE, L; DECLUE, T; PAVAN, P; KORTHALS, J; SOLC, H; MANGIONE, A; KITABCHI, A; TAYLOR, L; JONES, L; PITTS, K; BERTORINI, T; BITTLE, J; BURGHEN, G; FISHER, J; HUGHES, T; LINN, J; MEYER, D; MURPHY, W; JUSTICE, M; SHERMAN, A; WRIGHT, L; MURPHY, L; RASKIN, P; STROWIG, S; BASCO, M; CERCONE, S; RAMIREZ, L; ANAND, R; WILSON, C; GREENLEE, R; ANDERSON, W; MENDELSON, E; VANACEK, P; HOWARD, J; OUSLEY, C; YATES, B; CONGER, D; MAGUIRE, B; BIGGS, M; NEWTON, B; SHERILL, K; ZINMAN, B; BARNIE, A; EHRLICH, R; DANEMAN, D; PERLMAN, K; LEITER, L; GOTTESMAN, I; DEVENYI, R; MORTIMER, C; MOFFAT, K; GORDON, A; FERGUSON, R; CAMELON, K; SIMKINS, S; LITTLEFIELD, C; RODIN, G; HARTLEY, K; KWAN, J; GNANAPANDITHEN, D; ROGERS, S; HAYE, L; ROSE, J; MEZEI, S; BUNPHY, B; MACLEAN, S; MACKEEN, L; MANDELCORN, M; NELLIS, P; RUTTAN, L; WILSONSMITH, D; PALMER, J; GINSBERG, J; HIRSCH, I; KINYOUN, J; DOERR, H; MAUSETH, R; SWEENEY, K; VANOTTINGHAM, L; THOMSON, L; GREENBAUM, C; SAMESHIMA, L; FARKASHIRSCH, R; ROSENBAUM, G; RUBNER, N; BROWN, T; KRAFT, G; BROECKEL, J; KARLSEN, M; KHAKPOUR, D; RAMIREZ, M; SMIT, B; MIX, L; DUPRE, J; COLBY, P; RODGER, W; HRAMIAK, I; JENNER, M; CANNY, C; BROWN, W; SMITH, T; HARTH, J; BONDY, S; BEATH, S; MCCABE, S; GOUCHIE, C; BLANCHARD, K; MCCALLUM, J; JUNG, S; SUETANG, A; LORENZ, R; LIPPS, J; MCRAE, J; MAY, J; MAY, M; CAMPBELL, P; FEMAN, S; KILROY, A; PULLIAM, C; SCHLUNDT, D; JANNASCH, K; DAVIS, D; CULLEN, N; ADKINS, T; SNELL, M; VIRTS, K; QUESENBERRY, L; SANTIAGO, J; LEVANDOSKI, L; WHITE, N; MCGILL, J; BUBB, J; SCHMIDT, L; STRASBERG, Y; CASSO, M; NOETZEL, M; OLK, R; BONIUK, I; GRAND, M; THOMAS, M; WILLIAMS, D; NOBEL, G; KACIZAK, R; ORT, E; DAHL, J; BREEDING, L; HOFFMEYER, G; BILYEU, P; BLANK, J; WALTERS, C; BODNAR, J; RODRIGUEZ, P; ERICKSON, M; HEDRICK, S; TAMBORLANE, W; AHERN, J; SHERWIN, R; GATCOMB, P; STOESSEL, K; HELD, N; EBERSOLE, J; SCANLON, I; LOUARD, R; WILDSTEIN, C; BILODEAU, D; FONG, K; OTTAVIANO, D; LARSON, C; CROFFORD, OB; LACHIN, J; CLEARY, P; THOMPSON, D; KENNY, D; LAN, S; LAN, G; BRENNEMAN, A; OWEN, W; ADAMS, K; ARNOLD, D; CAMPANELL, R; LORING, N; SCHEIRER, P; BECKER, D; LAMAS, D; DUNEGAN, C; VEERAMACHANENI, H; WILLIAMS, C; ABDULBAAQIY, S; KASSOFF, A; ADAMS, K; GRANT, I; HEATON, R; DORMAN, J; SPIELMAN, R; KLEIN, R; SIEBERT, C; SILVERMAN, R; PFEIFER, M; SCHUMER, M; MORAN, M; FARQUHAR, J; ENGLAND, J; WIEDMEYER, H; ROHLFING, C; DAVIS, M; HUBBARD, L; MAGLI, Y; THOMAS, S; ONOFREY, J; JENSEN, K; BROTHERS, R; ANSAY, S; ARMSTRONG, J; BADAL, D; VANDERHOOFYOUNG, M; ESSER, B; GEITHMAN, P; HURLBURT, D; REIMERS, J; KEWLEY, K; MINER, K; STEFFES, M; BUCKSA, J; RYAN, C; CATANZARO, R; LUKES, A; BAGOVICH, G; WOODFILL, T; CROW, R; HUGHLETT, J; SWANSON, C; BUZZARD, I; STEVENS, M; SIELAFF, B; PICKERING, B; SCHAKEL, S; HERMAN, W; DASBACH, E; SONGER, T; JANES, G; DEEB, L; EWART, R; ORCHARD, T; CLARK, C; CUTTER, G; DAVIS, M; DEMETS, D; FERRIS, F; FURBERG, C; HORTON, E; KEEN, J; LOCKWOOD, D; PALMBERG, P; ROURKE, B; TSIATIS, A; LEVY, R; FRANK, R; GRIZZLE, J; RUBENSTEIN, A; SCHNEIDER, J; SKYLER, J; NATHAN, DM; GENUTH, S; LACHIN, J; CLEARY, P; CROFFORD, O; DAVIS, M; RAND, L; SIEBERT, C			THE EFFECT OF INTENSIVE TREATMENT OF DIABETES ON THE DEVELOPMENT AND PROGRESSION OF LONG-TERM COMPLICATIONS IN INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUCOSE CONTROL; METABOLIC CONTROL; GLYCEMIC CONTROL; RETINOPATHY; AGE; PREVALENCE; DIAGNOSIS; INFUSION; RISK	Background. Long-term microvascular and neurologic complications cause major morbidity and mortality in patients with insulin-dependent diabetes mellitus (IDDM). We examined whether intensive treatment with the goal of maintaining blood glucose concentrations close to the normal range could decrease the frequency and severity of these complications. Methods. A total of 1441 patients with IDDM - 726 with no retinopathy at base line (the primary-prevention cohort) and 715 with mild retinopathy (the secondary-intervention cohort) were randomly assigned to intensive therapy administered either with an external insulin pump or by three or more daily insulin injections and guided by frequent blood glucose monitoring or to conventional therapy with one or two daily insulin injections. The patients were followed for a mean of 6.5 years, and the appearance and progression of retinopathy and other complications were assessed regularly. Results. In the primary-prevention cohort, intensive therapy reduced the adjusted mean risk for the development of retinopathy by 76 percent (95 percent confidence interval, 62 to 85 percent), as compared with conventional therapy. In the secondary-intervention cohort, intensive therapy slowed the progression of retinopathy by 54 percent (95 percent confidence interval, 39 to 66 percent) and reduced the development of proliferative or severe nonproliferative retinopathy by 47 percent (95 percent confidence interval, 14 to 67 percent). In the two cohorts combined, intensive therapy reduced the occurrence of microalbuminuria (urinary albumin excretion of greater-than-or-equal-to 40 mg per 24 hours) by 39 percent (95 percent confidence interval, 21 to 52 percent), that of albuminuria (urinary albumin excretion of greater-than-or-equal-to 300 mg per 24 hours) by 54 percent (95 percent confidence interval, 19 to 74 percent), and that of clinical neuropathy by 60 percent (95 percent confidence interval, 38 to 74 percent). The chief adverse event associated with intensive therapy was a two-to-threefold increase in severe hypoglycemia. Conclusions. Intensive therapy effectively delays the onset and slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients with IDDM.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, BRONX, NY 10461 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; CORNELL UNIV, MED CTR, NEW YORK, NY 10021 USA; HENRY FORD HOSP, DETROIT, MI 48202 USA; INT DIABET CTR, MINNEAPOLIS, MN USA; JOSLIN DIABET CTR, BOSTON, MA USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; MED UNIV S CAROLINA, CHARLESTON, SC 29425 USA; NORTHWESTERN UNIV, EVANSTON, IL 60201 USA; UNIV BRITISH COLUMBIA, VANCOUVER V6T 1W5, BC, CANADA; UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; UNIV IOWA, IOWA CITY, IA 52242 USA; UNIV MARYLAND, SCH MED, BALTIMORE, MD 21201 USA; UNIV MICHIGAN, ANN ARBOR, MI 48109 USA; UNIV MINNESOTA, CENT BIOCHEM LAB, MINNEAPOLIS, MN 55455 USA; UNIV MISSOURI, CENT BACKUP LAB HBAIC, COLUMBIA, MO 65201 USA; UNIV NEW MEXICO, SCH MED, ALBUQUERQUE, NM 87131 USA; UNIV PENN, CHILDRENS HOSP, PHILADELPHIA, PA 19104 USA; UNIV PITTSBURGH, PITTSBURGH, PA 15260 USA; UNIV S FLORIDA, TAMPA, FL 33620 USA; UNIV TENNESSEE, KNOXVILLE, TN 37996 USA; UNIV TEXAS, SW MED CTR, DALLAS, TX 75230 USA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; UNIV WASHINGTON HOSP, SEATTLE, WA 98105 USA; UNIV WESTERN ONTARIO, LONDON N6A 3K7, ONTARIO, CANADA; VANDERBILT UNIV, NASHVILLE, TN 37240 USA; WASHINGTON UNIV, ST LOUIS, MO 63130 USA; YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA; NIDDKD, PROGRAM OFF, BETHESDA, MD USA; SO ILLINOIS UNIV, CENT AUTONOM CODING UNIT, CARBONDALE, IL 62901 USA; UNIV WISCONSIN, CENT FUNDUS PHOTOG READING CTR, MADISON, WI 53706 USA; WESTERN PSYCHIAT INST & CLIN, CENT NEUROBEHAV CODING UNIT, PITTSBURGH, PA 15261 USA; UNIV MINNESOTA, CENT ECG READING UNIT, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, CENT NUTR CODING UNIT, MINNEAPOLIS, MN 55455 USA	Yeshiva University; Albert Einstein College of Medicine; Case Western Reserve University; Cornell University; Henry Ford Health System; Henry Ford Hospital; International Diabetes Center; Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Massachusetts General Hospital; Mayo Clinic; Medical University of South Carolina; Northwestern University; University of British Columbia; University of California System; University of California San Diego; University of Iowa; University System of Maryland; University of Maryland Baltimore; University of Michigan System; University of Michigan; University of Minnesota System; University of Minnesota Twin Cities; University of Missouri System; University of Missouri Columbia; University of New Mexico; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; State University System of Florida; University of South Florida; University of Tennessee System; University of Tennessee Knoxville; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Toronto; University of Washington; University of Washington Seattle; Western University (University of Western Ontario); Vanderbilt University; Washington University (WUSTL); Yale University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Southern Illinois University System; Southern Illinois University; University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	SHAMOON, H (corresponding author), DCCT, RES GRP, BOX NDIC DCCT, BETHESDA, MD 20892 USA.		Hoffman, Robert/E-3252-2011; Cutter, Gary/AAY-5392-2021; Dasbach, Erik/AAP-6801-2021; Link, Thomas M. M/E-7522-2012; Walters, Carl/D-5714-2012; Zinman, Bernard/E-7266-2013; Leiter, Lawrence/AAG-4059-2020; Hramiak, Irene/G-3305-2011; Rice, Treva K/D-1385-2009; Goldbaum, Michael/AAG-4258-2020	Cutter, Gary/0000-0002-8455-980X; Goldbaum, Michael/0000-0002-7721-2736; Cavallerano, Jerry/0000-0003-3702-5570; Zeitler, Rodney/0000-0003-1394-7079				[Anonymous], 1991, Ophthalmology, V98, P823; [Anonymous], 1991, Ophthalmology, V98, P786; BRINCHMANNHANSEN O, 1988, ARCH OPHTHALMOL-CHIC, V106, P1242; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; COHEN AJ, 1987, DIABETES, V36, P944, DOI 10.2337/diabetes.36.8.944; DAHLJORGENSEN K, 1985, BRIT MED J, V290, P811, DOI 10.1136/bmj.290.6471.811; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; DCCT Res Grp, 1988, DIABETES CARE, V11, P725; DCCT Res Grp, 1988, DIABETES CARE, V11, P567; DCCT Res Grp, 1987, DIABETES CARE, V10, P1; DCCT Res Grp, 1987, ARCH OPHTHALMOL-CHIC, V105, P1344; DCCT Res Grp, 1988, DIABETES, V37, P476; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; DECKERT T, 1978, DIABETOLOGIA, V14, P363, DOI 10.1007/BF01228130; DORMAN JS, 1984, DIABETES, V33, P271, DOI 10.2337/diabetes.33.3.271; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; ENGERMAN R, 1977, DIABETES, V26, P760, DOI 10.2337/diabetes.26.8.760; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; GOLDSTEIN DE, 1987, CLIN CHEM, V33, P2267; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1988, JAMA-J AM MED ASSOC, V260, P2864, DOI 10.1001/jama.260.19.2864; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P359; LAURITZEN T, 1985, DIABETES, V34, P74, DOI 10.2337/diab.34.3.S74; LAURITZEN T, 1983, LANCET, V1, P200; LAWSON PM, 1982, BRIT J OPHTHALMOL, V66, P762, DOI 10.1136/bjo.66.12.762; LEE ET, 1980, STATISTICAL METHODS, P88; MCCULLAGH P, 1989, GENERALIZED LINEAR M, P194; NATHAN DM, 1986, DIABETES, V35, P797, DOI 10.2337/diabetes.35.7.797; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SCHUMER M, 1988, AM J MED, V85, P137, DOI 10.1016/0002-9343(88)90406-8; SHERWIN RS, 1984, NEW ENGL J MED, V311, P365, DOI 10.1056/NEJM198408093110604; SIEBERT C, 1993, CONTROL CLIN TRIALS, V14, P30, DOI 10.1016/0197-2456(93)90048-I; Snedecor G.W., 1980, STAT METHODS, V7; TYGSTRUP N, 1982, RANDOMIZED CLIN TRIA, P174; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; 1988, DCCT88116462AS DEPT; IN PRESS J CLIN EXP; 1993, DCCT93183382 DEP COM; 1989, CONTROLLED CLIN TRIA, V10, P83; 1984, NIH851468 PUBL	43	17424	17841	40	1422	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					977	986		10.1056/nejm199309303291401	http://dx.doi.org/10.1056/nejm199309303291401			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366922	Bronze			2022-12-28	WOS:A1993LY58700001
J	BRITT, AB; CHEN, JJ; WYKOFF, D; MITCHELL, D				BRITT, AB; CHEN, JJ; WYKOFF, D; MITCHELL, D			A UV-SENSITIVE MUTANT OF ARABIDOPSIS DEFECTIVE IN THE REPAIR OF PYRIMIDINE-PYRIMIDINONE(6-4) DIMERS	SCIENCE			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; 6-4 PHOTOPRODUCTS; ESCHERICHIA-COLI; DNA DAMAGE; ULTRAVIOLET-RADIATION; CELLS; GENE; THALIANA; REMOVAL	Plants are continually subjected to ultraviolet-B (UV-B) irradiation (290 to 320 nanometers) as a component of sunlight, which induces a variety of types of damage to the plant DNA. Repair of the two major DNA photoproducts was analyzed in wild-type Arabidopsis thaliana and in a mutant derivative whose growth was sensitive to UV-B radiation. In wild-type seedlings, repair of cyclobutane pyrimidine dimers occurred more slowly in the dark than in the light; repair of this photoproduct was not affected in the mutant. Repair, in the dark, of pyrimidine-pyrimidinone(6-4) dimers was defective in the UV-sensitive mutant.	UNIV TEXAS,MD ANDERSON CANC RES CTR,DEPT CARCINOGENESIS,SMITHVILLE,TX 78957	University of Texas System; UTMD Anderson Cancer Center	BRITT, AB (corresponding author), UNIV CALIF DAVIS,BOT SECT,DAVIS,CA 95616, USA.							ALLARD R. W., 1956, HILGARDIA, V24, P235; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BRASH DE, 1982, NATURE, V298, P189, DOI 10.1038/298189a0; BRASH DE, 1985, J BIOL CHEM, V260, P1438; CLEAVER JE, 1987, MOL CELL BIOL, V7, P3353, DOI 10.1128/MCB.7.9.3353; Fisher RA, 1928, J GENET, V20, P79, DOI 10.1007/BF02983317; FRANKLIN WA, 1986, MUTAT RES, V165, P1, DOI 10.1016/0167-8817(86)90002-7; FRANKLIN WA, 1984, P NATL ACAD SCI-BIOL, V81, P3821, DOI 10.1073/pnas.81.12.3821; FREDERICK JE, 1988, PHOTOCHEM PHOTOBIOL, V47, P571, DOI 10.1111/j.1751-1097.1988.tb08846.x; GANESAN AK, 1981, DNA REPAIR LABORAT A, V1, P89; KARENTZ D, 1991, J PHYCOL, V27, P326, DOI 10.1111/j.0022-3646.1991.00326.x; Klekowski E, 1988, MUTATION DEV SELECTI; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Koornneef M., 1990, ARABIDOPSIS INFO SER, V27, P1; KRANZ AR, 1987, GENETIC RESOURCES AR, V24, P421; MCLENNAN AG, 1987, MUTAT RES, V181, P1, DOI 10.1016/0027-5107(87)90281-8; MITCHELL DL, 1985, MUTAT RES, V143, P109, DOI 10.1016/S0165-7992(85)80018-X; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; PANG QS, 1991, PLANT PHYSIOL, V95, P536, DOI 10.1104/pp.95.2.536; QUAITE FE, 1992, NATURE, V358, P576, DOI 10.1038/358576a0; SANCAR A, 1983, CELL, V33, P249, DOI 10.1016/0092-8674(83)90354-9; SHURE M, 1983, CELL, V35, P225, DOI 10.1016/0092-8674(83)90225-8; SMALL GD, 1987, MUTAT RES, V181, P31, DOI 10.1016/0027-5107(87)90284-3; STAPLETON AE, 1992, PLANT CELL, V4, P1353, DOI 10.1105/tpc.4.11.1353; THOMAS DC, 1989, J BIOL CHEM, V264, P18005; THOMPSON LH, 1989, MUTAGENESIS, V4, P140, DOI 10.1093/mutage/4.2.140; VELEMINSKY J, 1990, MUTATION ENV, V340, P195; WALBOT V, 1985, TRENDS GENET, V1, P65; ZDZIENICKA MZ, 1992, MUTAT RES, V273, P73, DOI 10.1016/0921-8777(92)90051-4; 1970, ISCO TABLES	30	147	163	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1571	1574		10.1126/science.8372351	http://dx.doi.org/10.1126/science.8372351			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372351				2022-12-28	WOS:A1993LX47400028
J	CHULAGRAFF, Q; DOE, CQ				CHULAGRAFF, Q; DOE, CQ			NEUROBLAST SPECIFICATION AND FORMATION REGULATED BY WINGLESS IN THE DROSOPHILA CNS	SCIENCE			English	Article							ACHAETE-SCUTE COMPLEX; NEUROGENESIS; MELANOGASTER; EXPRESSION; EPIDERMIS; PRODUCT; PROTEIN; GENES	The Drosophila central nervous system (CNS) develops from a heterogeneous population of neural stem cells (neuroblasts), yet the genes regulating neuroblast determination remain unknown. The segmentation gene wingless is regionally expressed in the neuroectoderm from which neuroblasts develop. A conditional wingless mutation is used to inactivate CNS function without affecting segmentation. The stripe of wingless-expressing neuroectoderm generates apparently normal neuroblasts after wingless inactivation; however, adjacent anterior and posterior neuroectoderm requires wingless nonautonomously for subsequent neuroblast determination and formation. Loss of wingless results in the absence or duplication of identified neuroblasts, highlighting its role in generating neuroblast diversity in the CNS.	UNIV ILLINOIS, DEPT CELL & STRUCT BIOL, URBANA, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign								ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1990, ANNU REV GENET, V24, P387; CHULAGRAFF Q, UNPUB; Cui X, UNPUB; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1992, DEVELOPMENT, V116, P855; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GOODMAN CS, 1993, DEV DROSOPHILA; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; SKAER H, 1992, DEVELOPMENT, V116, P745; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; YANG XH, 1993, GENE DEV, V7, P504, DOI 10.1101/gad.7.3.504	21	149	150	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 17	1993	261	5128					1594	1597		10.1126/science.8372355	http://dx.doi.org/10.1126/science.8372355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372355				2022-12-28	WOS:A1993LX47400035
J	ARRUDA, S; BOMFIM, G; KNIGHTS, R; HUIMABYRON, T; RILEY, LW				ARRUDA, S; BOMFIM, G; KNIGHTS, R; HUIMABYRON, T; RILEY, LW			CLONING OF AN MYCOBACTERIUM-TUBERCULOSIS DNA FRAGMENT ASSOCIATED WITH ENTRY AND SURVIVAL INSIDE CELLS	SCIENCE			English	Article							TUBERCLE-BACILLI; MYCOBACTERIA; ANTIGEN; PROTEIN	Mycobacterium tuberculosis infects one-third of the world's human population. This widespread infection depends on the organism's ability to escape host defenses by gaining entry and surviving inside the macrophage. DNA sequences of M. tuberculosis have been cloned; these confer on a nonpathogenic Escherichia coli strain an ability to invade HeLa cells, augment macrophage phagocytosis, and survive for at least 24 hours inside the human macrophage. This capacity to gain entry into mammalian cells and survive inside the macrophage was localized to two distinct loci on the cloned M. tuberculosis DNA fragment.	CORNELL UNIV,MED CTR,COLL MED,DIV INT MED,NEW YORK,NY 10021; NEW YORK BLOOD CTR,NEW YORK,NY 10021	Cornell University; New York Blood Center			Arruda, Sergio/AAO-3987-2021		FIC NIH HHS [TW00018] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		ANDERSON BE, 1990, INFECT IMMUN, V58, P2760, DOI 10.1128/IAI.58.9.2760-2769.1990; ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; DRAPER P, 1970, NATURE, V228, P860, DOI 10.1038/228860a0; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HARTMAN AB, 1990, J BACTERIOL, V172, P1905, DOI 10.1128/jb.172.4.1905-1915.1990; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; LOWRIE DB, 1983, J MED MICROBIOL, V16, P1, DOI 10.1099/00222615-16-1-1; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; RASTOGI N, 1990, RES MICROBIOL, V141, P217, DOI 10.1016/0923-2508(90)90034-N; SHEPARD CC, 1957, J EXP MED, V105, P39, DOI 10.1084/jem.105.1.39; YAMAMOTO T, 1958, Int J Lepr, V26, P111	12	301	332	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1454	1457		10.1126/science.8367727	http://dx.doi.org/10.1126/science.8367727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367727				2022-12-28	WOS:A1993LW54900035
J	DEVARY, Y; ROSETTE, C; DIDONATO, JA; KARIN, M				DEVARY, Y; ROSETTE, C; DIDONATO, JA; KARIN, M			NF-KAPPA-B ACTIVATION BY ULTRAVIOLET-LIGHT NOT DEPENDENT ON A NUCLEAR SIGNAL	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; C-JUN; CELL-PROLIFERATION; GENE ACTIVATION; PROTEIN-KINASE; 65-KD SUBUNIT; REL; TRANSDUCTION	Exposure of mammalian cells to radiation triggers the ultraviolet (UV) response, which includes activation of activator protein-1 (AP-1) and nuclear factor kappa B (NF-kappaB). This was postulated to occur by induction of a nuclear signaling cascade by damaged DNA. Recently, induction of AP-1 by UV was shown to be mediated by a pathway involving Src tyrosine kinases and the Ha-Ras small guanosine triphosphate-binding protein, proteins located at the plasma membrane. It is demonstrated here that the same pathway mediates induction of NF-kappaB by UV. Because inactive NF-kappaB is stored in the cytosol, analysis of its activation directly tests the involvement of a nuclear-initiated signaling cascade. Enucleated cells are fully responsive to UV both in NF-kappaB induction and in activation of another key signaling event. Therefore, the UV response does not require a signal generated in the nucleus and is likely to be initiated at or near the plasma membrane.	UNIV CALIF SAN DIEGO, SCH MED, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [P01CA050528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES004151, R01ES004151] Funding Source: NIH RePORTER; NCI NIH HHS [CA50528] Funding Source: Medline; NIEHS NIH HHS [ES04151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIDONATO JA, UNPUB; DINTER H, 1987, EMBO J, V6, P4067, DOI 10.1002/j.1460-2075.1987.tb02752.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FORRUM F, 1969, BIOCHEM J, V115, P465; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HIBI M, IN PRESS GENES DEV; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; KAMPS MP, 1986, MOL CELL BIOL, V6, P751, DOI 10.1128/MCB.6.3.751; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVITZKI A, 1991, METHOD ENZYMOL, V201, P347; MERCURIO F, 1992, DNA CELL BIOL, V11, P523, DOI 10.1089/dna.1992.11.523; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; POSTE G, 1972, EXP CELL RES, V73, P273, DOI 10.1016/0014-4827(72)90049-3; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; ROSETTE C, UNPUB; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; VALERIE K, 1990, New Biologist, V2, P712; VALERIE K, 1988, NATURE, V333, P78, DOI 10.1038/333078a0; WALLACE BM, 1992, SCIENCE, V257, P1211, DOI 10.1126/science.1519057; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4	46	595	619	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 10	1993	261	5127					1442	1445		10.1126/science.8367725	http://dx.doi.org/10.1126/science.8367725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367725				2022-12-28	WOS:A1993LW54900031
J	LOCKSLEY, RM; REINER, SL; HATAM, F; LITTMAN, DR; KILLEEN, N				LOCKSLEY, RM; REINER, SL; HATAM, F; LITTMAN, DR; KILLEEN, N			HELPER T-CELLS WITHOUT CD4 - CONTROL OF LEISHMANIASIS IN CD4-DEFICIENT MICE	SCIENCE			English	Article							MURINE CUTANEOUS LEISHMANIASIS; CLASS-II MOLECULES; IFN-GAMMA; MONOCLONAL-ANTIBODY; SUSCEPTIBLE BALB/C; INTERFERON-GAMMA; INVOLVEMENT; RESISTANCE; INVIVO; IL-4	Expression of either the CD4 or CD8 glycoproteins discriminates two functionally distinct lineages of T lymphocytes. A null mutation in the gene encoding CD4 impairs the development of the helper cell lineage that is normally defined by CD4 expression. Infection of CD4-null mice with Leishmania has revealed a population of functional helper T cells that develops despite the absence of CD4. These CD8- alphabetaT cell receptor+ T cells are major histocompatibility complex class II-restricted and produce interferon-gamma when challenged with parasite antigens. These results indicate that T lymphocyte lineage commitment and peripheral function need not depend on the function of CD4.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	LOCKSLEY, RM (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.				NIAID NIH HHS [AI30663] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTOINE JC, 1991, INFECT IMMUN, V59, P764, DOI 10.1128/IAI.59.3.764-775.1991; BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; BELOSEVIC M, 1989, J IMMUNOL, V143, P266; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; FONG TAT, 1989, J IMMUNOL, V143, P2887; HATAM F, UNPUB; HEINZEL FP, 1991, P NATL ACAD SCI USA, V88, P7011, DOI 10.1073/pnas.88.16.7011; HOLADAY BJ, 1991, J IMMUNOL, V147, P1653; HUANG L, 1992, J EXP MED, V176, P699, DOI 10.1084/jem.176.3.699; JANEWAY CA, 1993, CURR BIOL, V3, P282, DOI 10.1016/0960-9822(93)90179-R; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KILLEEN N, UNPUB; KUBOTA H, 1992, J IMMUNOL, V149, P1143; MILON G, 1986, J IMMUNOL, V136, P1467; MITCHELL GF, 1983, J IMMUNOGENET, V10, P395; MORRIS L, 1992, J IMMUNOL, V149, P2715; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; REINER SL, 1993, SCIENCE, V259, P1457, DOI 10.1126/science.8451641; REINER SL, UNPUB; REINER SL, IN PRESS J IMMUNOL M; SADICK MD, 1990, J EXP MED, V171, P115, DOI 10.1084/jem.171.1.115; TITUS RG, 1987, EUR J IMMUNOL, V17, P1429, DOI 10.1002/eji.1830171007; TITUS RG, 1985, J IMMUNOL, V135, P2108; TSICOPOULOS A, 1992, J IMMUNOL, V148, P2058; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZLOTNIK A, 1992, J IMMUNOL, V149, P1211	28	243	247	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1448	1451		10.1126/science.8367726	http://dx.doi.org/10.1126/science.8367726			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367726				2022-12-28	WOS:A1993LW54900033
J	MARTINI, CJM; GRENHOLM, G				MARTINI, CJM; GRENHOLM, G			INSTITUTIONAL RESPONSIBILITY IN GRADUATE MEDICAL-EDUCATION AND HIGHLIGHTS OF HISTORICAL DATA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,DEPT DATA SYST,CHICAGO,IL 60610	American Medical Association	MARTINI, CJM (corresponding author), AMER MED ASSOC,OFF VICE PRESIDENT MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							MORRIS TQ, 1993, TAKING CHARGE GRADUA, P197; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; 1966, GRADUATE ED PHYSICIA, P79; 1993, PHYSICIAN PAYMENT RE, P72	4	16	16	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1053	1060		10.1001/jama.270.9.1053	http://dx.doi.org/10.1001/jama.270.9.1053			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350447				2022-12-28	WOS:A1993LU51200005
J	DELONG, A; CALDERONURREA, A; DELLAPORTA, SL				DELONG, A; CALDERONURREA, A; DELLAPORTA, SL			SEX DETERMINATION GENE TASSELSEED2 OF MAIZE ENCODES A SHORT-CHAIN ALCOHOL-DEHYDROGENASE REQUIRED FOR STAGE-SPECIFIC FLORAL ORGAN ABORTION	CELL			English	Article							NUCLEOTIDE-SEQUENCE; ZEA-MAYS; AC; IDENTIFICATION; FLOWERS; CDNAS; ENTA	Maize produces separate unisexual flowers through programed abortion of preformed organ primordia. In the male inflorescence (tassel), stamen primordia develop to sexual maturity, while gynoecia (pistil primordia) are aborted. In tasselseed2 (ts2) mutant plants, floral structures in the tassel adopt a female developmental program. Here we report the transposon tagging and cloning of the TS2 gene, which plays a late but pivotal role In determining the sexual fate of floral meristems. Shortly before abortion of the gynoecium, Ts2 mRNA is expressed subepidermally in that primordium. Phenotypic instability of the Activator (Ac)-induced allele ts2-m1 indicates that late restoration of TS2 action in somatic tissues, which is correlated with Ac excision, reactivates the male developmental program. The predicted amino acid sequence of the Ts2 protein shows significant similarity to short-chain alcohol dehydrogenases, particularly hydroxysteroid dehydrogenases.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06511	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038148] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38148] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonnett OT, 1940, J AGRIC RES, V60, P0025; CHEN J, 1993, IN PRESS MAIZE HDB; CHEN JC, 1987, GENETICS, V117, P109; CHENG PC, 1983, AM J BOT, V70, P450, DOI 10.2307/2443252; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMET PS, 1987, EMBO J, V6, P295, DOI 10.1002/j.1460-2075.1987.tb04753.x; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DAWE RK, 1990, DEV BIOL, V142, P233, DOI 10.1016/0012-1606(90)90167-H; DELLAPORTA SL, 1993, IN PRESS PLANT CELL; DELLAPORTA SL, 1993, IN PRESS MAIZE HDB; Emerson RA, 1920, J HERED, V11, P65, DOI 10.1093/oxfordjournals.jhered.a101971; EMERSON RA, 1932, 6TH P INT C GEN, V1, P141; FEDOROFF N, 1983, CELL, V35, P235, DOI 10.1016/0092-8674(83)90226-X; Fedoroff N, 1989, MOBILE DNA, P377; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOPALSRIVASTAVA R, 1990, J BACTERIOL, V172, P7011; HANSEN DJ, 1976, CROP SCI, V16, P371, DOI 10.2135/cropsci1976.0011183X001600030013x; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; IRISH EE, 1993, AM J BOT, V80, P292, DOI 10.2307/2445352; IRISH EE, 1989, PLANT CELL, V1, P737, DOI 10.1105/tpc.1.8.737; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; Jackson DP, 1991, MOL PLANT PATHOL, P163; JANY KD, 1984, FEBS LETT, V165, P6, DOI 10.1016/0014-5793(84)80003-4; LANGDALE JA, 1988, GENE DEV, V2, P106, DOI 10.1101/gad.2.1.106; LAZARTE JE, 1979, AM J BOT, V66, P753, DOI 10.2307/2442462; LIU J, 1989, J BACTERIOL, V171, P791, DOI 10.1128/jb.171.2.791-798.1989; LYNDON RF, 1985, HDB FLOWERING, P313; MCDANIEL CN, 1988, PLANTA, V175, P13, DOI 10.1007/BF00402877; Moore T.C., 1989, BIOCH PHYSL PLANT HO, P255; NAHLIK MS, 1989, J BACTERIOL, V171, P784, DOI 10.1128/jb.171.2.784-790.1989; NICKERSON NORTON H., 1955, ANN MISSOURI BOT GARDEN, V42, P195, DOI 10.2307/2394655; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Phipps IF, 1928, J HERED, V19, P399, DOI 10.1093/oxfordjournals.jhered.a103030; Sambrook J., 1989, MOL CLONING; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STIEFEL V, 1988, PLANT MOL BIOL, V11, P483, DOI 10.1007/BF00039029; Weatherwax P., 1916, B TORREY BOT CLUB, V43, P127; Yampolsky C., 1922, BIBLIOTHECA GENETICA, V3, P1; YIN SJ, 1991, EUR J BIOCHEM, V197, P359, DOI 10.1111/j.1432-1033.1991.tb15919.x	41	265	302	0	53	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					757	768		10.1016/0092-8674(93)90522-R	http://dx.doi.org/10.1016/0092-8674(93)90522-R			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358795				2022-12-28	WOS:A1993LU59200018
J	KITZHABER, JA				KITZHABER, JA			RATIONING IN ACTION - PRIORITIZING HEALTH-SERVICES IN AN ERA OF LIMITS - THE OREGON EXPERIENCE	BRITISH MEDICAL JOURNAL			English	Article								How do we decide who should receive the benefits that medical science has to offer? One approach to this decision process, that used by the state of Oregon, is described: who and what are covered, and how health care is financed and delivered, are considered. Oregon's priorities were set on the basis of broad consensus. The objective of health care reform, it was agreed, is to improve, maintain, or restore health-not universal coverage, access to health care, or cost containment. A Health Services Commission was created to consider clinical effectiveness and, through public involvement, to attempt to integrate social values into the priority list. Oregon's legislature can use the list to develop an overall health policy which recognises that health can be maintained only if investments in several related areas are balanced.			KITZHABER, JA (corresponding author), HUNDREDTH MERIDIAN LTD,POB 961,SALEM,OR 97308, USA.							HLTH CARE COMMON	1	52	52	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					373	377		10.1136/bmj.307.6900.373	http://dx.doi.org/10.1136/bmj.307.6900.373			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374424	Green Published, Bronze			2022-12-28	WOS:A1993LR76800027
J	GRAHAM, ANJ; LOWRY, KG; MCGUIGAN, JA				GRAHAM, ANJ; LOWRY, KG; MCGUIGAN, JA			ANESTHESIA FOR THORACIC SYMPATHECTOMY	BRITISH MEDICAL JOURNAL			English	Letter											GRAHAM, ANJ (corresponding author), ROYAL VICTORIA HOSP,REG THORAC SURG UNIT,BELFAST BT12 6BJ,NORTH IRELAND.							QUINN AC, 1993, BRIT MED J, V306, P1752, DOI 10.1136/bmj.306.6894.1752-b	1	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					326	326		10.1136/bmj.307.6899.326	http://dx.doi.org/10.1136/bmj.307.6899.326			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374400	Green Published			2022-12-28	WOS:A1993LQ51600066
J	ARNOLD, JMO; TEASELL, RW; MACLEOD, AP; BROWN, JE; CARRUTHERS, SG				ARNOLD, JMO; TEASELL, RW; MACLEOD, AP; BROWN, JE; CARRUTHERS, SG			INCREASED VENOUS ALPHA-ADRENOCEPTOR RESPONSIVENESS IN PATIENTS WITH REFLEX SYMPATHETIC DYSTROPHY	ANNALS OF INTERNAL MEDICINE			English	Note						REFLEX SYMPATHETIC DYSTROPHY; RECEPTORS, ADRENERGIC-ALPHA; NOREPINEPHRINE; HEMIPLEGIA; SYMPATHETIC NERVOUS SYSTEM		Reflex sympathetic dystrophy is a symptom complex characterized by vasomotor instability, hyperaesthesia, and pain. Hypothesizing that these symptoms could reflect diminished sympathetic innervation with resultant alpha-adrenoceptor hyper-responsiveness, we studied 11 patients who developed upper-limb reflex sympathetic dystrophy after hemiplegia or trauma and 11 normal controls who were similar in age to the study patients. The diameter of superficial hand veins was measured using a linear variable differential transformer during local infusion of saline and increasing concentrations of noradrenaline. The limbs affected with reflex sympathetic dystrophy showed marked alpha-adrenoceptor hyper-responsiveness, that is, less noradrenaline was required to cause 50% venoconstriction (1.5 compared with 6.8 ng/min, P = 0.001). The unaffected limb in patients with reflex sympathetic dystrophy also showed hyper-responsiveness to noradrenaline when compared with values in normal controls (6.8 compared with 27.4 ng/min P = 0.01), with such hyper-responsiveness being more marked in patients with hemiplegia. The findings provide the first direct evidence in humans of hyper-responsiveness of vascular alpha-adrenoceptors to noradrenaline in reflex sympathetic dystrophy.	VICTORIA GEN HOSP, HALIFAX B3H 2Y9, NS, CANADA; UNIV WESTERN ONTARIO, UNIV HOSP, LONDON N6A 5A5, ONTARIO, CANADA	Dalhousie University; University of Victoria; Western University (University of Western Ontario)	ARNOLD, JMO (corresponding author), VICTORIA HOSP, 375 S ST, LONDON N6A 4G5, ONTARIO, CANADA.		Arnold, Malcolm/G-2869-2011					ALRADI AO, 1985, CLIN PHARMACOL THER, V38, P495, DOI 10.1038/clpt.1985.214; BEJ MD, 1991, ARCH NEUROL-CHICAGO, V48, P912, DOI 10.1001/archneur.1991.00530210038020; Cannon WB, 1949, SUPERSENSITIVITY DEN; DRUMMOND PD, 1991, BRAIN, V114, P2025, DOI 10.1093/brain/114.5.2025; KOLTZENBURG M, 1991, TRENDS PHARMACOL SCI, V12, P399, DOI 10.1016/0165-6147(91)90615-Y; KOZIN F, 1979, ARTHRITIS ALLIED CON; ROSEN L, 1989, MICROVASC RES, V37, P289, DOI 10.1016/0026-2862(89)90047-2; SWEET WH, 1985, EVALUATION TREATMENT, P149; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WALLIN BG, 1976, SENSORY FUNCTIONS SK, V27, P489	10	138	140	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					619	621		10.7326/0003-4819-118-8-199304150-00008	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00008			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8383935				2022-12-28	WOS:A1993KW47000008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			WARNING ABOUT VIBRIO INFECTIONS AND RAW MOLLUSCAN SHELLFISH CONSUMPTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1361	1361		10.1001/jama.269.11.1361	http://dx.doi.org/10.1001/jama.269.11.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8382752				2022-12-28	WOS:A1993KQ85700005
J	JELINEK, LJ; LOK, S; ROSENBERG, GB; SMITH, RA; GRANT, FJ; BIGGS, S; BENSCH, PA; KUIJPER, JL; SHEPPARD, PO; SPRECHER, CA; OHARA, PJ; FOSTER, D; WALKER, KM; CHEN, LHJ; MCKERNAN, PA; KINDSVOGEL, W				JELINEK, LJ; LOK, S; ROSENBERG, GB; SMITH, RA; GRANT, FJ; BIGGS, S; BENSCH, PA; KUIJPER, JL; SHEPPARD, PO; SPRECHER, CA; OHARA, PJ; FOSTER, D; WALKER, KM; CHEN, LHJ; MCKERNAN, PA; KINDSVOGEL, W			EXPRESSION CLONING AND SIGNALING PROPERTIES OF THE RAT GLUCAGON RECEPTOR	SCIENCE			English	Article							ADENYL CYCLASE SYSTEM; PLASMA MEMBRANES; HEPATOCYTES; PROTEIN; TRANSDUCTION; BINDING; LIVER	Glucagon and the glucagon receptor are a primary source of control over blood glucose concentrations and are especially important to studies of diabetes in which the loss of control over blood glucose concentrations clinically defines the disease. A complementary DNA clone for the glucagon receptor was isolated by an expression cloning strategy, and the receptor protein was expressed in several kidney cell lines. The cloned receptor bound glucagon and caused an increase in the intracellular concentration of adenosine 3', 5'-monophosphate (cAMP). The cloned glucagon receptor also transduced a signal that led to an increased concentration of intracellular calcium. The glucagon receptor is similar to the calcitonin and parathyroid hormone receptors. It can transduce signals leading to the accumulation of two different second messengers, cAMP and calcium.	ZYMOGENET INC,4225 ROOSEVELT WAY NE,SEATTLE,WA 98105	Zymogenet Inc.								ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BHARUCHA DB, 1990, J BIOL CHEM, V265, P3070; CHABRE O, 1992, MOL ENDOCRINOL, V6, P551, DOI 10.1210/me.6.4.551; CHAREST R, 1983, J BIOL CHEM, V258, P8769; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK L, UNPUB; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAGNYPOURMIR I, 1989, ENDOCRINOLOGY, V124, P2635, DOI 10.1210/endo-124-5-2635; LIN HY, 1991, SCIENCE, V254, P1022, DOI 10.1126/science.1658940; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; POHL SL, 1971, J BIOL CHEM, V246, P1849; RODBELL M, 1971, J BIOL CHEM, V246, P1861; ROSENBERG G, UNPUB; SISTARE FD, 1985, J BIOL CHEM, V260, P2744; SMITH RE, UNPUB, P54011; SONNE O, 1978, J BIOL CHEM, V253, P3203; SPRECHER C, UNPUB; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNGER RH, 1992, TXB ENDOCRINOLOGY, P1255; UNGER RH, 1990, DIABETES MELLITUS TH; UNSON CG, 1989, PEPTIDES, V10, P1171, DOI 10.1016/0196-9781(89)90010-7; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0	28	385	408	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 12	1993	259	5101					1614	1616		10.1126/science.8384375	http://dx.doi.org/10.1126/science.8384375			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8384375				2022-12-28	WOS:A1993KR54300040
J	JOHNSON, SH				JOHNSON, SH			JUDICIAL-REVIEW OF DISCIPLINARY ACTION FOR SEXUAL MISCONDUCT IN THE PRACTICE OF MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTACT		ST LOUIS UNIV,SCH MED,DEPT INTERNAL MED,ST LOUIS,MO 63104	Saint Louis University	JOHNSON, SH (corresponding author), ST LOUIS UNIV,SCH LAW,CTR HLTH LAW STUDIES,3700 LINDELL BLVD,ST LOUIS,MO 63108, USA.							APPELBAUM PS, 1991, AM J PSYCHIAT, V148, P1466; BARKER WT, 1992, NATL LJ         0629, P17; BARKER WT, 1992, NATL LAW J      0629, P14; BORRUSO MT, 1991, AM J LAW MED, V17, P289; Coleman Phyllis, 1988, Oklahoma Law Rev, V41, P1; GARTRELL NK, 1992, WESTERN J MED, V157, P139; GILLAM J, 1993, LOS ANGELES TIM 0415, P8; Glasgow J.B., 1992, BOSTON COLL LAW REV, V33, P645; HYAMS AL, 1993, AM J LAW MED, V18, P171; Jorgenson L, 1991, William Mary Law Rev, V32, P645; JORGENSON LM, 1992, ARKANSAS LAW REV, V45, P459; LEBOEUF D, 1988, HARV WOMENS LJ, V11, P83; MURIEL RH, 1992, LOY U CHI LJ, V23, P309; PRESCOTT JM, 1992, MIL LAW REV, V135, P21; STRASBURGER LH, 1991, AM J PSYCHIAT, V148, P859; TUITE CH, 1992, ABA J, V78, P34; 1993, COLUMBUS DISPAT 0418, pD4; 1991, JAMA-J AM MED ASSOC, V266, P2741; 1991, FINAL REPORT TASK FO; 1992, CODE MED ETHICS CURR	20	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1596	1600		10.1001/jama.270.13.1596	http://dx.doi.org/10.1001/jama.270.13.1596			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ334	8371472				2022-12-28	WOS:A1993LZ33400035
J	WALDROP, MM				WALDROP, MM			JOBS IN SOCIAL-SCIENCE .3. COGNITIVE NEUROSCIENCE - A WORLD WITH A FUTURE	SCIENCE			English	Article														Waldrop, M Mitchell/0000-0002-8063-1472					0	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1805	&		10.1126/science.8378783	http://dx.doi.org/10.1126/science.8378783			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LY584	8378783				2022-12-28	WOS:A1993LY58400045
J	BARLOWE, C; SCHEKMAN, R				BARLOWE, C; SCHEKMAN, R			SEC12 ENCODES A GUANINE-NUCLEOTIDE-EXCHANGE FACTOR ESSENTIAL FOR TRANSPORT VESICLE BUDDING FROM THE ER	NATURE			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; MEMBRANE GLYCOPROTEIN; GOLGI-APPARATUS; BREFELDIN-A; YEAST; RAS; ARF	IN yeast a type II integral membrane glycoprotein that is essential for transport vesicle budding from the endoplasmic reticulum (ER) is encoded by SEC12 (refs 1-3). SAR1 was discovered as a multi-copy copy suppressor of the sec12-1ts strain and encodes a GTPase of M(r) 21,000 (21K) also essential for vesicle budding from the ER4,5. Sar1 is a peripherally associated membrane protein which shows enhanced membrane binding in cells containing elevated levels of Sec12 protein (refs 6, 7). We show here that a purified fragment of Sec12 promotes guanine-nucleotide dissociation from Sar1 whereas the purified mutant Sec12-1 has only 15% of the wild-type activity. GTP hydrolysis by Sar1 is not enhanced by Sec12, but is stimulated more than 50-fold by a mixture of Sec12 and Sec23, a GTPase-activating protein specific for Sar1 (ref. 8). We propose that Sec12 catalyses Sar1 guanine-nucleotide exchange in a process that recruits Sar1 to a vesicle formation site on the ER membrane.	UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	Howard Hughes Medical Institute; University of California System; University of California Berkeley								BARLOWE C, 1993, J BIOL CHEM, V268, P873; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DENFERT C, 1991, MOL CELL BIOL, V11, P5727, DOI 10.1128/MCB.11.11.5727; DENFERT C, 1992, EMBO J, V11, P4205, DOI 10.1002/j.1460-2075.1992.tb05514.x; DENFERT C, 1991, J CELL BIOL, V114, P663, DOI 10.1083/jcb.114.4.663; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; MOCKRIN SC, 1980, BIOCHEMISTRY-US, V19, P5359, DOI 10.1021/bi00564a033; MOYA M, 1993, NATURE, V361, P460, DOI 10.1038/361460a0; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; NAKANO A, 1989, J CELL BIOL, V109, P2677, DOI 10.1083/jcb.109.6.2677; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; SALAMA N, IN PRESS EMBO J; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIKORSKI RS, 1989, GENETICS, V122, P19; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WEISS O, 1989, J BIOL CHEM, V264, P21066; WUESTENHUBE LJ, 1992, METHOD ENZYMOL, V219, P212; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	28	370	377	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					347	349		10.1038/365347a0	http://dx.doi.org/10.1038/365347a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377826				2022-12-28	WOS:A1993LY49600054
J	MUNTONI, F; CAU, M; GANAU, A; CONGIU, R; ARVEDI, G; MATEDDU, A; MARROSU, MG; CIANCHETTI, C; REALDI, G; CAO, A; MELIS, MA				MUNTONI, F; CAU, M; GANAU, A; CONGIU, R; ARVEDI, G; MATEDDU, A; MARROSU, MG; CIANCHETTI, C; REALDI, G; CAO, A; MELIS, MA			BRIEF REPORT - DELETION OF THE DYSTROPHIN MUSCLE-PROMOTER REGION ASSOCIATED WITH X-LINKED DILATED CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DUCHENNE MUSCULAR-DYSTROPHY; MITOCHONDRIAL-DNA; GENE; MYOPATHY; PROTEIN; BRAIN; POLYMORPHISMS; PRODUCT; SERIES; LOCUS		IST NEUROPSICHIATRIA INFANTILE,CAGLIARI,ITALY; IST CLIN & BIOL ETA EVOLUT,CAGLIARI,ITALY; IST CLIN MED GEN & TERAPIA MED,SASSARI,ITALY				Ganau, Antonello/D-6899-2012; Cianchetti, Carlo/ABD-9536-2021	GANAU, Antonello/0000-0002-7053-293X	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BEGGS AH, 1990, HUM GENET, V86, P45; BEGGS AH, 1991, AM J HUM GENET, V49, P54; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; BIES RD, 1992, NUCLEIC ACIDS RES, V20, P1725, DOI 10.1093/nar/20.7.1725; BIORCK G, 1964, ACTA MED SCAND, V176, P407; BOYCE FM, 1991, P NATL ACAD SCI USA, V88, P1276, DOI 10.1073/pnas.88.4.1276; CASAZZA F, 1988, J NEUROL, V235, P496, DOI 10.1007/BF00314256; CHAMBERLAIN JS, 1988, NUCLEIC ACIDS RES, V16, P11141, DOI 10.1093/nar/16.23.11141; CSANADY M, 1976, CARDIOLOGY, V61, P122, DOI 10.1159/000169753; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; FEENER CA, 1991, AM J HUM GENET, V48, P621; GOLD R, 1992, MUSCLE NERVE, V15, P214, DOI 10.1002/mus.880150214; GOSPE SM, 1989, NEUROLOGY, V39, P1277, DOI 10.1212/WNL.39.10.1277; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HUNSAKER RH, 1982, AM J MED, V73, P235, DOI 10.1016/0002-9343(82)90184-X; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KUNKEL LM, 1991, ETIOLOGY HUMAN DIS D, P51; LANE RJM, 1980, NEUROLOGY, V30, P497, DOI 10.1212/WNL.30.5.497; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MICHELS VV, 1985, AM J CARDIOL, V55, P1232, DOI 10.1016/0002-9149(85)90675-7; MUNTONI F, 1989, FEBS LETT, V252, P95, DOI 10.1016/0014-5793(89)80896-8; MUNTONI F, 1993, J NEUROL NEUROSUR PS, V56, P26, DOI 10.1136/jnnp.56.1.26; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; OUDET C, 1991, AM J HUM GENET, V49, P311; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; RINGEL SP, 1977, ARCH NEUROL-CHICAGO, V34, P408, DOI 10.1001/archneur.1977.00500190042006; SCHMIDT MA, 1988, AM J MED GENET, V31, P135, DOI 10.1002/ajmg.1320310116; SUNOHARA N, 1990, ANN NEUROL, V28, P634, DOI 10.1002/ana.410280506; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; VITIELLO L, 1992, J MED GENET, V29, P127, DOI 10.1136/jmg.29.2.127; YAZAWA M, 1987, EUR NEUROL, V27, P13, DOI 10.1159/000116122; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D; 1979, NOMENCLATURE CRITERI	35	338	343	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					921	925		10.1056/NEJM199309233291304	http://dx.doi.org/10.1056/NEJM199309233291304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361506				2022-12-28	WOS:A1993LX75100004
J	EMANUEL, EJ; BRETT, AS				EMANUEL, EJ; BRETT, AS			MANAGED COMPETITION AND THE PATIENT-PHYSICIAN RELATIONSHIP	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNIVERSAL HEALTH-INSURANCE; HMO DISENROLLMENT; PROMOTE QUALITY; PLAN; ECONOMY; 1990S		NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215		EMANUEL, EJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115, USA.							BRETT AS, 1992, NEW ENGL J MED, V326, P1353, DOI 10.1056/NEJM199205143262010; DIAMOND P, 1992, ECONOMETRICA, V60, P1233, DOI 10.2307/2951520; EMANUEL EZEKIEL J., 1991, ENDS HUMAN LIFE MED, P178; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; FREIDSON E, 1973, MILBANK FUND Q, V51, P473, DOI 10.2307/3349630; HENNELLY VD, 1983, MED CARE, V21, P348, DOI 10.1097/00005650-198303000-00007; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LONG SH, 1988, MED CARE, V26, P927, DOI 10.1097/00005650-198810000-00001; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; RELMAN AS, 1993, NEW ENGL J MED, V328, P133, DOI 10.1056/NEJM199301143280212; SCHROEDER JL, 1985, JAMA-J AM MED ASSOC, V254, P3080, DOI 10.1001/jama.254.21.3080; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SCHWARTZ WB, 1992, HEALTH AFFAIR, V11, P100, DOI 10.1377/hlthaff.11.2.100; SIMMONS HE, 1992, NEW ENGL J MED, V327, P1525, DOI 10.1056/NEJM199211193272113; SORENSEN AA, 1981, MED CARE, V19, P766, DOI 10.1097/00005650-198107000-00007; STARR P, 1993, HEALTH AFFAIR, V12, P7, DOI 10.1377/hlthaff.12.suppl_1.7; TONER R, 1993, NY TIMES        0228, P8; TONOER R, 1993, NY TIMES        0228, P1; Travis M, 1989, J Health Care Mark, V9, P75; 1992, NY TIMES        1202, pA22; 1992, NY TIMES        1203, pA24	23	75	75	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					879	882		10.1056/NEJM199309163291213	http://dx.doi.org/10.1056/NEJM199309163291213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355749				2022-12-28	WOS:A1993LW55100013
J	PROTOPOPOV, V; GOVINDAN, B; NOVICK, P; GERST, JE				PROTOPOPOV, V; GOVINDAN, B; NOVICK, P; GERST, JE			HOMOLOGS OF THE SYNAPTOBREVIN VAMP FAMILY OF SYNAPTIC VESICLE PROTEINS FUNCTION ON THE LATE SECRETORY PATHWAY IN SACCHAROMYCES-CEREVISIAE	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; ADENYLYL CYCLASE COMPLEX; SACCHAROMYCES-CEREVISIAE; YEAST; IDENTIFICATION; GENES; RAS; CAP; PURIFICATION; TRANSPORT	The yeast S. cerevisiae possesses two genes, SNC1 and SNC2, that encode homologs of vertebrate synaptic vesicle-associated membrane proteins, also known as synaptobrevins. Here we describe the cloning of SNC2 and demonstrate that yeast lacking both SNC genes are deficient in normal bulk secretion, accumulate large numbers of post-Golgi vesicles, and display a variety of conditional lethal phenotypes. In addition, we show that yeast Snc proteins localize to post-Golgi transport vesicles that accumulate in a late-acting sec mutant. Our findings clearly place the Snc proteins on the late secretory pathway in S. cerevisiae and provide direct in vivo evidence that synaptobrevin-like proteins mediate the targeting and transport of secretory proteins.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA	Yale University	PROTOPOPOV, V (corresponding author), CUNY MT SINAI SCH MED, DEPT CELL BIOL & ANAT, NEW YORK, NY 10029 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035370, R01GM035370] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35370] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; CAIN CC, 1992, J BIOL CHEM, V267, P11681; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GERST JE, 1991, MOL CELL BIOL, V11, P1248, DOI 10.1128/MCB.11.3.1248; GERST JE, 1992, P NATL ACAD SCI USA, V89, P4338, DOI 10.1073/pnas.89.10.4338; Goldstein A, 1975, Methods Enzymol, V42, P504; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; NEWMAN AP, 1992, EMBO J, V11, P3609, DOI 10.1002/j.1460-2075.1992.tb05445.x; NEWMAN AP, 1992, MOL CELL BIOL, V12, P3663, DOI 10.1128/MCB.12.8.3663; NEWMAN AP, 1987, J CELL BIOL, V105, P1587, DOI 10.1083/jcb.105.4.1587; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; Rose MD., 1990, METHODS YEAST GENETI; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WALWORTH NC, 1992, MOL CELL BIOL, V12, P2017, DOI 10.1128/MCB.12.5.2017; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; WRIGHT R, 1989, METHOD CELL BIOL, V31, P473	35	265	268	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					855	861		10.1016/0092-8674(93)90465-3	http://dx.doi.org/10.1016/0092-8674(93)90465-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374953				2022-12-28	WOS:A1993LX29200011
J	MAYNARD, N; BIHARI, D; BEALE, R; SMITHIES, M; BALDOCK, G; MASON, R; MCCOLL, I				MAYNARD, N; BIHARI, D; BEALE, R; SMITHIES, M; BALDOCK, G; MASON, R; MCCOLL, I			ASSESSMENT OF SPLANCHNIC OXYGENATION BY GASTRIC TONOMETRY IN PATIENTS WITH ACUTE CIRCULATORY FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY ILL PATIENTS; TUMOR NECROSIS FACTOR; INTRAMURAL PH; TISSUE OXYGENATION; PREDICTIVE VALUE; INTRAMUCOSAL PH; SEPSIS; INFECTION; ENDOTOXEMIA; CONSUMPTION	Objective.- To investigate the importance of splanchnic ischemia in patients with acute circulatory failure by comparing gastric intramucosal pH as measured by tonometry with conventional methods of assessing adequacy of tissue oxygenation. Design.- Prospective cohort of patients with acute circulatory failure in first 24 hours after admission to the intensive care unit. Setting.- Two general intensive care units in London, England. Patients.- Consecutive sample of 83 patients of varying diagnostic categories that required pulmonary artery catheterization. Main Outcome Measures.- Gastric intramucosal pH and hemodynamic, oxygen transport, and metabolic variables were measured on admission and at 12 hours and 24 hours after admission. Prediction of outcome (death or survival) by each measurement was assessed by sensitivity, specificity, and logistic regression analysis. Results.- Mean 24-hour Acute Physiology and Chronic Health Evaluation (APACHE II) score was 20.3. There were significant differences in mean gastric intramucosal pH between survivors and nonsurvivors on admission and at 24 hours, (7.40 vs 7.28, 7.40 vs 7.24, respectively; P<.001). Admission heart rate was higher (116 vs 101 beats per minute; P<.003) and mean arterial pressure lower (82 vs 97 mm Hg; P<.01) in nonsurvivors. There were no consistent differences in cardiac index, oxygen delivery, and oxygen uptake between survivors and nonsurvivors. Admission arterial pH was significantly lower (7.3 vs 7.36; P<.003), base excess more negative (-5.3 vs - 1.9; P<.001), and lactate concentration higher (3.14 vs 1.91 mmol/L; P<.03) in nonsurvivors. Gastric intramucosal pH had a sensitivity of 88% for predicting death and a likelihood ratio of 2.32, higher than for any other variable. Only gastric intramucosal pH at 24 hours independently predicted outcome. Conclusions.- Gastric intramucosal pH was the most reliable indicator of adequacy of tissue oxygenation in this group of patients. Inadequate regional blood flow as detected by a reduction in gastric intramucosal pH, but not by systemic measures, is an important contributor to morbidity and mortality in intensive care units.	GUYS HOSP,DEPT INTENS CARE,LONDON SE1 9RT,ENGLAND; LEWISHAM HOSP,DEPT INTENS CARE,LONDON SE13 6LH,ENGLAND; GUYS HOSP,DEPT SURG,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust								ANTONSSON JB, 1990, AM J PHYSIOL, V259, pG519, DOI 10.1152/ajpgi.1990.259.4.G519; ASTIZ M, 1988, CIRC SHOCK, V26, P311; BAILEY RW, 1982, SURG FORUM, V33, P194; BALDOCK G, 1991, SURV ANAESTHESIOL, V35, P178; BAUE AE, 1975, ARCH SURG-CHICAGO, V110, P779; BERGOFSKY EH, 1964, J CLIN INVEST, V43, P193, DOI 10.1172/JCI104904; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BIHARI D, 1983, CARE CRITICALLY ILL, P189; BIHARI D, 1991, SURV ANAESTHESIOL, V35, P182; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; BOYD O, 1993, LANCET, V341, P142, DOI 10.1016/0140-6736(93)90005-2; CERRA FB, 1987, SURGERY, V101, P1; CERRA FB, 1988, PERSPECTIVES CRITICA, V1, P30; CUNNINGHAM J A, 1987, Current Surgery, V44, P229; DAHN MS, 1988, INTENS CARE MED, V14, P373, DOI 10.1007/BF00262891; DAHN MS, 1987, SURGERY, V101, P69; DANTZKER D, 1989, CRIT CARE CLIN, V5, P81; DAWSON AM, 1965, NATURE, V206, P943, DOI 10.1038/206943b0; DOGLIO GR, 1991, CRIT CARE MED, V19, P1037, DOI 10.1097/00003246-199108000-00011; DRIKS MR, 1987, NEW ENGL J MED, V317, P1376, DOI 10.1056/NEJM198711263172204; FIDDIANGREEN RG, 1987, CRIT CARE MED, V15, P153, DOI 10.1097/00003246-198702000-00015; FIDDIANGREEN RG, 1982, J SURG RES, V33, P39, DOI 10.1016/0022-4804(82)90007-5; FIDDIANGREEN RG, 1983, GASTROENTEROLOGY, V85, P613; FIDDIANGREEN RG, 1989, SPLANCHNIC ISCHEMIA, P349; FINK MP, 1991, CRIT CARE MED, V19, P627, DOI 10.1097/00003246-199105000-00009; GILMOUR DG, 1980, BRIT J SURG, V67, P82, DOI 10.1002/bjs.1800670204; GRUM CM, 1984, J APPL PHYSIOL, V56, P1065, DOI 10.1152/jappl.1984.56.4.1065; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; GYS T, 1988, CRIT CARE MED, V16, P1222, DOI 10.1097/00003246-198812000-00009; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEARD SO, 1991, CRIT CARE MED, V19, P271, DOI 10.1097/00003246-199102000-00025; HOTCHKISS RS, 1992, JAMA-J AM MED ASSOC, V267, P1503, DOI 10.1001/jama.267.11.1503; LANDOW L, 1991, CRIT CARE MED, V19, P1226, DOI 10.1097/00003246-199110000-00003; MAYNARD ND, 1991, BRIT MED J, V303, P1007, DOI 10.1136/bmj.303.6809.1007; McIver MA, 1926, AM J PHYSIOL, V76, P92, DOI 10.1152/ajplegacy.1926.76.1.92; MCNEIL BJ, 1975, NEW ENGL J MED, V293, P211, DOI 10.1056/NEJM197507312930501; MEAKINS JL, 1980, SURG CLIN N AM, V60, P117; MEAKINS JL, 1989, SPLANCHNIC ISCHEMIA, P339; MICHIE HR, 1989, BRIT J SURG, V76, P670, DOI 10.1002/bjs.1800760706; MOVAT HZ, 1987, FASEB J, V46, P97; NELSON DP, 1988, J APPL PHYSIOL, V64, P2410, DOI 10.1152/jappl.1988.64.6.2410; PARKER MM, 1987, CRIT CARE MED, V15, P923, DOI 10.1097/00003246-198710000-00006; PAYNE CD, 1986, GLIM SYSTEM RELEASE; SHOEMAKER WC, 1973, ARCH SURG-CHICAGO, V106, P630; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SIBBALD WJ, 1989, CLIN ASPECTS O2 TRAN, P102; TAKALA J, 1991, CLIN NUTR, V10, pS3; VINCENT JL, 1990, INTENS CARE MED, V16, pS145, DOI 10.1007/BF01785244; WARDLE EN, 1987, LIVER, V7, P63; WILMORE DW, 1980, ANN SURG, V192, P491, DOI 10.1097/00000658-198010000-00008; Wright CI, 1934, J GEN PHYSIOL, V17, P657, DOI 10.1085/jgp.17.5.657	52	322	337	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1203	1210		10.1001/jama.270.10.1203	http://dx.doi.org/10.1001/jama.270.10.1203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355382				2022-12-28	WOS:A1993LV64900025
J	KOMORI, T; OKADA, A; STEWART, V; ALT, FW				KOMORI, T; OKADA, A; STEWART, V; ALT, FW			LACK OF N-REGIONS IN ANTIGEN RECEPTOR VARIABLE REGION GENES OF TDT-DEFICIENT LYMPHOCYTES	SCIENCE			English	Article							T-CELL RECEPTOR; GAMMA-DELTA; JUNCTIONAL DIVERSITY; B-CELL; V(D)J RECOMBINATION; CHAIN DIVERSITY; STEM-CELLS; EXPRESSION; INSERTION; SEGMENTS	During the assembly of immunoglobulin and T cell receptor variable region genes from variable (V), diversity (D), and joining (J) segments, the germline-encoded repertoire is further diversified by processes that include the template-independent addition of nucleotides (N regions) at gene segment junctions. Terminal deoxynucleotidyl transferase (TdT)-deficient lymphocytes had no N regions in their variable region genes, which shows that TdT is responsible for N region addition. In addition, certain variable region genes appeared at increased frequency in TdT-deficient thymocytes, which indicates that N region addition also influences repertoire development by alleviating sequence-specific constraints imposed on the joining of particular V, D, and J segments.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	KOMORI, T (corresponding author), CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020047, R01AI020047] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20047] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGUILAR LK, 1991, J IMMUNOL, V146, P1348; ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ASARNOW DM, 1993, NATURE, V362, P158, DOI 10.1038/362158a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; BANGS LA, 1991, J IMMUNOL, V146, P1996; BOGUE M, 1991, EMBO J, V10, P3647, DOI 10.1002/j.1460-2075.1991.tb04931.x; BOLLUM JF, 1974, ENZYMES, V10, P145; CARLSSON L, 1990, INT IMMUNOL, V2, P639, DOI 10.1093/intimm/2.7.639; CARLSSON L, 1992, INT IMMUNOL, V4, P549, DOI 10.1093/intimm/4.5.549; CHANG LMS, 1971, BIOCHEM BIOPH RES CO, V44, P124, DOI 10.1016/S0006-291X(71)80167-5; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; COLEMAN MS, 1974, P NATL ACAD SCI USA, V71, P4404, DOI 10.1073/pnas.71.11.4404; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; ELLIOT JF, 1968, NATURE, V331, P627; FEENEY AJ, 1991, J EXP MED, V174, P115, DOI 10.1084/jem.174.1.115; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GARMAN RD, 1986, CELL, V45, P733, DOI 10.1016/0092-8674(86)90787-7; GELLERT M, 1992, TRENDS GENET, V8, P408, DOI 10.1016/0168-9525(92)90322-U; GEORGE JF, 1992, J IMMUNOL, V148, P1230; GILLFILLAN S, 1993, SCIENCE, V261, P1175; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KALLENBACH S, 1992, P NATL ACAD SCI USA, V89, P2799, DOI 10.1073/pnas.89.7.2799; KOMORI T, UNPUB; KUNG PC, 1976, J EXP MED, V141, P855; KYES S, 1991, P NATL ACAD SCI USA, V88, P7830, DOI 10.1073/pnas.88.17.7830; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LIEBER MR, 1988, P NATL ACAD SCI USA, V85, P8588, DOI 10.1073/pnas.85.22.8588; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCCAFFREY R, 1973, P NATL ACAD SCI USA, V70, P36; MCCORMACK WT, 1991, P NATL ACAD SCI USA, V88, P7699, DOI 10.1073/pnas.88.17.7699; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; MEEK K, 1990, SCIENCE, V250, P820, DOI 10.1126/science.2237433; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; SCHWAGER J, 1991, EMBO J, V10, P2461, DOI 10.1002/j.1460-2075.1991.tb07785.x; SILVERSTONE AE, 1976, J EXP MED, V144, P544; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; TONEGAWA S, 1983, NATURE, V302; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	50	382	387	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1171	1175		10.1126/science.8356451	http://dx.doi.org/10.1126/science.8356451			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356451				2022-12-28	WOS:A1993LU58600033
J	DRESSER, R				DRESSER, R			DEFINING SCIENTIFIC MISCONDUCT - THE RELEVANCE OF MENTAL STATE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SCIENCE; FRAUD		CASE WESTERN RESERVE UNIV,SCH MED,CTR BIOMED ETH,CLEVELAND,OH 44106	Case Western Reserve University	DRESSER, R (corresponding author), CASE WESTERN RESERVE UNIV,SCH LAW,11075 E BLVD,CLEVELAND,OH 44106, USA.							CHUBIN DE, 1985, MINERVA, V23, P175, DOI 10.1007/BF01099941; DENNETT DC, 1987, INT STANCE; DONG E, 1991, CHRON HIGHER EDUC, V38, pA52; FASS RA, 1990, ETHICS HIGHER ED, P170; Friedman P J, 1992, Law Med Health Care, V20, P17; FRIEDMAN PJ, 1988, JAMA-J AM MED ASSOC, V260, P1937; Gainer Ronald L., 1988, RUTGERS LJ, V19, P575; GOODSTEIN D, 1991, AM SCHOLAR, V60, P505; HAMILTON DP, 1992, SCIENCE, V255, P1345, DOI 10.1126/science.255.5050.1345; HANSEN KD, 1991, FASEB J, V5, P2512, DOI 10.1096/fasebj.5.11.1868976; HILLMAN H, 1987, NATURE, V326, P736, DOI 10.1038/326736b0; HILTS PJ, 1991, NY TIMES        0331; KADISH SH, 1989, CRIMINAL LAW ITS PRO, P229; KEETON WP, 1984, PROSSER KEETON TORTS, V727, P740; KOSHLAND DE, 1987, SCIENCE, V235, P141, DOI 10.1126/science.3798097; MISHKIN B, 1988, JAMA-J AM MED ASSOC, V260, P1932; MISHKIN B, 1992, PROFESSIONAL ETH WIN, P5; MISHKIN B, 1991, PROFESIONAL ETHI SPR, V4, P3; MOONEY C, 1992, CHRON HIGHER EDUC, V38, pA13; MOONEY CJ, 1992, CHRON HIGHER EDUC, V38, pA18; PETSKO GA, 1988, NATURE, V335, P109, DOI 10.1038/335109a0; ROBINSON PH, 1983, STANFORD LAW REV, V35, P681, DOI 10.2307/1228658; SCHMAUS W, 1983, CONN MED, V47, P155; SHAPIRO MF, 1985, NEW ENGL J MED, V312, P731, DOI 10.1056/NEJM198503143121128; SINGER R, 1988, RUTGERS LAW J, V19, P519; STEWART WW, 1987, NATURE, V325, P207, DOI 10.1038/325207a0; ZUCKERMAN H, 1984, SCI TECHNOL, V9, P7; 1985, MODEL PENAL CODE, P243; 1992, RESPONSIBLE SCI ENSU; 1988, GUIDELINES INVESTIGA; 1985, MODEL PENAL CODE, P21; 1989, RESPONSIBLE CONDUCT; 1982, NAPOLITANO PRINCETON, V186; 1991, FED REG         0514, V56, P22286; 1989, CLIN RES, V37, P510; 1989, FED REG         0808, V54, P32446	36	21	21	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 17	1993	269	7					895	897						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KL474	8373455				2022-12-28	WOS:A1993KL47400028
J	ZHANG, SLJ; JACKSON, MB				ZHANG, SLJ; JACKSON, MB			GABA-ACTIVATED CHLORIDE CHANNELS IN SECRETORY NERVE-ENDINGS	SCIENCE			English	Article							GAMMA-AMINOBUTYRIC-ACID; SENSORY NEURONS; PATCH-CLAMP; SYNAPTIC TRANSMISSION; TRANSMITTER RELEASE; PYRAMIDAL CELLS; SPINAL NEURONS; TERMINALS; RAT; INHIBITION	Neurotransmitters acting on presynaptic terminals regulate synaptic transmission and plasticity. Because of the difficulty of direct electrophysiological recording from small presynaptic terminals, little is known about the ion channels that mediate these actions or about the mechanisms by which transmitter secretion is altered. The patch-clamp technique is used to show that the predominant inhibitory presynaptic neurotransmitter, gamma-aminobutyric acid (GABA), activates a GABA(A) receptor and gates a chloride channel in the membranes of peptidergic nerve terminals of the posterior pituitary. The opening of a chloride channel by GABA weakly depolarizes the nerve terminal membrane and blocks action potentials. In this way, GABA limits secretion by retarding the spread of excitation into the terminal arborization.	UNIV WISCONSIN,SCH MED,CTR NEUROSCI,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison	ZHANG, SLJ (corresponding author), UNIV WISCONSIN,SCH MED,DEPT PHYSIOL,MADISON,WI 53706, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030016, R37NS030016] Funding Source: NIH RePORTER; NINDS NIH HHS [NS30016] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUGUSTINE GJ, 1990, J PHYSIOL-LONDON, V431, P343, DOI 10.1113/jphysiol.1990.sp018333; BIELEFELDT K, 1992, J PHYSIOL-LONDON, V458, P41, DOI 10.1113/jphysiol.1992.sp019405; BORMANN J, 1985, P NATL ACAD SCI USA, V82, P2168, DOI 10.1073/pnas.82.7.2168; BORMANN J, 1988, P NATL ACAD SCI USA, V85, P9336, DOI 10.1073/pnas.85.23.9336; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; BOWERY N, 1989, TRENDS PHARMACOL SCI, V10, P401, DOI 10.1016/0165-6147(89)90188-0; Davidoff RA, 1985, NEUROTRANSMITTER ACT, P3; DOLPHIN AC, 1987, J PHYSIOL-LONDON, V386, P1; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; GAGE PW, 1992, TRENDS NEUROSCI, V15, P46, DOI 10.1016/0166-2236(92)90025-4; GAHWILER BH, 1985, P NATL ACAD SCI USA, V82, P1558, DOI 10.1073/pnas.82.5.1558; GAINER H, 1986, NEUROENDOCRINOLOGY, V43, P557, DOI 10.1159/000124582; HAMILL OP, 1983, NATURE, V305, P805, DOI 10.1038/305805a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEIDELBERGER R, 1991, P NATL ACAD SCI USA, V88, P7135, DOI 10.1073/pnas.88.16.7135; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; JACKSON MB, 1982, J NEUROSCI, V2, P889; JACKSON MB, 1991, P NATL ACAD SCI USA, V88, P380, DOI 10.1073/pnas.88.2.380; KUFFLER SW, 1984, NEURON BRAIN; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LIM NF, 1990, NATURE, V344, P449, DOI 10.1038/344449a0; LIN JW, 1988, J NEUROSCI, V8, P1313; NEWBERRY NR, 1985, J PHYSIOL-LONDON, V360, P161, DOI 10.1113/jphysiol.1985.sp015610; NORDMANN JJ, 1977, J ANAT, V123, P213; OERTEL WH, 1982, P NATL ACAD SCI-BIOL, V79, P675, DOI 10.1073/pnas.79.2.675; RUDOMIN P, 1990, TRENDS NEUROSCI, V13, P499, DOI 10.1016/0166-2236(90)90084-N; SARIDAKI E, 1989, J ENDOCRINOL, V121, P343, DOI 10.1677/joe.0.1210343; TACHIBANA M, 1987, P NATL ACAD SCI USA, V84, P3501, DOI 10.1073/pnas.84.10.3501; TALEB O, 1987, PFLUG ARCH EUR J PHY, V409, P620, DOI 10.1007/BF00584663; THORN PJ, 1991, J PHYSIOL-LONDON, V432, P283; TOMIKO SA, 1983, NATURE, V301, P706, DOI 10.1038/301706a0; VINCENT SR, 1982, NEUROENDOCRINOLOGY, V34, P117, DOI 10.1159/000123288	34	145	151	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					531	534		10.1126/science.8380942	http://dx.doi.org/10.1126/science.8380942			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8380942				2022-12-28	WOS:A1993KJ07900040
J	THOMPSON, SC; JOLLEY, D; MARKS, R				THOMPSON, SC; JOLLEY, D; MARKS, R			REDUCTION OF SOLAR KERATOSES BY REGULAR SUNSCREEN USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MALIGNANT-MELANOMA; PROTECTION; SKIN; ASSOCIATION; RADIATION; MICE	Background. The incidence of and mortality from skin cancer are increasing in many countries. In view of the added concern about ozone depletion, many organizations are promoting the regular use of sunscreens to prevent skin cancer, despite the absence of evidence that these products have this effect. Solar (actinic) keratosis is a precursor of squamous-cell carcinoma of the skin. Methods. We conducted a randomized, controlled trial of the effect on solar keratoses of daily use of a broad-spectrum sunscreen cream with a sun-protection factor of 17 in 588 people 40 years of age or older in Australia during one summer (September 1991 to March 1992). The subjects applied either a sunscreen cream or the base cream minus the active ingredients of the sunscreen to the head, neck, forearms, and hands. Results. The mean number of solar keratoses increased by 1.0 per subject in the base-cream group and decreased by 0.6 in the sunscreen group (difference, 1.53; 95 percent confidence interval, 0.81 to 2.25). The sunscreen group had fewer new lesions (rate ratio, 0.62; 95 percent confidence interval, 0.54 to 0.71) and more remissions (odds ratio, 1.53; 95 percent confidence interval, 1.29 to 1.80) than the base-cream group. There was a dose-response relation: the amount of sunscreen cream used was related to both the development of new lesions and the remission of existing ones. Conclusions. Regular use of sunscreens prevents the development of solar keratoses and, by implication, possibly reduces the risk of skin cancer in the long term.	UNIV MELBOURNE,ST VINCENTS HOSP,DEPT MED,FITZROY,VIC 3065,AUSTRALIA; ANTI CANC COUNCIL VICTORIA,CARLTON,VIC,AUSTRALIA; HLTH & COMMUNITY SERV DEPT,MELBOURNE,VIC,AUSTRALIA	St Vincent's Hospital Melbourne; University of Melbourne; Cancer Council Victoria			Thompson, Sandra/H-5955-2014	Thompson, Sandra/0000-0003-0327-7155				ARMSTRONG BK, 1988, J DERMATOL SURG ONC, V14, P835, DOI 10.1111/j.1524-4725.1988.tb03588.x; BRUCE WR, 1981, CANCER-AM CANCER SOC, V47, P1121, DOI 10.1002/1097-0142(19810301)47:5+<1121::AID-CNCR2820471310>3.0.CO;2-K; COLDIRON BM, 1992, J AM ACAD DERMATOL, V27, P653, DOI 10.1016/0190-9622(92)70233-6; COLE CA, 1986, PHOTOCHEM PHOTOBIOL, V43, P275, DOI 10.1111/j.1751-1097.1986.tb05605.x; DIFFEY BL, 1991, BRIT J DERMATOL, V124, P258, DOI 10.1111/j.1365-2133.1991.tb00570.x; GREEN AC, 1985, J NATL CANCER I, V74, P977; GURISH MF, 1981, J INVEST DERMATOL, V76, P246, DOI 10.1111/1523-1747.ep12526084; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MARKS R, 1985, CANCER, V56, P2332; MARKS R, 1993, INT J CANCER, V53, P585, DOI 10.1002/ijc.2910530410; MARKS R, 1988, ARCH DERMATOL, V124, P1039, DOI 10.1001/archderm.124.7.1039; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; MUIR CS, 1987, IARC SCI PUBLICATION, V88; PATHAK MA, 1982, J AM ACAD DERMATOL, V7, P285, DOI 10.1016/S0190-9622(82)70117-3; PATHAK MA, 1985, J DERMATOL SURG ONC, V11, P575, DOI 10.1111/j.1524-4725.1985.tb01897.x; PRESTON DS, 1992, NEW ENGL J MED, V327, P1651; Rothman K, 1986, MODERN EPIDEMIOLOGY; SKOLNICK AA, 1991, JAMA-J AM MED ASSOC, V265, P3218; YOUNG AR, 1983, BRIT J DERMATOL, V109, P705; 1982, DHHS PHS8250179 PUBL, P55; 1986, 26041986 STAND ASS A	22	531	541	0	44	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1147	1151		10.1056/NEJM199310143291602	http://dx.doi.org/10.1056/NEJM199310143291602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377777	Bronze			2022-12-28	WOS:A1993MA66700002
J	BRANCH, W; PELS, RJ; LAWRENCE, RS; ARKY, R				BRANCH, W; PELS, RJ; LAWRENCE, RS; ARKY, R			BECOMING A DOCTOR - CRITICAL-INCIDENT REPORTS FROM 3RD-YEAR MEDICAL-STUDENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									HARVARD UNIV,SCH MED,BOSTON,MA 02115; ROCKEFELLER FDN,NEW YORK,NY 10036	Harvard University; Harvard Medical School								BRANCH W, 1991, J GEN INTERN MED, V6, P573, DOI 10.1007/BF02598231; BRANCH WT, 1991, ANN INTERN MED, V114, P482, DOI 10.7326/0003-4819-114-6-482; Brookfield S., 1990, FOSTERING CRITICAL R, P177; FLANAGAN JC, 1954, PSYCHOL BULL, V51, P327, DOI 10.1037/h0061470; MEZIROW J, 1990, FOSTERING CRITICAL R, V2, P1; Smith III A.C., 1989, TEACH LEARN MED, V1, P101; TOSTESON DC, 1990, NEW ENGL J MED, V322, P234, DOI 10.1056/NEJM199001253220405	7	106	106	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1130	1132		10.1056/NEJM199310073291518	http://dx.doi.org/10.1056/NEJM199310073291518			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ640	8371749				2022-12-28	WOS:A1993LZ64000031
J	RANSOHOFF, DF; GRACIE, WA				RANSOHOFF, DF; GRACIE, WA			TREATMENT OF GALLSTONES	ANNALS OF INTERNAL MEDICINE			English	Review							SHOCK-WAVE LITHOTRIPSY; NATIONAL COOPERATIVE GALLSTONE; LAPAROSCOPIC CHOLECYSTECTOMY; NATURAL-HISTORY; GALLBLADDER CANCER; SYMPTOMATIC GALLSTONES; GALL-STONES; FOLLOW-UP; RADIOLUCENT GALLSTONES; CHENODEOXYCHOLIC ACID	Purpose. To critically review the risks and benefits of therapy for asymptomatic and symptomatic persons with gallstones who are considering therapy to prevent future episodes of biliary pain or complications including acute cholecystitis, pancreatitis, or gallbladder cancer. Data Sources: Review of English-language literature regarding the natural history of persons with gallstones and the operative mortality rates for open cholecystectomy and laparoscopic cholecystectomy. Mathematical simulation modeling was used to derive estimates of lifetime risks for gallstone-related mortality and for life expectancy, for prophylactic cholecystectomy and expectant management, for men and women of different ages. Results: For persons with asymptomatic gallstones, natural history is so benign that treatment is generally not recommended. For persons with symptomatic gallstones, (that is, that have caused an episode of biliary pain), the rate for subsequent pain is high so that many persons probably choose cholecystectomy to avoid pain; however, about 30% of persons who have had pain do not have further episodes of pain. The expected loss of life for persons with symptomatic stones managed expectantly is roughly several months, on average, and may not be considered high enough in itself to warrant therapy. Although laparoscopic cholecystectomy has become popular with patients and physicians, its safety is yet unknown compared with open cholecystectomy. Conclusion: Prophylactic cholecystectomy should be recommended for most persons with symptomatic gallstones unless the person wants to try a period of watchful waiting to see if pain recurs. Nonsurgical therapy may be suitable for persons with high operative risk. For persons with asymptomatic gallstones, watchful waiting is the best course.			RANSOHOFF, DF (corresponding author), UNIV N CAROLINA, CB 7105, CHAPEL HILL, NC 27599 USA.							ALBERT MB, 1990, ANN INTERN MED, V113, P164, DOI 10.7326/0003-4819-113-2-164; ALTMAN LK, 1992, NY TIMES        0726, P1; ALTMAN LK, 1992, NY TIMES        0614, P21; ANDRENSANDBERG A, 1985, ANN SURG, V201, P328; ATTILI AF, 1991, DEV GASTRO, V12, P47; BASS EB, 1991, GASTROENTEROLOGY, V101, P189, DOI 10.1016/0016-5085(91)90477-3; BENNION LJ, 1979, NEW ENGL J MED, V300, P873, DOI 10.1056/NEJM197904193001601; BERK JE, 1968, MOD TREAT, V5, P505; BERK RN, 1973, RADIOLOGY, V106, P29, DOI 10.1148/106.1.29; BISHOP YM, 1969, NATIONAL HALOTHANE S, P238; BURNETT D, 1989, DIGEST DIS SCI, V34, P1011, DOI 10.1007/BF01536365; CAPOCACCIA L, 1991, RECENT ADV EPIDEMIOL, P37; CAROLI A, 1992, GUT, V33, P698, DOI 10.1136/gut.33.5.698; COMFORT MW, 1948, ANN SURG, V128, P931, DOI 10.1097/00000658-194811000-00005; CUCCHIARO G, 1989, ANN SURG, V209, P149, DOI 10.1097/00000658-198902000-00002; CUCCHIARO G, 1990, DIGEST DIS SCI, V35, P417, DOI 10.1007/BF01536912; CUSCHIERI A, 1991, AM J SURG, V161, P385, DOI 10.1016/0002-9610(91)90603-B; DIEHL AK, 1983, JAMA-J AM MED ASSOC, V250, P2323, DOI 10.1001/jama.250.17.2323; Dubois F, 1991, Surg Laparosc Endosc, V1, P52; EHNMARK E, 1939, ACTA CHIR SCAND    S, V57, P1; ERLINGER S, 1984, HEPATOLOGY, V4, P308, DOI 10.1002/hep.1840040222; FRENCH EB, 1963, BMJ-BRIT MED J, P135, DOI 10.1136/bmj.2.5350.135; FRIEDMAN GD, 1989, J CLIN EPIDEMIOL, V42, P127, DOI 10.1016/0895-4356(89)90086-3; FROMM H, 1992, VIEWPOINTS DIG DIS, V24, P1; GILLILAND TM, 1990, SURG GYNECOL OBSTET, V170, P39; GLAMBEK I, 1989, SCAND J GASTROENTERO, V24, P277, DOI 10.3109/00365528909093046; GLEESON D, 1990, Q J MED, V76, P711; GODREY PJ, 1984, GUT, V25, P1029, DOI 10.1136/gut.25.10.1029; Gomand L, 1966, Tijdschr Gastroenterol, V9, P594; GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209; GRACIE WA, 1982, NEW ENGL J MED, V307, P798, DOI 10.1056/NEJM198209233071305; Gracie WA, 1985, GALLSTONES, P27; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P1018, DOI 10.1001/jama.1993.03500080066034; HEATON KW, 1991, GUT, V32, P316, DOI 10.1136/gut.32.3.316; HENSON DE, 1992, CANCER, V70, P1493, DOI 10.1002/1097-0142(19920915)70:6<1493::AID-CNCR2820700608>3.0.CO;2-U; HUTCHEON DF, 1979, JAMA-J AM MED ASSOC, V241, P823, DOI 10.1001/jama.241.8.823; JARVINEN HJ, 1980, ANN SURG, V191, P501; JORGENSEN T, 1990, SCAND J GASTROENTERO, V25, P335, DOI 10.3109/00365529009095495; JORGENSEN T, 1989, HEPATOLOGY, V9, P856, DOI 10.1002/hep.1840090611; LASSON A, 1987, SCAND J GASTROENTERO, V22, P897, DOI 10.3109/00365528708991932; LOWENFELS AB, 1985, JNCI-J NATL CANCER I, V75, P77; LOWENFELS AB, 1989, INT J EPIDEMIOL, V18, P50, DOI 10.1093/ije/18.1.50; LUND J, 1960, ANN SURG, V151, P153, DOI 10.1097/00000658-196002000-00001; MAGNUSON TH, 1989, ARCH SURG-CHICAGO, V124, P1195; MARINGHINI A, 1990, HEPATOLOGY, V12, P900; MARINGHINI A, 1987, ANN INTERN MED, V107, P30, DOI 10.7326/0003-4819-107-1-30; MCSHERRY CK, 1985, ANN SURG, V202, P59; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; MORGENSTERN L, 1992, ARCH SURG-CHICAGO, V127, P400; MORI H, 1992, RADIOLOGY, V184, P735, DOI 10.1148/radiology.184.3.1509058; NAIMARK D, 1992, MED DECIS MAKING, V12, P344; NENNER RP, 1992, NEW YORK STATE J MED, V92, P179; NEWMAN HF, 1968, AM J GASTROENTEROL, V50, P476; NEWMAN HF, 1964, GERIATRICS, V19, P453; NEWMAN HF, 1959, INT ABSTR SURG, V109, P1; ODONNELL LDJ, 1988, GUT, V29, P655, DOI 10.1136/gut.29.5.655; PERISSAT J, 1991, AM J SURG, V161, P371, DOI 10.1016/0002-9610(91)90600-I; PETERS JH, 1991, SURGERY, V110, P769; PETERSON R, 1915, SURG GYNECOL OBSTET, V20, P284; PIEHLER JM, 1978, SURG GYNECOL OBSTET, V147, P929; PODDA M, 1989, GASTROENTEROLOGY, V96, P222, DOI 10.1016/0016-5085(89)90784-1; PRICE WH, 1963, BRIT MED J, P138, DOI 10.1136/bmj.2.5350.138; RALSTON D E, 1965, Minn Med, V48, P327; RANSOHOFF DF, 1983, ANN INTERN MED, V99, P199, DOI 10.7326/0003-4819-99-2-199; RANSOHOFF DF, 1990, AM J MED, V88, P154, DOI 10.1016/0002-9343(90)90466-Q; RANSON JHC, 1979, ANN SURG, V189, P654, DOI 10.1097/00000658-197905000-00016; RAUTE M, 1988, LANGENBECK ARCH CHIR, V373, P345, DOI 10.1007/BF01272553; RODA E, 1992, GASTROENTEROLOGY, V102, P372, DOI 10.1016/0016-5085(92)91833-P; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROS E, 1987, GUT, V28, P1500, DOI 10.1136/gut.28.11.1500; SACKMANN M, 1988, NEW ENGL J MED, V318, P393, DOI 10.1056/NEJM198802183180701; SALEN G, 1989, DIGEST DIS SCI, V34, pS39, DOI 10.1007/BF01536661; SAMA C, 1990, SEMIN LIVER DIS, V10, P149, DOI 10.1055/s-2008-1040469; SAMA C, 1992, HEPATOLOGY, V16, pA87; SCHOENFIELD LJ, 1981, ANN INTERN MED, V95, P257, DOI 10.7326/0003-4819-95-3-257; SONNENBERG A, 1991, DIGEST DIS SCI, V36, P949, DOI 10.1007/BF01297146; Spaw A T, 1991, Surg Laparosc Endosc, V1, P2; STRASBERG SM, 1992, HEPATOLOGY, V16, P820, DOI 10.1002/hep.1840160332; THISTLE JL, 1984, ANN INTERN MED, V101, P171, DOI 10.7326/0003-4819-101-2-171; THISTLE JL, 1989, NEW ENGL J MED, V320, P633, DOI 10.1056/NEJM198903093201004; Truesdell ED, 1944, ANN SURG, V119, P232, DOI 10.1097/00000658-194402000-00007; VILLANOVA N, 1989, GASTROENTEROLOGY, V97, P726, DOI 10.1016/0016-5085(89)90644-6; VOYLES CR, 1991, AM J SURG, V161, P365, DOI 10.1016/0002-9610(91)90599-9; WAY LW, 1981, PRACT GASTROENTEROL, V5, P42; WEINSTEIN MC, 1982, CIRCULATION, V66, P56; Weinstein MC, 1980, CLIN DECISION ANAL; WENCKERT A, 1966, GASTROENTEROLOGY, V50, P376; WENCKERT A, 1969, ACTA CHIR SCAND, V135, P701; WHITE LJ, 1988, ANN INTERN MED, V109, P752, DOI 10.7326/0003-4819-109-9-752; WILSON P, 1991, LANCET, V338, P795, DOI 10.1016/0140-6736(91)90674-E; YANG HY, 1992, DIGEST DIS SCI, V37, P912, DOI 10.1007/BF01300390; 1977, HOSPITAL MORTALITY P; 1975, HOSPITAL MORTALITY P	93	135	139	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				606	619		10.7326/0003-4819-119-7_Part_1-199310010-00010	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00010			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363172				2022-12-28	WOS:A1993MA29100010
J	SILVERMAN, ME				SILVERMAN, ME			IMAGES IN CLINICAL MEDICINE - PARADOXICAL EMBOLUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											SILVERMAN, ME (corresponding author), EMORY UNIV,SCH MED,ATLANTA,GA 30322, USA.								0	10	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					930	930						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361507				2022-12-28	WOS:A1993LX75100006
J	ARIEFF, AI; AYUS, JC				ARIEFF, AI; AYUS, JC			ENDOMETRIAL ABLATION COMPLICATED BY FATAL HYPONATREMIC ENCEPHALOPATHY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							PERMANENT BRAIN-DAMAGE; MENORRHAGIA; VASOPRESSIN; SURGERY; WOMEN	Objectives.- To investigate the occurrence of hyponatremic encephalopathy and the effects of therapy for symptomatic hyponatremia on outcome in women undergoing endometrial ablation. Design and Setting.- Consultations from university-affiliated and community hospitals from June 1991 to June 1992. Patients.- Four generally healthy women who underwent elective endometrial ablation for dysfunctional bleeding and developed hyponatremic encephalopathy. Interventions.- Three patients were promptly treated with hypertonic (514 mmol/L) sodium chloride such that the serum sodium level increased from 102 to 123 mmol/L within 24 hours. The fourth patient was not treated until after suffering grand mal seizures followed by respiratory arrest. Main Outcome Measures.- Of the four patients who developed hyponatremic encephalopathy, the diagnosis was established before respiratory arrest occurred in three. The operative procedure was terminated and all three were aggressively treated with intravenous hypertonic sodium chloride. which raised the serum sodium level to modestly hyponatremic levels (120 to 130 mmol/L). All three completely recovered without sequelae. The fourth patient suffered respiratory arrest before therapy could be initiated. The patient remained comatose, and central diabetes mellitus and insipidus developed. She never regained consciousness and died after several days. Autopsy revealed cerebral edema and tonsillar herniation. Results.- The mean (+/-SD) preoperative serum sodium level was 138+/-1 mmol/L; at the time of diagnosis of hyponatremia, it was 107+/-13 mmol/L. In two patients, hyponatremic encephalopathy was diagnosed intraoperatively because of tremulousness and either hypothermia or hypoxemia. In the other two patients, the diagnosis was made postoperatively because of headache, nausea, emesis, and in one of these patients, respiratory arrest. Conclusions.- Women undergoing elective endometrial ablation can develop severe symptomatic hyponatremia, which can be fatal. The presence of symptoms suggesting hypo-osmolality should lead to immediate measurement of plasma sodium level. If hyponatremia with hypo-osmolality is present, early and appropriate therapy for the hyponatremia should be instituted before respiratory insufficiency occurs.	UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94143; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	University of California System; University of California San Francisco; Baylor College of Medicine	ARIEFF, AI (corresponding author), VET AFFAIRS MED CTR,DEPT MED,GERIATR SECT,4150 CLEMENT ST,SAN FRANCISCO,CA 94121, USA.				NIA NIH HHS [R01 AG 08575] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008575] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1992, ANN INTERN MED, V117, P891, DOI 10.7326/0003-4819-117-11-891; AYUS JC, IN PRESS ENDOCRINOL; BEAL JL, 1989, CAN J ANAESTH, V36, P278, DOI 10.1007/BF03010765; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; DEUTSCH S, 1966, ANESTHESIOLOGY, V27, P250, DOI 10.1097/00000542-196627030-00003; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; GARLSON KJ, 1993, NEW ENGL J MED, V328, P856; GARRY R, 1991, BRIT J OBSTET GYNAEC, V98, P357, DOI 10.1111/j.1471-0528.1991.tb13425.x; LEFLER HT, 1991, OBSTET GYNECOL, V77, P949; LOFFER FD, 1987, OBSTET GYNECOL, V69, P679; OSBORNE GA, 1991, ANAESTH INTENS CARE, V19, P217, DOI 10.1177/0310057X9101900211; PHIPPS JH, 1990, OBSTET GYNECOL, V76, P876, DOI 10.1097/00006250-199011000-00032; THOMAS TH, 1979, BRIT J SURG, V66, P540, DOI 10.1002/bjs.1800660806; VANBOVEN MJ, 1989, ANESTHESIOLOGY, V71, P449, DOI 10.1097/00000542-198909000-00023	17	130	132	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1230	1232		10.1001/jama.270.10.1230	http://dx.doi.org/10.1001/jama.270.10.1230			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355387				2022-12-28	WOS:A1993LV64900030
J	FLORESROMO, L; SHIELDS, J; HUMBERT, Y; GRABER, P; AUBRY, JP; GAUCHAT, JF; AYALA, G; ALLET, B; CHAVEZ, M; BAZIN, H; CAPRON, M; BONNEFOY, JY				FLORESROMO, L; SHIELDS, J; HUMBERT, Y; GRABER, P; AUBRY, JP; GAUCHAT, JF; AYALA, G; ALLET, B; CHAVEZ, M; BAZIN, H; CAPRON, M; BONNEFOY, JY			INHIBITION OF AN IN-VIVO ANTIGEN-SPECIFIC IGE RESPONSE BY ANTIBODIES TO CD23	SCIENCE			English	Article							NORMAL HUMAN-LYMPHOCYTES; LOW-AFFINITY RECEPTOR; FC-EPSILON RECEPTORS; INTERFERON-GAMMA; MONOCLONAL-ANTIBODY; MOLECULAR-STRUCTURE; EXPRESSION; INTERLEUKIN-4; CDNA; INDUCTION	Immunoglobulin E (IgE) mediates many allergic responses. CD23 is a 45-kilodalton type II transmembrane glycoprotein expressed in many cell types. It is a low-affinity IgE receptor and interacts specifically with CD21, thereby modulating IgE production by B lymphocytes in vitro. In an in vivo model of an allergen-specific IgE response, administration of a rabbit polyclonal antibody to recombinant human truncated CD23 resulted in up to 90 percent inhibition of ovalbumin-specific IgE synthesis. Both Fabs and intact IgG inhibited IgE production in vitro and in vivo. Thus, CD23 participates in the regulation of IgE synthesis in vivo and so could be important in allergic disease.	GLAXO INST MOLEC BIOL,CP 674,CH-1228 GENEVA,SWITZERLAND; UNIV CATHOLIQUE LOUVAIN,FAC MED,EXPTL IMMUNOL UNIT,B-1200 BRUSSELS,BELGIUM; CTR IMMUNOL & BIOL PARASITAIRE,CNRS 624,INSERM,U167,F-59019 LILLE,FRANCE	GlaxoSmithKline; Universite Catholique Louvain; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille								ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; AUBRY JP, 1993, J IMMUNOL METHODS, V159, P161, DOI 10.1016/0022-1759(93)90154-Y; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BAZIN H, UNPUB; BETTLER B, 1989, P NATL ACAD SCI USA, V86, P7566, DOI 10.1073/pnas.86.19.7566; BONNEFOY JY, 1987, J IMMUNOL, V138, P2970; BONNEFOY JY, 1990, EUR J IMMUNOL, V20, P139, DOI 10.1002/eji.1830200120; COFFMAN RL, 1986, J IMMUNOL, V136, P949; DEFRANCE T, 1987, J EXP MED, V165, P1459, DOI 10.1084/jem.165.6.1459; DELESPESSE G, 1989, IMMUNOL TODAY, V10, P159, DOI 10.1016/0167-5699(89)90173-4; DELESPESSE G, 1992, IMMUNOL REV, V125, P76; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FISCHER E, 1991, J IMMUNOL, V146, P865; FLORESROMO L, UNPUB; GOLLNICK SO, 1990, J IMMUNOL, V144, P1974; GRABER P, UNPUB; HENCHOZ S, UNPUB; IKUTA K, 1987, P NATL ACAD SCI USA, V84, P819, DOI 10.1073/pnas.84.3.819; KAWABE T, 1988, J IMMUNOL, V141, P1376; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KLEIN NJ, 1993, INT IMMUNOL, V5, P293, DOI 10.1093/intimm/5.3.293; KOLB JP, 1991, ADV PROSTAGLANDIN TH, P997; LUDIN C, 1987, EMBO J, V6, P109, DOI 10.1002/j.1460-2075.1987.tb04726.x; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MANOUVRIEZ P, 1984, J IMMUNOL, V133, P3274; MUNOZ JJ, 1990, CELL IMMUNOL, V127, P327, DOI 10.1016/0008-8749(90)90136-F; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PENE J, 1989, J CELL BIOCHEM, V39, P253, DOI 10.1002/jcb.240390305; POCHON S, 1992, J EXP MED, V176, P389, DOI 10.1084/jem.176.2.389; PRINZ JC, 1990, EUR J IMMUNOL, V20, P1259, DOI 10.1002/eji.1830200610; THYPHRONITIS G, 1989, P NATL ACAD SCI USA, V86, P5580, DOI 10.1073/pnas.86.14.5580; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; YODOI J, 1979, J IMMUNOL, V123, P455; YUKAWA K, 1987, J IMMUNOL, V138, P2576	34	112	120	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					1038	1041		10.1126/science.8351517	http://dx.doi.org/10.1126/science.8351517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351517				2022-12-28	WOS:A1993LT74700032
J	LIU, P; TARLE, SA; HAJRA, A; CLAXTON, DF; MARLTON, P; FREEDMAN, M; SICILIANO, MJ; COLLINS, FS				LIU, P; TARLE, SA; HAJRA, A; CLAXTON, DF; MARLTON, P; FREEDMAN, M; SICILIANO, MJ; COLLINS, FS			FUSION BETWEEN TRANSCRIPTION FACTOR CBF-BETA/PEBP2-BETA AND A MYOSIN HEAVY-CHAIN IN ACUTE MYELOID-LEUKEMIA	SCIENCE			English	Article							VIRUS ENHANCERS; NUCLEAR FACTOR; SHORT ARM; T-CELL; CHROMOSOME-16; PROTEIN; TRANSLOCATION; KINASE; GENE; CORE	The pericentric inversion of chromosome 16 [inv(16)(p13q22)] is a characteristic karyotypic abnormality associated with acute myeloid leukemia, most commonly of the M4Eo subtype. The 16p and 16q breakpoints were pinpointed by yeast artificial chromosome and cosmid cloning, and the two genes involved in this inversion were identified. On 16q the inversion occurred near the end of the coding region for CBFbeta, also known as PEBP2beta, a subunit of a heterodimeric transcription factor regulating genes expressed in T cells; on 16p a smooth muscle myosin heavy chain (SMMHC) gene (MYH11) was interrupted. In six of six inv(16) patient samples tested, an in-frame fusion messenger RNA was demonstrated that connected the first 165 amino acids of CBFbeta with the tail region of SMMHC. The repeated coiled coil of SMMHC may result in dimerization of the CBFbeta fusion protein, which in turn would lead to alterations in transcriptional regulation and contribute to leukemic transformation.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV MICHIGAN,MED CTR,DEPT HUMAN GENET,HOWARD HUGHES MED INST,ANN ARBOR,MI 48109; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Liu, Paul/A-7976-2012; Marlton, Paula/F-3026-2011	Liu, Paul/0000-0002-6779-025X; 	NATIONAL CANCER INSTITUTE [P01CA055164] Funding Source: NIH RePORTER; NCI NIH HHS [CA55164] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARTHUR DC, 1983, BLOOD, V61, P994; BAE SC, 1993, ONCOGENE, V8, P809; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Callen D. F., 1992, American Journal of Human Genetics, V51, pA57; CALLEN DF, 1992, GENOMICS, V13, P1178, DOI 10.1016/0888-7543(92)90035-Q; DAUWERSE JG, 1992, BLOOD, V79, P1299; DENG Z, IN PRESS GENOMICS; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; HEIM S, 1992, CANCER, V70, P1701, DOI 10.1002/1097-0142(19920915)70:4+<1701::AID-CNCR2820701609>3.0.CO;2-S; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KIEHART DP, 1990, CELL, V60, P347, DOI 10.1016/0092-8674(90)90583-Z; LEBEAU MM, 1983, NEW ENGL J MED, V309, P630, DOI 10.1056/NEJM198309153091103; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LIU P, 1992, SOMAT CELL MOLEC GEN, V18, P7, DOI 10.1007/BF01233445; LIU P, IN PRESS BLOOD; LIU PL, UNPUB; MARLTON P, UNPUB; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUOKA R, 1993, AM J MED GENET, V46, P61, DOI 10.1002/ajmg.1320460110; MITELMAN F, 1992, GENE CHROMOSOME CANC, V5, P57, DOI 10.1002/gcc.2870050109; NAGAI R, 1988, P NATL ACAD SCI USA, V85, P1047, DOI 10.1073/pnas.85.4.1047; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; OGAWA E, IN PRESS P NATL ACAD; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PETERSON C, 1991, GENE, V107, P279, DOI 10.1016/0378-1119(91)90328-9; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; SUGITA K, 1989, J VIROL, V63, P1715, DOI 10.1128/JVI.63.4.1715-1720.1989; SWAROOP A, IN PRESS CYTOGENET C; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WESSELS JW, 1991, BLOOD, V77, P1555; YANAGISAWA K, 1991, BLOOD, V78, P451; 1984, CANCER GENET CYTOGEN, V11, P275	40	655	677	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					1041	1044		10.1126/science.8351518	http://dx.doi.org/10.1126/science.8351518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351518				2022-12-28	WOS:A1993LT74700033
J	VEEKEN, H				VEEKEN, H			MALARIA AND GOLD FEVER	BRITISH MEDICAL JOURNAL			English	Article								The mineral rich territory of the Yanomami Indians of northern Brazil has been invaded by miners-who have destroyed the environment and introduced disease. Medecins Sans Frontieres agreed to help combat the malaria epidemic. Conditions in the rainforest and villages and the health care facilities are described. Mere medical aid cannot prevent the Yanomami from being decimated.			VEEKEN, H (corresponding author), MEDECINS SANS FRONTIERES,POB 10014,1001 EA AMSTERDAM,NETHERLANDS.								0	6	6	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					433	434		10.1136/bmj.307.6901.433	http://dx.doi.org/10.1136/bmj.307.6901.433			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374458	Green Published, Bronze			2022-12-28	WOS:A1993LR89500023
J	TIDSWELL, P; DASSISFONSECA, A				TIDSWELL, P; DASSISFONSECA, A			GENERALIZED SEIZURE DUE TO TERFENADINE	BRITISH MEDICAL JOURNAL			English	Letter											TIDSWELL, P (corresponding author), PINDERFIELDS HOSP,WAKEFIELD WF1 4DG,ENGLAND.							1992, CURRENT PROBLEMS, V35, P1	1	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					241	241		10.1136/bmj.307.6898.241-c	http://dx.doi.org/10.1136/bmj.307.6898.241-c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369689	Bronze, Green Published			2022-12-28	WOS:A1993LP31400028
J	CARLBERG, C; BENDIK, I; WYSS, A; MEIER, E; STURZENBECKER, LJ; GRIPPO, JF; HUNZIKER, W				CARLBERG, C; BENDIK, I; WYSS, A; MEIER, E; STURZENBECKER, LJ; GRIPPO, JF; HUNZIKER, W			2 NUCLEAR SIGNALING PATHWAYS FOR VITAMIN-D	NATURE			English	Article							HUMAN OSTEOCALCIN GENE; D RECEPTOR; THYROID-HORMONE; RETINOIC ACID; ELEMENTS; BINDING; 1,25-DIHYDROXYVITAMIN-D3; SUPERFAMILY; EXPRESSION; CELLS	THE dihydroxylated form of vitamin D3(1,25-dihydroxy-D3) mediates a biological response by binding to intracellular receptors1-4 which belong to the steroid receptor superfamily5. These receptors act as ligand-dependent transcription factors that bind to specific DNA sequences (reviewed in refs 6-9). We have identified two classes of vitamin D response elements that are activated either by the vitamin D receptor (VDR) alone or by heterodimers of VDR and the retinoid-X receptor-alpha (RXR-alpha)10. The motif GGGTGA arranged as a direct repeat with a spacing of six nucleotides or as a palindrome without spacing, or as an inverted palindrome with a 12-nucleotide spacing, confers vitamin D inducibility mediated by VDR alone. A second class of response elements, composed of directly repeated pairs of motifs (GGTCCA, AGGTCA, or GGGTGA) spaced by three nucleotides, is synergistically activated by RXR and VDR, but only in the presence of both ligands. Thus, the RXR ligand and the nature of the response element determine whether a nuclear receptor is co-regulated by RXR.	F HOFFMANN LA ROCHE & CO LTD, DEPT PHARMA RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; HOFFMANN LA ROCHE INC, DEPT TOXICOL & PATHOL, NUTLEY, NJ 07110 USA	Roche Holding; Roche Holding			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; DELUCA HF, 1990, KIDNEY INT, V38, pS2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; HAUSSLER MR, 1988, RECENT PROG HORM RES, V44, P263; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; KIEWER SA, 1992, NATURE, V355, P446; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LIAO J, 1990, P NATL ACAD SCI USA, V87, P9751, DOI 10.1073/pnas.87.24.9751; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MINGHETTI PP, 1988, FASEB J, V2, P3043, DOI 10.1096/fasebj.2.15.2847948; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OZONO K, 1990, J BIOL CHEM, V265, P21881; PIKE JW, 1991, ANNU REV NUTR, V11, P189, DOI 10.1146/annurev.nu.11.070191.001201; ROSS TK, 1992, P NATL ACAD SCI USA, V89, P256, DOI 10.1073/pnas.89.1.256; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULE R, 1990, CELL, V61, P497, DOI 10.1016/0092-8674(90)90531-I; SONE T, 1991, MOL ENDOCRINOL, V5, P1578, DOI 10.1210/mend-5-11-1578; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	32	530	534	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 18	1993	361	6413					657	660		10.1038/361657a0	http://dx.doi.org/10.1038/361657a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8382345				2022-12-28	WOS:A1993KM77600070
J	KELLERMANN, AL; RIVARA, FP; RUSHFORTH, NB; BANTON, JG; REAY, DT; FRANCISCO, JT; LOCCI, AB; PRODZINSKI, J; HACKMAN, BB; SOMES, G				KELLERMANN, AL; RIVARA, FP; RUSHFORTH, NB; BANTON, JG; REAY, DT; FRANCISCO, JT; LOCCI, AB; PRODZINSKI, J; HACKMAN, BB; SOMES, G			GUN OWNERSHIP AS A RISK FACTOR FOR HOMICIDE IN THE HOME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FATAL VIOLENCE; SUICIDE; VICTIMIZATION; CONSUMPTION; ASSAULTS; HANDGUNS; SMOKING; DEATHS	Background. It is unknown whether keeping a firearm in the home confers protection against crime or, instead, increases the risk of violent crime in the home. To study risk factors for homicide in the home, we identified homicides occurring in the homes of victims in three metropolitan counties. Methods. After each homicide, we obtained data from the police or medical examiner and interviewed a proxy for the victim. The proxies' answers were compared with those of control subjects who were matched to the victims according to neighborhood, sex, race, and age range. Crude and adjusted odds ratios were calculated with matched-pairs methods. Results. During the study period, 1860 homicides occurred in the three counties, 444 of them (23.9 percent) in the home of the victim. After excluding 24 cases for various reasons, we interviewed proxy respondents for 93 percent of the victims. Controls were identified for 99 percent of these, yielding 388 matched pairs. As compared with the controls, the victims more often lived alone or rented their residence. Also, case households more commonly contained an illicit-drug user, a person with prior arrests, or someone who had been hit or hurt in a fight in the home. After controlling for these characteristics, we found that keeping a gun in the home was strongly and independently associated with an increased risk of homicide (adjusted odds ratio, 2.7; 95 percent confidence interval, 1.6 to 4.4). Virtually all of this risk involved homicide by a family member or intimate acquaintance. Conclusions. The use of illicit drugs and a history of physical fights in the home are important risk factors for homicide in the home. Rather than confer protection, guns kept in the home are associated with an increase in the risk of homicide by a family member or intimate acquaintance.	HARBORVIEW INJURY PREVENT & RES CTR, SEATTLE, WA USA; UNIV TENNESSEE CTR HLTH SCI, DEPT INTERNAL MED, MEMPHIS, TN 38163 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT PREVENT MED, MEMPHIS, TN 38163 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT BIOSTAT & EPIDEMIOL, MEMPHIS, TN 38163 USA; UNIV TENNESSEE CTR HLTH SCI, DEPT PATHOL, MEMPHIS, TN 38163 USA; UNIV WASHINGTON, DEPT PEDIAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT EPIDEMIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; CASE WESTERN RESERVE UNIV, DEPT BIOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT EPIDEMIOL & BIOSTAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CTR ADOLESCENT HLTH, CLEVELAND, OH 44106 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University					PHS HHS [CCR 403519, CCR 402424] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BRENT DA, 1988, ARCH GEN PSYCHIAT, V45, P581, DOI 10.1001/archpsyc.1988.01800300079011; BRENT DA, 1991, JAMA-J AM MED ASSOC, V266, P2989, DOI 10.1001/jama.266.21.2989; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; Cook PJ., 1979, POLICY STUDIES REV A, V3, P743; HAMMETT M, 1992, Morbidity and Mortality Weekly Report, V41, P1; HOLLINGSHEAD AB, 1958, SOCIAL CLASS MENTAL, P387; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KELLERMANN AL, 1990, AM J EPIDEMIOL, V131, P1080, DOI 10.1093/oxfordjournals.aje.a115600; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; KELLERMANN AL, 1992, J TRAUMA, V33, P1, DOI 10.1097/00005373-199207000-00001; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; MACK TM, 1986, JNCI-J NATL CANCER I, V76, P49; MERCY JA, 1989, AM J PUBLIC HEALTH, V79, P595, DOI 10.2105/AJPH.79.5.595; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; REISS AJ, 1993, UNDERSTANDING PREVEN, P42; SALTZMAN LE, 1992, JAMA-J AM MED ASSOC, V267, P3043, DOI 10.1001/jama.267.22.3043; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; STARK E, 1991, VIOLENCE AM PUBLIC H, P123; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; WARR M, 1983, SOC FORCES, V61, P1033, DOI 10.2307/2578277; WEIL DS, 1992, JAMA-J AM MED ASSOC, V267, P3033, DOI 10.1001/jama.267.22.3033; WINTEMUTE GJ, 1987, JAMA-J AM MED ASSOC, V257, P3107, DOI 10.1001/jama.257.22.3107; WRIGHT JD, 1983, WEAPONS CRIME VIOLEN, P212; YU MC, 1983, CANCER RES, V43, P6077; 1992, CPH537 BUR CENS PUBL; 1978, ATTITUDES AM ELECTOR; 1992, CP137 BUR CENS PUBL; 1989, AM J PREV MED S, V5, P223; 1992, CP149 BUR CENS PUBL; 1992, CP144 BUR CENS PUBL; 1992, CPH549 BUR CENS PUBL; 1992, CPH544 BUR CENS PUBL	35	493	494	3	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1084	1091		10.1056/NEJM199310073291506	http://dx.doi.org/10.1056/NEJM199310073291506			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371731				2022-12-28	WOS:A1993LZ64000006
J	BARINAGA, M				BARINAGA, M			AUTOIMMUNE-DISEASES - TREATING ARTHRITIS WITH TOLERANCE	SCIENCE			English	Editorial Material																		1993, SCIENCE, V259, P1263	1	3	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1669	1670		10.1126/science.8378767	http://dx.doi.org/10.1126/science.8378767			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378767				2022-12-28	WOS:A1993LY58400009
J	ANDREWS, BJ; MASON, SW				ANDREWS, BJ; MASON, SW			GENE-EXPRESSION AND THE CELL-CYCLE - A FAMILY AFFAIR	SCIENCE			English	Editorial Material							DNA-SYNTHESIS GENES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; POSITIVE FEEDBACK; BUDDING YEAST; G1 CYCLINS; S-PHASE; SWI4; START; ACTIVATION				ANDREWS, BJ (corresponding author), UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA.			Mason, Stephen/0000-0002-6662-9624				ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BREEDEN L, 1991, GENE DEV, V5, P1183, DOI 10.1101/gad.5.7.1183; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; La Thangue N B, 1993, Trends Cell Biol, V3, P75, DOI 10.1016/0962-8924(93)90067-B; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; MERRILL GF, 1992, BIOESSAYS, V14, P823, DOI 10.1002/bies.950141206; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; NASMYTH K, COMMUNICATION; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEVINS JR, 1992, NATURE, V358, P375, DOI 10.1038/358375a0; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1069, DOI 10.1128/MCB.13.2.1069; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x	25	26	27	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1543	1544		10.1126/science.8372349	http://dx.doi.org/10.1126/science.8372349			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372349				2022-12-28	WOS:A1993LX47400020
J	AGGER, WA				AGGER, WA			PREDATOR AND PREY	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											AGGER, WA (corresponding author), GUNDERSON CLIN LTD, 1836 SOUTH AVE, LA CROSSE, WI 54601 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					526	526		10.7326/0003-4819-119-6-199309150-00014	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00014			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357121				2022-12-28	WOS:A1993LZ27500014
J	HILBERG, F; AGUZZI, A; HOWELLS, N; WAGNER, EF				HILBERG, F; AGUZZI, A; HOWELLS, N; WAGNER, EF			C-JUN IS ESSENTIAL FOR NORMAL MOUSE DEVELOPMENT AND HEPATOGENESIS	NATURE			English	Article							CELL-CYCLE PROGRESSION; FOS; DIFFERENTIATION; EXPRESSION; ONCOGENE; MUTATION; DEFECTS; GROWTH; RB	THE proto-oncogene c-jun is the cellular homologue of v-jun, the transforming oncogene of the avian sarcoma virus 17 (ref. 1). c-jun encodes one major component of the AP-1 transcription factor complex and is expressed in many organs during mouse development and in the adult2-4. Because of its rapid induction in cells following growth stimulation and the presence of AP-1 binding sites in the promoter regions of many genes, the c-Jun protein is thought to have important functions in cell proliferation and differentiation2,5-10. But embryonic stem (ES) cells lacking c-Jun are viable and have a normal in vitro differentiation capacity, although c-Jun appears to be important for growth of teratocarcinomas in vivo11. To define the function of c-jun better, targeted ES cells were used to generate mice lacking c-Jun. Here we report that heterozygous mutant mice appear normal, but embryos lacking c-Jun die at mid- to late-gestation and exhibit impaired hepatogenesis, altered fetal liver erythropoiesis and generalized oedema. Interestingly, c-jun-/- ES cells can participate efficiently in the development of all somatic cells in chimaeric mice except liver cells, further suggesting an essential function of c-Jun in hepatogenesis.	RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)			Aguzzi, Adriano/A-3351-2008	Wagner, Erwin F/0000-0001-7872-0196; Aguzzi, Adriano/0000-0002-0344-6708				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CARTER R, 1991, ONCOGENE, V6, P229; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN DR, 1993, ONCOGENE, V8, P443; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HILBERG F, 1992, ONCOGENE, V7, P2371; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MANSOUR SL, 1993, DEVELOPMENT, V117, P13; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; ZATIOUKAL K, 1990, LAB INVEST, V62, P427	22	469	477	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					179	181		10.1038/365179a0	http://dx.doi.org/10.1038/365179a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371760				2022-12-28	WOS:A1993LW44200053
J	RIVO, ML; SATCHER, D				RIVO, ML; SATCHER, D			IMPROVING ACCESS TO HEALTH-CARE THROUGH PHYSICIAN WORKFORCE REFORM - DIRECTIONS FOR THE 21ST-CENTURY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-SCHOOLS; SYSTEM		MEHARRY MED COLL,NASHVILLE,TN 37208	Meharry Medical College	RIVO, ML (corresponding author), US HLTH RESOURCES & SERV ADM,BUR HLTH PROFESS,DIV MED,5600 FISHERS LANE,ROOM 4C-25,ROCKVILLE,MD 20857, USA.							ALTMAN S, 1992, MAR NAT PRIM CAR C W; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; CLINTON B, 1992, NEW ENGL J MED, V327, P804, DOI 10.1056/NEJM199209103271112; DIETRICH AJ, 1988, JAMA-J AM MED ASSOC, V250, P3145; EISENBERG J, 1986, DOCTORS DECISIONS CO; FUCHS VR, 1990, NEW ENGL J MED, V323, P884, DOI 10.1056/NEJM199009273231306; GINZBERG E, 1992, NEW ENGL J MED, V327, P1310, DOI 10.1056/NEJM199210293271812; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; KEITH SN, 1985, NEW ENGL J MED, V313, P1519, DOI 10.1056/NEJM198512123132406; KILLIAN CD, 1993, CENSUS GRADUATE MED; Lohr K N, 1986, Med Care, V24, pS1; LUNDBERG GD, 1992, JAMA-J AM MED ASSOC, V268, P2082; MARTINI CJM, 1993, JAMA-J AM MED ASSOC, V270, P1053, DOI 10.1001/jama.270.9.1053; MULHAUSEN R, 1989, JAMA-J AM MED ASSOC, V261, P1930, DOI 10.1001/jama.261.13.1930; MULLAN F, 1992, MILBANK Q, V70, P381, DOI 10.2307/3350065; NUTTING P, 1992, NEW ENGL J MED, V327, P424; RICKETTS TC, 1991, HRSA91407P US DEP HL; ROBACK G, 1992, PHYSICIAN CHARACERIS, P57; ROBAK G, 1992, PHYSICIAN CHARACTERI; ROLAND M, 1988, BRIT MED J, V297, P599, DOI 10.1136/bmj.297.6648.599; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1665, DOI 10.1001/jama.267.12.1665; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V268, P1559, DOI 10.1001/jama.268.12.1559; SALIVE ME, 1991, AM J PREV MED, V7, P445, DOI 10.1016/S0749-3797(18)30885-7; SATCHER D, 1990, 2ND HLTH RES SERV AD; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WEINER JP, 1991, HRSA91406P US DEP HL; 1992, RURAL HLTH PROFESSIO; 1992, PRACTICING PREVENTIV; 1992, 8TH US DEP HLTH HUM; 1992, IMPROVING ACCESS HLT; 1981, HRA81651 US DEP HLTH; 1991, SOCIOECONOMIC FACTBO; 1992, BHPR PHYSICIAN FOREC; 1988, PHYSICIAN SUPPLY UTI; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1991, HEALTHY AM PRACTITIO; 1991, MINORITY STUDENTS ME; 1962, HLTH MANPOWER SOURCE; 1991, PB91188813; 1991, GRADUATING STUDENT Q; 1992, 1992 AM ASS COLL OST	41	95	95	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1074	1078		10.1001/jama.270.9.1074	http://dx.doi.org/10.1001/jama.270.9.1074			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350450				2022-12-28	WOS:A1993LU51200008
J	HEDEGAARD, M; HENRIKSEN, TB; SABROE, S; SECHER, NJ				HEDEGAARD, M; HENRIKSEN, TB; SABROE, S; SECHER, NJ			PSYCHOLOGICAL DISTRESS IN PREGNANCY AND PRETERM DELIVERY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-BIRTH-WEIGHT; PSYCHOSOCIAL STRESS; GESTATIONAL-AGE; SOCIAL SUPPORT; RISK-FACTORS; MORTALITY; DETERMINANTS; INFANTS	Objective-To investigate if psychological distress during pregnancy is associated with increased risk of preterm delivery. Design-Prospective, population based, follow up study with repeated measures of psychological distress (general health questionnaire), based on the use of questionnaires. Setting-Antenatal care clinic and delivery ward, Aarhus University Hospital, Denmark. Subjects-8719 women with singleton pregnancies attending antenatal care for the initial visit between 1 August 1989 and 30 September 1991; 5872 women (67%) completed all questionnaires. Main outcome measure-Preterm delivery. Estimation of gestational age at delivery was mainly based on early ultrasound measurements. Results-In 197 cases (3.6%) the woman delivered prematurely (less than 259 days). A dose-response relation between psychological distress in the 30th week of pregnancy and risk of preterm delivery was found, but distress measured in the 16th week was not related to preterm delivery. Control of confounding was secured by the use of multivariate logistic regression models. Relative risk for preterm delivery was 1.22 (95% confidence interval 0.84 to 1.79) for moderate distress and 1.75 (1.20 to 2.54) for high distress in comparison to low distress. Conclusions-Psychological distress later in pregnancy is associated with an increased risk of preterm delivery. Future interventional studies should focus on ways of lowering psychological distress in late pregnancy.	AARHUS UNIV, INST EPIDEMIOL & SOCIAL MED, DK-8000 AARHUS, DENMARK	Aarhus University	HEDEGAARD, M (corresponding author), AARHUS UNIV HOSP, DEPT OBSTET & GYNAECOL, PERINATAL EPIDEMIOL RES UNIT, DK-8000 AARHUS, DENMARK.							ARMITAGE P, 1987, STATISTICAL METHODS; BECH P, 1990, Ugeskrift for Laeger, V152, P383; BECH P, 1987, PSYCHOPATHOLOGY, V20, P169, DOI 10.1159/000284496; BECK NC, 1980, J PSYCHOSOM RES, V24, P343, DOI 10.1016/0022-3999(80)90026-4; BERKOWITZ GS, 1983, J PSYCHOSOM RES, V27, P283, DOI 10.1016/0022-3999(83)90050-8; BROOKE OG, 1989, BRIT MED J, V298, P795, DOI 10.1136/bmj.298.6676.795; Cronbach Lee J., 1990, ESSENTIALS PSYCHOL T, V5th; ERIKSEN PS, 1985, ACTA OBSTET GYN SCAN, V64, P65, DOI 10.3109/00016348509154690; Goldberg DP, 1972, DETECTION PSYCHIAT I; GREELAND S, 1978, AM J PUBLIC HEALTH, V79, P340; GRENNERT L, 1978, ACTA OBSTET GYN SCAN, P5; HADDERSALGRA M, 1988, DEV MED CHILD NEUROL, V30, P482; HAKULINEN A, 1988, ACTA PAEDIATR SCAND, V77, P340, DOI 10.1111/j.1651-2227.1988.tb10658.x; HEINONEN K, 1988, LANCET, V2, P204; HOFFMAN HJ, 1984, CLIN OBSTET GYNECOL, V27, P539, DOI 10.1097/00003081-198409000-00004; HOMER CJ, 1990, AM J PUBLIC HEALTH, V80, P173, DOI 10.2105/AJPH.80.2.173; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; I Chalmers, 1988, OXFORD DATABASE PERI; KLEBANOFF MA, 1990, NEW ENGL J MED, V323, P1040, DOI 10.1056/NEJM199010113231506; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; LANG RE, 1983, NEUROENDOCRINOLOGY, V37, P314, DOI 10.1159/000123566; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCDONALD RL, 1968, PSYCHOSOM MED, V30, P222, DOI 10.1097/00006842-196803000-00007; MCDOWELL J, 1987, MEASURING HLTH GUIDE; MUTALE T, 1991, BRIT J OBSTET GYNAEC, V98, P166, DOI 10.1111/j.1471-0528.1991.tb13363.x; NEWTON RW, 1984, BRIT MED J, V288, P1191, DOI 10.1136/bmj.288.6425.1191; NUCKOLLS KB, 1972, AM J EPIDEMIOL, V95, P431, DOI 10.1093/oxfordjournals.aje.a121410; OAKLEY A, 1990, BRIT J OBSTET GYNAEC, V97, P155, DOI 10.1111/j.1471-0528.1990.tb01741.x; OMER H, 1988, AM J PSYCHIAT, V145, P1507; SPENCER B, 1989, BRIT J OBSTET GYNAEC, V96, P281, DOI 10.1111/j.1471-0528.1989.tb02387.x; STEIN A, 1987, BRIT MED J, V295, P291, DOI 10.1136/bmj.295.6593.291; VERLOOVEVANHORICK SP, 1986, LANCET, V1, P55; VILLAR J, 1992, NEW ENGL J MED, V327, P1266, DOI 10.1056/NEJM199210293271803; WHO (WorldHealthOrganization), 1977, ACTA OBSTET GYNECOL, V56, P247; WILLIAMS CC, 1975, J PSYCHOSOM RES, V19, P123, DOI 10.1016/0022-3999(75)90059-8	35	315	322	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					234	239		10.1136/bmj.307.6898.234	http://dx.doi.org/10.1136/bmj.307.6898.234			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369684	Bronze, Green Published			2022-12-28	WOS:A1993LP31400022
J	HINSHAW, K; COOPER, K; HENSHAW, R; ELREFAEY, H; RISPIN, R; SMITH, N; TEMPLETON, A				HINSHAW, K; COOPER, K; HENSHAW, R; ELREFAEY, H; RISPIN, R; SMITH, N; TEMPLETON, A			MANAGEMENT OF UNCOMPLICATED MISCARRIAGE - RANDOMIZED TRIALS ARE POSSIBLE	BRITISH MEDICAL JOURNAL			English	Letter											HINSHAW, K (corresponding author), UNIV ABERDEEN,ABERDEEN MATERN HOSP,DEPT OBSTET & GYNAECOL,ABERDEEN AB9 2ZD,SCOTLAND.			Hinshaw, Kim/0000-0003-0468-4326; cooper, kevin/0000-0003-1486-0071				BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; ELREFAEY H, 1992, BRIT MED J, V305, P1399, DOI 10.1136/bmj.305.6866.1399; HENSHAW RC, 1993, BMJ-BRIT MED J, V306, P894, DOI 10.1136/bmj.306.6882.894; SHARMA JB, 1993, BRIT MED J, V306, P1540, DOI 10.1136/bmj.306.6891.1540-b; SMITH LFP, 1993, BRIT MED J, V306, P1540, DOI 10.1136/bmj.306.6891.1540-c	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					259	259		10.1136/bmj.307.6898.259-a	http://dx.doi.org/10.1136/bmj.307.6898.259-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369702	Green Published			2022-12-28	WOS:A1993LP31400052
J	UNDERWOOD, MJ; BAILEY, JS				UNDERWOOD, MJ; BAILEY, JS			CORONARY-BYPASS SURGERY SHOULD NOT BE OFFERED TO SMOKERS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; CIGARETTE-SMOKING; RISK-FACTORS; MYOCARDIAL-INFARCTION; CARDIAC-SURGERY; ARTERY SURGERY; DISEASE; GRAFTS; ATHEROSCLEROSIS; THROMBOSIS		DAVID RYDDERCH HLTH CTR, BIRMINGHAM B32 3SD, ENGLAND; KINGS COLL SCH MED & DENT, LONDON SE5 8RX, ENGLAND; SOUTHAMPTON GEN HOSP, WESSEX NEUROL CTR, SOUTHAMPTON SO9 4XY, HANTS, ENGLAND	University of London; King's College London; University of Southampton	UNDERWOOD, MJ (corresponding author), GROBY RD HOSP, DEPT CARDIOTHORAC SURG, LEICESTER LE3 9QE, ENGLAND.		Underwood, Malcolm John/L-6823-2016					BADIMON JJ, 1990, CORONARY ARTERY DIS, V1, P170, DOI 10.1097/00019501-199003000-00005; BOSCH X, 1991, European Heart Journal, V12, P170; BROOK RH, 1988, LANCET, V1, P750; CAMERON EWJ, 1990, BRIT MED J, V300, P1219, DOI 10.1136/bmj.300.6734.1219; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; CARREL T, 1991, THORAC CARDIOV SURG, V39, P85, DOI 10.1055/s-2007-1013938; CRIQUI MH, 1980, CIRCULATION, V62, P70; DOUGENIS D, 1992, EUR HEART J, V13, P9, DOI 10.1093/oxfordjournals.eurheartj.a060055; ENGBLOM E, 1992, EUR HEART J, V13, P232, DOI 10.1093/oxfordjournals.eurheartj.a060152; FIELDING JE, 1985, NEW ENGL J MED, V313, P491, DOI 10.1056/NEJM198508223130807; FISHER L, 1983, CIRCULATION, V68, P951; FITZGERALD GA, 1988, AM HEART J, V115, P267, DOI 10.1016/0002-8703(88)90648-5; FITZGIBBON GM, 1987, CAN MED ASSOC J, V136, P45; FUSTER V, 1981, CIRCULATION, V63, P546, DOI 10.1161/01.CIR.63.3.546; GALEA G, 1985, J CLIN PATHOL, V38, P978, DOI 10.1136/jcp.38.9.978; GOLDMAN S, 1988, CIRCULATION, V77, P1324, DOI 10.1161/01.CIR.77.6.1324; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GREENHALGH RM, 1981, BRIT J SURG, V68, P605, DOI 10.1002/bjs.1800680903; IVERT TSA, 1988, SCAND J THORAC CARD, V22, P111; KIRKLIN JW, 1991, J AM COLL CARDIOL, V17, P543; LEVINE PH, 1973, CIRCULATION, V48, P619, DOI 10.1161/01.CIR.48.3.619; NAGACHINTA T, 1987, J INFECT DIS, V156, P967, DOI 10.1093/infdis/156.6.967; NAIR UR, 1989, J CARDIOVASC SURG, V30, P656; NEITZEL GF, 1986, ARTERIOSCLEROSIS, V6, P594, DOI 10.1161/01.ATV.6.6.594; NIKUTTA P, 1990, Journal of the American College of Cardiology, V15, p181A; PEDUZZI P, 1987, AM J CARDIOL, V59, P1017, DOI 10.1016/0002-9149(87)90841-1; RAMANATHAN KB, 1990, J AM COLL CARDIOL, V15, P1493, DOI 10.1016/0735-1097(90)92816-K; SILVERMAN KJ, 1984, NEW ENGL J MED, V310, P1712, DOI 10.1056/NEJM198406283102606; SMITH SH, 1983, ARCH PATHOL LAB MED, V107, P13; SOLYMOSS BC, 1988, CIRCULATION, V78, P140; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; SUTTORP MJ, 1992, EUR HEART J, V13, P238, DOI 10.1093/oxfordjournals.eurheartj.a060153; VEKKALA K, 1990, SCAN J THORAC CARDIO, V24, P1; WARNER MA, 1989, MAYO CLIN PROC, V64, P609, DOI 10.1016/S0025-6196(12)65337-3; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WISEMAN S, 1989, BRIT MED J, V299, P643, DOI 10.1136/bmj.299.6700.643	36	73	73	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 17	1993	306	6884					1047	1048		10.1136/bmj.306.6884.1047	http://dx.doi.org/10.1136/bmj.306.6884.1047			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KY448	8357372	Green Published, Bronze			2022-12-28	WOS:A1993KY44800025
J	VANOSTADE, X; VANDENABEELE, P; EVERAERDT, B; LOETSCHER, H; GENTZ, R; BROCKHAUS, M; LESSLAUER, W; TAVERNIER, J; BROUCKAERT, P; FIERS, W				VANOSTADE, X; VANDENABEELE, P; EVERAERDT, B; LOETSCHER, H; GENTZ, R; BROCKHAUS, M; LESSLAUER, W; TAVERNIER, J; BROUCKAERT, P; FIERS, W			HUMAN TNF MUTANTS WITH SELECTIVE ACTIVITY ON THE P55 RECEPTOR	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; HUMAN CELL-LINES; FACTOR-ALPHA; MUTATIONAL ANALYSIS; CYTOLYTIC ACTIVITY; RECOMBINANT HUMAN; INDUCTION; INVITRO; VARIETY; LETHAL	THE remarkable ability of tumour necrosis factor (TNF), especially in combination with interferon, selectively to kill or inhibit malignant cell lines is so far unmatched by any other combination of cytokines1-4. But clinical trials in cancer patients have on the whole been disappointing5-7, and it has been estimated that a TNF dose would be effective only at 5-25 times the maximum tolerated dose 4. High TNF concentrations give a much more pronounced antitumour activity in mice1,8-10, in which murine TNF is about 50-fold more systemically toxic than human TNF11,12. . But there is little or no species specificity in cytotoxicity of murine TNF and human TNF on human as well as on murine cell lines13,14. This dual action of TNF may be explained by the existence of two types of receptor for TNF15,16: the smaller, TNF-R55, is present on most cells and particularly on those susceptible to the cytotoxic action of TNF17; the larger, TNF-R75, is also present on many cell types15,16, especially those of myeloid origin, and is strongly expressed on stimulated T and B lymphocytes18. In mice, human TNF binds only to murine TNF-R55 (ref. 15), which can then mediate cytotoxic activity on malignant cells15-17,19. As human TNF does not bind to murine TNF-R75, the latter must be responsible for the much enhanced systemic toxicity of murine TNF. Human TNF can, however, become toxic in mice when a second pathway is activated1,11,20. There is no reciprocal situation in the human system: human and murine TNF bind almost equally well to the two human TNF receptors. Here we describe human TNF mutants that still interact with the human TNF-R55 receptor but which have largely lost their ability to bind to human TNF-R75. Activation of TNF-R55 is sufficient to trigger cytotoxic activity towards transformed cells. One representative human TNF mutant retains its antitumour activity in nude mice carrying tumours derived from human cancers. Under the appropriate conditions, such human TNF mutants are expected to induce less systemic toxicity in man, while still exerting their direct antitumour effect.	F HOFFMANN LA ROCHE & CO LTD,PHARMACEUT RES NEW TECHNOL,CH-4002 BASEL,SWITZERLAND; ROCHE RES,B-9000 GHENT,BELGIUM	Roche Holding	VANOSTADE, X (corresponding author), STATE UNIV GHENT,MOLEC BIOL LAB,KL LEDEGANCKSTR 35,B-9000 GHENT,BELGIUM.		Vandenabeele, Peter/C-8597-2009; Van Ostade, Xaveer WMP/D-1702-2015; Vandenabeele, Peter/AAD-5793-2022; Tavernier, Jan/AAG-3636-2019; Van Ostade, Xaveer/AAG-9587-2020	Van Ostade, Xaveer WMP/0000-0003-4078-3014; Vandenabeele, Peter/0000-0002-6669-8822; 				BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; BROUCKAERT P, 1992, LYMPHOKINE CYTOK RES, V11, P193; BROUCKAERT P, 1992, EUR J IMMUNOL, V22, P981, DOI 10.1002/eji.1830220416; BROUCKAERT PGG, 1986, INT J CANCER, V38, P763, DOI 10.1002/ijc.2910380521; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DELALUNA S, 1988, GENE, V62, P121; EVERAERDT B, 1989, BIOCHEM BIOPH RES CO, V163, P378, DOI 10.1016/0006-291X(89)92146-3; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; FRANSEN L, 1986, CELL IMMUNOL, V100, P260, DOI 10.1016/0008-8749(86)90025-0; GEHR G, 1992, J IMMUNOL, V149, P911; HELLER RA, 1992, CELL, V70, P47; KRAMER SM, 1988, CANCER RES, V48, P920; LESSLAUER W, 1991, EUR J IMMUNOL, V21, P2883, DOI 10.1002/eji.1830211134; LIENARD D, 1992, J CLIN ONCOL, V10, P52, DOI 10.1200/JCO.1992.10.1.52; LOETSCHER H, 1991, CANCER CELL-MON REV, V3, P221; MALIK STA, 1992, TUMOR NECROSIS FACTO, P239; OLD LJ, 1990, TUMOR NECROSIS FACTOR : STRUCTURE, MECHANISM OF ACTION, ROLE IN DISEASE AND THERAPY, P1; PLAETINCK G, 1987, EUR J IMMUNOL, V17, P1835, DOI 10.1002/eji.1830171224; Spriggs D. R., 1992, TUMOR NECROSIS FACTO, P383; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TAGUCHI T, 1991, BIOTHERAPY, V3, P177, DOI 10.1007/BF02172090; TAKAHASHI N, 1991, CANCER RES, V51, P2366; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; VANDENABEELE P, 1990, LYMPHOKINE RES, V9, P381; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713	28	180	208	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 21	1993	361	6409					266	269						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8380906				2022-12-28	WOS:A1993KH61400062
J	VETRIE, D; VORECHOVSKY, I; SIDERAS, P; HOLLAND, J; DAVIES, A; FLINTER, F; HAMMARSTROM, L; KINNON, C; LEVINSKY, R; BOBROW, M; SMITH, CIE; BENTLEY, DR				VETRIE, D; VORECHOVSKY, I; SIDERAS, P; HOLLAND, J; DAVIES, A; FLINTER, F; HAMMARSTROM, L; KINNON, C; LEVINSKY, R; BOBROW, M; SMITH, CIE; BENTLEY, DR			THE GENE INVOLVED IN X-LINKED AGAMMAGLOBULINEMIA IS A MEMBER OF THE SRC FAMILY OF PROTEIN-TYROSINE KINASES	NATURE			English	Article							TRANSCRIBED SEQUENCES; DNA FRAGMENTS; CLOSE LINKAGE; GENOMIC DNA; FEATURES; IDENTIFICATION; EXPRESSION; SELECTION; MUTATIONS; PP60V-SRC	X-linked agammaglobulinaemia (XLA) is a human immunodeficiency caused by failure of pre-B cells in the bone marrow to develop into circulating mature B cells. A novel gene has been isolated which maps to the XLA locus, is expressed in B cells, and shows mutations in families with the disorder. The gene is a member of the src family of proto-oncogenes which encode protein-tyrosine kinases. This is, to our knowledge, the first evidence that mutations in a src-related gene are involved in human genetic disease.	KAROLINSKA INST, NOVUM, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN; UMEA UNIV, APPL CELL & MOLEC BIOL UNIT, S-90187 UMEA, SWEDEN; INST CHILD HLTH, MOLEC IMMUNOL UNIT, LONDON WC1N 1EH, ENGLAND	Karolinska Institutet; Umea University; University of London; University College London	VETRIE, D (corresponding author), UMDS GUYS & ST THOMASS HOSP, DIV MED & MOLEC GENET, GUYS TOWER, LONDON SE1 9RT, ENGLAND.		Kinnon, Christine/A-1585-2010	Vetrie, David/0000-0003-2075-4662; Sideras, Paschalis/0000-0003-0701-1258	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BENTLEY DR, 1992, GENOMICS, V12, P534, DOI 10.1016/0888-7543(92)90445-X; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BRUTON OC, 1952, PEDIATRICS, V9, P722; BUCKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CAMPANA D, 1990, J IMMUNOL, V145, P1675; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DUYK GM, 1990, P NATL ACAD SCI USA, V87, P8995, DOI 10.1073/pnas.87.22.8995; FEARON ER, 1987, NEW ENGL J MED, V316, P427, DOI 10.1056/NEJM198702193160802; GREEN PM, 1989, EMBO J, V8, P1067, DOI 10.1002/j.1460-2075.1989.tb03474.x; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GUIOLI S, 1989, HUM GENET, V84, P19, DOI 10.1007/BF00210664; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOLLAND J, IN PRESS GENOMICS; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; Korn Bernhard, 1992, Human Molecular Genetics, V1, P235, DOI 10.1093/hmg/1.4.235; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KWAN SP, 1986, J CLIN INVEST, V77, P649, DOI 10.1172/JCI112351; KWAN SP, 1990, GENOMICS, V6, P238, DOI 10.1016/0888-7543(90)90562-9; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LEPRINCE C, 1992, EUR J IMMUNOL, V22, P2093, DOI 10.1002/eji.1830220820; LIU P, 1989, SCIENCE, V246, P813, DOI 10.1126/science.2479099; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MALCOLM S, 1987, HUM GENET, V77, P172, DOI 10.1007/BF00272387; MANO H, 1990, ONCOGENE, V5, P1781; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MYERS RM, 1985, NATURE, V313, P495, DOI 10.1038/313495a0; OREILLY MAJ, IN PRESS GENOMICS; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTT J, 1986, HUM GENET, V74, P280; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARL ER, 1978, J IMMUNOL, V120, P1169; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; ROBERTS RG, 1991, AM J HUM GENET, V49, P298; ROSEN FS, 1984, NEW ENGL J MED, V311, P235, DOI 10.1056/NEJM198407263110406; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEALEY PG, 1985, NUCLEIC ACIDS RES, V13, P1905, DOI 10.1093/nar/13.6.1905; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIDERAS P, 1992, J IMMUNOL, V149, P244; SMART JE, 1981, P NATL ACAD SCI-BIOL, V78, P6013, DOI 10.1073/pnas.78.10.6013; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STEINITZ M, 1986, EUR J IMMUNOL, V16, P187, DOI 10.1002/eji.1830160214; VETRIE D, IN PRESS GENOMICS; VORECHOVSKY I, IN PRESS IMMUNODEFIC; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903	62	1205	1250	4	34	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 21	1993	361	6409					226	233		10.1038/361226a0	http://dx.doi.org/10.1038/361226a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KH614	8380905				2022-12-28	WOS:A1993KH61400048
J	GALIONE, A				GALIONE, A			CYCLIC ADP-RIBOSE - A NEW WAY TO CONTROL CALCIUM	SCIENCE			English	Editorial Material							SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; MICROSOMES; RELEASE; CELLS; CA-2+; STREPTOZOTOCIN; ALLOXAN; ENZYME; CA2+				GALIONE, A (corresponding author), UNIV OXFORD,DEPT PHARMACOL,MANFIELD RD,OXFORD OX1 3QT,ENGLAND.		Galione, Antony/E-5884-2011	Galione, Antony/0000-0002-4132-7646				BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; CURRIE KPM, 1992, MOL BIOL CELL, V3, P1415, DOI 10.1091/mbc.3.12.1415; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; EPEL D, 1977, SCI AM, V237, P128, DOI 10.1038/scientificamerican1177-128; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GALIONE A, 1992, TRENDS PHARMACOL SCI, V13, P304, DOI 10.1016/0165-6147(92)90096-O; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P1211; GRAPENGIESSER E, 1990, TOXICOLOGY, V63, P263, DOI 10.1016/0300-483X(90)90189-N; GYLFE E, 1991, CELL CALCIUM, V12, P29; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; IINO M, 1992, NATURE, V360, P76, DOI 10.1038/360076a0; ISLAM MS, 1992, FEBS LETT, V296, P287, DOI 10.1016/0014-5793(92)80306-2; KOSHIYAMA H, 1991, J BIOL CHEM, V266, P16985; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1991, J BIOL CHEM, V266, P2276; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1984, NATURE, V309, P562, DOI 10.1038/309562a0; ROSSIER MF, 1991, TRENDS NEUROSCI, V14, P310, DOI 10.1016/0166-2236(91)90143-I; RUSKINO N, 1987, J BIOL CHEM, V264, P11725; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; WHITAKER M, 1984, NATURE, V312, P636, DOI 10.1038/312636a0; YAMAMOTO H, 1981, NATURE, V294, P284, DOI 10.1038/294284a0	29	233	235	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					325	326		10.1126/science.8380506	http://dx.doi.org/10.1126/science.8380506			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8380506				2022-12-28	WOS:A1993KG62400022
J	BRAY, GA				BRAY, GA			USE AND ABUSE OF APPETITE-SUPPRESSANT DRUGS IN THE TREATMENT OF OBESITY	ANNALS OF INTERNAL MEDICINE			English	Article							ATYPICAL BETA-ADRENOCEPTOR; PULMONARY-HYPERTENSION; WEIGHT-LOSS; DOUBLE-BLIND; FENFLURAMINE; FLUOXETINE; DEXFENFLURAMINE; TERM; EFFICACY; TRIAL	Most of the available appetite-suppressant drugs act on noradrenergic and possibly dopaminergic receptors to produce satiety. A smaller number increase excess neuronal serotonin levels by blocking serotonin reuptake or by increasing its release. All these drugs produce significantly greater weight loss than does placebo in most studies. Abuse is a problem with amphetamine, methamphetamine, and benzphetamine, whereas other drugs have minimal or no potential for abuse. Weight loss can be sustained for up to 36 months. Net weight loss, compared with placebo, ranges from 2 to 10 kg, and weight regain after terminating drug treatment proves that drugs do not work when not taken. The stigma of obesity, the public opprobrium toward obese persons, and regulatory rigidity have led to unjustified distrust in the potential of drug treatment for obesity.	LOUISIANA STATE UNIV, BATON ROUGE, LA 70803 USA	Louisiana State University System; Louisiana State University	BRAY, GA (corresponding author), PENNINGTON BIOMED RES CTR, 6400 PERKINS RD, BATON ROUGE, LA 70808 USA.							ALLEN GS, 1975, J INT MED RES, V3, P40; ARCH JRS, 1984, NATURE, V309, P163, DOI 10.1038/309163a0; ASTRUP A, 1992, AM J CLIN NUTR, V55, P246; ATANASSOFF PG, 1992, LANCET, V339, P436, DOI 10.1016/0140-6736(92)90129-Q; ATKINSON RL, 1977, INT J OBESITY, V1, P113; BAIRD IM, 1977, INT J OBESITY, V1, P271; BANDISODE MS, 1975, CURR THER RES CLIN E, V18, P816; Banting W, 1863, COMMUNICATION; BLUNDELL JE, 1992, AM J CLIN NUTR, V55, P155, DOI 10.1093/ajcn/55.1.155s; BOLDING OT, 1974, CURR THER RES CLIN E, V16, P40; BRAY GA, 1988, DIABETES METAB REV, V4, P653, DOI 10.1002/dmr.5610040704; BRAY GA, 1990, INT J OBESITY, V14, P909; BRAY GA, 1991, NUTR REV, V49, P33, DOI 10.1111/j.1753-4887.1991.tb02990.x; BRAY GA, 1991, ANN INTERN MED, V115, P152, DOI 10.7326/0003-4819-115-2-152; BRAY GA, 1992, AM J CLIN NUTR, V55, pS1; BRAY GA, 1976, OBESE PATIENT, P1; BRUN LD, 1988, INT J OBESITY, V12, P423; CAMPBELL CJ, 1977, PRACTITIONER, V218, P851; CONNACHER AA, 1988, BRIT MED J, V296, P1217, DOI 10.1136/bmj.296.6631.1217; CRAIGHEAD LW, 1981, ARCH GEN PSYCHIAT, V38, P763; DAHMS WT, 1978, AM J CLIN NUTR, V31, P774, DOI 10.1093/ajcn/31.5.774; DARGA LL, 1991, AM J CLIN NUTR, V54, P321, DOI 10.1093/ajcn/54.2.321; DEFELICE EA, 1973, CURR THER RES CLIN E, V15, P358; DENT RW, 1975, CURR THER RES CLIN E, V18, P132; DOUGLAS JG, 1981, BMJ-BRIT MED J, V283, P881, DOI 10.1136/bmj.283.6296.881; DOUGLAS JG, 1983, LANCET, V1, P384; ENZI G, 1988, CLIN NEUROPHARMACOL, V11, pS173; ENZI G, 1976, J INT MED RES, V4, P305, DOI 10.1177/030006057600400504; FERGUSON JM, 1987, INT J OBESITY, V11, P163; FINER N, 1988, CLIN NEUROPHARMACOL, V11, pS179; FINER N, 1985, CURR THER RES CLIN E, V38, P847; GRAY DS, 1992, INT J OBESITY, V16, P193; GRIBOFF SI, 1975, CURR THER RES CLIN E, V17, P535; Griffiths R, 1979, ADV BEHAV PHARMACOL, V2, P163; GUYGRAND B, 1989, LANCET, V2, P1142; HADLER AJ, 1968, J CLIN PHARMACOL N D, V8, P113, DOI 10.1002/j.1552-4604.1968.tb00256.x; HADLER AJ, 1967, CURR THER RES CLIN E, V9, P462; HAUGEN HN, 1975, J CLIN PHARMACOL, V8, P71; HEBER KR, 1975, MED J AUSTRALIA, V2, P566, DOI 10.5694/j.1326-5377.1975.tb106063.x; KORNHABE.A, 1973, PSYCHOSOMATICS, V14, P162; KUMAHARA Y, 1985, CLIN EVAL, V13, P461; LANGLOIS KJ, 1974, CURR THER RES CLIN E, V16, P289; LEVINE LR, 1989, INT J OBESITY, V13, P635; MARCUS MD, 1990, AM J PSYCHIAT, V147, P876; MCKAY RH, 1975, RECENT ADV OBESITY R, P388; MCMURRAY J, 1986, BRIT MED J, V292, P239, DOI 10.1136/bmj.292.6515.239-a; MCQUARRIE HG, 1975, CURR THER RES CLIN E, V17, P437; MIACH PJ, 1976, MED J AUSTRALIA, V2, P378, DOI 10.5694/j.1326-5377.1976.tb130259.x; MIZRAHI A, 1974, J INT MED RES, V2, P317, DOI 10.1177/030006057400200414; MUNRO JF, 1968, BRIT MED J, V1, P352, DOI 10.1136/bmj.1.5588.352; NOBLE RE, 1990, CURR THER RES CLIN E, V47, P612; NOBLE RE, 1971, CURR THER RES CLIN E, V13, P685; NOLAN GR, 1975, CURR THER RES CLIN E, V18, P332; OST LG, 1976, ADDICT BEHAV, V1, P331, DOI 10.1016/0306-4603(76)90041-1; PIJL H, 1991, INT J OBESITY, V15, P237; POUWELS HMM, 1990, EUR RESPIR J, V3, P606; SANDERS M, 1976, MED J AUSTRALIA, V2, P576; SCHTEINGART DE, 1992, INT J OBESITY, V16, P487; SCHWARTZ LN, 1975, J INT MED RES, V3, P328, DOI 10.1177/030006057500300508; SEDGWICK JP, 1975, PRACTITIONER, V214, P418; SHARMA RK, 1973, CLIN PEDIATR, V12, P145, DOI 10.1177/000992287301200308; SMITH RG, 1975, BRIT MED J, V3, P284, DOI 10.1136/bmj.3.5978.284; STEEL JM, 1973, PRACTITIONER, V211, P232; THORPE PC, 1975, CURR THER RES CLIN E, V17, P149; TISDALE SA, 1976, CURR THER RES CLIN E, V19, P589; TRUANT AP, 1972, CURR THER RES CLIN E, V14, P726; VERNACE BJ, 1974, OBESITY BARIAT MED, V3, P124; WALKER BR, 1977, J INT MED RES, V5, P85, DOI 10.1177/030006057700500202; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; WEINTRAUB M, 1986, CLIN PHARMACOL THER, V39, P501, DOI 10.1038/clpt.1986.87; WEINTRAUB M, 1984, ARCH INTERN MED, V144, P1143, DOI 10.1001/archinte.144.6.1143; WEINTRAUB M, 1989, MED CLIN N AM, V73, P237, DOI 10.1016/S0025-7125(16)30701-5; WEINTRAUB M, 1983, CLIN PHARMACOL THER, V33, P621, DOI 10.1038/clpt.1983.84; Wise PJ, 1975, OBESITY BARIATRIC ME, V4, P102; [No title captured]; 1985, ANN INTERN MED, V103, P173; [No title captured]	77	149	153	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				707	713		10.7326/0003-4819-119-7_Part_2-199310011-00016	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00016			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363202				2022-12-28	WOS:A1993MA33000016
J	CALANDRA, T; ZINNER, SH; VISCOLI, C; DEBOCK, R; GAYA, H; MEUNIER, F; KLASTERSKY, J; GLAUSER, MP; NINOVE, D; LANGENAEKEN, J; PAESMANS, M; GALAZZO, M; GIDDEY, M; BILLE, J; HADJDJILANI, A; MASSIMO, L; MORONI, C; CASTAGNOLA, E; SANZ, M; FERSTER, A; DEBOCK, R; MEUNIER, F; KLASTERSKY, J; PADMOS, A; GALLAGHER, J; COMETTA, A; GLAUSER, MP; CALANDRA, T; LOPEZ, A; MARTINEZDALMAU, A; POGLIANI, E; HEMMER, R; DICATO, M; RIES, F; PORCELLINI, A; LEGRAND, JC; PORCELLINI, A; ESTAVOYER, JM; FOLLATH, F; SEITANIDES, B; ZINNER, S; BROWNE, M; NIKOSKELAINEN, J; ROSSI, M; MASERA, G				CALANDRA, T; ZINNER, SH; VISCOLI, C; DEBOCK, R; GAYA, H; MEUNIER, F; KLASTERSKY, J; GLAUSER, MP; NINOVE, D; LANGENAEKEN, J; PAESMANS, M; GALAZZO, M; GIDDEY, M; BILLE, J; HADJDJILANI, A; MASSIMO, L; MORONI, C; CASTAGNOLA, E; SANZ, M; FERSTER, A; DEBOCK, R; MEUNIER, F; KLASTERSKY, J; PADMOS, A; GALLAGHER, J; COMETTA, A; GLAUSER, MP; CALANDRA, T; LOPEZ, A; MARTINEZDALMAU, A; POGLIANI, E; HEMMER, R; DICATO, M; RIES, F; PORCELLINI, A; LEGRAND, JC; PORCELLINI, A; ESTAVOYER, JM; FOLLATH, F; SEITANIDES, B; ZINNER, S; BROWNE, M; NIKOSKELAINEN, J; ROSSI, M; MASERA, G			EFFICACY AND TOXICITY OF SINGLE DAILY DOSES OF AMIKACIN AND CEFTRIAXONE VERSUS MULTIPLE DAILY DOSES OF AMIKACIN AND CEFTAZIDIME FOR INFECTION IN PATIENTS WITH CANCER AND GRANULOCYTOPENIA	ANNALS OF INTERNAL MEDICINE			English	Article						DOSE-RESPONSE RELATIONSHIP, DRUG; AMIKACIN; CEFTAZIDIME; CEFTRIAXONE; DRUG TOXICITY	EMPIRIC ANTIBIOTIC-THERAPY; BETA-LACTAM COMBINATION; RANDOMIZED TRIAL; PLUS AMIKACIN; NEUTROPENIC CHILDREN; AUDITORY TOXICITY; FEBRILE; AMINOGLYCOSIDE; NETILMICIN; TOBRAMYCIN	Objective. To compare the efficacy and toxicity of single daily dosing of amikacin and ceftriaxone with that of multiple daily dosing of amikacin and ceftazidime for febrile episodes in patients with cancer and granulocytopenia. Design: A prospective, randomized, unblinded, multicenter trial. Setting: Twenty-one tertiary care or university medical centers. Patients: Six hundred seventy-seven patients with cancer and granulocytopenia (858 febrile episodes). Interventions: Random assignment to empiric therapy with a single daily dose of amikacin (20 mg/kg) and ceftriaxone (adults, 30 mg/kg; children, 80 mg/kg) (24-hour group) or with multiple daily doses of amikacin (6.5 mg/kg every 8 hours) and ceftazidime (33 mg/kg every 8 hours) (8-hour group). Measurements: Percentage response to each regimen and occurrence of nephrotoxicity and ototoxicity. Results. Single daity dosing of amikacin and ceftriaxone was as effective as multiple daily dosing of amikacin and ceftazidime (71% compared with 74%; difference, -3%; 95% CI, -10% to 3%; P > 0.2). Equivalent responses also were noted for each category of infection. Median peak (30 minutes after a 60-minute infusion) serum concentrations of amikacin were higher in the 24-hour group than in the 8-hour group (45.6 compared with 21 mug/mL, P < 0.001), whereas trough (preinfusion) levels were lower (0.9 compared with 2 mug/mL, P < 0.001). Nephrotoxicity was 3% in the 24-hour group and 2% in the 8-hour group (difference, 1%; CI, -1% to 4%). Increases in serum creatinine, however, were delayed (P = 0.048) and smaller (P = 0.06) in the 24-hour group than in the 8-hour group and occurred almost exclusively after other nephrotoxic drugs were added. Audiometry was only done in 144 patients (21%). Ototoxicity was 9% in the 24-hour group and 7% in the 8-hour group (difference, 2%; CI, -7% to 11 %; P > 0.2). Further infections developed in 15% and 12% of patients, respectively (difference, 3%; CI, -2% to 9%). The overall mortality rate was 11% in both treatment groups (difference, 0%; CI, -5% to 5%). Conclusions: Single daily dosing of amikacin and ceftriaxone was as effective and no more toxic than multiple daily dosing of amikacin and ceftazidime for the empiric therapy of infection in patients with cancer and granulocytopenia.	ROGER WILLIAMS GEN HOSP, DEPT MED, DIV INFECT DIS, PROVIDENCE, RI 02908 USA; INST JULES BORDET, DEPT MED, B-1000 BRUSSELS, BELGIUM; CHU VAUDOIS, DEPT INTERNAL MED, DIV INFECT DIS, CH-1011 LAUSANNE, SWITZERLAND; IST GIANNINA GASLINI, I-16148 GENOA, ITALY; HOSP UNIV LA FE, VALENCIA, SPAIN; HOP UNIV ENFANTS, BRUSSELS, BELGIUM; UNIV ZIEKENHUIS ANTWERPEN, EDEGEM, BELGIUM; KING FAISAL SPECIALIST HOSP & RES CTR, RIYADH, SAUDI ARABIA; GEISINGER MED CLIN, CTR CANC, DANVILLE, PA USA; HOSP GEN VALLE HEBRON, BARCELONA, SPAIN; HOSP XERAL VIGO, VIGO, SPAIN; OSPED SAN GERARDO, MONZA, ITALY; CTR HOSP LUXEMBOURG, LUXEMBOURG, LUXEMBOURG; OSPED CIVILE, PESARO, ITALY; HOP CIVIL, CHARLEROI, BELGIUM; CTR TRAPIANTI MIDOLLO OSSEO, CREMONA, ITALY; CHU BESANCON, F-25030 BESANCON, FRANCE; KANTONSSPITAL, CH-4004 BASEL, SWITZERLAND; METAXAS MEM HOSP, PIRAEUS, GREECE; UNIV TURKU, CENT HOSP, SF-20520 TURKU 52, FINLAND; OSPED MONZA, MONZA, ITALY	Roger Williams Medical Center; Institut Jules Bordet; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Genoa; IRCCS Istituto Giannina Gaslini; Hospital Universitari i Politecnic La Fe; University of Antwerp; King Faisal Specialist Hospital & Research Center; Geisinger Medical Center; Hospital Universitari Vall d'Hebron; Complexo Hospitalario Universitario de Vigo; San Gerardo Hospital; Luxembourg Hospital Center; Universite de Franche-Comte; CHU Besancon; Kantonsspital Aarau AG (KSA); University of Basel; University of Turku	CALANDRA, T (corresponding author), PICOWER INST MED RES, 350 COMMUNITY DR, MANHASSET, NY 11030 USA.		Castagnola, Elio/J-4454-2016; Sanz, Miguel A./F-7485-2018; Castagnola, Elio/C-1865-2012; Calandra, Thierry/D-9017-2015	Castagnola, Elio/0000-0002-5336-8429; Sanz, Miguel A./0000-0003-1489-1177; Castagnola, Elio/0000-0002-5336-8429; Calandra, Thierry/0000-0003-3051-1285				BARZA M, 1980, ANTIMICROB AGENTS CH, V17, P707, DOI 10.1128/AAC.17.4.707; BENDER JF, 1978, J INFECT DIS, V137, P14; BLASER J, 1985, ANTIMICROB AGENTS CH, V27, P343, DOI 10.1128/AAC.27.3.343; BODEY GP, 1979, AM J MED, V67, P608, DOI 10.1016/0002-9343(79)90242-0; BRUMMETT RE, 1989, ANTIMICROB AGENTS CH, V33, P797, DOI 10.1128/AAC.33.6.797; CALANDRA T, 1987, NEW ENGL J MED, V317, P1692; CALANDRA T, 1991, J INFECT DIS, V163, P951; Calandra T, 1991, Infect Dis Clin North Am, V5, P817; DEJONGH CA, 1986, AM J MED, V80, P101; Dixon W. J., 1990, BMDP STATISTICAL SOF; FAINSTEIN V, 1983, J ANTIMICROB CHEMOTH, V12, P101, DOI 10.1093/jac/12.suppl_A.101; FAN ST, 1988, J ANTIMICROB CHEMOTH, V22, P69, DOI 10.1093/jac/22.1.69; FELD R, 1985, ARCH INTERN MED, V145, P1083, DOI 10.1001/archinte.145.6.1083; GERBER AU, 1985, J ANTIMICROB CHEMOTH, V15, P201, DOI 10.1093/jac/15.suppl_A.201; GILBERT DN, 1991, ANTIMICROB AGENTS CH, V35, P399, DOI 10.1128/AAC.35.3.399; HANSEN M, 1988, Journal of Drug Development, V1, P119; ISENBERG HD, 1991, MANUAL CLIN MICROBIO, P2; KAFETZIS DA, 1991, J ANTIMICROB CHEMOTH, V27, P105, DOI 10.1093/jac/27.suppl_C.105; KLASTERSKY J, 1986, ANTIMICROB AGENTS CH, V29, P263, DOI 10.1128/AAC.29.2.263; LAU WK, 1977, AM J MED, V62, P959, DOI 10.1016/0002-9343(77)90669-6; LERNER AM, 1983, LANCET, V1, P1123; Lerner S A, 1980, Am J Otolaryngol, V1, P169, DOI 10.1016/S0196-0709(80)80012-3; LERNER SA, 1986, AM J MED, V80, P98, DOI 10.1016/0002-9343(86)90486-9; LEVISON ME, 1992, ANN INTERN MED, V117, P693, DOI 10.7326/0003-4819-117-8-693; LOVE LJ, 1979, AM J MED, V66, P603, DOI 10.1016/0002-9343(79)91170-7; MALLER R, 1991, J ANTIMICROB CHEMOTH, V27, P121, DOI 10.1093/jac/27.suppl_C.121; MALLER R, 1988, J ANTIMICROB CHEMOTH, V22, P75, DOI 10.1093/jac/22.1.75; MATTIE H, 1989, J ANTIMICROB CHEMOTH, V24, P281, DOI 10.1093/jac/24.3.281; MEUNIER F, 1991, ANTIMICROB AGENTS CH, V35, P873, DOI 10.1128/AAC.35.5.873; MEUNIER F, 1991, J ANTIMICROB CHEMOTH, V27, P129, DOI 10.1093/jac/27.suppl_C.129; MOORE RD, 1984, ANN INTERN MED, V100, P352, DOI 10.7326/0003-4819-100-3-352; NORDSTROM L, 1990, J ANTIMICROB CHEMOTH, V25, P159, DOI 10.1093/jac/25.1.159; NOVAKOVA I, 1991, ANTIMICROB AGENTS CH, V35, P672, DOI 10.1128/AAC.35.4.672; PIZZO PA, 1986, NEW ENGL J MED, V315, P552, DOI 10.1056/NEJM198608283150905; POWELL SH, 1983, J INFECT DIS, V147, P918, DOI 10.1093/infdis/147.5.918; PRINS JM, 1993, LANCET, V341, P335, DOI 10.1016/0140-6736(93)90137-6; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; Sahm D.H., 1991, MANUAL CLIN MICROBIO; Shamody H. J., 1991, MANUAL CLIN MICROBIO, V5, P1117; SHENEP JL, 1988, NEW ENGL J MED, V319, P1053, DOI 10.1056/NEJM198810203191604; SMITH CR, 1977, NEW ENGL J MED, V296, P350, DOI 10.1056/NEJM197702172960701; SMITH CR, 1980, NEW ENGL J MED, V302, P1106, DOI 10.1056/NEJM198005153022002; STURM AW, 1989, J INFECT DIS, V159, P931, DOI 10.1093/infdis/159.5.931; TERBRAAK EW, 1990, AM J MED, V89, P58, DOI 10.1016/0002-9343(90)90099-Y; TULKENS P M, 1988, Journal of Drug Development, V1, P71; VANDERAUWERA P, 1987, ANTIMICROB AGENTS CH, V31, P1061, DOI 10.1128/AAC.31.7.1061; VISCOLI C, 1991, REV INFECT DIS, V13, P397; VISCOLI C, 1991, J ANTIMICROB CHEMOTH, V27, P113, DOI 10.1093/jac/27.suppl_C.113; VOGELMAN B, 1986, J PEDIATR-US, V108, P835, DOI 10.1016/S0022-3476(86)80754-5; WADE JC, 1978, LANCET, V2, P604; WINSTON DJ, 1991, ANN INTERN MED, V115, P849, DOI 10.7326/0003-4819-115-11-849; WINSTON DJ, 1984, AM J MED, V77, P442, DOI 10.1016/0002-9343(84)90100-1; ZINNER SH, 1983, J CLIN ONCOL, V1, P597; [No title captured]	54	184	187	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				584	593		10.7326/0003-4819-119-7_Part_1-199310010-00006	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363169				2022-12-28	WOS:A1993MA29100006
J	HYMAN, FN; SEMPOS, E; SALTSMAN, J; GLINSMANN, WH				HYMAN, FN; SEMPOS, E; SALTSMAN, J; GLINSMANN, WH			EVIDENCE FOR SUCCESS OF CALORIC RESTRICTION IN WEIGHT-LOSS AND CONTROL - SUMMARY OF DATA FROM INDUSTRY	ANNALS OF INTERNAL MEDICINE			English	Article							OBESITY; DIET; MAINTENANCE; PROGRAM	Data voluntarily supplied by industry were examined to evaluate the success of commercial weight loss programs and products. Information about the safe loss of weight, the maintenance of this lowered weight, and resultant health benefits were reviewed. Information was received from companies that produce over-the-counter preparations designed for persons with a small weight loss goal and from physician-supervised programs for morbidly obese persons placed on very-low-calorie diets. Regardless of the products used, successful weight loss and control was limited and required individualized programs consisting of restricted caloric intake, behavior modification, and exercise. Although some manufacturers of physician-supervised weight loss products for obese persons have defined the effectiveness of their programs with controlled clinical studies, other industry programs have only begun to accurately assess their effectiveness or safety. Given the importance to public health of reducing obesity, rigorous studies on current weight control practices should be pursued aggressively.			HYMAN, FN (corresponding author), USDA, DIV NUTR, WASHINGTON, DC 20204 USA.							ANDERSON JW, 1991, J AM DIET ASSOC, V91, P1582; BRADLEY MH, 1990, CURR THER RES CLIN E, V47, P429; BURGESS NS, 1991, J AM DIET ASSOC, V91, P430; DONNELLY JE, 1991, AM J CLIN NUTR, V54, P56, DOI 10.1093/ajcn/54.1.56; FRIIS R, 1987, J CLIN GASTROENTEROL, V9, P204, DOI 10.1097/00004836-198704000-00019; FUKUDA M, 1989, DIABETES RES CLIN PR, V7, P61, DOI 10.1016/0168-8227(89)90047-8; GATENBY SJ, 1991, INT J OBESITY S1, V15, P29; HEBER D, 1990, INT J OBESITY S2, V14, P106; HOVELL MF, 1988, AM J PUBLIC HEALTH, V78, P663, DOI 10.2105/AJPH.78.6.663; KANDERS BS, 1989, INT J OBESITY, V13, P131; Kirschner M A, 1979, J Med Soc N J, V76, P175; KIRSCHNER MA, 1988, INT J OBESITY, V12, P69; LOCKWOOD DH, 1984, ANNU REV MED, V35, P373, DOI 10.1146/annurev.med.35.1.373; MIURA J, 1989, INT J OBESITY, V13, P73; PAVLOU KN, 1989, AM J CLIN NUTR, V49, P1115, DOI 10.1093/ajcn/49.5.1115; SURATT PM, 1987, CHEST, V92, P631, DOI 10.1378/chest.92.4.631; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1992, IN PRESS ARCH INT ME; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251	19	22	22	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				681	687		10.7326/0003-4819-119-7_Part_2-199310011-00011	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363197				2022-12-28	WOS:A1993MA33000011
J	FOSTER, KR; BERNSTEIN, DE; HUBER, PW				FOSTER, KR; BERNSTEIN, DE; HUBER, PW			SCIENCE AND THE TOXIC TORT	SCIENCE			English	Editorial Material									CROWELL & MORING,WASHINGTON,DC 20004; MANHATTAN INST,NEW YORK,NY 10017		FOSTER, KR (corresponding author), UNIV PENN,DEPT BIOENGN,PHILADELPHIA,PA 19104, USA.							BERGER MA, 1991, PROCEDURAL EVIDENTIA; Bernstein D, 1990, REV LITIG, V10, P117; CORNFELD R, 1993, PHANTOM RISK SCI INF, P401; CORNFELD R, 1989, TOXICS L REP, V381; FOSTER KR, 1992, HEALTH PHYS, V62, P429, DOI 10.1097/00004032-199205000-00007; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HUBER PW, 1991, GALILEOS REVENGE JUN; LASAGNA L, 1993, PHANTOM RISK SCI INT, P101; Lee Tahirih V., 1988, YALE L POLY REV, V6, P480; LUSTERMI, 1983, PHANTOM RISK SCI INF, P379; MILLS JL, 1993, PHANTOM RISK SCI INF, P87; Rothman KJ, 1988, CAUSAL INFERENCE; SUSSER M, 1991, AM J EPIDEMIOL, V133, P635, DOI 10.1093/oxfordjournals.aje.a115939; 1989, ANN INTERN MED, V111, P168; 1993, SCI TECHNOLOGY JUDIC	15	11	11	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1509	&		10.1126/science.8372345	http://dx.doi.org/10.1126/science.8372345			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372345				2022-12-28	WOS:A1993LX47400008
J	CURTIS, R; ADRYAN, KM; ZHU, Y; HARKNESS, PJ; LINDSAY, RM; DISTEFANO, PS				CURTIS, R; ADRYAN, KM; ZHU, Y; HARKNESS, PJ; LINDSAY, RM; DISTEFANO, PS			RETROGRADE AXONAL-TRANSPORT OF CILIARY NEUROTROPHIC FACTOR IS INCREASED BY PERIPHERAL-NERVE INJURY	NATURE			English	Article							FACTOR PREVENTS; SCIATIC-NERVE; MOTOR NEURONS; GROWTH-FACTOR; RAT; DEGENERATION; EXPRESSION; RECEPTOR; INVIVO; BDNF	CILIARY neurotrophic factor (CNTF) promotes the survival of several populations of neurons. including sensory and motor neurons1-4. Although CNTF is abundant in adult sciatic nerve, the mature protein lacks a signal sequence and is not secreted; therefore, it has been proposed to act as a lesion factor3. The identification of a functional CNTF receptor revealed ligand-specific phosphorylation cascades and gene induction5. However, it is not clear how these signal-transducing events are elicited in neuronal cell bodies that may be distant from the source of CNTF. We report here that CNTF can be retrogradely transported by adult sensory neurons. More importantly, sensory and motor neurons both show greatly increased transport of CnTF following peripheral nerve lesion. Axotomy-induced increases in retrograde transport of neurotrophic factors may be an important response of neuronal cell bodies during regeneration.			CURTIS, R (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DISTEFANO PS, 1992, NEURON, V8, P983, DOI 10.1016/0896-6273(92)90213-W; FERGUSON IA, 1991, J COMP NEUROL, V313, P60; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HANSSON HA, 1987, CELL TISSUE RES, V247, P241; HELGREN M, 1992, SOC NEUR ABSTR, V18, P619; HENDRY IA, 1974, BRAIN RES, V68, P103, DOI 10.1016/0006-8993(74)90536-8; HOLMLUND T H, 1992, Neurology, V42, P369; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JOHNSON EM, 1988, TRENDS NEUROSCI, V11, P299, DOI 10.1016/0166-2236(88)90090-2; MARCHALONIS JJ, 1969, BIOCHEM J, V113, P299, DOI 10.1042/bj1130299; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SENIUK N, 1992, BRAIN RES, V572, P300, DOI 10.1016/0006-8993(92)90489-V; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E	27	225	232	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					253	255		10.1038/365253a0	http://dx.doi.org/10.1038/365253a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371780				2022-12-28	WOS:A1993LX47100054
J	KUNIN, CM; WHITE, LV; HUA, TH				KUNIN, CM; WHITE, LV; HUA, TH			A REASSESSMENT OF THE IMPORTANCE OF LOW-COUNT BACTERIURIA IN YOUNG-WOMEN WITH ACUTE URINARY SYMPTOMS	ANNALS OF INTERNAL MEDICINE			English	Article						BACTINURIA; URINARY TRACT INFECTIONS; COLONY COUNT, MICROBIAL; ESCHERICHIA-COLI; STAPHYLOCOCCUS	ACUTE URETHRAL SYNDROME; TRACT INFECTION; DYSURIA	Objective: To determine whether a statistical association exists between ''low-count'' bacteriuria (> 10(2) to 10(4) colony-forming units/mL) and acute urinary symptoms in young women. Design: Prospective, case-control study. Setting: Gynecology clinic at a student health center. Patients: Women with or without urinary or vaginal symptoms. Measurements: History of urinary infections and sexual activity. Quantitative determination of bacteriuria and pyuria and bacterial species; urine leukocyte esterase test; specific gravity; creatinine levels; vaginal leukocytes; and in-vitro culture of urine. Results: The frequency of recent sexual activity, pregnancies, and contraceptive practices was not statistically different between women with acute urinary symptoms and asymptomatic controls. Escherichia coli and Staphylococcus saprophyticus were the only microorganisms statistically associated with urinary symptoms and pyuria (P < 0.001). Low counts of these organisms were found in 10.2% of asymptomatic women. As the bacterial count increased, the association between these organisms and symptoms increased, and a step-wise increase occurred in the frequency and magnitude of pyuria, but the specific gravity and urine creatinine levels remained unchanged. Escherichia coli, even at low counts, grew well in the patients' own urine. Pyuria (>20 leukocytes/mm3) was present in 19.6% of asymptomatic women and was associated with vaginal leukorrhea. Conclusions: ''Low-count'' bacteriuria was statistically more frequent among young women with urinary symptoms than among asymptomatic controls. The low counts could not be explained by dilution of the urine or failure of the bacteria to grow well in the patients' urine. These findings suggest that the infection was not established in the bladder urine and that ''low-count'' bacteriuria might be an early phase of urinary tract infection.			KUNIN, CM (corresponding author), OHIO STATE UNIV, DEPT INTERNAL MED, ROOM M110, STARLING LOVING HALL, 320 W 10TH AVE, COLUMBUS, OH 43210 USA.							BROOKS D, 1972, LANCET, V2, P893; BRUMFITT W, 1981, LANCET, V2, P393; CATTELL WR, 1974, BRIT MED J, V4, P136, DOI 10.1136/bmj.4.5937.136; COX CE, 1968, J UROLOGY, V99, P632, DOI 10.1016/S0022-5347(17)62762-9; DANS PE, 1976, JOHNS HOPKINS MED J, V138, P13; FIHN SD, 1988, J INFECT DIS, V157, P196, DOI 10.1093/infdis/157.1.196; GALLAGHER DJ, 1965, BMJ-BRIT MED J, V1, P622, DOI 10.1136/bmj.1.5435.622; KASS EH, 1955, AM J MED, V18, P764, DOI 10.1016/0002-9343(55)90190-X; KOMAROFF AL, 1984, NEW ENGL J MED, V310, P368, DOI 10.1056/NEJM198402093100607; Kunin C., 1987, DETECTION PREVENTION; KUNIN CM, 1980, JAMA-J AM MED ASSOC, V243, P134; KUNIN CM, 1992, CLIN INFECT DIS, V15, P1041, DOI 10.1093/clind/15.6.1041; MASKELL R, 1979, LANCET, V1, P1058; MCDONALD MI, 1982, J UROLOGY, V128, P517, DOI 10.1016/S0022-5347(17)53025-6; MCGUCKIN MB, 1980, J UROLOGY, V124, P240, DOI 10.1016/S0022-5347(17)55385-9; MOND NC, 1965, LANCET, V1, P514; MOORE T, 1965, LANCET, V1, P626; NORDEN CW, 1968, J CLIN INVEST, V47, P2689, DOI 10.1172/JCI105952; O'Grady F, 1966, Br J Urol, V38, P156, DOI 10.1111/j.1464-410X.1966.tb09694.x; OGRADY FW, 1970, LANCET, V2, P1208; PAQUIN AJ, 1965, J CLIN INVEST, V44, P1084; PFAU A, 1977, J UROLOGY, V118, P292, DOI 10.1016/S0022-5347(17)57976-8; PLATT R, 1983, AM J MED, V75, P44, DOI 10.1016/0002-9343(83)90072-4; SANFORD JP, 1956, AM J MED, V20, P88, DOI 10.1016/0002-9343(56)90175-9; SCHLESSELMAN JJ, 1982, CASE CONTROL STUDIES, P203; STAMEY TA, 1971, CALIF MED, V115, P1; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; STAMM WE, 1981, NEW ENGL J MED, V304, P956, DOI 10.1056/NEJM198104163041608; STAMM WE, 1982, NEW ENGL J MED, V307, P463, DOI 10.1056/NEJM198208193070802; STEENSBERG J, 1969, BMJ-BRIT MED J, V4, P390, DOI 10.1136/bmj.4.5680.390; TAPSALL JW, 1975, LANCET, V2, P637; WASHINGTON JA, 1990, ANN INTERN MED, V112, P387, DOI 10.7326/0003-4819-112-5-387; WONG ES, 1983, ANNU REV MED, V34, P337, DOI 10.1146/annurev.me.34.020183.002005	33	118	122	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					454	460		10.7326/0003-4819-119-6-199309150-00002	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357110				2022-12-28	WOS:A1993LZ27500002
J	MANDEL, SJ; BRENT, GA; LARSEN, PR				MANDEL, SJ; BRENT, GA; LARSEN, PR			LEVOTHYROXINE THERAPY IN PATIENTS WITH THYROID-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Review							L-THYROXINE THERAPY; THYROTROPIN-RELEASING-HORMONE; PATIENTS RECEIVING THYROXINE; SENSITIVE IMMUNORADIOMETRIC ASSAY; I IODOTHYRONINE DEIODINASE; BONE-MINERAL DENSITY; NON-TOXIC GOITER; HYPOTHYROID PATIENTS; SUBCLINICAL HYPOTHYROIDISM; REPLACEMENT THERAPY	Purpose: To review the indications for and the proper monitoring of levothyroxine therapy in patients with thyroid disease. Data Sources: Relevant English language articles published from 1966 to 1992 were identified through a MEDLINE search and manual searches of both identified articles and selected endocrinology texts. Study Selection: Studies, case reports, and review articles that contained data on the pathophysiologic aspects of relevant thyroid disorders and on the pharmacologic aspects of, indications for, and administration of levothyroxine therapy. Data Extraction: Data on the epidemiology, clinical manifestations, complications, and treatment of thyroid disorders were analyzed with respect to patient selection, methods, diagnostic criteria, and conclusions. These data were used to develop a rational approach to the management of such patients. Results of Data Synthesis: Levothyroxine is a reliable and commonly prescribed drug to treat thyroid disease, but excessive dosage may have adverse effects. In patients with hypothyroidism, levothyroxine is used as replacement therapy. For most patients, therapy can be initiated with a full replacement dosage (1.6 mug/kg body weight), which is usually 75 to 100 mug/day for women and 100 to 150 mug/d for men. The goal is to normalize the serum thyroid-stimulating hormone concentration. Levothyroxine is also used to suppress the serum thyroid-stimulating hormone concentration. A trial of thyroid-stimulating hormone suppressive therapy is indicated for most patients with benign solitary nonfunctioning thyroid nodules and for those with a history of thyroid cancer. Levothyroxine in non-thyroid-stimulating hormone-suppressive doses may also be indicated for patients with nontoxic multinodular goiter and for certain patients after lobectomy for benign thyroid nodules. Conclusions: With proper patient monitoring, levothyroxine replacement therapy should be effective, inexpensive, and free of complications. Recommendations for thyroid-stimulating hormone suppression with levothyroxine are based on risk-benefit considerations of the biologic characteristics of the thyroid disorder and the individual patient.	BRIGHAM & WOMENS HOSP, DIV THYROID, 75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NIDDK NIH HHS [5 R01 DK 36256, 1 R01 DK 43714, 5 T32 DK07529] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043714, T32DK007529, R01DK036256] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AIZAWA T, 1978, J CLIN ENDOCR METAB, V47, P560, DOI 10.1210/jcem-47-3-560; ALTHAUS BU, 1988, CLIN ENDOCRINOL, V28, P157, DOI 10.1111/j.1365-2265.1988.tb03651.x; ANDERSON PE, 1990, SURG GYNECOL OBSTET, V171, P309; AREM R, 1990, ARCH INTERN MED, V150, P2097, DOI 10.1001/archinte.150.10.2097; ARLOT S, 1991, INTENS CARE MED, V17, P16, DOI 10.1007/BF01708403; BADILLO J, 1963, JAMA-J AM MED ASSOC, V184, P151; BANG U, 1985, ACTA ENDOCRINOL-COP, V109, P214, DOI 10.1530/acta.0.1090214; BANOVAC K, 1989, ARCH INTERN MED, V149, P809, DOI 10.1001/archinte.149.4.809; BEARCROFT CP, 1991, CLIN ENDOCRINOL, V34, P115, DOI 10.1111/j.1365-2265.1991.tb00280.x; BECKPECCOZ P, 1985, NEW ENGL J MED, V312, P1085, DOI 10.1056/NEJM198504253121703; BELL GM, 1985, CLIN ENDOCRINOL, V22, P83, DOI 10.1111/j.1365-2265.1985.tb01068.x; BELL GM, 1983, CLIN ENDOCRINOL, V18, P511, DOI 10.1111/j.1365-2265.1983.tb02881.x; BERGHOUT A, 1990, LANCET, V336, P193, DOI 10.1016/0140-6736(90)91730-X; BERGLUND J, 1990, ACTA CHIR SCAND, V156, P433; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1992, ENDOCR REV, V13, P207, DOI 10.1210/er.13.2.207; BIGOS ST, 1978, J CLIN ENDOCR METAB, V46, P317, DOI 10.1210/jcem-46-2-317; BLACKBURN CM, 1954, J CLIN INVEST, V33, P819, DOI 10.1172/JCI102953; BLOCK WJ, 1952, JAMA-J AM MED ASSOC, V150, P259, DOI 10.1001/jama.1952.03680040001001; BRABANT G, 1987, J CLIN ENDOCR METAB, V65, P83, DOI 10.1210/jcem-65-1-83; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; BROWN ME, 1980, ANN INTERN MED, V92, P491, DOI 10.7326/0003-4819-92-4-491; BROWNING MCK, 1988, CLIN CHEM, V34, P696; BURGER A, 1976, J CLIN INVEST, V58, P255, DOI 10.1172/JCI108466; BURMEISTER LA, 1992, J CLIN ENDOCR METAB, V75, P344, DOI 10.1210/jc.75.2.344; CADY B, 1988, SURGERY, V104, P947; CADY B, 1983, SURGERY, V94, P978; CARON P, 1990, CLIN ENDOCRINOL, V33, P519, DOI 10.1111/j.1365-2265.1990.tb03889.x; CARR D, 1988, CLIN ENDOCRINOL, V28, P325, DOI 10.1111/j.1365-2265.1988.tb01219.x; CELANI MF, 1990, ACTA ENDOCRINOL-COP, V123, P603, DOI 10.1530/acta.0.1230603; CHEUNG PSY, 1989, WORLD J SURG, V13, P818, DOI 10.1007/BF01658447; COOPER DS, 1984, ANN INTERN MED, V101, P18, DOI 10.7326/0003-4819-101-1-18; DAVIES PH, 1992, J CLIN ENDOCR METAB, V74, P1189, DOI 10.1210/jc.74.5.1189; DEGROOT LJ, 1990, J CLIN ENDOCR METAB, V71, P414, DOI 10.1210/jcem-71-2-414; DEGROOT LJ, 1989, J CLIN ENDOCR METAB, V69, P925, DOI 10.1210/jcem-69-5-925; DELUCA F, 1986, EUR J PEDIATR, V145, P77, DOI 10.1007/BF00441860; DEMKE DM, 1989, NEW ENGL J MED, V321, P1341; EHRMANN DA, 1989, ARCH INTERN MED, V149, P369; ENGLAND ML, 1986, AM J MED SCI, V292, P264, DOI 10.1097/00000441-198611000-00002; FABER J, 1985, J CLIN ENDOCR METAB, V61, P1093, DOI 10.1210/jcem-61-6-1093; FABER J, 1990, J CLIN ENDOCR METAB, V70, P49, DOI 10.1210/jcem-70-1-49; FAGLIA G, 1979, J CLIN ENDOCR METAB, V48, P989, DOI 10.1210/jcem-48-6-989; FIGGE J, 1990, ANN INTERN MED, V113, P553, DOI 10.7326/0003-4819-113-7-553; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; FISHER DA, 1991, J CLIN ENDOCR METAB, V72, P523, DOI 10.1210/jcem-72-3-523; FOGELFELD L, 1989, NEW ENGL J MED, V320, P835, DOI 10.1056/NEJM198903303201304; FORFAR JC, 1985, Q J MED, V57, P857; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; GEFFNER DL, 1975, J CLIN INVEST, V55, P224, DOI 10.1172/JCI107925; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; GOW SM, 1987, J CLIN ENDOCR METAB, V64, P364, DOI 10.1210/jcem-64-2-364; GRANT CS, 1988, SURGERY, V104, P954; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; HARMON SM, 1991, ANN INTERN MED, V115, P658, DOI 10.7326/0003-4819-115-8-658_2; HARVEY RD, 1991, J CLIN ENDOCR METAB, V72, P1189, DOI 10.1210/jcem-72-6-1189; HAVRANKOVA J, 1992, ANN INTERN MED, V117, P445, DOI 10.7326/0003-4819-117-5-445_3; HAY ID, 1981, ANN INTERN MED, V95, P456, DOI 10.7326/0003-4819-95-4-456; HAY ID, 1990, ENDOCRIN METAB CLIN, V19, P545, DOI 10.1016/S0889-8529(18)30310-4; Hays M T, 1991, Thyroid, V1, P241, DOI 10.1089/thy.1991.1.241; HAYS MT, 1988, ENDOCR RES, V14, P203, DOI 10.3109/07435808809032986; HEGEDUS L, 1987, BRIT MED J, V294, P801, DOI 10.1136/bmj.294.6575.801; HEGEDUS L, 1991, CLIN ENDOCRINOL, V35, P235, DOI 10.1111/j.1365-2265.1991.tb03528.x; HELFAND M, 1990, ANN INTERN MED, V113, P450, DOI 10.7326/0003-4819-113-6-450; HENNESSEY JV, 1986, ANN INTERN MED, V105, P11, DOI 10.7326/0003-4819-105-1-11; HINTZE G, 1989, EUR J CLIN INVEST, V19, P527, DOI 10.1111/j.1365-2362.1989.tb00270.x; HOLVEY DN, 1964, ARCH INTERN MED, V113, P89, DOI 10.1001/archinte.1964.00280070091015; HYLANDER B, 1985, ACTA ENDOCRINOL-COP, V108, P65, DOI 10.1530/acta.0.1080065; ISLEY WL, 1987, ANN INTERN MED, V107, P517, DOI 10.7326/0003-4819-107-4-517; JENNINGS PE, 1984, BRIT MED J, V289, P1645, DOI 10.1136/bmj.289.6459.1645; KABADI UM, 1989, ARCH INTERN MED, V149, P2209, DOI 10.1001/archinte.149.10.2209; KAPLAN MM, 1992, THYROID, V2, P147, DOI 10.1089/thy.1992.2.147; KAPLAN MM, 1983, AM J MED, V74, P272, DOI 10.1016/0002-9343(83)90626-5; KAPLAN MM, 1992, THYROID, V2, P57, DOI 10.1089/thy.1992.2.57; KEATING FR, 1961, PROG CARDIOVASC DIS, V3, P364, DOI 10.1016/S0033-0620(61)90004-4; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; LADENSON PW, 1984, AM J MED, V77, P261, DOI 10.1016/0002-9343(84)90701-0; LADENSON PW, 1990, AM J MED, V88, P638, DOI 10.1016/0002-9343(90)90532-I; Larsen P R, 1972, Trans Assoc Am Physicians, V85, P309; LARSEN PR, 1987, J CLIN ENDOCR METAB, V64, P1089; LARSEN PR, 1982, NEW ENGL J MED, V306, P23; LEBOFF MS, 1982, METABOLISM, V31, P900, DOI 10.1016/0026-0495(82)90179-2; MACKERROW SD, 1992, ANN INTERN MED, V117, P1014, DOI 10.7326/0003-4819-117-12-1014; MALOOF F, 1955, ENDOCRINOLOGY, V56, P209, DOI 10.1210/endo-56-2-209; MANDEL SJ, 1992, J CLIN ENDOCR METAB, V75, P1133, DOI 10.1210/jc.75.4.1133; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MAZZAFERRI EL, 1987, SEMIN ONCOL, V14, P315; MCCONAHEY WM, 1986, MAYO CLIN PROC, V61, P978, DOI 10.1016/S0025-6196(12)62641-X; MORITA T, 1989, J CLIN ENDOCR METAB, V69, P227, DOI 10.1210/jcem-69-2-227; NICOLOFF JT, 1985, MED CLIN N AM, V69, P1005, DOI 10.1016/S0025-7125(16)31002-1; NYSTROM E, 1988, CLIN ENDOCRINOL, V29, P63, DOI 10.1111/j.1365-2265.1988.tb00250.x; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; PEREIRA VG, 1982, J ENDOCRINOL INVEST, V5, P331, DOI 10.1007/BF03350523; PERSSON CPA, 1982, WORLD J SURG, V6, P391, DOI 10.1007/BF01657664; READ DG, 1970, J CLIN ENDOCR METAB, V30, P798, DOI 10.1210/jcem-30-6-798; REESJONES RW, 1977, METABOLISM, V26, P1213, DOI 10.1016/0026-0495(77)90113-5; REVERTER JL, 1992, CLIN ENDOCRINOL, V36, P25, DOI 10.1111/j.1365-2265.1992.tb02898.x; RIDGWAY EC, 1972, ANN INTERN MED, V77, P549, DOI 10.7326/0003-4819-77-4-549; ROSENBAUM RL, 1982, ANN INTERN MED, V96, P53, DOI 10.7326/0003-4819-96-1-53; ROSENTHAL MJ, 1987, JAMA-J AM MED ASSOC, V258, P209, DOI 10.1001/jama.258.2.209; ROSS DS, 1990, J CLIN ENDOCR METAB, V71, P764, DOI 10.1210/jcem-71-3-764; ROSS DS, 1990, ENDOCRIN METAB CLIN, V19, P719, DOI 10.1016/S0889-8529(18)30318-9; ROSS DS, 1989, J CLIN ENDOCR METAB, V69, P684, DOI 10.1210/jcem-69-3-684; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SAWIN CT, 1977, J CLIN ENDOCR METAB, V44, P273, DOI 10.1210/jcem-44-2-273; SAWIN CT, 1989, JAMA-J AM MED ASSOC, V261, P2653, DOI 10.1001/jama.261.18.2653; SAWIN CT, 1985, ARCH INTERN MED, V145, P1386, DOI 10.1001/archinte.145.8.1386; SAWIN CT, 1983, AM J MED, V75, P206, DOI 10.1016/0002-9343(83)91192-0; SCHIMPFF SC, 1980, ANN INTERN MED, V92, P91, DOI 10.7326/0003-4819-92-1-91; SETH J, 1984, BRIT MED J, V289, P1334, DOI 10.1136/bmj.289.6455.1334; SHERMAN SI, 1991, AM J MED, V90, P367, DOI 10.1016/0002-9343(91)90578-L; SILVERBERG E, 1984, CA-CANCER J CLIN, V34, P7; SPENCER CA, 1990, J CLIN ENDOCR METAB, V70, P453, DOI 10.1210/jcem-70-2-453; SPENCER CA, 1986, J CLIN ENDOCR METAB, V63, P349, DOI 10.1210/jcem-63-2-349; SPERBER AD, 1992, ARCH INTERN MED, V152, P183, DOI 10.1001/archinte.152.1.183; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; SURKS MI, 1990, JAMA-J AM MED ASSOC, V263, P1529, DOI 10.1001/jama.263.11.1529; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; TAKAMATSU J, 1985, J CLIN ENDOCR METAB, V61, P672, DOI 10.1210/jcem-61-4-672; TAKASU N, 1990, LANCET, V336, P1084, DOI 10.1016/0140-6736(90)92567-2; TOFT AD, 1991, CLIN ENDOCRINOL, V34, P103, DOI 10.1111/j.1365-2265.1991.tb00278.x; TOFT AD, 1988, MAYO CLIN PROC, V63, P1035, DOI 10.1016/S0025-6196(12)64921-0; TUNBRIDGE WMG, 1981, BRIT MED J, V282, P258, DOI 10.1136/bmj.282.6260.258; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; WEHMANN RE, 1983, SOUTHERN MED J, V76, P969, DOI 10.1097/00007611-198308000-00007; WEINBERG AD, 1983, ARCH INTERN MED, V143, P893, DOI 10.1001/archinte.143.5.893; WENNLUND A, 1986, ACTA ENDOCRINOL-COP, V113, P47, DOI 10.1530/acta.0.1130047; WILCOX AH, 1987, CLIN ENDOCRINOL, V27, P205, DOI 10.1111/j.1365-2265.1987.tb01146.x; 1988, NATIONAL PRESCRIPTIO; 1990, US PHARMACOPEIA NATI, P764	130	233	241	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					492	502		10.7326/0003-4819-119-6-199309150-00009	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00009			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357116				2022-12-28	WOS:A1993LZ27500009
J	MIN, KT; HILDITCH, CM; DIEDERICH, B; ERRINGTON, J; YUDKIN, MD				MIN, KT; HILDITCH, CM; DIEDERICH, B; ERRINGTON, J; YUDKIN, MD			SIGMA(F), THE 1ST COMPARTMENT-SPECIFIC TRANSCRIPTION FACTOR OF BACILLUS-SUBTILIS, IS REGULATED BY AN ANTI-SIGMA FACTOR THAT IS ALSO A PROTEIN-KINASE	CELL			English	Article							BACILLUS-SUBTILIS; GENE-EXPRESSION; NUCLEOTIDE-SEQUENCE; RNA-POLYMERASE; LOCUS SPOIIA; CELL-TYPE; SPORULATION; CLONING; DNA; MUTATIONS	The establishment of compartment-specific transcription in sporulating cells of B. subtilis is governed at the level of the activity of transcription factor sigma(F). Genetic experiments have suggested that SpollAA and SpollAB, the other products of the sigma(F) operon, are involved in regulating sigma(F) activity. This activity is inhibited in the predivisional cell but specifically released from inhibition in the prespore about 1.5 hr after sporulation is induced. We now show that purified SpollAB inhibits transcription directed by sigma(F) in vitro. We note that the amino acid sequence of SpollAB shows some similarity to a group of bacterial histidine protein kinases, and we find that SpollAB is indeed a protein kinase that phosphorylates SpollAA on a serine residue. We suggest that this phosphorylation is responsible for the compartment-specific release of sigma(F) activity, perhaps through the formation of a tight complex between SpollAB and phosphorylated SpollAA.	UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,OXFORD OX1 3RE,ENGLAND	University of Oxford	MIN, KT (corresponding author), UNIV OXFORD,DEPT BIOCHEM,MICROBIOL UNIT,OXFORD OX1 3QU,ENGLAND.		Errington, Jeff/G-1832-2011	Errington, Jeff/0000-0002-6977-9388; min, kyung-tai/0000-0003-0983-4258				BENSON AK, 1993, P NATL ACAD SCI USA, V90, P2330, DOI 10.1073/pnas.90.6.2330; BENSON AK, 1992, J BACTERIOL, V174, P749, DOI 10.1128/jb.174.3.749-757.1992; BOYLAN SA, 1992, J BACTERIOL, V174, P3695, DOI 10.1128/JB.174.11.3695-3706.1992; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CHALLONERCOURTN.IJ, 1993, IN PRESS J BACTERIOL; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; ERRINGTON J, 1985, FEBS LETT, V188, P184, DOI 10.1016/0014-5793(85)80368-9; ERRINGTON J, 1987, J GEN MICROBIOL, V133, P493; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; ERRINGTON J, 1984, J GEN MICROBIOL, V130, P2615; ERRINGTON J, 1992, MOL MICROBIOL, V6, P689, DOI 10.1111/j.1365-2958.1992.tb01517.x; FORT P, 1985, J GEN MICROBIOL, V131, P1091; FORT P, 1984, J GEN MICROBIOL, V130, P2147; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARLOW E, 1988, ANTIBODIES LABORATOR; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JONAS RM, 1989, J BACTERIOL, V171, P5226, DOI 10.1128/jb.171.9.5226-5228.1989; KALMAN S, 1990, J BACTERIOL, V172, P5575, DOI 10.1128/jb.172.10.5575-5585.1990; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Moran C., 1990, MOL BIOL METHODS BAC, P267; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; PARTRIDGE SR, 1991, MOL MICROBIOL, V5, P757, DOI 10.1111/j.1365-2958.1991.tb00746.x; PARTRIDGE SR, 1993, MOL MICROBIOL, V8, P945, DOI 10.1111/j.1365-2958.1993.tb01639.x; RATHER PN, 1990, J BACTERIOL, V172, P709, DOI 10.1128/jb.172.2.709-715.1990; Sambrook J, 1989, MOL CLONING LABORATO; SAVVA D, 1984, J GEN MICROBIOL, V130, P2137; SCHMIDT R, 1990, P NATL ACAD SCI USA, V87, P9221, DOI 10.1073/pnas.87.23.9221; STERLINI JM, 1969, BIOCHEM J, V113, P29, DOI 10.1042/bj1130029; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN DX, 1991, J BACTERIOL, V173, P2977, DOI 10.1128/JB.173.9.2977-2984.1991; SUN DX, 1989, GENE DEV, V3, P141, DOI 10.1101/gad.3.2.141; SUSSMAN MD, 1991, J BACTERIOL, V173, P291, DOI 10.1128/jb.173.1.291-300.1991; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YUDKIN MD, 1985, J GEN MICROBIOL, V131, P959; YUDKIN MD, 1987, J GEN MICROBIOL, V133, P475	45	223	229	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					735	742		10.1016/0092-8674(93)90520-Z	http://dx.doi.org/10.1016/0092-8674(93)90520-Z			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358793				2022-12-28	WOS:A1993LU59200016
J	BIRD, AG; GORE, SM; BURNS, SM; DUGGIE, JG				BIRD, AG; GORE, SM; BURNS, SM; DUGGIE, JG			STUDY OF INFECTION WITH HIV AND RELATED RISK-FACTORS IN YOUNG OFFENDERS INSTITUTION	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To estimate the prevalence of infection with HIV in young offenders in Scotland and to obtain information about related risk factors and previous tests for HIV. Design-Voluntary anonymous study with subjects giving saliva samples for testing for HIV and completing questionnaires about risk factors. Setting-Polmont Young Offenders' Institution near Falkirk, Scotland. Subjects-421 of 424 available male prisoners in Polmont. The questionnaires of 17 of the prisoners were excluded because of inaccuracies. Main outcome measures-Prevalence of infection with HIV and related risk behaviour. Results-68 (17%) of prisoners admitted misuse of intravenous drugs, of whom 17 (25%) admitted having injected drugs while in prison. Three subjects admitted having anal intercourse while in prison. Prevalence of misuse of intravenous drugs varied geographically: 28% (33/120) of prisoners from Glasgow compared with 9% (7/81) of those from Edinburgh and Fife. A high level of heterosexual activity was reported, with 36% (142/397) of prisoners claiming to have had six or more female sexual partners in the year before they were imprisoned. Altogether 8% (32/389) of prisoners had previously taken a personal test for HIV: 50% (9/18) of those who had started misusing intravenous drugs before 1989, 18% (9/49) of those who started misuse later, and only 4% (14/322) of those who had not misused intravenous drugs. No saliva sample tested positive for antibodies to HIV, but 96 prisoners requested a confidential personal test for HIV as a result of heightened awareness generated by the study. Conclusions-Voluntary, anonymous HIV surveys can achieve excellent compliance in prisons, and the interest generated by the study suggests that prisons may be suitable sites for providing education and drug rehabilitation for a young male population at high risk of future infection with HIV.	INST PUBL HLTH,MRC,BIOSTAT UNIT,CAMBRIDGE CB2 2SR,ENGLAND; CITY HOSP EDINBURGH,REG VIRUS LAB,EDINBURGH EH10 5SB,MIDLOTHIAN,SCOTLAND; HLTH CTR,GRP MED PRACTICE,GRANGEMOUTH FK3 9EL,SCOTLAND	MRC Biostatistics Unit; University of Cambridge	BIRD, AG (corresponding author), CHURCHILL HOSP,DEPT IMMUNOL,OXFORD OX3 7LJ,ENGLAND.							BIRD AG, 1992, AIDS, V6, P725, DOI 10.1097/00002030-199207000-00017; BIRD AG, IN PRESS AIDS; GORE SM, 1992, LANCET, V340, P907, DOI 10.1016/0140-6736(92)93313-C; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; 1992, NATURE, V360, P407	5	41	43	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					228	231		10.1136/bmj.307.6898.228	http://dx.doi.org/10.1136/bmj.307.6898.228			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369682	Bronze, Green Published			2022-12-28	WOS:A1993LP31400020
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CHOLESTEROL TEST KIT TO BE AVAILABLE OVER-THE-COUNTER FOR HOME USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1776	1776						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8384667				2022-12-28	WOS:A1993KW25000007
J	DIXON, DA; KOWALCZYKOWSKI, SC				DIXON, DA; KOWALCZYKOWSKI, SC			THE RECOMBINATION HOTSPOT-CHI IS A REGULATORY SEQUENCE THAT ACTS BY ATTENUATING THE NUCLEASE ACTIVITY OF THE ESCHERICHIA-COLI RECBCD ENZYME	CELL			English	Article							ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; BACTERIOPHAGE-LAMBDA; EXONUCLEASE-V; PHAGE-LAMBDA; RECD MUTANTS; DNA; ORIENTATION; DEOXYRIBONUCLEASE; SPECIFICITY	The RecBCD enzyme is a multifunctional enzyme that is essential for homologous recombination in E. coli. In vitro, the RecBCD enzyme degrades linear double-stranded DNA nonspecifically during the process of unwinding the double-stranded DNA. Here we demonstrate that this DNA degradation is asymmetric, with the strand that is 3' terminal at the entry site of RecBCD enzyme being degraded much more vigorously than the 5' terminal strand. Furthermore, interaction with the recombination hotspot chi causes an attenuation of the nuclease activity but not of the helicase activity and is accompanied by a pause of RecBCD enzyme at the chi site. These results demonstrate that chi is a unique regulatory element that acts by controlling the degradative function of RecBCD enzyme and, thereby, enhancing its recombination function.	UNIV CALIF DAVIS,MOLEC BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,CELL BIOL SECT,DAVIS,CA 95616; UNIV CALIF DAVIS,BIOCHEM SECT,DAVIS,CA 95616; NORTHWESTERN UNIV,SCH MED,DEPT MOLEC BIOL,CHICAGO,IL 60611	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Northwestern University	DIXON, DA (corresponding author), UNIV CALIF DAVIS,MICROBIOL SECT,DAVIS,CA 95616, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041347] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-41347] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMUNDSEN SK, 1990, GENETICS, V126, P25; AMUNDSEN SK, 1986, P NATL ACAD SCI USA, V83, P5558, DOI 10.1073/pnas.83.15.5558; BRAEDT G, 1989, P NATL ACAD SCI USA, V86, P871, DOI 10.1073/pnas.86.3.871; CHAUDHURY AM, 1984, P NATL ACAD SCI-BIOL, V81, P7850, DOI 10.1073/pnas.81.24.7850; CHENG KC, 1989, GENETICS, V123, P5; CLEAVER JE, 1972, BIOCHIM BIOPHYS ACTA, V262, P116, DOI 10.1016/0005-2787(72)90224-9; DABERT P, 1992, P NATL ACAD SCI USA, V89, P12073, DOI 10.1073/pnas.89.24.12073; DIXON DA, 1991, CELL, V66, P361, DOI 10.1016/0092-8674(91)90625-9; DOWER NA, 1981, P NATL ACAD SCI-BIOL, V78, P7033, DOI 10.1073/pnas.78.11.7033; EGGLESTON AK, 1993, IN PRESS J MOL BIOL; EICHLER DC, 1977, J BIOL CHEM, V252, P499; EMMERSON PT, 1967, J BACTERIOL, V93, P1729, DOI 10.1128/JB.93.5.1729-1731.1967; FAULDS D, 1979, J MOL BIOL, V131, P681, DOI 10.1016/0022-2836(79)90197-9; GANESAN S, 1993, J MOL BIOL, V229, P67, DOI 10.1006/jmbi.1993.1008; GOLDMARK PJ, 1972, J BIOL CHEM, V247, P1849; HOWARDFLANDERS P, 1966, GENETICS, V53, P1137; KOBAYASHI I, 1982, P NATL ACAD SCI-BIOL, V79, P5981, DOI 10.1073/pnas.79.19.5981; KOWALCZYKOWSKI SC, 1990, UCLA S MOL CELLULAR, P357; LAM ST, 1974, GENETICS, V77, P425; LEBOWITZ J, 1985, THESIS J HOPKINS U B; LOVETT ST, 1988, GENETICS, V120, P37; MACKAY V, 1976, J BIOL CHEM, V251, P3716; PALAS KM, 1990, J BIOL CHEM, V265, P3447; PONTICELLI AS, 1985, CELL, V41, P145, DOI 10.1016/0092-8674(85)90069-8; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; ROMAN LJ, 1992, J BIOL CHEM, V267, P4207; ROMAN LJ, 1991, P NATL ACAD SCI USA, V88, P3367, DOI 10.1073/pnas.88.8.3367; RUYECHAN WT, 1975, BIOCHEMISTRY-US, V14, P5529, DOI 10.1021/bi00696a023; Sambrook J, 1989, MOL CLONING LABORATO; SCHULTZ DW, 1983, J BACTERIOL, V155, P664, DOI 10.1128/JB.155.2.664-680.1983; SMITH GR, 1981, CELL, V24, P429, DOI 10.1016/0092-8674(81)90333-0; SMITH GR, 1984, COLD SPRING HARB SYM, V49, P485, DOI 10.1101/SQB.1984.049.01.055; SMITH GR, 1988, MICROBIOL REV, V52, P1; SMITH GR, 1990, NUCLEIC ACIDS MOL BI, V4, P78; SMITH JV, 1981, SCOT EDUC REV, V13, P25; STAHL FW, 1975, J MOL BIOL, V94, P203, DOI 10.1016/0022-2836(75)90078-9; STAHL FW, 1990, GENETICS, V126, P519; TAYLOR A, 1980, CELL, V22, P447, DOI 10.1016/0092-8674(80)90355-4; TAYLOR AF, 1985, CELL, V41, P153, DOI 10.1016/0092-8674(85)90070-4; TAYLOR AF, 1992, P NATL ACAD SCI USA, V89, P5226, DOI 10.1073/pnas.89.12.5226; TAYLOR AF, 1985, J MOL BIOL, V185, P431, DOI 10.1016/0022-2836(85)90414-0; TAYLOR AF, 1988, GENETIC RECOMBINATIO, P231; Telander-Muskavitch K.M, 1981, ENZYMES, P233; Thaler D.S., 1988, MECH CONSEQUENCES DN, P413; THALER DS, 1989, GENOME, V31, P53, DOI 10.1139/g89-013; WRIGHT M, 1971, J BIOL CHEM, V246, P6543	46	203	206	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 9	1993	73	1					87	96		10.1016/0092-8674(93)90162-J	http://dx.doi.org/10.1016/0092-8674(93)90162-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KW753	8384931				2022-12-28	WOS:A1993KW75300010
J	WANG, LY; TAVERNA, FA; HUANG, XP; MACDONALD, JF; HAMPSON, DR				WANG, LY; TAVERNA, FA; HUANG, XP; MACDONALD, JF; HAMPSON, DR			PHOSPHORYLATION AND MODULATION OF A KAINATE RECEPTOR (GLUR6) BY CAMP-DEPENDENT PROTEIN-KINASE	SCIENCE			English	Article							RETINAL HORIZONTAL CELLS; PHOSPHATASES; ENHANCEMENT; NEURONS	Ligand-gated ion channels gated by glutamate constitute the major excitatory neurotransmitter system in the mammalian brain. The functional modulation of GluR6, a kainate-activated glutamate receptor, by adenosine 3',5'-monophosphate-dependent protein kinase A (PKA) was examined with receptors expressed in human embryonic kidney cells. Kainate-evoked currents underwent a rapid desensitization that was blocked by lectins. Kainate currents were potentiated by intracellular perfusion of PKA, and this potentiation was blocked by co-application of an inhibitory peptide. Site-directed mutagenesis was used to identify the site or sites of phosphorylation on GluR6. Although mutagenesis of two serine residues, Ser684 and Ser666, was required for complete abolition of the PKA-induced potentiation, Ser684 may be the preferred site of phosphorylation in native GluR6 receptor complexes. These results indicate that glutamate receptor function can be directly modulated by protein phosphorylation and suggest that a dynamic regulation of excitatory receptors could be associated with some forms of learning and memory in the mammalian brain.	UNIV TORONTO,DEPT PHYSIOL,MED SCI BLDG,1 KINGS COLL,TORONTO M5S 1A8,ONTARIO,CANADA; UNIV TORONTO,FAC PHARM,TORONTO M5S 2S2,ON,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO M5S 1A8,ONTARIO,CANADA	University of Toronto; University of Toronto; University of Toronto								BARNES JM, 1992, PROG NEUROBIOL, V39, P113, DOI 10.1016/0301-0082(92)90007-2; BETTLER B, 1992, NEURON, V8, P257, DOI 10.1016/0896-6273(92)90292-L; CHAVEZNORIEGA LE, 1992, BRAIN RES, V574, P85, DOI 10.1016/0006-8993(92)90803-H; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHEN L, 1991, NEURON, V7, P391; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; DUNWIDDIE TV, 1992, J NEUROSCI, V12, P506; EGEBJERG J, 1991, NATURE, V351, P745, DOI 10.1038/351745a0; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Kaczmarek L. K., 1987, NEUROMODULATION; KELLER BU, 1992, EMBO J, V11, P891, DOI 10.1002/j.1460-2075.1992.tb05127.x; KENNEDY MB, 1989, CELL, V59, P777, DOI 10.1016/0092-8674(89)90601-6; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KNAPP AG, 1987, NATURE, V325, P437, DOI 10.1038/325437a0; KNAPP AG, 1990, P NATL ACAD SCI USA, V87, P767, DOI 10.1073/pnas.87.2.767; LIMAN ER, 1989, BRAIN RES, V481, P399, DOI 10.1016/0006-8993(89)90822-6; LIN SS, 1991, TRENDS NEUROSCI, V14, P273, DOI 10.1016/0166-2236(91)90136-I; RAYMOND LA, IN PRESS NATURE; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SOMMER B, 1992, TRENDS PHARMACOL SCI, V13, P291, DOI 10.1016/0165-6147(92)90088-N; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; Wang L., UNPUB; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455	26	185	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1173	1175		10.1126/science.8382377	http://dx.doi.org/10.1126/science.8382377			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8382377				2022-12-28	WOS:A1993KM91700042
J	SWARTZ, KJ; MERRITT, A; BEAN, BP; LOVINGER, DM				SWARTZ, KJ; MERRITT, A; BEAN, BP; LOVINGER, DM			PROTEIN-KINASE-C MODULATES GLUTAMATE RECEPTOR INHIBITION OF CA2+ CHANNELS AND SYNAPTIC TRANSMISSION	NATURE			English	Article							OMEGA-CONOTOXIN; HIPPOCAMPAL-NEURONS; PERIPHERAL NEURONS; CALCIUM CHANNELS; PHORBOL ESTERS; RAT; DESENSITIZATION; PHOSPHORYLATES; TRANSMITTER; EXCITATION	FAST synaptic transmission in the central nervous system can be modulated by neurotransmitters and second-messenger pathways. For example, transmission at glutamatergic synapses can be depressed by the metabotropic glutamate receptor1,2, providing autoreceptor-mediated negative feedback. Metabotropic glutamate receptor inhibition of Ca2+ channels may contribute to this pathway3-6. In contrast, stimulation of protein kinase C can enhance excitatory synaptic transmission7, whereas both depression and enhancement of Ca2+ current have been reported8. Here we show that in hippocampal CA3 and cortical pyramidal neurons, activation of protein kinase C enhances current through N-type Ca2+ channels and, in addition, dramatically reduces G protein-dependent inhibition of these same channels by the metabotropic glutamate receptor. In parallel experiments on fast excitatory transmission at corticostriatal synapses, kinase C activators were similarly found to reduce the inhibitory effect produced by stimulation of the metabotropic glutamate receptor. The results show that second-to-second control of Ca2+ channels by the metabotropic glutamate receptor can itself be modulated on a slower timescale by protein kinase C. These mechanisms may be used in the control of fast excitatory synaptic transmission.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Vanderbilt University	SWARTZ, KJ (corresponding author), HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115, USA.							ANWYL R, 1991, BRAIN RES REV, V16, P265, DOI 10.1016/0165-0173(91)90010-6; AOSAKI T, 1989, PFLUG ARCH EUR J PHY, V414, P150, DOI 10.1007/BF00580957; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BOSMA MM, 1989, P NATL ACAD SCI USA, V86, P2943, DOI 10.1073/pnas.86.8.2943; CORDINGLEY GE, 1986, BRIT J PHARMACOL, V88, P847, DOI 10.1111/j.1476-5381.1986.tb16258.x; DUTAR P, 1988, NEURON, V1, P585, DOI 10.1016/0896-6273(88)90108-0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HIRNING LD, 1988, SCIENCE, V239, P57, DOI 10.1126/science.2447647; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; IRVING AJ, 1990, EUR J PHARMACOL, V186, P363, DOI 10.1016/0014-2999(90)90462-F; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; LEEBLUNDBERG LMF, 1985, P NATL ACAD SCI USA, V82, P5651, DOI 10.1073/pnas.82.17.5651; LESTER RAJ, 1990, NEURON, V4, P741, DOI 10.1016/0896-6273(90)90200-Y; LIPSCOMBE D, 1988, Society for Neuroscience Abstracts, V14, P153; LOVINGER DM, 1991, NEUROSCI LETT, V129, P17, DOI 10.1016/0304-3940(91)90710-B; MADISON D V, 1989, Society for Neuroscience Abstracts, V15, P16; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; NORTH RA, 1989, BRIT J PHARMACOL, V98, P13, DOI 10.1111/j.1476-5381.1989.tb16855.x; ODELL TJ, 1991, J PHYSIOL-LONDON, V436, P739, DOI 10.1113/jphysiol.1991.sp018577; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; PALMER E, 1989, EUR J PHARMACOL, V166, P585, DOI 10.1016/0014-2999(89)90383-X; PLUMMER MR, 1989, NEURON, V2, P1453, DOI 10.1016/0896-6273(89)90191-8; POLLOCK WK, 1986, BIOCHEM J, V234, P67, DOI 10.1042/bj2340067; RANE SG, 1989, NEURON, V3, P239, DOI 10.1016/0896-6273(89)90037-8; REGAN LJ, 1991, NEURON, V6, P269, DOI 10.1016/0896-6273(91)90362-4; SAHARA Y, 1991, Society for Neuroscience Abstracts, V17, P1168; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SCHOEPP DD, 1988, BIOCHEM PHARMACOL, V37, P4299, DOI 10.1016/0006-2952(88)90610-7; SCHOLZ KP, 1992, NEURON, V8, P1139, DOI 10.1016/0896-6273(92)90134-Y; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; THOMPSON SM, 1992, J PHYSIOL-LONDON, V451, P347, DOI 10.1113/jphysiol.1992.sp019168	35	194	196	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					165	168		10.1038/361165a0	http://dx.doi.org/10.1038/361165a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8380626				2022-12-28	WOS:A1993KG46600063
J	COLLIER, AC; COOMBS, RW; FISCHL, MA; SKOLNIK, PR; NORTHFELT, D; BOUTIN, P; HOOPER, CJ; KAPLAN, LD; VOLBERDING, PA; DAVIS, LG; HENRARD, DR; WELLER, S; COREY, L				COLLIER, AC; COOMBS, RW; FISCHL, MA; SKOLNIK, PR; NORTHFELT, D; BOUTIN, P; HOOPER, CJ; KAPLAN, LD; VOLBERDING, PA; DAVIS, LG; HENRARD, DR; WELLER, S; COREY, L			COMBINATION THERAPY WITH ZIDOVUDINE AND DIDANOSINE COMPARED WITH ZIDOVUDINE ALONE IN HIV-1 INFECTION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS-1; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS; ZIDOVUDINE; DIDANOSINE; DRUG THERAPY, COMBINATION	AIDS-RELATED COMPLEX; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PHASE-I TRIAL; VIRUS INFECTION; 2',3'-DIDEOXYINOSINE DDI; REVERSE-TRANSCRIPTASE; AZT; SENSITIVITY; INDIVIDUALS; RESISTANCE	Objective: To assess safety, pharmacokinetics, and in-vivo virologic activity of five different combination regimens of zidovudine and didanosine compared with zidovudine alone in patients with human immunodeficiency virus type 1 (HIV-1) infection. Design: Open-label, partially randomized, dose-ranging study. Setting: University-affiliated, medical center clinics. Patients: A total of 69 patients with HIV-1 infection, CD4+ cell counts fewer than 400 cells/mm3, and fewer than 121 days of previous zidovudine treatment. Interventions: Fifty-five patients received combination therapy with zidovudine and didanosine, and 14 received zidovudine therapy alone (600 mg/d). Daily dosages in milligrams of zidovudine and didanosine, respectively, in the five combination groups were 150 and 90 mg, 300 and 334 mg, 600 and 334 mg, 300 and 500 mg, and 600 and 500 mg. Measurements: CD4+ cell counts, HIV-1 RNA titers in plasma, and toxic effects. Results: The combination regimens were associated with higher and more sustained increases in CD4+ cells than zidovudine alone, even after adjustment for initial CD4+ counts and previous zidovudine therapy (P < 0.001). The median increase in CD4+ cell counts was 166 cells/mm3 with combination therapy and 77 cells/mm3 with zidovudine alone (P = 0.001) and did not differ statistically among the five combination regimens. Human immunodeficiency virus type 1 RNA titers in plasma decreased in 15 (83%) of 18 combination-therapy recipients compared with 2 of 7 zidovudine-alone recipients (P = 0.017). No pharmacokinetic interactions were seen between zidovudine and didanosine. Toxicity rates were low among all treatment groups. A greater decrease in hemoglobin levels was seen with the regimen using zidovudine alone (-8 g/L) compared with combination regimens using the same zidovudine dose (-1.5 g/L, P = 0.03). Conclusions: Combination therapy with zidovudine and didanosine produced larger and more sustained increases in CD4+ cell counts, more frequent decreases in plasma HIV-1 RNA titers, and more stable hematologic status than zidovudine therapy alone. The effects of this combination on the progression of HIV disease merit further study, to provide information about clinical outcome, because this was a relatively small study based on surrogate markers of HIV-1 infection.	UNIV WASHINGTON, PACIFIC MED CTR, SEATTLE, WA 98144 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA; UNIV MIAMI, SCH MED, MIAMI, FL 33152 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA; ABBOTT LABS, N CHICAGO, IL 60064 USA; UNIV WASHINGTON, HLTH SCI CTR SC42, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Miami; Tufts University; Tufts Medical Center; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Burroughs Wellcome Fund; Abbott Laboratories; University of Washington; University of Washington Seattle			Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NCRR NIH HHS [RR-37] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BOUCHER CAB, 1990, LANCET, V336, P585, DOI 10.1016/0140-6736(90)93391-2; CHOI SS, 1993, ANN INTERN MED, V118, P674, DOI 10.7326/0003-4819-118-9-199305010-00003; COOLEY TP, 1990, NEW ENGL J MED, V322, P1340, DOI 10.1056/NEJM199005103221902; COOMBS RW, 1993, IN PRESS J CLIN MICR; DORNSIFE RE, 1991, ANTIMICROB AGENTS CH, V35, P322, DOI 10.1128/AAC.35.2.322; FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; HENRARD DR, 1992, AIDS RES HUM RETROV, V8, P47, DOI 10.1089/aid.1992.8.47; JOHNSON VA, 1991, J INFECT DIS, V164, P646, DOI 10.1093/infdis/164.4.646; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KNUPP CA, 1990, J CHROMATOGR-BIOMED, V533, P282, DOI 10.1016/S0378-4347(00)82215-X; LAMBERT JS, 1990, NEW ENGL J MED, V322, P1333, DOI 10.1056/NEJM199005103221901; LAND S, 1990, J INFECT DIS, V161, P326, DOI 10.1093/infdis/161.2.326; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TADEPALLI SM, 1990, CLIN CHEM, V36, P897; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1990, LANCET, V336, P526, DOI 10.1016/0140-6736(90)92085-V	26	134	135	2	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					786	793		10.7326/0003-4819-119-8-199310150-00003	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379600				2022-12-28	WOS:A1993MB49600003
J	KIRSCHSTEIN, R				KIRSCHSTEIN, R			LARGEST UNITED-STATES CLINICAL-TRIAL EVER GETS UNDER WAY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KIRSCHSTEIN, R (corresponding author), NIH,BETHESDA,MD 20892, USA.								0	6	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1521	1521		10.1001/jama.270.13.1521	http://dx.doi.org/10.1001/jama.270.13.1521			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371454				2022-12-28	WOS:A1993LZ33400005
J	BLAIR, SN; SHATEN, J; BROWNELL, K; COLLINS, G; LISSNER, L				BLAIR, SN; SHATEN, J; BROWNELL, K; COLLINS, G; LISSNER, L			BODY-WEIGHT CHANGE, ALL-CAUSE MORTALITY, AND CAUSE-SPECIFIC MORTALITY IN THE MULTIPLE RISK FACTOR INTERVENTION TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							RESTING METABOLIC-RATE; HEALTH; VARIABILITY; WRESTLERS; EXERCISE; REGAIN; MRFIT; MEN	Objective: To evaluate the relation between weight variability and death in high-risk, middle-aged men participating in the Multiple Risk Factor Intervention Trial (MRFIT). Design: Cohort study with 3.8 years of follow-up. Setting. Multicenter, collaborative, primary prevention trial conducted at 22 clinical centers in the United States. Participants: Men (n = 10 529) who were 35 to 57 years old at baseline and who were in the upper 10% to 15% of risk for coronary heart disease because of smoking, high blood pressure, and elevated cholesterol level. Participants were seen at least annually for 6 to 7 years for medical evaluations in study clinical centers. Measurements. Death from cardiovascular disease (228 deaths) and from all causes (380 deaths). Results: The primary measure of weight variability was the intrapersonal standard deviation of weight (ISD), which was calculated from measured weights obtained at clinic visits during a 6- to 7-year period. All-cause death rates per 1000 person-years of follow-up across ISD quartiles were 8.28, 8.25,10.57, and 11.07 from the first to fourth quartiles, respectively. After adjusting for baseline risk factors associated with weight change, the relative risk for all-cause mortality in the fourth, compared with the first quartile was 1.64 (95% CI, 1.21 to 2.23). Cardiovascular death and ISD showed a similar pattern. The association between weight change and death was not observed in the heaviest men. Conclusion: Greater weight variability was associated with a greater risk for cardiovascular disease and all-cause mortality in some types of high-risk men.	UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; YALE UNIV, NEW HAVEN, CT 06520 USA	University of Minnesota System; University of Minnesota Twin Cities; Yale University	BLAIR, SN (corresponding author), COOPER INST AEROB RES, 12330 PRESTON RD, DALLAS, TX 75230 USA.							[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BENFARI RC, 1981, PREV MED, V10, P426, DOI 10.1016/0091-7435(81)90059-1; BROWNELL KD, 1989, MED CLIN N AM, V73, P185, DOI 10.1016/S0025-7125(16)30698-8; COX DR, 1972, J R STAT SOC B, V34, P187; GERARDOGETTENS T, 1991, AM J PHYSIOL, V260, pR518, DOI 10.1152/ajpregu.1991.260.3.R518; HAAN M, 1986, AM J EPIDEMIOL, V124, P513; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; JEBB SA, 1991, INT J OBESITY, V15, P367; KJELSBERG MO, 1990, JAMA-J AM MED ASSOC, V263, P1795; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; MELBY CL, 1990, AM J CLIN NUTR, V52, P409, DOI 10.1093/ajcn/52.3.409; MELLIN LM, 1986, DISORDERED EATING CH; PUGLIESE MT, 1987, PEDIATRICS, V80, P175; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; Statistical design considerations in the multiple risk factor intervention trial (MRFIT), 1977, J CHRON DIS, V30, P261; STEEN SN, 1988, JAMA-J AM MED ASSOC, V260, P47, DOI 10.1001/jama.260.1.47; VANDALE D, 1989, AM J CLIN NUTR, V49, P409, DOI 10.1093/ajcn/49.3.409; 1988, DHHS8850210 US DEP H; 1985, PROVISIONAL DATA HLT	23	220	222	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				749	757		10.7326/0003-4819-119-7_Part_2-199310011-00024	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00024			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363210				2022-12-28	WOS:A1993MA33000024
J	HOLDEN, C				HOLDEN, C			CAREERS 93 - A SURVIVAL GUIDE	SCIENCE			English	Editorial Material																			0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1765	&		10.1126/science.8378776	http://dx.doi.org/10.1126/science.8378776			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378776				2022-12-28	WOS:A1993LY58400035
J	FACELLI, JC; GRANT, DM				FACELLI, JC; GRANT, DM			DETERMINATION OF MOLECULAR SYMMETRY IN CRYSTALLINE NAPHTHALENE USING SOLID-STATE NMR	NATURE			English	Article							CHEMICAL-SHIFT TENSORS; AROMATIC-COMPOUNDS; C-13	DIFFRACTION techniques have shown that the crystal structure of naphthalene has a unit cell with C(i) symmetry1-7. These studies were unable, however, to resolve any departure of the molecular structure from the D2h symmetry observed in the gaseous state. We found recently8 that the solid-state C-13-nuclear magnetic resonance (NMR) chemical shifts for naphthalene exhibit the C(i) symmetry of the unit cell. If these chemical-shift data reflect structural distortions of the molecule, rather than simply intermolecular effects on the shifts owing to the C(i) symmetry of the environment of each molecule, one could assert that the NMR data are able to reveal structural information beyond the limits of the diffraction methods. Here we show that this is the case by performing ab initio quantum-mechanical calculations of the C-13 chemical shifts for naphthalene, and their derivatives, with respect to structural parameters. We find that intermolecular shift terms (which of necessity exhibit C(i) symmetry) can account for only about 30% of the maximum deviations from D2h symmetry; the remainder must therefore result from structural distortions of the molecules below D2h symmetry. This sensitivity of NMR chemical shifts to very small changes in molecular structure opens up the possibility of using solid-state NMR along with quantum-chemical methods to refine structural parameters obtained from diffraction methods.	UNIV UTAH,UTAH SUPERCOMP INST,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah	FACELLI, JC (corresponding author), UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112, USA.			facelli, julio/0000-0003-1449-477X				ABRAHAMS SC, 1949, ACTA CRYSTALLOGR, V2, P233, DOI 10.1107/S0365110X49000618; ALDERMAN DW, 1993, J MAGN RESON SER A, V101, P188, DOI 10.1006/jmra.1993.1029; Bragg W. H., 1921, P PHYS SOC LOND, V34, P33; BROCK CP, 1982, ACTA CRYSTALLOGR B, V38, P2218, DOI 10.1107/S0567740882008358; Chesnut D. B., 1989, ANN REP NMR SPECTROS, V21, P51, DOI DOI 10.1016/S0066-4103(08)60121-0; CRUICKSHANK DWJ, 1957, ACTA CRYSTALLOGR, V10, P504, DOI 10.1107/S0365110X57001826; DITCHFIELD R, 1974, MOL PHYS, V27, P789, DOI 10.1080/00268977400100711; Dunning Jr T.H., 1977, MODERN THEORE CHEM, V3, P1; GRANT DM, 1993, NATO ADV SCI INST SE, V386, P367; JAMESON AK, 1987, CHEM PHYS LETT, V134, P461, DOI 10.1016/0009-2614(87)87173-7; ORENDT AM, 1992, J AM CHEM SOC, V114, P2832, DOI 10.1021/ja00034a012; PAWLEY GS, 1969, ACTA CRYSTALL B-STRU, VB 25, P2009, DOI 10.1107/S0567740869005073; Ponomarev V. I., 1976, Soviet Physics - Crystallography, V21, P215; Robertson J. M., 1933, P R SOC LONDON A, V142, P674; SHERWOOD MH, 1991, J AM CHEM SOC, V113, P750, DOI 10.1021/ja00003a003; WOLINSKI K, 1990, J AM CHEM SOC, V112, P8251, DOI 10.1021/ja00179a005	16	90	90	0	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					325	327		10.1038/365325a0	http://dx.doi.org/10.1038/365325a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377823				2022-12-28	WOS:A1993LY49600046
J	STEERE, AC				STEERE, AC			SERONEGATIVE LYME-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PENICILLIN; ARTHRITIS				STEERE, AC (corresponding author), TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853				DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1988, LANCET, V1, P1191; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; KALISH R A, 1991, Arthritis and Rheumatism, V34, pS43; LIU N Y, 1989, Arthritis and Rheumatism, V32, pS46; SCHOEN RT, 1991, ARTHRITIS RHEUM, V34, P1056, DOI 10.1002/art.1780340817; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401	8	14	15	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1369	1369						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360974				2022-12-28	WOS:A1993LW34500038
J	STOLLBERGER, C; SLANY, J; SCHUSTER, I; LEITNER, H; WINKLER, WB; KARNIK, R				STOLLBERGER, C; SLANY, J; SCHUSTER, I; LEITNER, H; WINKLER, WB; KARNIK, R			THE PREVALENCE OF DEEP VENOUS THROMBOSIS IN PATIENTS WITH SUSPECTED PARADOXICAL EMBOLISM	ANNALS OF INTERNAL MEDICINE			English	Article						THROMBOPHLEBITIS; EMBOLISM; HEART SEPTAL DEFECTS, ATRIAL; ECHOCARDIOGRAPHY; PHLEBOGRAPHY	PATENT FORAMEN OVALE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; PULMONARY-EMBOLISM; VEIN THROMBOSIS; STROKE; ISCHEMIA; AUTOPSY	Objective: To determine the prevalence of venous thrombosis in patients with suspected paradoxical embolism. Design: Observational study. Patients: Two hundred sixty-four patients with clinically suspected embolic events underwent contrast transesophageal echocardiographic evaluation. Forty-nine patients (24 women, 25 men) had a patent foramen ovale. Forty-one patients had acute stroke, and 8 had acute limb ischemia. Setting. Echocardiography laboratory of a community hospital. Measurements: The presence of a patent foramen ovale was assessed by transesophageal contrast echocardiography. Forty-two patients had venographic evaluation of the lower-extremity venous system. Results: Venous thrombosis was clinically suspected in 6 patients and documented in 24 of the 42 patients with patent foramen ovale who underwent venographic study (57%; 95% CI, 41% to 72%). Venous thrombosis was confined to calf or popliteal veins in 15 cases. Fifteen of 17 patients who had venographic evaluation within 7 days of the index event had thrombosis compared with 9 of 25 patients who had later evaluations (P = 0.001). More patients with venous thrombosis than without venous thrombosis had a history of previous thromboembolism (13 of 24 compared with 1 of 8, respectively; P = 0.001). Conclusion: When a patent foramen ovale is detected in a patient with embolism, occult leg vein thrombosis is frequently present.			STOLLBERGER, C (corresponding author), KRANKENANSTALT RUDOLFSTIFTUNG WIEN, JUCHGASSE 25, A-1030 VIENNA, AUSTRIA.							ARCHER SL, 1991, CIRCULATION, V84, P693; ASINGER RW, 1989, ARCH NEUROL-CHICAGO, V46, P727; BILLER J, 1987, ARCH NEUROL-CHICAGO, V44, P740, DOI 10.1001/archneur.1987.00520190046016; DITULLIO M, 1992, ANN INTERN MED, V117, P461, DOI 10.7326/0003-4819-117-6-461; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB114, DOI 10.1016/S0735-1097(86)80013-4; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; INGELFINGER JA, 1987, BIOSTATISTICS CLIN M; KARNIK R, 1992, AM J CARDIOL, V69, P560, DOI 10.1016/0002-9149(92)91006-P; LECHAT P, 1988, NEW ENGL J MED, V318, P1148, DOI 10.1056/NEJM198805053181802; LEE RJ, 1991, STROKE, V22, P734, DOI 10.1161/01.STR.22.6.734; MCCARTHY ST, 1977, LANCET, V2, P800; PEARSON AC, 1991, J AM COLL CARDIOL, V17, P66, DOI 10.1016/0735-1097(91)90705-E; SANDLER DA, 1989, J ROY SOC MED, V82, P203, DOI 10.1177/014107688908200407; STAHL JA, 1990, CIRCULATION, V82, P109; STOLLBERGER C, 1993, AM J CARDIOL, V71, P604, DOI 10.1016/0002-9149(93)90521-D; TURPIE AGG, 1987, LANCET, V1, P523; WEBSTER MWI, 1988, LANCET, V2, P11; WITTLICH N, 1988, CIRCULATION, V78, P441; 1968, DOCUMENTA GEIGY WISS	20	159	165	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					461	465		10.7326/0003-4819-119-6-199309150-00003	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357111				2022-12-28	WOS:A1993LZ27500003
J	AUBOURG, P; ADAMSBAUM, C; LAVALLARDROUSSEAU, MC; ROCCHICCIOLI, F; CARTIER, N; JAMBAQUE, I; JAKOBEZAK, C; LEMAITRE, A; BOUREAU, F; WOLF, C; BOUGNERES, PF				AUBOURG, P; ADAMSBAUM, C; LAVALLARDROUSSEAU, MC; ROCCHICCIOLI, F; CARTIER, N; JAMBAQUE, I; JAKOBEZAK, C; LEMAITRE, A; BOUREAU, F; WOLF, C; BOUGNERES, PF			A 2-YEAR TRIAL OF OLEIC AND ERUCIC ACIDS (LORENZO OIL) AS TREATMENT FOR ADRENOMYELONEUROPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; FATTY-ACYL-COAS; PERIPHERAL-NERVE; MULTIPLE-SCLEROSIS; PROBABLE VARIANT; THERAPY; PLASMA; GENERATIONS; ELONGATION; MICROSOMES	Background. Adrenomyeloneuropathy is an X-linked recessive disorder characterized by myelopathy, peripheral neuropathy, and cerebral demyelination, which develop in association with the accumulation of very-long-chain fatty acids. The administration of oleic and erucic acids inhibits the synthesis of very-long-chain fatty acids. Recently such dietary treatment has been widely publicized as a possible cure for this disease. Methods. We conducted an open trial in 14 men with adrenomyeloneuropathy, 5 symptomatic heterozygous women, and 5 boys (mean age, 13 years) with preclinical adrenomyeloneuropathy. The patients ate a low-fat diet and received daily doses of glycerol trioleate oil (1.7 g per kilogram of body weight) and glycerol trierucate oil (0.3 g per kilogram). Clinical manifestations, cerebral and spinal cord magnetic resonance imaging (MRI) scans, nerve conduction, and brain-stem auditory and somatosensory evoked potentials were studied prospectively over 18 to 48 months. Plasma levels of very-long-chain fatty acids and the side effects of erucic acid were monitored monthly. Results. By week 10, plasma very-long-chain fatty acid levels declined nearly to normal. Nonetheless, over a mean follow-up of 33 months none of the 14 men with adrenomyeloneuropathy improved. In nine men there was functional deterioration, coincident in four with new cerebral lesions on MRI. In a single patient there was a reduction in cerebellar demyelination, but without clinical improvement. In one of the five asymptomatic boys signs of myelopathy developed. There were no changes in the symptomatic heterozygous women. There was some improvement in peroneal-nerve conduction, but no detectable clinical improvement. Conduction to the parietal cortex (T12-P37 interpeak latency) worsened in both the symptomatic men and the boys with preclinical adrenomyeloneuropathy. There was no change in other somatosensory evoked potentials or in brain-stem auditory evoked potentials. Asymptomatic thrombocytopenia (<100,000 cells per cubic millimeter) was noted in six patients. Conclusions. In this open trial we found no evidence of a clinically relevant benefit from dietary treatment with oleic and erucic acids (''Lorenzo's oil'') in patients with adrenomyeloneuropathy.	HOP ST VINCENT DE PAUL, DEPT RADIOL, F-75674 PARIS 14, FRANCE; HOP ST VINCENT DE PAUL, DEPT NEUROL, F-75674 PARIS 14, FRANCE; HOP ST VINCENT DE PAUL, DEPT PEDIAT ENDOCRINOL, F-75674 PARIS 14, FRANCE; HOP ST ANTOINE, DEPT NEUROPHYSIOL, F-75571 PARIS 12, FRANCE; HOP ST ANTOINE, DEPT BIOCHEM, F-75571 PARIS 12, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	AUBOURG, P (corresponding author), HOP ST VINCENT DE PAUL, INSERM, U342, 82 AVE DENFERT ROCHEREAU, F-75674 PARIS 14, FRANCE.		cartier, nathalie/C-3103-2012	cartier, nathalie/0000-0003-2298-5261				ALLEN JP, 1982, SOUTHERN MED J, V75, P877, DOI 10.1097/00007611-198207000-00031; ASKANAS V, 1979, NEW ENGL J MED, V301, P588, DOI 10.1056/NEJM197909133011105; AUBOURG P, 1992, NEUROLOGY, V42, P85, DOI 10.1212/WNL.42.1.85; AUBOURG P, 1990, NEW ENGL J MED, V322, P1860, DOI 10.1056/NEJM199006283222607; AUBOURG P, 1985, J LIPID RES, V26, P263; BERKOVIC SF, 1983, AUST NZ J MED, V13, P594, DOI 10.1111/j.1445-5994.1983.tb02611.x; BOURRE JM, 1976, BIOCHIM BIOPHYS ACTA, V424, P1, DOI 10.1016/0005-2760(76)90043-6; BROWN FR, 1982, JOHNS HOPKINS MED J, V151, P164; BUDKA H, 1976, J NEUROL, V213, P237, DOI 10.1007/BF00312873; CHAZOT G, 1979, REV NEUROL, V135, P211; DAVIS LE, 1979, AM J MED, V66, P342, DOI 10.1016/0002-9343(79)90562-X; DUPREY J, 1980, ANN ENDOCRINOL-PARIS, V41, P355; ELRINGTON GM, 1989, J NEUROL NEUROSUR PS, V52, P310, DOI 10.1136/jnnp.52.3.310; FEDERICO A, 1988, J INHERIT METAB DIS, V11, P169, DOI 10.1007/BF01804227; GASTAUT JL, 1988, REV NEUROL-FRANCE, V144, P338; GRIFFIN JW, 1977, NEUROLOGY, V27, P1107, DOI 10.1212/WNL.27.12.1107; GRIMES AM, 1983, ARCH NEUROL-CHICAGO, V40, P574, DOI 10.1001/archneur.1983.04050080074015; HARRISJONES JN, 1955, J CLIN ENDOCR METAB, V15, P739, DOI 10.1210/jcem-15-6-739; HAUSER SL, 1983, NEW ENGL J MED, V308, P173, DOI 10.1056/NEJM198301273080401; HOLMAN RT, 1979, AM J CLIN NUTR, V32, P2390, DOI 10.1093/ajcn/32.12.2390; JACK CR, 1990, RADIOLOGY, V176, P205, DOI 10.1148/radiology.176.1.2353093; JULIEN J, 1981, EUR NEUROL, V20, P367, DOI 10.1159/000115263; KURODA S, 1983, ACTA NEUROPATHOL, V60, P149, DOI 10.1007/BF00685361; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; MARSDEN CD, 1982, NEUROLOGY, V32, P1031, DOI 10.1212/WNL.32.9.1031; MARTIN JJ, 1982, J NEUROL, V226, P221, DOI 10.1007/BF00313395; MOSER AB, 1987, ANN NEUROL, V21, P240, DOI 10.1002/ana.410210305; Moser H. W., 1991, TREATMENT GENETIC DI, P111; MOSER HW, 1991, DEV NEUROSCI-BASEL, V13, P254, DOI 10.1159/000112170; MOSER HW, 1992, J INHERIT METAB DIS, V15, P645, DOI 10.1007/BF01799621; MOSER HW, 1989, METABOLIC BASIS INHE, V2, P1511; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; OHNO T, 1984, J NEUROL, V231, P167, DOI 10.1007/BF00313932; ONEILL BP, 1985, NEUROLOGY, V35, P1233, DOI 10.1212/WNL.35.8.1233; ONEILL BP, 1981, NEUROLOGY, V31, P151, DOI 10.1212/WNL.31.2.151; PECKHAM RS, 1982, AM J MED, V72, P173, DOI 10.1016/0002-9343(82)90606-4; PROBST A, 1980, ACTA NEUROPATHOL, V49, P105, DOI 10.1007/BF00690750; RIZZO WB, 1986, NEUROLOGY, V36, P357, DOI 10.1212/WNL.36.3.357; RIZZO WB, 1989, NEUROLOGY, V39, P1415, DOI 10.1212/WNL.39.11.1415; RIZZO WB, 1987, ANN NEUROL, V21, P232, DOI 10.1002/ana.410210304; ROBB RA, 1989, IEEE T MED IMAGING, V8, P217, DOI 10.1109/42.34710; RONDOT P, 1984, ANN MED INTERNE, V135, P542; ROSEN FS, 1993, NATURE, V361, P695; ROUAUD R, 1986, REV FR ENDOCRINOL CL, V27, P509; SAITOH T, 1988, BIOCHIM BIOPHYS ACTA, V960, P410; SCHAUMBURG HH, 1977, NEUROLOGY, V27, P1114, DOI 10.1212/WNL.27.12.1114; TANAKA K, 1985, J NEUROL, V232, P73, DOI 10.1007/BF00313904; UZIEL G, 1991, DEV NEUROSCI-BASEL, V13, P274, DOI 10.1159/000112173; VERCRUYSSEN A, 1982, J NEUROL SCI, V56, P327, DOI 10.1016/0022-510X(82)90153-8; ZINKHAM WH, 1993, NEW ENGL J MED, V328, P1126, DOI 10.1056/NEJM199304153281513	50	183	189	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					745	752		10.1056/NEJM199309093291101	http://dx.doi.org/10.1056/NEJM199309093291101			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350883	Bronze			2022-12-28	WOS:A1993LV64200001
J	FU, XD				FU, XD			SPECIFIC COMMITMENT OF DIFFERENT PREMESSENGER RNAS TO SPLICING BY SINGLE SR PROTEINS	NATURE			English	Article							TRACT-BINDING PROTEIN; POLYPYRIMIDINE TRACT; CONSERVED FAMILY; FACTOR SC35; COMPLEXES; COMPONENTS; NUCLEUS; SITE; SF2; U1	HIGHER eukaryotic cells express a family of essential splicing factors with a characteristic RNA-binding domain and serine/arginine-rich (SR) motif. These SR proteins, which include SC35(2-6) and SF2/ASF7-12, are conserved from Drosophila to man, are required for early steps of spliceosome assembly, and can influence splice-site selections. To address their mechanisms of action, SR proteins were examined for their role in committing pre-messenger RNA to the splicing pathway. I report here that SC35 was sufficient on its own to form a committed complex with human beta-globin pre-mRNA. Examination of other SR proteins and pre-mRNA substrates revealed that single SR proteins committed different pre-mRNAs to splicing with pronounced substrate specificity. These results suggest that splicing of different pre-mRNAs may require distinct sets of SR proteins, and that the commitment by SR proteins may be a critical step at which alternative and tissue-specific splicing is regulated.			FU, XD (corresponding author), UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.							BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BENNETT M, 1992, MOL CELL BIOL, V12, P3156; CHOI YD, 1986, SCIENCE, V231, P1534, DOI 10.1126/science.3952495; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GE H, 1991, CELL, V66, P372; GIL A, 1991, GENE DEV, V5, P1224, DOI 10.1101/gad.5.7.1224; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; MING T, 1993, CELL, V74, P105; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	25	253	264	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					82	85		10.1038/365082a0	http://dx.doi.org/10.1038/365082a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361546				2022-12-28	WOS:A1993LV64600060
J	RIVO, ML; JACKSON, DM; CLARE, FL				RIVO, ML; JACKSON, DM; CLARE, FL			COMPARING PHYSICIAN WORKFORCE REFORM RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											RIVO, ML (corresponding author), US HLTH RESOURCES & SERV ADM,BUR HLTH PROFESS,DIV MED,5600 FISHERS LN,ROOM 4C-25,ROCKVILLE,MD 20857, USA.							MACY J, 1992, J MACY JR F ANN REPO; 1993, 1993 ANN REPORT C; 1992, IMPROVING ACCESS HLT; 1993, PRIMARY CARE WORKFOR	4	51	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1083	1084		10.1001/jama.270.9.1083	http://dx.doi.org/10.1001/jama.270.9.1083			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350452				2022-12-28	WOS:A1993LU51200010
J	VANDEURSEN, J; HEERSCHAP, A; OERLEMANS, F; RUITENBEEK, W; JAP, P; TERLAAK, H; WIERINGA, B				VANDEURSEN, J; HEERSCHAP, A; OERLEMANS, F; RUITENBEEK, W; JAP, P; TERLAAK, H; WIERINGA, B			SKELETAL-MUSCLES OF MICE DEFICIENT IN MUSCLE CREATINE-KINASE LACK BURST ACTIVITY	CELL			English	Article							NUCLEAR MAGNETIC-RESONANCE; BETA-GUANIDINOPROPIONIC ACID; EMBRYONIC STEM-CELLS; M-LINE; SATURATION-TRANSFER; ENERGY-TRANSPORT; RAT MUSCLE; PHOSPHOCREATINE; METABOLISM; SHUTTLE	To understand the physiological role of the creatine kinase-phosphocreatine (CK-PCr) system in muscle bioenergetics, a null mutation of the muscle CK (M-CK) gene was introduced into the germline of mice. Mutant mice show no alterations in absolute muscle force, but lack the ability to perform burst activity. Their fast-twitch fibers have an increased intermyofibrillar mitochondrial volume and an increased glycogenolytic/glycolytic potential. PCr and ATP levels are normal in resting M-CK-deficient muscles, but rates of high energy phosphate exchange between PCr and ATP are at least 20-fold reduced. Strikingly, PCr levels decline normally during muscle exercise, suggesting that M-CK-mediated conversion is not the only route for PCr utilization in active muscle.	CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT DIAGNOST RADIOL, 6500 HB NIJMEGEN, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT PAEDIAT, 6500 HB NIJMEGEN, NETHERLANDS; CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT NEUROL, 6500 HB NIJMEGEN, NETHERLANDS	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	VANDEURSEN, J (corresponding author), CATHOLIC UNIV NIJMEGEN, FAC MED SCI, DEPT CELL BIOL & HISTOL, 6500 HB NIJMEGEN, NETHERLANDS.		Heerschap, Arend/G-5228-2010; Wieringa, Berend/A-5346-2011	Wieringa, Berend/0000-0001-9192-8020				ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; BESSMAN SP, 1985, ANNU REV BIOCHEM, V54, P831, DOI 10.1146/annurev.bi.54.070185.004151; BLONDET P, 1987, J MAGN RESON, V71, P342, DOI 10.1016/0022-2364(87)90066-7; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BROSNAN MJ, 1993, AM J PHYSIOL, V264, pC151, DOI 10.1152/ajpcell.1993.264.1.C151; BROWN TR, 1977, P NATL ACAD SCI USA, V74, P3627, DOI 10.1073/pnas.74.9.3627; BUSKIN JN, 1985, J MOL EVOL, V22, P334, DOI 10.1007/BF02115689; CHANCE B, 1986, P NATL ACAD SCI USA, V83, P9458, DOI 10.1073/pnas.83.24.9458; CHEVLI R, 1979, BIOCHEM MED METAB B, V21, P162, DOI 10.1016/0006-2944(79)90068-1; COOPERSTEIN SJ, 1951, J BIOL CHEM, V189, P665; DANTZIG JA, 1991, J PHYSIOL-LONDON, V432, P639, DOI 10.1113/jphysiol.1991.sp018405; DAVULURI SP, 1981, COMP BIOCHEM PHYS B, V69, P329, DOI 10.1016/0305-0491(81)90322-9; DEGENS H, 1993, MECH AGEING DEV, V66, P299, DOI 10.1016/0047-6374(93)90016-K; DUBOWITZ V, 1985, MUSCLE BIOPSY MODERN; DUNN JF, 1991, BIOCHIM BIOPHYS ACTA, V1096, P115, DOI 10.1016/0925-4439(91)90048-E; FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735; FITCH CD, 1974, J BIOL CHEM, V249, P1060; FITCH CD, 1980, METABOLISM, V29, P686, DOI 10.1016/0026-0495(80)90115-8; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GADIAN DG, 1981, BIOCHEM J, V194, P215, DOI 10.1042/bj1940215; GORI Z, 1988, BRIT J EXP PATHOL, V69, P639; Heerschap A, 1988, NMR Biomed, V1, P27, DOI 10.1002/nbm.1940010106; HSIEH PS, 1988, MAGNET RESON MED, V7, P56, DOI 10.1002/mrm.1910070107; IYENGAR MR, 1984, J MUSCLE RES CELL M, V5, P527, DOI 10.1007/BF00713259; JACOBUS WE, 1985, BIOCHEM BIOPH RES CO, V133, P1035, DOI 10.1016/0006-291X(85)91240-9; KORETSKY AP, 1985, MAGNET RESON MED, V2, P586, DOI 10.1002/mrm.1910020610; KUSHMERICK MJ, 1985, AM J PHYSIOL, V248, pC542, DOI 10.1152/ajpcell.1985.248.5.C542; KUSHMERICK MJ, 1992, P NATL ACAD SCI USA, V89, P7521, DOI 10.1073/pnas.89.16.7521; Lillie RD, 1976, HISTOPATHOLOGIC TECH, V4th; MAINWOOD GW, 1982, CAN J PHYSIOL PHARM, V60, P98, DOI 10.1139/y82-016; MATTHEWS PM, 1982, BIOCHIM BIOPHYS ACTA, V721, P312, DOI 10.1016/0167-4889(82)90084-2; Maughan D, 1989, Prog Clin Biol Res, V315, P137; MCGILVERY RW, 1974, J BIOL CHEM, V249, P5845; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MEYER RA, 1984, AM J PHYSIOL, V246, pC365, DOI 10.1152/ajpcell.1984.246.5.C365; MEYER RA, 1982, AM J PHYSIOL, V242, pC1, DOI 10.1152/ajpcell.1982.242.1.C1; MEYER RA, 1985, AM J PHYSIOL, V248, pC279, DOI 10.1152/ajpcell.1985.248.3.C279; MEYER RA, 1986, AM J PHYSIOL, V250, pC264, DOI 10.1152/ajpcell.1986.250.2.C264; REES D, 1989, MAGNET RESON MED, V9, P39, DOI 10.1002/mrm.1910090107; SAKS VA, 1976, FEBS LETT, V62, P293, DOI 10.1016/0014-5793(76)80078-6; Sambrook J, 1989, MOL CLONING LABORATO; SHOUBRIDGE EA, 1985, BIOCHEM J, V232, P125, DOI 10.1042/bj2320125; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P72, DOI 10.1016/0167-4889(84)90038-7; SHOUBRIDGE EA, 1987, AM J PHYSIOL, V252, pC532, DOI 10.1152/ajpcell.1987.252.5.C532; SHOUBRIDGE EA, 1984, BIOCHIM BIOPHYS ACTA, V805, P79, DOI 10.1016/0167-4889(84)90039-9; SMEITINK J, 1992, ANN CLIN BIOCHEM, V29, P196, DOI 10.1177/000456329202900213; Srere PA., 1969, METHODS ENZYMOLOGY, P3, DOI DOI 10.1016/0076-6879(69)13005-0; TURNER DC, 1973, P NATL ACAD SCI USA, V70, P702, DOI 10.1073/pnas.70.3.702; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; VANDEURSEN J, 1992, GENOMICS, V12, P340, DOI 10.1016/0888-7543(92)90383-4; VANDEURSEN J, 1991, NUCLEIC ACIDS RES, V19, P2637, DOI 10.1093/nar/19.10.2637; VEECH RL, 1979, J BIOL CHEM, V254, P6538; WALLIMANN T, 1983, J MUSCLE RES CELL M, V4, P429, DOI 10.1007/BF00711948; WALLIMANN T, 1978, P NATL ACAD SCI USA, V75, P4296, DOI 10.1073/pnas.75.9.4296; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WALLIMANN T, 1984, J BIOL CHEM, V259, P5238; Wallimann T, 1989, Prog Clin Biol Res, V315, P159; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; YAMASHITA K, 1991, J MUSCLE RES CELL M, V12, P37, DOI 10.1007/BF01781172; YOSHIZAKI K, 1990, BIOCHIM BIOPHYS ACTA, V1051, P144, DOI 10.1016/0167-4889(90)90186-H; ZAHLER R, 1992, AM J PHYSIOL, V262, pH1022, DOI 10.1152/ajpheart.1992.262.4.H1022; ZWEIER JL, 1991, J BIOL CHEM, V266, P20296	64	278	285	1	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					621	631		10.1016/0092-8674(93)90510-W	http://dx.doi.org/10.1016/0092-8674(93)90510-W			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358791				2022-12-28	WOS:A1993LU59200006
J	COX, GA; COLE, NM; MATSUMURA, K; PHELPS, SF; HAUSCHKA, SD; CAMPBELL, KP; FAULKNER, JA; CHAMBERLAIN, JS				COX, GA; COLE, NM; MATSUMURA, K; PHELPS, SF; HAUSCHKA, SD; CAMPBELL, KP; FAULKNER, JA; CHAMBERLAIN, JS			OVEREXPRESSION OF DYSTROPHIN IN TRANSGENIC MDX MICE ELIMINATES DYSTROPHIC SYMPTOMS WITHOUT TOXICITY	NATURE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; EXPRESSION; MOUSE; GLYCOPROTEIN; PROTEIN; DEFICIENCY; MEMBRANE; COMPLEX	DUCHENNE and Becker muscular dystrophy (DMD and BMD) are X-linked recessive diseases caused by defective expression of dystrophin1,2. The mdx mouse, an animal model for DMD, has a mutation that eliminates expression of the 427K muscle and brain isoforms of dystrophin1,3,4. Although these animals do not display overt muscle weakness or impaired movement, the diaphragm muscle of the mdx mouse is severely affected and shows progressive myofibre degeneration and fibrosis which closely resembles the human disease5,6. Here we explore the feasibility of gene therapy for DMD by examining the potential of a full-length dystrophin transgene to correct dystrophic symptoms in mdx mice. We find that expression of dystrophin in muscles of transgenic mdx mice eliminates the morphological and immunohistological symptoms of muscular dystrophy. In addition, overexpression of dystrophin prevents the development of the abnormal mechanical properties associated with dystrophic muscle without causing deleterious side effects. Our results provide functional evidence for the feasibility of gene therapy for DMD.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,INST GERONTOL,ANN ARBOR,MI 48109; UNIV MICHIGAN,SCH MED,CTR HUMAN GENOME,ANN ARBOR,MI 48109; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Iowa; University of Iowa; University of Washington; University of Washington Seattle				Campbell, Kevin/0000-0003-2066-5889; Chamberlain, Jeffrey/0000-0001-5299-0059				AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; BROOKS SV, 1991, J PHYSIOL-LONDON, V436, P701, DOI 10.1113/jphysiol.1991.sp018574; CHAMBERLAIN JS, 1993, MOL CELL BIOL MUSCUL, P167; CHAPMAN VM, 1989, P NATL ACAD SCI USA, V86, P1292, DOI 10.1073/pnas.86.4.1292; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; EMERY AEH, 1987, OXFORD MONOG MED GEN, V15; ERVASTI JM, 1991, J BIOL CHEM, V266, P9161; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FAULKNER JA, 1990, AM J PHYSIOL, V259, P259; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOGAN B, 1986, MANIPULATING MOUSE E; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; JAYNES JB, 1986, MOL CELL BIOL, V6, P2855, DOI 10.1128/MCB.6.8.2855; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; LEE CC, 1991, NATURE, V349, P334, DOI 10.1038/349334a0; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; OHLENDIECK K, 1991, NEURON, V7, P499, DOI 10.1016/0896-6273(91)90301-F; OHLENDIECK K, 1993, NEUROLOGY, V43, P795, DOI 10.1212/WNL.43.4.795; OHLENDIECK K, 1991, J CELL BIOL, V115, P1685, DOI 10.1083/jcb.115.6.1685; PARTRIDGE T, 1991, NEUROPATH APPL NEURO, V17, P353, DOI 10.1111/j.1365-2990.1991.tb00735.x; RAGOT T, 1993, NATURE, V361, P647, DOI 10.1038/361647a0; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; WATKINS SC, 1989, MUSCLE NERVE, V12, P861, DOI 10.1002/mus.880121013; WELLS DJ, 1992, HUM MOL GENET, V1, P35	27	253	261	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					725	729		10.1038/364725a0	http://dx.doi.org/10.1038/364725a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355788	Green Published			2022-12-28	WOS:A1993LT67700061
J	TUCKER, PK; LUNDRIGAN, BL				TUCKER, PK; LUNDRIGAN, BL			RAPID EVOLUTION OF THE SEX-DETERMINING LOCUS IN OLD-WORLD MICE AND RATS	NATURE			English	Article							MYOTONIC-DYSTROPHY; DETERMINING REGION; Y-CHROMOSOME; CTG REPEAT; FRAGILE-X; GENE; SRY; INSTABILITY; EXPANSION; MUTATION	THE Y chromosome-linked sex determining locus (Sry) responsible for testis determination in mammals1-5 contains a DNA-binding motif (HMG box) that is conserved across species of marsupial and placental mammals (infraclasses Metatheria and Eutheria, respectively)1,4,6,7. But little to no sequence similarity is observed in flanking sequences between these two infraclasses, or among orders within each infraclass. We investigated the rate and pattern of evolution for the coding sequence of Sry in Old World mice and rats (subfamily Murinae). We found typical rates of synonymous substitution throughout the gene, but high rates of non-synonymous substitution, especially in the C-terminal (non-HMG box) region, when compared to other genes8. This region is also characterized by a frame-shift mutation and variation in a trinucleotide repeat motif. These data suggest that the non-box region is either functionally unconstrained or has undergone species-specific adaptive divergence.	UNIV MICHIGAN, DEPT BIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	TUCKER, PK (corresponding author), UNIV MICHIGAN, MUSEUM ZOOL, ANN ARBOR, MI 48109 USA.							ALTSCHUL SF, 1986, B MATH BIOL, V48, P603, DOI 10.1016/S0092-8240(86)90010-8; ASLANIDIS C, 1992, NATURE, V355, P548, DOI 10.1038/355548a0; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BUXTON J, 1992, NATURE, V355, P547, DOI 10.1038/355547a0; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; Jukes T., 1969, MAMMALIAN PROTEIN ME, P21; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LOVELLBADGE R, 1993, PHILOS T R SOC B, V339, P159, DOI 10.1098/rstb.1993.0012; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; NEI M, 1986, MOL BIOL EVOL, V3, P418; OHUIGIN C, 1992, J MOL EVOL, V35, P377, DOI 10.1007/BF00171816; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SU H, 1993, AM J HUM GENET, V52, P24; TUCKER PK, 1992, MAMM GENOME, V3, P254, DOI 10.1007/BF00292153; TUCKER PK, 1993, METHOD ENZYMOL, V224, P517, DOI 10.1016/0076-6879(93)24038-V; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; 1993, HUNTINGTONS DISEASE, V72, P971	27	214	220	0	10	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					715	717		10.1038/364715a0	http://dx.doi.org/10.1038/364715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355784	Green Published			2022-12-28	WOS:A1993LT67700057
J	HAM, C				HAM, C			RATIONING IN ACTION - PRIORITY SETTING IN THE NHS - REPORTS FROM 6 DISTRICTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article								District health authorities must make choices on the use of their funds and the priorities that should be pursued. In future they may be able to place greater weight on the views of local people and evidence on cost effectiveness of different services. This paper reviews developments in a recent study of six district health authorities with an interest in priority setting. On the whole they had avoided excluding services entirely from their contracts; they experienced difficulty in comparing different services, and made more progress by analysing priorities within individual service areas than by comparing quite different services. The absence of information to guide priority setting was a major problem. A major effort had been made to involve the public in decision making, and a range of tools and methods developed to support work on priority setting. The impact of the work done so far has varied; district health authorities are still at an early stage in developing their work on priority setting.			HAM, C (corresponding author), UNIV BIRMINGHAM, CTR HLTH SERV MANAGEMENT, BIRMINGHAM B15 2RT, ENGLAND.							HAM C, IN PRESS PRIORITY SE; Ham C, 1988, HLTH CARE VARIATIONS; HEGINBOTHAM C, 1992, PURCHASING DILEMMAS; 1992, CHOICES HLTH CARE; 1992, CORE SERVICES 1993 4; 1993, EFFECTIVE HLTH CARE	6	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	1993	307	6901					435	438		10.1136/bmj.307.6901.435	http://dx.doi.org/10.1136/bmj.307.6901.435			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374459	Green Published, Bronze			2022-12-28	WOS:A1993LR89500024
J	POTTS, SR				POTTS, SR			SECONDARY SYPHILIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											POTTS, SR (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL 60611, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1993	329	3					176	176						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL460	8355764				2022-12-28	WOS:A1993LL46000006
J	ERREDE, B; GARTNER, A; ZHOU, ZQ; NASMYTH, K; AMMERER, G				ERREDE, B; GARTNER, A; ZHOU, ZQ; NASMYTH, K; AMMERER, G			MAP KINASE-RELATED FUS3 FROM SACCHAROMYCES-CEREVISIAE IS ACTIVATED BY STE7 INVITRO	NATURE			English	Article							SIGNAL TRANSDUCTION; YEAST; CLN2; GENE	PHEROMONE-STIMULATED haploid yeast cells undergo a differentiation process that allows them to mate1. Transmission of the intracellular signal involves threonine and tyrosine phosphorylation of the redundant FUS3 and KSS1 kinases, which are members. of the MAP kinase family2-4. FUS3/KSS1 phosphorylation depends on two additional kinases, STE11 and STE7 (refs 2, 5, 6). Genetic analyses predict an ordered pathway where STE11 acts before STE7 and FUS3/KSS1 (refs 2, 7). Here we report that STE7 is a dual-specificity kinase that modifies FUS3 at the appropriate sites and stimulates its catalytic activity in vitro. From these data and previous genetic results, we argue that STE7 is the physiological activator of FUS3. Recent indications that MA kinase activators are related to STE7 suggest that signal transduction pathways in many, if not all, eukaryotic organisms use homologous kinase cascades8-10.	INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599; UNIV VIENNA,INST ALLGEMEINE BIOCHEM,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,LUDWIG BOLTZMANN FORSCHUNGSSTELLE,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of North Carolina; University of North Carolina Chapel Hill; University of Vienna; Ludwig Boltzmann Institute; University of Vienna				Gartner, Anton/0000-0003-4639-9902; Nasmyth, Kim/0000-0001-7030-4403				BOULTON TG, 1990, SCIENCE, V249, P476; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GEITZ RD, 1988, GENE, V74, P527; HOWE LR, 1992, CELL, V71, P355; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; NAKIELNY S, 1992, FEBS LETT, V308, P183, DOI 10.1016/0014-5793(92)81271-M; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; WU J, 1992, BIOCHEM J, V285, P701, DOI 10.1042/bj2850701; ZHOU Z, IN PRESS MOL CELL BI	21	160	165	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					261	264		10.1038/362261a0	http://dx.doi.org/10.1038/362261a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8384702				2022-12-28	WOS:A1993KT02600061
J	DIMARIO, JX; FERNYAK, SE; STOCKDALE, FE				DIMARIO, JX; FERNYAK, SE; STOCKDALE, FE			MYOBLASTS TRANSFERRED TO THE LIMBS OF EMBRYOS ARE COMMITTED TO SPECIFIC FIBER FATES	NATURE			English	Article							MYOGENIC CELL LINEAGES; SKELETAL-MUSCLE FIBERS; HEAVY-CHAIN ISOFORMS; THYROID-HORMONE; NEURAL CONTROL; AVIAN LIMB; MYOSIN; EXPRESSION	IN the limb bud of the 5-day-old avian embryo, when primary muscle fibre formation is beginning and before specific muscles appear, differences in the expression of fast and slow myosin heavy chain genes can be detected among primary fibres of the premuscle masses1,2. Myoblasts that form colonies of fibres of specific types can be isolated from these limb buds3. To assess the role of myoblast commitment in specifying fibre types during embryonic development, we cloned myoblasts of specific types from embryonic and adult muscles, transfected them with a reporter gene, and transferred them into developing limb buds. After transfer, cloned myoblasts formed fibres in the limb with the same patterns of myosin heavy chain gene expression as the fibres they formed in cell culture. These results demonstrate that initial skeletal muscle fibre type diversity during avian limb development can originate, in part, from the commitment of distinct myoblast types to the formation of specific fibre types.	STANFORD UNIV,MED CTR,SCH MED,STANFORD,CA 94305	Stanford University								BUTLER J, 1988, DEVELOPMENT, V102, P763; CROW MT, 1986, DEV BIOL, V113, P238, DOI 10.1016/0012-1606(86)90126-0; EVERETT AW, 1984, BIOCHEMISTRY-US, V23, P1596, DOI 10.1021/bi00303a002; FELDMAN JL, 1991, DEV BIOL, V143, P320, DOI 10.1016/0012-1606(91)90083-F; GAUTHIER GF, 1984, DEV BIOL, V105, P144, DOI 10.1016/0012-1606(84)90270-7; HARRIS AJ, 1989, DEVELOPMENT, V107, P751; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; MCLENNAN IS, 1983, DEV BIOL, V98, P287, DOI 10.1016/0012-1606(83)90359-7; MILLER JB, 1989, DEV BIOL, V136, P393, DOI 10.1016/0012-1606(89)90265-0; MILLER JB, 1986, J CELL BIOL, V103, P2197, DOI 10.1083/jcb.103.6.2197; MILLER JB, 1986, P NATL ACAD SCI USA, V83, P3860, DOI 10.1073/pnas.83.11.3860; ORDAHL CP, 1986, UCLA S MOL CELL BIOL, V29, P547; PAGE S, 1992, DEV BIOL, V154, P118, DOI 10.1016/0012-1606(92)90053-J; PETTE D, 1985, MUSCLE NERVE, V8, P676, DOI 10.1002/mus.880080810; SOFER W, 1968, J BIOL CHEM, V243, P3110; STOCKDALE FE, 1987, DEV BIOL, V123, P1, DOI 10.1016/0012-1606(87)90420-9; STOCKDALE FE, 1992, DEV BIOL, V154, P284, DOI 10.1016/0012-1606(92)90068-R	18	91	91	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					165	167		10.1038/362165a0	http://dx.doi.org/10.1038/362165a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8383807				2022-12-28	WOS:A1993KR02800062
J	ITOHARA, S; MOMBAERTS, P; LAFAILLE, J; IACOMINI, J; NELSON, A; CLARKE, AR; HOOPER, ML; FARR, A; TONEGAWA, S				ITOHARA, S; MOMBAERTS, P; LAFAILLE, J; IACOMINI, J; NELSON, A; CLARKE, AR; HOOPER, ML; FARR, A; TONEGAWA, S			T-CELL RECEPTOR DELTA-GENE MUTANT MICE - INDEPENDENT GENERATION OF ALPHA-BETA T-CELLS AND PROGRAMMED REARRANGEMENTS OF GAMMA-DELTA TCR GENES	CELL			English	Article							DENDRITIC EPIDERMAL-CELLS; JUNCTIONAL SEQUENCES; ANTIGEN RECEPTORS; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; CHAIN DIVERSITY; STEM-CELLS; SCID MICE; EXPRESSION; THYMOCYTES	T cells bearing T cell receptor (TCR) gamma and delta chain heterodimers are first generated early in ontogeny. They form distinct subsets that differ in their TCR repertoires and tissue distribution. Disruption of the mouse TCR Cdelta gene segment by a gene targeting method caused the complete loss of T cells bearing TCR gammadelta chains, but had little or no effect on the development of T cells bearing TCR alphabeta chains. The analyses of TCR gamma and delta genes in the mutant mice suggest that intracellular mechanisms acting at the level of DNA rearrangement play key roles in the differential gamma and delta gene rearrangements and in the generation of the highly restricted junctional sequences during fetal thymic development.	MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195; UNIV EDINBURGH,AGR & FOOD RES COUNCIL,CTR GENOME RES,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); University of Washington; University of Washington Seattle; University of Edinburgh			Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014; Itohara, Shigeyoshi/I-8769-2012	Itohara, Shigeyoshi/0000-0002-2410-9989; Clarke, Alan/0000-0002-4281-426X				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; AVNER PR, 1978, IMMUNOGENETICS, V7, P103, DOI 10.1007/BF01843995; BONNEVILLE M, 1990, J EXP MED, V171, P1015, DOI 10.1084/jem.171.4.1015; BONNEVILLE M, 1989, NATURE, V342, P931, DOI 10.1038/342931a0; BOORSMA DM, 1986, J MICROSC-OXFORD, V143, P197, DOI 10.1111/j.1365-2818.1986.tb02777.x; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; ELLIOTT JF, 1988, NATURE, V331, P627; FARR AG, 1991, J HISTOCHEM CYTOCHEM, V40, P651; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; FERRICK DA, 1989, CELL, V57, P483, DOI 10.1016/0092-8674(89)90923-9; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; GARMAN RD, 1986, CELL, V45, P733, DOI 10.1016/0092-8674(86)90787-7; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HAVRAN WL, 1990, NATURE, V344, P68, DOI 10.1038/344068a0; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; IKUTA K, 1990, CELL, V62, P863, DOI 10.1016/0092-8674(90)90262-D; ISHIDA I, 1990, P NATL ACAD SCI USA, V87, P3067, DOI 10.1073/pnas.87.8.3067; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITOHARA S, 1989, P NATL ACAD SCI USA, V86, P5094, DOI 10.1073/pnas.86.13.5094; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; IWASATO T, 1992, EUR J IMMUNOL, V22, P101, DOI 10.1002/eji.1830220116; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KORMAN AJ, 1988, J EXP MED, V168, P1021, DOI 10.1084/jem.168.3.1021; KUBO RT, 1989, J IMMUNOL, V142, P2736; LACY MJ, 1989, P NATL ACAD SCI USA, V86, P1023, DOI 10.1073/pnas.86.3.1023; LAFAILLE JJ, 1990, IMMUNOL TODAY, V11, P75, DOI 10.1016/0167-5699(90)90030-D; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MAEDA K, 1987, P NATL ACAD SCI USA, V84, P6536, DOI 10.1073/pnas.84.18.6536; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NIXONFULTON JL, 1988, J IMMUNOL, V141, P1897; PARDOLL DM, 1987, NATURE, V326, P79, DOI 10.1038/326079a0; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; RAULET DH, 1985, NATURE, V314, P103, DOI 10.1038/314103a0; ROTHENBERG E, 1983, J IMMUNOL, V130, P1627; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TAKAGAKI Y, 1989, J IMMUNOL, V142, P2112; WINOTO A, 1989, NATURE, V338, P430, DOI 10.1038/338430a0	51	468	471	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					337	348		10.1016/0092-8674(93)90112-4	http://dx.doi.org/10.1016/0092-8674(93)90112-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381716				2022-12-28	WOS:A1993KM16200005
J	LU, Y; HALL, T; GAY, LS; DONELSON, JE				LU, Y; HALL, T; GAY, LS; DONELSON, JE			POINT MUTATIONS ARE ASSOCIATED WITH A GENE DUPLICATION LEADING TO THE BLOOD-STREAM REEXPRESSION OF A TRYPANOSOME METACYCLIC VSG	CELL			English	Article							SURFACE GLYCOPROTEIN GENE; VARIABLE ANTIGEN TYPES; BRUCEI-RHODESIENSE; BLOOD-STREAM; EXPRESSION; CONVERSION; DNA; TRANSCRIPTION; PSEUDOGENES; EQUIPERDUM	African trypanosomes evade the immune response of their hosts by sequentially expressing different variant surface glycoproteins (VSGs). We isolated a bloodstream trypanosome clone of Trypanosoma brucei rhodesiense that expresses a VSG normally present during the metacyclic stage of the parasite in the insect vector. Associated with the bloodstream reexpression of this metacyclic VSG is a gene conversion in which the duplicated, expressed gene of 1650 nt contains 11 scattered point mutations when compared with its donor gene. Analysis of an uncloned population of bloodstream trypanosomes revealed another VSG reexpressor of the same donor gene in which the coding region had undergone 24 point mutations. The mutations are unique to the duplicated gene and appear to be nontemplated. The generation of these mutations provides a way for the trypanosome to increase further its antigenic diversity.	UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52242; HOWARD HUGHES MED INST,IOWA CITY,IA 52242; WALTER REED ARMY INST RES,DEPT IMMUNOL,DIV COMMUNICABLE DIS & IMMUNOL,WASHINGTON,DC 20307	University of Iowa; Howard Hughes Medical Institute; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	LU, Y (corresponding author), UNIV IOWA,GENET PHD PROGRAM,IOWA CITY,IA 52242, USA.		Donelson, John E/F-5795-2010					BALTZ T, 1991, EMBO J, V10, P1653, DOI 10.1002/j.1460-2075.1991.tb07688.x; BARNES DA, 1990, MOL BIOCHEM PARASIT, V41, P101, DOI 10.1016/0166-6851(90)90101-Q; BLACKBURN EH, 1984, CELL, V36, P447, DOI 10.1016/0092-8674(84)90238-1; BORST P, 1982, MOL BIOCHEM PARASIT, V6, P13, DOI 10.1016/0166-6851(82)90049-4; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BORST P, 1983, GENETIC REARRANGEMEN, P207; CAMPBELL GH, 1979, AM J TROP MED HYG, V28, P974, DOI 10.4269/ajtmh.1979.28.974; CROWE JS, 1983, NATURE, V306, P389, DOI 10.1038/306389a0; DELAUW MF, 1987, MOL BIOCHEM PARASIT, V23, P9, DOI 10.1016/0166-6851(87)90181-2; DONELSON JE, 1985, MICROBIOL REV, V49, P107, DOI 10.1128/MMBR.49.2.107-125.1985; ESSER KM, 1982, J IMMUNOL, V129, P1715; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KAMPER SM, 1992, MOL BIOCHEM PARASIT, V53, P33, DOI 10.1016/0166-6851(92)90004-4; KUNKEL TA, 1988, CELL, V53, P837, DOI 10.1016/S0092-8674(88)90189-4; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LENARDO MJ, 1986, MOL CELL BIOL, V6, P1991, DOI 10.1128/MCB.6.6.1991; LENARDO MJ, 1984, P NATL ACAD SCI-BIOL, V81, P6642, DOI 10.1073/pnas.81.21.6642; LUMSDEN WHR, 1982, SYST PARASITOL, V4, P373, DOI 10.1007/BF00009977; MAIZELS N, 1989, TRENDS GENET, V5, P4, DOI 10.1016/0168-9525(89)90004-8; MATTHEWS KR, 1990, NUCLEIC ACIDS RES, V18, P7219, DOI 10.1093/nar/18.24.7219; MCCORMACK WT, 1991, ANNU REV IMMUNOL, V9, P219; PAYS E, 1983, CELL, V34, P371, DOI 10.1016/0092-8674(83)90371-9; REDDY LV, 1990, BIOCHEM BIOPH RES CO, V169, P730, DOI 10.1016/0006-291X(90)90392-Z; RICEFICHT AC, 1982, NATURE, V298, P676, DOI 10.1038/298676a0; ROTH C, 1989, P NATL ACAD SCI USA, V86, P9375, DOI 10.1073/pnas.86.23.9375; Sambrook J, 1989, MOL CLONING LABORATO; SCHOLLER JK, 1989, MOL BIOCHEM PARASIT, V35, P11, DOI 10.1016/0166-6851(89)90137-0; SHAH JS, 1987, MOL BIOCHEM PARASIT, V24, P163, DOI 10.1016/0166-6851(87)90103-4; THON G, 1989, GENE DEV, V3, P1247, DOI 10.1101/gad.3.8.1247; TURNER CMR, 1988, PARASITOLOGY, V97, P269, DOI 10.1017/S0031182000058479; TURNER CMR, 1989, PARASITOLOGY, V99, P67, DOI 10.1017/S0031182000061035; TURNER CMR, 1986, PARASITOLOGY, V92, P67, DOI 10.1017/S0031182000063459; UMAR A, 1991, P NATL ACAD SCI USA, V88, P4902, DOI 10.1073/pnas.88.11.4902; VANDERPLOEG LHT, 1984, CELL, V36, P459, DOI 10.1016/0092-8674(84)90239-3; VANDERPLOEG LHT, 1991, NEW BIOL, V3, P324; VANDERPLOEG LHT, 1982, NUCLEIC ACIDS RES, V10, P5905, DOI 10.1093/nar/10.19.5905	36	48	48	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					397	406		10.1016/0092-8674(93)90116-8	http://dx.doi.org/10.1016/0092-8674(93)90116-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381717				2022-12-28	WOS:A1993KM16200009
J	JUNGMANN, J; REINS, HA; SCHOBERT, C; JENTSCH, S				JUNGMANN, J; REINS, HA; SCHOBERT, C; JENTSCH, S			RESISTANCE TO CADMIUM MEDIATED BY UBIQUITIN-DEPENDENT PROTEOLYSIS	NATURE			English	Article							CONJUGATING ENZYMES; PROTEIN-DEGRADATION; YEAST; CLONING; GENE; ENCODES	CADMIUM is a potent poison for living cells. In man, chronic exposure to low levels of cadmium results in damage to kidneys and has been linked to neoplastic disease and ageing, and acute exposure can cause damage to a variety of organs and tissues1. Cadmium reacts with thiol groups and can substitute for zinc in certain proteins2, but the reason for its toxicity in vivo remains uncertain. In eukaryotes, an important selective proteolysis pathway for the elimination of abnormal proteins that are generated under normal or stress conditions is ATP-dependent and mediated by the ubiquitin system3-5. Substrates of this pathway are first recognized by ubiquitin-conjugating enzymes5-7 (or auxiliary factors) which covalently attach ubiquitin, a small and highly conserved protein, to specific internal lysine residues of proteolytic substrates. Ubiquitinated substrates are then degraded by the proteasome, a multisubunit protease complex 8-10. Here we show that expression of this ubiquitin-dependent proteolysis pathway in yeast is activated in response to cadmium exposure and that mutants deficient in specific ubiquitin-conjugating enzymes are hypersensitive to cadmium. Moreover, mutants in the proteasome are hypersensitive to cadmium, suggesting that cadmium resistance is mediated in part by degradation of abnormal proteins. This indicates that a major reason for cadmium toxicity may be cadmium-induced formation of abnormal proteins.	MAX PLANCK GESELL,FRIEDRICH MIESCHER LAB,SPEMANNSTR 37-39,W-7400 TUBINGEN,GERMANY; UNIV BAYREUTH,INST PFLANZENPHYSIOL,W-8580 BAYREUTH,GERMANY	Eberhard Karls University of Tubingen; Max Planck Society; University of Bayreuth								Ausubel FM., 2006, ENZYMATIC MANIPULATI; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1986, REV CELL BIOL, V7, P25; GRILL E, 1985, SCIENCE, V230, P674, DOI 10.1126/science.230.4726.674; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HERSHKO A, 1991, TRENDS BIOCHEM SCI, V16, P265, DOI 10.1016/0968-0004(91)90101-Z; HOUGH R, 1986, J BIOL CHEM, V261, P2400; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jentsch S, 1992, Trends Cell Biol, V2, P98, DOI 10.1016/0962-8924(92)90013-D; JENTSCH S, 1990, TRENDS BIOCHEM SCI, V15, P195, DOI 10.1016/0968-0004(90)90161-4; JENTSCH S, 1992, REV GENET, V26, P177; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; PHELPS A, 1991, BIOCHEMISTRY-US, V30, P248, DOI 10.1021/bi00215a035; SANCHEZ Y, 1992, EMBO J, V11, P2357, DOI 10.1002/j.1460-2075.1992.tb05295.x; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sherman F., 1986, METHODS YEAST GENETI; STOEPPLER M, 1985, CADMIUM; VALLEE BL, 1972, ANNU REV BIOCHEM, V41, P91, DOI 10.1146/annurev.bi.41.070172.000515; VANNOCKER S, 1991, P NATL ACAD SCI USA, V88, P10297, DOI 10.1073/pnas.88.22.10297; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	24	236	242	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					369	371		10.1038/361369a0	http://dx.doi.org/10.1038/361369a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8381213				2022-12-28	WOS:A1993KJ59000063
J	ANDRES, R; MULLER, DC; SORKIN, JD				ANDRES, R; MULLER, DC; SORKIN, JD			LONG-TERM EFFECTS OF CHANGE IN BODY-WEIGHT ON ALL-CAUSE MORTALITY - A REVIEW	ANNALS OF INTERNAL MEDICINE			English	Article							GUIDELINES; LONGEVITY; AMERICANS; MEN; VARIABILITY; POPULATION; HEALTH; DEATH; AGE	Objective: To summarize published studies analyzing the effects of long-term change in body weight on all-cause mortality and have not been reported elsewhere in these proceedings. Data Sources: Thirteen reports from 11 diverse population studies, 7 from the United States and 4 from Europe. Study Selection: All studies included a weight change period of 4 or more years, followed by a mortality assessment period of 8 or more years. All weight changes occurred in persons 17 years or older. Data Extraction: Data from individual studies are presented as number of participants, number of deaths, ages at initial and final weight measurements, duration of the mortality follow-up period, consideration of cigarette smoking and other potential confounders, exclusion criteria, temporal separation between the weight change and mortality follow-up periods, and the association between weight change and all-cause mortality. Data Synthesis: Results are summarized by weight change associated with the lowest mortality rate and by the effects of long-term weight loss on mortality rate. Conclusions: Despite the diversity of the populations studied, the degree of ''clinical clean-up'' at entry, the techniques used to assess weight change, and the differences in analytic techniques (including consideration of potentially confounding variables), certain conclusions may be drawn. Evidence suggests that the highest mortality rates occur in adults who either have lost weight or have gained excessive weight. The lowest mortality rates are generally associated with modest weight gains.			ANDRES, R (corresponding author), NIA, GERONTOL RES CTR, 4940 EASTERN AVE, BALTIMORE, MD 21224 USA.							ANDRES R, 1985, PRINCIPLES GERIATRIC, P311; [Anonymous], 1983, Statistical Bulletin, Metropolitan Life Insurance Company, V64, P2; AVONS P, 1983, LANCET, V1, P1104; BRAY GA, 1992, AM J CLIN NUTR, V55, P481, DOI 10.1093/ajcn/55.2.481a; CALLAWAY CW, 1991, AM J CLIN NUTR, V54, P171, DOI 10.1093/ajcn/54.1.171a; DEEG DJH, 1990, ARCH GERONTOL GERIAT, V10, P97, DOI 10.1016/0167-4943(90)90048-B; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; LISSNER L, 1990, INT J OBESITY, V14, P373; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; RHOADS GG, 1983, LANCET, V1, P492; SCHROLL M, 1981, DAN MED BULL, V28, P106; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; WILLIAMSON DF, 1993, ANN INTERN MED, V119, P731, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00021; 1989, DIET HLTH IMPLICATIO, P563; 1990, DIETARY GUIDELINES A	21	201	206	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				737	743		10.7326/0003-4819-119-7_Part_2-199310011-00022	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00022			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363208				2022-12-28	WOS:A1993MA33000022
J	PAVLETICH, NP; PABO, CO				PAVLETICH, NP; PABO, CO			CRYSTAL-STRUCTURE OF A 5-FINGER GLI-DNA COMPLEX - NEW PERSPECTIVES ON ZINC FINGERS	SCIENCE			English	Article							TRANSCRIPTION FACTOR-IIIA; 5S RNA GENE; WILMS-TUMOR LOCUS; KRUPPEL FAMILY; BINDING-SITES; YEAST ADR1; PROTEIN; XENOPUS; RECOGNITION; SEQUENCE	Zinc finger proteins, of the type first discovered in transcription factor IIIA (TFIIIA), are one of the largest and most important families of DNA-binding proteins. The crystal structure of a complex containing the five Zn fingers from the human GLI oncogene and a high-affinity DNA binding site has been determined at 2.6 angstrom resolution. Finger one does not contact the DNA. Fingers two through five bind in the major groove and wrap around the DNA, but lack the simple, strictly periodic arrangement observed in the Zif268 complex. Fingers four and five of GLI make extensive base contacts in a conserved nine base-pair region, and this section of the DNA has a conformation intermediate between B-DNA and A-DNA. Analyzing the GLI complex and comparing it with Zif268 offers new perspectives on Zn finger-DNA recognition.	MIT, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031471] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-31471] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR V2 1 MANUAL; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CLEMENS KR, 1992, P NATL ACAD SCI USA, V89, P10822, DOI 10.1073/pnas.89.22.10822; DICKERSON RE, 1989, PROGRAM NEWHELIX; FAIRALL L, 1989, EMBO J, V8, P1809, DOI 10.1002/j.1460-2075.1989.tb03575.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAYES JJ, 1992, J MOL BIOL, V227, P407, DOI 10.1016/0022-2836(92)90897-S; HAYES JJ, 1992, BIOCHEMISTRY-US, V31, P11600, DOI 10.1021/bi00161a045; HUBER PW, 1991, J BIOL CHEM, V266, P3278; HUBER PW, 1991, P NATL ACAD SCI USA, V88, P10801, DOI 10.1073/pnas.88.23.10801; JACOBS G, 1990, New Biologist, V2, P583; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINZLER KW, 1990, MOL CELL BIOL, V10, P634, DOI 10.1128/MCB.10.2.634; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P9396, DOI 10.1021/bi00103a002; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LIAO XB, 1992, J MOL BIOL, V223, P857, DOI 10.1016/0022-2836(92)90248-I; MCCALL M, 1986, NATURE, V322, P661, DOI 10.1038/322661a0; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; NEKLUDOVA L, UNPUB; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PARRAGA G, 1988, SCIENCE, V241, P1489, DOI 10.1126/science.3047872; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PAVLETICH NP, UNPUB; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROBERTS WM, 1989, CANCER RES, V49, P5407; ROULD MR, 1989, PROGRAM DSCALEAD; RUPPERT JM, 1990, MOL CELL BIOL, V10, P5408, DOI 10.1128/MCB.10.10.5408; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Saenger W., 1984, PRINCIPLES NUCLEIC A, VDM79; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; TONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489; TRAVERS AA, 1992, CURR OPIN STRUC BIOL, V2, P71; TREISMAN J, 1989, NATURE, V341, P335, DOI 10.1038/341335a0; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X; 1979, SERC4 DAR LAB	49	632	672	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 24	1993	261	5129					1701	1707		10.1126/science.8378770	http://dx.doi.org/10.1126/science.8378770			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378770				2022-12-28	WOS:A1993LY58400017
J	NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; SHINKAI, Y; LOUIE, MC; FIELDS, LE; LUCAS, PJ; STEWART, V; ALT, FW; LOH, DY				NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; KUIDA, K; SHINKAI, Y; LOUIE, MC; FIELDS, LE; LUCAS, PJ; STEWART, V; ALT, FW; LOH, DY			DISAPPEARANCE OF THE LYMPHOID SYSTEM IN BCL-2 HOMOZYGOUS MUTANT CHIMERIC MICE	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; FOLLICULAR LYMPHOMA; TRANSGENIC MICE; C-MYC; CHROMOSOMAL BREAKPOINT; B-CELLS; EXPRESSION; SURVIVAL; CLONING; PROTEIN	The bcl-2 proto-oncogene can prevent the death of many cell types. Mice were generated that were chimeric for the homozygous inactivation of bcl-2. Lymphocytes without Bcl-2 differentiated into phenotypically mature cells. However, in vitro, the mature T cells that lacked Bcl-2 had shorter life-spans and increased sensitivity to glucocorticoids and gamma-irradiation. In contrast, stimulation of CD3 inhibited the death of these cells. T and B cells with no Bcl-2 disappeared from the bone marrow, thymus, and periphery by 4 weeks of age. Thus, Bcl-2 was dispensable for lymphocyte maturation, but was required for a stable immune system after birth.	WASHINGTON UNIV, SCH MED, DEPT MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT GENET, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63110 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,DEPT GENET, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; CTR BLOOD RES, BOSTON, MA 02115 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM)			Shinkai, Yoichi/N-3909-2014	Shinkai, Yoichi/0000-0002-6051-2484	NIAID NIH HHS [AI 15322] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI015322] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Maniatis T., 1982, MOL CLONING; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NAKAYAMA K, UNPUB; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1991, NATURE, V353, P71, DOI 10.1038/353071a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROBERTSON EJ, 1987, EMBRYO DERIVED STEM; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; STRASSER A, 1990, CURR TOP MICROBIOL, V166, P175; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786	36	386	396	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1584	1588		10.1126/science.8372353	http://dx.doi.org/10.1126/science.8372353			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372353				2022-12-28	WOS:A1993LX47400032
J	MITRAKOU, A; FANELLI, C; VENEMAN, T; PERRIELLO, G; CALDERONE, S; PLATANISIOTIS, D; RAMBOTTI, A; RAPTIS, S; BRUNETTI, P; CRYER, P; GERICH, J; BOLLI, G				MITRAKOU, A; FANELLI, C; VENEMAN, T; PERRIELLO, G; CALDERONE, S; PLATANISIOTIS, D; RAMBOTTI, A; RAPTIS, S; BRUNETTI, P; CRYER, P; GERICH, J; BOLLI, G			REVERSIBILITY OF UNAWARENESS OF HYPOGLYCEMIA IN PATIENTS WITH INSULINOMAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEFECTIVE GLUCOSE COUNTERREGULATION; DEPENDENT DIABETES-MELLITUS; GLYCEMIC THRESHOLDS; AUTONOMIC NEUROPATHY; RESPONSES; SYMPTOMS; PITUITARY; SECRETION; HUMANS	Background. A lack of appropriate autonomic warning symptoms before the development of neuroglycopenia occurs frequently in patients with diabetes mellitus. The pathogenesis of this phenomenon is unclear, but it is associated with intensive insulin therapy, prolonged duration of diabetes, frequent episodes of hypoglycemia, and impaired glucose counterregulation. Recently, it has been proposed that repeated episodes of hypoglycemia may themselves induce the phenomenon. Methods. To test this hypothesis and to determine whether the phenomenon is reversible, we assessed autonomic and neuroglycopenic symptoms, counterregulatory hormonal responses, and cognitive function during stepped hypoglycemic-clamp studies in 6 patients with insulinomas before and approximately six months after curative surgery and in 14 normal subjects matched for age, weight, and sex. Results. Before surgery, the patients with insulinomas had lower scores than the normal subjects for autonomic symptoms (mean [+/-SD], 3.5+/-0.8 vs. 9.6+/-4.5) and neuroglycopenic symptoms (2.8+/-1.5 vs. 8.9+/-5.3). The patients also had impaired counterregulatory hormonal responses (their plasma epinephrine, norepinephrine, glucagon, growth hormone, and cortisol responses before surgery were 187+/-227 pg per milliliter [1.03+/-1.25 nmol per liter], 223+/-85 pg per milliliter [1.32+/-0.50 nmol per liter], 86+/-21 ng per liter, 7.4+/-5.2 mug per liter, and 12.1+/-1.5 mug per deciliter [334+/-41 nmol per liter], respectively, as compared with 842+/-439 pg per milliliter [4.63+/-2.41 nmol per liter], 519+/-150 pg per milliliter [3.07+/-0.89 nmol per liter], 201+/-58 ng per liter, 25.3+/-13.7 mug per liter, and 26.3+/-1.2 mug per deciliter [726+/-33 nmol per liter in the normal subjects) and less deterioration in cognitive function than the normal subjects during hypoglycemia (sum of z scores for seven tests of cognitive function, 1.7+/-1.9 vs. 8.9+/-3,5) (P<0.02 for all comparisons). Surgical cure reversed all these abnormalities (P not significant for all comparisons with the normal subjects). Conclusions. Hypoglycemia itself can induce unawareness of the autonomic and neuroglycopenic symptoms of hypoglycemia and decrease the counterregulatory hormonal responses to hypoglycemia.	WHITTIER INST DIABET & ENDOCRINOL, 9894 GENESEE AVE, LA JOLLA, CA 92037 USA; WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; UNIV PERUGIA, IST MED INTERNA & SCI ENDOCRINE & METAB, I-06100 PERUGIA, ITALY; UNIV ATHENS, DEPT INTERNAL MED PROPAEDEUT 2, ATHENS, GREECE	Washington University (WUSTL); University of Perugia; National & Kapodistrian University of Athens				FANELLI, Carmine Giuseppe/0000-0003-4063-158X	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000056] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00036, RR00056] Funding Source: Medline; NIDDK NIH HHS [DK29411] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIEL SA, 1991, DIABETES CARE, V14, P109, DOI 10.2337/diacare.14.2.109; AMIEL SA, 1987, NEW ENGL J MED, V316, P1376, DOI 10.1056/NEJM198705283162205; AMIEL SA, 1988, DIABETES, V37, P901, DOI 10.2337/diabetes.37.7.901; ARKY RA, 1988, NEW ENGL J MED, V318, P1523; Banting FG, 1923, BRIT MED J, V1923, P8, DOI 10.1136/bmj.1.3236.8; CLARKE WL, 1991, DIABETES, V40, P680, DOI 10.2337/diabetes.40.6.680; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; DAVIDSON MB, 1986, NEW ENGL J MED, V314, P849; DAVIS MR, 1991, J CLIN ENDOCR METAB, V72, P788, DOI 10.1210/jcem-72-4-788; DAVIS MR, 1991, J CLIN ENDOCR METAB, V73, P995, DOI 10.1210/jcem-73-5-995; FANELLI C, 1992, DIABETES S1, V41, pA30; FANELLI C, 1992, GIORNALE ITALIANO DI, V12, P269; FRIER BM, 1988, DIABETOLOGIA, V31, P421, DOI 10.1007/BF00271586; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; GRIMALDI A, 1989, DIABETES METAB, V15, P209; GRIMALDI A, 1990, HORM METAB RES, V22, P90, DOI 10.1055/s-2007-1004858; HELLER SR, 1987, LANCET, V2, P359; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; MARAN A, 1992, DIABETIC MED, V9, P765, DOI 10.1111/j.1464-5491.1992.tb01889.x; MITRAKOU A, 1991, AM J PHYSIOL, V260, pE67, DOI 10.1152/ajpendo.1991.260.1.E67; RYDER REJ, 1990, BMJ-BRIT MED J, V301, P783, DOI 10.1136/bmj.301.6755.783; SCHWARTZ NS, 1987, J CLIN INVEST, V79, P777, DOI 10.1172/JCI112884; VEA H, 1992, DIABETIC MED, V9, P950, DOI 10.1111/j.1464-5491.1992.tb01738.x; WIDOM B, 1990, ANN INTERN MED, V112, P904, DOI 10.7326/0003-4819-112-12-904; WIDOM B, 1992, DIABETES, V41, P1597, DOI 10.2337/diabetes.41.12.1597; Zar J.H., 1999, ZAR KUHR 5 2019, V4th	27	168	173	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					834	839		10.1056/NEJM199309163291203	http://dx.doi.org/10.1056/NEJM199309163291203			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355741				2022-12-28	WOS:A1993LW55100003
J	SERIES, F; MARC, I; CORMIER, Y; LAFORGE, J				SERIES, F; MARC, I; CORMIER, Y; LAFORGE, J			UTILITY OF NOCTURNAL HOME OXIMETRY FOR CASE-FINDING IN PATIENTS WITH SUSPECTED SLEEP-APNEA HYPOPNEA SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						OXIMETRY; SLEEP APNEA SYNDROMES; POLYSOMNOGRAPHY; HYPOPNEA	POSITIVE AIRWAY PRESSURE; DAYTIME SLEEPINESS; OXYGEN DESATURATION; TERM TREATMENT	Objective: To evaluate prospectively the validity of home oximetry for case finding in patients clinically suspected of having the sleep apnea hypopnea syndrome (SAHS). Design: Blinded comparison of home oximetry and polysomnographic nocturnal recordings. Setting: Sleep clinic of a tertiary referral center. Patients: A total of 240 outpatients referred because of reported sleep disturbances or daytime hypersomnia compatible with the diagnosis of SAHS. Measurements: All participants had nocturnal home oximetry followed by a conventional polysomnographic study. The two recordings were interpreted blindly. Home oximetry test results were classified as abnormal (suspicion of sleep-related breathing abnormalities) in the presence of repetitive, short-duration arterial oxyhemoglobin saturation (Sa(O2)) fluctuations without any absolute or relative decrease in the Sa(O2) threshold. The diagnosis of SAHS was confirmed when the apnea-plus-hypopnea index was greater than 10. Results: Based on the results of the polysomnographic sleep study, 110 patients had SAHS (apnea-plus-hypopnea index, 38.1 +/- 2.5/h; mean +/- SE). Home oximetry test results were interpreted as abnormal in 176 patients (this included 108 patients with SAHS and 68 without SAHS) and were read as normal in 62 patients without SAHS and in 2 with SAHS. Home oximetry testing had a sensitivity of 108/110 or 98.2% (95% CI, 93.6% to 99.8%); a specificity of 62/130 or 47.7% (CI, 38.8% to 56.6%); a positive predictive value of 108/176 or 61.4%; and a negative predictive value of 62/64 or 96.9%. Conclusions: A negative home oximetry test result is helpful in ruling out the diagnosis of SAHS in patients clinically suspected of having this syndrome, because a negative test result reduced the probability from 54.1% to 3.1% in our patients. However, a positive oximetry test increased the probability from 46% to 61.4% in our group of patients.			SERIES, F (corresponding author), HOP LAVAL, CTR PNEUMOL, UNITE RECH, 2725 CHEMIN STE FOY, ST FOY G1V 4G5, PQ, CANADA.			Marc, Isabelle/0000-0001-6060-8550				ALLAN M A, 1990, American Review of Respiratory Disease, V141, pA858; [Anonymous], 1989, AM REV RESPIR DIS, V139, P559; [Anonymous], 1992, SLEEP, V15, P174; BLOCK AJ, 1979, NEW ENGL J MED, V300, P513, DOI 10.1056/NEJM197903083001001; BRADLEY TD, 1985, J APPL PHYSIOL, V59, P1364, DOI 10.1152/jappl.1985.59.5.1364; CHADHA TS, 1982, AM REV RESPIR DIS, V125, P644; FARNEY RJ, 1986, CHEST, V89, P533, DOI 10.1378/chest.89.4.533; FINDLEY LJ, 1983, J APPL PHYSIOL, V55, P1777, DOI 10.1152/jappl.1983.55.6.1777; GEORGE CF, 1988, AM REV RESPIR DIS, V137, P1238, DOI 10.1164/ajrccm/137.5.1238; GOULD GA, 1988, AM REV RESPIR DIS, V137, P895, DOI 10.1164/ajrccm/137.4.895; GUILLEMINAULT C, 1991, CHEST, V99, P40, DOI 10.1378/chest.99.1.40; GYULAY S, 1993, AM REV RESPIR DIS, V147, P50, DOI 10.1164/ajrccm/147.1.50; GYULAY S, 1987, SLEEP, V10, P130, DOI 10.1093/sleep/10.2.130; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; KRIEGER J, 1991, CHEST, V100, P917, DOI 10.1378/chest.100.4.917; LAVIE P, 1983, SLEEP, V6, P312, DOI 10.1093/sleep/6.4.312; PARTINEN M, 1990, CHEST, V97, P27, DOI 10.1378/chest.97.1.27; PENZEL T, 1990, SLEEP, V13, P175, DOI 10.1093/sleep/13.2.175; PEPIN JL, 1991, CHEST, V99, P1151, DOI 10.1378/chest.99.5.1151; PETER JH, 1986, EUR J RESPIR DIS, V69, P451; RAPOPORT DM, 1982, NEW ENGL J MED, V307, P931, DOI 10.1056/NEJM198210073071507; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; SERIES F, 1990, AM REV RESPIR DIS, V141, P1522, DOI 10.1164/ajrccm/141.6.1522; SERIES F, 1989, EUR RESPIR J, V2, P26; SMIRNE S, 1983, SLEEP WAKE DISORDERS, P61; SULLIVAN CE, 1983, AM REV RESPIR DIS, V128, P177, DOI 10.1164/arrd.1983.128.1.177; SVANBORG E, 1990, CHEST, V98, P1341, DOI 10.1378/chest.98.6.1341; WILLIAMS AJ, 1991, CHEST, V100, P631, DOI 10.1378/chest.100.3.631; WITTIG RM, 1984, AM REV RESPIR DIS, V129, P244	29	175	203	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					449	453		10.7326/0003-4819-119-6-199309150-00001	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00001			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357109				2022-12-28	WOS:A1993LZ27500001
J	CHOW, LML; FOURNEL, M; DAVIDSON, D; VEILLETTE, A				CHOW, LML; FOURNEL, M; DAVIDSON, D; VEILLETTE, A			NEGATIVE REGULATION OF T-CELL RECEPTOR SIGNALING BY TYROSINE PROTEIN-KINASE P50(CSK)	NATURE			English	Article							ANTIGEN RECEPTOR; C-SRC; RESPONSIVENESS; ACTIVATION; GENE; PHOSPHORYLATION; ENHANCEMENT; EXPRESSION; RETROVIRUS; CLONING	TYROSINE protein phosphorylation is necessary for antigen receptor-mediated activation of T lymphocytes1. This signal is generated at least in part by the Src-related tyrosine protein kinases p56lck and p59fynT (refs 2, 3). The activity of these two enzymes is repressed by phosphorylation of a conserved carboxy-terminal tyrosine residue2,3. Recent studies suggest that this inhibitory phosphorylation may be caused by p50csk (for C-terminal Src kinase), a tyrosine protein kinase which accumulates most abundantly in thymus and spleen4-8. To investigate the function of Csk in T lymphocytes and characterize the processes regulating T-cell receptor (TCR) signalling, we examined the effects of overexpression of Csk on the physiology of an antigen-specific mouse T-cell line. We report here that p50csk negatively regulates TCR-induced tyrosine protein phosphorylation and lymphokine production. This provides evidence for the involvement of Csk in the regulation of T-cell activation.	MCGILL UNIV,DEPT BIOCHEM,ROOM 715B,MCINTYRE MED SCI BLDG,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MONTREAL GEN HOSP,DEPT MED,DIV MED ONCOL,MONTREAL H3G 1A4,QUEBEC,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University				Chow, Lionel/0000-0001-8447-063X				ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; Ausubel FM, 1988, MOL REPROD DEV; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARTANEN J, 1991, ONCOGENE, V6, P2013; RESKEKUNZ AB, 1985, EUR J IMMUNOL, V15, P1048, DOI 10.1002/eji.1830151017; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Sambrook J, 1989, MOL CLONING LABORATO; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SILLATY SN, 1990, ANAL BIOCHEM, V185, P194; SILVERMAN L, 1992, J CELL BIOL, V119, P415, DOI 10.1083/jcb.119.2.415; STAERZ UD, 1985, J IMMUNOL, V134, P3994; TAKEYA T, 1982, J VIROL, V44, P1; TAYLOR SS, 1992, ANNU REV CELL BIOL, V8, P429, DOI 10.1146/annurev.cb.08.110192.002241; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B	27	252	260	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					156	160		10.1038/365156a0	http://dx.doi.org/10.1038/365156a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371758				2022-12-28	WOS:A1993LW44200047
J	MORRISON, PJ; NEVIN, NC				MORRISON, PJ; NEVIN, NC			PEUTZ-JEGHERS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MORRISON, PJ (corresponding author), BELFAST CITY HOSP,BELFAST BT9 7AB,NORTH IRELAND.								0	4	4	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					774	774						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350887				2022-12-28	WOS:A1993LV64200006
J	SCHNEIDER, W; NOLL, DC; COHEN, JD				SCHNEIDER, W; NOLL, DC; COHEN, JD			FUNCTIONAL TOPOGRAPHIC MAPPING OF THE CORTICAL RIBBON IN HUMAN VISION WITH CONVENTIONAL MRI SCANNERS	NATURE			English	Article							STRIATE CORTEX; BRAIN; ORGANIZATION; DEPENDENCE; AREAS; BLOOD; TIME	THE human brain has anatomically distinct areas in which processing is laid out in space at the millimetre level with substantial variation across individuals. Activity occurs along a cortical ribbon 1.5-3 mm thick1 in response to specific stimuli2,3. Here we report the first use of cortical ribbon analysis on humans using non-invasive functional magnetic resonance imaging techniques performed with a conventional 1.5 T MRI scanner. Changes in activation were detected using T2*-weighted, gradient echo imaging sequences. Subjects observed partial field, flashing checkerboard patterns (left-right, top-bottom, half rings, and wedges). Stimuli produced magnetic resonance signal changes in the 1-8% range, varying at the millimetre scale, which showed contralateral vertically reflected patterns of activation in the visual cortex. To compare the spatial topographies across subjects, computer algorithms were used to control for the subject-unique folding of cortex, providing a flattened cortical ribbon identifying four topographically distinct areas.	PITTSBURGH NMR INST, PITTSBURGH, PA 15213 USA; CARNEGIE MELLON UNIV, DEPT PSYCHOL, PITTSBURGH, PA 15213 USA	Carnegie Mellon University	SCHNEIDER, W (corresponding author), UNIV PITTSBURGH, 3939 O HARA ST, PITTSBURGH, PA 15260 USA.		Noll, Douglas C/D-8124-2014	Noll, Douglas C/0000-0002-0983-3805				BAILEY P, 1951, ISOCORTEX MAN; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; CLARKE S, 1990, J COMP NEUROL, V298, P188, DOI 10.1002/cne.902980205; FOX PT, 1984, J NEUROPHYSIOL, V51, P1109, DOI 10.1152/jn.1984.51.5.1109; FOX PT, 1988, J CEREBR BLOOD F MET, V8, P642, DOI 10.1038/jcbfm.1988.111; FRIEDMAN HR, 1989, J NEUROSCI, V9, P4111; GLASSNER AS, 1990, GRAPHIC GEMS, P587; GLICKSTEIN M, 1987, TRENDS NEUROSCI, V10, P350, DOI 10.1016/0166-2236(87)90066-X; HAXBY JV, 1991, P NATL ACAD SCI USA, V88, P1621, DOI 10.1073/pnas.88.5.1621; HAXBY JV, IN PRESS FUNCTIONAL; KENNEDY DN, 1989, IEEE T MED IMAGING, V8, P1, DOI 10.1109/42.20356; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; PRESS WH, 1986, NUMERICAL RECIPES AR; RAICHLE ME, 1988, HDB PHYSL, P643; SHULMAN RG, 1993, P NATL ACAD SCI USA, V90, P3127, DOI 10.1073/pnas.90.8.3127; THULBORN KR, 1982, BIOCHIM BIOPHYS ACTA, V714, P265, DOI 10.1016/0304-4165(82)90333-6; TOOTELL RBH, 1988, J NEUROSCI, V8, P1531; ZEKI S, 1991, J NEUROSCI, V11, P641	19	166	169	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					150	152		10.1038/365150a0	http://dx.doi.org/10.1038/365150a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371756				2022-12-28	WOS:A1993LW44200045
J	WARD, H; DAY, S; MEZZONE, J; DUNLOP, L; DONEGAN, C; FARRAR, S; WHITAKER, L; HARRIS, JRW; MILLER, DL				WARD, H; DAY, S; MEZZONE, J; DUNLOP, L; DONEGAN, C; FARRAR, S; WHITAKER, L; HARRIS, JRW; MILLER, DL			PROSTITUTION AND RISK OF HIV - FEMALE PROSTITUTES IN LONDON	BRITISH MEDICAL JOURNAL			English	Article								Objective-To measure the prevalence of HIV and to describe established risk factors in female prostitutes. Design-A cross sectional survey. Setting-A genitourinary medicine clinic, streets, and magistrates' courts in London. Subjects-280 female prostitutes recruited between April 1989 and August 1991. Main outcome measures-Infection with HIV-1, reported risk behaviours, and prevalence of sexually transmitted infections. Results-228 of the women had HIV tests, and two (0.9% (95% confidence interval 0% to 2.1%)) were infected with HIV-1. Reported use of condoms was high for commercial clients and low for non-paying partners: 98% (251/255) of women used condoms with all clients and 12% (25/207) with non-paying partners for vaginal intercourse. Twenty two women were current or past injecting drug users. Of the 193 women examined for sexually transmitted infections, 27 had an acute infection (gonorrhoea, chlamydia, trichomonas, or primary genital herpes) at the time of interview. Infection was associated with younger age and increasing numbers of non-paying sexual partners, but not with duration of prostitution, numbers of clients, or reports of condom failures. When age and numbers of non-paying partners were analysed by logistic regression they remained significantly associated with sexually transmitted infections. Conclusions-A large and diverse sample of prostitutes had a low prevalence of infection with HIV and high levels of use of condoms in commercial sex. There was a significant risk of other sexually transmitted infections associated with prostitutes' non-commercial sexual relationships, in which unprotected sex is common. Interventions to reduce the risk of sexually transmitted infections in prostitutes should address both commercial and non-commercial sexual partnerships.	ST MARYS HOSP,SCH MED,DEPT GENITOURINARY MED,LONDON W2 1PG,ENGLAND	Imperial College London	WARD, H (corresponding author), ST MARYS HOSP,SCH MED,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND.		Ward, Helen/A-1836-2009	Ward, Helen/0000-0001-8238-5036; Day, Sophie/0000-0002-9822-9094				DAY S, 1988, BRIT MED J, V297, P1585, DOI 10.1136/bmj.297.6663.1585; Day S., 1990, AIDS DRUGS PROSTITUT, P61; JOHNSON AM, 1988, AIDS, V2, P369, DOI 10.1097/00002030-198810000-00006; MCKEGANEY N, 1992, BMJ-BRIT MED J, V305, P801, DOI 10.1136/bmj.305.6857.801; THOMAS RM, 1989, BMJ-BRIT MED J, V299, P148, DOI 10.1136/bmj.299.6692.148; WARD H, 1992, BRIT MED J, V304, P1635, DOI 10.1136/bmj.304.6842.1635-e; WARD H, 1992, 9 P INT C AIDS 3 STD, pC276; 1993, AIDS, V7, P401	8	59	60	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					356	358		10.1136/bmj.307.6900.356	http://dx.doi.org/10.1136/bmj.307.6900.356			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374417	Green Published, Bronze			2022-12-28	WOS:A1993LR76800018
J	WOOLFREY, S; GAMMACK, NS; DEWAR, MS; BROWN, PJE				WOOLFREY, S; GAMMACK, NS; DEWAR, MS; BROWN, PJE			FLUOXETINE-WARFARIN INTERACTION	BRITISH MEDICAL JOURNAL			English	Letter											WOOLFREY, S (corresponding author), WANSBECK GEN HOSP,ASHINGTON NE63 9JJ,NORTHD,ENGLAND.							CLAIRE RJ, 1991, AM J PSYCHIAT, V148, P1604; STOCKLEY IH, 1991, DRUG INTERACTIONS SO; 1991, MEREC B, V2, P29; 1992, BRIT NATIONAL FORMUL; 1992, AHFS DRUG INFORMATIO, V92	5	41	42	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					241	241		10.1136/bmj.307.6898.241-b	http://dx.doi.org/10.1136/bmj.307.6898.241-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369688	Bronze, Green Published			2022-12-28	WOS:A1993LP31400027
J	LASALLE, GL; ROBERT, JJ; BERRARD, S; RIDOUX, V; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; MALLET, J				LASALLE, GL; ROBERT, JJ; BERRARD, S; RIDOUX, V; STRATFORDPERRICAUDET, LD; PERRICAUDET, M; MALLET, J			AN ADENOVIRUS VECTOR FOR GENE-TRANSFER INTO NEURONS AND GLIA IN THE BRAIN	SCIENCE			English	Article							COLI BETA-GALACTOSIDASE; MOUSE; VIRUS; RAT; EXPRESSION; SYSTEM	The efficient introduction of genetic material into quiescent nerve cells is important in the study of brain function and for gene therapy of neurological disorders. A replication-deficient adenoviral vector that contained a reporter gene encoding beta-galactosidase infected rat nerve cells in vitro and in vivo. Beta-galactosidase was expressed in almost all sympathetic neurons and astrocytes in culture. After stereotactic inoculations into the rat hippocampus and the substantia nigra, beta-galactosidase activity was detected for 2 months. Infected cells were identified as microglial cells, astrocytes, or neurons with anatomical, morphological, and immunohistochemical criteria. No obvious cytopathic effect was observed.	CNRS,GENET MOLEC NEUROTRANSMISS & PROC DEGENERAT LAB,C9923,F-91198 GIF SUR YVETTE,FRANCE; CNRS,INST ALFRED FESSARD,UNITE PROPRE RECH 2212,F-91198 GIF SUR YVETTE,FRANCE; INST GUSTAVE ROUSSY,CNRS,UA 1301,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								CHIOCCA E A, 1990, New Biologist, V2, P739; DOBSON AT, 1990, NEURON, V5, P353, DOI 10.1016/0896-6273(90)90171-B; FINK DJ, 1992, HUM GENE THER, V3, P11, DOI 10.1089/hum.1992.3.1-11; GELLER AI, 1990, P NATL ACAD SCI USA, V87, P1149, DOI 10.1073/pnas.87.3.1149; GELLER AI, 1988, SCIENCE, V241, P1667, DOI 10.1126/science.2843986; Hawrot E, 1979, Methods Enzymol, V58, P574; HAYES CE, 1974, J BIOL CHEM, V249, P1904; KRISTENSSON K, 1974, BRAIN RES, V69, P189, DOI 10.1016/0006-8993(74)90001-8; LAFAY F, 1991, VIROLOGY, V183, P320, DOI 10.1016/0042-6822(91)90145-2; MARTIN X, 1983, BRAIN RES, V273, P253, DOI 10.1016/0006-8993(83)90850-8; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; QUANTIN B, 1992, P NATL ACAD SCI USA, V89, P2581, DOI 10.1073/pnas.89.7.2581; ROBINSON AP, 1986, IMMUNOLOGY, V57, P239; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; ROSENFELD MA, 1991, SCIENCE, V252, P431, DOI 10.1126/science.2017680; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; STRATFORDPERRIC.L, 1991, HUMAN GENE TRANSFER, P51; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902	19	422	710	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					988	990		10.1126/science.8382374	http://dx.doi.org/10.1126/science.8382374			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8382374				2022-12-28	WOS:A1993KL80000048
J	GOODRICH, JM; BOWDEN, RA; FISHER, L; KELLER, C; SCHOCH, G; MEYERS, JD				GOODRICH, JM; BOWDEN, RA; FISHER, L; KELLER, C; SCHOCH, G; MEYERS, JD			GANCICLOVIR PROPHYLAXIS TO PREVENT CYTOMEGALOVIRUS DISEASE AFTER ALLOGENEIC MARROW TRANSPLANT	ANNALS OF INTERNAL MEDICINE			English	Article						CYTOMEGALIC INCLUSION DISEASE; BONE MARROW TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; GANCICLOVIR; CYTOMEGALOVIRUSES	VIRUS INFECTION; MONOCLONAL-ANTIBODY; BLOOD LEUKOCYTES; CONTROLLED TRIAL; RAPID DETECTION; RECIPIENTS; PNEUMONIA; IMMUNOGLOBULIN; COMBINATION; VIREMIA	Objective: To study the efficacy and toxicity of ganciclovir prophylaxis given at engraftment to cytomegalovirus (CMV)-seropositive, allogeneic bone marrow transplant recipients. Design: A double-blind, placebo-controlled study. Setting:The Fred Hutchinson Cancer Research Center, a referral marrow transplant center. Patients: This study was conducted from November 1990 to August 1991. Ninety-three CMV-seropositive patients were entered into the study before marrow transplant, with 64 patients randomized to receive the study drug after marrow engraftment. Thirty-one patients received placebo, and 33 received ganciclovir. The dose was 5 mg/kg body weight administered intravenously twice daily for 5 days, followed by once daily until day 100 after transplant. Measurements: Outcome variables measured were CMV infection, monitored by weekly cultures, and neutropenia, defined as an absolute neutrophil count of 0.750 x 10(-9)/L for 2 consecutive days. Cytomegalovirus disease and mortality were secondary end points. Results: Fourteen (45%) placebo recipients developed CMV infection in the first 100 days after marrow transplant compared with one (3%) ganciclovir recipient (P < 0.001). Nine (29%) placebo recipients developed CMV disease compared with no cases in the ganciclovir group during the first 100 days (P < 0.001). Neutropenia occurred in 10 ganciclovir recipients (30%) compared with no cases in the placebo group during the period of observation (P = 0.001). In a separate analysis, patients on ganciclovir who became neutropenic were at greater risk (relative risk, 4.3; P = 0.02) for bacterial infection. Mortality between the two study groups did not differ statistically at 100 and 180 days. Conclusion: Ganciclovir given prophylactically after engraftment is effective in suppressing CMV infection and disease. Neutropenia is an important side effect of ganciclovir use and is associated with an increased risk for bacterial infection.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; UNIV WASHINGTON, SCH MED, SEATTLE, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle					NCI NIH HHS [CA 18029, CA 15704] Funding Source: Medline; NHLBI NIH HHS [HL 36444] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704, P01CA018029] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036444] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINSON K, 1991, BRIT J HAEMATOL, V79, P57, DOI 10.1111/j.1365-2141.1991.tb08007.x; BUHLES WC, 1988, REV INFECT DIS, V10, pS495; EMANUEL D, 1988, ANN INTERN MED, V109, P777, DOI 10.7326/0003-4819-109-10-777; GERNA G, 1991, J INFECT DIS, V164, P488, DOI 10.1093/infdis/164.3.488; GLEAVES CA, 1984, J CLIN MICROBIOL, V19, P917, DOI 10.1128/JCM.19.6.917-919.1984; GOODRICH JM, 1991, NEW ENGL J MED, V325, P1601, DOI 10.1056/NEJM199112053252303; JIWA NM, 1989, TRANSPLANTATION, V48, P72, DOI 10.1097/00007890-198907000-00017; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEAY S, 1988, REV INFECT DIS, V10, pS563; MANTEL N, 1966, CANCER CHEMOTHERAPY, V50, P163, DOI DOI 10.1073/PNAS.0308531101; MERIGAN TC, 1992, NEW ENGL J MED, V326, P1182, DOI 10.1056/NEJM199204303261803; MEYERS JD, 1988, NEW ENGL J MED, V318, P70, DOI 10.1056/NEJM198801143180202; MEYERS JD, 1990, J INFECT DIS, V162, P373, DOI 10.1093/infdis/162.2.373; MEYERS JD, 1986, J INFECT DIS, V153, P478, DOI 10.1093/infdis/153.3.478; REED EC, 1988, ANN INTERN MED, V109, P783, DOI 10.7326/0003-4819-109-10-783; REED EC, 1990, ANN INTERN MED, V112, P505, DOI 10.7326/0003-4819-112-7-505; SCHMIDT GM, 1988, TRANSPLANTATION, V46, P905; SCHMIDT GM, 1991, NEW ENGL J MED, V324, P1005, DOI 10.1056/NEJM199104113241501; VANDERBIJ W, 1988, J MED VIROL, V25, P179, DOI 10.1002/jmv.1890250208	19	551	564	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1993	118	3					173	178		10.7326/0003-4819-118-3-199302010-00003	http://dx.doi.org/10.7326/0003-4819-118-3-199302010-00003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KJ439	8380242				2022-12-28	WOS:A1993KJ43900003
J	LIN, LL; WARTMANN, M; LIN, AY; KNOPF, JL; SETH, A; DAVIS, RJ				LIN, LL; WARTMANN, M; LIN, AY; KNOPF, JL; SETH, A; DAVIS, RJ			CPLA2 IS PHOSPHORYLATED AND ACTIVATED BY MAP KINASE	CELL			English	Article							EPIDERMAL-GROWTH-FACTOR; ARACHIDONOYL-HYDROLYZING PHOSPHOLIPASE-A2; CA2+-SENSITIVE CYTOSOLIC PHOSPHOLIPASE-A2; SERINE THREONINE KINASES; SIGNAL-REGULATED KINASES; MACROPHAGE CELL-LINE; FACTOR RECEPTOR; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS	Treatment of cells with agents that stimulate the release of arachidonic acid causes increased serine phosphorylation and activation of cytosolic phospholipase A2 (cPLA2). Here we report that cPLA2 is a substrate for mitogen-activated protein (MAP) kinase. Moreover, phosphorylation by MAP kinase increases the enzymatic activity of cPLA2. The site of cPLA2 phosphorylation by MAP kinase, Ser-505, is identical to the major site of cPLA2 phosphorylation observed in phorbol ester-treated cells. Replacement of Ser-505 with Ala resulted in a mutant cPLA2 that is not a substrate for MAP kinase and causes little or no enhanced agonist-stimulated arachidonate release from intact cells. Taken together, these data indicate that MAP kinase mediates, at least in part, the agonist-induced activation of cPLA2.	UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,PROGRAM MOLEC MED,WORCESTER,MA 01605	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	LIN, LL (corresponding author), GENET INST,SMALL MOLECULE DRUG DISCOVERY GRP,CAMBRIDGE,MA 02140, USA.				NATIONAL CANCER INSTITUTE [R01CA058396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA58396] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN NG, 1990, J BIOL CHEM, V265, P11487; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AXELROD J, 1988, TRENDS NEUROSCI, V11, P117, DOI 10.1016/0166-2236(88)90157-9; BIRD TA, 1991, J BIOL CHEM, V266, P22661; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHAO W, 1990, J BIOL CHEM, V265, P17576; CHATANI Y, 1992, J BIOL CHEM, V267, P9911; CHUNG J, 1991, P NATL ACAD SCI USA, V88, P4981, DOI 10.1073/pnas.88.11.4981; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; Dennis EA, 1983, ENZYMES, P307; FERRELL JE, 1990, MOL CELL BIOL, V10, P3020, DOI 10.1128/MCB.10.6.3020; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GOLDBERG HJ, 1990, BIOCHEM J, V267, P461, DOI 10.1042/bj2670461; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRONICH JH, 1990, BIOCHEM J, V271, P37, DOI 10.1042/bj2710037; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANAHAN DJ, 1986, ANNU REV BIOCHEM, V55, P483, DOI 10.1146/annurev.bi.55.070186.002411; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; HER JH, 1991, NUCLEIC ACIDS RES, V19, P3743, DOI 10.1093/nar/19.13.3743; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KAUFMAN R J, 1990, Technique (Philadelphia), V2, P221; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; LALLEMAIN GL, 1991, CELL REGUL, V2, P6475; LESLIE CC, 1988, BIOCHIM BIOPHYS ACTA, V963, P476, DOI 10.1016/0005-2760(88)90316-5; LESLIE CC, 1991, J BIOL CHEM, V266, P11366; LIN LL, 1992, J BIOL CHEM, V267, P23451; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PFEILSCHIFTER J, 1989, EUR J BIOCHEM, V181, P237, DOI 10.1111/j.1432-1033.1989.tb14717.x; PIOMELLI D, 1991, P NATL ACAD SCI USA, V88, P6470; POSADA J, 1991, MOL CELL BIOL, V11, P2517, DOI 10.1128/MCB.11.5.2517; POSADA J, 1992, MOL BIOL CELL, V3, P583, DOI 10.1091/mbc.3.6.583; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SCHALKWIJK CG, 1990, BIOCHIM BIOPHYS ACTA, V1044, P139, DOI 10.1016/0005-2760(90)90229-Q; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SETH A, 1991, J BIOL CHEM, V266, P23521; SHARP JD, 1991, J BIOL CHEM, V266, P14850; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WIJKANDER J, 1991, EUR J BIOCHEM, V202, P873, DOI 10.1111/j.1432-1033.1991.tb16445.x	66	1729	1758	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 29	1993	72	2					269	278		10.1016/0092-8674(93)90666-E	http://dx.doi.org/10.1016/0092-8674(93)90666-E			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KK038	8381049				2022-12-28	WOS:A1993KK03800011
J	JACOBSON, MD; BURNE, JF; KING, MP; MIYASHITA, T; REED, JC; RAFF, MC				JACOBSON, MD; BURNE, JF; KING, MP; MIYASHITA, T; REED, JC; RAFF, MC			BCL-2 BLOCKS APOPTOSIS IN CELLS LACKING MITOCHONDRIAL-DNA	NATURE			English	Article							MEMBRANE PROTEIN; SURVIVAL; DEATH; TRANSLOCATION; FIBROBLASTS; EXPRESSION; ANTIBODIES; PRODUCT; LINES	WHEN the mammalian proto-oncogene bcl-2 is overexpressed it can protect various types of cells both from normal and from experimentally induced apoptosis1-6, but the molecular mechanisms involved are unknown. Although the Bcl-2 protein is membrane-associated7-10, its subcellular location is controversial: two studies have suggested that it is mainly associated with the nuclear envelope and endoplasmic reticulum8,10, whereas another study has suggested that it is mainly located in the inner mitochondrial membrane9. The latter study has suggested that Bcl-2 might protect cells from apoptosis by altering mitochondrial function and that mitochondria may be involved in apoptosis9,11. Here we report that human mutant cell lines that lack mitochondrial DNA (mtDNA), and therefore do not have a functional respiratory chain, can still be induced to die by apoptosis, and that they can be protected from apoptosis by the overexpression of bcl-2, suggesting that neither apoptosis nor the protective effect of bcl-2 depends on mitochondrial respiration. We also show that the Bcl-2 protein in overexpressing cells is associated with the nuclear envelope and endoplasmic reticulum, as well as with mitochondria.	COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; LA JOLLA CANC RES FDN,INST CANC RES,LA JOLLA,CA 92037	Columbia University; Sanford Burnham Prebys Medical Discovery Institute	JACOBSON, MD (corresponding author), UNIV LONDON UNIV COLL,DEPT BIOL,MRC,DEV NEUROBIOL PROGRAMME,MEDAWAR BLDG,LONDON WC1E 6BT,ENGLAND.							ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; ATTARDI G, 1991, PROGR NEUROPATHOLOGY, P75; ATTARDI G, 1988, REV CELL BIOL, V41, P278; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BASSENDINE MF, 1992, HEPATOLOGY, V15, P545, DOI 10.1002/hep.1840150329; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; FUNG CH, 1980, J BIOL CHEM, V255, P676; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; HARTSCH M, 1985, EUR J BIOCHEM, V150, P559; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; LIU YJ, 1991, EUR J IMMUNOL, V21, P1905, DOI 10.1002/eji.1830210819; LOUVARD D, 1982, J CELL BIOL, V92, P92, DOI 10.1083/jcb.92.1.92; MAGAUD JP, 1988, J IMMUNOL METHODS, V106, P95, DOI 10.1016/0022-1759(88)90276-1; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NAKAGAWA M, 1987, EXP CELL RES, V168, P44, DOI 10.1016/0014-4827(87)90414-9; NAPIER RM, 1988, PLANTA, V176, P519, DOI 10.1007/BF00397659; NAPIER RM, 1992, J CELL SCI, V102, P261; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SUDOYO H, 1990, J NEUROL SCI, V98, P185, DOI 10.1016/0022-510X(90)90259-P; TSUJIMOTO Y, 1987, ONCOGENE, V2, P3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	32	736	763	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					365	369		10.1038/361365a0	http://dx.doi.org/10.1038/361365a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8381212				2022-12-28	WOS:A1993KJ59000062
J	STRAUS, SE; COHEN, JI; TOSATO, G; MEIER, J				STRAUS, SE; COHEN, JI; TOSATO, G; MEIER, J			EPSTEIN-BARR-VIRUS INFECTIONS - BIOLOGY, PATHOGENESIS, AND MANAGEMENT	ANNALS OF INTERNAL MEDICINE			English	Discussion						EPSTEIN-BARR VIRUS; B-LYMPHOCYTES; INFECTIOUS MONONUCLEOSIS; BURKITTS LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS	LINKED LYMPHOPROLIFERATIVE SYNDROME; BONE-MARROW TRANSPLANTATION; LATENT MEMBRANE-PROTEIN; ORAL HAIRY LEUKOPLAKIA; T-CELL EPITOPE; B-CELLS; APLASTIC-ANEMIA; EPITHELIAL-CELLS; HODGKINS-DISEASE; VIRAL LATENCY	Epstein-Barr virus (EBV) encodes genes that ensure its persistence in human B lymphocytes. Some of the genes encourage B-cell proliferation; others are poised to evade or defeat immune recognition. Immune restraints on the virus, however, are typically so effective that most infections are never symptomatic. In contrast, acute infectious mononucleosis, a self-limited lymphoproliferative illness, is common in adolescents and young adults. Unbridled proliferative illnesses arise when cellular immunity is grossly defective. Treatment of EBV-associated syndromes is largely supportive. Antiviral drugs have no proven role except in patients with oral hairy leukoplakia. Vaccine development is technically feasible but is not considered a high priority for developed nations.	US FDA, CTR BIOL EVALUAT & RES, IMMUNOL LAB, BETHESDA, MD 20014 USA	US Food & Drug Administration (FDA)	STRAUS, SE (corresponding author), NIAID, MED VIROL SECT, CLIN INVEST LAB, BLDG 10, ROOM 11N228, BETHESDA, MD 20892 USA.			Tosato, Giovanna/0000-0003-1663-3227; Meier, Jeffery/0000-0001-9491-1697				ANDERSSON J, 1986, J INFECT DIS, V153, P283, DOI 10.1093/infdis/153.2.283; ANDERSSON J, 1987, INFECTION, V15, pS14, DOI 10.1007/BF01650106; ANDERSSON J, 1988, AM J MED, V85, P107; ANTILA V, 1962, ACTA MED SCAND, V171, P345; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARANSKI B, 1988, ANN INTERN MED, V109, P695, DOI 10.7326/0003-4819-109-9-695; BENDER CE, 1967, J AMER MED ASSOC, V199, P529, DOI 10.1001/jama.199.8.529; BENNIKE T, 1951, ARCH INTERN MED, V87, P181, DOI 10.1001/archinte.1951.03810020003001; BIRX DL, 1990, BLOOD, V76, P2303; BRANDFONBRENER A, 1986, ARCH INTERN MED, V146, P337, DOI 10.1001/archinte.146.2.337; BURROWS SR, 1990, J VIROL, V64, P3974, DOI 10.1128/JVI.64.8.3974-3976.1990; BURROWS SR, 1990, J EXP MED, V171, P345, DOI 10.1084/jem.171.1.345; COHEN JI, 1991, MEDICINE, V70, P137, DOI 10.1097/00005792-199103000-00005; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; COLBY BM, 1980, J VIROL, V34, P560, DOI 10.1128/JVI.34.2.560-568.1980; Collins M, 1984, J Am Coll Health, V33, P101; COPEMAN H A, 1956, Med J Aust, V43, P925; CROSS M, 1991, CELL, V64, P271, DOI 10.1016/0092-8674(91)90638-F; DOMMERBY H, 1986, J LARYNGOL OTOL, V100, P573, DOI 10.1017/S0022215100099680; EVANS AS, 1975, J INFECT DIS, V12, P645; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FILATOW NJ, 1885, LEKTUSH OB OSTRIKU I; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; FISCHER A, 1991, NEW ENGL J MED, V324, P1451, DOI 10.1056/NEJM199105233242102; FRENKEL EP, 1956, JAMA-J AM MED ASSOC, V162, P885, DOI 10.1001/jama.1956.72970260004010a; GARNER JS, 1983, INFECT CONT HOSP EP, V4, P245; GERBER P, 1969, LANCET, V1, P593; GILLIGAN K, 1990, P NATL ACAD SCI USA, V87, P8790, DOI 10.1073/pnas.87.22.8790; GOLDEN HD, 1973, J INFECT DIS, V127, P471, DOI 10.1093/infdis/127.4.471; GORDON J, 1984, J EXP MED, V159, P1554, DOI 10.1084/jem.159.5.1554; GRATAMA JW, 1988, P NATL ACAD SCI USA, V85, P8693, DOI 10.1073/pnas.85.22.8693; GREENSPAN JS, 1985, NEW ENGL J MED, V313, P1564, DOI 10.1056/NEJM198512193132502; GRIERSON H, 1987, ANN INTERN MED, V106, P538, DOI 10.7326/0003-4819-106-4-538; GRISHABER JE, 1988, AM J HEMATOL, V28, P273, DOI 10.1002/ajh.2830280412; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HO M, 1988, TRANSPLANTATION, V45, P719, DOI 10.1097/00007890-198804000-00011; HORWITZ CA, 1985, J INFECT DIS, V151, P1150, DOI 10.1093/infdis/151.6.1150; HSU DH, 1990, SCIENCE, V250, P830, DOI 10.1126/science.2173142; JONES JF, 1988, NEW ENGL J MED, V318, P733, DOI 10.1056/NEJM198803243181203; JONES K, 1992, IN PRESS CLIN RES; Kano K, 1977, Curr Top Microbiol Immunol, V77, P43; KATZ MH, 1991, J INFECT DIS, V164, P1240, DOI 10.1093/infdis/164.6.1240; KIEFF E, 1990, VIROLOGY, P1889; KLEIN E, 1969, J AMER COLL HEALTH A, V17, P446; KLEIN G, 1989, CELL, V58, P5, DOI 10.1016/0092-8674(89)90394-2; LAZARUS KH, 1981, PEDIATRICS, V67, P907; LI QX, 1992, NATURE, V356, P347, DOI 10.1038/356347a0; LONGNECKER R, 1991, J VIROL, V65, P3681, DOI 10.1128/JVI.65.7.3681-3692.1991; MAKI DG, 1982, AM J SPORT MED, V10, P162, DOI 10.1177/036354658201000308; MCGOWAN JE, 1992, J INFECT DIS, V165, P1, DOI 10.1093/infdis/165.1.1; MILLER G, 1990, J INFECT DIS, V161, P833, DOI 10.1093/infdis/161.5.833; MILLER G, 1990, VIROLOGY, P1921; MORGAN AJ, 1989, J MED VIROL, V29, P74, DOI 10.1002/jmv.1890290114; MOSS DJ, 1981, NATURE, V291, P664, DOI 10.1038/291664a0; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; MURRAY RJ, 1990, P NATL ACAD SCI USA, V87, P2906, DOI 10.1073/pnas.87.8.2906; NYE FJ, 1973, J HYG-CAMBRIDGE, V71, P151, DOI 10.1017/S0022172400046325; OKANO M, 1990, CLIN IMMUNOL IMMUNOP, V54, P410, DOI 10.1016/0090-1229(90)90054-T; OKANO M, 1988, Clinical Microbiology Reviews, V1, P300; OKANO M, 1989, J CLIN IMMUNOL, V9, P48, DOI 10.1007/BF00917127; PAGANO JS, 1983, J ANTIMICROB CHEMOTH, V12, P113, DOI 10.1093/jac/12.suppl_B.113; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PIKE SE, 1991, P NATL ACAD SCI USA, V88, P11081, DOI 10.1073/pnas.88.24.11081; PROUT C, 1966, J AMER COLL HEALTH A, V15, P62; PURTILO DT, 1977, NEW ENGL J MED, V297, P1077, DOI 10.1056/NEJM197711172972001; RESNICK L, 1988, JAMA-J AM MED ASSOC, V259, P384, DOI 10.1001/jama.259.3.384; RICKINSON AB, 1990, EPSTEINBARR VIRUS RE, P75; ROWE M, 1991, J EXP MED, V173, P147, DOI 10.1084/jem.173.1.147; ROWE M, 1989, ADV VIRAL ONCOL, V8, P237; SCALA G, 1990, J EXP MED, V172, P61, DOI 10.1084/jem.172.1.61; SCHLOSSBERG D, 1989, INFECTIOUS MONONUCLE; SCHOOLEY RT, 1986, ANN INTERN MED, V104, P636, DOI 10.7326/0003-4819-104-5-636; SCHOOLEY RT, 1990, PRINCIPLES PRACTICE, V3, P1172; SCHUMACHER HR, 1963, ANN INTERN MED, V58, P217, DOI 10.7326/0003-4819-58-2-217; SHAPIRO RS, 1988, NEW ENGL J MED, V318, P1334; SHEARER WT, 1985, NEW ENGL J MED, V312, P1151, DOI 10.1056/NEJM198505023121804; SIXBEY JW, 1986, LANCET, V2, P1122; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SIXBEY JW, 1989, LANCET, V2, P761; SMITH JN, 1956, ANN INTERN MED, V44, P861, DOI 10.7326/0003-4819-44-5-861; STAUS SE, 1992, ANNU REV MED, V43, P437; STRAUS SE, 1988, J INFECT DIS, V157, P405, DOI 10.1093/infdis/157.3.405; STRAUS SE, 1990, ANTIVIR AGENTS VIR, P647; STRAUSS SE, 1989, INFECTIOUS MONONUCLE, P8; SULLIVAN JL, 1982, AM J MED, V73, P262, DOI 10.1016/0002-9343(82)90102-4; SUMAYA CV, 1986, J INFECT DIS, V154, P864, DOI 10.1093/infdis/154.5.864; SVEDMYR E, 1984, CLIN IMMUNOL IMMUNOP, V30, P437, DOI 10.1016/0090-1229(84)90029-1; SWAMINATHAN S, 1991, P NATL ACAD SCI USA, V88, P1546, DOI 10.1073/pnas.88.4.1546; SWENDEMAN S, 1987, EMBO J, V6, P1637, DOI 10.1002/j.1460-2075.1987.tb02412.x; TANNER J, 1991, J CLIN INVEST, V88, P239, DOI 10.1172/JCI115283; THOMAS JA, 1990, TRANSPLANTATION, V49, P944, DOI 10.1097/00007890-199005000-00022; THORLEYLAWSON DA, 1987, P NATL ACAD SCI USA, V84, P5384, DOI 10.1073/pnas.84.15.5384; TOSATO G, 1990, J VIROL, V64, P3033, DOI 10.1128/JVI.64.6.3033-3041.1990; TOSATO G, 1987, ADV CANCER RES, P49; VANDERHORST C, 1991, J INFECT DIS, V164, P788, DOI 10.1093/infdis/164.4.788; VIEIRA P, 1991, P NATL ACAD SCI USA, V88, P1172, DOI 10.1073/pnas.88.4.1172; WAKASUGI H, 1987, P NATL ACAD SCI USA, V84, P804, DOI 10.1073/pnas.84.3.804; WALDO RT, 1981, SOUTHERN MED J, V74, P1159, DOI 10.1097/00007611-198109000-00040; WANG F, 1987, J CLIN INVEST, V79, P7, DOI 10.1172/JCI112810; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; YAO QY, 1989, INT J CANCER, V43, P67, DOI 10.1002/ijc.2910430115; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; YOUNG LS, 1991, J VIROL, V65, P2868, DOI 10.1128/JVI.65.6.2868-2874.1991	107	303	322	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1993	118	1					45	58		10.7326/0003-4819-118-1-199301010-00009	http://dx.doi.org/10.7326/0003-4819-118-1-199301010-00009			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KE605	8380053				2022-12-28	WOS:A1993KE60500009
J	WERNICK, RM; SMITH, DL; HOUGHTON, DC; PHILLIPS, DS; BOOTH, JL; RUNCKEL, DN; JOHNSON, DS; BROWN, KK; GABOURY, CL				WERNICK, RM; SMITH, DL; HOUGHTON, DC; PHILLIPS, DS; BOOTH, JL; RUNCKEL, DN; JOHNSON, DS; BROWN, KK; GABOURY, CL			RELIABILITY OF HISTOLOGIC SCORING FOR LUPUS NEPHRITIS - A COMMUNITY-BASED EVALUATION	ANNALS OF INTERNAL MEDICINE			English	Article						LUPUS NEPHRITIS; GLOMERULONEPHRITIS; HISTOLOGIC TECHNIQUES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); KIDNEY FAILURE, CHRONIC	TERM FOLLOW-UP; PROGNOSTIC FACTORS; INTEROBSERVER VARIABILITY; OBSERVER VARIATION; CLINICAL METHODS; GLOMERULONEPHRITIS; CLASSIFICATION; PREDNISONE; CYCLOPHOSPHAMIDE; ERYTHEMATOSUS	Objective: To determine the reliability of the National Institutes of Health (NIH)-modified semiquantitative histologic scoring system for lupus nephritis. Design: Cross-sectional study, repeated after 8 to 9 months. Setting: Four community hospitals and one university medical center. Participants: Five pathologists, all experienced in reading renal biopsy specimens, assessed 25 specimens that had been obtained from patients with a clinical diagnosis of systemic lupus erythematosus and showed diffuse proliferative glomerulonephritis. Measurements: Biopsy specimens were scored independently and blindly by pathologists for components of nephritis chronicity and activity. Reliability was measured by percentage agreement, intraclass correlation coefficient or kappa statistic, and individual reader effect on the group arithmetic mean. Results: As scored by the readers, the mean chronicity index score varied from 2.3 to 4.8 on a 12-point scale (P = 0.001) and the mean activity index score varied from 5.8 to 11.4 on a 24-point scale (P = 0.0001). Pairs of readers gave scores within 1 point for the chronicity index and within 2 points for the activity index in 50% of cases, and risk group assignments based on chronicity index (three strata) and activity index (two strata) were concordant in 59% and 76% of cases, respectively. Intraclass correlation coefficients for inter-reader agreement were 0.58 for the chronicity index (P < 0.01) and 0.52 for the activity index (P < 0.01). Intrareader agreement was uniformly higher than inter-reader agreement, but mean intraclass correlation coefficients exceeded 0.70 for only 1 of the 10 index components. Repeated readings yielded chronicity index scores that were more than 1 point discordant in 45% of cases and activity index scores that were more than 2 points discordant in 43% of cases. Risk group assignment changed on the basis of chronicity index and activity index in 36% and 21% of cases, respectively. Conclusions: In a nonreferral setting, the NIH-modified scoring system for lupus nephritis is only moderately reproducible and, if used to prognosticate renal outcome, may result in erroneous predictions of risk for renal failure and response to therapy.	OREGON HLTH SCI UNIV, DEPT PATHOL, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT NEPHROL, PORTLAND, OR 97201 USA; VET AFFAIRS MED CTR, PORTLAND, OR 97207 USA; OREGON HLTH SCI UNIV, DEPT PUBL HLTH & PREVENT MED, PORTLAND, OR 97201 USA; ST VINCENT HOSP & MED CTR, DEPT PATHOL, PORTLAND, OR 97227 USA; GOOD SAMARITAN HOSP, PORTLAND, OR USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Saint Vincents Hospital Manhattan	WERNICK, RM (corresponding author), PROVIDENCE MED CTR, 4805 NE GLISAN ST, PORTLAND, OR 97213 USA.							ALEXOPOULOS E, 1990, KIDNEY INT, V37, P100, DOI 10.1038/ki.1990.14; APPEL GB, 1978, MEDICINE, V57, P371, DOI 10.1097/00005792-197809000-00001; APPEL GB, 1987, AM J MED, V83, P877, DOI 10.1016/0002-9343(87)90645-0; AUSTIN HA, 1984, KIDNEY INT, V25, P689, DOI 10.1038/ki.1984.75; AUSTIN HA, 1983, AM J MED, V75, P382, DOI 10.1016/0002-9343(83)90338-8; AUSTIN HA, 1986, NEW ENGL J MED, V314, P614, DOI 10.1056/NEJM198603063141004; BALDWIN DS, 1970, ANN INTERN MED, V73, P929, DOI 10.7326/0003-4819-73-6-929; BALOW JE, 1984, NEW ENGL J MED, V311, P491, DOI 10.1056/NEJM198408233110802; BALOW JE, 1987, ANN INTERN MED, V106, P79, DOI 10.7326/0003-4819-106-1-79; BALOW JE, 1988, HOSP PRACT, V23, P129; BANFI G, 1985, Q J MED, V55, P153; BARTKO JJ, 1966, PSYCHOL REP, V19, P3, DOI 10.2466/pr0.1966.19.1.3; CARETTE S, 1983, ANN INTERN MED, V99, P1, DOI 10.7326/0003-4819-99-1-1; DONADIO JV, 1972, ANN INTERN MED, V77, P829, DOI 10.7326/0003-4819-77-6-829; ESDAILE JM, 1989, Q J MED, V72, P779; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; GAMBA G, 1991, NEPHRON, V57, P75, DOI 10.1159/000186220; KLINKHOFF AV, 1988, J RHEUMATOL, V15, P492; KORAN LM, 1975, NEW ENGL J MED, V293, P695, DOI 10.1056/NEJM197510022931405; KORAN LM, 1975, NEW ENGL J MED, V293, P642, DOI 10.1056/NEJM197509252931307; LAITMAN RS, 1989, AM J MED, V87, P132; LEVEY AS, 1992, ANN INTERN MED, V116, P114, DOI 10.7326/0003-4819-116-2-114; MAGIL AB, 1988, KIDNEY INT, V34, P511, DOI 10.1038/ki.1988.211; MCCUNE WJ, 1988, NEW ENGL J MED, V318, P1423, DOI 10.1056/NEJM198806023182203; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; NOSSENT HC, 1990, ARTHRITIS RHEUM, V33, P970, DOI 10.1002/art.1780330708; PILLEMER SR, 1988, J RHEUMATOL, V15, P284; PIRANI CL, 1964, NEPHRON, V1, P230, DOI 10.1159/000179336; PIRANI CL, 1968, PATHOL ANNU, V3, P249; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P424; RUSH PJ, 1986, KIDNEY INT, V29, P1066, DOI 10.1038/ki.1986.108; SACKETT DL, 1980, CAN MED ASSOC J, V123, P499; SCHWARTZ MM, 1992, KIDNEY INT, V42, P743, DOI 10.1038/ki.1992.342; SCHWARTZ MM, 1989, KIDNEY INT, V36, P891, DOI 10.1038/ki.1989.276; SHANES JG, 1987, CIRCULATION, V75, P401, DOI 10.1161/01.CIR.75.2.401; SILCOCKS PBS, 1983, J CLIN PATHOL, V36, P1269, DOI 10.1136/jcp.36.11.1269; SISSONS HA, 1975, POSTGRAD MED J, V51, P685, DOI 10.1136/pgmj.51.600.685; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; THOMAS GDH, 1983, J CLIN PATHOL, V36, P385, DOI 10.1136/jcp.36.4.385	40	52	53	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					805	811		10.7326/0003-4819-119-8-199310150-00006	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379602				2022-12-28	WOS:A1993MB49600006
J	CASLEYSMITH, JR; MORGAN, RG; PILLER, NB				CASLEYSMITH, JR; MORGAN, RG; PILLER, NB			TREATMENT OF LYMPHEDEMA OF THE ARMS AND LEGS WITH 5,6-BENZO-[ALPHA]-PYRONE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LYMPHOEDEMA	Background. Benzopyrones can reduce the volume of high-protein edema fluid by stimulating proteolysis. These compounds provide a method for removing excess protein and its consequent edema and reduce its clinical sequelae, such as chronic inflammation and secondary infections. Methods. We conducted a randomized, double-blind, placebo-controlled, crossover trial of 5,6-benzo-[alpha]-pyrone in 31 patients with postmastectomy lymphedema of the arm and 21 patients with lymphedema of the leg of various causes. This agent is also known as 56 BaP, 1,2-benzopyrone, and coumarin, although it has no anticoagulant activity. The patients received 400 mg of the active drug or placebo, each for six months. Results. During the placebo period, lymphedema often worsened, especially in the arms. Measurements of limb volume showed that the active drug reduced the mean amount of edema fluid in the arms from 46 percent above normal to 26 percent above normal (P<0.001) and the amount in the legs from 25 percent to 17 percent above normal (P<0.001). The circumference of the arms was reduced from 17 percent to 13 percent above normal, and the circumference of the legs from 11 percent to 7 percent above normal (P<0.001). The softness of the limb tissue was increased (P<0.001), and elevated skin temperatures were reduced (P<0.001). There were fewer attacks of secondary acute inflammation (P = 0.01). Bursting pains and feelings of hardness were decreased, as were feelings of tightness, tension, swelling, and heaviness; limb mobility also improved. The active drug was preferred to the placebo by 93 percent of the patients (P<0.001). Side effects - mild nausea or diarrhea - occurred in seven patients taking the active drug. None withdrew f rom the trial, and the side effects disappeared after the first month of therapy. Conclusions. 5,6-Benzo-[alpha]-pyrone results in slow but safe reduction of lymphedema of the extremities.	FLINDERS UNIV S AUSTRALIA,MED CTR,DEPT SURG,BEDFORD PK,SA 5042,AUSTRALIA; FLINDERS UNIV S AUSTRALIA,FAC HLTH SCI,BEDFORD PK,SA 5042,AUSTRALIA	Flinders University South Australia; Flinders University South Australia	CASLEYSMITH, JR (corresponding author), UNIV ADELAIDE,HENRY THOMAS LAB MICROCIRCULAT RES,BOX 498 GPO,ADELAIDE,SA 5001,AUSTRALIA.			Piller, Neil/0000-0002-3148-4293				Braun H D, 1971, Munch Med Wochenschr, V113, P1630; Casley-Smith J R, 1992, Australas J Dermatol, V33, P61, DOI 10.1111/j.1440-0960.1992.tb00081.x; Casley-Smith J.R., 1986, HIGH PROTEIN OEDEMAS; CASLEYSMITH JR, 1981, J PATHOL, V133, P243, DOI 10.1002/path.1711330307; CASLEYSMITH JR, 1985, LYMPHOLOGY, V18, P175; CASLEYSMITH JR, 1993, ANN TROP MED PARASIT, V87, P247, DOI 10.1080/00034983.1993.11812763; CASLEYSMITH JR, 1986, THERAPIEWOCHE, V36, P1068; CASLEYSMITH JR, 1992, PROGR LYMPHOLOGY, V13, P537; CASLEYSMITH JR, IN PRESS BMJ; CLODIUS L, 1983, LYMPHANGIOLOGY, P683; Clodius L., 1982, ADV LYMPHOLOGY, P471; CLUZAN R, 1990, PROGR LYMPHOLOGY, V12, P453; DESPREZCURELY JP, 1985, PROGR LYMPHOLOGY, V10, P203; FOLDI E, 1989, ANN PLAS SURG, V22, P505; FOLDI M, 1991, LEHRBUCH LYMPHOLOGIE; PILLER NB, 1976, LYMPHOLOGY, V9, P127; PILLER NB, 1988, BRIT J PLAST SURG, V41, P20, DOI 10.1016/0007-1226(88)90139-7; SWEDBORG I, 1977, SCAND J REHABIL MED, V9, P131; SWEDBORG I, 1981, SCAND J REHABIL MED, V13, P23; 1984, WHO TECH REP SER, V702, P1	20	212	220	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1158	1163		10.1056/NEJM199310143291604	http://dx.doi.org/10.1056/NEJM199310143291604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377779				2022-12-28	WOS:A1993MA66700004
J	NADOL, JB				NADOL, JB			HEARING-LOSS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INNER-EAR; DOUBLE-BLIND; OTITIS-MEDIA; MANIFESTATIONS; MENINGITIS; THERAPY; PHARMACOKINETICS; OTOTOXICITY; GENTAMICIN; TOBRAMYCIN		HARVARD UNIV, SCH MED, DEPT OTOL & LARYNGOL, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	NADOL, JB (corresponding author), MASSACHUSETTS EYE & EAR INFIRM, DEPT OTOLARYNGOL, 243 CHARLES ST, BOSTON, MA 02114 USA.							BARNA BP, 1988, LARYNGOSCOPE, V98, P251; BHATT S, 1991, LARYNGOSCOPE, V101, P1285, DOI 10.1002/lary.5541011206; BOHNE BA, 1985, LARYNGOSCOPE, V95, P818; BOSHER SK, 1980, ACTA OTO-LARYNGOL, V90, P40, DOI 10.3109/00016488009131696; BRAMA I, 1980, ARCH OTOLARYNGOL, V106, P215; BROWN KS, 1969, MED CLIN N AM, V53, P741, DOI 10.1016/S0025-7125(16)32731-6; BYL FM, 1977, LARYNGOSCOPE, V87, P372, DOI 10.1288/00005537-197703000-00010; CALDARELLI DD, 1986, AM J OTOL, V7, P210; CARRUTHERS D. G., 1945, Medical Journal of Australia, V1, P315; CHESON BD, 1976, AM J MED, V60, P549, DOI 10.1016/0002-9343(76)90722-1; CODY DTR, 1971, LARYNGOSCOPE, V81, P1208, DOI 10.1288/00005537-197108000-00004; David AC., 1983, HEARING SCI HEARING, P35; DAVIGNON M, 1964, ARCHIV OTOLARYNGOL, V80, P136, DOI 10.1001/archotol.80.2.136; DAVIS LE, 1983, AM J OTOLARYNG, V4, P347, DOI 10.1016/S0196-0709(83)80022-2; DEY FL, 1970, NEW ENGL J MED, V282, P467, DOI 10.1056/NEJM197002262820902; DOBROWSKI JM, 1985, OTOLARYNG HEAD NECK, V93, P798, DOI 10.1177/019459988509300619; DRYJA TP, 1990, NATURE, V343, P364, DOI 10.1038/343364a0; EMMETT JR, 1986, OTOLARYNG HEAD NECK, V94, P611; EVERBERG G, 1960, Acta Otolaryngol, V51, P615, DOI 10.3109/00016486009124539; FEDERSPIL P, 1976, J INFECT DIS, V134, pS200, DOI 10.1093/infdis/134.Supplement_1.S200; FISCH L, 1955, LANCET, V2, P370; FISHER CM, 1961, J NEUROPATH EXP NEUR, V20, P323, DOI 10.1097/00005072-196107000-00001; FORBES SB, 1943, ANN OTO RHINOL LARYN, V52, P109; FOY C, 1990, AM J HUM GENET, V46, P1017; FRASER GR, 1984, J MED GENET, V1, P118; Fraser W I, 1968, J Ment Defic Res, V12, P322; FRIEDMANN I, 1973, Journal of Laryngology and Otology, V87, P449, DOI 10.1017/S0022215100077136; GENTILE A, 1967, DHHS PHS1000 PUBL; Guild S.R., 1944, ANN OTO RHINOL LARYN, V53, P246; HARDY JB, 1973, ARCH OTOLARYNGOL, V98, P230; HARRIS JP, 1989, AM J OTOL, V10, P193; HAYES D, 1982, AGING COMMUNICATION, V96, P503; HEALY LA, 1978, SYSTEMIC MANIFESTATI; HILDESHEIMER M, 1990, ARCH OTOLARYNGOL, V116, P820; HOTCHKISS D, 1989, DEMOGRAPHIC ASPECTS; HOUCK JR, 1992, OTOLARYNG HEAD NECK, V106, P92, DOI 10.1177/019459989210600134; HUGHES GB, 1984, LARYNGOSCOPE, V94, P758; JAFFE BF, 1970, LARYNGOSCOPE, V80, P788, DOI 10.1288/00005537-197005000-00010; JEANES A L, 1960, Tubercle, V41, P109; JOSEPH JM, 1987, ELECTR RESPONSE AUDI, V19, P141; Konigsmark B.W., 1976, GENETIC METABOLIC DE; KONIGSMARK BW, 1969, NEW ENGL J MED, V281, P713, DOI 10.1056/NEJM196909252811306; KONIGSMARK BW, 1971, LARYNGOSCOPE, V81, P759, DOI 10.1288/00005537-197105000-00017; KRESKY B, 1962, ARCH PEDIATR, V79, P63; KROBOTH PD, 1983, ARCH INTERN MED, V143, P1263, DOI 10.1001/archinte.143.6.1263; KWOK OT, 1989, AM J OTOLARYNG, V10, P1, DOI 10.1016/0196-0709(89)90086-0; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LEBEL MH, 1988, NEW ENGL J MED, V319, P964, DOI 10.1056/NEJM198810133191502; Lerner S A, 1980, Am J Otolaryngol, V1, P169, DOI 10.1016/S0196-0709(80)80012-3; Lerner SA, 1981, AMINOGLYCOSIDE OTOTO; MCCABE BF, 1979, ANN OTO RHINOL LARYN, V88, P585, DOI 10.1177/000348947908800501; MCKENNA MJ, 1992, IMMUNOBIOLOGY IN OTOLOGY, RHINOLOGY AND LARYNGOLOGY, P101; MEYERHOFF WL, 1979, LARYNGOSCOPE, V89, P1; MICHEL O, 1992, ANN OTO RHINOL LARYN, V101, P390, DOI 10.1177/000348949210100503; MOSCICKI R, 1988, J ALLERGY CLIN IMMUN, V81, P217, DOI 10.1016/0091-6749(88)90432-0; MYERS EN, 1965, NEW ENGL J MED, V273, P587, DOI 10.1056/NEJM196509092731104; NADOL JB, 1992, LARYNGOSCOPE, V102, P1153, DOI 10.1288/00005537-199210000-00010; NADOL JB, 1978, LARYNGOSCOPE, V88, P739; NADOL JB, 1988, ANNU REV MED, V39, P491, DOI 10.1146/annurev.med.39.1.491; Nadol JB, 1981, AGING COMMUNICATION, P63; NADOL JB, 1989, MENIERES DISEASE PAT; NADOL JB, 1980, 5TH P INT C MORPH MA, P181; NANCE WE, 1975, OTOLARYNG CLIN N AM, V8, P19; NOFFSINGER D, 1972, ACTA OTO-LARYNGOL, P1; OLSSON JE, 1991, LARYNGOSCOPE, V101, P1; OSGUTHORPE JD, 1988, AM ACADEMY OTOLARYNG; PAPARELLA MM, 1973, LARYNGOSCOPE, V83, P1510, DOI 10.1288/00005537-197309000-00010; PAUGH DR, 1991, OTOLARYNG HEAD NECK, V104, P517, DOI 10.1177/019459989110400416; Peitersen E, 1966, Acta Otolaryngol, V61, P189, DOI 10.3109/00016486609127055; PFALTZ CR, 1986, CONTROVERSIAL ASPECT, P2; PUKANDER J, 1982, ACTA OTO-LARYNGOL, V94, P479, DOI 10.3109/00016488209128938; ROBERTSON M S, 1962, J Laryngol Otol, V76, P655, DOI 10.1017/S0022215100059855; Ruben R.J., 1982, CHOLESTEATOMA MASTOI, P111; SANK D, 1963, VOLTA REV, V65, P461; Schuknecht H. F., 1974, PATHOLOGY EAR, P388; SCHUKNECHT HF, 1991, ADV OTO-RHINO-LARYNG, V46, P50; SCHUKNECHT HF, 1969, NEW ENGL J MED, V280, P1154, DOI 10.1056/NEJM196905222802105; SCHWEITZER VG, 1984, ARCH OTOLARYNGOL, V110, P258; SMITH CR, 1980, NEW ENGL J MED, V302, P1106, DOI 10.1056/NEJM198005153022002; SNIDER WD, 1983, ANN NEUROL, V14, P403, DOI 10.1002/ana.410140404; STEWART TJ, 1975, ARCH OTOLARYNGOL, V101, P91; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; STRAUSS M, 1983, LARYNGOSCOPE, V93, P1554, DOI 10.1288/00005537-198312000-00007; VERNON M, 1967, EXCEPT CHILDREN, V33, P289, DOI 10.1177/001440296703300501; VERNON M, 1967, EXCEPT CHILDREN, V34, P5, DOI 10.1177/001440296703400101; WILSON WR, 1980, ARCH OTOLARYNGOL, V106, P772; WOOLF NK, 1985, ANN OTO RHINOL LARYN, V94, P350; WURSTER CF, 1982, OTOLARYNG HEAD NECK, V90, P126, DOI 10.1177/019459988209000121; ZOLLER M, 1979, ANN OTO RHINOL LARYN, V88, P160, DOI 10.1177/000348947908800202; ZOLLER M, 1978, ARCH OTOLARYNGOL, V104, P63; 1990, DHHS PHS901504 NAT C; 1989, REPORT TASK FORCE NA; 1970, HUMAN COMMUNICATION; 1973, ARCH OTOLARYNGOL, V98, P397; 1991, DHHS NIH913189 NAT I	95	161	166	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1092	1102		10.1056/NEJM199310073291507	http://dx.doi.org/10.1056/NEJM199310073291507			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371732				2022-12-28	WOS:A1993LZ64000007
J	CHIK, CL; FRIEDMAN, A; MERRIAM, GR; GAHL, WA				CHIK, CL; FRIEDMAN, A; MERRIAM, GR; GAHL, WA			PITUITARY-TESTICULAR FUNCTION IN NEPHROPATHIC CYSTINOSIS	ANNALS OF INTERNAL MEDICINE			English	Article						CYSTINOSIS; KIDNEY TRANSPLANTATION; TESTOSTERONE; KIDNEY FAILURE, CHRONIC; HYPOGONADISM	PLASMA TESTOSTERONE; HORMONE-SECRETION; LH; COMPLICATIONS; INSUFFICIENCY; HYPOGONADISM; CHILDREN; SUBUNITS; INVITRO; PATIENT	Objective: To evaluate reproductive function in patients with cystinosis and in renal transplant recipients without cystinosis. Design: Cross-sectional study. Setting: Clinical Center, National Institutes of Health. Patients: Ten male patients, 15 to 28 years old, with nephropathic cystinosis and renal allografts formed the study group; 11 renal transplant recipients who had a primary renal disorder other than cystinosis and were matched with study patients for age and renal function served as the control group. Measurements: Tanner staging, serum gonadotropin determinations, and testosterone and testosterone-binding globulin assessments. Selected patients also had a human chorionic gonadotropin (HCG) stimulation test, a gonadotropin-releasing hormone (GnRH) stimulation test, and serial sampling for luteinizing hormone (LH). Main Results: Although testosterone levels were within normal limits in 7 of 10 patients with cystinosis, the mean testosterone level in patients with cystinosis was 11.5 +/- 2.0 nmol/L compared with 24.2 +/- 3.0 nmol/L in control patients (P < 0.005). No patient with cystinosis reached Tanner stage 5 (full pubertal development), whereas 9 of 11 control patients did. Seven of 10 patients with cystinosis had elevations in LH or follicle-stimulating hormone (FSH) levels, suggesting testicular failure. These patients also had normal LH and FSH responses after GnRH stimulation, increased LH pulse frequency, and reduced testosterone response after HCG stimulation. In comparison, only 3 of 11 control patients had minimally elevated gonadotropin levels, and all 11 had normal testosterone levels. Microscopic testicular examination in one patient showed cystine crystals, germinal dysplasia, increased fibrosis, and Leydig cell hyperplasia. Conclusions: Abnormalities in the pituitary-testicular axis are common in male patients with cystinosis. These changes appear to be related to the disease cystinosis and not to treated renal failure per se.	NICHHD, HUMAN GENET BRANCH, BLDG 10, ROOM 95-242, BETHESDA, MD 20892 USA; UNIV WISCONSIN, MADISON, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Wisconsin System; University of Wisconsin Madison								ADAMSON MD, 1989, SEMIN NEPHROL, V9, P147; AMMENTI A, 1986, EUR J PEDIATR, V145, P548, DOI 10.1007/BF02429061; BLACKMAN MR, 1981, J CLIN ENDOCR METAB, V53, P39, DOI 10.1210/jcem-53-1-39; BLACKMAN MR, 1980, JNCI-J NATL CANCER I, V65, P81; CHAN AM, 1970, AM J MED, V48, P678, DOI 10.1016/S0002-9343(70)80002-X; DUFAU ML, 1972, CLIN CHIM ACTA, V37, P109, DOI 10.1016/0009-8981(72)90421-4; DUFAU ML, 1976, J CLIN ENDOCR METAB, V42, P958, DOI 10.1210/jcem-42-5-958; FINK JK, 1989, ARCH NEUROL-CHICAGO, V46, P543, DOI 10.1001/archneur.1989.00520410077027; FIVUSH B, 1988, J PEDIATR-US, V112, P49, DOI 10.1016/S0022-3476(88)80119-7; FIVUSH B, 1987, AM J DIS CHILD, V141, P1087, DOI 10.1001/archpedi.1987.04460100065027; FRANCHIMONT P, 1974, CLIN ENDOCRINOL, V3, P27, DOI 10.1111/j.1365-2265.1974.tb03293.x; Gahl W A, 1986, Adv Pediatr, V33, P95; GAHL WA, 1986, J PEDIATR-US, V109, P605, DOI 10.1016/S0022-3476(86)80221-9; GAHL WA, 1988, ANN INTERN MED, V109, P557, DOI 10.7326/0003-4819-109-7-557; GAHL WA, 1987, NEW ENGL J MED, V316, P971, DOI 10.1056/NEJM198704163161602; GAHL WA, 1982, J BIOL CHEM, V257, P9570; GAHL WA, 1987, PEDIATR NEPHROL, V1, P260, DOI 10.1007/BF00849221; GAHL WA, 1988, NEW ENGL J MED, V319, P1461, DOI 10.1056/NEJM198812013192206; GAHL WA, 1982, SCIENCE, V217, P1263, DOI 10.1126/science.7112129; GAHL WA, 1989, METABOLIC BASIS INHE, V2, P2619; GROSS KM, 1985, J CLIN ENDOCR METAB, V60, P197, DOI 10.1210/jcem-60-1-197; JONAS AJ, 1987, AM J MED, V83, P966, DOI 10.1016/0002-9343(87)90661-9; KAISERKUPFER MI, 1986, ARCH OPHTHALMOL-CHIC, V104, P706, DOI 10.1001/archopht.1986.01050170096030; KOURIDES IA, 1974, ENDOCRINOLOGY, V94, P1411, DOI 10.1210/endo-94-5-1411; LUCKY AW, 1977, J PEDIATR-US, V91, P204, DOI 10.1016/S0022-3476(77)80813-5; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; MATSUMOTO AM, 1984, J CLIN ENDOCR METAB, V58, P609, DOI 10.1210/jcem-58-4-609; MERRIAM GR, 1982, AM J PHYSIOL, V243, pE310, DOI 10.1152/ajpendo.1982.243.4.E310; ODELL WD, 1966, METABOLIS, V15, P287, DOI 10.1016/0026-0495(66)90142-9; ODELL WD, 1967, J LAB CLIN MED, V70, P973; REISS RE, 1988, NEW ENGL J MED, V319, P223, DOI 10.1056/NEJM198807283190406; ROTH JC, 1972, J CLIN ENDOCR METAB, V35, P926, DOI 10.1210/jcem-35-6-926; SAEZ JM, 1979, J CLIN ENDOCR METAB, V49, P278, DOI 10.1210/jcem-49-2-278; SMALS AGH, 1979, J CLIN ENDOCR METAB, V49, P12, DOI 10.1210/jcem-49-1-12; SMALS AGH, 1974, ACTA ENDOCRINOL-COP, V77, P753, DOI 10.1530/acta.0.0770753; SONIES BC, 1990, NEW ENGL J MED, V323, P565, DOI 10.1056/NEJM199008303230903; SPRATT DI, 1987, J CLIN ENDOCR METAB, V64, P283, DOI 10.1210/jcem-64-2-283; THOENE JG, 1976, J CLIN INVEST, V58, P180, DOI 10.1172/JCI108448; WINTER JSD, 1972, J CLIN ENDOCR METAB, V34, P348, DOI 10.1210/jcem-34-2-348; WOLLENSEN F, 1976, METABOLISM, V8, P845	40	55	58	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				568	575		10.7326/0003-4819-119-7_Part_1-199310010-00004	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363167				2022-12-28	WOS:A1993MA29100004
J	SMALL, T				SMALL, T			THE RIGHT CHOICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1416	1416		10.1001/jama.270.12.1416	http://dx.doi.org/10.1001/jama.270.12.1416			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371430				2022-12-28	WOS:A1993LX17300009
J	EWIGMAN, BG; CRANE, JP; FRIGOLETTO, FD; LEFEVRE, ML; BAIN, RP; MCNELLIS, D				EWIGMAN, BG; CRANE, JP; FRIGOLETTO, FD; LEFEVRE, ML; BAIN, RP; MCNELLIS, D			EFFECT OF PRENATAL ULTRASOUND SCREENING ON PERINATAL OUTCOME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED CONTROLLED TRIAL; TWIN PREGNANCY; RISK POPULATION; FETAL GROWTH; GESTATION; FETUSES; VIEW	Background. Many clinicians advocate routine ultrasound screening during pregnancy to detect congenital anomalies, multiple-gestation pregnancies, fetal growth disorders, placental abnormalities, and errors in the estimation of gestational age. However, it is not known whether the detection of these conditions through screening leads to interventions that improve perinatal outcome. Methods. We conducted a randomized trial involving 15,151 pregnant women at low risk for perinatal problems to determine whether ultrasound screening decreased the frequency of adverse perinatal outcomes. The women randomly assigned to the ultrasound-screening group underwent one sonographic examination at 15 to 22 weeks of gestation and another at 31 to 35 weeks. The women in the control group underwent ultrasonography only for medical indications, as identified by their physicians. Adverse perinatal outcome was defined as fetal death, neonatal death, or neonatal morbidity such as intraventricular hemorrhage. Results. The mean numbers of sonograms obtained per woman in the ultrasound-screening and control groups were 2.2 and 0.6, respectively. The rate of adverse perinatal outcome was 5.0 percent among the infants of the women in the ultrasound-screening group and 4.9 percent among the infants of the women in the control group (relative risk, 1.0; 95 percent confidence interval, 0.9 to 1.2; P = 0.85). The rates of preterm delivery and the distribution of birth weights were nearly identical in the two groups. The ultrasonographic detection of congenital anomalies had no effect on perinatal outcome. There were no significant differences between the groups in perinatal outcome in the subgroups of women with post-date pregnancies, multiple-gestation pregnancies, or infants who were small for gestational age. Conclusions. Screening ultrasonography did not improve perinatal outcome as compared with the selective use of ultrasonography on the basis of clinician judgment.	WASHINGTON UNIV,SCH MED,DEPT OBSTET & GYNECOL,ST LOUIS,MO 63110; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT OBSTET & GYNECOL,BOSTON,MA 02115; GEORGE WASHINGTON UNIV,CTR BIOSTAT,ROCKVILLE,MD; NICHHD,BETHESDA,MD 20892	Washington University (WUSTL); Harvard University; Brigham & Women's Hospital; Harvard Medical School; George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	EWIGMAN, BG (corresponding author), UNIV MISSOURI,HLTH SCI CTR MA303,SCH MED,DEPT FAMILY & COMMUNITY MED,1 HOSP DR,COLUMBIA,MO 65212, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U01HD021140, U01HD021017, U01HD019897] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ASHWORTH MF, 1990, BRIT J OBSTET GYNAEC, V97, P878, DOI 10.1111/j.1471-0528.1990.tb02441.x; BAKKETEIG LS, 1984, LANCET, V2, P207; BENNETT MJ, 1982, BRIT J OBSTET GYNAEC, V89, P338, DOI 10.1111/j.1471-0528.1982.tb05074.x; BERWICK DM, 1985, MED CARE, V23, P881, DOI 10.1097/00005650-198507000-00005; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555, DOI 10.1016/0002-9378(76)90748-1; BROCKS V, 1991, Fetal Diagnosis and Therapy, V6, P37; CHITTY LS, 1991, BRIT MED J, V303, P1165, DOI 10.1136/bmj.303.6811.1165; CROWTHER CA, 1990, BRIT J OBSTET GYNAEC, V97, P872, DOI 10.1111/j.1471-0528.1990.tb02440.x; EWIGMAN B, 1990, OBSTET GYNECOL, V76, P189; EWIGMAN B, 1991, J ULTRAS MED, V10, P427; EWIGMAN BG, 1989, J FAM PRACTICE, V29, P660; HOLLANDER M, 1973, NONPARAMETRIC STATIS; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LARSEN T, 1992, BRIT J OBSTET GYNAEC, V99, P469, DOI 10.1111/j.1471-0528.1992.tb13783.x; LEOPOLD GR, 1986, J ULTRAS MED, V5, P241; LEVI S, 1992, J ULTRAS MED, V11, P188; MACLENNAN AH, 1990, LANCET, V335, P267, DOI 10.1016/0140-6736(90)90079-K; NEILSON JP, 1984, BRIT MED J, V289, P1179, DOI 10.1136/bmj.289.6453.1179; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SECHER NJ, 1987, BRIT J OBSTET GYNAEC, V94, P105, DOI 10.1111/j.1471-0528.1987.tb02334.x; WALDENSTROM U, 1988, LANCET, V2, P585; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; Wei LJ, 1989, CONTROL CLIN TRIALS, V10, P126; WLADIMIROFF JW, 1980, ACTA OBSTET GYN SCAN, V59, P177, DOI 10.3109/00016348009154637; WOOLF SH, 1990, ARCH INTERN MED, V150, P2451, DOI 10.1001/archinte.150.12.2451; YOUNGBLOOD JP, 1989, J FAM PRACTICE, V29, P657; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]; [No title captured]	33	498	511	0	15	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					821	827		10.1056/NEJM199309163291201	http://dx.doi.org/10.1056/NEJM199309163291201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355740				2022-12-28	WOS:A1993LW55100001
J	BACK, NA; LINNEMANN, CC; PFALLER, MA; STANECK, JL; MORTHLAND, V				BACK, NA; LINNEMANN, CC; PFALLER, MA; STANECK, JL; MORTHLAND, V			RECURRENT EPIDEMICS CAUSED BY A SINGLE STRAIN OF ERYTHROMYCIN-RESISTANT STAPHYLOCOCCUS-AUREUS - THE IMPORTANCE OF MOLECULAR EPIDEMIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL INFECTIONS; GEL-ELECTROPHORESIS; NASAL CARRIER; PLASMID DNA; OUTBREAK; NURSERY	Objective.-To compare the accuracy of clinical epidemiologic findings with results of molecular epidemiologic analysis in identifying the source of recurrent epidemics of erythromycin-resistant Staphylococcus aureus (ERSA) infections in a well-baby nursery. Design.-Epidemic investigations with retrospective and prospective microbiological surveillance. Staphylococcus aureus isolates were evaluated by plasmid analysis and genotyping. Setting.-A well-baby nursery in a 700-bed university teaching hospital with approximately 250 deliveries per month. Patients.-Newborn, infants who developed ERSA infections during 1990 and 1991. Intervention.-Traditional infection control measures, including cohorting of infected infants and hand washing, were implemented. Personnel were cultured for nasal carriage of S aureus during both epidemics. Employees carrying ERSA were removed from the nursery and treated with mupirocin. Results.-In the first epidemic, 15 infants were infected with ERSA. A nursing assistant who cared for most of the infants was found to be a carrier of ERSA. She was removed from the nursery and the epidemic resolved. Fifteen months after the first epidemic ended, an epidemic that involved 11 infants began. The attending physician had a facial furuncle and was found to be a carrier of ERSA. The physician was treated and the epidemic resolved. Plasmid and genotyping showed the ERSA organisms from both epidemics were the same. The employee implicated in the first epidemic did not have the epidemic strain, but the physician who attended during both epidemics did. Conclusions.-Traditional epidemic investigations may lead to false conclusions that can only be recognized with molecular epidemiologic techniques. For these techniques to be useful in the control of outbreaks, plasmid analysis and/or genotyping must be readily available.	UNIV CINCINNATI,COLL MED,DEPT INFECT CONTROL,CINCINNATI,OH 45221; OREGON HLTH SCI UNIV,DEPT PATHOL,PORTLAND,OR 97201; UNIV CINCINNATI,COLL MED,DEPT MED,CINCINNATI,OH 45221; UNIV CINCINNATI,COLL MED,DEPT PATHOL & LAB MED,CINCINNATI,OH 45221	University System of Ohio; University of Cincinnati; Oregon Health & Science University; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati								BELANI A, 1986, INFECT CONT HOSP EP, V7, P487, DOI 10.1017/S0195941700065097; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GOERING RV, 1990, J CLIN MICROBIOL, V28, P426, DOI 10.1128/JCM.28.3.426-429.1990; HALL LMC, 1989, EPIDEMIOL INFECT, V103, P183, DOI 10.1017/S095026880003048X; HARTSTEIN AI, 1989, J CLIN MICROBIOL, V27, P1874, DOI 10.1128/JCM.27.8.1874-1879.1989; HEDBERG K, 1990, PEDIATR INFECT DIS J, V9, P268, DOI 10.1097/00006454-199004000-00009; ICHIYAMA S, 1991, J CLIN MICROBIOL, V29, P2690, DOI 10.1128/JCM.29.12.2690-2695.1991; John J F Jr, 1989, Infect Dis Clin North Am, V3, P683; Kloos WE, 1991, MANUAL CLIN MICROBIO, P222; LIGHT IJ, 1972, PEDIATRICS, V49, P15; LINNEMANN CC, 1991, AM J MED, V91, pS238, DOI 10.1016/0002-9343(91)90375-8; NAKASHIMA AK, 1984, INFECT CONT HOSP EP, V5, P326, DOI 10.1017/S0195941700060513; PFALLER MA, 1991, DIAGN MICR INFEC DIS, V14, P209, DOI 10.1016/0732-8893(91)90034-D; RHINEHART E, 1987, ARCH INTERN MED, V147, P521, DOI 10.1001/archinte.147.3.521; ZUCCARELLI AJ, 1990, J CLIN MICROBIOL, V28, P97, DOI 10.1128/JCM.28.1.97-102.1990; 1984, MIA3 NAT COMM CLIN L	17	27	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1329	1333		10.1001/jama.270.11.1329	http://dx.doi.org/10.1001/jama.270.11.1329			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360968				2022-12-28	WOS:A1993LW34500030
J	HENKEL, T; MACHLEIDT, T; ALKALAY, I; KRONKE, M; BEN-NERIAH, Y; BAEUERLE, PA				HENKEL, T; MACHLEIDT, T; ALKALAY, I; KRONKE, M; BEN-NERIAH, Y; BAEUERLE, PA			RAPID PROTEOLYSIS OF I-KAPPA-B-ALPHA IS NECESSARY FOR ACTIVATION OF TRANSCRIPTION FACTOR NF-KAPPA-B	NATURE			English	Article							PROTEIN-KINASE-C; TUMOR-NECROSIS-FACTOR; DNA-BINDING; INHIBITOR; PHOSPHORYLATION; INTERLEUKIN-1; PRECURSOR; ENHANCER; INVITRO; CELLS	INDUCIBLE gene expression in eukaryotes is mainly controlled by the activity of transcriptional activator proteins, such as NF-kappaB (refs 1-3), a factor activated upon treatment of cells with phorbol esters, lipopolysaccharide4, interleukin-1 and tumour necrosis factor-alpha5. Activation of NF-kappaB involves release of the inhibitory subunit IkappaB from a cytoplasmic complex with the DNA-binding subunits Rel-A (formerly p65) and p50 (refs 6, 7). Cell-free experiments have suggested that protein kinase C and other kinases transfer phosphoryl groups onto IkappaB causing release of IkappaB and subsequent activation of NF-kappaB8-10. Here we report that IkappaB-alpha (formerly MAD-3)11 is degraded in cells after stimulation with phorbol ester, interleukin-1, lipopolysaccharide and tumour necrosis factor-alpha, an event coincident with the appearance of active NF-kappaB. Treatment of cells with various protease inhibitors or an antioxidant completely prevented the inducible decay of IkappaB-alpha as well as the activation of NF-kappaB. Our findings suggest that the activation of NF-kappaB relies on an inducible degradation of IkappaB-alpha through a cytoplasmic, chymotrypsin-like protease. In intact cells, phosphorylation of IkappaB-alpha is apparently not sufficient for activation of NF-kappaB.	GENE CTR, MOLEC BIOL LAB, KLOPFERSPITZ 18A, W-8033 MARTINSRIED, GERMANY; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91010 JERUSALEM, ISRAEL; TECH UNIV MUNICH, INST MIKROBIOL & HYG, W-8000 MUNICH 2, GERMANY	Hebrew University of Jerusalem; Technical University of Munich			Ben-Neriah, Yinon/L-6285-2019					BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BAEUERLE PA, 1988, COLD SPRING HARB SYM, V53, P786; BAEUERLE PA, 1991, MOL ASPECTS CELL REG, V6, P409; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOMSZTYK K, 1991, CELL REGUL, V2, P329, DOI 10.1091/mbc.2.4.329; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; DEMARTIN R, IN PRESS EMBO J; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; MEICHLE A, 1990, J BIOL CHEM, V265, P8339; MEYER M, IN PRESS EMBO J; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHRECK R, IN PRESS METH ENZYM; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; WALL R, 1986, P NATL ACAD SCI USA, V83, P295, DOI 10.1073/pnas.83.2.295; ZABEL U, 1990, CELL, V61, P255, DOI 10.1016/0092-8674(90)90806-P; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	29	1117	1134	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					182	185		10.1038/365182a0	http://dx.doi.org/10.1038/365182a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371761				2022-12-28	WOS:A1993LW44200054
J	YOUNGSON, C; NURSE, C; YEGER, H; CUTZ, E				YOUNGSON, C; NURSE, C; YEGER, H; CUTZ, E			OXYGEN SENSING IN AIRWAY CHEMORECEPTORS	NATURE			English	Article							NEURO-EPITHELIAL BODIES; RAT CAROTID-BODY; MEMBRANE PATCHES; CYTOCHROME-B; PO2 SENSOR; L-DOPA; CELLS; LUNG; HYPOXIA; LOCALIZATION	PULMONARY neuroepithelial bodies, composed of innervated clusters of amine- and peptide-containing cells, are widely distributed throughout the airway mucosa of human and animal lungs1-3. Structurally, neuroepithelial bodies resemble chemoreceptors (such as carotid body, taste buds) and are thought to function as hypoxia-sensitive airway sensors4. Evidence for this is indirect, however, and the mechanism of oxygen sensing by these cells is unknown. Here we culture neuroepithelial bodies isolated from rabbit fetal lungs and identify voltage-activated potassium, calcium and sodium currents using the whole-cell patch clamp technique. Upon exposure to hypoxia there is a reversible reduction (25-30%) in the outward potassium current, with no change in inward currents. In addition, we demonstrate the expression of an oxygen-binding protein (b-cytochrome, NADPH oxidase) on the plasma membrane of these cells. The identification of an oxygen-sensing mechanism (namely the presence of an O2-sensitive potassium channel coupled to an O2 sensor protein5) in the cells of pulmonary neuroepithelial bodies indicates that they are transducers of the hypoxia stimulus and hence may function as airway chemoreceptors in the regulation of respiration.	HOSP SICK CHILDREN, RES INST, DEPT PATHOL, 555 UNIV AVE, TORONTO M5G 1X8, ONTARIO, CANADA; MCMASTER UNIV, DEPT BIOL, HAMILTON L8S 4K1, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); McMaster University; University of Toronto								ACKER H, 1989, FEBS LETT, V256, P75, DOI 10.1016/0014-5793(89)81721-1; CHO T, 1989, CELL TISSUE RES, V255, P353; CUTZ E, 1990, ARTERIAL CHEMORECEPTION, P432; CUTZ E, 1985, LAB INVEST, V53, P672; CUTZ E, 1984, ENDOCRINE LUNG HLTH, P210; GAZDAR AF, 1988, CANCER RES, V48, P4078; GONZALEZ C, 1992, TRENDS NEUROSCI, V15, P146, DOI 10.1016/0166-2236(92)90357-E; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERTZBERG T, 1990, J PHYSIOL-LONDON, V425, P211, DOI 10.1113/jphysiol.1990.sp018099; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; LAUWERYNS JM, 1986, EXP LUNG RES, V11, P319, DOI 10.3109/01902148609062833; LAUWERYNS JM, 1973, Z ZELLFORSCH MIK ANA, V145, P521, DOI 10.1007/BF00306722; LAUWERYNS JM, 1977, CELL TISSUE RES, V182, P425; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; MOODY TW, 1981, SCIENCE, V214, P1246, DOI 10.1126/science.6272398; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; PERRIN D G, 1991, Pediatric Pathology, V11, P431; POLAK JM, 1993, ANAT REC, V236, P169, DOI 10.1002/ar.1092360120; SCHULLER HM, 1991, EXP LUNG RES, V17, P837, DOI 10.3109/01902149109064321; STEA A, 1992, NEUROSCIENCE, V47, P727, DOI 10.1016/0306-4522(92)90180-A; Sternberger LA, 1979, IMMUNOCYTOCHEMISTRY, P104; STUART AE, 1974, CELL TISSUE RES, V153, P55, DOI 10.1007/BF00225445; ZACCONE G, 1992, ACTA ZOOL-STOCKHOLM, V73, P177, DOI 10.1111/j.1463-6395.1992.tb01185.x	27	384	391	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					153	155		10.1038/365153a0	http://dx.doi.org/10.1038/365153a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371757				2022-12-28	WOS:A1993LW44200046
J	KIRSCHSTEIN, R				KIRSCHSTEIN, R			SLEEP RESEARCH HAS BROAD SWEEP	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											KIRSCHSTEIN, R (corresponding author), NIH,BETHESDA,MD 20892, USA.							KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1172	1172		10.1001/jama.270.10.1172	http://dx.doi.org/10.1001/jama.270.10.1172			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355369				2022-12-28	WOS:A1993LV64900005
J	YESALIS, CE; KENNEDY, NJ; KOPSTEIN, AN; BAHRKE, MS				YESALIS, CE; KENNEDY, NJ; KOPSTEIN, AN; BAHRKE, MS			ANABOLIC-ANDROGENIC STEROID USE IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG-USE; DEPENDENCE; SCHOOL; SYMPTOMS; MEN	Objective.- To estimate the size of the anabolic-androgenic steroid (AAS) user population in the United States, to examine characteristics of AAS users, and to explore the association between AAS use and the use of other illicit drugs as well as self-reported aggressive behaviors. Design.- A cross-sectional study using data from the 1991 National Household Survey on Drug Abuse. Study Population.- The survey covered the population aged 12 years and older living in households in the United States. The results of the survey were based on personal interviews combined with self-administered questionnaires from 32 594 respondents. These respondents were randomly selected by means of a stratified multistage area sample of the household population. Results.- Estimates based on data from the National Household Survey on Drug Abuse indicated that there are more than 1 million current or former AAS users in this country, with more than half of the lifetime user population being 26 years of age or older. More than 300 000 individuals used AAS in the past year. Males had higher levels of AAS use during their lifetime than females (0.9% and 0.1%, respectively; P<.01). The median age of first use of AAS for the study population was 18 years; for 12- to 17-year-olds, the median age of initiation was 15 years. Among 12- to 34-year-olds, AAS use was significantly and positively associated with the use of other illicit drugs (P<.05), cigarettes (12- to 17-year-olds only; P<.01), and alcohol (P<.01). Furthermore, AAS use is highly correlated with self-reported aggressive behavior (P<.01) and crimes against property (P<.01). Conclusions.- These results indicate that AAS use impacts a large number of men and women from various racial and age groups across the nation. While causal inferences cannot be made regarding the associations between AAS use and use of other drugs as well as antisocial behavior, these findings should enhance our ability to profile the typical AAS user.	CTR SUBST ABUSE PREVENT, POLICY & PLANNING UNIT, ROCKVILLE, MD USA; NIDA, STAT & ANAL BRANCH, ROCKVILLE, MD USA; UNIV ILLINOIS, DEPT EPIDEMIOL & BIOSTAT, CHICAGO, IL 60680 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	YESALIS, CE (corresponding author), PENN STATE UNIV, DEPT HLTH POLICY & ADM, 115 HENDERSON BLDG, UNIV PK, PA 16802 USA.							ANDERSON W, 1991, PHYSICIAN SPORTSMED, V2, P91; ANNITTO WJ, 1980, J CLIN PSYCHIAT, V41, P143; [Anonymous], 1978, MAIL TELEPHONE SURVE; [Anonymous], 1990, LANCET, V336, P955; Bahrke M. S., 1993, ANABOLIC STEROIDS SP, P161; BAHRKE MS, 1990, NEW ENGL J MED, V323, P834; BAHRKE MS, 1992, AM J SPORT MED, V20, P717, DOI 10.1177/036354659202000613; Brower K. J., 1989, CLIN SPORTS MED, V1, P171; BROWER KJ, 1989, AM J PSYCHIAT, V146, P1075; BROWER KJ, 1989, J CLIN PSYCHIAT, V50, P31; BROWER KJ, 1990, AM J PSYCHIAT, V147, P510; BROWER KJ, 1991, BRIT J ADDICT, V86, P759; BUCKLEY W E, 1988, Journal of the American Medical Association, V260, P3441, DOI 10.1001/jama.260.23.3441; CHOI P Y L, 1990, Human Psychopharmacology, V5, P349, DOI 10.1002/hup.470050407; Cochran W.G., 2007, SAMPLING TECHNIQUES; CONACHER GN, 1989, AM J PSYCHIAT, V146, P679; DALBY JT, 1992, AM J PSYCHIAT, V149, P271; DIMEFF R, 1991, Medicine and Science in Sports and Exercise, V23, pS18; Duchaine D, 1989, UNDERGROUND STEROID, V2; DURANT RH, 1993, NEW ENGL J MED, V328, P922, DOI 10.1056/NEJM199304013281304; ELOFSON G, 1990, PHYSICIAN SPORTSMED, V19, P15; FRIEDL KE, 1993, ANABOLIC STEROIDS SP, P107; FRIENHAR J, 1985, J CLIN PSYCHIAT, V46, P354; Goldman B, 1984, DEATH LOCKER ROOM ST; HANNAN CJ, 1991, PSYCHONEUROENDOCRINO, V16, P335, DOI 10.1016/0306-4530(91)90019-P; HAUPT HA, 1984, AM J SPORT MED, V12, P469, DOI 10.1177/036354658401200613; HAYS L, 1992, J CLIN PSYCHIAT, V53, P130; HAYS LR, 1990, AM J PSYCHIAT, V147, P122; JOHNSTON LD, 1990, MONITORING FUTURE CO; JOHNSTON LD, 1991, MONITORING FUTURE CO; Kochakian C.D., 1993, ANABOLIC STEROIDS SP, P3; KOCHAKIAN CD, 1976, ANABOLIC ANDROGENIC; KROWCHUK DP, 1989, AM J DIS CHILD, V143, P486, DOI 10.1001/archpedi.1989.02150160116023; KRUSKEMPER HL, 1968, ANABOLIC STEROIDS; Lefavi R. G., 1990, J SPORT BEHAVIOR, V13, P157, DOI [10.1002/hup.470050407, DOI 10.1002/HUP.470050407]; LINDSTROM M, 1990, J INTERN MED, V227, P407, DOI 10.1111/j.1365-2796.1990.tb00179.x; MCCLARY SA, 1985, J DRUG EDUC, V15, P49, DOI 10.2190/0CE6-NDFE-BY7P-U6XJ; PERRY PJ, 1990, AM J SPORT MED, V18, P422, DOI 10.1177/036354659001800416; POPE HG, 1988, PHYSICIAN SPORTSMED, V16, P75, DOI 10.1080/00913847.1988.11709554; POPE HG, 1988, AM J PSYCHIAT, V145, P487; POPE HG, 1990, J CLIN PSYCHIAT, V51, P28; ROSS J, 1989, 1988 1989 SURVEY SUB; RYAN AJ, 1981, FED PROC, V40, P2682; SMART RG, 1978, DRUG ALCOHOL DEPEN, V3, P265, DOI 10.1016/0376-8716(78)90080-7; STRAUSS R H, 1985, Journal of the American Medical Association, V253, P2871, DOI 10.1001/jama.253.19.2871; SU TP, 1993, JAMA-J AM MED ASSOC, V269, P2760, DOI 10.1001/jama.269.21.2760; TAYLOR W N, 1987, Chiropractic Sports Medicine, V1, P47; Taylor W. N., 1991, MACHO MED HIST ANABO; TAYLOR WN, 1987, PHYSICIAN SPORTSMED, V15, P140, DOI 10.1080/00913847.1987.11709356; TAYLOR WN, 1982, ANABOLIC STEROIDS AT; TRICKER R, 1989, J DRUG EDUC, V19, P313, DOI 10.2190/EGT5-4YWD-QX15-FLKK; UZYCH L, 1992, CAN J PSYCHIAT, V37, P23, DOI 10.1177/070674379203700106; Wadler G., 1989, DRUGS ATHLETE; WHITEHEAD R, 1992, J FAM PRACTICE, V35, P401; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181; Wright J E, 1980, Exerc Sport Sci Rev, V8, P149, DOI 10.1249/00003677-198000080-00007; WRIGHT JE, 1982, ANABOLIC STEROIDS SP, V2; WRIGHT JE, 1978, ANABOLIC STEROIDS SP; Yesalis C. E., 1993, ANABOLIC STEROIDS SP, P49; YESALIS CE, 1989, SPORTS MED, V8, P129, DOI 10.2165/00007256-198908030-00001; 1977, MED SCI SPORTS EXERC, V9, P11; 1991, REPORT INTERAGENCY T; 1992, ADM921887 NAT I DRUG; 1984, MED SCI SPORTS EXERC, V19, P13; [No title captured]; 1990, JAMA-J AM MED ASSOC, V264, P2923; 1990, ANABOLIC REFERENCE U, V22, P3	67	254	259	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1217	1221		10.1001/jama.270.10.1217	http://dx.doi.org/10.1001/jama.270.10.1217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355384				2022-12-28	WOS:A1993LV64900027
J	MASU, Y; WOLF, E; HOLTMANN, B; SENDTNER, M; BREM, G; THOENEN, H				MASU, Y; WOLF, E; HOLTMANN, B; SENDTNER, M; BREM, G; THOENEN, H			DISRUPTION OF THE CNTF GENE RESULTS IN MOTOR-NEURON DEGENERATION	NATURE			English	Article							CILIARY NEUROTROPHIC FACTOR; TYPE-2 ASTROCYTE DEVELOPMENT; CHOLINERGIC DIFFERENTIATION; NEURONOTROPHIC FACTOR; REGIONAL DISTRIBUTION; FACTOR PREVENTS; MESSENGER-RNA; GROWTH-FACTOR; SPINAL-CORD; RAT-BRAIN	CNTF is a cytosolic molecule expressed postnatally in myelinating Schwann cells and in a subpopulation of astrocytes. Although CNTF administration prevents lesion-mediated and genetically determined motor neuron degeneration, its physiological function remained elusive. Here it is reported that abolition of CNTF gene expression by homologous recombination results in a progressive atrophy and loss of motor neurons in adult mice, which is functionally reflected by a small but significant reduction in muscle strength.	LUDWIG MAXIMILIANS UNIV MUNCHEN, INST MOLEK TIERZUCHT, D-80539 MUNICH, GERMANY	University of Munich	MASU, Y (corresponding author), MAX PLANCK INST PSYCHIAT, NEUROCHEM ABT, KLOPFERSPITZ 18A, D-82152 MARTINSRIED, GERMANY.		Sendtner, Michael/J-1542-2012; Wolf, Eckhard/AAT-7500-2021; Sendtner, Michael/M-8137-2014	Sendtner, Michael/0000-0002-4737-2974; Wolf, Eckhard/0000-0002-0430-9510; Sendtner, Michael/0000-0002-4737-2974				ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CORK LC, 1989, LAB INVEST, V61, P69; DOBREA GM, 1992, DEV BRAIN RES, V66, P209, DOI 10.1016/0165-3806(92)90082-8; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; IP NY, 1991, J NEUROSCI, V11, P3124; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; LILLIEN LE, 1988, NEURON, V1, P485, DOI 10.1016/0896-6273(88)90179-1; LILLIEN LE, 1990, NEURON, V5, P111, DOI 10.1016/0896-6273(90)90301-U; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; LUFT JH, 1961, J BIOPHYS BIOCHEM CY, V9, P409, DOI 10.1083/jcb.9.2.409; MAGAL E, 1991, DEV BRAIN RES, V63, P141, DOI 10.1016/0165-3806(91)90074-S; MCNEIL PL, 1990, J CELL SCI, V96, P549; MEYER M, 1992, J CELL BIOL, V119, P45, DOI 10.1083/jcb.119.1.45; Meyer O A, 1979, Neurobehav Toxicol, V1, P233; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; MUNSAT TL, 1988, NEUROLOGY, V38, P409, DOI 10.1212/WNL.38.3.409; OPPENHEIM RW, 1986, J COMP NEUROL, V246, P281, DOI 10.1002/cne.902460211; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAO MS, 1992, DEVELOPMENT, V116, P731; RAO MS, 1993, J NEUROBIOL, V24, P215, DOI 10.1002/neu.480240208; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SABATII DR, 1963, J CELL BIOL, V7, P19; SENDTNER M, 1991, J CELL SCI, P103; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; TETZLAFF W, 1988, GLIA, V1, P90, DOI 10.1002/glia.440010110; WOLF E, 1993, THERIOGENOLOGY, V37, P341; 1989, SAS STATR USERS GUID, V2, P891	38	540	562	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1993	365	6441					27	32		10.1038/365027a0	http://dx.doi.org/10.1038/365027a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361533	Green Submitted			2022-12-28	WOS:A1993LV64600043
J	FULLER, LE				FULLER, LE			PRIMARY CARING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1033	1033		10.1001/jama.1993.03510090017004	http://dx.doi.org/10.1001/jama.1993.03510090017004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350443				2022-12-28	WOS:A1993LU51200001
J	MOLBAK, K; HOJLYNG, N; GOTTSCHAU, A; SA, JCC; INGHOLT, L; DASILVA, APJ; AABY, P				MOLBAK, K; HOJLYNG, N; GOTTSCHAU, A; SA, JCC; INGHOLT, L; DASILVA, APJ; AABY, P			CRYPTOSPORIDIOSIS IN INFANCY AND CHILDHOOD MORTALITY IN GUINEA-BISSAU, WEST-AFRICA	BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; DIARRHEA	Objective-To investigate the epidemiology of and mortality from cryptosporidiosis in young children in Guinea Bissau, West Africa. Design-Three year community study of an open cohort followed up weekly. Setting-301 randomly selected houses in a semi-urban area in the capital, Bissau. Subjects-1315 children aged less than 4 years. Main outcome measures-Cryptosporidium infection detected by examination of stools during episode of diarrhoea and death of a child. Results-Cryptosporidium spp were found in 239 (7.4%) out of 3215 episodes of diarrhoea. The parasite was most common in younger children (median age 12 months) and at the beginning of the rainy seasons. The prevalence of cryptosporidiosis was 15% (77/513) in cases of persistent diarrhoea compared with 6.1% (148/2428) in diarrhoea lasting less than two weeks (p < 0-0001). Cryptosporidiosis was associated with excess mortality in children who had the infection in infancy, and this excess mortality persisted into the second year of life (relative mortality 2.9 (95% confidence interval 1.7 to 4.9)). The excess mortality could not be explained by malnutrition, or by socioeconomic factors, hygienic conditions, or breast feeding. Conclusions-Cryptosporidiosis is an important cause of death in otherwise healthy children in developing countries.	STATENS SERUM INST,PARASITOL LAB,DK-2300 COPENHAGEN,DENMARK; STATENS SERUM INST,DEPT STAT,DK-2300 COPENHAGEN,DENMARK; NATL PUBL HLTH LAB,BISSAU,GUINEA BISSAU	Statens Serum Institut; Statens Serum Institut	MOLBAK, K (corresponding author), STATENS SERUM INST,EPIDEMIOL RES UNIT,ARTILLERIVEJ 5,DK-2300 COPENHAGEN,DENMARK.			Aaby, Peter/0000-0001-8331-1389; Molbak, Kare/0000-0002-3100-4990				ALLEN AVH, 1970, J CLIN PATHOL, V23, P545, DOI 10.1136/jcp.23.6.545; ARGENZIO RA, 1990, GASTROENTEROLOGY, V98, P1129, DOI 10.1016/0016-5085(90)90325-U; CROSS J H, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P257; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; FRIPP PJ, 1991, J INFECTION, V23, P93, DOI 10.1016/0163-4453(91)94239-G; HENRIKSEN SA, 1981, ACTA VET SCAND, V22, P594; HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LAXER MA, 1990, AM J TROP MED HYG, V42, P131, DOI 10.4269/ajtmh.1990.42.131; LISSE IM, 1990, J IMMUNOL METHODS, V129, P49, DOI 10.1016/0022-1759(90)90419-V; MATA L, 1984, AM J TROP MED HYG, V33, P24, DOI 10.4269/ajtmh.1984.33.24; MOLBAK K, 1990, PEDIATR INFECT DIS J, V9, P566, DOI 10.1097/00006454-199008000-00008; PAL S, 1989, T ROY SOC TROP MED H, V83, P520, DOI 10.1016/0035-9203(89)90274-5; POULSEN AG, 1989, LANCET, V1, P827, DOI 10.1016/S0140-6736(89)92281-2; SALLON S, 1988, AM J DIS CHILD, V142, P312, DOI 10.1001/archpedi.1988.02150030086027; SEMBA RD, 1993, LANCET, V341, P5, DOI 10.1016/0140-6736(93)92478-C; SU SX, 1992, PARASITOL TODAY, V8, P24; 1988, B WORLD HEALTH ORGAN, V66, P709	18	99	101	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					417	420		10.1136/bmj.307.6901.417	http://dx.doi.org/10.1136/bmj.307.6901.417			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374453	Bronze, Green Published			2022-12-28	WOS:A1993LR89500016
J	DAY, C; PRIMHAK, RA				DAY, C; PRIMHAK, RA			CURRENT PRACTICES IN NEONATAL INTENSIVE-CARE IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article									JESSOP HOSP WOMEN,SHEFFIELD S3 7RE,S YORKSHIRE,ENGLAND									GREISEN G, 1989, Ugeskrift for Laeger, V151, P1612; ROBSON E, 1982, ARCH DIS CHILD, V57, P184, DOI 10.1136/adc.57.3.184; SILVERMAN WA, 1980, RETROLENTAL FIBROPLA, P69	3	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					362	362		10.1136/bmj.307.6900.362	http://dx.doi.org/10.1136/bmj.307.6900.362			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374420	Green Published, Bronze			2022-12-28	WOS:A1993LR76800021
J	PATEL, R; SHENOY, MM				PATEL, R; SHENOY, MM			LEFT-VENTRICULAR ANEURYSM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PATEL, R (corresponding author), CONEY ISL HOSP,BROOKLYN,NY 11235, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					246	246						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8355765				2022-12-28	WOS:A1993LM68200005
J	MCLELLAN, AT; ARNDT, IO; METZGER, DS; WOODY, GE; OBRIEN, CP				MCLELLAN, AT; ARNDT, IO; METZGER, DS; WOODY, GE; OBRIEN, CP			THE EFFECTS OF PSYCHOSOCIAL SERVICES IN SUBSTANCE-ABUSE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							METHADONE-MAINTENANCE; DRUG-ABUSE; SEVERITY; PSYCHOTHERAPY; SUCCESS	Objective.-To examine whether the addition of counseling, medical care, and psychosocial services improves the efficacy of methadone hydrochloride therapy in the rehabilitation of opiate-dependent patients. Design.-Random assignment to one of three treatment groups for a 6-month clinical trial: (1) minimum methadone services (MMS)-methadone alone (a minimum of 60 mg/d) with no other services; (2) standard methadone services (SMS) -same dose of methadone plus counseling; or (3) enhanced methadone services (EMS)-same dose of methadone plus counseling and on-site medical/psychiatric, employment, and family therapy. Setting.-The methadone maintenance program of the Philadelphia (Pa) Veterans Affairs Medical Center. Subjects.-Ninety-two male intravenous opiate users in methadone maintenance treatment. Results.-While methadone treatment alone (MMS) was associated with reductions in opiate use, 69% of these subjects had to be ''protectively transferred'' from the trial because of unremitting use of opiates or cocaine, or medical/psychiatric emergencies. This was significantly different from the 41% of SMS subjects and 19% of EMS subjects who met the criteria. End-of-treatment data (at 24 weeks) showed minimal improvements among the 10 MMS patients who completed the trial. The SMS group showed significantly more and larger improvements than did the MMS group; and the EMS group showed significantly better outcomes than did the SMS group. Minimum methadone services subjects who had been ''protectively transferred'' to standard care showed significant reductions in opiate and cocaine use within 4 weeks. Conclusions.-Methadone alone (even in substantial doses) may only be effective for a minority of eligible patients. The addition of basic counseling was associated with major increases in efficacy; and the addition of on-site professional services was even more effective.	UNIV PENN,SCH MED,DEPT PSYCHIAT,PHILADELPHIA,PA 19104	University of Pennsylvania	MCLELLAN, AT (corresponding author), PHILADELPHIA VET AFFAIRS MED CTR,PENN VA CTR STUDIES ADDICT,DEPT PSYCHIAT,UNIV AVE,BLDG 7,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA005634] Funding Source: NIH RePORTER; NIDA NIH HHS [DA05634] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALLISON M, 1985, INT J ADDICT, V20, P1321, DOI 10.3109/10826088509047770; BALE RN, 1980, ARCH GEN PSYCHIAT, V37, P1436; Ball J.C., 2012, EFFECTIVENESS METHAD; COOPER JR, 1989, JAMA-J AM MED ASSOC, V262, P1664, DOI 10.1001/jama.262.12.1664; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; DOLAN MP, 1986, BEHAV THER, V17, P470, DOI 10.1016/S0005-7894(86)80076-4; Hubbard RL, 1989, DRUG ABUSE TREATMENT; JOE GW, 1991, INT J ADDICT, V26, P1; LOSCUITO L, 1984, INT J ADDICT, V19, P232; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1988, J NERV MENT DIS, V176, P423, DOI 10.1097/00005053-198807000-00004; MCLELLAN AT, 1983, ARCH GEN PSYCHIAT, V40, P620; MCLELLAN AT, 1982, JAMA-J AM MED ASSOC, V247, P1423, DOI 10.1001/jama.247.10.1423; MCLELLAN AT, 1992, J NERV MENT DIS, V180, P100; NEWMAN RG, 1987, NEW ENGL J MED, V317, P447, DOI 10.1056/NEJM198708133170710; STITZER ML, 1986, DRUG ALCOHOL DEPEN, V18, P341, DOI 10.1016/0376-8716(86)90097-9; WOODY GE, 1983, ARCH GEN PSYCHIAT, V40, P639; WOODY GE, 1984, AM J PSYCHIAT, V141, P1172; YANCOVITZ SR, 1991, AM J PUBLIC HEALTH, V81, P1185, DOI 10.2105/AJPH.81.9.1185	19	641	648	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 21	1993	269	15					1953	1959		10.1001/jama.269.15.1953	http://dx.doi.org/10.1001/jama.269.15.1953			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	KX215	8385230				2022-12-28	WOS:A1993KX21500024
J	NIGHTINGALE, SL				NIGHTINGALE, SL			DRONABINOL APPROVED FOR USE IN ANOREXIA ASSOCIATED WITH WEIGHT-LOSS IN PATIENTS WITH AIDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1986, JAMA-J AM MED ASSOC, V256, P817	1	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1361	1361		10.1001/jama.269.11.1361	http://dx.doi.org/10.1001/jama.269.11.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8382752				2022-12-28	WOS:A1993KQ85700007
J	TSUDA, L; INOUE, YH; YOO, MA; MIZUNO, M; HATA, M; LIM, YM; ADACHIYAMADA, T; RYO, H; MASAMUNE, Y; NISHIDA, Y				TSUDA, L; INOUE, YH; YOO, MA; MIZUNO, M; HATA, M; LIM, YM; ADACHIYAMADA, T; RYO, H; MASAMUNE, Y; NISHIDA, Y			A PROTEIN-KINASE SIMILAR TO MAP KINASE ACTIVATOR ACTS DOWNSTREAM OF THE RAF KINASE IN DROSOPHILA	CELL			English	Article							EGF RECEPTOR HOMOLOG; FAINT-LITTLE-BALL; TYROSINE KINASE; EMBRYONIC-DEVELOPMENT; NUCLEOTIDE-SEQUENCE; TERMINAL ANLAGEN; GENE TORSO; PATTERN; LOCUS; MELANOGASTER	D-raf, a Drosophila homolog of Raf-1, plays key roles in multiple signal transduction pathways. Dsor1, a putative factor downstream of D-raf, was genetically identified by screening of dominant suppressors of D-raf. Dsor1Su1 mapped on X chromosome significantly suppressed the D-raf mutant phenotypes, and the loss-of-function mutations of Dsor1 showed phenotypes similar to those of the D-raf null mutations. Dsor1Su1 also significantly suppressed the mutations of other terminal class genes acting further upstream of D-raf. Molecular cloning of Dsor1 revealed its product with striking similarity to the microtubule-associated protein (MAP) kinase activator and yeast PBS2, STE7, and byr1. Our genetic results demonstrate the connection between raf and the highly conserved protein kinase cascade involving MAP kinase in vivo.	KANAZAWA UNIV,GRAD SCH NAT SCI & TECHNOL,KANAZAWA,ISHIKAWA 920,JAPAN; PUSAN NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,PUSAN 607,SOUTH KOREA; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Kanazawa University; Pusan National University; Nagoya University	TSUDA, L (corresponding author), AICHI CANC CTR,RES INST,EXPTL RADIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.							AMBROSIO L, 1989, DEVELOPMENT, V106, P145; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON NG, 1991, BIOCHEM J, V277, P573, DOI 10.1042/bj2770573; BACCARINI M, 1991, J BIOL CHEM, V266, P10941; BASLER K, 1988, CELL, V54, P299; BIGGS WH, 1992, P NATL ACAD SCI USA, V89, P6295, DOI 10.1073/pnas.89.14.6295; BOGUSLAWSKI G, 1987, P NATL ACAD SCI USA, V84, P5848, DOI 10.1073/pnas.84.16.5848; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEGELMANN A, 1986, DEV BIOL, V115, P479, DOI 10.1016/0012-1606(86)90268-X; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lawrence P.A., 1986, P229; LEE RM, 1992, J BIOL CHEM, V267, P1088; LI P, 1991, CELL, V64, P479, DOI 10.1016/0092-8674(91)90228-Q; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; MARSH L, 1991, ANNU REV CELL BIOL, V7, P699, DOI 10.1146/annurev.cellbio.7.1.699; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PERRIMON N, 1985, DEV BIOL, V110, P480, DOI 10.1016/0012-1606(85)90105-8; PERRIMON N, 1986, GENETICS, V113, P695; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; POSTLETHWAIT JH, 1978, GENETICS BIOL DROS C, V2, P359; PRICE JV, 1989, CELL, V56, P1085, DOI 10.1016/0092-8674(89)90641-7; RAPP UR, 1991, ONCOGENE, V6, P495; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J, 1989, MOL CLONING LABORATO; SCHEJTER ED, 1989, CELL, V56, P1093, DOI 10.1016/0092-8674(89)90642-9; SCHUPBACH T, 1986, ROUX ARCH DEV BIOL, V195, P302, DOI 10.1007/BF00376063; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; STRECKER TR, 1989, SCIENCE, V243, P1062, DOI 10.1126/science.2922596; STRECKER TR, 1986, DEV BIOL, V113, P64, DOI 10.1016/0012-1606(86)90108-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WEISCHAUS E, 1986, DROSOPHILA PRACTICAL, P199	49	208	214	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					407	414		10.1016/0092-8674(93)90117-9	http://dx.doi.org/10.1016/0092-8674(93)90117-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381718				2022-12-28	WOS:A1993KM16200010
J	HIGGINS, M; DAGOSTINO, R; KANNEL, W; COBB, J				HIGGINS, M; DAGOSTINO, R; KANNEL, W; COBB, J			BENEFITS AND ADVERSE-EFFECTS OF WEIGHT-LOSS - OBSERVATIONS FROM THE FRAMINGHAM-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-WEIGHT; FOLLOW-UP; CARDIOVASCULAR-DISEASE; MORTALITY; VARIABILITY; LONGEVITY; HEALTH; RISK	Objective: To identify the benefits and adverse effects of weight loss. Design: Longitudinal, epidemiologic study in a defined population. Participants: Men and women (n = 2500) who were between 35 and 54 years old at baseline, followed for 20 years in Framingham, Massachusetts. Measurements: Height, weight, lipid levels, blood pressure, smoking status, diet, physical activity, prevalent and incident cardiovascular disease, diabetes, other diseases, and mortality rate were assessed. Results: Compared with those whose body mass index (BMI) or weight changed least, men and women who lost weight during a 10-year period were older, heavier, and had higher blood pressures and cholesterol levels initially but had the smallest gains in blood pressure and cholesterol levels. However, rates of cigarette smoking were higher, and rates of smoking cessation were lower. During 20 years of further follow-up, death rates were highest in those whose BMI decreased and in those with the highest BMI at study entry. Relative risks for death from cardiovascular disease, coronary heart disease, and all causes were significantly greater by 33% to 61% in men whose BMI decreased after adjusting for age and risk factors for cardiovascular disease. In women, weight loss and weight gain were associated with higher relative risks for cardiovascular disease and coronary heart disease, but only the 38% increase in total mortality rate among women who lost weight was statistically significant after adjusting for age. Conclusions: Weight loss was associated with improvements in blood pressure and cholesterol levels but also with continued cigarette smoking, prevalent and incident cardiovascular disease, diabetes mellitus, other diseases, and higher death rates. Leanness and maintenance of stable weight were beneficial to risk factors, and to the prevention of morbidity, and death.			HIGGINS, M (corresponding author), NHLBI, DEPT EPIDEMIOL & BIOMETRY, 2C08 FED BLDG, 7550 WISCONSIN AVE, BETHESDA, MD 20892 USA.							ANDERSON KM, 1992, OBESITY; [Anonymous], 1992, Ann Intern Med, V116, P942; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; CORNONIHUNTLEY JC, 1991, J CLIN EPIDEMIOL, V44, P743, DOI 10.1016/0895-4356(91)90126-T; CUPPLES LA, 1986, FRAMINGHAM STUDY EPI; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; HAMM P, 1989, AM J EPIDEMIOL, V129, P312, DOI 10.1093/oxfordjournals.aje.a115135; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KANNEL WB, 1989, EATING SLEEPING SEX; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; Lissner L., 1989, Obesity in Europe 88. Proceedings of the 1st European Congress on Obesity, 5-6 June, 1988, Stockholm, Sweden., P55; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; SHURTLEFF D, 1974, DHEW NIH74599 PUBL; STEVENS J, 1990, INT J OBESITY, V14, P385; TERRY RB, 1992, INT J OBESITY, V16, P417	19	118	122	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				758	763		10.7326/0003-4819-119-7_Part_2-199310011-00025	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00025			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363211				2022-12-28	WOS:A1993MA33000025
J	LEVY, AS; HEATON, AW				LEVY, AS; HEATON, AW			WEIGHT CONTROL PRACTICES OF UNITED-STATES ADULTS TRYING TO LOSE WEIGHT	ANNALS OF INTERNAL MEDICINE			English	Article							BEHAVIOR; OBJECTIVES	Objective: To estimate the relative prevalence of different types and combinations of practices among weight-loss practitioners and to describe the relations between individual characteristics and various features of weight-loss regimens. Design: A telephone survey of a random digit-dialed probability sample of adults in the continental United States who reported that they were trying to lose weight. Participants: A total of 1431 persons 18 years or older who were attempting to lose weight. Measurements: Self-reports of a detailed inventory of more than 35 specific practices that might be used as part of a voluntary weight-loss plan, along with information about individual characteristics such as current weight, weight-loss history, demographic profile, motivations to lose weight, sources of information, and knowledge about diet and health. Results: The average respondent had a current weight-loss attempt lasting from 5 to 6 months, had tried a similar plan before, and had averaged one attempt a year for the past 2 years. Seventy-one percent of women and 62% of men reported that they were both changing their diet and exercising more as part of a current weight-loss attempt. Frequently reported weight-loss practices included weighing oneself regularly (71% and 70% for women and men, respectively), walking (58% and 44%), using diet soft drinks (52% and 45%), taking vitamins and minerals (33% and 26%), counting calories (25% and 17%), skipping meals (21% and 20%), using commercial meal replacements, (15% and 13%), taking diet pills (14% and 7%), and participating in organized weight-loss programs (13% and 5%). Sex, education, and overweight status influenced the choice of a weight-loss practice. Conclusions: Individual approaches to weight-loss vary and are characterized by their duration and by their recurrent nature. Policy efforts should be directed toward increasing the long-term effectiveness of individual weight-loss plans.			LEVY, AS (corresponding author), USDA, CTR FOOD SAFETY & APPL NUTR, DIV MARKET STUDIES, HFS-727, 200 C ST NW, WASHINGTON, DC 20204 USA.							DAGNOLI J, ADVERTISING AGE 1223, P3; DAGNOLI J, ADVERTISING AGE 1223, P25; DANFORD DE, 1991, J AM DIET ASSOC, V91, P1517; DWYER JT, 1970, J AM DIET ASSOC, V56, P510; EMMONS L, 1992, J AM DIET ASSOC, V92, P306; Health. & N.R.C.U.C.o.D.a., 1989, DIET HLTH IMPLICATIO; JEFFERY RW, 1984, AM J PUBLIC HEALTH, V74, P349, DOI 10.2105/AJPH.74.4.349; STEPHENSON MG, 1987, PUBLIC HEALTH REP, V102, P61; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; 1992, FACTS WEIGHT LOSS PR; 1988, DHHS PHS8850210 US D	13	151	153	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				661	666		10.7326/0003-4819-119-7_Part_2-199310011-00007	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363193				2022-12-28	WOS:A1993MA33000007
J	IGLEHART, JK				IGLEHART, JK			THE AMERICAN HEALTH-CARE SYSTEM - TEACHING HOSPITALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		FOX PD, 1993, HEALTH AFFAIR, V12, P85, DOI 10.1377/hlthaff.12.1.85; IGLEHART JK, 1992, NEW ENGL J MED, V326, P962, DOI 10.1056/NEJM199204023261426; IGLEHART JK, 1985, NEW ENGL J MED, V312, P1400, DOI 10.1056/NEJM198505233122133; IGLEHART JK, 1982, NEW ENGL J MED, V307, P132, DOI 10.1056/NEJM198207083070233; KANE NM, 1993, UNPUB REPORT FINANCI; KASSIRER JP, 1992, NEW ENGL J MED, V326, P945, DOI 10.1056/NEJM199204023261408; KNAPP RM, 1992, ACAD MED, V67, P452, DOI 10.1097/00001888-199207000-00006; RUSH, 1993, PRUDENTIAL SIGN AGRE; Stockman D A, 1981, Health Aff (Millwood), V1, P5, DOI 10.1377/hlthaff.1.1.5; 1993, INTERIM REPORT NATIO; 1993, ACADEMIC MED HLTH CA; 1992, NEW ENGL J MED, V327, P1467; 1993, REPORT RECOMMENDATIO; 1992, IMPROVING ACCESS HLT; 1993, PRIMARY CARE WORKFOR; 1992, NEW ENGL J MED, V327, P742; 1992, FINANCING GRADUATE M; 1993, ANN REPORT C; 1989, TEACHING HOSPITALS M; 1993, NEW ENGL J MED, V328, P366; 1993, COMPETING MATURE HLT; 1992, REPORT F; 1993, NEW ENGL J MED, V329, P372	23	56	56	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1052	1056		10.1056/NEJM199309303291428	http://dx.doi.org/10.1056/NEJM199309303291428			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LY587	8366921				2022-12-28	WOS:A1993LY58700038
J	DAVIES, GJ; DODSON, GG; HUBBARD, RE; TOLLEY, SP; DAUTER, Z; WILSON, KS; HJORT, C; MIKKELSEN, JM; RASMUSSEN, G; SCHULEIN, M				DAVIES, GJ; DODSON, GG; HUBBARD, RE; TOLLEY, SP; DAUTER, Z; WILSON, KS; HJORT, C; MIKKELSEN, JM; RASMUSSEN, G; SCHULEIN, M			STRUCTURE AND FUNCTION OF ENDOGLUCANASE-V	NATURE			English	Article							3-DIMENSIONAL STRUCTURE; PROTEIN STRUCTURES; CELLULASES; REFINEMENT	CELLULOSE is the major polysaccharide component of plant cell walls and is the most abundant organic compound on the planet. A number of bacterial1 and fungal2 organisms can use cellulose as a food source, possessing cellulases (cellobiohydrolases and endoglucanases) that can catalyse the hydrolysis of the beta-(1,4) glycosidic bonds. They can be classified into seven distinct families3. The three-dimensional structures of members of two of these families are known4,5. Here we report the structure of a third cellulase, endoglucanase V, whose sequence is not represented in any of the above families. The enzyme is structurally distinct from the previously determined cellulases but is similar to a recently characterized plant defence protein6. The active site region resembles that of lysozyme, despite the lack of structural similarity between these two enzymes.	DESY,EMBL,HAMBURG OUTSTN,W-2000 HAMBURG 52,GERMANY; NOVO NORDISK AS,DK-2880 BAGSVAERD,DENMARK	European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Novo Nordisk	DAVIES, GJ (corresponding author), UNIV YORK,DEPT CHEM,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Davies, Gideon J/A-9042-2011	Davies, Gideon J/0000-0002-7343-776X; Wilson, Keith/0000-0002-3581-2194				BEGUIN P, 1992, BIOCHEM SOC T, V20, P42, DOI 10.1042/bst0200042; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P365, DOI 10.1098/rspb.1967.0034; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HIGASHI T, 1989, J APPL CRYSTALLOGR, V22, P9, DOI 10.1107/S0021889888009562; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JUY M, 1992, NATURE, V357, P89, DOI 10.1038/357089a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUDVIGSEN S, 1992, BIOCHEMISTRY-US, V31, P8783, DOI 10.1021/bi00152a014; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROUVINEN J, 1990, SCIENCE, V249, P380, DOI 10.1126/science.2377893; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; WOOD TM, 1992, BIOCHEM SOC T, V20, P46, DOI 10.1042/bst0200046; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; 1979, SUITE PROGRAMS PROTE	20	122	128	2	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					362	364		10.1038/365362a0	http://dx.doi.org/10.1038/365362a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377830				2022-12-28	WOS:A1993LY49600059
J	SCHUSTER, SC; SWANSON, RV; ALEX, LA; BOURRET, RB; SIMON, MI				SCHUSTER, SC; SWANSON, RV; ALEX, LA; BOURRET, RB; SIMON, MI			ASSEMBLY AND FUNCTION OF A QUATERNARY SIGNAL-TRANSDUCTION COMPLEX MONITORED BY SURFACE-PLASMON RESONANCE	NATURE			English	Article							BACTERIAL CHEMOTAXIS; RESPONSE REGULATOR; PROTEIN-PHOSPHORYLATION; KINASE CHEA; RECEPTOR; PATHWAY; SYSTEM; SITE	WE have used surface plasmon resonance biosensor technology to monitor the assembly and dynamics of a signal transduction complex which controls chemotaxis in Escherichia coli. A quaternary complex formed which consisted of the response regulator CheY, the histidine protein kinase CheA, a coupling protein CheW and a membrane-bound chemoreceptor Tar. Using various experimental conditions and mutant proteins, we have shown that the complex dissociates under conditions that favour phosphorylation of CheY. Direct physical analysis of interactions among proteins in this signal transduction pathway provides evidence for a previously unrecognized binding interaction between the kinase and its substrate. This interaction may be important for enhancing substrate specificity and preventing 'crosstalk' with other systems. The approach is generally applicable to furthering our understanding of how signalling complexes transduce intracellular messages.			SCHUSTER, SC (corresponding author), CALTECH,DIV BIOL,PASADENA,CA 91125, USA.		Bourret, Robert/X-3606-2019	Bourret, Robert/0000-0002-6666-9220; Swanson, Ronald/0000-0002-6486-2676				BORKOVICH KA, 1992, P NATL ACAD SCI USA, V89, P6756, DOI 10.1073/pnas.89.15.6756; BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BORKOVICH KA, 1990, CELL, V63, P1339, DOI 10.1016/0092-8674(90)90429-I; BOURRET RB, 1991, REV BIOCH, V60, P401; GEGNER JA, 1992, CELL, V70, P975, DOI 10.1016/0092-8674(92)90247-A; GEGNER JA, 1991, P NATL ACAD SCI USA, V88, P750, DOI 10.1073/pnas.88.3.750; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; HESS JF, 1988, NATURE, V336, P139, DOI 10.1038/336139a0; HESS JF, 1987, P NATL ACAD SCI USA, V84, P7609, DOI 10.1073/pnas.84.21.7609; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; LUKAT GS, 1992, P NATL ACAD SCI USA, V89, P718, DOI 10.1073/pnas.89.2.718; MALMQVIST M, 1993, NATURE, V361, P186, DOI 10.1038/361186a0; MILLIGAN DL, 1988, J BIOL CHEM, V263, P6268; NINFA EG, 1991, J BIOL CHEM, V266, P9764; SAMBLES JR, 1991, CONTEMP PHYS, V32, P173, DOI 10.1080/00107519108211048; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SPRINGER MS, 1979, NATURE, V280, P279, DOI 10.1038/280279a0; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; SWANSON RV, 1993, MOL MICROBIOL, V8, P435, DOI 10.1111/j.1365-2958.1993.tb01588.x; SWANSON RV, 1993, BIOCHEMISTRY-US, V32, P7623, DOI 10.1021/bi00081a004; VOLZ K, 1991, J BIOL CHEM, V266, P15511; WOLFE AJ, 1993, P NATL ACAD SCI USA, V90, P1518, DOI 10.1073/pnas.90.4.1518; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6	25	223	229	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					343	347		10.1038/365343a0	http://dx.doi.org/10.1038/365343a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377825				2022-12-28	WOS:A1993LY49600053
J	LEGORRETA, AP; SILBER, JH; COSTANTINO, GN; KOBYLINSKI, RW; ZATZ, SL				LEGORRETA, AP; SILBER, JH; COSTANTINO, GN; KOBYLINSKI, RW; ZATZ, SL			INCREASED CHOLECYSTECTOMY RATE AFTER THE INTRODUCTION OF LAPAROSCOPIC CHOLECYSTECTOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To examine if overall cost savings may fail to result from laparoscopic (''closed'') cholecystectomy if it also results in an increased total rate of cholecystectomies or generates additional costs unassociated with the open procedure. Outcome Measures.-Inpatient and outpatient expenditures, incidence rates, and length of inpatient stay data for 6909 health maintenance organization enrollees with gallbladder complaints were analyzed from 1988 through 1992 using claims data from a large, private practice-based health maintenance organization. Results.-The incidence of cholecystectomy and total health maintenance organization expenditures on gallbladder disease have increased since the introduction of laparoscopic closed cholecystectomy. The rate of cholecystectomy procedures per 1000 enrollees increased from 1.35 in 1988 to 2.15 in 1992 (P<.001). Total annual medical expenditures on gallbladder disease per 1000 enrollees (in 1992 dollar's) rose 11.4% during the study period (P<.001), despite a concurrent 25.1 % decline in the unit cost (physician and hospital cost) for cholecystectomy procedures (P<.001). During the same study period, no significant change was noted in the rate of appendectomy per 1000 enrollees (0.76 in 1988 to 0.73 in 1992), which is a measure of nonelective surgical care, or in the inguinal hernia repair rate (2.01 in 1988 to 2.19 in 1992), which has a physician and patient discretionary component similar to that of cholecystectomy. Conclusions.-The introduction of laparoscopic gallbladder surgery resulted in rising rates of cholecystectomy for a population of patients in a private, independent practice-based health maintenance organization. Such a rise was not seen for hernia repair surgery or appendectomy. It seems that the use of laparoscopic cholecystectomy, a new technology touted as reducing health care costs, may result in an increased consumption of health care resources due to changes in the indications for gallbladder surgery.	US HEALTHCARE, BLUE BELL, PA 19422 USA; UNIV PENN, SCH MED, DEPT PEDIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, LEONARD DAVIS INST HLTH ECON, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	LEGORRETA, AP (corresponding author), US QUAL ALGORITHMS, 980 JOLLY RD, BLUE BELL, PA 19422 USA.							BAIRD DR, 1992, AM SURGEON, V58, P206; BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G; CHUNG RS, 1992, CLEV CLIN J MED, V59, P186, DOI 10.3949/ccjm.59.2.186; FURMAN R, 1992, AM SURGEON, V58, P55; GUTMAN H, 1988, AM J GASTROENTEROL, V83, P545; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P1018, DOI 10.1001/jama.1993.03500080066034; HOLOHAN TV, 1991, LANCET, V338, P801, DOI 10.1016/0140-6736(91)90678-I; JOHNSTON DE, 1993, NEW ENGL J MED, V328, P412, DOI 10.1056/NEJM199302113280608; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; MORRISON DF, 1983, APPL LINEAR STAT MET, P312; RANSOHOFF DF, 1990, AM J MED, V88, P154, DOI 10.1016/0002-9343(90)90466-Q; RUWE PA, 1992, RADIOLOGY, V183, P335, DOI 10.1148/radiology.183.2.1561332; STEIN SC, 1991, ANN EMERG MED, V20, P1286, DOI 10.1016/S0196-0644(05)81066-2; SZCZEPURA AK, 1991, BRIT MED J, V303, P1435, DOI 10.1136/bmj.303.6815.1435; VITALE GC, 1991, AM J SURG, V161, P396, DOI 10.1016/0002-9610(91)90606-E; WOLFE BM, 1991, JAMA-J AM MED ASSOC, V265, P1573, DOI 10.1001/jama.265.12.1573; 1993, CPT DETAILED REPORT	17	277	281	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1429	1432		10.1001/jama.270.12.1429	http://dx.doi.org/10.1001/jama.270.12.1429			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371441				2022-12-28	WOS:A1993LX17300025
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA GUIDELINE ON WOMEN IN CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1991, JAMA-J AM MED ASSOC, V265, P182	1	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1290	1290		10.1001/jama.270.11.1290	http://dx.doi.org/10.1001/jama.270.11.1290			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360956				2022-12-28	WOS:A1993LW34500006
J	RICE, T; BROWN, ER; WYN, R				RICE, T; BROWN, ER; WYN, R			HOLES IN THE JACKSON-HOLE APPROACH TO HEALTH-CARE REFORM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSURANCE; MEDICAID; PARTICIPATION; ORGANIZATION; PHYSICIANS; OUTCOMES; LESSONS; COSTS; PLAN; PPO		UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT COMMUNITY HLTH SCI, LOS ANGELES, CA USA	University of California System; University of California Los Angeles	RICE, T (corresponding author), UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT HLTH SERV, LOS ANGELES, CA 90024 USA.							ANDERSON MD, 1987, HEALTH AFFAIR, V6, P71, DOI 10.1377/hlthaff.6.1.71; BATAVIA AI, 1988, AM REHABIL, V14, P9; BERK ML, 1992, HEALTH AFFAIR, V4, P145; BROWN ER, 1990, ANNU REV PUBL HEALTH, V11, P377; BROWN R, 1987, BIASED SELECTION MED; BUCK C, 1993, RURAL HLTH CARE IMPR; DEJONG G, 1989, MILBANK Q, V67, P311, DOI 10.2307/3350148; DIEHR P, 1990, MED CARE, V28, P1073, DOI 10.1097/00005650-199011000-00008; Ellwood P M, 1992, Health Econ, V1, P149, DOI 10.1002/hec.4730010303; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1989, HEALTH AFFAIR, V8, P33, DOI 10.1377/hlthaff.8.3.33; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; Epstein A M, 1988, Health Care Financ Rev, V10, P51; FIELDING JE, 1993, HLTH AFF S, V10, P216; GABEL JR, 1992, HEALTH AFFAIR, V11, P186, DOI 10.1377/hlthaff.11.4.186; GABEL JR, 1989, INQUIRY-J HEALTH CAR, V26, P419; GARNICK DW, 1990, MED CARE, V28, P894, DOI 10.1097/00005650-199010000-00004; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HADLEY J, 1979, HEALTH SERV RES, V14, P266; HESTER JA, 1987, MILBANK Q, V65, P575, DOI 10.2307/3349981; JONES SB, 1990, INQUIRY-J HEALTH CAR, V27, P161; JONES SB, 1991, WHERE MARKETPLACE CO; KOLODINSKY M, 1989, DEV SLIDING FEE SCAL; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; LIGHT DW, 1992, JAMA-J AM MED ASSOC, V267, P2503, DOI 10.1001/jama.267.18.2503; Lohr K N, 1986, Med Care, V24, pS1; LUFT HS, 1980, MED CARE, V18, P1, DOI 10.1097/00005650-198001000-00001; LUFT HS, 1981, HLTH MAINTENANCE ORG; MARQUIS SM, 1985, DEMAND SUPPLEMENTARY; MERLIS M, 1993, MEDICAID SOURCE BOOK; Morrisey MA, 1992, PRICE SENSITIVITY HL; NEWHOUSE JP, 1993, HEALTH AFFAIR, V12, P152, DOI 10.1377/hlthaff.12.suppl_1.152; NEWHOUSE JP, 1985, MED CARE, V23, P960, DOI 10.1097/00005650-198508000-00003; PERLOFF JD, 1987, J HEALTH POLIT POLIC, V12, P221, DOI 10.1215/03616878-12-2-221; Reece R L, 1988, Minn Med, V71, P733; RICE T, 1990, HEALTH POLICY, V16, P1, DOI 10.1016/0168-8510(90)90436-H; ROBINSON JC, 1991, INQUIRY-J HEALTH CAR, V28, P107; SCHLESINGER M, 1993, HEALTH AFFAIR, V12, P123, DOI 10.1377/hlthaff.12.suppl_1.123; SCHLESINGER M, 1986, MILBANK Q, V64, P189, DOI 10.2307/3349970; SHAW DA, 1992, MINN MED, V75, P24; THOMAS JW, 1986, MED CARE, V24, P259, DOI 10.1097/00005650-198603000-00008; TONER R, 1993, NY TIMES        0228, V3, P1; TONER R, 1993, NY TIMES        0228, V3, P8; WARE JE, 1986, LANCET, V1, P1017; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; ZWANZIGER J, 1991, MED CARE, V29, P142, DOI 10.1097/00005650-199102000-00006; 1992, EFFECTS MANAGED CARE; 1992, MEDICAID OREGONS MAN; 1988, STUDY FEDERAL EMPLOY; 1991, PATTERNS HMO ENROLLM	50	26	26	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1357	1362		10.1001/jama.270.11.1357	http://dx.doi.org/10.1001/jama.270.11.1357			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360971				2022-12-28	WOS:A1993LW34500035
J	BARDWELL, JCA; BECKWITH, J				BARDWELL, JCA; BECKWITH, J			THE BONDS THAT TIE - CATALYZED DISULFIDE BOND FORMATION	CELL			English	Review							ENDOPLASMIC-RETICULUM; PROTEIN; ISOMERASE		UNIV REGENSBURG,INST BIOPHYS & PHYS BIOCHEM,W-8400 REGENSBURG,GERMANY	University of Regensburg	BARDWELL, JCA (corresponding author), HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,BOSTON,MA 02115, USA.							ANFINSEN CB, 1961, P NATL ACAD SCI USA, V47, P1309, DOI 10.1073/pnas.47.9.1309; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; CREIGHTON TE, 1980, J MOL BIOL, V142, P43, DOI 10.1016/0022-2836(80)90205-3; CREIGHTON TE, 1993, IN PRESS J MOL BIOL; FREEDMAN RB, 1989, BIOCHEM SOC SYMP, V55, P167; HAWKINS HC, 1991, BIOCHEM J, V275, P341, DOI 10.1042/bj2750341; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; LAMANTIA ML, 1993, CELL, V74, P899, DOI 10.1016/0092-8674(93)90469-7; LUNDSTROM J, 1993, BIOCHEMISTRY-US, V32, P6649, DOI 10.1021/bi00077a018; LYLES MM, 1991, BIOCHEMISTRY-US, V30, P613, DOI 10.1021/bi00217a004; MARTIN JL, 1993, IN PRESS NATURE; MORJANA NA, 1991, BIOCHEMISTRY-US, V30, P4985, DOI 10.1021/bi00234a021; NOIVA R, 1992, J BIOL CHEM, V267, P3553; NOIVA R, 1993, IN PRESS J BIOL CHEM; WEISSMAN JS, 1993, IN PRESS NATURE; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; WUNDERLICH M, 1993, IN PRESS BIOCHEMISTR; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016	20	130	135	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					769	771		10.1016/0092-8674(93)90455-Y	http://dx.doi.org/10.1016/0092-8674(93)90455-Y			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374949				2022-12-28	WOS:A1993LX29200001
J	CANTOR, JC; BAKER, LC; HUGHES, RG				CANTOR, JC; BAKER, LC; HUGHES, RG			PREPAREDNESS FOR PRACTICE - YOUNG PHYSICIANS VIEWS OF THEIR PROFESSIONAL-EDUCATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-EDUCATION; REFORM	Objective.-To describe the views of young physicians (younger than age 45 years) regarding the appropriateness of specific aspects of medical training that have often been criticized as inadequate. Design.-Proportional analysis of survey data, stratified by medical school type and graduate medical education specialty and adjusted for demographics. Setting.-National sample of 4756 allopathic and osteopathic physicians trained in allopathic residencies representing a variety of practice settings. Dependent Variables.-Overall satisfaction with medical training, including medical school through residency and fellowship; satisfaction with preparedness for five aspects of practice and six types of patients; and satisfaction with the amount of time spent in each of six training settings. Results.-Eighty percent of young physicians reported that their formal medical training did an excellent or good job of preparing them for medical practice. Much smaller proportions (21% to 78%) reported excellent or good preparation to treat specific conditions or types of patients, and few (3%) reported being well prepared to manage business aspects of practice. Large proportions (35% to 63%) would prefer to have received more training in settings outside of hospitals, including managed care settings (67%). Significant differences in preparedness were observed by type of training; those trained in general and family practice reported better preparedness along many dimensions than did those trained in general internal medicine. Conclusions.-Young physicians generally confirm critiques of medical training noted by scholars and commissions. Health care reform is likely to increase the urgency for remedial action.			CANTOR, JC (corresponding author), ROBERT WOOD JOHNSON FDN,COLL RD,POB 2316,PRINCETON,NJ 08543, USA.			Baker, Laurence/0000-0001-5032-794X				BLOOM SW, 1992, REPORT COMMISSION ME; CANTOR JC, 1991, JAMA-J AM MED ASSOC, V265, P1002, DOI 10.1001/jama.265.8.1002; COHEN AB, 1990, HEALTH AFFAIR, V9, P138, DOI 10.1377/hlthaff.9.4.138; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; COTTON P, 1991, JAMA-J AM MED ASSOC, V266, P2802, DOI 10.1001/jama.266.20.2802; COX BG, 1985, METHODOLOGICAL ISSUE, pCH7; EBERT RH, 1988, HEALTH AFFAIR, V7, P5, DOI 10.1377/hlthaff.7.2.5; ENARSON C, 1992, JAMA-J AM MED ASSOC, V268, P1141, DOI 10.1001/jama.268.9.1141; HANFT RS, 1991, MAY HLTH CAR FIN ADM; Shugars DA, 1991, HLTH AM PRACTITIONER; SULLIVAN CB, 1992, HEALTH AFFAIR, V11, P172, DOI 10.1377/hlthaff.11.4.172; SULLIVAN CB, 1991, HEALTH AFFAIR, V10, P104, DOI 10.1377/hlthaff.10.2.104	12	168	168	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1035	1040		10.1001/jama.270.9.1035	http://dx.doi.org/10.1001/jama.270.9.1035			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350444				2022-12-28	WOS:A1993LU51200002
J	WEITHAUS, B				WEITHAUS, B			ALLIED HEALTH ACCREDITATION FACES MAJOR CHANGES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											WEITHAUS, B (corresponding author), AMER MED ASSOC,DIV ALLIED HLTH & ACCREDITAT,515 N STATE ST,CHICAGO,IL 60610, USA.							ATWELL RH, 1991, CHRON HIGHER ED 1120, pA52; BORZO G, 1993, AM MED NEWS     0312, P29; CLARK WG, 1993, AGNEDA SOURCE BOOK C, pF1; COOPER K, 1991, WASH POST       0904, pA17; GUPTA GC, 1993, ALLIED HLTH ED DIREC, P284; GUPTA GC, 1993, ALLIED HLTH ED DIREC, P302; Leatherman C., 1993, CHRON HIGHER EDUC, pA15; PERRIN KL, 1993, CHORN HIGHER ED 0203, pB4; WEISS S, 1991, NY TIMES        1120, pB8; WEISS S, 1993, NY TIMES        0224, pA13; 1992, CHRON HIGHER ED 0108, pA36; 1992, WASHINGTON POST 0123, pA24; 1992, CHRON HIGHER ED 0108, pA24; 1991, HIGHER ED NATL  1209, P1; 1991, WASHINGTON POST 1212, pA26; 1993, COPA BOARDS PLAN DIS	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1094	1096						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350456				2022-12-28	WOS:A1993LU51200014
J	WAGNER, H; FROST, B				WAGNER, H; FROST, B			DISPARITY-SENSITIVE CELLS IN THE OWL HAVE A CHARACTERISTIC DISPARITY	NATURE			English	Article							CATS VISUAL-CORTEX; INTERAURAL TIME DIFFERENCE; BARN OWL; BINOCULAR ORGANIZATION; BRAIN-STEM; NEURONS; TELENCEPHALON; WULST; DEPTH	WE experience the visual world as being three-dimensional. A major source of depth information derives from the slightly different views of each eye, leading to small variations in the retinal images ('disparities'). Neurons sensitive to visual disparities are thought to form the neural basis of stereo vision1-10. Barn owls2,3 as well as several mammalian species1,4-10 have neurons that are sensitive to visual disparities. But how visual disparities are represented in the brain has been a matter of discussion ever since the first disparity-sensitive neurons were found some 25 years ago. Here we adopt a new approach to this problem and study the neural computation of visual disparities with a paradigm borrowed from auditory research. The measurement of interaural time difference (ITD) has many similarities with the measurement of visual disparity on the formal, algorithmic level. We speculate that the similarities might extend to the level of neural computation. The neural representation of ITD is well understood11-18, and we have studied the representation of disparities with visual stimuli analogous to those successfully used in acoustic experiments. For example, ITD is converted in the brain to a pathlength on an axon that, owing to the finite conduction velocity in neurons, exactly matches the external ITD. This pathlength is called 'characteristic delay,12. Our results suggest that there is an analogue of the characteristic delay in stereo vision which we propose to call 'characteristic disparity'.	MAX PLANCK INST BIOL CYBERNET,D-72076 TUBINGEN,GERMANY	Max Planck Society	WAGNER, H (corresponding author), QUEENS UNIV,DEPT PSYCHOL,KINGSTON K7L 3N6,ONTARIO,CANADA.		Wagner, Hermann/G-5454-2012	Wagner, Hermann/0000-0002-8191-7595				BARLOW HB, 1967, J PHYSIOL-LONDON, V193, P327, DOI 10.1113/jphysiol.1967.sp008360; BLAKE R, 1991, TRENDS NEUROSCI, V14, P445, DOI 10.1016/0166-2236(91)90043-T; CARR CE, 1990, J NEUROSCI, V10, P3227; DEANGELIS GC, 1991, NATURE, V352, P156, DOI 10.1038/352156a0; HAMMOND P, 1991, EXP BRAIN RES, V87, P615; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; JEFFRESS LA, 1948, J COMP PHYSIOL PSYCH, V41, P35, DOI 10.1037/h0061495; JULESZ B, 1971, F CYCLOPEAN PERCEPTI; KARTEN HJ, 1973, J COMP NEUROL, V150, P253, DOI 10.1002/cne.901500303; Konishi M., 1988, AUDITORY FUNCTION NE, P721; MASKE R, 1984, VISION RES, V24, P1921, DOI 10.1016/0042-6989(84)90026-9; MOISEFF A, 1989, J COMP PHYSIOL A, V164, P637, DOI 10.1007/BF00614506; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P101, DOI 10.1113/jphysiol.1978.sp012490; NOMURA M, 1990, BIOL CYBERN, V63, P237, DOI 10.1007/BF00195863; OHZAWA I, 1986, J NEUROPHYSIOL, V56, P243, DOI 10.1152/jn.1986.56.1.243; OHZAWA I, 1986, J NEUROPHYSIOL, V56, P221, DOI 10.1152/jn.1986.56.1.221; OHZAWA I, 1990, SCIENCE, V249, P1037, DOI 10.1126/science.2396096; Pettigrew J.D., 1990, P283; PETTIGREW JD, 1979, PROC R SOC SER B-BIO, V204, P435, DOI 10.1098/rspb.1979.0038; PETTIGREW JD, 1976, SCIENCE, V193, P675, DOI 10.1126/science.948741; POGGIO GF, 1985, VISION RES, V25, P397, DOI 10.1016/0042-6989(85)90065-3; ROSE JE, 1966, J NEUROPHYSIOL, V29, P288, DOI 10.1152/jn.1966.29.2.288; STEINBACH MJ, 1973, VISION RES, V13, P889, DOI 10.1016/0042-6989(73)90055-2; SULLIVAN WE, 1986, P NATL ACAD SCI USA, V83, P8400, DOI 10.1073/pnas.83.21.8400; TAKAHASHI T, 1986, J NEUROSCI, V6, P3413; WAGNER H, 1987, J NEUROSCI, V7, P3105; Yin T.C.T., 1984, DYNAMIC ASPECTS NEOC, P263	27	54	54	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					796	798		10.1038/364796a0	http://dx.doi.org/10.1038/364796a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355804				2022-12-28	WOS:A1993LU58100054
J	OATES, BC; SIDEBOTTOM, AJ; MAXWELL, SRJ				OATES, BC; SIDEBOTTOM, AJ; MAXWELL, SRJ			EFFICACY OF HEPATITIS-B VACCINATION - KNOWLEDGE AMONG CLINICAL MEDICAL-STUDENTS	BRITISH MEDICAL JOURNAL			English	Article									QUEEN ELIZABETH HOSP,BIRMINGHAM MED SCH,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								FOLLETT EAC, 1990, S SERIES, V28, P32; GILSON R, 1992, PRESCRIBER, V3, P94; HADLER SC, 1986, NEW ENGL J MED, V315, P209, DOI 10.1056/NEJM198607243150401; WESTMORELAND D, 1990, EPIDEMIOL INFECT, V104, P499, DOI 10.1017/S0950268800047506; ZANETTI AR, 1990, VACCINE, V8, P205, DOI 10.1016/0264-410X(90)90046-O	5	11	12	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					301	301		10.1136/bmj.307.6899.301	http://dx.doi.org/10.1136/bmj.307.6899.301			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374379	Bronze, Green Published			2022-12-28	WOS:A1993LQ51600021
J	GOLDBERG, YP; ROMMENS, JM; ANDREW, SE; HUTCHINSON, GB; LIN, BY; THEILMANN, J; GRAHAM, R; GLAVES, ML; STARR, E; MCDONALD, H; NASIR, J; SCHAPPERT, K; KALCHMAN, MA; CLARKE, LA; HAYDEN, MR				GOLDBERG, YP; ROMMENS, JM; ANDREW, SE; HUTCHINSON, GB; LIN, BY; THEILMANN, J; GRAHAM, R; GLAVES, ML; STARR, E; MCDONALD, H; NASIR, J; SCHAPPERT, K; KALCHMAN, MA; CLARKE, LA; HAYDEN, MR			IDENTIFICATION OF AN ALU RETROTRANSPOSITION EVENT IN CLOSE PROXIMITY TO A STRONG CANDIDATE GENE FOR HUNTINGTONS-DISEASE	NATURE			English	Article							DNA-SEQUENCES; INSERTION; REGIONS; FAMILY; D4S95	HUNTINGTON'S disease (HD) is a late-onset autosomal dominant neuropsychiatric disorder presenting in mid-adult life with personality disturbance and involuntary movements, cognitive and affective disturbance, and inexorable progression to death1. The underlying genetic defect has been mapped to chromosomal band 4p16.3 (refs 2, 3). Analysis of specific recombination events in some families with HD has further refined the location of the HD defect to a 2.2 megabase DNA interval4,5. Using a direct complementary DNA selection strategy we have identified at least seven transcriptional units within the minimal region believed to contain the HD gene. Screening with one of the cDNA clones identified an Alu insertion in genomic DNA from two persons with HD which showed complete cosegregation with the disease in these families but was not found in 1,000 control chromosomes. Two genes including the previously identified alpha-adducin gene and another that encodes for a 12-kilobase transcript, map in close proximity to the Alu insertion site. The 12-kilobase transcript should be regarded as a strong candidate for the HD gene.	HOSP SICK CHILDREN,DEPT GENET,TORONTO M5G 1X8,ONTARIO,CANADA; UNIV BRITISH COLUMBIA,DEPT MED GENET,VANCOUVER V6T 1Z4,BC,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of British Columbia			Rommens, Johanna/AAT-7465-2021; Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419; Clarke, Lorne/0000-0003-0512-7281; Nasir, Jamal/0000-0001-6378-5616				ANDREW S, 1992, GENOMICS, V13, P301, DOI 10.1016/0888-7543(92)90246-O; BATES GP, 1991, AM J HUM GENET, V49, P7; BATES GP, 1992, NAT GENET, V1, P180, DOI 10.1038/ng0692-180; BATZER MA, 1991, GENOMICS, V9, P481, DOI 10.1016/0888-7543(91)90414-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIELS GR, 1985, NUCLEIC ACIDS RES, V13, P8939, DOI 10.1093/nar/13.24.8939; Goldberg Y. P., 1992, Human Molecular Genetics, V1, P669, DOI 10.1093/hmg/1.9.669; GUSELLA JF, 1983, NATURE, V306, P234, DOI 10.1038/306234a0; Hayden MR., 1981, HUNTINGTONS CHOREA, P45; HUTCHINSON GB, 1992, NUCLEIC ACIDS RES, V20, P3453, DOI 10.1093/nar/20.13.3453; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; MACDONALD ME, 1992, NAT GENET, V1, P99, DOI 10.1038/ng0592-99; MATERZ AG, 1990, NUCLEIC ACIDS RES, V18, P6091; MURATANI K, 1991, P NATL ACAD SCI USA, V88, P11315, DOI 10.1073/pnas.88.24.11315; ROBBINS C, 1989, AM J HUM GENET, V44, P422; SNELL RG, 1989, J MED GENET, V26, P673, DOI 10.1136/jmg.26.11.673; SNELL RG, 1992, AM J HUM GENET, V51, P357; TAYLOR SAM, 1992, NAT GENET, V2, P223, DOI 10.1038/ng1192-223; THEILMANN J, 1989, J MED GENET, V26, P676, DOI 10.1136/jmg.26.11.676; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Vidaud Dominique, 1993, European Journal of Human Genetics, V1, P30; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG HS, 1986, AM J HUM GENET, V3, P392; WEBER B, 1992, NAT GENET, V2, P216, DOI 10.1038/ng1192-216; ZUO J, 1992, HUM MOL GENET, V1, P149, DOI 10.1093/hmg/1.3.149	25	41	46	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 25	1993	362	6418					370	373		10.1038/362370a0	http://dx.doi.org/10.1038/362370a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8384324				2022-12-28	WOS:A1993KU17600070
J	HOLZ, GG; KUHTREIBER, WM; HABENER, JF				HOLZ, GG; KUHTREIBER, WM; HABENER, JF			PANCREATIC BETA-CELLS ARE RENDERED GLUCOSE-COMPETENT BY THE INSULINOTROPIC HORMONE GLUCAGON-LIKE PEPTIDE-1(7-37)	NATURE			English	Article							ELECTRICAL-ACTIVITY; B-CELLS; GENE-EXPRESSION; CA-2+ CHANNELS; PROTEIN-KINASE; ATP; CURRENTS; RELEASE; ACTIVATION; MODULATION	NON-INSULIN-DEPENDENT diabetes mellitus (NIDDM, type 2 diabetes) is a disorder of glucose homeostasis characterized by hyperglycaemia, peripheral insulin resistance, impaired hepatic glucose metabolism, and diminished glucose-dependent secretion of insulin from pancreatic beta-cells1. Glucagon-like-peptide-1(7-37) (GLP-1)2 is an intestinally derived hormone that may be useful for the treatment of NIDDM because it acts in vivo to increase the level of circulating insulin, and thus lower the concentration of blood glucose3,4. This therapeutic effect may result from the ability of GLP-1 to compensate for a defect in the glucose signalling pathway that regulates insulin secretion from beta-cells. In support of this concept we report here that GLP-1 confers glucose sensitivity to glucose-resistant beta-cells, a phenomenon we term glucose competence. Induction of glucose competence by GLP-1 results from its synergistic interaction with glucose to inhibit metabolically regulated potassium channels that are also targeted for inhibition by sulphonylurea drugs commonly used in the treatment of NIDDM5. Glucose competence allows membrane depolarization, the generation of action potentials, and Ca2+ influx, events that are known to trigger insulin secretion6,7.			HOLZ, GG (corresponding author), HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HOWARD HUGHES MED INST,MOLEC ENDOCRINOL LAB,BOSTON,MA 02114, USA.		Holz, George G/A-3386-2012	Holz, George/0000-0002-1781-3580	NIDDK NIH HHS [R01 DK045817, R01 DK045817-06A2] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; BLACKMORE PF, 1991, FEBS LETT, V283, P7, DOI 10.1016/0014-5793(91)80541-A; DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434; EDDLESTONE GT, 1985, AM J PHYSIOL, V248, pC145, DOI 10.1152/ajpcell.1985.248.1.C145; FALKE LC, 1989, FEBS LETT, V251, P167, DOI 10.1016/0014-5793(89)81448-6; FEHMANN HC, 1991, ENDOCRINOLOGY, V128, P2880, DOI 10.1210/endo-128-6-2880; FEHMANN HC, 1992, ENDOCRINOLOGY, V130, P159, DOI 10.1210/en.130.1.159; GERICH JE, 1989, NEW ENGL J MED, V321, P1231; GOKE R, 1988, J ENDOCRINOL, V116, P357, DOI 10.1677/joe.0.1160357; GUTNIAK M, 1992, NEW ENGL J MED, V326, P1316, DOI 10.1056/NEJM199205143262003; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HENQUIN JC, 1984, ENDOCRINOLOGY, V115, P1125, DOI 10.1210/endo-115-3-1125; HIRIART M, 1988, J GEN PHYSIOL, V91, P617, DOI 10.1085/jgp.91.5.617; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; MOJSOV S, 1986, J BIOL CHEM, V261, P1880; MOJSOV S, 1987, J CLIN INVEST, V79, P616, DOI 10.1172/JCI112855; NATHAN DM, 1992, DIABETES CARE, V15, P270, DOI 10.2337/diacare.15.2.270; NICHOLS CG, 1991, J GEN PHYSIOL, V97, P1095, DOI 10.1085/jgp.97.5.1095; PIPELEERS D, 1982, P NATL ACAD SCI-BIOL, V79, P7322, DOI 10.1073/pnas.79.23.7322; PRENTKI M, 1987, FEBS LETT, V220, P103, DOI 10.1016/0014-5793(87)80884-0; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RAJAN AS, 1989, DIABETES, V38, P874, DOI 10.2337/diabetes.38.7.874; RIBALET B, 1989, J GEN PHYSIOL, V94, P693, DOI 10.1085/jgp.94.4.693; SHERMAN A, 1988, BIOPHYS J, V54, P411, DOI 10.1016/S0006-3495(88)82975-8; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SMITH PA, 1990, FEBS LETT, V261, P187, DOI 10.1016/0014-5793(90)80667-8; THORENS B, 1992, P NATL ACAD SCI USA, V89, P8641, DOI 10.1073/pnas.89.18.8641; UNGER RH, 1992, WILLIAMS TXB ENDOCRI, P1255; WANG J, 1992, ENDOCRINOLOGY, V131, P146, DOI 10.1210/en.131.1.146; WANG WH, 1991, P NATL ACAD SCI USA, V88, P9722, DOI 10.1073/pnas.88.21.9722; WEIR GC, 1989, DIABETES, V38, P338, DOI 10.2337/diabetes.38.3.338	32	475	513	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 28	1993	361	6410					362	365		10.1038/361362a0	http://dx.doi.org/10.1038/361362a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ590	8381211	Green Accepted			2022-12-28	WOS:A1993KJ59000061
J	HAYES, DL; VLIETSTRA, RE				HAYES, DL; VLIETSTRA, RE			PACEMAKER MALFUNCTION	ANNALS OF INTERNAL MEDICINE			English	Review							SHOCK-WAVE LITHOTRIPSY; DDD PACEMAKER; LEAD FRACTURE; RADIATION-THERAPY; EXPERIENCE; DEFIBRILLATION; COMPLICATIONS; MANAGEMENT; FAILURE; PATIENT	The field of cardiac pacing has expanded rapidly in recent years. Engineering improvements and microprocessor technology have resulted in a vast increase in pacemaker technology. The ''high-tech'' edge of cardiac pacing often discourages all but the pacemaker specialist from approaching a malfunctioning pacemaker. Electrocardiographic signs of pacemaker malfunction can be grouped into four categories: failure to output, failure to capture, undersensing, and inappropriate pacemaker rate. For each of these categories, there may be true malfunctions and pseudomalfunctions. In addition, environmental sources of electromagnetic interference, both within and outside the hospital environment, can result in pacemaker malfunction. Approaching pacemaker malfunction with these categories in mind should help minimize confusion.	WATSON CLIN, DEPT CARDIOL, LAKELAND, FL 33804 USA		HAYES, DL (corresponding author), MAYO CLIN & MAYO FDN, DIV CARDIOVASC DIS & INTERNAL MED, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ADAMEC R, 1982, PACE, V5, P146, DOI 10.1111/j.1540-8159.1982.tb02205.x; ALAGONA P, 1989, PACE, V12, P619, DOI 10.1111/j.1540-8159.1989.tb02707.x; ALT E, 1987, THORAC CARDIOV SURG, V35, P101, DOI 10.1055/s-2007-1020206; AYLWARD P, 1979, PACE, V2, P462, DOI 10.1111/j.1540-8159.1979.tb05222.x; Barold S S, 1985, Cardiol Clin, V3, P565; BEAVER BB, 1986, PACE, V9, P65, DOI 10.1111/j.1540-8159.1986.tb05362.x; BERMAN N D, 1987, Canadian Journal of Cardiology, V3, P63; BERTUSO J, 1986, PACE, V9, P685, DOI 10.1111/j.1540-8159.1986.tb05416.x; BROOKS C, 1988, AM J EMERG MED, V6, P591, DOI 10.1016/0735-6757(88)90097-6; CAMPO A, 1983, ANN EMERG MED, V12, P32, DOI 10.1016/S0196-0644(83)80131-0; CHEN D, 1990, ARCH PHYS MED REHAB, V71, P27; CLARKE B, 1989, PACE, V12, P1077, DOI 10.1111/j.1540-8159.1989.tb01929.x; CONKLIN EF, 1975, J THORAC CARDIOV SUR, V69, P1; COOPER D, 1988, PACE, V11, P1607, DOI 10.1111/j.1540-8159.1988.tb06280.x; DREIFUS LS, 1986, PACE, V9, P371, DOI 10.1111/j.1540-8159.1986.tb04491.x; FETTER J, 1989, PACE, V12, P1494, DOI 10.1111/j.1540-8159.1989.tb06154.x; FROHLIG G, 1988, J AM COLL CARDIOL, V11, P806, DOI 10.1016/0735-1097(88)90215-X; FURMAN S, 1982, PACE, V5, P486, DOI 10.1111/j.1540-8159.1982.tb02265.x; FYKE FE, 1988, PACE, V11, P1571, DOI 10.1111/j.1540-8159.1988.tb06276.x; GABRY MD, 1987, PACE, V10, P1322, DOI 10.1111/j.1540-8159.1987.tb04968.x; GOULD L, 1988, CLIN CARDIOL, V11, P581, DOI 10.1002/clc.4960110814; GOULD L, 1981, PACE, V4, P575, DOI 10.1111/j.1540-8159.1981.tb06230.x; GRIECO JG, 1989, ANN THORAC SURG, V47, P453, DOI 10.1016/0003-4975(89)90393-7; GRIFFIN JC, 1986, PACE, V9, P387, DOI 10.1111/j.1540-8159.1986.tb04493.x; HAUSER RG, 1986, PACE, V9, P1277, DOI 10.1111/j.1540-8159.1986.tb06708.x; HAYES DL, 1985, PACE, V8, P192, DOI 10.1111/j.1540-8159.1985.tb05750.x; HAYES DL, 1988, MAYO CLIN PROC, V63, P236, DOI 10.1016/S0025-6196(12)65096-4; HAYES DL, 1987, J AM COLL CARDIOL, V10, P782, DOI 10.1016/S0735-1097(87)80270-X; HAYES DL, 1984, PACEMAKER LEADS, P317; HAYES DL, 1989, PRACTICE CARDIAC PAC, P497; HEINZ M, 1990, PACE, V13, P560; JANOSIK DL, 1987, AM J CARDIOL, V60, P1030, DOI 10.1016/0002-9149(87)90347-X; KATZENBERG CA, 1982, PACE, V5, P156, DOI 10.1111/j.1540-8159.1982.tb02207.x; LEE RW, 1986, AM J MED, V81, P883, DOI 10.1016/0002-9343(86)90361-X; LEVINE PA, 1986, ANN THORAC SURG, V41, P313, DOI 10.1016/S0003-4975(10)62777-4; MARKEWITZ A, 1986, PACE, V9, P1014, DOI 10.1111/j.1540-8159.1986.tb06663.x; MICKLEY H, 1989, CLIN CARDIOL, V12, P412, DOI 10.1002/clc.4960120713; MUGICA J, 1984, PACE, V2, P513; PARSONNET V, 1989, J AM COLL CARDIOL, V13, P917, DOI 10.1016/0735-1097(89)90236-2; PHILLIPS R, 1986, PACE, V9, P1166, DOI 10.1111/j.1540-8159.1986.tb06688.x; PLESS P, 1986, PACE, V9, P739, DOI 10.1111/j.1540-8159.1986.tb05423.x; RASMUSSEN MJ, 1988, MAYO CLIN PROC, V63, P443, DOI 10.1016/S0025-6196(12)65639-0; REIFFEL JA, 1985, PACE, V8, P369, DOI 10.1111/j.1540-8159.1985.tb05773.x; ROSENTHAL JE, 1990, CARDIAC ELECTROPHYSI, P409; STOKES KB, 1986, PACE, V9, P1160, DOI 10.1111/j.1540-8159.1986.tb06687.x; SUZUKI Y, 1988, PACE, V11, P326, DOI 10.1111/j.1540-8159.1988.tb05011.x; SWEESY MW, 1988, PACE, V11, P1512, DOI 10.1111/j.1540-8159.1988.tb06266.x; URSELL S, 1990, ELECTRICAL THERAPY C, P205	48	42	43	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					828	835		10.7326/0003-4819-119-8-199310150-00009	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379604				2022-12-28	WOS:A1993MB49600009
J	BERRIOS, DC; HEARST, N; COATES, TJ; STALL, R; HUDES, ES; TURNER, H; EVERSLEY, R; CATANIA, J				BERRIOS, DC; HEARST, N; COATES, TJ; STALL, R; HUDES, ES; TURNER, H; EVERSLEY, R; CATANIA, J			HIV ANTIBODY TESTING AMONG THOSE AT RISK FOR INFECTION - THE NATIONAL AIDS BEHAVIORAL SURVEYS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; SEXUAL-BEHAVIOR; CONDOM USE; PREVALENCE; FREQUENCY; ADULTS; BIAS	Objective.-To determine the prevalence of testing for human immunodeficiency virus (HIV) antibody among adults with various risk factors for infection, particularly those residing in large metropolitan areas where the bulk of cases of acquired immunodeficiency syndrome (AIDS) have occurred. Design.-A nationwide, population-based telephone survey eliciting testing, sexual, and injection drug use histories. Participants.-A total of 2673 randomly chosen US residents and 8263 randomly chosen residents of 23 metropolitan areas containing 64% of reported cases of AIDS. Interventions.-None. Main Outcome Measure.-Testing for HIV antibody. Main Results.-Overall, rates of individuals ever tested were only slightly higher in the urban areas (23%) than in the nation as a whole (21%). Testing frequencies were low among all risk groups (less than 40%), except men engaging in same-sex sexual activity (60%) and male and female injection drug users (46% and 73%, respectively). The low rate of testing (35%) among the largest risk group, heterosexual men and women engaging in unprotected sexual intercourse with multiple partners, was particularly worrisome. Conclusions.-To encourage antibody testing among the many at risk for infection who have not yet been tested, promotional campaigns should explain the universal susceptibility to infection among those at risk, and the availability of prophylactic medical therapies and social support services to persons who are HIV-seropositive. As there were comparable levels of risk-taking behavior among subjects in both samples, these campaigns must be designed to reach all segments of the population.	UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94105 USA	University of California System; University of California San Francisco	BERRIOS, DC (corresponding author), UNIV CALIF SAN FRANCISCO, CTR AIDS PREVENT STUDIES, DEPT MED, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94105 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043892, P50MH042459, R01MH046240] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459, MH43892, MH46240] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAJOS N, 1991, 7TH INT C AIDS FLOR, V1, P405; BERRIOS DC, 1992, ARCH INTERN MED, V152, P397, DOI 10.1001/archinte.152.2.397; BIDDLECOM MA, 1991, VITAL HLTH STAT 207, V13; Bradburn NM, 1979, IMPROVING INTERVIEW; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; CATANIA JA, 1990, EVAL PROGRAM PLANN, V13, P19, DOI 10.1016/0149-7189(90)90005-H; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P565; COATES TJ, 1988, AM PSYCHOL, V43, P859, DOI 10.1037/0003-066X.43.11.859; FAY RE, 1989, SCIENCE, V243, P338, DOI 10.1126/science.2911744; FAY RE, 1989, SCIENCE, V244, P1531; GOSTIN LO, 1989, JAMA-J AM MED ASSOC, V261, P1621; HARDY AM, 1991, VITAL HLTH STAT 206, V13; HARDY AM, 1991, VITAL HLTH STAT 204, V13; HINGSON R, 1989, PREV MED, V18, P806, DOI 10.1016/0091-7435(89)90016-9; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; KANOUSE D, 1991, AIDS RELATED KNOWLED; KEETER S, 1988, AM J PREV MED, V4, P146, DOI 10.1016/S0749-3797(18)31187-5; LAVRAKAS PJ, 1987, TELEPHONE SURVEY MET; LINDENBAUM S, 1991, EVALUATING AIDS PREV, P223; MCQUEEN D, 1989, 1 U ED RES UN HLTH B; MICHAEL RT, 1989, MMWR-MORBID MORTAL W, V38, P429; MICHAEL RT, 1989, MMWR-MORBID MORTAL W, V38, P423; ROWE M, 1989, INTERGOVERNMENTAL AI, P2; SMITH TW, 1991, FAM PLANN PERSPECT, V23, P102, DOI 10.2307/2135820; THORNBERRY OT, 1988, WILEY S PRO, P25; WEISS R, 1988, NEW ENGL J MED, V319, P1010, DOI 10.1056/NEJM198810133191509; 1987, RTILOGIT PROCEDURE L; 1991, HIV AIDSD SURVEILLAN, P1; 1991, MMWR MORB MORTAL WKL, V40, P666; 1987, MMET MOTN MOTYSL EKL, V36, P509; 1982, RTIFREQS PROGRAM COM	33	99	100	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1576	1580		10.1001/jama.270.13.1576	http://dx.doi.org/10.1001/jama.270.13.1576			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371468				2022-12-28	WOS:A1993LZ33400031
J	LARNER, AC; DAVID, M; FELDMAN, GM; IGARASHI, K; HACKETT, RH; WEBB, DSA; SWEITZER, SM; PETRICOIN, EF; FINBLOOM, DS				LARNER, AC; DAVID, M; FELDMAN, GM; IGARASHI, K; HACKETT, RH; WEBB, DSA; SWEITZER, SM; PETRICOIN, EF; FINBLOOM, DS			TYROSINE PHOSPHORYLATION OF DNA-BINDING PROTEINS BY MULTIPLE CYTOKINES	SCIENCE			English	Article							INTERFERON-ALPHA; TRANSCRIPTION FACTOR; SIGNAL TRANSDUCTION; GENE; ACTIVATOR; ISGF-3; GAMMA	Interferon-alpha (IFN-alpha) and IFN-gamma regulate gene expression by tyrosine phosphorylation of several transcription factors that have the 91-kilodalton (p91) protein of interferon-stimulated gene factor-3 (ISGF-3) as a common component. Interferon-activated protein complexes bind enhancers present in the promoters of early response genes such as the high-affinity Fcgamma receptor gene (FcgammaRI). Treatment of human peripheral blood monocytes or basophils with interleukin-3 (IL-3), IL-5, IL-10, or granulocyte-macrophage colony-stimulating factor (GM-CSF) activated DNA binding proteins that recognized the IFN-gamma response region (GRR) located in the promoter of the FcgammaRI gene. Although tyrosine phosphorylation was required for the assembly of each of these GRR binding complexes, only those formed as a result of treatment with IFN-gamma or IL-10 contained p91. Instead, complexes activated by IL-3 or GM-CSF contained a tyrosine-phosphorylated protein of 80 kilodaltons. Induction of FcgammaRI RNA occurred only with IFN-gamma and IL-10, whereas pretreatment of cells with GM-CSF or IL-3 inhibited IFN-gamma induction of FcgammaRI RNA. Thus, several cytokines other than interferons can activate putative transcription factors by tyrosine phosphorylation.			LARNER, AC (corresponding author), CTR BIOL EVALUAT & RES,DIV CYTOKINE BIOL,BETHESDA,MD 20892, USA.							DAVID M, 1993, J BIOL CHEM, V268, P6593; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; LARNER AC, UNPUB; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; WILSON KC, 1992, P NATL ACAD SCI USA, V89, P11964, DOI 10.1073/pnas.89.24.11964	14	355	364	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1730	1733		10.1126/science.8378773	http://dx.doi.org/10.1126/science.8378773			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378773				2022-12-28	WOS:A1993LY58400025
J	FANG, GW; CECH, TR				FANG, GW; CECH, TR			THE BETA-SUBUNIT OF OXYTRICHA TELOMERE-BINDING PROTEIN PROMOTES G-QUARTET FORMATION BY TELOMERIC DNA	CELL			English	Article							MACRONUCLEAR DNA; MESSENGER-RNA; ATP HYDROLYSIS; 3' TERMINUS; COMPLEX; RIBONUCLEOPROTEIN; DIMERIZATION; SPLICEOSOME; MECHANISM; GENES	Telomeres, the ends of linear chromosomes, typically consist of tandem repeats of simple G-rich sequences. At high concentrations, single-stranded telomeric DNA can form dimers and tetramers involving G-quartets. We show that under physiological conditions, the beta subunit of the Oxytricha telomere-binding protein greatly accelerates G-quartet formation. The reaction occurs with oligonucleotides ending in the Oxytricha (T4G4T4G4) and Tetrahymena (T2G4T2G4) telomeric sequences; the sequence preceding these telomeric repeats can be nontelomeric, single-, or double-stranded. Protein deletion analysis indicates that the carboxy-terminal highly basic domain of the beta subunit, which is dispensible for telomeric complex formation, is sufficient for mediating G-quartet formation. The finding that a telomeric protein acts as a molecular chaperone for G-quartet formation provides a strong argument that such DNA structures exist in vivo at chromosome telomeres.			FANG, GW (corresponding author), UNIV COLORADO, HOWARD HUGHES MED INST, DEPT CHEM & BIOCHEM, BOULDER, CO 80309 USA.				NIGMS NIH HHS [GM28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028039, R37GM028039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULELA F, 1992, NATURE, V360, P280, DOI 10.1038/360280a0; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; BLACKBURN EH, 1984, ANNU REV BIOCHEM, V53, P163, DOI 10.1146/annurev.bi.53.070184.001115; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; CHEONG CJ, 1992, BIOCHEMISTRY-US, V31, P8406, DOI 10.1021/bi00151a003; DARLIX JL, 1990, J MOL BIOL, V216, P689, DOI 10.1016/0022-2836(90)90392-Y; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FANG GW, 1993, P NATL ACAD SCI USA, V90, P6056, DOI 10.1073/pnas.90.13.6056; FANG GW, 1993, GENE DEV, V7, P870, DOI 10.1101/gad.7.5.870; GELLERT M, 1962, P NATL ACAD SCI USA, V48, P2013, DOI 10.1073/pnas.48.12.2013; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HENDERSON ER, 1989, MOL CELL BIOL, V9, P345, DOI 10.1128/MCB.9.1.345; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; KANG C, 1992, NATURE, V356, P126, DOI 10.1038/356126a0; KARPEL RL, 1980, BIOCHEMISTRY-US, V19, P4674, DOI 10.1021/bi00561a021; KARPEL RL, 1982, BIOCHEM, V21, P2101; Klobutcher L.A., 1986, P111; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P10717, DOI 10.1021/bi00500a001; LIPPS HJ, 1980, P NATL ACAD SCI-BIOL, V77, P4104, DOI 10.1073/pnas.77.7.4104; LIU ZP, 1993, P NATL ACAD SCI USA, V90, P3157, DOI 10.1073/pnas.90.8.3157; MARQUET R, 1991, NUCLEIC ACIDS RES, V19, P2349, DOI 10.1093/nar/19.9.2349; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MURCHIE AIH, 1992, NUCLEIC ACIDS RES, V20, P49, DOI 10.1093/nar/20.1.49; OKA Y, 1987, NUCLEIC ACIDS RES, V15, P8877, DOI 10.1093/nar/15.21.8877; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PRICE CM, 1987, GENE DEV, V1, P783, DOI 10.1101/gad.1.8.783; PRICE CM, 1989, BIOCHEMISTRY-US, V28, P769, DOI 10.1021/bi00428a053; RAGHURAMAN MK, 1989, CELL, V59, P719, DOI 10.1016/0092-8674(89)90018-4; RAGHURAMAN MK, 1990, NUCLEIC ACIDS RES, V18, P4543, DOI 10.1093/nar/18.15.4543; ROTH M, 1985, CELL, V41, P411, DOI 10.1016/S0092-8674(85)80014-3; SAMBROOK J, 1989, MOL CLONING, pB16; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SEN D, 1992, BIOCHEMISTRY-US, V31, P65, DOI 10.1021/bi00116a011; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SEN D, 1988, NATURE, V334, P364, DOI 10.1038/334364a0; SMITH FW, 1992, NATURE, V356, P164, DOI 10.1038/356164a0; SUNDQUIST WI, 1993, P NATL ACAD SCI USA, V90, P3393, DOI 10.1073/pnas.90.8.3393; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SWANSON MS, 1988, EMBO J, V7, P3519, DOI 10.1002/j.1460-2075.1988.tb03228.x; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; WANG Y, 1992, BIOCHEMISTRY-US, V31, P8112, DOI 10.1021/bi00150a002; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	53	250	253	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					875	885		10.1016/0092-8674(93)90467-5	http://dx.doi.org/10.1016/0092-8674(93)90467-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374954				2022-12-28	WOS:A1993LX29200013
J	ROBINSON, PJ; SONTAG, JM; LIU, JP; FYKSE, EM; SLAUGHTER, C; MCMAHON, H; SUDHOF, TC				ROBINSON, PJ; SONTAG, JM; LIU, JP; FYKSE, EM; SLAUGHTER, C; MCMAHON, H; SUDHOF, TC			DYNAMIN GTPASE REGULATED BY PROTEIN-KINASE-C PHOSPHORYLATION IN NERVE-TERMINALS	NATURE			English	Article							TEMPERATURE-SENSITIVE MUTANT; REVERSIBLE BLOCKAGE; INTACT SYNAPTOSOMES; MEMBRANE RETRIEVAL; DROSOPHILA; ENDOCYTOSIS; DEPHOSPHORYLATION; MICROTUBULES; SHIBIRE; RELEASE	DYNAMIN is a microtubule-binding protein with a microtubule-activated GTPase activity1-3. The gene encoding dynamin is mutated in shibire4,5, a Drosophila mutant defective in endocytosis in nerve terminals and other cells6-9. These observations place dynamin into two distinct functional contexts, suggesting roles in microtubule-based motility or in endocytosis. We report here that dynamin is identical to the neuronal phosphoprotein dephosphin (P96), originally identified by its stimulus-dependent dephosphorylation in nerve terminals10-13. Dynamin is a protein doublet of M(r) 94 and 96K arising by alternative splicing of its primary transcript. In the nerve terminal, both forms of dynamin are phosphorylated by protein kinase C (PKC) and are quantitatively dephosphorylated on excitation. In vitro, dynamin is also phosphorylated by casein kinase II which inhibits PKC phosphorylation. Phosphorylation by PKC but not by casein kinase II enhances the GTPase activity of dynamin 12-fold. The dynamins are therefore a group of nerve terminal phosphoproteins whose GTPase is regulated by phosphorylation in parallel with synaptic vesicle recycling. The regulation of dynamin GTPase could serve as the trigger for the rapid endocytosis of synaptic vesicles after exocytosis.	UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; JOHN HUNTER HOSP, ENDOCRINE UNIT, NEWCASTLE, NSW 2310, AUSTRALIA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; John Hunter Hospital; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Liu, Jun-Ping/AAA-5521-2020; Robinson, Phillip J/G-4008-2011	Liu, Jun-Ping/0000-0001-7442-2116; Robinson, Phillip J/0000-0002-7878-0313				CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; FAIRE K, 1992, P NATL ACAD SCI USA, V89, P8376, DOI 10.1073/pnas.89.17.8376; HARLOW E, 1988, ANTIBODIES LABORATOR; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; KESSELL I, 1989, P NATL ACAD SCI USA, V86, P4968, DOI 10.1073/pnas.86.13.4968; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; LINCOLN TM, 1983, METHOD ENZYMOL, V99, P62; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; ROBINSON PJ, 1991, FEBS LETT, V282, P388, DOI 10.1016/0014-5793(91)80520-D; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1992, J BIOL CHEM, V267, P21637; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SIHRA TS, 1992, J BIOL CHEM, V267, P1983; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; [No title captured]	21	259	264	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 9	1993	365	6442					163	166		10.1038/365163a0	http://dx.doi.org/10.1038/365163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371759				2022-12-28	WOS:A1993LW44200049
J	ROULEAU, GA; MEREL, P; LUTCHMAN, M; SANSON, M; ZUCMAN, J; MARINEAU, C; HOANGXUAN, K; DEMCZUK, S; DESMAZE, C; PLOUGASTEL, B; PULST, SM; LENOIR, G; BIJLSMA, E; FASHOLD, R; DUMANSKI, J; DEJONG, P; PARRY, D; ELDRIGE, R; AURIAS, A; DELATTRE, O; THOMAS, G				ROULEAU, GA; MEREL, P; LUTCHMAN, M; SANSON, M; ZUCMAN, J; MARINEAU, C; HOANGXUAN, K; DEMCZUK, S; DESMAZE, C; PLOUGASTEL, B; PULST, SM; LENOIR, G; BIJLSMA, E; FASHOLD, R; DUMANSKI, J; DEJONG, P; PARRY, D; ELDRIGE, R; AURIAS, A; DELATTRE, O; THOMAS, G			ALTERATION IN A NEW GENE ENCODING A PUTATIVE MEMBRANE-ORGANIZING PROTEIN CAUSES NEUROFIBROMATOSIS TYPE-2	NATURE			English	Article							BILATERAL ACOUSTIC NEUROFIBROMATOSIS; GRADIENT GEL-ELECTROPHORESIS; HUMAN-CHROMOSOME 22; SUBUNIT NF-H; POLYPOSIS-COLI; DNA FRAGMENTS; MENINGIOMA; TALIN; EZRIN; HOMOLOGY	Neurofibromatosis type 2 (NF2) is a monogenic dominantly inherited disease predisposing carriers to develop nervous system tumours. To identify the genetic defect, the region between two flanking polymorphic markers on chromosome 22 was cloned and several genes identified. One is the site of germ-line mutations in NF2 patients and of somatic mutations in NF2-related tumours. Its deduced product has homology with proteins at the plasma membrane and cytoskeleton interface, a previously unknown site of action of tumour suppressor genes in humans.	MONTREAL GEN HOSP,RES INST,MONTREAL H3G 1A4,QUEBEC,CANADA; INST CURIE,GENET TUMEURS LAB,INSERM,CJF 9201,F-75231 PARIS 05,FRANCE; CEDARS SINAI MED CTR,NEUROGENET LAB,LOS ANGELES,CA 90048; INT AGCY RES CANC,F-69372 LYON,FRANCE; UNIV AMSTERDAM,INST HUMAN GENET,1105 AZ AMSTERDAM,NETHERLANDS; UNIV ERLANGEN NURNBERG,INST HUMAN GENET,W-8520 ERLANGEN,GERMANY; KAROLINSKA INST,DEPT CLIN GENET,S-10401 STOCKHOLM 60,SWEDEN; LAWRENCE LIVERMORE NATL LAB,CTR HUMAN GENOME,LIVERMORE,CA 94550; NCI,CLIN EPIDEMIOL BRANCH,BETHESDA,MD 20892	McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Cedars Sinai Medical Center; World Health Organization; International Agency for Research on Cancer (IARC); University of Amsterdam; University of Erlangen Nuremberg; Karolinska Institutet; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ROULEAU, GA (corresponding author), MCGILL UNIV,CTR RECH NEUROSCI,MONTREAL H3A 2T5,QUEBEC,CANADA.		j, zucman-rossi/AAV-3594-2021; zucman-rossi, Jessica/B-5098-2009; Plougastel-Douglas, Beatrice/Q-3186-2019; Hoang-Xuan, Khe/O-7527-2017	j, zucman-rossi/0000-0002-5687-0334; zucman-rossi, Jessica/0000-0002-5687-0334; Plougastel-Douglas, Beatrice/0000-0002-6389-561X; Desmaze, Chantal/0000-0003-0777-8854				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BIJLSMA EK, 1992, GENE CHROMOSOME CANC, V5, P201, DOI 10.1002/gcc.2870050305; CHEN LC, 1991, CANCER RES, V32, P300; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; COUTURIER J, 1990, CANCER GENET CYTOGEN, V45, P55, DOI 10.1016/0165-4608(90)90066-J; DELATTRE O, 1991, GENOMICS, V9, P721, DOI 10.1016/0888-7543(91)90366-M; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DESMAZE C, 1992, GENE CHROMOSOME CANC, V5, P30, DOI 10.1002/gcc.2870050105; DUMANSKI JP, 1990, HUM GENET, V84, P219, DOI 10.1007/BF00200562; DUMANSKI JP, 1990, CANCER RES, V50, P5863; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FONTAINE B, 1991, GENOMICS, V10, P280, DOI 10.1016/0888-7543(91)90513-E; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HENIKOFF S, 1984, GENE, V28, P357; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P253, DOI 10.1016/0165-4608(89)90192-1; KAHRE O, 1992, MOL CELL BIOL, V12, P4242; KOZAC M, 1966, NUCLEIC ACIDS RES, V16, P8125; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LEES JF, 1988, EMBO J, V7, P1947, DOI 10.1002/j.1460-2075.1988.tb03032.x; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; LINDSAY S, 1987, NATURE, V327, P336, DOI 10.1038/327336a0; Maniatis T, 1989, DECONTAMINATION DILU; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MATTEI MG, 1988, HUM GENET, V80, P293, DOI 10.1007/BF01790100; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NAROD SA, 1992, AM J HUM GENET, V51, P486; OKAMOTO M, 1988, NATURE, V331, P273, DOI 10.1038/331273a0; OLSCHWANG S, 1993, AM J HUM GENET, V52, P273; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1987, NATURE, V329, P246, DOI 10.1038/329246a0; RUTTLEDGE MH, IN PRESS NEUROLOGY; SEIZINGER BR, 1986, NATURE, V322, P644, DOI 10.1038/322644a0; SEIZINGER BR, 1987, CELL, V49, P589, DOI 10.1016/0092-8674(87)90534-4; SEIZINGER BR, 1987, P NATL ACAD SCI USA, V84, P5419, DOI 10.1073/pnas.84.15.5419; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; TANAKA N, 1992, GENE CHROMOSOME CANC, V5, P399, DOI 10.1002/gcc.2870050416; TOS M, 1984, J LARYNGOL OTOL, V98, P685, DOI 10.1017/S0022215100147292; TURUNEN O, 1989, J BIOL CHEM, V264, P16727; VANLEEUWEN C, 1991, NUCLEIC ACIDS RES, V19, P5805, DOI 10.1093/nar/19.20.5805; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402	43	1138	1172	0	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 10	1993	363	6429					515	521		10.1038/363515a0	http://dx.doi.org/10.1038/363515a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LF939	8379998				2022-12-28	WOS:A1993LF93900040
J	PIMPLIKAR, SW; SIMONS, K				PIMPLIKAR, SW; SIMONS, K			REGULATION OF APICAL TRANSPORT IN EPITHELIAL-CELLS BY A G(S) CLASS OF HETEROTRIMERIC G-PROTEIN	NATURE			English	Article							GTP-BINDING PROTEINS; MDCK CELLS; SURFACE; MASTOPARAN; MEMBRANES; DOMAINS	THE role of heterotrimeric GTP-binding proteins in signal transduction is well established1. They might also be involved in vesicular transport2-6. Here we show that in the epithelial cell line Madin-Darby Canine Kidney, transport of influenza haemagglutinin protein to the apical surface is stimulated and that of vesicular stomatitis virus glycoprotein to the basolateral surface is retarded by AlF(3-5) treatment. Treatment of cells with the reagents known to influence the G(i) class of G proteins affected only the basolateral pathway whereas reagents acting on the G(s) class of G proteins specifically affected the apical pathway. In permeabilized cells, antibodies raised against the N-terminal domain of the alpha-subunit of G(s) inhibited the transport of haemagglutinin from the trans-Golgi network to apical surface but not between the endoplasmic reticulum and Golgi complex. These observations demonstrate involvement of a G(s) class of heterotrimeric G proteins, besides that of the G(i), in vesicular transport2. Moreover, the apical and the basolateral pathways in epithelial cells seem to be regulated by G(s) and G(i) proteins, respectively, in the trans-Golgi network.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,POSTFACH 102209,W-6900 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Simons, Kai/0000-0002-9231-9996				BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BOMSEL M, 1991, Journal of Cell Biology, V115, p195A; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; DONALDSON JG, 1991, SCIENCE, V254, P850; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAZIRO Y, 1991, REV BIOCH, V60, P349; KOBAYASHI T, 1992, FEBS LETT, V300, P227, DOI 10.1016/0014-5793(92)80851-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; MATLIN KS, 1984, J CELL BIOL, V99, P2131, DOI 10.1083/jcb.99.6.2131; RINDLER MJ, 1984, J CELL BIOL, V98, P1304, DOI 10.1083/jcb.98.4.1304; SARGIACOMO M, 1989, J CELL BIOL, V109, P2117; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987	23	187	189	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 1	1993	362	6419					456	458		10.1038/362456a0	http://dx.doi.org/10.1038/362456a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8385268				2022-12-28	WOS:A1993KV42400086
J	EPSTEIN, RJ				EPSTEIN, RJ			6 AUTHORS IN SEARCH OF A CITATION - VILLAINS OR VICTIMS OF THE VANCOUVER CONVENTION	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To analyse trends in the number of authors per article over the past 10 years. Design-Analysis of articles from random volumes of eight biomedical journals. Subjects-Cell, Nature, Proceedings of the National Academy of Sciences USA (PNAS), Journal of Clinical Investigation (JCI), Biochemical and Biophysical Research Communications (BBRC), Journal of Clinical Oncology (JCO), New England Journal of Medicine (NEJM), Lancet. Main outcome measures-Median and modal numbers of authors. Results-All journals except Cell and Nature showed a trend towards increasing authorship numbers over the study period. The trend was most noticeable in journals such as JCO which feature clinical research. General medical journals (Lancet, NEJM) with a median of six to seven authors per article published far fewer seven author than six author studies, which suggests that author number may be influenced by the Vancouver convention which precludes citation of more than six authors. Conclusions-The phenomenon of expanding authorship in biomedical journal articles is not explained by the hypothesis that newer research technologies have necessitated more extensive collaboration. Rather, the data suggest that conferral of authorship may sometimes have a volitional component which contributes to rising author numbers. It is proposed that replacement of the Vancouver convention with a ''first author, last author'' citation system may help stem this rise in author numbers.			EPSTEIN, RJ (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT MED,DIV CELL & MOLEC BIOL,BOSTON,MA 02115, USA.							ALVAREZDARDET C, 1985, NEW ENGL J MED, V312, P1521; BURMAN KD, 1982, ANN INTERN MED, V97, P602, DOI 10.7326/0003-4819-97-4-602; HAMILTON DP, 1990, SCIENCE, V250, P1331, DOI 10.1126/science.2255902; SOBAL J, 1990, NEW ENGL J MED, V323, P488; 1990, ETHICS POLICY SCI PU, P175	5	68	71	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					765	767		10.1136/bmj.306.6880.765	http://dx.doi.org/10.1136/bmj.306.6880.765			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	8369041	Green Published, Bronze			2022-12-28	WOS:A1993KU17300028
J	CARSON, SA; BUSTER, JE				CARSON, SA; BUSTER, JE			CURRENT CONCEPTS - ECTOPIC PREGNANCY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LOCAL METHOTREXATE INJECTION; CONSERVATIVE LAPAROSCOPIC TREATMENT; HUMAN CHORIONIC-GONADOTROPIN; UNRUPTURED TUBAL PREGNANCY; MEDICAL-TREATMENT; CLINICAL-TRIAL; LINEAR SALPINGOSTOMY; EXPECTANT MANAGEMENT; SONOGRAPHIC CONTROL; FALLOPIAN-TUBE				CARSON, SA (corresponding author), UNIV TENNESSEE CTR HLTH SCI,DEPT OBSTET & GYNECOL,DIV REPROD ENDOCRINOL & INFERTIL,MEMPHIS,TN 38163, USA.							ABOULGHAR MA, 1990, HUM REPROD, V5, P887, DOI 10.1093/oxfordjournals.humrep.a137204; ALTARAS M, 1988, BRIT J OBSTET GYNAEC, V95, P1321, DOI 10.1111/j.1471-0528.1988.tb06826.x; BENGTSSON G, 1992, OBSTET GYNECOL, V79, P589; BORNSTEIN S, 1987, J REPROD MED, V32, P590; BRUHAT MA, 1980, FERTIL STERIL, V33, P411; BRUMSTED J, 1988, OBSTET GYNECOL, V71, P889; BYRJALSEN C, 1991, ANN CHIR GYNAECOL FE, V80, P381; CARSON SA, 1991, FERTIL STERIL, V55, P629; CHAPRON C, 1992, HUM REPROD, V7, P422, DOI 10.1093/oxfordjournals.humrep.a137662; CHAPRON C, 1991, EUR J OBSTET GYN R B, V41, P187, DOI 10.1016/0028-2243(91)90022-D; CHU E, 1990, J BIOL CHEM, V265, P8470; DANIELL JF, 1984, FERTIL STERIL, V41, P558; DECHERNEY AH, 1987, OBSTET GYNECOL, V70, P948; Ectopic pregnancy-United States 1988-1989, 1992, MMWR-MORBID MORTAL W, V41, P591; EMERSON DS, 1992, RADIOLOGY, V183, P413, DOI 10.1148/radiology.183.2.1561342; FEICHTINGER W, 1989, ARCH GYNECOL OBSTET, V246, P85, DOI 10.1007/BF00934124; FEICHTINGER W, 1987, LANCET, V1, P381; FERNANDEZ H, 1991, HUM REPROD, V6, P1474, DOI 10.1093/oxfordjournals.humrep.a137292; FERNANDEZ H, 1992, 48TH ANN M AM FERT S; FRYDMAN R, 1989, FERTIL STERIL, V52, P734; GARCIA AJ, 1987, FERTIL STERIL, V48, P395; GARCIA AJ, 1988, FERTIL STERIL, V49, P382, DOI 10.1016/S0015-0282(16)59741-6; GOLDSTEIN DP, 1986, 34 ANN M AM COLL OBS, P40; HAANS LCF, 1987, EUR J OBSTET GYN R B, V24, P63, DOI 10.1016/0028-2243(87)90039-6; HENDERSON SR, 1989, AM J OBSTET GYNECOL, V160, P1462, DOI 10.1016/0002-9378(89)90871-5; HENRY M, 1992, 48TH ANN M AM FERT S; HUBER J, 1989, INT J GYNECOL OBSTET, V29, P153, DOI 10.1016/0020-7292(89)90846-1; ICHINOE K, 1987, AM J OBSTET GYNECOL, V156, P484, DOI 10.1016/0002-9378(87)90315-2; Isaacs J, 1992, J Miss State Med Assoc, V33, P81; JOHNS DA, 1986, FERTIL STERIL, V46, P703; KARSTEN U, 1990, ZBL GYNAKOL, V112, P467; KECKSTEIN J, 1990, BRIT J OBSTET GYNAEC, V97, P352, DOI 10.1111/j.1471-0528.1990.tb01814.x; KENIGSBERG D, 1987, FERTIL STERIL, V47, P702; KOJIMA E, 1990, OBSTET GYNECOL, V75, P723; KOOI GS, 1991, THESIS TILBURG; KOOI S, 1990, FERTIL STERIL, V54, P580; LANG PF, 1990, LANCET, V336, P78, DOI 10.1016/0140-6736(90)91593-Y; LEACH RE, 1989, J REPROD MED, V34, P324; LENTON EA, 1982, FERTIL STERIL, V37, P773; LINDBLOM B, 1990, FERTIL STERIL, V54, P404; LINDBLOM B, 1992, CURR OPIN OBSTET GYN, V4, P400; LINDBLOM B, 1987, LANCET, V1, P776; MECKE H, 1991, GEBURTSH FRAUENHEILK, V51, P549, DOI 10.1055/s-2007-1026197; MENARD A, 1990, FERTIL STERIL, V54, P47; MIYAZAKI Y, 1983, Hokkaido Journal of Medical Science, V58, P132; MOTTLA GL, 1992, FERTIL STERIL, V57, P685; NEIMAN RA, 1985, J RHEUMATOL, V12, P354; ORY SJ, 1986, AM J OBSTET GYNECOL, V154, P1299, DOI 10.1016/0002-9378(86)90716-7; PANSKY M, 1989, AM J OBSTET GYNECOL, V161, P393, DOI 10.1016/0002-9378(89)90529-2; PANSKY M, 1989, LANCET, V2, P967; POULY JL, 1986, FERTIL STERIL, V46, P1093; PREVOST RR, 1992, CLIN PHARMACY, V11, P529; RISQUEZ F, 1992, FERTIL STERIL, V58, P1131; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; SAND PK, 1986, AM J OBSTET GYNECOL, V155, P324, DOI 10.1016/0002-9378(86)90819-7; SAUER MV, 1987, FERTIL STERIL, V48, P752; SEGNA RA, 1990, OBSTET GYNECOL, V76, P945; SEIFER DB, 1990, OBSTET GYNECOL, V76, P1121; SILVA PD, 1988, OBSTET GYNECOL, V72, P944; STOVALL TG, 1992, FERTIL STERIL, V57, P456; STOVALL TG, 1991, OBSTET GYNECOL, V77, P749; STOVALL TG, 1991, OBSTET GYNECOL, V77, P754; STOVALL TG, 1990, FERTIL STERIL, V54, P537; TANAKA T, 1982, FERTIL STERIL, V37, P851; TULANDI T, 1992, FERTIL STERIL, V58, P98; VERCO CJ, 1991, AUST NZ J OBSTET GYN, V31, P168, DOI 10.1111/j.1479-828X.1991.tb01810.x; VERMESH M, 1989, OBSTET GYNECOL, V73, P400; WOLF GC, 1991, J REPROD MED, V36, P489; ZAKUT H, 1989, BRIT J OBSTET GYNAEC, V96, P725, DOI 10.1111/j.1471-0528.1989.tb03290.x; 1990, ACOG TECH B, V150, P1	70	148	152	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1174	1181						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377783				2022-12-28	WOS:A1993MA66700008
J	NORTH, RL; ROTHENBERG, KH				NORTH, RL; ROTHENBERG, KH			PARTNER NOTIFICATION AND THE THREAT OF DOMESTIC VIOLENCE AGAINST WOMEN WITH HIV-INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PREGNANCY				NORTH, RL (corresponding author), UNIV MARYLAND,SCH LAW,BALTIMORE,MD 21201, USA.							AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; Beauchamp TLC, 2019, PRINCIPLES BIOMEDICA; HELTON AS, 1987, AM J PUBLIC HEALTH, V77, P1337, DOI 10.2105/AJPH.77.10.1337; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; PADIAN NS, 1991, JAMA-J AM MED ASSOC, V266, P1664; WEISSMAN G, 1991, Journal of Primary Prevention, V12, P49, DOI 10.1007/BF01326541; WORTH D, 1989, STUD FAMILY PLANN, V20, P297, DOI 10.2307/1966433; 1990, VOLUNTARY HIV COUNSE; 1992, MMWR MORB MORTAL WKL, V41; 1992, HIV AM REPORT NATION; 1991, VIOLENCE WOMEN; 1993, MMWR MORB MORTAL WKL, V42, P47	12	78	78	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1194	1196		10.1056/NEJM199310143291612	http://dx.doi.org/10.1056/NEJM199310143291612			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MA667	8377787	Green Published			2022-12-28	WOS:A1993MA66700012
J	CARSON, JL; STROM, BL; DUFF, A; GUPTA, A; SHAW, M; LUNDIN, FE; DAS, K				CARSON, JL; STROM, BL; DUFF, A; GUPTA, A; SHAW, M; LUNDIN, FE; DAS, K			ACUTE-LIVER-DISEASE ASSOCIATED WITH ERYTHROMYCINS, SULFONAMIDES, AND TETRACYCLINES	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS, TOXIC; ERYTHROMYCIN; SULFONAMIDES; TETRACYCLINES; HOSPITALIZATION	TRIMETHOPRIM-SULFAMETHOXAZOLE; INTRAHEPATIC CHOLESTASIS; HEPATIC CHOLESTASIS; SKIN RASH; HEPATOTOXICITY; SULFASALAZINE; MINOCYCLINE; ETHYLSUCCINATE; FAILURE	Objective: To determine whether erythromycins, sulfonamides, and tetracyclines are associated with an increased risk for acute hepatitis. Design: Case-control study. Setting: Medicaid billing data from Michigan and Florida between 1980 and 1987. Patients: The 107 cases included patients hospitalized with acute symptomatic hepatitis without an identifiable cause of liver disease noted in the medical record. Four controls per case were randomly selected and were matched for age, sex, and state. Results: Five cases (4.7%) and four controls (0.9%) were exposed to erythromycins, yielding an odds ratio of 5.2 (95% CI, 1.1 to 26.6). No case or control was exposed to erythromycin estolate. Eight cases (7.5%) and three controls (0.7%) were exposed to oral sultonamides, yielding an odds ratio of 11.4 (CI, 2.7 to 67.8). All (except one control) had received trimethoprimsulfamethoxazole. Five cases (4.7%) and four controls (0.9%) were exposed to tetracyclines, yielding an odds ratio of 5.2 (CI, 1.4 to 19.7). The results did not change substantively for erythromycin or sulfonamides after adjustment using multiple logistic regression for age, sex, state, and use of other hepatotoxic drugs. With tetracyclines, however, the odds ratio decreased to 3.6 (CI, 0.9 to 14.3). Associations were also seen with isoniazid (P = 0.008) and rifampicin (P = 0.04). The number of patients developing acute symptomatic liver disease resulting in hospitalization for each million patients treated with a 10-day course of erythromycin was 2.28 cases; for sulfonamides, this figure was 4.8 cases; and for tetracycline, the figure was 1.56 cases. Conclusion: Erythromycin, sulfonamides, and tetracyclines are associated with acute symptomatic hepatitis resulting in hospitalization. Given the widespread use of these drugs, they will be among the more common drugs associated with hepatitis.	UNIV PENN, SCH MED, CTR CLIN EPIDEMIOL & BIOSTAT, PHILADELPHIA, PA 19104 USA; HLTH INFORMAT DESIGNS INC, ARLINGTON, VA USA; US FDA, DIV DRUG & BIOL PROD EXPERIENCE, EPIDEMIOL DEV BRANCH, ROCKVILLE, MD 20857 USA	University of Pennsylvania; US Food & Drug Administration (FDA)	CARSON, JL (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DIV GEN INTERNAL MED, 97 PATERSON ST, NEW BRUNSWICK, NJ 08903 USA.				FDA HHS [FD-U-000079] Funding Source: Medline	FDA HHS		ALBERTIFLOR JJ, 1989, AM J GASTROENTEROL, V84, P1577; BAUM C, 1989, SPONTANEOUS REPORTIN, P107; BURETTE A, 1984, ARCH INTERN MED, V144, P1491, DOI 10.1001/archinte.144.7.1491; CARSON JL, 1992, CLIN PHARMACOL THER, V52, P214, DOI 10.1038/clpt.1992.132; CARSON JL, 1993, ARCH INTERN MED, V153, P1331, DOI 10.1001/archinte.153.11.1331; CARSON JL, 1989, MEDICAID DATA BASES, P173; CHATHAM WW, 1983, SOUTHERN MED J, V76, P1195, DOI 10.1097/00007611-198309000-00040; Combes B, 1972, Prog Liver Dis, V4, P589; COTO H, 1981, SOUTHERN MED J, V74, P897, DOI 10.1097/00007611-198107000-00035; DAVIES MG, 1989, BRIT MED J, V298, P1523, DOI 10.1136/bmj.298.6686.1523-c; DIEHL AM, 1984, AM J MED, V76, P931, DOI 10.1016/0002-9343(84)91013-1; DITTLER EL, 1962, AM J GASTROENTEROL, V38, P691; DUJOVNE CA, 1967, NEW ENGL J MED, V277, P785, DOI 10.1056/NEJM196710122771503; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FARMER CD, 1963, GASTROENTEROLOGY, V45, P157; FRENEAUX E, 1988, HEPATOLOGY, V8, P1056, DOI 10.1002/hep.1840080513; FRIES J, 1966, NEW ENGL J MED, V274, P95, DOI 10.1056/NEJM196601132740209; GAFTER U, 1979, NY STATE J MED, P87; GHISHAN FK, 1983, CLIN PEDIATR, V22, P212, DOI 10.1177/000992288302200310; GILBERT FI, 1962, JAMA-J AM MED ASSOC, V182, P1048; GULLEY RM, 1979, AM J GASTROENTEROL, V72, P561; HAVENS WP, 1962, JAMA-J AM MED ASSOC, V180, P30, DOI 10.1001/jama.1962.03050140032007; INMAN WHW, 1983, BRIT MED J, V286, P1954, DOI 10.1136/bmj.286.6382.1954; IWARSON S, 1979, ACTA MED SCAND, V206, P219; JACOBS E, 1978, GASTROENTEROLOGY, V75, P1193; JOHNSON DF, 1961, NEW ENGL J MED, V265, P1200, DOI 10.1056/NEJM196112142652407; JONES JK, 1989, DETERMINING CAUSATIO, P275; KEEFFE EB, 1982, DIGEST DIS SCI, V27, P701, DOI 10.1007/BF01393764; KLATSKIN G, 1956, DISEASE LIVER, P367; KOHLSTAEDT KG, 1961, JAMA-J AM MED ASSOC, V178, P89, DOI 10.1001/jama.1961.03040400091023; KONTTINEN A, 1972, ACTA MED SCAND, V191, P389; Lessler JT, 1984, MEDICAID DATA SOURCE; LUNZER MR, 1975, GASTROENTEROLOGY, V68, P1284; MAGEE G, 1982, DIGEST DIS SCI, V27, P1044, DOI 10.1007/BF01391754; MANTEL N, 1959, J NATL CANCER I, V22, P719; MIHAS AA, 1978, JAMA-J AM MED ASSOC, V239, P2590, DOI 10.1001/jama.239.24.2590; MIN DI, 1992, PHARMACOTHERAPY, V12, P68; MUNOZ SJ, 1990, HEPATOLOGY, V12, P342, DOI 10.1002/hep.1840120223; PETERS RL, 1967, AM J SURG, V113, P622, DOI 10.1016/0002-9610(67)90308-X; POLAND GA, 1986, AM J MED, V81, P707, DOI 10.1016/0002-9343(86)90562-0; RANSOHOFF DF, 1981, GASTROENTEROLOGY, V80, P816; ROBINSON MM, 1962, AM J MED SCI, V243, P502, DOI 10.1097/00000441-196204000-00012; SCHENKER S, 1975, DRUGS LIVER, P269; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SCHULTZ JC, 1963, NEW ENGL J MED, V269, P999, DOI 10.1056/NEJM196311072691903; SHARP JR, 1980, ANN INTERN MED, V92, P14, DOI 10.7326/0003-4819-92-1-14; SMITH MD, 1982, AUST NZ J MED, V12, P76, DOI 10.1111/j.1445-5994.1982.tb02433.x; SOTOLONGO RP, 1978, GASTROENTEROLOGY, V75, P95; Strieker BH, 1985, DRUG INDUCED HEPATIC, P153; STROM BL, 1985, CLIN PHARMACOL THER, V38, P359, DOI 10.1038/clpt.1985.188; SULLIVAN D, 1980, JAMA-J AM MED ASSOC, V243, P1074; TANNER AR, 1986, BRIT MED J, V293, P1072, DOI 10.1136/bmj.293.6554.1072-a; THIES PW, 1984, ARCH INTERN MED, V144, P1691, DOI 10.1001/archinte.144.8.1691; TONDER M, 1974, SCAND J GASTROENTERO, V9, P93; ZIMMERMAN HJ, 1987, DISEASES LIVER, P591; 1973, ADVERSE REACTIONS SE, V10; 1984, AUST DRUG REACTIONS, V2; 1980, ICD9CM COMM PROF HOS	58	56	57	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				576	583		10.7326/0003-4819-119-7_Part_1-199310010-00005	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363168				2022-12-28	WOS:A1993MA29100005
J	SPRECHER, DL; HARRIS, BV; GOLDBERG, AC; ANDERSON, EC; BAYUK, LM; RUSSELL, BS; CRONE, DS; QUINN, C; BATEMAN, J; KUZMAK, BR; ALLGOOD, LD				SPRECHER, DL; HARRIS, BV; GOLDBERG, AC; ANDERSON, EC; BAYUK, LM; RUSSELL, BS; CRONE, DS; QUINN, C; BATEMAN, J; KUZMAK, BR; ALLGOOD, LD			EFFICACY OF PSYLLIUM IN REDUCING SERUM-CHOLESTEROL LEVELS IN HYPERCHOLESTEROLEMIC PATIENTS ON HIGH-FAT OR LOW-FAT DIETS	ANNALS OF INTERNAL MEDICINE			English	Article						PSYLLIUM; HYPERCHOLESTEROLEMIA; DIETARY FATS; LIPOPROTEIN, LDL CHOLESTEROL; CHOLESTEROL	CORONARY HEART-DISEASE; FECAL STEROID-EXCRETION; OAT-BRAN; MODERATE HYPERCHOLESTEROLEMIA; DENSITY LIPOPROTEIN; PRUDENT DIET; PLASMA; MEN; FIBER; MILD	Objectives: To determine the efficacy of psyllium in reducing serum cholesterol levels in patients on high- or low-fat diets. Design: Double-blind, placebo-controlled, 16-week parallel trial. The study included an 8-week baseline period and an 8-week treatment period. Patients: Healthy men and women, 21 to 70 years old, with primary hypercholesterolemia (total serum cholesterol greater-than-or-equal-to 5.7 mmol/L [220 mg/dL]). Thirty-seven participants followed a high-fat diet and 81 participants followed a low-fat diet. Intervention: Participants were randomly assigned to either psyllium, 5.1 g twice a day, or placebo. Measurements: Fasting lipid and apolipoprotein concentrations, including direct low-density lipoprotein (LDL) cholesterol quantification; nutritional analyses of 4 days of 7-day food records to monitor dietary compliance; and physical examinations, clinical chemistry and hematologic studies, and urinalysis to assess treatment safety. Main Results: Psyllium recipients in both the high- and low-fat diet groups showed small but significant decreases (P < 0.05) in total cholesterol and low-density lipoprotein (LDL) cholesterol levels. Total cholesterol and LDL cholesterol levels decreased 5.8% and 7.2%, respectively, in psyllium recipients on high-fat diets and 4.2% and 6.4%, respectively, in psyllium recipients on low-fat diets. No significant difference was seen in LDL cholesterol response when psyllium recipients on low- and high-fat diets were compared (P > 0.2). No significant reductions in lipid-levels were observed in placebo recipients. Based on the National Cholesterol Education Program LDL cholesterol classification system, 39% of the psyllium recipients improved in LDL cholesterol classification (P < 0.0001) compared with 20.3% of placebo recipients (P > 0.2). Conclusions: Psyllium produces a modest but significant improvement in total cholesterol and LDL cholesterol levels in persons on either low-fat or high-fat diets. Psyllium, when added to a prescribed low-fat diet, may obviate the need for typical lipid-lowering medications or may prove to be a valuable adjunct to other treatments in patients with moderately elevated LDL cholesterol levels.	WASHINGTON UNIV, LIPID RES CLIN, ST LOUIS, MO 63110 USA; PROCTER & GAMBLE CO, CINCINNATI, OH 45241 USA	Washington University (WUSTL); Procter & Gamble	SPRECHER, DL (corresponding author), UNIV CINCINNATI, CTR LIPID RES,LIPID RES CLIN,231 BETHESDA AVE, K PAVIL, 2ND FLOOR, CINCINNATI, OH 45267 USA.							ABRAHAM ZD, 1988, AM J CLIN NUTR, V47, P67; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; ANDERSON JW, 1991, AM J CLIN NUTR, V54, P678, DOI 10.1093/ajcn/54.4.678; ANDERSON JW, 1988, ARCH INTERN MED, V148, P292, DOI 10.1001/archinte.148.2.292; ANDERSON JW, 1986, AM J GASTROENTEROL, V81, P907; ANDERSON JW, 1984, AM J CLIN NUTR, V40, P1146, DOI 10.1093/ajcn/40.6.1146; ANDERSON JW, 1991, ARCH INTERN MED, V151, P1597, DOI 10.1001/archinte.151.8.1597; BELL LP, 1989, JAMA-J AM MED ASSOC, V261, P3419, DOI 10.1001/jama.261.23.3419; BUCOLO G, 1973, CLIN CHEM, V19, P476; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; DAVIDSON MH, 1991, JAMA-J AM MED ASSOC, V265, P1833, DOI 10.1001/jama.265.14.1833; EVERSON GT, 1991, ARTERIOSCLER THROMB, V11, pA1429; FORMAN DT, 1968, P SOC EXP BIOL MED, V127, P1060; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GRUNDY SM, 1988, ARTERIOSCLEROSIS, V8, P95, DOI 10.1161/01.ATV.8.1.95; HJERMANN I, 1981, LANCET, V2, P1303; JUDD PA, 1981, AM J CLIN NUTR, V34, P2061, DOI 10.1093/ajcn/34.10.2061; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KRITCHEVSKY D, 1978, AM J CLIN NUTR, V31, pS65, DOI 10.1093/ajcn/31.10.S65; LEVIN EG, 1990, ARCH INTERN MED, V150, P1822, DOI 10.1001/archinte.150.9.1822; LIPSKY H, 1990, J CLIN PHARMACOL, V30, P699, DOI 10.1002/j.1552-4604.1990.tb03629.x; NAITO HK, 1984, CLIN CHEM THEORY ANA; NEAL GW, 1990, SOUTH MED J, V83, P1131, DOI 10.1097/00007611-199010000-00005; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; REMMELL PS, 1980, J AM DIET ASSOC, V76, P351; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SCHONFELD G, 1974, J CLIN INVEST, V54, P236, DOI 10.1172/JCI107758; SCHONFELD G, 1974, J CLIN INVEST, V53, P1458, DOI 10.1172/JCI107694; STORY JA, 1981, ADV LIPID RES, V18, P229; SWAIN JF, 1990, NEW ENGL J MED, V322, P147, DOI 10.1056/NEJM199001183220302; TIETYEN J L, 1990, FASEB Journal, V4, pA527; TURPEINEN O, 1979, INT J EPIDEMIOL, V8, P99, DOI 10.1093/ije/8.2.99; VAHOUNY GV, 1982, DIETARY FIBER HLTH D, P203; VANHORN LV, 1986, J AM DIET ASSOC, V86, P759; 1991, STATXAXT VERSION 2; 1974, DHEW NIH75628 NAT HE	38	73	74	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				545	554		10.7326/0003-4819-119-7_Part_1-199310010-00001	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363164				2022-12-28	WOS:A1993MA29100001
J	LIGHTFOOT, RW; LUFT, BJ; RAHN, DW; STEERE, AC; SIGAL, LH; ZOSCHKE, DC; GARDNER, P; BRITTON, MC; KAUFMAN, RL				LIGHTFOOT, RW; LUFT, BJ; RAHN, DW; STEERE, AC; SIGAL, LH; ZOSCHKE, DC; GARDNER, P; BRITTON, MC; KAUFMAN, RL			EMPIRIC PARENTERAL ANTIBIOTIC-TREATMENT OF PATIENTS WITH FIBROMYALGIA AND FATIGUE AND A POSITIVE SEROLOGIC RESULT FOR LYME-DISEASE - A COST-EFFECTIVENESS ANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							ERYTHEMA MIGRANS BORRELIOSIS; LINKED IMMUNOSORBENT-ASSAY; NEUROLOGIC MANIFESTATIONS; ARTHRITIS; ABNORMALITIES; FREQUENCY; EPIDEMIC; TESTS	Purpose: To examine the cost-effectiveness of empirical, parenteral antibiotic treatment of patients with chronic fatigue and myalgia and a positive serologic result for Lyme disease who lack classic manifestations. Data Sources: Peer-reviewed journals, opinion of experts in the field, and published epidemiologic reports. Study Selection: Consensus by authors on articles that indicated methods for patient selection; on criteria used for diagnosis; on immunologic methods used for classifying patients; on the dose and duration of therapy; and on criteria by which responses to therapy were ascertained. Data Extraction: In a cost-effectiveness model, the costs and benefits of empirical parenteral therapy for patients seropositive for Lyme disease were compared with a strategy in which only patients having classical symptoms of Lyme disease were treated. Data Synthesis. In areas endemic for Lyme disease, the incidence of false-positive serologic results in patients with nonspecific myalgia or fatigue exceeds by four to one the incidence of true-positive results in patients with nonclassical infections. Treatment of the former group of patients costs $86 221 for each true-positive patient treated. The empirical strategy causes 29 cases of drug toxicity for every case in the more conservative strategy. If patients were willing to pay $3485 to eliminate anxiety about not treating possible true Lyme disease, the empirical strategy would break even. Conclusion: For most patients with a positive Lyme antibody titer whose only symptoms are nonspecific myalgia or fatigue the risks and costs of empirical parenteral antibiotic therapy exceed the benefits. Only when the value of patient anxiety about leaving a positive test untreated exceeds the cost of such therapy is the empirical treatment cost-effective.	SUNY, HLTH SCI CTR, STONY BROOK, NY 11794 USA; MED COLL GEORGIA, AUGUSTA, GA 30912 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA; UNIV MED & DENT NEW JERSEY, NEW BRUNSWICK, NJ 08903 USA; UNIV MINNESOTA, MINNEAPOLIS, MN 55455 USA; PALO ALTO MED CLIN, PALO ALTO, CA 94301 USA; UNIV SO CALIF, MED CTR, LOS ANGELES, CA 90089 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; SUNY Maritime College; University System of Georgia; Augusta University; Tufts Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Minnesota System; University of Minnesota Twin Cities; Palo Alto Medical Foundation Research Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California	LIGHTFOOT, RW (corresponding author), UNIV KENTUCKY, MED CTR, DIV RHEUMATOL, KENTUCKY CLIN J515, LEXINGTON, KY 40536 USA.			Steere, Allen/0000-0002-5268-9853; Luft, Benjamin/0000-0001-9008-7004				ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; BENNETT R M, 1989, Journal of Rheumatology, V16, P58; CAPERTON EM, 1990, ARCH INTERN MED, V150, P1677, DOI 10.1001/archinte.150.8.1677; Centers for Disease Control and Prevention (CDC), 1993, MMWR Morb Mortal Wkly Rep, V42, P39; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; Felson D T, 1989, J Rheumatol Suppl, V19, P7; GOLDENBERG DL, 1990, ARTHRITIS RHEUM, V33, P381, DOI 10.1002/art.1780330311; GOLIGHTLY MG, 1993, AM J CLIN PATHOL, V99, P168, DOI 10.1093/ajcp/99.2.168; HALPERIN JJ, 1989, NEUROLOGY, V39, P753, DOI 10.1212/WNL.39.6.753; HALPERIN JJ, 1987, NEUROLOGY, V37, P1700, DOI 10.1212/WNL.37.11.1700; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HSU V, 1993, IN PRESS ARTHRITIS R; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; LUFT BJ, 1988, ANN NY ACAD SCI, V539, P532; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; SAYAHTAHERIALTAIE S, 1993, DIAGN MICR INFEC DIS, V16, P43, DOI 10.1016/0732-8893(93)90129-U; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SIGAL LH, 1992, PEDIATRICS, V90, P523; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; STEER AC, 1983, ANN INTERN MED, V99, P767, DOI 10.7326/0003-4819-99-6-767; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; Tsai T F, 1989, Conn Med, V53, P324; WILKINSON HW, 1984, YALE J BIOL MED, V57, P567; WOLFE F, 1993, IN PRESS J MUSCULOSK; 1990, CONNECTICUT EPIDEMIO, V10, P9	37	71	74	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					503	509		10.7326/0003-4819-119-6-199309150-00010	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357117				2022-12-28	WOS:A1993LZ27500010
J	LUFT, BJ; GARDNER, P; LIGHTFOOT, RW; BRITTON, MC; KAUFMAN, RL; RAHN, DW; SIGAL, LH; STEERE, AC; ZOSCHKE, DC				LUFT, BJ; GARDNER, P; LIGHTFOOT, RW; BRITTON, MC; KAUFMAN, RL; RAHN, DW; SIGAL, LH; STEERE, AC; ZOSCHKE, DC			APPROPRIATENESS OF PARENTERAL ANTIBIOTIC-TREATMENT FOR PATIENTS WITH PRESUMED LYME-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article														Luft, Benjamin/0000-0001-9008-7004				LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010	1	9	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					518	518						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357119				2022-12-28	WOS:A1993LZ27500012
J	WILLIAMS, JW; SIMEL, DL				WILLIAMS, JW; SIMEL, DL			DOES THIS PATIENT HAVE SINUSITIS - DIAGNOSING ACUTE SINUSITIS BY HISTORY AND PHYSICAL-EXAMINATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MAXILLARY SINUSITIS; CHILDREN; NASAL; RADIOGRAPHY; ULTRASONOGRAPHY; INFECTIONS; ULTRASOUND; ETIOLOGY; SYMPTOMS; SINUSES		UNIV TEXAS,HLTH SCI CTR,DIV GEN INTERNAL MED,SAN ANTONIO,TX 78284; VET AFFAIRS MED CTR,AMBULATORY CARE SERV,DURHAM,NC; VET AFFAIRS MED CTR,CTR HLTH SERV RES PRIMARY CARE,DURHAM,NC; DUKE UNIV,MED CTR,DIV GEN INTERNAL MED,DURHAM,NC 27710	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University	WILLIAMS, JW (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR,AMBULATORY CARE SERV,7400 MERTON MINTER BLVD,SAN ANTONIO,TX 78284, USA.		Williams, John/AAM-4572-2020; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558				AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; AXELSSON A, 1976, ORL J OTO-RHINO-LARY, V38, P298, DOI 10.1159/000275288; BALLANTYNE J C, 1949, J Laryngol Otol, V63, P337, DOI 10.1017/S0022215100046557; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BERG O, 1985, LARYNGOSCOPE, V95, P851; BERG O, 1981, ANN OTO RHINOL LARYN, V90, P272, DOI 10.1177/000348948109000316; BURTOFF S, 1947, ARCH OTOLARYNGOL, V45, P516; CARSON JL, 1985, NEW ENGL J MED, V312, P463, DOI 10.1056/NEJM198502213120802; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; GUYTON AC, 1986, TXB MED PHYSL, P477; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; HAYWARD MWJ, 1990, CLIN RADIOL, V41, P163, DOI 10.1016/S0009-9260(05)80959-6; HOLLINSHEAD WH, 1985, TXB ANATOMY, P982; KOGUTT MS, 1973, PEDIATRICS, V52, P121; LOYAL V, 1976, OTOLARYNGOL CLIN N A, V9, P213; MACKAY I, 1989, RHINITIS MECHANISMS, P169; MCCLEAN DC, 1970, CLIN PEDIATR, V9, P342; MCNEILL R A, 1963, J Laryngol Otol, V77, P1009, DOI 10.1017/S0022215100061673; OTTEN FWA, 1989, INT J PEDIATR OTORHI, V18, P9, DOI 10.1016/0165-5876(89)90225-5; RACHELEFSKY GS, 1990, J ASTHMA, V27, P1, DOI 10.3109/02770909009073287; ROHR AS, 1986, J ALLERGY CLIN IMMUN, V78, P58, DOI 10.1016/0091-6749(86)90115-6; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SHAPIRO GG, 1986, J ALLERGY CLIN IMMUN, V77, P59, DOI 10.1016/0091-6749(86)90324-6; SIMEL DL, 1987, MED DECIS MAKING, V7, P107, DOI 10.1177/0272989X8700700208; SIMON HB, 1987, PRIMARY CARE MED OFF, P883; SMITH MEN, 1961, J LARYNGOL OTOL, V75, P93; Swischuk L. E., 1982, RADIOGRAPHICS, V2, P241; UNGER JM, 1984, LARYNGOSCOPE, V94, P1319; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; VOLTOLINI FER, 1889, DTCH MED WOCHENSCHR, V15, P340; WALD ER, 1986, PEDIATRICS, V77, P795; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; WILLIAMS JW, 1992, J GEN INTERN MED, V7, P481, DOI 10.1007/BF02599447; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; 1977, NATIONAL AMBULATORY	37	121	123	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1242	1246		10.1001/jama.270.10.1242	http://dx.doi.org/10.1001/jama.270.10.1242			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355389				2022-12-28	WOS:A1993LV64900032
J	SCHNEIDER, R; UNGER, G; STARK, R; SCHNEIDERSCHERZER, E; THIEL, HJ				SCHNEIDER, R; UNGER, G; STARK, R; SCHNEIDERSCHERZER, E; THIEL, HJ			IDENTIFICATION OF A STRUCTURAL GLYCOPROTEIN OF AN RNA VIRUS AS A RIBONUCLEASE	SCIENCE			English	Article							HOG-CHOLERA VIRUS; VIRAL DIARRHEA VIRUS; SELF-INCOMPATIBILITY; NUCLEOTIDE-SEQUENCE; MOLECULAR-CLONING; NICOTIANA-ALATA; SEMINAL RNASE; PESTIVIRUS; ACID	One of the three structural glycoproteins of classical swine fever virus (CSFV) is E0, a disulfide-bonded homodimer that induces virus-neutralizing antibodies and occurs in a virion-bound as well as a secreted form. E0 was shown to be similar to a family of fungal and plant ribonucleases. Purified E0 from CSFV-infected cells was a potent ribonuclease specific for uridine and inhibitable by zinc ions.	FED RES CTR VIRUS DIS ANIM, D-72076 TUBINGEN, GERMANY		SCHNEIDER, R (corresponding author), UNIV INNSBRUCK, FAC NAT SCI, DEPT BIOCHEM, A-6020 INNSBRUCK, AUSTRIA.							ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; BENNER SA, 1989, TRENDS BIOCHEM SCI, V14, P396, DOI 10.1016/0968-0004(89)90282-X; BROWN PH, 1986, PLANT PHYSIOL, V82, P801, DOI 10.1104/pp.82.3.801; COLLETT MS, 1988, VIROLOGY, V165, P191, DOI 10.1016/0042-6822(88)90672-1; COLLETT MS, 1988, VIROLOGY, V165, P200, DOI 10.1016/0042-6822(88)90673-3; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DALESSIO G, 1991, TRENDS BIOCHEM SCI, V16, P104, DOI 10.1016/0968-0004(91)90042-T; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; HORIUCHI H, 1988, J BIOCHEM-TOKYO, V103, P408, DOI 10.1093/oxfordjournals.jbchem.a122284; KAWATA Y, 1988, EUR J BIOCHEM, V176, P683, DOI 10.1111/j.1432-1033.1988.tb14331.x; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MEYERS G, 1989, VIROLOGY, V171, P555, DOI 10.1016/0042-6822(89)90625-9; RUMENAPF T, 1993, J VIROL, V67, P3288; SCHNEIDER R, 1992, TRENDS BIOCHEM SCI, V17, P468, DOI 10.1016/0968-0004(92)90490-Z; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SIMONS TJB, 1991, J MEMBRANE BIOL, V123, P63, DOI 10.1007/BF01993964; STARK RE, UNPUB; TAMBURRINI M, 1990, EUR J BIOCHEM, V190, P145, DOI 10.1111/j.1432-1033.1990.tb15557.x; THIEL HJ, 1991, J VIROL, V65, P4705, DOI 10.1128/JVI.65.9.4705-4712.1991; VESCIA S, 1980, CANCER RES, V40, P3740; WEILAND E, 1992, J VIROL, V66, P3677, DOI 10.1128/JVI.66.6.3677-3682.1992	21	157	179	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1169	1171		10.1126/science.8356450	http://dx.doi.org/10.1126/science.8356450			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356450				2022-12-28	WOS:A1993LU58600032
J	EICHENBAUM, H				EICHENBAUM, H			THINKING ABOUT BRAIN-CELL ASSEMBLIES	SCIENCE			English	Editorial Material							INFERIOR TEMPORAL CORTEX; INFEROTEMPORAL CORTEX; SINGLE NEURONS; HIPPOCAMPUS; MACAQUE; MICROELECTRODES; ORGANIZATION; PATTERNS; NETWORK; FACES				EICHENBAUM, H (corresponding author), SUNY,CTR BEHAV NEUROSCI,STONY BROOK,NY 11794, USA.							ABELES M, 1988, J NEUROPHYSIOL, V60, P909, DOI 10.1152/jn.1988.60.3.909; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; AUSTIN K B, 1990, Society for Neuroscience Abstracts, V16, P263; BARLOW HB, 1985, Q J EXP PSYCHOL-A, V37, P121, DOI 10.1080/14640748508400927; Bostock E, 1991, Hippocampus, V1, P193, DOI 10.1002/hipo.450010207; BUZHAKI G, 1992, SCIENCE, V256, P1025; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; DESIMONE R, 1984, J NEUROSCI, V4, P2051; EICHENBAUM H, 1989, J NEUROSCI, V9, P2764; EICHENBAUM H, 1993, TRENDS NEUROSCI, V16, P163, DOI 10.1016/0166-2236(93)90140-H; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; EICHENBAUM H, 1986, J ELECTROPHYSIOL TEC, V13, P189; Freeman WJ, 1975, MASS ACTION NERVOUS; GEORGOPOULOS AP, 1993, SCIENCE, V268, P47; GERSTEIN GL, 1985, J NEUROSCI, V5, P881; GOCHIN PM, 1991, EXP BRAIN RES, V84, P505; GOCHIN PM, IN PRESS J NEUROPHYS; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; HEBB DO, 1949, ORG BEHAVIOR; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KUPERSTEIN M, 1986, EXP BRAIN RES, V61, P438; LINSKER R, 1986, P NATL ACAD SCI USA, V83, P8390, DOI 10.1073/pnas.83.21.8390; MICHALSKI A, 1983, EXP BRAIN RES, V51, P97; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; PERRETT DI, 1987, TRENDS NEUROSCI, V10, P358, DOI 10.1016/0166-2236(87)90071-3; REITBOECK HJP, 1983, IEEE T SYST MAN CYB, V13, P676, DOI 10.1109/TSMC.1983.6313060; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; SHAPIRO ML, 1993, BEHAV NEUROSCI, V107, P34, DOI 10.1037/0735-7044.107.1.34; Sherrington C., 1941, MAN HIS NATURE; Squire L. R., 1987, MEMORY BRAIN; WIENER SI, 1989, J NEUROSCI, V9, P2737; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	34	88	89	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					993	994		10.1126/science.8351525	http://dx.doi.org/10.1126/science.8351525			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351525				2022-12-28	WOS:A1993LT74700020
J	FRANKLYN, JA; DAYKIN, J; YOUNG, J; OATES, GD; SHEPPARD, MC				FRANKLYN, JA; DAYKIN, J; YOUNG, J; OATES, GD; SHEPPARD, MC			FINE-NEEDLE ASPIRATION CYTOLOGY IN DIFFUSE OR MULTINODULAR GOITER COMPARED WITH SOLITARY THYROID-NODULES	BRITISH MEDICAL JOURNAL			English	Article									BIRMINGHAM GEN HOSP,THYROID CLIN,BIRMINGHAM,ENGLAND; UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT PATHOL,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham	FRANKLYN, JA (corresponding author), UNIV BIRMINGHAM,QUEEN ELIZABETH HOSP,DEPT MED,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.							MAZZAFERRI EL, 1993, NEW ENGL J MED, V328, P553; MILLER JM, 1979, JAMA-J AM MED ASSOC, V241, P481, DOI 10.1001/jama.241.5.481; ROJESKI MT, 1985, NEW ENGL J MED, V313, P428, DOI 10.1056/NEJM198508153130707; TUNBRIDGE WMG, 1977, CLIN ENDOCRINOL, V7, P481, DOI 10.1111/j.1365-2265.1977.tb01340.x; 1975, SER MBI, V5	5	43	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					240	240		10.1136/bmj.307.6898.240	http://dx.doi.org/10.1136/bmj.307.6898.240			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369686	Green Published, Bronze			2022-12-28	WOS:A1993LP31400024
J	TOYOSHIMA, C; SASABE, H; STOKES, DL				TOYOSHIMA, C; SASABE, H; STOKES, DL			3-DIMENSIONAL CRYOELECTRON MICROSCOPY OF THE CALCIUM-ION PUMP IN THE SARCOPLASMIC-RETICULUM MEMBRANE	NATURE			English	Article							FUNCTIONAL CONSEQUENCES; TRANSMEMBRANE DOMAIN; X-RAY; CA-2+-ATPASE; MUTATIONS; ORGANIZATION; DIFFRACTION; LOCATION; PROTEINS; SECTOR	THE ATP-driven calcium pump (Ca2+-ATPase) is an integral membrane protein (M(r) 110K) which relaxes striated muscle by pumping calcium out of the cytoplasm into the sarcoplasmic reticulum against a large concentration gradient1. Recent efforts have attempted to relate the sequence of Ca2+-ATPase to its structure and function. In particular, site-directed mutagenesis has identified critical amino-acid residues2-6, and its predicted secondary structure, which includes ten transmembrane helices7, has gained experimental support8-10. But direct visualization of the molecule has so far been limited to the cytoplasmic domains at low resolution11,12. We present here the three-dimensional structure of Ca2+-ATPase in the native sarcoplasmic reticulum membrane at 14 angstrom resolution, determined by cryo-electron microscopy and helical image analysis. The structure shows an unexpected transmembrane organization, consisting of three distinct segments, one of which is highly inclined. These features can be related to earlier predictions of secondary structure.	UNIV VIRGINIA, HLTH SCI CTR,DEPT MOLEC PHYSIOL & BIOL PHYS, JORDAN HALL,BOX 449, CHARLOTTESVILLE, VA 22908 USA; TOKYO INST TECHNOL, DEPT BIOL SCI, MEGURO KU, TOKYO 152, JAPAN; RIKEN, FRONTIER RES PROGRAM, WAKO, SAITAMA 35101, JAPAN	University of Virginia; Tokyo Institute of Technology; RIKEN			Toyoshima, Chikashi/R-4153-2019	Toyoshima, Chikashi/0000-0001-9640-0778				ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CASTELLANI L, 1985, J MOL BIOL, V185, P579, DOI 10.1016/0022-2836(85)90073-7; CLARKE DM, 1990, J BIOL CHEM, V265, P6262; CLARKE DM, 1990, J BIOL CHEM, V265, P17405; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; DUPONT Y, 1973, NATURE, V244, P555, DOI 10.1038/244555a0; DUX L, 1983, J BIOL CHEM, V258, P2599; GREEN NM, 1992, ACTA PHYSIOL SCAND, V146, P59; GREEN NM, 1989, BIOCHEM SOC T, V17, P970; HERBETTE L, 1985, BIOCHIM BIOPHYS ACTA, V817, P103, DOI 10.1016/0005-2736(85)90073-2; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MATTHEWS I, 1990, J BIOL CHEM, V265, P18737; MEISSNER G, 1973, BIOCHIM BIOPHYS ACTA, V298, P246, DOI 10.1016/0005-2736(73)90355-6; SACHS G, 1992, J BIOENERG BIOMEMBR, V24, P301; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; TOYOSHIMA C, 1989, ULTRAMICROSCOPY, V30, P439, DOI 10.1016/0304-3991(89)90076-4; VILSEN B, 1989, J BIOL CHEM, V264, P21024	21	217	217	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 1	1993	362	6419					469	471		10.1038/362469a0	http://dx.doi.org/10.1038/362469a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KV424	8385269				2022-12-28	WOS:A1993KV42400090
J	OHTSUBO, M; ROBERTS, JM				OHTSUBO, M; ROBERTS, JM			CYCLIN-DEPENDENT REGULATION OF G(1) IN MAMMALIAN FIBROBLASTS	SCIENCE			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; CELL-DIVISION CYCLE; DNA-REPLICATION; FISSION YEAST; PROTEIN-KINASE; G1-SPECIFIC CYCLINS; GENETIC-CONTROL; SIZE CONTROL; G1 CYCLIN; S-PHASE	Eukaryotic cells become committed to proliferate during the G1 phase of the cell cycle. In budding yeast, commitment occurs when the catalytic subunit of a protein kinase, encoded by the CDC28 gene (the homolog of the fission yeast cdc2+ gene), binds to a positively acting regulatory subunit, a cyclin. Related kinases are also required for progression through the G1 phase in higher eukaryotes. The role of cyclins in controlling G1 progression in mammalian cells was tested by construction of fibroblasts that constitutively overexpress human cyclin E. This was found to shorten the duration of G1, decrease cell size, and diminish the serum requirement for the transition from G1 to S phase. These observations show that cyclin levels can be rate-limiting for G1 progression in mammalian cells and suggest that cyclin synthesis may be the target of physiological signals that control cell proliferation.	UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98145 USA	University of Washington; University of Washington Seattle	OHTSUBO, M (corresponding author), FRED HUTCHINSON CANC RES CTR, DEPT BASIC SCI, SEATTLE, WA 98104 USA.			ohtsubo, motoaki/0000-0002-2479-3178				BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CROSS F, 1989, ANNU REV CELL BIOL, V5, P341; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; CROSS FR, COMMUNICATOIN; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FANTES P, 1977, EXP CELL RES, V107, P377, DOI 10.1016/0014-4827(77)90359-7; FIRPO EJ, UNPUB; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; HADWIGER JA, 1989, P NATL ACAD SCI USA, V86, P6255, DOI 10.1073/pnas.86.16.6255; HARTWELL LH, 1973, GENETICS, V74, P267; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUNT T, 1989, CURR OPIN CELL BIOL, V1, P2286; JOHNSTON GC, 1977, EXP CELL RES, V105, P79, DOI 10.1016/0014-4827(77)90154-9; KARN J, 1989, ONCOGENE, V4, P773; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MACIEIRACOELHO A, 1973, TISSUE CULTURE METHO, P412; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NASMYTH K, 1979, J CELL SCI, V39, P215; NASMYTH KA, 1979, J CELL SCI, V36, P155; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NORWOOD T, UNPUB; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; NURSE P, 1977, EXP CELL RES, V107, P365, DOI 10.1016/0014-4827(77)90358-5; OHTSUBO M, UNPUB; OYAMA VI, 1956, P SOC EXP BIOL MED, V91, P305, DOI 10.3181/00379727-91-22245; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARDEE AB, 1978, ANNU REV BIOCHEM, V47, P715, DOI 10.1146/annurev.bi.47.070178.003435; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PINES J, 1990, NEW BIOL, V2, P289; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; QUASTLER H, 1959, EXP CELL RES, V17, P420, DOI 10.1016/0014-4827(59)90063-1; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; ROBERTS JAG, UNPUB; SHERR C, COMMUNICATION; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STANCEL G, 1978, P NATL ACAD SCI USA, V75, P6295; SUDBERY PE, 1980, NATURE, V288, P401, DOI 10.1038/288401a0; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZETTERBERG A, 1985, P NATL ACAD SCI USA, V82, P5365, DOI 10.1073/pnas.82.16.5365; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	57	719	745	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 26	1993	259	5103					1908	1912		10.1126/science.8384376	http://dx.doi.org/10.1126/science.8384376			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU172	8384376				2022-12-28	WOS:A1993KU17200035
J	CARLSON, KJ; NICHOLS, DH; SCHIFF, I				CARLSON, KJ; NICHOLS, DH; SCHIFF, I			CURRENT CONCEPTS - INDICATIONS FOR HYSTERECTOMY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC PELVIC PAIN; PROSTAGLANDIN-SYNTHETASE INHIBITORS; TOTAL ABDOMINAL HYSTERECTOMY; LONG-TERM; BILATERAL OOPHORECTOMY; PSYCHOLOGICAL-ASPECTS; LEIOMYOMATA UTERI; REPRODUCTIVE AGE; UNITED-STATES; DOUBLE-BLIND		MASSACHUSETTS GEN HOSP, VINCENT MEM GYNECOL SERV, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, MED SERV, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					AHRQ HHS [R01 HS06121] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006121] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON ABM, 1976, LANCET, V1, P774; BEARD RW, 1991, BRIT J OBSTET GYNAEC, V98, P988, DOI 10.1111/j.1471-0528.1991.tb15336.x; BERKELEY AS, 1983, SURG GYNECOL OBSTET, V156, P319; BONDUELLE M, 1991, POSTGRAD MED J, V67, P833, DOI 10.1136/pgmj.67.791.833; COPPEN A, 1981, LANCET, V1, P126; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; DERMAN SG, 1991, OBSTET GYNECOL, V77, P591; DICKER RC, 1982, AM J OBSTET GYNECOL, V144, P841, DOI 10.1016/0002-9378(82)90362-3; DICKER RC, 1982, JAMA-J AM MED ASSOC, V248, P323, DOI 10.1001/jama.248.3.323; DOMENIGHETTI G, 1985, NEW ENGL J MED, V313, P1482; FRIEDMAN AJ, 1991, OBSTET GYNECOL, V77, P720; FRIEDMAN AJ, 1988, FERTIL STERIL, V49, P404; GANNON MJ, 1991, BRIT MED J, V303, P1362, DOI 10.1136/bmj.303.6814.1362; GARRY R, 1990, BRIT J OBSTET GYNAEC, V97, P199, DOI 10.1111/j.1471-0528.1990.tb01779.x; GATH D, 1982, BRIT J PSYCHIAT, V140, P335, DOI 10.1192/bjp.140.4.335; GOULD D, 1985, J ADV NURS, V10, P315, DOI 10.1111/j.1365-2648.1985.tb00825.x; GRIFFITHJONES MD, 1991, BRIT J UROL, V67, P295, DOI 10.1111/j.1464-410X.1991.tb15138.x; HAYASHI RH, 1984, OBSTET GYNECOL, V63, P806; HORM JW, 1984, NCI NIH851837 PUBL; JEQUIER AM, 1976, BRIT J UROL, V49, P437, DOI 10.1111/j.1464-410X.1976.tb06676.x; JONES HW, 1990, CLIN OBSTET GYNECOL, V33, P826, DOI 10.1097/00003081-199012000-00018; JONES MW, 1990, CONTEMP OBSTET GYNEC, V35, P36; KURMAN RJ, 1985, CANCER, V56, P403, DOI 10.1002/1097-0142(19850715)56:2<403::AID-CNCR2820560233>3.0.CO;2-X; LANGER R, 1989, OBSTET GYNECOL, V74, P205; LEE NC, 1984, AM J OBSTET GYNECOL, V150, P283, DOI 10.1016/S0002-9378(84)90366-1; LOFFER FD, 1990, OBSTET GYNECOL, V76, P836, DOI 10.1097/00006250-199011000-00023; MAHEUX R, 1988, 12TH WORLD C GYN OBS; MALONE LJ, 1969, OBSTET GYNECOL, V34, P200; MARTIN RL, 1980, JAMA-J AM MED ASSOC, V244, P350; MATTA WHM, 1989, BRIT J OBSTET GYNAEC, V96, P200, DOI 10.1111/j.1471-0528.1989.tb01663.x; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; OWEN PR, 1984, AM J OBSTET GYNECOL, V148, P96, DOI 10.1016/S0002-9378(84)80039-3; PARYS BT, 1989, BRIT J UROL, V64, P594, DOI 10.1111/j.1464-410X.1989.tb05316.x; PETERS AAW, 1991, OBSTET GYNECOL, V77, P740; PETRUCCO OM, 1992, BRIT J OBSTET GYNAEC, V99, P34, DOI 10.1111/j.1471-0528.1992.tb13538.x; PISCITELLI JT, 1987, OBSTET GYNECOL, V69, P541; PYPER RJD, 1991, BRIT J OBSTET GYNAEC, V98, P1049, DOI 10.1111/j.1471-0528.1991.tb15345.x; REITER RC, 1990, OBSTET GYNECOL, V75, P428; REITER RC, 1992, OBSTET GYNECOL, V79, P481; RENAER M, 1979, AM J OBSTET GYNECOL, V134, P75, DOI 10.1016/0002-9378(79)90799-3; RICHARDS DH, 1974, LANCET, V2, P983; ROE AM, 1988, DIGEST DIS SCI, V33, P1159, DOI 10.1007/BF01535794; ROOS NP, 1984, AM J PUBLIC HEALTH, V74, P327, DOI 10.2105/AJPH.74.4.327; RYAN MM, 1989, BRIT J PSYCHIAT, V154, P516, DOI 10.1192/bjp.154.4.516; SANDBERG SI, 1985, MED CARE, V23, P1067, DOI 10.1097/00005650-198509000-00005; SIDDLE N, 1987, FERTIL STERIL, V47, P94; SPEROFF T, 1991, AM J OBSTET GYNECOL, V164, P165, DOI 10.1016/0002-9378(91)90649-C; STOVALL TG, 1990, OBSTET GYNECOL, V75, P676; UTIAN W H, 1975, International Journal of Gynecology and Obstetrics, V13, P97; VERVEST HAM, 1988, ACTA OBSTET GYN SCAN, V67, P141, DOI 10.3109/00016348809004187; WALKER E, 1988, AM J PSYCHIAT, V145, P75; WENNBERG JE, 1982, SOC SCI MED, V16, P811, DOI 10.1016/0277-9536(82)90234-9; WINGO PA, 1985, AM J OBSTET GYNECOL, V152, P803, DOI 10.1016/S0002-9378(85)80067-3; WRIGHT TC, 1992, OBSTET GYNECOL, V79, P173; 1987, VITAL HLTH STATIS 13, V92; 1992, VITAL HLTH STATIS 13, V112; 1988, HYSTERECTOMIES NEW Y	57	255	262	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 25	1993	328	12					856	860						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KT814	8357364				2022-12-28	WOS:A1993KT81400007
J	MAYERJAEKEL, RE; OHKURA, H; GOMES, R; SUNKEL, CE; BAUMGARTNER, S; HEMMINGS, BA; GLOVER, DM				MAYERJAEKEL, RE; OHKURA, H; GOMES, R; SUNKEL, CE; BAUMGARTNER, S; HEMMINGS, BA; GLOVER, DM			THE 55 KD REGULATORY SUBUNIT OF DROSOPHILA PROTEIN PHOSPHATASE-2A IS REQUIRED FOR ANAPHASE	CELL			English	Article							FISSION YEAST; OKADAIC ACID; TYROSINE PHOSPHATASE; MELANOGASTER GENOME; ACTIVATES P34CDC2; GENE; KINASE; EXPRESSION; ENCODES; SITES	The gene encoding the Drosophila protein phosphatase 2A 55 kd regulatory subunit (PR55) is located at 85F and directs the synthesis of differentially spliced transcripts. Maternal RNAs are present at very high levels in early embryos and decline around cellularization. Zygotic transcripts are present mainly in the developing embryonic nervous system and gonads. Transcripts are uniformly distributed in third instar larval discs and testes and at lower levels in the proliferative centers of the brain. Mutations in abnormal anaphase resolution (aar) are rescued by the wild-type gene for PR55. aar mutants display intact lagging chromatids that have undergone separation from their sisters, but that remain at the position formerly occupied by the metaphase plate, as well as anaphase figures that show bridging chromatin having two centromeric regions.	UNIV DUNDEE, DEPT ANAT & PHYSIOL, CELL CYCLE GENET GRP, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND; UNIV PORTO, CTR CITOL EXPTL, P-4100 OPORTO, PORTUGAL; UNIV PORTO, INST CIENCIAS BIOMED ABEL SALAZAR, P-4100 OPORTO, PORTUGAL	University of Dundee; Universidade do Porto; Universidade do Porto	MAYERJAEKEL, RE (corresponding author), FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND.		Gomes, Rui/AAE-9130-2022; Gomes, Rui APL/M-1803-2015; Sunkel, Claudio E/J-3352-2013; Baumgartner, Stefan/A-5879-2011	Gomes, Rui/0000-0002-7242-6540; Gomes, Rui APL/0000-0002-7242-6540; Sunkel, Claudio E/0000-0002-2963-9380; Baumgartner, Stefan/0000-0001-5320-8321; Ohkura, Hiroyuki/0000-0003-4059-431X; Glover, David/0000-0003-0956-0103				ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; AGOSTINIS P, 1992, EUR J BIOCHEM, V205, P241, DOI 10.1111/j.1432-1033.1992.tb16774.x; ALPHEY L, 1992, CELL, V69, P977, DOI 10.1016/0092-8674(92)90616-K; AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BAUMGARTNER S, 1987, GENE DEV, V1, P1247, DOI 10.1101/gad.1.10.1247; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHEN MX, 1992, FEBS LETT, V306, P54, DOI 10.1016/0014-5793(92)80836-6; COHEN PTW, 1990, FEBS LETT, V268, P355, DOI 10.1016/0014-5793(90)81285-V; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOONAN JH, 1989, CELL, V57, P987, DOI 10.1016/0092-8674(89)90337-1; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; GOMES R, 1993, J CELL SCI, V104, P1; GONZALEZ C, 1991, EXP CELL RES, V192, P10, DOI 10.1016/0014-4827(91)90150-S; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; JESSUS C, 1991, DEVELOPMENT, V111, P813; JUERGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283; KARESS RE, 1989, J CELL BIOL, V109, P2951, DOI 10.1083/jcb.109.6.2951; KEMPHUES KJ, 1983, GENETICS, V105, P345; KHEWGOODALL Y, 1988, FEBS LETT, V238, P265, DOI 10.1016/0014-5793(88)80493-9; King R. C., 1970, OVARIAN DEV DROSOPHI; KINOSHITA N, 1991, COLD SH Q B, V56, P621; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; KUMAGAI A, 1992, CELL, V70, P139, DOI 10.1016/0092-8674(92)90540-S; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; LLAMAZARES S, 1991, GENE DEV, V5, P2153, DOI 10.1101/gad.5.12a.2153; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; MAYER RE, 1991, BIOCHEMISTRY-US, V30, P3589, DOI 10.1021/bi00229a001; MAYER RE, 1991, ADV PROTEIN PHOSPHAT, V6, P265; MAYERJAEKEL RE, 1992, MOL BIOL CELL, V3, P287, DOI 10.1091/mbc.3.3.287; MCCLINTOCK B, 1951, COLD SPRING HARB SYM, V16, P13, DOI 10.1101/SQB.1951.016.01.004; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; MOUNT SM, 1992, NUCLEIC ACIDS RES, V20, P4255, DOI 10.1093/nar/20.16.4255; MOZER B, 1985, MOL CELL BIOL, V5, P885, DOI 10.1128/MCB.5.4.885; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; ORGAD S, 1990, FEBS LETT, V275, P44, DOI 10.1016/0014-5793(90)81435-Q; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAUNDERS RDC, 1989, NUCLEIC ACIDS RES, V17, P9027, DOI 10.1093/nar/17.22.9027; SHEARN A, 1971, P NATL ACAD SCI USA, V68, P2594, DOI 10.1073/pnas.68.10.2594; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V25, P1; SIDENKIAMOS I, 1990, NUCLEIC ACIDS RES, V18, P6261, DOI 10.1093/nar/18.21.6261; SMITH DA, 1985, GENETICS, V110, P647; SOLA MM, 1991, BIOCHIM BIOPHYS ACTA, V1094, P211, DOI 10.1016/0167-4889(91)90011-L; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STONE SR, 1987, BIOCHEMISTRY-US, V26, P7215, DOI 10.1021/bi00397a003; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; VANDRE DD, 1992, J CELL SCI, V101, P79; WILLIAMS BC, 1992, J CELL BIOL, V118, P759, DOI 10.1083/jcb.118.4.759; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988	63	195	198	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 26	1993	72	4					621	633		10.1016/0092-8674(93)90080-A	http://dx.doi.org/10.1016/0092-8674(93)90080-A			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8382567				2022-12-28	WOS:A1993KP16500016
J	SHIN, YK; LEVINTHAL, C; LEVINTHAL, F; HUBBELL, WL				SHIN, YK; LEVINTHAL, C; LEVINTHAL, F; HUBBELL, WL			COLICIN-E1 BINDING TO MEMBRANES - TIME-RESOLVED STUDIES OF SPIN-LABELED MUTANTS	SCIENCE			English	Article							CHANNEL; PEPTIDE; INSERTION; SPECTRA	To investigate the mechanism of interaction of the toxin colicin E1 with membranes, three cysteine substitution mutants and the wild type of the channel-forming fragment were spin labeled at the unique thiol. Time-resolved interaction of these labeled proteins with phospholipid vesicles was investigated with stopped-flow electron paramagnetic resonance spectroscopy. The fragment interacts with neutral bilayers at low pH, indicating that the interaction is hydrophobic rather than electrostatic. The interaction occurs in at least two distinct steps: (i) rapid adsorption to the surface; and (ii) slow, rate-limiting insertion of the hydrophobic central helices into the membrane interior.	UNIV CALIF LOS ANGELES,JULES STEIN EYE INST,LOS ANGELES,CA 90024; COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Columbia University; University of California System; University of California Los Angeles			Barker, Gareth J/C-9616-2009	Barker, Gareth J/0000-0002-5214-7421	NEI NIH HHS [EY05216] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY005216, R01EY005216] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; BERLINER LJ, 1982, ANAL BIOCHEM, V119, P450, DOI 10.1016/0003-2697(82)90612-1; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BULLOCK JO, 1983, J BIOL CHEM, V258, P9908; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; CLEVELAND MV, 1983, P NATL ACAD SCI-BIOL, V80, P3706, DOI 10.1073/pnas.80.12.3706; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; GOORMAGHTIGH E, 1991, EUR J BIOCHEM, V202, P1299, DOI 10.1111/j.1432-1033.1991.tb16503.x; GREENHALGH DA, 1991, P NATL ACAD SCI USA, V88, P8626, DOI 10.1073/pnas.88.19.8626; HUBBELL WL, 1987, REV SCI INSTRUM, V58, P1879, DOI 10.1063/1.1139536; JIANG JJ, 1992, BIOCHEMISTRY-US, V31, P1331, DOI 10.1021/bi00120a008; LAKEY JH, 1991, J MOL BIOL, V218, P639, DOI 10.1016/0022-2836(91)90707-D; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LAKEY JH, 1991, EUR J BIOCHEM, V196, P559; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LIU Q R, 1986, Proteins Structure Function and Genetics, V1, P218, DOI 10.1002/prot.340010304; MEIROVITCH E, 1984, J PHYS CHEM-US, V88, P3454, DOI 10.1021/j150660a018; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; RATH P, 1991, BIOPHYS J, V59, P516, DOI 10.1016/S0006-3495(91)82268-8; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; TODD AP, 1989, PROTEINS, V6, P294, DOI 10.1002/prot.340060312; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; WORMALD MR, 1990, EUR J BIOCHEM, V191, P155, DOI 10.1111/j.1432-1033.1990.tb19105.x; WU G, 1992, THESIS U CALIFORNIA	30	147	149	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 12	1993	259	5097					960	963		10.1126/science.8382373	http://dx.doi.org/10.1126/science.8382373			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL800	8382373				2022-12-28	WOS:A1993KL80000039
J	MOHLEBOETANI, JC; SCHUCHAT, A; PLIKAYTIS, BD; SMITH, JD; BROOME, CV				MOHLEBOETANI, JC; SCHUCHAT, A; PLIKAYTIS, BD; SMITH, JD; BROOME, CV			COMPARISON OF PREVENTION STRATEGIES FOR NEONATAL GROUP-B STREPTOCOCCAL INFECTION - A POPULATION-BASED ECONOMIC-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SELECTIVE INTRAPARTUM CHEMOPROPHYLAXIS; METROPOLITAN ATLANTA; COST-EFFECTIVENESS; DISEASE; TRANSMISSION; COLONIZATION; MENINGITIS; VACCINES; SEQUELAE	Background.-Intrapartum antibiotics can prevent early-onset neonatal group B streptococcal (GBS) disease but have not been widely used. Obstacles include difficulty in implementing screening for GBS colonization and uncertainty about cost-effectiveness. The GBS vaccines for disease prevention are now being developed. Methods.-We developed a decision analysis model and used standard cost-effectiveness and cost-benefit analysis methods. We compared the outcomes and costs of the recent practice of no intervention with those expected for three prevention strategies: (1) intrapartum antibiotics administered to colonized women with labor complications, (2) an alternative strategy that does not require screening but uses epidemiologic criteria and labor complications to target intrapartum antibiotics, and (3) maternal vaccination. We used data from multistate population-based surveillance to estimate the potential impact of each strategy on disease and costs in the United States. Results.-Intrapartum antibiotic prophylaxis of high-risk women identified by screening could prevent approximately 3300 cases (47% of neonatal disease) annually in the United States and could save approximately $16 million in direct medical costs. Chemoprophylaxis of high-risk women identified using epidemiologic criteria could potentially be equally effective (3200 Gases prevented) and would avoid the logistical difficulties of screening; the net savings would be approximately $66 million. Vaccinating 80% of pregnant women with a vaccine that prevents 80% of cases among infants born at or after 34 weeks of gestation would prevent approximately 41 00 neonatal cases annually with a net savings of $131 million. Conclusions.-Universal prenatal screening for GBS and chemoprophylaxis of colonized women with labor complications is likely to be cost-beneficial in the United States. Development of alternative strategies should be further explored for populations in which GBS screening is impractical. Continued development of a GBS vaccine is an important public health priority.	CTR DIS CONTROL & PREVENT, EPIDEM INTELLIGENCE SERV, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, PREVENT MED RESIDENCY PROGRAM, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, MENINGITIS & SPECIAL PATHOGENS BRANCH, ATLANTA, GA USA; CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, BIOSTAT & INFORMAT MANAGEMENT BRANCH, ATLANTA, GA USA; GEORGIA STATE DEPT HUMAN RESOURCES, ATLANTA, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Mohle-Boetani, Janet/AAH-4221-2019					ALLARDICE JG, 1982, AM J OBSTET GYNECOL, V142, P617, DOI 10.1016/S0002-9378(16)32429-2; BAKER CJ, 1985, REV INFECT DIS, V7, P458; BAKER CJ, 1990, INFECT DIS, P742; BOYER KM, 1986, NEW ENGL J MED, V314, P1665, DOI 10.1056/NEJM198606263142603; BOYER KM, 1988, CLIN PERINATOL, V15, P831, DOI 10.1016/S0095-5108(18)30677-8; BOYER KM, 1983, J INFECT DIS, V148, P810, DOI 10.1093/infdis/148.5.810; CHIN KC, 1985, J PEDIATR-US, V106, P819, DOI 10.1016/S0022-3476(85)80365-6; EASMON CSF, 1983, BRIT J OBSTET GYNAEC, V90, P633, DOI 10.1111/j.1471-0528.1983.tb09280.x; EDWARDS MS, 1985, J PEDIATR-US, V106, P717, DOI 10.1016/S0022-3476(85)80342-5; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; FARO S, 1981, AM J OBSTET GYNECOL, V139, P686, DOI 10.1016/0002-9378(81)90486-5; GIBBS RS, 1992, PEDIATR INFECT DIS J, V11, P179, DOI 10.1097/00006454-199203000-00001; HALL CB, 1992, PEDIATRICS, V90, P775; HASLAM RHA, 1978, AJDC, V131, P845; LAYDE PM, 1979, AM J PUBLIC HEALTH, V69, P566, DOI 10.2105/AJPH.69.6.566; MANDELL GL, 1990, GOODMAN GILMANS PHAR, P1081; PAOLETTI LC, 1992, J CLIN INVEST, V89, P203, DOI 10.1172/JCI115564; PHIBBS CS, 1986, PEDIATRICS, V78, P829; REGAN JA, 1991, OBSTET GYNECOL, V77, P604; ROBBINS JB, 1990, J INFECT DIS, V161, P821, DOI 10.1093/infdis/161.5.821; SCHUCHAT A, 1990, J INFECT DIS, V162, P672, DOI 10.1093/infdis/162.3.672; SCHWARTZ B, 1991, JAMA-J AM MED ASSOC, V266, P1112, DOI 10.1001/jama.266.8.1112; STRAYPEDERSEN B, 1983, SEX TRANSM DIS, V10, P167, DOI 10.1097/00007435-198311000-00001; STRICKLAND DM, 1990, AM J OBSTET GYNECOL, V163, P4, DOI 10.1016/S0002-9378(11)90654-1; WALD ER, 1986, PEDIATRICS, V77, P217; WEINSTEIN MC, 1977, NEW ENGL J MED, V296, P716, DOI 10.1056/NEJM197703312961304; YANCEY MK, 1992, OBSTET GYNECOL, V80, P1038; YOW MD, 1979, JAMA-J AM MED ASSOC, V241, P1245, DOI 10.1001/jama.241.12.1245; Zangwill Kenneth M., 1992, Morbidity and Mortality Weekly Report, V41, P25; 1992, ACOG TECHNICAL B, V170; 1991, HLTH US 1990; 1991, MONTHLY VITAL STATIS, V39, P1; 1992, STATISTICAL ABSTRACT	33	131	133	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1442	1448		10.1001/jama.270.12.1442	http://dx.doi.org/10.1001/jama.270.12.1442			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371444				2022-12-28	WOS:A1993LX17300028
J	WANG, LM; MYERS, MG; SUN, XJ; AARONSON, SA; WHITE, M; PIERCE, JH				WANG, LM; MYERS, MG; SUN, XJ; AARONSON, SA; WHITE, M; PIERCE, JH			IRS-1 - ESSENTIAL FOR INSULIN-STIMULATED AND IL-4-STIMULATED MITOGENESIS IN HEMATOPOIETIC-CELLS	SCIENCE			English	Article							TYROSINE KINASE-ACTIVITY; GTPASE-ACTIVATING PROTEIN; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3'-KINASE; JUXTAMEMBRANE REGION; ATP-BINDING; RECEPTOR; PHOSPHORYLATION; GROWTH; RAS	Although several interleukin-3 (IL-3)-dependent cell lines proliferate in response to IL-4 or insulin, the 32D line does not. Insulin and IL-4 sensitivity was restored to 32D cells by expression of IRS-1, the principal substrate of the insulin receptor. Although 32D cells possessed receptors for both factors, they lacked the IRS-1-related protein, 4PS, which becomes phosphorylated by tyrosine in insulin- or IL-4-responsive lines after stimulation. These results indicate that factors that bind unrelated receptors can use similar mitogenic signaling pathways in hematopoietic cells and that 4PS and IRS-1 are functionally similar proteins that are essential for insulin- and IL-4-induced proliferation.	NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; HARVARD UNIV,SCH MED,DEPT MED,JOSLIN DIABET CTR,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.					NIDDK NIH HHS [DK-43808] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043808] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACKER JM, 1991, BIOCHEMISTRY-US, V30, P6366, DOI 10.1021/bi00240a003; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BURGERING BMT, 1989, MOL CELL BIOL, V9, P4312, DOI 10.1128/MCB.9.10.4312; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CHUANG LM, IN PRESS P NATL ACAD; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GREENBERGER JS, 1983, FED PROC, V42, P2762; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KELLER SR, 1993, BIOCHIM BIOPHYS ACTA, V1172, P323, DOI 10.1016/0167-4781(93)90222-Y; LEGROS GS, 1985, J IMMUNOL, V135, P4009; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MOSELY B, 1989, CELL, V59, P335; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PIERCE JR, UNPUB; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	31	415	419	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1591	1594		10.1126/science.8372354	http://dx.doi.org/10.1126/science.8372354			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372354				2022-12-28	WOS:A1993LX47400034
J	WITYK, RJ; LAPEYROLERIE, D; STEIN, BD				WITYK, RJ; LAPEYROLERIE, D; STEIN, BD			RAPID BRAIN CALCIFICATION AFTER ISCHEMIC STROKE	ANNALS OF INTERNAL MEDICINE			English	Note							CT DEMONSTRATION		JOHNS HOPKINS UNIV, SCH MED, BALTIMORE, MD 21205 USA	Johns Hopkins University	WITYK, RJ (corresponding author), SINAI HOSP, DEPT MED, DIV NEUROL, 2401 W BELVADERE AVE, BALTIMORE, MD 21215 USA.		Stein, Bradley/O-8403-2019					AKMAL M, 1984, AM J PHYSIOL, V246, pF575, DOI 10.1152/ajprenal.1984.246.5.F575; ALFREY AC, 1980, RENAL ELECTROLYTE DI, P409; FRANKE CL, 1991, STROKE, V22, P1530, DOI 10.1161/01.STR.22.12.1530; KAPILA A, 1984, RADIOLOGY, V153, P685, DOI 10.1148/radiology.153.3.6494464; KUZUHARA S, 1985, J COMPUT ASSIST TOMO, V9, P268, DOI 10.1097/00004728-198503000-00007; LOWENTHAL A, 1986, HDB CLIN NEUROLOGY, V5, P417; MIDRONI G, 1992, NEUROLOGY, V42, P2144, DOI 10.1212/WNL.42.11.2144; PARFITT AM, 1969, ARCH INTERN MED, V124, P544, DOI 10.1001/archinte.124.5.544; SOUTHWOOD RL, 1990, DICP ANN PHARMAC, V24, P855, DOI 10.1177/106002809002400913; SWARTZ JD, 1983, J COMPUT ASSIST TOMO, V7, P476, DOI 10.1097/00004728-198306000-00017	10	6	6	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					490	491		10.7326/0003-4819-119-6-199309150-00008	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357115				2022-12-28	WOS:A1993LZ27500008
J	COLLMAN, JP; ZHANG, XM; LEE, VJ; UFFELMAN, ES; BRAUMAN, JI				COLLMAN, JP; ZHANG, XM; LEE, VJ; UFFELMAN, ES; BRAUMAN, JI			REGIOSELECTIVE AND ENANTIOSELECTIVE EPOXIDATION CATALYZED BY METALLOPORPHYRINS	SCIENCE			English	Article							SPANNING STEROIDAL METALLOPORPHYRINS; CYTOCHROME-P-450 MODEL COMPOUNDS; PICNIC-BASKET PORPHYRINS; TWIN-CORONET PORPHYRINS; OXYGEN ATOM TRANSFER; ASYMMETRIC EPOXIDATION; UNFUNCTIONALIZED OLEFINS; MANGANESE(V)-OXO COMPLEX; IRON PORPHYRINS; ACTIVE-SITE	Recent progress in regioselective and enantioselective epoxidations catalyzed by metalloporphyrins is discussed here, with an explanation of the biomimetic antecedents of this area and its relevance to synthetic applications. Classification of the catalysts that have been studied allows useful conclusions to be drawn about the development of this field. In particular, both the most promising biomimetic and practical catalysts have arisen from systems that can be systematically modified by convenient synthetic methodology.			COLLMAN, JP (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.		Zhang, Xumu/K-8746-2013	Zhang, Xumu/0000-0001-5700-0608	NIGMS NIH HHS [5R37-GM 17880] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017880] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartok M, 1980, CHEM ETHERS CROW 1 S, P609; COLLINS TJ, 1989, J AM CHEM SOC, V111, P4511, DOI 10.1021/ja00194a063; COLLINS TJ, 1990, J AM CHEM SOC, V112, P899, DOI 10.1021/ja00158a077; COLLMAN JP, 1985, J AM CHEM SOC, V107, P2000, DOI 10.1021/ja00293a034; COLLMAN JP, 1990, J AM CHEM SOC, V112, P5356, DOI 10.1021/ja00169a056; COLLMAN JP, 1984, P NATL ACAD SCI USA, V81, P3245, DOI 10.1073/pnas.81.10.3245; COLLMAN JP, 1993, J AM CHEM SOC, V115, P3834, DOI 10.1021/ja00062a083; COLLMAN JP, 1992, J CHEM SOC CHEM COMM, P1647, DOI 10.1039/c39920001647; COLLMAN JP, 1992, ADV CHEM SER, V230, P153; COLLMAN JP, 1988, J AM CHEM SOC, V110, P3477, DOI 10.1021/ja00219a023; COLLMAN JP, UNPUB; DAWSON JH, 1987, CHEM REV, V87, P1255, DOI 10.1021/cr00081a015; DECARVALHO ME, 1986, NEW J CHEM, V10, P223; DEMONTELLANO PR, 1986, CYTOCHROME P450 REAC; Fox B. G., 1990, BIOL OXIDATION SYSTE, V1, P367; GAO Y, 1987, J AM CHEM SOC, V109, P5765, DOI 10.1021/ja00253a032; GROVES JT, 1989, J AM CHEM SOC, V111, P2900, DOI 10.1021/ja00190a026; GROVES JT, 1990, J CHEM SOC CHEM COMM, P436, DOI 10.1039/c39900000436; GROVES JT, 1988, J AM CHEM SOC, V110, P8628, DOI 10.1021/ja00234a009; GROVES JT, 1990, J ORG CHEM, V55, P3628, DOI 10.1021/jo00298a046; GROVES JT, 1983, J AM CHEM SOC, V105, P5791, DOI 10.1021/ja00356a016; GROVES JT, 1987, J AM CHEM SOC, V109, P5045, DOI 10.1021/ja00250a059; GROVES JT, 1983, J AM CHEM SOC, V105, P5786, DOI 10.1021/ja00356a015; GUNTER MJ, 1991, COORDIN CHEM REV, V108, P115, DOI 10.1016/0010-8545(91)84001-L; HALTERMAN RL, 1991, J ORG CHEM, V56, P5253, DOI 10.1021/jo00018a008; HANSON RM, 1986, J ORG CHEM, V51, P1922, DOI 10.1021/jo00360a058; Hill C. L., 1989, ACTIVATION FUNCTIONA; IRIE R, 1990, TETRAHEDRON LETT, V31, P7345, DOI 10.1016/S0040-4039(00)88562-7; IRIE R, 1991, TETRAHEDRON-ASYMMETR, V2, P481, DOI 10.1016/S0957-4166(00)86102-9; IRIE R, 1991, TETRAHEDRON LETT, V32, P1055, DOI 10.1016/S0040-4039(00)74486-8; JACOBSEN EN, 1991, J AM CHEM SOC, V113, P6703, DOI 10.1021/ja00017a069; JACOBSEN EN, 1991, J AM CHEM SOC, V113, P7063, DOI 10.1021/ja00018a068; JACOBSEN EN, 1992, J ORG CHEM, V57, P4320; JERINA DM, 1974, SCIENCE, V185, P573, DOI 10.1126/science.185.4151.573; Johnson R.A, 1991, COMPR ORG SYNTH, V7, P389; JORGENSEN KA, 1990, CHEM REV, V90, P1483; JORGENSEN KA, 1989, CHEM REV, V89, P431; KATSUKI T, 1980, J AM CHEM SOC, V102, P5976; KONISHI K, 1992, J AM CHEM SOC, V114, P1313, DOI 10.1021/ja00030a029; LEE NH, 1991, TETRAHEDRON LETT, V32, P5055, DOI 10.1016/S0040-4039(00)93426-9; LEE NH, 1991, TETRAHEDRON LETT, V32, P6533, DOI 10.1016/0040-4039(91)80212-O; LICOCCIA S, 1991, MAGN RESON CHEM, V29, P1084, DOI 10.1002/mrc.1260291103; MAILLARD P, 1991, TETRAHEDRON LETT, V32, P4904; MANSUY D, 1985, J CHEM SOC CHEM COMM, P155, DOI 10.1039/c39850000155; MEUNIER B, 1992, CHEM REV, V92, P1411, DOI 10.1021/cr00014a008; MIRAFZAL GA, 1992, J AM CHEM SOC, V114, P10968, DOI 10.1021/ja00053a047; MUKAIYAMA T, 1993, CHEM LETT, P327, DOI 10.1246/cl.1993.327; NARUTA Y, 1989, CHEM LETT, P1269, DOI 10.1246/cl.1989.1269; NARUTA Y, 1993, B CHEM SOC JPN, V66, P158, DOI 10.1246/bcsj.66.158; NARUTA Y, 1991, J AM CHEM SOC, V113, P6865, DOI 10.1021/ja00018a024; NUGENT WA, 1993, SCIENCE, V259, P479, DOI 10.1126/science.259.5094.479; OKITA RT, 1992, TXB BIOCH CLIN CORRE, P981; OMALLEY S, 1989, J AM CHEM SOC, V111, P9116, DOI 10.1021/ja00207a027; OSTOVIC D, 1992, ACCOUNTS CHEM RES, V25, P314, DOI 10.1021/ar00019a007; OZAKI S, 1990, J CHEM SOC PERK T 2, P353, DOI 10.1039/p29900000353; PIRKLE WH, 1979, J ORG CHEM, V44, P1025, DOI 10.1021/jo01321a001; SAMSEL EG, 1985, J AM CHEM SOC, V107, P7606, DOI 10.1021/ja00311a064; SCHURIG V, 1992, CHEM REV, V92, P873, DOI 10.1021/cr00013a006; SRINIVASAN K, 1986, J AM CHEM SOC, V108, P2309, DOI 10.1021/ja00269a029; STILL WC, 1979, J AM CHEM SOC, V101, P2493, DOI 10.1021/ja00503a048; STINSON SC, 1992, CHEM ENG NEWS, V70, P46, DOI 10.1021/cen-v070n039.p046; SUSLICK KS, 1987, J CHEM SOC CHEM COMM, P200, DOI 10.1039/c39870000200; SUSLICK KS, 1989, ACTIVATION FUNCTIONA, P219; TABUSHI I, 1984, J AM CHEM SOC, V106, P6871, DOI 10.1021/ja00334a083; TRAYLOR TG, 1993, J AM CHEM SOC, V115, P2775, DOI 10.1021/ja00060a027; WAGLER TR, 1989, J ORG CHEM, V54, P1584, DOI 10.1021/jo00268a019; YAMADA T, 1992, CHEM LETT, P2231, DOI 10.1246/cl.1992.2231; ZHANG W, 1990, J AM CHEM SOC, V112, P2801, DOI 10.1021/ja00163a052; ZHANG W, 1991, J ORG CHEM, V56, P2296, DOI 10.1021/jo00007a012	69	444	462	1	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1404	1411		10.1126/science.8367724	http://dx.doi.org/10.1126/science.8367724			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367724				2022-12-28	WOS:A1993LW54900022
J	ADAMS, WL; YUAN, Z; BARBORIAK, JJ; RIMM, AA				ADAMS, WL; YUAN, Z; BARBORIAK, JJ; RIMM, AA			ALCOHOL-RELATED HOSPITALIZATIONS OF ELDERLY PEOPLE - PREVALENCE AND GEOGRAPHIC-VARIATION IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE PATIENTS; CONSUMPTION; DRINKERS; DRINKING; ABUSE; AGE	Objective.- To determine the prevalence, geographic variation, and charges to Medicare of alcohol-related hospitalizations among elderly people in the United States. Design.- A cross-sectional prevalence study using 1989 hospital claims data from the Health Care Financing Administration (HCFA). Rates were determined using (1) hospital claims records from the HCFA's Medicare Provider Analysis and Review Record (MEDPAR) database for all Medicare Part A beneficiaries aged 65 years and older, (2) county population estimates for 1985 from the Bureau of the Census; and (3) per capita consumption of alcohol by state in 1989 as estimated by the US Department of Health and Human Services. Setting.- Data include all hospital inpatient Medicare Part A beneficiaries aged 65 years and older in the United States in 1989. Results.- The prevalence of alcohol-related hospitalizations among people aged 65 years and older nationality in 1989 was 54.7 per 10 000 population for men and 14.8 per 10 000 for women. Comparison with hospital records showed that MEDPAR data had a sensitvity of 77% to detect alcohol-related hospitalizations. There was considerable geographic variation; prevalence ranged from 18.9 per 10 000 in Arkansas to 77.0 per 10 000 in Alaska. A strong correlation existed between alcohol-related hospitalizations and per capita consumption of alcohol by state (Spearman correlation coefficient, .64; P<.0001). In 1989, the hospital-associated charges to Medicare for all admissions where the primary diagnosis was alcohol related (N=33 039) totaled $233 543 500. Median charge per hospital stay was $4514. Conclusions.- Alcohol-related hospitalizations among elderly people are common; rates were similar to those for myocardial infarction as detected by the same method. The charges to Medicare for this preventable problem are considerable. Ecological analysis suggests that per capita consumption in the total US population predicts alcohol-related hospitalizations in the elderly population.	MED COLL WISCONSIN,DEPT MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DEPT PHARMACOL,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DIV BIOSTAT & CLIN EPIDEMIOL,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin								ADAMS WL, 1990, J AM GERIATR SOC, V38, P211, DOI 10.1111/j.1532-5415.1990.tb03493.x; BAILEY MB, 1965, Q J STUD ALCOHOL, V26, P19; BARNES GM, 1979, J AM GERIATR SOC, V27, P244, DOI 10.1111/j.1532-5415.1979.tb06125.x; BLAZER D, 1987, ARCH GEN PSYCHIAT, V44, P736; BRISTOW MF, 1992, BRIT J ADDICT, V87, P291; CAHALAN D, 1968, J STUD ALCOHOL, V29, P139; COULEHAN JL, 1987, ARCH INTERN MED, V147, P349, DOI 10.1001/archinte.147.2.349; CURTIS JR, 1989, J AM GERIATR SOC, V37, P310, DOI 10.1111/j.1532-5415.1989.tb05496.x; FISHER ES, 1990, AM J PUBLIC HEALTH, V80, P1487, DOI 10.2105/AJPH.80.12.1487; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; GLYNN RJ, 1985, AM J PUBLIC HEALTH, V75, P1413, DOI 10.2105/AJPH.75.12.1413; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Kirkpatrick B, 1988, Psychiatr Med, V6, P65; MANDERSCHEID RW, 1990, ADM901708 US DEP HLT; MANN RE, 1991, J STUD ALCOHOL, V52, P361, DOI 10.15288/jsa.1991.52.361; MCKIM WA, 1991, CAN J PUBLIC HEALTH, V82, P231; MEYERS A R, 1981, International Journal of Aging and Human Development, V14, P31, DOI 10.2190/XCDE-9EQY-5DNR-BUX7; Molgaard C A, 1990, J Community Health, V15, P239, DOI 10.1007/BF01350290; MOORE RD, 1986, J MED EDUC, V61, P46; MYERS JK, 1984, ARCH GEN PSYCHIAT, V41, P959; RUSH BR, 1986, J STUD ALCOHOL, V47, P1; SCHUCKIT MA, 1980, J CLIN PSYCHIAT, V41, P412; SMART RG, 1981, J PSYCHOACTIVE DRUGS, V13, P153, DOI 10.1080/02791072.1981.10524297; SMART RG, 1987, BRIT J ADDICT, V82, P285; STINSON FS, 1989, ALCOHOL HEALTH RES W, V13, P80; 1980, PHS801260 US DEP HLT; 1991, 20 US DEP HLTH HUM S; 1989, COUNTY POPULATION ES	29	172	173	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1222	1225		10.1001/jama.270.10.1222	http://dx.doi.org/10.1001/jama.270.10.1222			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV649	8355385				2022-12-28	WOS:A1993LV64900028
J	KAPPEN, LS; GOLDBERG, IH				KAPPEN, LS; GOLDBERG, IH			DNA CONFORMATION INDUCED ACTIVATION OF AN ENEDIYNE FOR SITE-SPECIFIC CLEAVAGE	SCIENCE			English	Article							NEOCARZINOSTATIN CHROMOPHORE; MISMATCHES; MECHANISM; DAMAGE; STRAND; BASES	Neocarzinostatin chromophore (NCS chrom) was found to induce site-specific cleavage at the 3' side of a bulge in single-stranded DNA in the absence of thiol. This reaction involved the oxidative formation of a DNA fragment with a nucleoside 5'-aldehyde at its 5' terminus and generated an ultraviolet light-absorbing and fluorescent species of post-activated drug containing tritium abstracted from the carbon at the 5' position of the target nucleotide. The DNAs containing point mutations that disrupt the bulge were not cleavage substrates and did not generate this drug product. Thus, DNA is an active participant in its own destruction, and NCS chrom may be useful as a probe for bulged structures in nucleic acids.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R35CA044257] Funding Source: NIH RePORTER; NCI NIH HHS [CA44257] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATTACHARYYA A, 1989, NUCLEIC ACIDS RES, V17, P6821, DOI 10.1093/nar/17.17.6821; CHIN DH, 1988, BIOCHEMISTRY-US, V27, P8106, DOI 10.1021/bi00421a020; GOLDBERG IH, 1991, ACCOUNTS CHEM RES, V24, P191, DOI 10.1021/ar00007a001; HATAYAMA T, 1978, P NATL ACAD SCI USA, V75, P3603, DOI 10.1073/pnas.75.8.3603; HENSENS OD, UNPUB; HSIEH CH, 1989, P NATL ACAD SCI USA, V86, P4833, DOI 10.1073/pnas.86.13.4833; KAPPEN LS, 1988, BIOCHEMISTRY-US, V27, P4331, DOI 10.1021/bi00412a021; KAPPEN LS, 1983, BIOCHEMISTRY-US, V22, P4872, DOI 10.1021/bi00290a002; KAPPEN LS, UNPUB; LAMOTHE M, 1993, J AM CHEM SOC, V115, P4483, DOI 10.1021/ja00064a010; LEE MD, 1991, ACCOUNTS CHEM RES, V24, P191; MYERS AG, 1987, TETRAHEDRON LETT, V28, P4493, DOI 10.1016/S0040-4039(00)96545-6; NAPIER MA, 1983, MOL PHARMACOL, V23, P500; RICE JA, 1989, BIOCHEMISTRY-US, V28, P4512, DOI 10.1021/bi00436a058; SUGIURA Y, 1989, P NATL ACAD SCI USA, V86, P7672, DOI 10.1073/pnas.86.20.7672; ZEIN N, 1993, P NATL ACAD SCI USA, V90, P2822, DOI 10.1073/pnas.90.7.2822	16	74	75	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1319	1321		10.1126/science.8362243	http://dx.doi.org/10.1126/science.8362243			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8362243				2022-12-28	WOS:A1993LV65600027
J	PARBOOSINGH, JT; GONDOCZ, ST				PARBOOSINGH, JT; GONDOCZ, ST			THE MAINTENANCE OF COMPETENCE PROGRAM OF THE ROYAL-COLLEGE-OF-PHYSICIANS-AND-SURGEONS-OF-CANADA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											PARBOOSINGH, JT (corresponding author), ROYAL COLL PHYSICIANS & SURGEONS,OFF FELLOWSHIP AFFAIRS,774 ECHO DR,OTTAWA K1S 5N8,ON,CANADA.								0	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1093	1093						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350455				2022-12-28	WOS:A1993LU51200013
J	HUERTA, PT; LISMAN, JE				HUERTA, PT; LISMAN, JE			HEIGHTENED SYNAPTIC PLASTICITY OF HIPPOCAMPAL CA1 NEURONS DURING A CHOLINERGICALLY INDUCED RHYTHMIC STATE	NATURE			English	Article							LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; DENTATE GYRUS; THETA-RHYTHM; PATTERNED STIMULATION; RECEPTOR SUBTYPES; RAT HIPPOCAMPUS; VISUAL-CORTEX; INDUCTION; RESPONSES	BRAIN cholinergic neurons are critical for memory function1,2 and their loss may contribute to memory impairment in Alzheimer's disease3. One role of cholinergic neurons is to elicit an oscillatory activity called theta rhythm4 in the hippocampus, a brain region involved in memory processing5. Theta rhythm occurs during periods of learning6,7, but its effect on the synaptic plasticity that underlies learning remains unclear. We have studied synaptic plasticity in hippocampal slices during theta-frequency oscillations induced by a cholinergic agonist8-10. Here we report that during these oscillations, synapses are in a state of heightened plasticity and can be modified by what would otherwise be ineffective stimulation. This heightened plasticity is sensitive to the timing of incoming stimuli with respect to the oscillatory activity. The results suggest that cholinergic systems may affect memory formation through the induction of an oscillatory state in which the requirements for synaptic plasticity are dramatically altered.	BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA	Brandeis University	HUERTA, PT (corresponding author), BRANDEIS UNIV, DEPT BIOL, WALTHAM, MA 02254 USA.			Huerta, Patricio/0000-0003-0270-2308				AIGNER TG, 1986, BEHAV NEURAL BIOL, V45, P81, DOI 10.1016/S0163-1047(86)80008-5; Alger B.E., 1984, BRAIN SLICES, P381; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BROCHER S, 1992, BRAIN RES, V573, P27, DOI 10.1016/0006-8993(92)90110-U; BURGARD EC, 1990, NEUROSCI LETT, V116, P34, DOI 10.1016/0304-3940(90)90382-J; CHRISTIE BR, 1992, NEURON, V9, P79, DOI 10.1016/0896-6273(92)90222-Y; Colom L V, 1991, Hippocampus, V1, P381, DOI 10.1002/hipo.450010406; COYLE JT, 1983, SCIENCE, V219, P1184, DOI 10.1126/science.6338589; DUTAR P, 1988, J NEUROSCI, V8, P4214; EICHENBAUM H, 1987, J NEUROSCI, V7, P716; FIBIGER HC, 1991, TRENDS NEUROSCI, V14, P220, DOI 10.1016/0166-2236(91)90117-D; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HALLIWELL JV, 1990, PROG BRAIN RES, V84, P255; KONOPACKI J, 1987, BRAIN RES, V405, P196, DOI 10.1016/0006-8993(87)91009-2; KONOPACKI J, 1988, BRAIN RES, V455, P110, DOI 10.1016/0006-8993(88)90119-9; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; MACVICAR BA, 1989, J PHYSIOL-LONDON, V417, P197, DOI 10.1113/jphysiol.1989.sp017797; MARKRAM H, 1992, J PHYSIOL-LONDON, V447, P513, DOI 10.1113/jphysiol.1992.sp019015; MARKRAM H, 1990, J PHYSIOL-LONDON, V427, P381, DOI 10.1113/jphysiol.1990.sp018177; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; Otto T, 1991, Hippocampus, V1, P181, DOI 10.1002/hipo.450010206; PAVLIDES C, 1988, BRAIN RES, V439, P383, DOI 10.1016/0006-8993(88)91499-0; ROSE GM, 1986, NEUROSCI LETT, V69, P244, DOI 10.1016/0304-3940(86)90487-8; SCHULZ PE, 1990, SOC NEUR ABSTR, V16, P655; Squire L. R., 1987, MEMORY BRAIN; STANTON PK, 1989, NATURE, V339, P215, DOI 10.1038/339215a0; TRAUB RD, 1992, J PHYSIOL-LONDON, V451, P653, DOI 10.1113/jphysiol.1992.sp019184; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646	29	459	465	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					723	725		10.1038/364723a0	http://dx.doi.org/10.1038/364723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355787				2022-12-28	WOS:A1993LT67700060
J	BROWN, JN; CROSBY, AC				BROWN, JN; CROSBY, AC			LESSON OF THE WEEK - ACUTE SOFT-TISSUE INJURIES OF THE CERVICAL-SPINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article											BROWN, JN (corresponding author), ROYAL HALLAMSHIRE HOSP, DEPT ACCID & EMERGENCY, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND.							CADOUX CG, 1987, ANN EMERG MED, V16, P738, DOI 10.1016/S0196-0644(87)80565-6; CLOWARD RB, 1958, J NEUROSURG, V15, P602, DOI 10.3171/jns.1958.15.6.0602; DAVIS SJ, 1991, RADIOLOGY, V180, P245, DOI 10.1148/radiology.180.1.2052703; FLANDERS AE, 1990, RADIOLOGY, V177, P25, DOI 10.1148/radiology.177.1.2399326; HARRIS WH, 1968, CLIN ORTHOP RELAT R, P163; MAULL KI, 1977, SOUTHERN MED J, V70, P477, DOI 10.1097/00007611-197704000-00033; PENNING L, 1981, AM J ROENTGENOL, V136, P553, DOI 10.2214/ajr.136.3.553; RINGENBERG BJ, 1988, ANN EMERG MED, V17, P792, DOI 10.1016/S0196-0644(88)80555-9	8	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	1993	307	6901					439	440		10.1136/bmj.307.6901.439	http://dx.doi.org/10.1136/bmj.307.6901.439			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374460	Bronze, Green Published			2022-12-28	WOS:A1993LR89500025
J	PERRY, IJ; GOSLING, P; SANGHERA, K; CHURCHILL, D; LUESLEY, DM; BEEVERS, DG				PERRY, IJ; GOSLING, P; SANGHERA, K; CHURCHILL, D; LUESLEY, DM; BEEVERS, DG			URINARY MICROALBUMIN EXCRETION IN EARLY-PREGNANCY AND GESTATIONAL-AGE AT DELIVERY	BRITISH MEDICAL JOURNAL			English	Article							ALBUMIN EXCRETION		SELLY OAK HOSP,DEPT BIOCHEM,BIRMINGHAM B29 6JD,ENGLAND; UNIV BIRMINGHAM,DUDLEY RD HOSP,DEPT MED,BIRMINGHAM B18 7QH,ENGLAND; UNIV BIRMINGHAM,DUDLEY RD HOSP,DEPT OBSTET,BIRMINGHAM B18 7QH,ENGLAND	University of Birmingham; University of Birmingham	PERRY, IJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH & PRIMARY CARE,LONDON NW3 2PF,ENGLAND.			Perry, Ivan/0000-0002-4965-9792	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CUNDY TF, 1992, DIABETIC MED, V9, P138, DOI 10.1111/j.1464-5491.1992.tb01750.x; LOPEZESPINOZA I, 1986, BRIT J OBSTET GYNAEC, V93, P176, DOI 10.1111/j.1471-0528.1986.tb07883.x; RODRIGUEZ MH, 1988, AM J OBSTET GYNECOL, V159, P1452, DOI 10.1016/0002-9378(88)90573-X; SALAFIA CM, 1991, AM J OBSTET GYNECOL, V165, P934, DOI 10.1016/0002-9378(91)90443-U; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					420	421		10.1136/bmj.307.6901.420	http://dx.doi.org/10.1136/bmj.307.6901.420			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374454	Bronze, Green Published			2022-12-28	WOS:A1993LR89500017
J	GORMAN, DM				GORMAN, DM			WAR ON DRUGS CONTINUES IN UNITED-STATES UNDER NEW LEADERSHIP	BRITISH MEDICAL JOURNAL			English	Article								Criticism of the ''war on drugs'' pursued under Republican administrations has grown in the United States. With the election of Bill Clinton many experts expected a shift from law enforcement policies to an approach favouring treatment and prevention. The budget announced in April, however, revealed no such shift in allocation of resources. Although the war on drugs has apparently failed to reduce the supply of cheap heroin and cocaine to the United States, the prevention strategy favoured by its opponents-school based prevention programmes-has not yet been shown to be effective in dealing with the concentration of drug misuse among the socially disadvantaged. In looking for new strategies Clinton must satisfy both liberals and conservatives in Congress, and community policing might therefore prove to be a politically expedient option.			GORMAN, DM (corresponding author), RUTGERS UNIV,CTR ALCOHOL STUDIES,BUSCH CAMPUS,POB 969,PISCATAWAY,NJ 08855, USA.							BAGNALL G, 1991, ED YOUNG DRINKERS; CLINTON B, 1992, PUTTING PEOPLE 1ST W; Currie E., 1993, RECKONING DRUGS CITI; DUNLAP E, 1992, J PSYCHOACTIVE DRUGS, V24, P307, DOI 10.1080/02791072.1992.10471656; Dunlap E., 1992, DRUGS CRIME SOCIAL I, P181; FALCO M, 1992, MAKING DRUG FREE AM; GORMAN DM, 1992, ALCOHOL ALCOHOLISM, V27, P583; GREENE JR, 1993, DRUGS COMMUNITY INVO, P141; KANDEL DB, 1991, AM J PUBLIC HEALTH, V81, P1064, DOI 10.2105/AJPH.81.8.1064; KELLY M, 1993, NY TIMES        0523, P20; LORION RP, 1992, J COMMUNITY PSYCHOL, V20, P3, DOI 10.1002/1520-6629(199201)20:1<3::AID-JCOP2290200102>3.0.CO;2-G; MASING M, 1993, NY TIMES BOOK R 0124, P10; MCNAGNY SE, 1992, JAMA-J AM MED ASSOC, V267, P1106, DOI 10.1001/jama.267.8.1106; REUTER P, 1993, WASHINGTON POST 0228, P1; Skogan W. G., 1993, DRUGS COMMUNITY INVO, P162; STALEY S, 1992, DRUG POLICY DECLINE; TABOR MBW, 1992, NY TIMES        1001, P1; TIERNEY J, 1993, NY TIMES        0620, P1; TREASTER JB, 1993, NY TIMES        0428, P15; TREASTER JB, 1993, NY TIMES        0417, P1; TREASTER JB, 1992, NY TIMES        0614; TREASTER JB, 1993, NY TIME         0412, P10; TREASTER JB, 1993, NY TIMES        0424, P8; WEIGHLEY RF, 1993, NEW YORK TIMES BK R, P12; WILLIAMS T, 1992, J CONTEMP ETHNOGR, V21, P343, DOI 10.1177/089124192021003003; 1993, INT J ADDICT, V28, pR2; 1992, DRUGS CRIME JUSTICE	27	6	6	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					369	371		10.1136/bmj.307.6900.369	http://dx.doi.org/10.1136/bmj.307.6900.369			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374422	Bronze, Green Published			2022-12-28	WOS:A1993LR76800025
J	BIBAS, M; ANDRIANI, A				BIBAS, M; ANDRIANI, A			HEPATITIS-C VIRUS AND CRYOGLOBULINEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											BIBAS, M (corresponding author), OSPED S GIACOMO,LATIAL CRYOGLOBULINEMIA COOPERAT STUDY GRP,I-00186 ROME,ITALY.		Bibas, Michele/E-7130-2013; françoise, lunel/B-7273-2015	françoise, lunel/0000-0002-1856-0300; Bibas, Michele/0000-0001-5689-7759				BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3	1	7	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1123	1123						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8384320				2022-12-28	WOS:A1993KX17800014
J	ASARNOW, DM; CADO, D; RAULET, DH				ASARNOW, DM; CADO, D; RAULET, DH			SELECTION IS NOT REQUIRED TO PRODUCE INVARIANT T-CELL RECEPTOR GAMMA-GENE JUNCTIONAL SEQUENCES	NATURE			English	Article							DELTA-ANTIGEN RECEPTORS; DIVERSITY; IDENTIFICATION; REARRANGEMENT; RECOGNITION; GENERATION; EPITHELIUM; ENHANCER; SEGMENTS; LOCUS	RECOMBINATION of V-, D- and J-gene segments can generate an enormous diversity of T-cell antigen receptor (TCR) gene sequences1,2. Although many gammadelta T cells fully exploit this diversification process, those in the epidermal and vaginal epithelium do not3,4, predominantly expressing invariant gammadelta receptors in which the V-(D)-J junctional sequences in almost all the productive rearrangements are identical. The almost exclusive use of identical TCRs by cells in these sites is thought to reflect recognition of a stress-induced autologous antigen5-8. To explain the prevalence of the invariant junctional sequences, it has been proposed that thymic selection operates on a population of originally diverse progenitor cells, resulting in a homogeneous repertoire9,10. Alternatively the invariant sequences may result from biases in the recombination machinery in the fetal thymic progenitors of these cells8,11,12. We report here the use of mice into which mutated TCR gamma-gene rearrangement substrates have been introduced as transgenes to demonstrate directly that the canonical TCR Vgamma3-Jgamma1 and Vgamma4-Jgamma1 sequences occur at high frequency in the absence of the possibility of selection for the protein products.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV IMMUNOL,489 LSA,BERKELEY,CA 94720	University of California System; University of California Berkeley				Raulet, David/0000-0002-1257-8649				ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ENGLER P, 1992, J EXP MED, V176, P1399, DOI 10.1084/jem.176.5.1399; GARMAN RD, 1986, CELL, V45, P733, DOI 10.1016/0092-8674(86)90787-7; GOLDMAN J, IN PRESS J EXP MED; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HELIG JS, 1986, NATURE, V322, P836; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P2204, DOI 10.1073/pnas.88.6.2204; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; NANDI D, 1991, J IMMUNOL, V147, P1773; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; SPENCER DM, 1991, P NATL ACAD SCI USA, V88, P800, DOI 10.1073/pnas.88.3.800; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0	21	97	97	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 11	1993	362	6416					158	160		10.1038/362158a0	http://dx.doi.org/10.1038/362158a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR028	8383806				2022-12-28	WOS:A1993KR02800060
J	ATKINSON, RL				ATKINSON, RL			PROPOSED STANDARDS FOR JUDGING THE SUCCESS OF THE TREATMENT OF OBESITY	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-CALORIE DIET; WEIGHT	The purpose of this report is to propose standards for the successful treatment of obesity. This process is somewhat arbitrary because obesity is a multifactorial disease and because standards need revision as diagnostic and treatment techniques improve. Weight loss, the classic standard of success, does not account for individual variability. Reduction in other measures of body size, such as body mass index, percentage of excess weight, and body fat, may be preferable. Improvement in known complications of obesity (diabetes mellitus, hypertension, hyperlipoproteinemia, sleep apnea, and psychosocial problems) are equally valid measures of success. Because obesity is a chronic disease, maintenance of weight loss is included as a standard of success. Response to obesity treatment varies, and thus criteria to define minimal, intermediate, and full success for each variable are necessary.			ATKINSON, RL (corresponding author), DEPT VET AFFAIRS MED CTR, MED RES SERV, HAMPTON, VA 23667 USA.		Atkinson, Richard/AAK-4953-2021					ANDERSEN T, 1988, INT J OBESITY, V12, P277; ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; Bray GA., 1976, OBESE PATIENT, P215; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MILLER A, 1974, AM J MED, V56, P144, DOI 10.1016/0002-9343(74)90591-9; PORIES WJ, 1992, AM J CLIN NUTR, V55, P582; SIMOPOULOS AP, 1984, ANN INTERN MED, V100, P285, DOI 10.7326/0003-4819-100-2-285; Stunkard AJ., 1976, PAIN OBESITY; WADDEN TA, 1989, INT J OBESITY, V13, P39; 1959, STAT B METROP LIFE F, V40, P1; 1985, ANN INTERN MED, V103, P977; 1980, HLTH NUTRITION EXAMI; 1989, DIET HLTH IMPLICATIO, P99	15	49	50	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				677	680		10.7326/0003-4819-119-7_Part_2-199310011-00010	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363196				2022-12-28	WOS:A1993MA33000010
J	SANCHO, S; MONGINI, T; TANJI, K; TAPSCOTT, SJ; WALKER, WF; WEINTRAUB, H; MILLER, AD; MIRANDA, AF				SANCHO, S; MONGINI, T; TANJI, K; TAPSCOTT, SJ; WALKER, WF; WEINTRAUB, H; MILLER, AD; MIRANDA, AF			ANALYSIS OF DYSTROPHIN EXPRESSION AFTER ACTIVATION OF MYOGENESIS IN AMNIOCYTES, CHORIONIC-VILLUS CELLS, AND FIBROBLASTS - A NEW METHOD FOR DIAGNOSING DUCHENNE MUSCULAR-DYSTROPHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL MUSCLE BIOPSY; PRENATAL-DIAGNOSIS; CDNA ANALYSIS; GENE; POLYMORPHISMS; DELETIONS; PROTEIN; POINT; LINES; MYOD	Background. DNA analysis of peripheral-blood leukocytes is routinely used to demonstrate mutations in the dystrophin gene in patients with Duchenne's or Becker's muscular dystrophy. In approximately 35 percent of patients, DNA studies are not informative; in these patients immunochemical analysis of a muscle-biopsy specimen can determine whether dystrophin, the protein product of the gene for Duchenne's dystrophy, is present at reduced levels or absent. DNA analysis can be performed in amniocytes or chorionic-villus cells to identify mutations of the dystrophic gene prenatally, but immunochemical testing for dystrophin cannot be performed because the protein is not expressed in these cells. Methods. To circumvent this limitation in prenatal diagnosis, we induced myogenesis in 21 cultures of skin fibroblasts, 49 amniocyte cultures, and 6 chorionic-villus cell cultures by infecting the cells with a retrovirus vector containing MyoD, a gene regulating myogenesis. Transfection of MyoD into cells that do not normally develop into muscle cells results in the production of a protein that switches on myogenesis. We performed immunocytochemical analysis for dystrophin in the MyoD-converted muscle cells. Results. We found that 60 of 61 myotube cultures from subjects with no family history of Duchenne's dystrophy expressed dystrophin. Both myotube cultures from the two patients with Becker's dystrophy also expressed dystrophin, but all cultures from nine patients and two fetuses with Duchenne's dystrophy were dystrophin-deficient. Conclusions. Immunocytochemical analysis of dystrophin in genetically altered non-muscle cells is feasible and may be applicable to the prenatal and postnatal diagnosis of Duchenne's muscular dystrophy when conventional DNA analysis is not informative.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,630 W 168TH ST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT NEUROL,NEW YORK,NY 10032; UNIV TURIN,NEUROL CLIN 2,I-10124 TURIN,ITALY; FRED HUTCHINSON CANC RES CTR,DEPT GENET,SEATTLE,WA 98104; FRED HUTCHINSON CANC RES CTR,DEPT MOLEC MED,SEATTLE,WA 98104	Columbia University; Columbia University; University of Turin; Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center			Mongini, Tiziana/E-9257-2012	Miller, Dusty/0000-0002-3736-3660	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045203] Funding Source: NIH RePORTER; Fondazione Telethon Funding Source: Custom	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Fondazione Telethon(Fondazione Telethon)		BEGGS AH, 1990, HUM GENET, V86, P45; BYERS TJ, 1992, NEUROLOGY, V42, P570; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; CLEMENS PR, 1991, AM J HUM GENET, V49, P951; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DENDUNNEN JT, 1989, AM J HUM GENET, V45, P835; EVANS MI, 1991, AM J OBSTET GYNECOL, V165, P728, DOI 10.1016/0002-9378(91)90318-L; FEENER CA, 1991, AM J HUM GENET, V48, P621; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; KOENIG M, 1989, AM J HUM GENET, V45, P498; KULLER JA, 1992, HUM GENET, V90, P34; LEV AA, 1987, J BIOL CHEM, V262, P15817; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MIRANDA AF, 1990, ADV EXP MED BIOL, V280, P205; MIRANDA AF, 1988, AM J PATHOL, V132, P410; MIRANDA AF, 1979, MUSCLE REGENERATION, P453; ROBERTS RG, 1992, P NATL ACAD SCI USA, V89, P2331, DOI 10.1073/pnas.89.6.2331; ROBERTS RG, 1991, AM J HUM GENET, V49, P298; SKLAR RM, 1990, NEUROLOGY, V40, P1854, DOI 10.1212/WNL.40.12.1854; SPECHT LA, 1993, MOL GENETIC BASIS NE, P613; WARD PA, 1989, AM J HUM GENET, V44, P270; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704	26	34	35	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					915	920		10.1056/NEJM199309233291303	http://dx.doi.org/10.1056/NEJM199309233291303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361505	Bronze			2022-12-28	WOS:A1993LX75100003
J	WARNER, MA; SHIELDS, SE; CHUTE, CG				WARNER, MA; SHIELDS, SE; CHUTE, CG			MAJOR MORBIDITY AND MORTALITY WITHIN 1 MONTH OF AMBULATORY SURGERY AND ANESTHESIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLICATIONS; INPATIENT; MINNESOTA; OUTCOMES; AGE	Objective.-To determine the incidence and time sequence of mortality and major morbidity after ambulatory surgery. Design.-Prospective outcome survey of patients at 16 to 72 hours and 30 days after their surgical procedures. Setting.-A tertiary care rural referral center providing ambulatory care. Patients.-A total of 38 598 patients aged 18 years and older undergoing 45 090 consecutive ambulatory procedures and anesthetics. Contact rates for 72 hours and 30 days were 99.94% and 95.9%, respectively. Main Outcome Measures.-Mortality and major morbidity incidences, including myocardial infarction, central nervous system deficit, pulmonary embolism, and respiratory failure. Results.-Thirty-three patients either experienced major morbidity or died (1:1366 [proportional risk]). Four patients died (1:11273), two of myocardial infarction and two in automobile accidents. No patient died of a medical complication within 1 week of surgery. Of the 31 patients who developed a major morbidity (1:1455), 14 (45%) had myocardial infarction (1:3220), seven (23%) had a central nervous system deficit (1:6441), five (16%) had pulmonary embolism (1:9018), and five (16%) had respiratory failure (1:9018). Four events (13%) occurred within 8 hours of surgery (1:11 273), 15 (48%) in the next 40 hours (1:3006), and 12 (39%) in the next 28 days (1:3758). Conclusion.-In this ambulatory surgical population, more than one third of major morbidity occurred 48 hours or later after surgery. Overall morbidity and mortality rates, however, were very low.	MAYO CLIN & MAYO GRAD SCH MED, DEPT EPIDEMIOL, ROCHESTER, MN 55901 USA; MAYO CLIN & MAYO GRAD SCH MED, ROCHESTER, MN 55901 USA	Mayo Clinic; Mayo Clinic	WARNER, MA (corresponding author), MAYO CLIN & MAYO GRAD SCH MED, DEPT ANESTHESIOL, 200 1ST ST SW, ROCHESTER, MN 55901 USA.							ANCONABERK VA, 1986, AM J PUBLIC HEALTH, V76, P1102, DOI 10.2105/AJPH.76.9.1102; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; DULL DL, 1990, ANESTH ANALG, V70, pS91; DUNCAN PG, 1992, ANESTH ANALG, V74, pS76; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; GOLD BS, 1989, JAMA-J AM MED ASSOC, V262, P3008, DOI 10.1001/jama.262.21.3008; HART R, 1982, STROKE, V13, P766, DOI 10.1161/01.STR.13.6.766; Hedden M, 1987, J Fla Med Assoc, V74, P411; HOSKING M P, 1989, Journal of the American Medical Association, V261, P1909, DOI 10.1001/jama.261.13.1909; HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310; KITZ DS, 1988, ANESTHESIOLOGY, V69, P383, DOI 10.1097/00000542-198809000-00016; MERIDY HW, 1982, ANESTH ANALG, V61, P921; NARR BJ, 1991, MAYO CLIN PROC, V66, P155, DOI 10.1016/S0025-6196(12)60487-X; NATOF HE, 1980, JAMA-J AM MED ASSOC, V244, P1116, DOI 10.1001/jama.244.10.1116; ORKIN FK, 1991, ANESTHESIA AMBULATOR, P86; PASTERNAK LR, 1993, PRINCIPLES PRACTICE, P2291; Ross AF, 1990, ANESTHESIA, P715; SILVERSTEIN MD, 1993, CLIN RES, V41, pA524; TINKER JH, 1982, SEMIN ANESTH, V1, P253; WARNER MA, 1988, ANN SURG, V207, P380, DOI 10.1097/00000658-198804000-00003; WARNER MA, 1989, MAYO CLIN PROC, V64, P609, DOI 10.1016/S0025-6196(12)65337-3; 1987, INT CLASSIFICATION D, P1	22	241	250	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1437	1441		10.1001/jama.270.12.1437	http://dx.doi.org/10.1001/jama.270.12.1437			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371443				2022-12-28	WOS:A1993LX17300027
J	LUCARELLI, G; GALIMBERTI, M; POLCHI, P; ANGELUCCI, E; BARONCIANI, D; GIARDINI, C; ANDREANI, M; AGOSTINELLI, F; ALBERTINI, F; CLIFT, RA				LUCARELLI, G; GALIMBERTI, M; POLCHI, P; ANGELUCCI, E; BARONCIANI, D; GIARDINI, C; ANDREANI, M; AGOSTINELLI, F; ALBERTINI, F; CLIFT, RA			MARROW TRANSPLANTATION IN PATIENTS WITH THALASSEMIA RESPONSIVE TO IRON CHELATION-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYCLOPHOSPHAMIDE; GRAFT	Background. Patients with homozygous beta-thalassemia, who have a good prognosis during treatment with conventional therapy, appear to have an especially high probability of hematologic cure with bone marrow transplantation, although the morbidity and mortality associated with such treatment are not established. Methods. The records of all patients with thalassemia who received bone marrow transplants from HLA-identical donors in Pesaro, Italy, were examined from October 1982 through May 1992. Detailed evaluation of the outcome was conducted in the 89 patients identified as being in class 1 according to the Pesaro classification, in which hepatomegaly, portal fibrosis, and the inadequacy of iron chelation therapy are considered independent risk factors, and the patients are classified as being in class 1 if none of these factors are present, class 2 if one or two of the factors are present, and class 3 if all three factors are present. Sixty-four of the patients had been prepared for transplantation with a drug regimen in current use that includes busulfan and cyclophosphamide followed by cyclosporine as prophylaxis against acute graft-versus-host disease (protocol 6). Results. There were seven deaths, all within 101 days of transplantation. Two of the 64 patients treated according to protocol 6 died. The probabilities of survival, rejection-free survival, death from causes unrelated to rejection, and rejection were 0.92, 0.85, 0.06, and 0.08, respectively, in the total group and 0.97, 0.93, 0.03, and 0.04 in the 64 patients treated according to protocol 6. Preliminary evidence suggests that there was useful unloading of tissue iron deposits. Conclusions. The high probability of cure with little early or late morbidity and mortality suggests that patients with class 1 thalassemia who have HLA-identical donors available should be treated by bone marrow transplantation. However, this was not a controlled trial, so we cannot directly compare the outcome with that of conventional treatment.	OSPED PESARO, CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA, PESARO, ITALY; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA; OSPED PESARO, DIV EMATOL, PESARO, ITALY	Fred Hutchinson Cancer Center			Andreani, Marco/AAA-5208-2020; Angelucci, Emanuele/AAC-1855-2021	Andreani, Marco/0000-0003-3451-3624; Angelucci, Emanuele/0000-0002-6512-6080; Baronciani, Donatella/0000-0001-6087-2431				BRESLOW N, 1974, BIOMETRICS, V30, P89, DOI 10.2307/2529620; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; LUCARELLI G, 1992, BLOOD, V80, P1603; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Muretto P, 1989, Prog Clin Biol Res, V309, P299; NESCI S, 1992, BONE MARROW TRANSPL, V10, P143; OLIVIERI NF, 1990, BLOOD S, V76, pA559; SANTOS GW, 1989, BONE MARROW TRANSPL, V4, P236; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; STORB R, 1991, BLOOD, V78, P1144, DOI 10.1182/blood.V78.4.1144.bloodjournal7841144; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; THOMAS ED, 1975, NEW ENGL J MED, V292, P895, DOI 10.1056/NEJM197504242921706; WEATHERALL D, 1992, BLOOD, V80, P1379	17	192	194	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					840	844		10.1056/NEJM199309163291204	http://dx.doi.org/10.1056/NEJM199309163291204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355742				2022-12-28	WOS:A1993LW55100004
J	BENNER, SA				BENNER, SA			CATALYSIS - DESIGN VERSUS SELECTION	SCIENCE			English	Editorial Material							ENZYMATIC INCORPORATION; BASE PAIR; RNA; DNA				BENNER, SA (corresponding author), SWISS FED INST TECHNOL,ORGAN CHEM LAB,CH-8092 ZURICH,SWITZERLAND.							ALLENMANN RK, 1989, THESIS EIDGENOSSISCH; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; CAMPBELL AP, IN PRESS P NATL ACAD; CHAKRAVARTY PK, 1973, EXPERIENTIA, V29, P786, DOI 10.1007/BF01946284; GILBERT W, 1986, NATURE, V319, P818; GUTTE B, 1979, NATURE, V281, P650, DOI 10.1038/281650a0; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10172, DOI 10.1021/bi00496a004; JOHNSSON K, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P166; JOHNSSON K, 1992, THESIS EIDGENOSSISCH; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LIOTTA LJ, 1993, J AM CHEM SOC, V115, P350, DOI 10.1021/ja00054a053; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; PICCIRILLI JA, 1990, NATURE, V343, P33, DOI 10.1038/343033a0; Rich A., 1962, HORIZONS BIOCH, P103; SWITZER C, 1989, J AM CHEM SOC, V111, P8322, DOI 10.1021/ja00203a067; VISSER CM, 1978, J MOL EVOL, V11, P171, DOI 10.1007/BF01733892; VONKIEDROWSKI G, 1992, NACHR CHEM TECH LAB, V40, P578; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468	21	10	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 10	1993	261	5127					1402	1403		10.1126/science.8367723	http://dx.doi.org/10.1126/science.8367723			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW549	8367723				2022-12-28	WOS:A1993LW54900021
J	PATEL, KJ; NEUBERGER, MS				PATEL, KJ; NEUBERGER, MS			ANTIGEN PRESENTATION BY THE B-CELL ANTIGEN RECEPTOR IS DRIVEN BY THE ALPHA-BETA SHEATH AND OCCURS INDEPENDENTLY OF ITS CYTOPLASMIC TYROSINES	CELL			English	Article							LYMPHOCYTES-B; IMMUNOGLOBULIN-M; CROSS-LINKING; T-CELLS; ENDOCYTOSIS; SURFACE; TRANSMEMBRANE; RECOGNITION; COMPLEX; IGM	Membrane immunoglobulin functions to internalize bound antigen for its subsequent processing and presentation to T cells. Although the five immunoglobulin isotypes exhibit considerable differences in their cytoplasmic domains, we show by use of matched B lymphoma transfectants that all isotypes manifest a similar high efficacy in antigen presentation. Experiments using mutant receptors reveal that this efficacy can be ascribed to the alpha/beta sheath of the receptor, where presentation correlates with internalization of polyvalent antigen. Efficient presentation is restored to a sheathless antigen receptor by providing it with only the cytoplasmic domain of the beta sheath polypeptide. This restoration of activity does not depend on the tyrosine residues in the beta cytoplasmic tail, implying that antigen receptor-mediated presentation can occur by a pathway distinct from that used by the Fc receptor FcgammaRIII.			PATEL, KJ (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.							AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; CASTEN LA, 1988, J IMMUNOL, V140, P404; CHEN WJ, 1990, J BIOL CHEM, V266, P5682; CHESNUT RW, 1981, J IMMUNOL, V126, P1075; DAVIDSON HW, 1990, J IMMUNOL, V144, P4101; DUBOIS PM, 1992, EUR J IMMUNOL, V22, P851, DOI 10.1002/eji.1830220333; GAY D, 1986, J IMMUNOL, V136, P2026; GOLD MR, 1991, P NATL ACAD SCI USA, V88, P3436, DOI 10.1073/pnas.88.8.3436; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KIM KJ, 1979, J IMMUNOL, V122, P549; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LANZAVEECHIA A, 1985, NATURE, V314, P538; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; LEVINE TP, 1991, CRIT REV BIOCHEM MOL, V26, P439, DOI 10.3109/10409239109086790; METEZEAU P, 1984, EMBO J, V3, P2235, DOI 10.1002/j.1460-2075.1984.tb02121.x; MOLLER G, 1993, IMMUNOL REV, V132; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; NEUBERGER MS, 1993, IMMUNOL REV, V132, P147, DOI 10.1111/j.1600-065X.1993.tb00841.x; NIEBLING WL, 1993, J IMMUNOL, V150, P2687; PARIKH VS, 1992, J EXP MED, V176, P1025, DOI 10.1084/jem.176.4.1025; PEAKER CJG, 1993, EUR J IMMUNOL, V23, P1359; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102; SHAW AC, 1990, CELL, V63, P381, DOI 10.1016/0092-8674(90)90171-A; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; SNIDER DP, 1989, J IMMUNOL, V143, P59; TISCH R, 1987, P NATL ACAD SCI USA, V84, P3831, DOI 10.1073/pnas.84.11.3831; TONY HP, 1985, J EXP MED, V161, P223, DOI 10.1084/jem.161.1.223; TONY HP, 1986, J EXP MED, V162, P1695; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; WILLIAMS GT, 1990, J EXP MED, V171, P947, DOI 10.1084/jem.171.3.947	37	93	93	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					939	946		10.1016/0092-8674(93)90473-4	http://dx.doi.org/10.1016/0092-8674(93)90473-4			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374958				2022-12-28	WOS:A1993LX29200019
J	WANG, H; KUNKEL, DD; MARTIN, TM; SCHWARTZKROIN, PA; TEMPEL, BL				WANG, H; KUNKEL, DD; MARTIN, TM; SCHWARTZKROIN, PA; TEMPEL, BL			HETEROMULTIMERIC K+ CHANNELS IN TERMINAL AND JUXTAPARANODAL REGIONS OF NEURONS	NATURE			English	Article							POTASSIUM-CHANNEL; SODIUM-CHANNELS; ION CHANNELS; FIBERS; SHAKER; BRAIN	VOLTAGE-GATED potassium (K+) channels display a wide variety of conductances and gating properties in vivo1-3. This diversity can be attributed not only to the presence of many K+-channel gene products, but also to the possibility that different K+-channel subunits co-assemble to form heteromultimeric channels in vivo. When expressed in Xenopus oocytes or transfected cells, K+-channel polypeptides assemble to form tetramers4. Certain combinations of Shaker-like subunits have been shown to co-assemble, forming heteromultimeric channels with distinct properties5-7. It is not known, however, whether K+-channel polypeptides form heteromultimeric channels in vivo. Here we describe the co-localization of two Shaker-like voltage-gated K+-channel proteins, mKv1.1 and mKv1.2, in the juxtaparanodal regions of nodes of Ranvier in myelinated axons, and in terminal fields of basket cells in mouse cerebellum. We also show that mKv1.1 and mKv1.2 can be co-immunoprecipitated with specific antibodies that recognize only one of them. These data indicate that the two polypeptides occur in subcellular regions where rapid membrane repolarization may be important and that they form heteromultimeric channels in vivo.	VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN 182-B,SEATTLE,WA 98108; UNIV WASHINGTON,SCH MED,DEPT MED & PHARMACOL SJ30,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT NEUROL SURG & PHYSIOL BIOPHYS RI20,SEATTLE,WA 98195	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle								Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLACK JA, 1989, GLIA, V2, P353, DOI 10.1002/glia.440020508; BOSMA MM, 1993, NEUR ABSTR, V19, P712; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; HARLOW E, 1988, ANTIBODIES LABORATOR; Hille B., 1991, IONIC CHANNELS EXCIT; HOPKINS WF, IN PRESS J NEUROSCI; HOPKINS WF, 1993, NEUR ABSTR, V19, P707; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; JAN LY, 1989, CELL, V56, P13, DOI 10.1016/0092-8674(89)90979-3; JOE EH, 1992, NATURE, V356, P333, DOI 10.1038/356333a0; KUNKEL DD, 1993, MICROSC RES TECHNIQ, V24, P67, DOI 10.1002/jemt.1070240107; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; OERTEL WH, 1981, NEUROSCIENCE, V6, P2715, DOI 10.1016/0306-4522(81)90115-9; Palay S. L., 1974, CEREBELLAR CORTEX CY; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; ROPER J, 1989, J PHYSIOL-LONDON, V416, P93; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SAFRONOV BV, 1993, J PHYSIOL-LONDON, V460, P675, DOI 10.1113/jphysiol.1993.sp019493; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TEMPEL BL, 1988, NATURE, V332, P837, DOI 10.1038/332837a0; WILSON GF, 1990, J NEUROSCI, V10, P3263	27	529	532	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					75	79		10.1038/365075a0	http://dx.doi.org/10.1038/365075a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361541				2022-12-28	WOS:A1993LV64600058
J	GILFILLAN, S; DIERICH, A; LEMEUR, M; BENOIST, C; MATHIS, D				GILFILLAN, S; DIERICH, A; LEMEUR, M; BENOIST, C; MATHIS, D			MICE LACKING TDT - MATURE ANIMALS WITH AN IMMATURE LYMPHOCYTE REPERTOIRE	SCIENCE			English	Article							T-CELL RECEPTOR; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; N-REGION DIVERSITY; PRE-B-CELLS; JUNCTIONAL DIVERSITY; SEQUENCE HOMOLOGIES; ANTIGEN RECEPTORS; CHAIN DIVERSITY; EXPRESSION; THYMUS	In adult animals, template-independent (or N) nucleotides are frequently added during the rearrangement of variable (V), diversity (D), and joining (J) segments of lymphocyte receptor genes, greatly enhancing junctional diversity. Receptor genes from adult mice carrying a mutation in the terminal deoxynucleotidyl transferase (TdT) gene have few N nucleotides, providing proof that this enzyme is essential for creating diversity. Unlike those from normal adults, receptor genes from adult mutant mice show extensive evidence of homology-directed recombination, suggesting that TdT blocks this process. Thus, switch-on of the TdT gene during the first week after birth provokes an even greater expansion of lymphocyte receptor diversity than had previously been thought.	INST CHIM BIOL,INSERM,U184,UNITE BIOL MOLEC,F-67085 STRASBOURG,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	GILFILLAN, S (corresponding author), INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES LAB,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE.							AGUILAR LK, 1991, J IMMUNOL, V146, P1348; ASARNOW DM, 1993, NATURE, V362, P158, DOI 10.1038/362158a0; ASARNOW DM, 1989, NATURE, V341, P60, DOI 10.1038/341060a0; BENOIST C, 1992, CURR OPIN IMMUNOL, V4, P2; BOGUE M, 1992, P NATL ACAD SCI USA, V89, P11011, DOI 10.1073/pnas.89.22.11011; BOGUE M, 1991, EMBO J, V10, P3647, DOI 10.1002/j.1460-2075.1991.tb04931.x; Bollum F.J., 1974, ENZYMES, P145; CANDEIAS S, 1991, J EXP MED, V174, P989, DOI 10.1084/jem.174.5.989; CARLSSON L, 1990, INT IMMUNOL, V2, P639, DOI 10.1093/intimm/2.7.639; CARLSSON L, 1992, INT IMMUNOL, V4, P549, DOI 10.1093/intimm/4.5.549; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; ELLIOTT JF, 1988, NATURE, V331, P627; FARRAR YJK, 1991, BIOCHEMISTRY-US, V30, P3075, DOI 10.1021/bi00226a014; FEENEY AJ, 1991, J EXP MED, V174, P115, DOI 10.1084/jem.174.1.115; FEENEY AJ, 1991, J IMMUNOL, V147, P4343; FEENEY AJ, 1992, J IMMUNOL, V149, P222; FEENEY AJ, 1990, J EXP MED, V172, P1377, DOI 10.1084/jem.172.5.1377; GEORGE JF, 1992, J IMMUNOL, V148, P1230; GILFILLAN S, UNPUB; GU H, 1990, EMBO J, V9, P2133, DOI 10.1002/j.1460-2075.1990.tb07382.x; ICHIHARA Y, 1989, EUR J IMMUNOL, V19, P1849, DOI 10.1002/eji.1830191014; ITOHARA S, 1990, P NATL ACAD SCI USA, V87, P7935, DOI 10.1073/pnas.87.20.7935; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KALLENBACH S, 1992, P NATL ACAD SCI USA, V89, P2799, DOI 10.1073/pnas.89.7.2799; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; LAFAILLE JJ, 1990, IMMUNOL TODAY, V11, P75, DOI 10.1016/0167-5699(90)90030-D; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDAU NR, 1987, MOL CELL BIOL, V7, P3237, DOI 10.1128/MCB.7.9.3237; LIEBER MR, 1992, CELL, V70, P873, DOI 10.1016/0092-8674(92)90237-7; MCCORMACK WT, 1991, P NATL ACAD SCI USA, V88, P7699, DOI 10.1073/pnas.88.17.7699; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SCHLEUSSNER C, 1992, THYMUS, V20, P195; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	37	350	354	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1175	1178		10.1126/science.8356452	http://dx.doi.org/10.1126/science.8356452			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356452				2022-12-28	WOS:A1993LU58600034
J	WHITFIELD, LS; LOVELLBADGE, R; GOODFELLOW, PN				WHITFIELD, LS; LOVELLBADGE, R; GOODFELLOW, PN			RAPID-SEQUENCE EVOLUTION OF THE MAMMALIAN SEX-DETERMINING GENE SRY	NATURE			English	Article							Y-CHROMOSOME; NUCLEOTIDE SUBSTITUTION; DETERMINING REGION; DNA; SELECTION; PROTEIN; ZFY	IN mammals, induction of male sex determination requires the Y-chromosome gene SRY1. SRY encodes a protein with a central 'high mobility group' domain (HMG box) of about 78 amino acids1-3 . HMG boxes are found in a wide variety of proteins that bind to DNA with high affinity but differing degrees of sequence specificity4. The human SRY protein binds to linear DNA with sequence specificity5 and to cruciform DNA structures without sequence specificity6. The DNA-binding activity of the SRY protein resides in the HMG box and mutations in this region are associated with sex reversal in XY females6-8. No function has been ascribed to the portions of the SRY protein outside the HMG box. SRY belongs to a family of genes that are related by sequence homology within the DNA-binding domain: the genes most similar to SRY (>60%) have been named SOX genes (SRY box genes). None of the known SOX genes is homologous to SRY outside the HMG-box region. Although SRY is an important developmental regulator, its sequence is poorly conserved between species apart from the HMG-box domain. Here we investigate the coding sequence of SR Y in primates and find that evolution has been rapid in the regions flanking the conserved domain. The high degree of sequence divergence and the frequency of non-synonymous mutations suggest either that the majority of the coding sequence has no functional significance or that directional selection has occurred.	NATL INST MED RES, MRC, EUKARYOT MOLEC GENET LAB, LONDON NW7 1AA, ENGLAND	MRC National Institute for Medical Research	WHITFIELD, LS (corresponding author), UNIV CAMBRIDGE, DEPT GENET, DOWNING ST, CAMBRIDGE CB2 2EH, ENGLAND.			Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; ELLIS N, 1990, NATURE, V344, P663, DOI 10.1038/344663a0; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1991, GENETICS, V127, P345; HUGHES AL, 1990, MOL BIOL EVOL, V7, P515; JAGER RJ, 1990, NATURE, V348, P452, DOI 10.1038/348452a0; JOHNS MB, 1989, ANAL BIOCHEM, V180, P276, DOI 10.1016/0003-2697(89)90430-2; KOOPMAN P, 1989, NATURE, V342, P940, DOI 10.1038/342940a0; LI WH, 1985, MOL BIOL EVOL, V2, P150; MALASPINA P, 1990, ANN HUM GENET, V54, P297, DOI 10.1111/j.1469-1809.1990.tb00385.x; NER S S, 1992, Current Biology, V2, P208, DOI 10.1016/0960-9822(92)90541-H; PALMER MS, 1990, P NATL ACAD SCI USA, V87, P1681, DOI 10.1073/pnas.87.5.1681; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SU H, 1993, AM J HUM GENET, V52, P24; 1991, GCG PROGRAM MANUAL G	22	338	371	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					713	715		10.1038/364713a0	http://dx.doi.org/10.1038/364713a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355783				2022-12-28	WOS:A1993LT67700056
J	BARNARD, MA; MCKEGANEY, NP; LEYLAND, AH				BARNARD, MA; MCKEGANEY, NP; LEYLAND, AH			RISK BEHAVIORS AMONG MALE CLIENTS OF FEMALE PROSTITUTES	BRITISH MEDICAL JOURNAL			English	Article											BARNARD, MA (corresponding author), UNIV GLASGOW,PUBL HLTH RES UNIT,GLASGOW G12 8RZ,SCOTLAND.		Leyland, Alastair/C-6069-2011	Leyland, Alastair/0000-0003-3741-7099				DAY S, 1988, BRIT MED J, V297, P1585, DOI 10.1136/bmj.297.6663.1585; LEONARD TL, 1989, AM J PUBLIC HEALTH, V79, P903, DOI 10.2105/AJPH.79.7.903; MCKEGANEY N, 1992, BMJ-BRIT MED J, V305, P801, DOI 10.1136/bmj.305.6857.801; McKeganey NP., 1992, AIDS DRUGS SEXUAL RI	4	34	34	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					361	362		10.1136/bmj.307.6900.361	http://dx.doi.org/10.1136/bmj.307.6900.361			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR768	8374419	Green Published, Bronze			2022-12-28	WOS:A1993LR76800020
J	DAVIDSON, JAH; HOSIE, HE				DAVIDSON, JAH; HOSIE, HE			LESSON OF THE WEEK - LIMITATIONS OF PULSE OXIMETRY - RESPIRATORY INSUFFICIENCY - A FAILURE OF DETECTION	BRITISH MEDICAL JOURNAL			English	Article									VICTORIA INFIRM,DEPT ANAESTHESIA,GLASGOW G41 9TY,SCOTLAND									BROWN EB, 1952, AM J PHYSIOL, V169, P56, DOI 10.1152/ajplegacy.1952.169.1.56; Severinghaus J W, 1986, J Clin Monit, V2, P270, DOI 10.1007/BF02851177	2	47	50	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					372	373		10.1136/bmj.307.6900.372	http://dx.doi.org/10.1136/bmj.307.6900.372			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374423	Bronze, Green Published			2022-12-28	WOS:A1993LR76800026
J	KLEIN, R				KLEIN, R			RATIONING IN ACTION - DIMENSIONS OF RATIONING - WHO SHOULD DO WHAT	BRITISH MEDICAL JOURNAL			English	Article								Priority setting is a complex interaction of multiple decisions at various levels in the organisation and constrained by history. There is no self evident set of ethical principles or analytical tools to determine what decisions we should take at various levels, nor is there an obvious or easy way to resolve the clash of claims on resources. To make priority setting more ''rational'' we should concentrate on the processes and structure of decision making and the relation of macro and micro decisions. The debate should promote reasoned, informed, and open argument, draw on a variety of perspectives, and involve a plurality of interests. The aim must be to build up, over time, the capacity to engage in continuous, collective argument.			KLEIN, R (corresponding author), UNIV BATH,CTR ANAL SOCIAL POLICY,BATH BA2 7AY,AVON,ENGLAND.							Beiner Ronald, 1983, POLITICAL JUDGMENT; Cooper M. H., 1975, RATIONING HLTH CARE; DUNNING AJ, 1992, REPORT GOVT COMMITTE; GROVES T, 1993, BRIT MED J, V306, P673; Ham C, 1988, HLTH CARE VARIATIONS; HUNTER D, 1993, RATIONING DILEMMAS H; KLEIN R, 1992, PATTERNS PRIORITIES; Parker R., 1975, SOCIAL WELFARE MODER, P204; 1992, REFORM HLTH CARE	9	63	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					309	311		10.1136/bmj.307.6899.309	http://dx.doi.org/10.1136/bmj.307.6899.309			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374382	Green Published, Bronze			2022-12-28	WOS:A1993LQ51600026
J	THOMSON, JA; LINCOLN, PJ; MORTIMER, P				THOMSON, JA; LINCOLN, PJ; MORTIMER, P			PATERNITY BY A SEEMINGLY INFERTILE VASECTOMIZED MAN	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON LONDON HOSP,COLL MED,DEPT HAEMATOL,LONDON E1 2AD,ENGLAND; CROYDEN COMMUNITY SERV,FAMILY PLANNING SERV,CROYDON,SURREY,ENGLAND	University of London; University College London								ALDERMAN PM, 1988, JAMA-J AM MED ASSOC, V259, P3142, DOI 10.1001/jama.259.21.3142; EDWARDS IS, 1979, BRIT MED J, V1, P87, DOI 10.1136/bmj.1.6156.87-a; PHILP T, 1984, BRIT MED J, V289, P77, DOI 10.1136/bmj.289.6437.77; PHILP T, 1984, BRIT J UROL, V56, P745, DOI 10.1111/j.1464-410X.1984.tb06161.x; SCHMIDT SS, 1988, JAMA-J AM MED ASSOC, V259, P3176, DOI 10.1001/jama.259.21.3176	5	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					299	300		10.1136/bmj.307.6899.299	http://dx.doi.org/10.1136/bmj.307.6899.299			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374377	Bronze, Green Published			2022-12-28	WOS:A1993LQ51600019
J	TEMPLETON, SF; CAUGHMAN, SW				TEMPLETON, SF; CAUGHMAN, SW			IMAGES IN CLINICAL MEDICINE - NECROBIOSIS LIPOIDICA DIABETICORUM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											TEMPLETON, SF (corresponding author), EMORY UNIV,SCH MED,DEPT DERMATOL,ATLANTA,GA 30322, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					320	320						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8355766				2022-12-28	WOS:A1993LN62100005
J	VERITY, CM; ROSS, EM; GOLDING, J				VERITY, CM; ROSS, EM; GOLDING, J			OUTCOME OF CHILDHOOD STATUS EPILEPTICUS AND LENGTHY FEBRILE CONVULSIONS - FINDINGS OF NATIONAL COHORT STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILDREN; SEIZURES; MORTALITY; EPILEPSY; BIRTH; LIFE	Objective-To study outcome after lengthy febrile convulsions and status epilepticus in children. Design-Population based birth cohort study. Setting-The child health and education study (16 004 neonatal survivors born in one week in April 1970). Subjects-Information available for 14 676 children. Outcome measures-Clinical information and tests of intellectual performance at five and 10 years after birth. Results-19 children had lengthy febrile convulsions and 18 had status epilepticus. Two children with status epilepticus died (one at 5 years old); neither death was directly due to the status epilepticus. Four of the 19 (21%) developed afebrile seizures after lengthy febrile convulsions compared with 14 of the 17 (82%) survivors after status epilepticus. Measures of intellectual performance were available for 33 of the 35 survivors: 23 were normal and 10 were not normal but eight of them had preceding developmental delay or neurological abnormality. Conclusion-The outcome in children after lengthy febrile convulsions and status epilepticus is better than reported from studies of selected groups and seems determined more by the underlying cause than by the seizures themselves.	UNIV LONDON KINGS COLL HOSP, DEPT COMMUNITY PAEDIAT, LONDON SE5 8RX, ENGLAND; UNIV BRISTOL, INST CHILD HLTH, DEPT PAEDIAT & PERINATAL EPIDEMIOL, BRISTOL BS8 1TH, AVON, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of Bristol	VERITY, CM (corresponding author), ADDENBROOKES HOSP, DEPT PAEDIAT, CAMBRIDGE CB2 2QQ, ENGLAND.			Golding, Jean/0000-0003-2826-3307				AICARDI J, 1971, DEV MED CHILD NEUROL, V13, P660; AICARDI J, 1970, EPILEPSIA, V11, P187, DOI 10.1111/j.1528-1157.1970.tb03880.x; Aicardi J, 1983, Adv Neurol, V34, P115; [Anonymous], 1981, Epilepsia, V22, P489; CHAMBERLAIN R, 1975, BRIT BIRTHS 1970, V1; Corsellis J A, 1983, Adv Neurol, V34, P129; DUNN DW, 1988, J CHILD NEUROL, V3, P167, DOI 10.1177/088307388800300303; ELLENBERG JH, 1986, NEW ENGL J MED, V314, P1085, DOI 10.1056/NEJM198604243141705; ELLENBERG JH, 1978, ARCH NEUROL-CHICAGO, V35, P17, DOI 10.1001/archneur.1978.00500250021004; FALCONER MA, 1964, ARCH NEUROL-CHICAGO, V10, P233, DOI 10.1001/archneur.1964.00460150003001; FOWLER M, 1957, ARCH DIS CHILD, V32, P67, DOI 10.1136/adc.32.162.67; FREEMAN JM, 1989, PEDIATRICS, V83, P444; HAUSER WA, 1990, NEUROLOGY, V40, P9; LEPPIK IE, 1990, NEUROLOGY, V40, P4; LOTHMAN E, 1990, NEUROLOGY, V40, P13; MAYTAL J, 1989, PEDIATRICS, V83, P323; MAYTAL J, 1990, PEDIATRICS, V86, P611; NELSON KB, 1978, PEDIATRICS, V61, P720; OXBURY JM, 1971, BRAIN, V94, P733, DOI 10.1093/brain/94.4.733; PHILLIPS SA, 1989, ARCH NEUROL-CHICAGO, V46, P74, DOI 10.1001/archneur.1989.00520370076023; SOFFER D, 1986, ANN NEUROL, V20, P737, DOI 10.1002/ana.410200616; VERITY CM, 1985, BRIT MED J, V290, P1307, DOI 10.1136/bmj.290.6478.1307; VERITY CM, 1985, BMJ-BRIT MED J, V290, P1311, DOI 10.1136/bmj.290.6478.1311; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373; VERITY CM, 1992, BMJ-BRIT MED J, V305, P857, DOI 10.1136/bmj.305.6858.857; WALLACE SJ, 1979, DEV MED CHILD NEUROL, V21, P28; YAGER JY, 1988, CAN J NEUROL SCI, V15, P402, DOI 10.1017/S0317167100028134; 1987, LANCET, V1, P958; [No title captured]	29	134	135	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1993	307	6898					225	228		10.1136/bmj.307.6898.225	http://dx.doi.org/10.1136/bmj.307.6898.225			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369681	Bronze, Green Published			2022-12-28	WOS:A1993LP31400019
J	RUEL, L; BOUROUIS, M; HEITZLER, P; PANTESCO, V; SIMPSON, P				RUEL, L; BOUROUIS, M; HEITZLER, P; PANTESCO, V; SIMPSON, P			DROSOPHILA SHAGGY KINASE AND RAT GLYCOGEN-SYNTHASE KINASE-3 HAVE CONSERVED ACTIVITIES AND ACT DOWNSTREAM OF NOTCH	NATURE			English	Article							PRONEURAL CLUSTERS; GENE; PROTEIN; EXPRESSION; PRODUCT; HOMOLOG; LOCUS; SEQUENCE; REPEATS; CELLS	DURING neurogenesis in Drosophila, groups of equipotential, neurally competent cells choose between epidermal and neural fates1-4. Notch, a phylogenetically conserved transmembrane protein5-9, may act as a receptor4,10 in a lateral signalling pathway in which a single neural precursor is chosen from each group and the neural fate of the other cells is inhibited, causing them to differentiate into epidermis11-13. Possible intracellular trans duction events mediating signals from Notch are, however, unknown. shaggy is also required for the lateral signal4,14 and encodes serine/threonine protein kinases15,16 with homology to the glycogen synthase kinase-3 (GSK-3) enzymes17 that act in signal transduction pathways in vertebrates17. We report here that, in transgenic flies, GSK-3beta can substitute for shaggy, and we also present a study of epistatic relationships between shaggy and gain and loss of function alleles of Notch. The results indicate that shaggy/GSK-3 is part of a signalling pathway downstream of Notch.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,F-67085 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg								BOUROUIS M, 1989, NATURE, V341, P442, DOI 10.1038/341442a0; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CAMPOSORTEGA J, IN PRESS DEV DROSOPH; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DOE CQ, 1985, DEV BIOL, V111, P206, DOI 10.1016/0012-1606(85)90446-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; GHYSEN A, 1988, GENE DEV, V2, P495, DOI 10.1101/gad.2.5.495; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HEITZLER P, IN PRESS DEVELOPMENT; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; RUEL L, IN PRESS EMBO J; SAKSELA K, 1992, ONCOGENE, V7, P347; SEKATH JB, 1992, DEVELOPMENT, V114, P939; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIMPSON P, 1990, DEVELOPMENT, V110, P927; SIMPSON P, 1989, DEVELOPMENT, V106, P57; STERN CURT, 1954, AMER SCI, V42, P213; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; Wigglesworth VB, 1940, J EXP BIOL, V17, P180; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; WOODGETT JR, 1991, TRENDS BIOCHEM SCI, V16, P177, DOI 10.1016/0968-0004(91)90071-3	28	186	188	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 8	1993	362	6420					557	560		10.1038/362557a0	http://dx.doi.org/10.1038/362557a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KW453	8385271				2022-12-28	WOS:A1993KW45300059
J	BAINTON, RJ; KUBO, KM; FENG, JN; CRAIG, NL				BAINTON, RJ; KUBO, KM; FENG, JN; CRAIG, NL			TN7 TRANSPOSITION - TARGET DNA RECOGNITION IS MEDIATED BY MULTIPLE TN7-ENCODED PROTEINS IN A PURIFIED INVITRO SYSTEM	CELL			English	Article							MU-B-PROTEIN; ESCHERICHIA-COLI; STRAND-TRANSFER; GEL-ELECTROPHORESIS; A-PROTEIN; SEQUENCE; ENDS; PURIFICATION; IMMUNITY; CLEAVAGE	We have reconstituted the transposition of the bacterial transposon Tn7 into its specific insertion site attTn7 with four purified Tn7-encoded proteins, TnsA+TnsB+ TnsC+TnsD, and ATP. TnsA+TnsB+TnsC form a ''core'' recombination machine that recognizes the transposon ends and executes DNA breakage and joining; TnsD specifically recognizes attTn7. TnsA+TnsB+TnsC are specifically targeted to attTn7 through the TnsD-dependent interaction of TnsC, a nonspecific DNA-binding protein, with attTn7. Recombination appears to be activated by the assembly of a nucleoprotein complex containing the DNA substrates and Tns proteins. We suggest that TnsC plays a central role in communication between the transposon and the target DNA, particularly in directing insertion away from DNAs already containing a copy of Tn7.	JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MOLEC BIOL & GENET, BALTIMORE, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	BAINTON, RJ (corresponding author), UNIV CALIF SAN FRANCISCO, GEORGE W HOOPER FDN, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.							ADZUMA K, 1989, CELL, V57, P41, DOI 10.1016/0092-8674(89)90170-0; ADZUMA K, 1988, CELL, V53, P257, DOI 10.1016/0092-8674(88)90387-X; ANDREWS BJ, 1987, J MOL BIOL, V193, P345, DOI 10.1016/0022-2836(87)90223-3; ARCISZEWSKA LK, 1991, J BIOL CHEM, V266, P21736; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BARTH PT, 1976, J BACTERIOL, V125, P800, DOI 10.1128/JB.125.3.800-810.1976; Berg DE, 1989, MOBILE DNA; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; CRAIG NL, 1989, MOBILE DNA, P211; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; ECHOLS H, 1990, J BIOL CHEM, V265, P14697; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN DI, 1988, CELL, V55, P545, DOI 10.1016/0092-8674(88)90213-9; GAMAS P, 1992, NUCLEIC ACIDS RES, V20, P2525, DOI 10.1093/nar/20.10.2525; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GAY NJ, 1986, BIOCHEM J, V234, P111, DOI 10.1042/bj2340111; GHRAYEB J, 1984, EMBO J, V3, P2437, DOI 10.1002/j.1460-2075.1984.tb02151.x; GRINGAUZ E, 1988, J BACTERIOL, V170, P2832, DOI 10.1128/jb.170.6.2832-2840.1988; HAUER B, 1984, MOL GEN GENET, V194, P149, DOI 10.1007/BF00383510; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; KUBO KM, 1990, J BACTERIOL, V172, P2774, DOI 10.1128/jb.172.5.2774-2778.1990; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CH, 1983, P NATL ACAD SCI-BIOL, V80, P6765, DOI 10.1073/pnas.80.22.6765; LICHTENSTEIN C, 1982, NATURE, V297, P601, DOI 10.1038/297601a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKOWN RL, 1988, J BACTERIOL, V170, P352, DOI 10.1128/jb.170.1.352-358.1988; MCKOWN RL, 1987, P NATL ACAD SCI USA, V84, P7807, DOI 10.1073/pnas.84.22.7807; ORLE KA, 1991, GENE, V104, P125, DOI 10.1016/0378-1119(91)90478-T; QADRI MI, 1989, J MOL BIOL, V207, P85, DOI 10.1016/0022-2836(89)90442-7; ROBINSON MK, 1977, J BACTERIOL, V129, P407, DOI 10.1128/JB.129.1.407-414.1977; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; SHAND RF, 1991, BIOCHEMISTRY-US, V30, P3082, DOI 10.1021/bi00226a015; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; SURETTE MG, 1991, J BIOL CHEM, V266, P17306; TANG Y, 1991, NUCLEIC ACIDS RES, V19, P3395, DOI 10.1093/nar/19.12.3395; WADDELL CS, 1989, P NATL ACAD SCI USA, V86, P3958, DOI 10.1073/pnas.86.11.3958; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; WRANA JL, 1989, NUCLEIC ACIDS RES, V17, P10119, DOI 10.1093/nar/17.23.10119	45	140	144	1	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					931	943		10.1016/0092-8674(93)90581-A	http://dx.doi.org/10.1016/0092-8674(93)90581-A			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8384534				2022-12-28	WOS:A1993KU17500013
J	ELIOT, LS; KANDEL, ER; SIEGELBAUM, SA; BLUMENFELD, H				ELIOT, LS; KANDEL, ER; SIEGELBAUM, SA; BLUMENFELD, H			IMAGING TERMINALS OF APLYSIA SENSORY NEURONS DEMONSTRATES ROLE OF ENHANCED CA2+ INFLUX IN PRESYNAPTIC FACILITATION	NATURE			English	Article							LONG-TERM POTENTIATION; GILL-WITHDRAWAL REFLEX; BEHAVIORAL SENSITIZATION; TRANSMITTER RELEASE; SYNAPTIC TRANSMISSION; CALCIUM; MODULATION; MECHANISM; SEROTONIN; CHANNELS	MODULATION of transmitter release underlies several forms of learning-related synaptic plasticity, including presynaptic facilitation and long-term potentiation1-4. Although the presynaptic terminals of most neurons are not accessible for direct study, it has often been possible to correlate changes in calcium influx in the cell body, owing to modulation of K+ or Ca2+ channels, with changes in release5-7. Some forms of presynaptic plasticity, however, do not involve changes in Ca2+ influx8-12. Moreover, the presence of multiple types of K+ and Ca2+ channels with different subcellular distributions makes the direct measurement of Ca2+ influx into presynaptic terminals essential. Using synapses reconstituted in culture between Aplysia sensory and motor neurons13, we have imaged Ca2+ influx in presynaptic terminal regions in response to action potentials, and demonstrate that presynaptic facilitation produced by 5-hydroxytryptamine involves enhanced Ca2+ influx through dihydropyridine (DHP)-insensitive Ca2+ channels14 present near release sites. This increased influx is attributable to spike broadening and is significantly correlated with the magnitude of presynaptic facilitation. By contrast, DHP-sensitive channels appear to aid the recovery from depression due to high-frequency stimulation.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROL & BEHAV,722 W 168TH ST,NEW YORK,NY 10032; HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute								BAXTER DA, 1989, J NEUROPHYSIOL, V62, P665, DOI 10.1152/jn.1989.62.3.665; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLUMENFELD H, 1990, NEURON, V5, P487, DOI 10.1016/0896-6273(90)90088-W; BLUMENFELD H, 1992, BIOPHYS J, V63, P1146, DOI 10.1016/S0006-3495(92)81670-3; BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; BRAHA O, IN PRESS J NEUROSCI; BYRNE JH, 1982, J NEUROPHYSIOL, V48, P431, DOI 10.1152/jn.1982.48.2.431; CASTELLUCCI V, 1976, SCIENCE, V194, P1176, DOI 10.1126/science.11560; DALE N, 1990, J PHYSIOL-LONDON, V421, P203, DOI 10.1113/jphysiol.1990.sp017941; DELANEY K, 1991, J NEUROSCI, V11, P2631; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; DUNLAP K, 1978, NATURE, V276, P837, DOI 10.1038/276837a0; EDMONDS B, 1990, SCIENCE, V250, P1142, DOI 10.1126/science.2174573; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GINGRICH KJ, 1985, J NEUROPHYSIOL, V53, P652, DOI 10.1152/jn.1985.53.3.652; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWKINS RD, IN PRESS A REV NEURO; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8794, DOI 10.1073/pnas.83.22.8794; HOCHNER B, 1986, P NATL ACAD SCI USA, V83, P8410, DOI 10.1073/pnas.83.21.8410; KLEIN M, 1980, P NATL ACAD SCI-BIOL, V77, P6912, DOI 10.1073/pnas.77.11.6912; LIPSCOMBE D, 1989, NATURE, V340, P639, DOI 10.1038/340639a0; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANSONHING H, 1989, NATURE, V341, P237, DOI 10.1038/341237a0; MERCER AR, 1991, SCIENCE, V254, P1811, DOI 10.1126/science.1662413; NERBONNE JM, 1987, J NEUROSCI, V7, P882; RAYPORT SG, 1986, J NEUROSCI, V6, P759; SIEGELBAUM SA, 1982, NATURE, V299, P413, DOI 10.1038/299413a0; SMITH SJ, 1985, P NATL ACAD SCI USA, V82, P622, DOI 10.1073/pnas.82.2.622	30	65	66	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 18	1993	361	6413					634	637		10.1038/361634a0	http://dx.doi.org/10.1038/361634a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM776	8382344				2022-12-28	WOS:A1993KM77600063
J	ROONEY, JF; STRAUS, SE; MANNIX, ML; WOHLENBERG, CR; ALLING, DW; DUMOIS, JA; NOTKINS, AL				ROONEY, JF; STRAUS, SE; MANNIX, ML; WOHLENBERG, CR; ALLING, DW; DUMOIS, JA; NOTKINS, AL			ORAL ACYCLOVIR TO SUPPRESS FREQUENTLY RECURRENT HERPES LABIALIS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						ACYCLOVIR; HERPES LABIALIS; VIRUS REPLICATION; IMMUNOCOMPETENCE	SIMPLEX VIRUS-INFECTION; GENITAL HERPES; ERYTHEMA MULTIFORME; PREVENTION; REACTIVATION	Objective: To determine whether oral acyclovir reduces the incidence of recurrent herpes labialis in otherwise healthy patients with proven frequently recurrent disease. Design: Randomized, double-blind, placebo-controlled, crossover trial. Setting: Outpatient facility of the Clinical Center, National Institutes of Health, Bethesda, Maryland. Patients: Fifty-six otherwise healthy adults who reported frequently recurrent herpes labialis (greater-than-or-equal-to 6 episodes/y) were enrolled into the study. During a 4-month observation period, 22 patients had herpes labialis two or more times and were eligible for study treatment. Interventions: Twenty-two patients were randomized to receive either acyclovir, 400 mg twice daily, or matched placebo for 4 months. After the first treatment period, patients were given the alternate treatment for another 4 months and were then taken off study medication to observe the first post-treatment recurrence. Recurrent outbreaks were determined by examination and by viral culture. Results: Twenty patients completed blind treatment with both acyclovir and placebo. The median time to first clinically documented recurrence was 46 days for placebo courses and 118 days for acyclovir courses (P = 0.05). The mean number of recurrences per 4-month treatment period was 1.80 episodes per patient during placebo treatment and 0.85 episodes per patient during acyclovir treatment (P = 0.009). The mean number of virologically confirmed recurrences per patient was 1.40 with placebo therapy compared with 0.40 with acyclovir (P = 0.003). Conclusions: Oral acyclovir, 400 mg twice daily, is effective in suppressing herpes labialis in immunocompetent adults confirmed to have frequently recurrent infection. Treatment with acyclovir in this study resulted in a 53% reduction in the number of clinical recurrences and a 71% reduction in virus culture-positive recurrences compared with placebo therapy.	NIAID, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	ROONEY, JF (corresponding author), NIDR, ORAL MED LAB, BLDG 30, ROOM 121, BETHESDA, MD 20892 USA.							DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; FAWCETT HA, 1983, BRIT MED J, V287, P798, DOI 10.1136/bmj.287.6395.798-a; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.2307/2333825; GEHAN EA, 1965, BIOMETRIKA, V52, P650, DOI 10.1093/biomet/52.3-4.650; GIBSON JR, 1986, DERMATOLOGICA, V172, P104, DOI 10.1159/000249307; GREEN JA, 1985, ANN INTERN MED, V102, P632, DOI 10.7326/0003-4819-102-5-632; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; LEIGH IM, 1988, AM J MED, V85, P34; LEMAK MA, 1986, J AM ACAD DERMATOL, V15, P50, DOI 10.1016/S0190-9622(86)70141-2; OVERALL JC, 1984, ANTIVIR AGENTS VIR, P251; RABORN GW, 1987, J AM DENT ASSOC, V115, P38, DOI 10.14219/jada.archive.1987.0211; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; SARAL R, 1988, AM J MED, V85, P57; SCHADELIN J, 1988, AM J MED, V85, P46; SEALE L, 1985, JAMA-J AM MED ASSOC, V254, P3435, DOI 10.1001/jama.254.24.3435; SIEGEL S, 1956, NONPARAMETRIC STAT, P63; SPRUANCE SL, 1988, JAMA-J AM MED ASSOC, V260, P1597, DOI 10.1001/jama.260.11.1597; SPRUANCE SL, 1991, J INFECT DIS, V163, P728, DOI 10.1093/infdis/163.4.728; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; STRAUS SE, 1988, JAMA-J AM MED ASSOC, V260, P2227, DOI 10.1001/jama.260.15.2227; STRAUS SE, 1984, ANN INTERN MED, V100, P522, DOI 10.7326/0003-4819-100-4-522; THOMAS RHM, 1985, BRIT J DERMATOL, V113, P731, DOI 10.1111/j.1365-2133.1985.tb02409.x; WADE JC, 1984, ANN INTERN MED, V100, P823, DOI 10.7326/0003-4819-100-6-823	23	98	102	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1993	118	4					268	272		10.7326/0003-4819-118-4-199302150-00004	http://dx.doi.org/10.7326/0003-4819-118-4-199302150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL457	8380540				2022-12-28	WOS:A1993KL45700004
J	ROSSAINT, R; FALKE, KJ; LOPEZ, F; SLAMA, K; PISON, U; ZAPOL, WM				ROSSAINT, R; FALKE, KJ; LOPEZ, F; SLAMA, K; PISON, U; ZAPOL, WM			INHALED NITRIC-OXIDE FOR THE ADULT RESPIRATORY-DISTRESS SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SELECTIVE PULMONARY VASODILATOR; CARDIAC-OUTPUT; PERFUSION DISTRIBUTIONS; CAPILLARY-PRESSURE; RELAXING FACTOR; BLOOD-FLOW; HYPERTENSION; NITROPRUSSIDE; VENTILATION; SHEEP	Background. The adult respiratory distress syndrome is characterized by pulmonary hypertension and right-to-left shunting of venous blood. We investigated whether inhaling nitric oxide gas would cause selective vasodilation of ventilated lung regions, thereby reducing pulmonary hypertension and improving gas exchange. Methods. Nine of 10 consecutive patients with severe adult respiratory distress syndrome inhaled nitric oxide in two concentrations for 40 minutes each. Hemodynamic variables, gas exchange, and ventilation-perfusion distributions were measured by means of multiple inert-gas-elimination techniques during nitric oxide inhalation; the results were compared with those obtained during intravenous infusion of prostacyclin. Seven patients were treated with continuous inhalation of nitric oxide in a concentration of 5 to 20 parts per million (ppm) for 3 to 53 days. Results. Inhalation of nitric oxide in a concentration of 18 ppm reduced the mean (+/-SE) pulmonary-artery pressure from 37+/-3 mm Hg to 30+/-2 mm Hg (P = 0.008) and decreased intrapulmonary shunting from 36+/-5 percent to 31+/-5 percent (P = 0.028). The ratio of the partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO2/FiO2), an index of the efficiency of arterial oxygenation, increased during nitric oxide administration from 152+/-15 mm Hg to 199+/-23 mm Hg (P = 0.008), although the mean arterial pressure and cardiac output were unchanged. Infusion of prostacyclin reduced pulmonary-artery pressure but increased intrapulmonary shunting and reduced the PaO2/FiO2 and systemic arterial pressure. Continuous nitric oxide inhalation consistently lowered the pulmonary-artery pressure and augmented the PaO2/FiO2 for 3 to 53 days. Conclusions. Inhalation of nitric oxide by patients with severe adult respiratory distress syndrome reduces the pulmonary-artery pressure and increases arterial oxygenation by improving the matching of ventilation with perfusion, without producing systemic vasodilation. Randomized, blinded trials will be required to determine whether inhaled nitric oxide will improve outcome.	FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW WEDDING,ANAESTHESIOL & OPERAT INTENS MED KLIN,W-1000 BERLIN 65,GERMANY; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT ANAESTHESIA,BOSTON,MA 02114	Free University of Berlin; Harvard University; Harvard Medical School; Massachusetts General Hospital			Pison, Ulrich/AAD-3463-2022	Pison, Ulrich/0000-0003-2880-5532	NHLBI NIH HHS [HL-42397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN SJ, 1987, J APPL PHYSIOL, V63, P1008, DOI 10.1152/jappl.1987.63.3.1008; ASHBAUGH DG, 1967, LANCET, V2, P319; BREEN PH, 1982, J APPL PHYSIOL, V53, P1273, DOI 10.1152/jappl.1982.53.5.1273; BRIGHAM KL, 1974, J CLIN INVEST, V54, P792, DOI 10.1172/JCI107819; CLUTTONBROCK J, 1967, BRIT J ANAESTH, V39, P388, DOI 10.1093/bja/39.5.388; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; ERDMANN AJ, 1975, CIRC RES, V37, P271, DOI 10.1161/01.RES.37.3.271; EVANS JW, 1977, J APPL PHYSIOL, V42, P889, DOI 10.1152/jappl.1977.42.6.889; FALKE K, 1991, American Review of Respiratory Disease, V143, pA248; FRATACCI MD, 1991, ANESTHESIOLOGY, V75, P990, DOI 10.1097/00000542-199112000-00011; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; FROSTELL CG, IN PRESS ANESTHESIOL; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GOTTLIEB SS, 1987, ANESTHESIOLOGY, V67, P203, DOI 10.1097/00000542-198708000-00009; GRUETTER CA, 1979, J CYCLIC NUCL PROT, V5, P211; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; HASCHEK WM, 1983, AM REV RESPIR DIS, V127, P28, DOI 10.1164/arrd.1983.127.1.28; Hays WL, 1988, STATISTICS; HUGOD C, 1979, INT ARCH OCC ENV HEA, V42, P159, DOI 10.1007/BF00377770; IGNARRO LJ, 1989, CIRC RES, V65, P1, DOI 10.1161/01.RES.65.1.1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JANSEN JRC, 1981, J APPL PHYSIOL, V51, P584, DOI 10.1152/jappl.1981.51.3.584; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUMA F, 1981, J BIOL CHEM, V256, P5518; LEWIS FR, 1979, J SURG RES, V27, P250, DOI 10.1016/0022-4804(79)90138-0; LYNCH JP, 1979, J APPL PHYSIOL, V46, P315, DOI 10.1152/jappl.1979.46.2.315; MELOT C, 1989, AM REV RESPIR DIS, V139, P106, DOI 10.1164/ajrccm/139.1.106; MONCADA S, 1991, PHARMACOL REV, V43, P109; MURRAY JF, 1989, AM REV RESPIR DIS, V139, P1065; ODA H, 1976, J JPN SOC AIR POLLUT, V11, P150; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RADERMACHER P, 1990, ANESTHESIOLOGY, V72, P238, DOI 10.1097/00000542-199002000-00005; RADERMACHER P, 1988, ANESTHESIOLOGY, V68, P152, DOI 10.1097/00000542-198801000-00030; RADERMACHER P, 1989, ANESTHESIOLOGY, V70, P601, DOI 10.1097/00000542-198904000-00008; RAPOPORT RM, 1983, CIRC RES, V52, P352, DOI 10.1161/01.RES.52.3.352; RINALDO J, 1982, AM REV RESPIR DIS, V126, P1030; ROSSAINT R, 1992, INT J ARTIF ORGANS, V15, P29, DOI 10.1177/039139889201500106; SANDOVAL J, 1983, J APPL PHYSIOL, V55, P1128, DOI 10.1152/jappl.1983.55.4.1128; SIBBALD WJ, 1983, CHEST, V84, P126, DOI 10.1378/chest.84.2.126; TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112; VLAHAKES GJ, 1981, CIRCULATION, V63, P87, DOI 10.1161/01.CIR.63.1.87; WAGNER PD, 1974, J APPL PHYSIOL, V36, P588, DOI 10.1152/jappl.1974.36.5.588; ZAPOL WM, 1977, NEW ENGL J MED, V296, P476, DOI 10.1056/NEJM197703032960903; ZAPOL WM, 1985, ACUTE RESPIRATORY FA, V24, P241; 1988, MMWR MORB MORTAL SS7, V37, P21	48	1384	1424	1	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1993	328	6					399	405		10.1056/NEJM199302113280605	http://dx.doi.org/10.1056/NEJM199302113280605			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KL584	8357359				2022-12-28	WOS:A1993KL58400005
J	LAMBDEN, PR; CAUL, EO; ASHLEY, CR; CLARKE, IN				LAMBDEN, PR; CAUL, EO; ASHLEY, CR; CLARKE, IN			SEQUENCE AND GENOME ORGANIZATION OF A HUMAN SMALL ROUND-STRUCTURED (NORWALK-LIKE) VIRUS	SCIENCE			English	Article							IMMUNE ELECTRON-MICROSCOPY; INFECTIOUS NONBACTERIAL GASTROENTERITIS; MOLECULAR-CLONING; OUTBREAK; AGENT	Small round-structured viruses (SRSVs), also known as Norwalk or Norwalk-like viruses, are the major worldwide cause of acute, epidemic nonbacterial gastroenteritis in humans. These viruses, which contain a single-stranded RNA genome, have remained refractory to molecular characterization because of the small amounts of virus in clinical samples and the absence of an animal model and an in vitro culture system. The complete genomic nucleotide sequence of an SRSV, Southampton virus, was determined. The 7696-nucleotide RNA genome encodes three open reading frames whose sequence and organization strongly support proposals that SRSVs are members of the Caliciviridae.	REG VIRUS LAB,PUBL HLTH LAB,BRISTOL BS2 8EL,ENGLAND		LAMBDEN, PR (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,SCH MED,DEPT MOLEC MICROBIOL,SOUTHAMPTON S09 4XY,ENGLAND.			Clarke, Ian/0000-0002-4938-1620				BLACKLOW NR, 1972, ANN INTERN MED, V76, P993, DOI 10.7326/0003-4819-76-6-993; CARTER MJ, 1992, VIROLOGY, V190, P443, DOI 10.1016/0042-6822(92)91231-I; CAUL EO, 1982, J MED VIROL, V9, P257, DOI 10.1002/jmv.1890090403; CAUL EO, 1979, LANCET, V2, P1292; CUBITT WD, 1987, CIBA F SYMP, V128, P126; DOLIN R, 1982, J INFECT DIS, V146, P184, DOI 10.1093/infdis/146.2.184; GREENBERG HB, 1981, J VIROL, V37, P994, DOI 10.1128/JVI.37.3.994-999.1981; GREENBERG HB, 1992, INFECT AGENT DIS, V1, P71; Hofmann M A, 1991, PCR Methods Appl, V1, P43; JIANG X, 1990, Science (Washington D C), V250, P1580; KAPIKIAN AZ, 1972, J VIROL, V10, P1075, DOI 10.1128/JVI.10.5.1075-1081.1972; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LAMBDEN PR, UNPUB; MATSUI SM, 1991, J CLIN INVEST, V87, P1456, DOI 10.1172/JCI115152; MEYERS G, 1991, VIROLOGY, V184, P664, DOI 10.1016/0042-6822(91)90436-F; MORENS DM, 1979, LANCET, V1, P964; OKADA S, 1990, J CLIN MICROBIOL, V28, P1244, DOI 10.1128/JCM.28.6.1244-1248.1990; PETHER JVS, 1983, J HYG-CAMBRIDGE, V91, P343, DOI 10.1017/S0022172400060368; TAM AW, 1991, VIROLOGY, V185, P120, DOI 10.1016/0042-6822(91)90760-9; THORNHILL TS, 1977, J INFECT DIS, V135, P20, DOI 10.1093/infdis/135.1.20; WYATT RG, 1974, J INFECT DIS, V129, P704; Zahorsky J., 1929, ARCH PEDIAT, V46, P391; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	23	300	314	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 22	1993	259	5094					516	519		10.1126/science.8380940	http://dx.doi.org/10.1126/science.8380940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8380940				2022-12-28	WOS:A1993KJ07900035
J	KOCH, C; MOLL, T; NEUBERG, M; AHORN, H; NASMYTH, K				KOCH, C; MOLL, T; NEUBERG, M; AHORN, H; NASMYTH, K			A ROLE FOR THE TRANSCRIPTION FACTORS MBP1 AND SWI4 IN PROGRESSION FROM G1 TO S-PHASE	SCIENCE			English	Article							DNA-SYNTHESIS GENES; CELL-CYCLE CONTROL; YEAST HO GENE; BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; DEPENDENT TRANSCRIPTION; PROTEIN; START	In budding yeast genes that encode G1 cyclins and proteins involved in DNA synthesis are transcriptionally activated in late G1. A transcription factor, called SBF, is composed of Swi4 and Swi6 proteins and activates transcription of G1 cyclin genes. A different, but related, complex called MBF binds to MCB elements (Mlu I cell cycle box) found in the promoter of most DNA synthesis genes. MBF contains Swi6 and a 120-kilodalton protein (p120). MBF was purified and the gene encoding p120 (termed MBP1) was cloned. A deletion of MBP1 was not lethal but led to deregulated expression of DNA synthesis genes, indicating a direct regulatory role for MBF in MCB-driven transcription. Mbp1 is related to Swi4. Strains deleted for both MBP1 and SWI4 were inviable, demonstrating that transcriptional activation by MBF and SBF has an important role in the transition from G1 to S phase.	BENDER & CO,A-1121 VIENNA,AUSTRIA		KOCH, C (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.		Koch, Christian/J-5716-2013; Koch, Christian/W-5731-2019	Koch, Christian/0000-0001-8407-4952; Nasmyth, Kim/0000-0001-7030-4403				AMON A, IN PRESS CELL; ANDREWS BJ, 1989, CELL, V57, P21, DOI 10.1016/0092-8674(89)90168-2; ANDREWS BJ, 1992, P NATL ACAD SCI USA, V89, P11852, DOI 10.1073/pnas.89.24.11852; ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; BORK P, COMMUNICATION; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; BURGLIN T, COMMUNICATION; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DIRICK L, 1991, NATURE, V351, P754, DOI 10.1038/351754a0; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JOHNSTON LH, 1992, NUCLEIC ACIDS RES, V20, P2403, DOI 10.1093/nar/20.10.2403; KOCH C, UNPUB; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MCINTOSH EM, 1991, MOL CELL BIOL, V11, P329, DOI 10.1128/MCB.11.1.329; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MILLER KY, 1992, GENE DEV, V6, P1770, DOI 10.1101/gad.6.9.1770; MOLL T, 1993, PHILOS T ROY SOC B, V340, P351, DOI 10.1098/rstb.1993.0078; NASMYTH K, 1985, CELL, V42, P225, DOI 10.1016/S0092-8674(85)80118-5; NASMYTH K, 1991, CELL, V66, P995, DOI 10.1016/0092-8674(91)90444-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OGAS J, 1991, CELL, V66, P1015, DOI 10.1016/0092-8674(91)90445-5; PRICE C, 1991, J MOL BIOL, V218, P543, DOI 10.1016/0022-2836(91)90700-G; PRIMIG M, 1992, NATURE, V358, P593, DOI 10.1038/358593a0; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; REYMOND A, 1992, MOL GEN GENET, V234, P449, DOI 10.1007/BF00538705; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SIDOROVA J, 1993, MOL CELL BIOL, V13, P1069, DOI 10.1128/MCB.13.2.1069; SORGER PK, 1989, PROTEIN FUNCTION PRA, P199; TABA H, 1991, GENE DEV, V5, P200; TANAKA K, 1992, EMBO J, V11, P4923, DOI 10.1002/j.1460-2075.1992.tb05599.x; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H	42	323	331	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 17	1993	261	5128					1551	1557		10.1126/science.8372350	http://dx.doi.org/10.1126/science.8372350			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX474	8372350				2022-12-28	WOS:A1993LX47400022
J	HALEVY, A; BRODY, B				HALEVY, A; BRODY, B			BRAIN-DEATH - RECONCILING DEFINITIONS, CRITERIA, AND TESTS	ANNALS OF INTERNAL MEDICINE			English	Article							STEM DEATH; CEREBRAL HEMISPHERES; DIABETES-INSIPIDUS; CESSATION; CHILDREN	Brain death has been discussed extensively for the last 25 years. Most investigators now believe that requiring death of the entire brain as the criterion for brain death in the Uniform Determination of Death Act and the standard clinical tests of brain death outlined in the Report of the Medical Consultants to the President's Commission have produced a satisfactory resolution of the issues surrounding the determination of death. However, we show that satisfying the standard medical tests does not guarantee that all brain functions have actually ceased and that there is tension between the legal criterion and the standard clinical tests. After considering and rejecting six possible reconciliations, we present an alternative approach that does not acknowledge any sharp dichotomy between life and death and incorporates the proposition that the questions of when care can be unilaterally discontinued, when organs can be harvested, and when a patient is ready for the services of an undertaker should be answered independent of any single account of death.	BAYLOR COLL MED, CTR ETHICS, HOUSTON, TX 77030 USA	Baylor College of Medicine								AGICH GJ, 1986, PHILOS PUBLIC AFF, V15, P267; ANGELL M, 1991, NEW ENGL J MED, V325, P511, DOI 10.1056/NEJM199108153250712; [Anonymous], 1968, JAMA, V205, P337; ARITA K, 1988, Neurological Surgery, V16, P1163; BARELLI A, 1990, CRIT CARE MED, V18, P322, DOI 10.1097/00003246-199003000-00016; Bernat J L, 1992, J Clin Ethics, V3, P21; BERNAT JL, 1981, ANN INTERN MED, V94, P389, DOI 10.1001/archinte.94.3.389; BERNAT JL, 1992, ARCH NEUROL-CHICAGO, V49, P569, DOI 10.1001/archneur.1992.00530290161027; BLEICH D, 1981, JUDAISM HEALING; BRODY BA, 1989, J MED PHILOS, V14, P369, DOI 10.1093/jmp/14.4.369; DELIYANNAKIS E, 1975, CLIN ELECTROENCEPHAL, V6, P75, DOI 10.1177/155005947500600205; ENGELHARDT HT, 1986, F BIOETHICS; FERBERT A, 1986, ELECTROEN CLIN NEURO, V65, P157, DOI 10.1016/0168-5597(86)90049-3; FISER DH, 1987, CRIT CARE MED, V15, P551, DOI 10.1097/00003246-198706000-00002; GREEN MB, 1980, PHILOS PUBLIC AFF, V9, P105; GRENVIK A, 1978, CRIT CARE MED, V6, P284, DOI 10.1097/00003246-197807000-00009; GRIGG MM, 1987, ARCH NEUROL-CHICAGO, V44, P948, DOI 10.1001/archneur.1987.00520210048018; HOHENEGGER M, 1990, EUR ARCH PSY CLIN N, V239, P267, DOI 10.1007/BF01738582; IVAN LP, 1990, TRANSPL P, V22, P993; KASS LR, 1971, SCIENCE, V173, P698, DOI 10.1126/science.173.3998.698; KIMURA R, 1989, J MED PHILOS, V14, P97, DOI 10.1093/jmp/14.1.97; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MILES SH, 1991, NEW ENGL J MED, V325, P512, DOI 10.1056/NEJM199108153250713; MOLLARET P., 1959, REV NEUROL [PARIS], V101, P3; MORISON RS, 1971, SCIENCE, V173, P694, DOI 10.1126/science.173.3998.694; Novitzky D., 1984, J HEART TRANSPLANT, V4, P63; OUTWATER KM, 1984, NEUROLOGY, V34, P1243, DOI 10.1212/WNL.34.9.1243; PALLIS C, 1983, BRIT MED J, V286, P284, DOI 10.1136/bmj.286.6361.284; RIX BA, 1990, J MED ETHICS, V16, P5, DOI 10.1136/jme.16.1.5; RODIN E, 1985, CLIN ELECTROENCEPHAL, V16, P63, DOI 10.1177/155005948501600202; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHRADER H, 1980, ACTA NEUROCHIR, V52, P239, DOI 10.1007/BF01402079; SMITH DR, 1986, CORNELL LAW REV, V71, P850; TRUOG RD, 1989, NEW ENGL J MED, V321, P388, DOI 10.1056/NEJM198908103210609; United States President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1981, DEFINING DEATH REPOR; Veatch R M, 1992, J Clin Ethics, V3, P181; VEATCH RM, 1975, J THANATOL, V3, P13; YOUNGNER SJ, 1992, ARCH NEUROL-CHICAGO, V49, P570, DOI 10.1001/archneur.1992.00530290162028; YOUNGNER SJ, 1989, JAMA-J AM MED ASSOC, V261, P2205, DOI 10.1001/jama.261.15.2205; YOUNGNER SJ, 1983, ANN INTERN MED, V99, P252, DOI 10.7326/0003-4819-99-2-252; 1991, JAMA-J AM MED ASSOC, V265, P1868; 1989, ASSIA, V1, P2	42	175	179	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					519	525		10.7326/0003-4819-119-6-199309150-00013	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00013			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357120				2022-12-28	WOS:A1993LZ27500013
J	INOUYE, SK; VISCOLI, CM; HORWITZ, RI; HURST, LD; TINETTI, ME				INOUYE, SK; VISCOLI, CM; HORWITZ, RI; HURST, LD; TINETTI, ME			A PREDICTIVE MODEL FOR DELIRIUM IN HOSPITALIZED ELDERLY MEDICAL PATIENTS BASED ON ADMISSION CHARACTERISTICS	ANNALS OF INTERNAL MEDICINE			English	Article						DELIRIUM; VISION DISORDERS; SEVERITY OF ILLNESS INDEX; COGNITION DISORDERS; BLOOD UREA NITROGEN	ACUTE CONFUSIONAL STATES; MINI-MENTAL STATE; COGNITIVE IMPAIRMENT; RISK-FACTORS; DEMENTIA; ILLNESS; INPATIENTS; MORTALITY; CRITERIA; FRACTURE	Objective: To prospectively develop and validate a predictive model for the occurrence of new delirium in hospitalized elderly medical patients based on characteristics present at admission. Design: Two prospective cohort studies done in tandem. Setting: University teaching hospital. Patients: The development cohort included 107 hospitalized general medical patients 70 years or older who did not have dementia or delirium at admission. The validation cohort included 174 comparable patients. Measurements: Patients were assessed daily for delirium using a standardized, validated instrument. The predictive model developed in the initial cohort was then validated in a separate cohort of patients. Results: Delirium developed in 27 of 107 patients (25%) in the development cohort. Four independent baseline risk factors for delirium were identified using proportional hazards analysis: These included vision impairment (adjusted relative risk, 3.5; 95% CI, 1.2 to 10.7); severe illness (relative risk, 3.5; CI, 1.5 to 8.2); cognitive impairment (relative risk, 2.8; CI, 1.2 to 6.7); and a high blood urea nitrogen/creatinine ratio (relative risk, 2.0; CI, 0.9 to 4.6). A risk stratification system was developed by assigning 1 point for each risk factor present. Rates of delirium for low- (0 points), intermediate-(1 to 2 points), and high-risk (3 to 4 points) groups were 9%, 23%, and 83% (P < 0.0001), respectively. The corresponding rates in the validation cohort, in which 29 of 174 patients (17%) developed delirium, were 3%, 16%, and 32% (P < 0.002). The rates of death or nursing home placement, outcomes potentially related to delirium, were 9%, 16%, and 42% (P = 0.02) in the development cohort and 3%, 14%, and 26% (P = 0.007) in the validation cohort. Conclusions: Delirium among elderly hospitalized patients is common, and a simple predictive model based on four risk factors can be used at admission to identify elderly persons at the greatest risk.	YALE UNIV, SCH MED, NEW HAVEN, CT 06510 USA	Yale University			Inouye, Sharon/R-7216-2019		NATIONAL INSTITUTE ON AGING [K08AG000524] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05443] Funding Source: Medline; NIA NIH HHS [1K08AG00524-01] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BECK S, 1981, RANDR226214HHS RAND, V14, P72; BEDFORD PD, 1959, BRIT MED J, V2, P185, DOI 10.1136/bmj.2.5145.185; BERGMANN K, 1974, Age and Ageing, V3, P174, DOI 10.1093/ageing/3.3.174; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P78; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; Brannstrom B, 1991, Scand J Caring Sci, V5, P3; Cameron DE, 1941, PSYCHIAT QUART, V15, P47, DOI 10.1007/BF01613953; CAMERON DJ, 1987, J AM GERIATR SOC, V35, P1007, DOI 10.1111/j.1532-5415.1987.tb04004.x; CAVANAUGH SV, 1983, GEN HOSP PSYCHIAT, V5, P15, DOI 10.1016/0163-8343(83)90038-5; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; Chisholm S E, 1982, J Gerontol Nurs, V8, P87; Cox D. R., 1984, ANAL SURVIVAL DATA; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P343; FEINSTEIN AR, 1987, CLINIMETRICS, P195; FIELDS SD, 1986, J AM GERIATR SOC, V34, P579, DOI 10.1111/j.1532-5415.1986.tb05763.x; FIELDS SD, 1986, ARCH INTERN MED, V146, P1593, DOI 10.1001/archinte.146.8.1593; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FOREMAN MD, 1989, RES NURS HEALTH, V12, P21, DOI 10.1002/nur.4770120105; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; GENT M, 1979, THROMB HAEMOSTASIS, V41, P123; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; GUZE SB, 1964, AM J PSYCHIAT, V120, P878, DOI 10.1176/ajp.120.9.878; GUZE SB, 1967, ARCH GEN PSYCHIAT, V17, P365; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hodkinson H M, 1973, J R Coll Physicians Lond, V7, P305; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; JOHNSON JC, 1990, J GERONTOL, V45, pM113, DOI 10.1093/geronj/45.3.M113; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KAY DWK, 1956, J MENT SCI, V102, P129, DOI 10.1192/bjp.102.426.129; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P283; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LAMONT CT, 1983, J AM GERIATR SOC, V31, P282, DOI 10.1111/j.1532-5415.1983.tb04872.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Levkoff S E, 1986, Annu Rev Gerontol Geriatr, V6, P1; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MAGAZINER J, 1989, AM J PUBLIC HEALTH, V79, P274, DOI 10.2105/AJPH.79.3.274; PURDLE FR, 1981, ANN EMERG MED, V10, P455, DOI 10.1016/S0196-0644(81)80276-4; RABINS PV, 1982, BRIT J PSYCHIAT, V140, P149, DOI 10.1192/bjp.140.2.149; ROCKWOOD K, 1990, J CLIN EPIDEMIOL, V43, P971, DOI 10.1016/0895-4356(90)90080-9; ROCKWOOD K, 1989, J AM GERIATR SOC, V37, P150, DOI 10.1111/j.1532-5415.1989.tb05874.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; ROSIN AJ, 1966, J CHRON DIS, V19, P307, DOI 10.1016/0021-9681(66)90134-2; ROTH M, 1955, J MENT SCI, V101, P281, DOI 10.1192/bjp.101.423.281; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SEEMAN TE, 1988, SOC SCI MED, V26, P737, DOI 10.1016/0277-9536(88)90065-2; SEYMOUR DG, 1980, AGE AGEING, V9, P137, DOI 10.1093/ageing/9.3.137; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; UHLMANN RF, 1987, J GERONTOL, V42, P33, DOI 10.1093/geronj/42.1.33; VENTRY IM, 1982, EAR HEARING, V3, P128, DOI 10.1097/00003446-198205000-00006; WARSHAW GA, 1982, JAMA-J AM MED ASSOC, V248, P847, DOI 10.1001/jama.248.7.847; WEDDINGTON WW, 1982, PSYCHOSOMATICS, V23, P1232; WILLIAMS MA, 1985, RES NURS HEALTH, V8, P31, DOI 10.1002/nur.4770080107; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; 1984, BMDP COMPUTER PROGRA; 1988, SAS SOFTWARE SYSTEM	58	586	609	0	28	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					474	481		10.7326/0003-4819-119-6-199309150-00005	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357112				2022-12-28	WOS:A1993LZ27500005
J	MARTINI, CJM				MARTINI, CJM			MEDICAL WORKFORCE PLANNING AND MEDICAL-EDUCATION - ATTAINING CONSENSUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											MARTINI, CJM (corresponding author), AMER MED ASSOC,MED EDUC GRP,OFF VICE PRESIDENT MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							BARKUN H, 1993, COMMUNICATION   0324; CALLTORP J, 1990, HLTH POLICY, V15, P112; FEIL EC, 1993, JAMA-J AM MED ASSOC, V269, P2659, DOI 10.1001/jama.269.20.2659; FLEXNER A, 1910, MED ED US CANADA, P173; JOHNS MME, 1993, JAMA-J AM MED ASSOC, V269, P3156, DOI 10.1001/jama.269.24.3156; MAUDSLEY RF, 1993, PROPOSAL TRAINING CA; MAYNARD M, 1990, HLTH POLICY, V15, P20; MJLLAN F, 1993, HLTH AFF S, V12, P138; NAKATANI H, 1987, WORLD HLTH STAT, V40, P330; PAGE L, 1993, AM MED NEWS     0802, P4; PAGE L, 1993, AM MED NEWS     0517, P51; REYNOLDS R, 1993, NY TIMES        0601, pA14; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1074, DOI 10.1001/jama.270.9.1074; RIVO ML, 1993, JAMA-J AM MED ASSOC, V270, P1083, DOI 10.1001/jama.270.9.1083; SCHWARTZ A, 1993, JAMA-J AM MED ASSOC, V270, P1079, DOI 10.1001/jama.270.9.1079; 1968, 1965 68 ROY COMM MED; 1993, AM MED NEWS     0802, P6	17	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1101	1104						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU512	8350459				2022-12-28	WOS:A1993LU51200017
J	RANDRIAMAMPITA, C; TSIEN, RY				RANDRIAMAMPITA, C; TSIEN, RY			EMPTYING OF INTRACELLULAR CA2+ STORES RELEASES A NOVEL SMALL MESSENGER THAT STIMULATES CA2+ INFLUX	NATURE			English	Article							PLASMA-MEMBRANE; HUMAN-NEUTROPHILS; CALCIUM CHANNELS; MAST-CELLS; T-CELLS; CA-2+; PERMEABILITY; ENTRY; LYMPHOCYTES; FIBROBLASTS	INTRACELLULAR Ca2+ signals that last more than a few minutes after the onset of stimulation depend critically on influx of extracellular Ca2+. Such Ca2+ influx can be triggered in many cell types by depletion of intracellular Ca2+ stores without detectable elevations of known messengers. The mechanism by which store depletion can control plasma membrane Ca2+ permeability remains controversial1-7. Here we present evidence for a novel soluble mediator. Calcium depletion of a lymphocyte cell line caused the messenger to be released from intracellular organelles into the cytoplasm and to a much lesser extent into the extracellular medium. The messenger caused Ca2+ influx when applied to macrophages, astrocytoma cells, and fibroblasts and was therefore named CIF (or Ca2+-influx factor). CIF appears to have hydroxyls (or hydroxyl and amino groups) on adjacent carbons, a phosphate, and a M(r) under 500.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,LA JOLLA,CA 92093; ECOLE NORMALE SUPER,NEUROBIOL LAB,F-75231 PARIS 05,FRANCE; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093	University of California System; University of California San Diego; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); Howard Hughes Medical Institute; University of California System; University of California San Diego				Randriamampita, Clotilde/0000-0001-8594-7831				ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; ALVAREZ J, 1992, FASEB J, V6, P786, DOI 10.1096/fasebj.6.2.1537469; BAHNSON TD, 1993, J BIOL CHEM, V268, P10808; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHOW SC, 1990, J BIOL CHEM, V265, P902; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; FULCERI R, 1993, BIOCHEM J, V289, P299, DOI 10.1042/bj2890299; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GREENBERG S, 1988, J BIOL CHEM, V263, P10337; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JALINK K, 1990, J BIOL CHEM, V265, P12232; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KUNO M, 1987, NATURE, V326, P301, DOI 10.1038/326301a0; LEE HC, 1989, J BIOL CHEM, V264, P1608; LI WWF, 1993, J BIOL CHEM, V268, P12003; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MASON MJ, 1991, J BIOL CHEM, V266, P10872; MASON MJ, 1993, AM J PHYSIOL, V264, pC654, DOI 10.1152/ajpcell.1993.264.3.C654; MASON MJ, 1991, J BIOL CHEM, V266, P20856; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; OSIPCHUK Y, 1992, NATURE, V359, P241, DOI 10.1038/359241a0; PANDOL SJ, 1990, J BIOL CHEM, V265, P12846; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TSIEN RY, 1990, CELL CALCIUM, V11, P93, DOI 10.1016/0143-4160(90)90063-Z; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; ZHANG H, 1991, J CELL BIOL, V114, P155, DOI 10.1083/jcb.114.1.155; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	31	860	865	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					809	814		10.1038/364809a0	http://dx.doi.org/10.1038/364809a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355806				2022-12-28	WOS:A1993LU58100058
J	LOGAN, RFA; LITTLE, J; HAWTIN, PG; HARDCASTLE, JD				LOGAN, RFA; LITTLE, J; HAWTIN, PG; HARDCASTLE, JD			EFFECT OF ASPIRIN AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS ON COLORECTAL ADENOMAS - CASE-CONTROL STUDY OF SUBJECTS PARTICIPATING IN THE NOTTINGHAM FECAL OCCULT BLOOD SCREENING-PROGRAM	BRITISH MEDICAL JOURNAL			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUG; AUTOCHTHONOUS INTESTINAL TUMORS; LARGE-BOWEL CANCER; COLON CARCINOGENESIS; INDOMETHACIN TREATMENT; RAT; INHIBITION; PIROXICAM; POLYPOSIS; SULINDAC	Objective-To examine the relation between the use of aspirin and non-steroidal anti-inflammatory drugs and the presence of asymptomatic colorectal adenomas. Design-Case-control study of subjects participating in a randomised controlled trial of faecal occult blood screening for colorectal cancer. Data on analgesics and other drugs were obtained from a questionnaire which was mainly concerned with diet and was administered by an interviewer. Setting-Nottingham. Subjects-147 patients with positive results in faecal occult blood tests who were found to have colorectal adenomas (cases), 153 age and sex matched control subjects with negative results in such tests (negative controls), and 176 control subjects with positive results in the tests who were found not to have colorectal adenomas (positive controls). Main outcome measures-Relative risk of developing colorectal adenomas according to frequency and duration of use of analgesics. Results-Cases reported taking less aspirin and non-steroidal anti-inflammatory drugs than the negative controls, with the estimated relative risk for any use being 0.49 (95% confidence interval 0.3 to 0.8). The inverse association was less strong when cases were compared with the positive controls (0.66 (0.4 to 1.1)). The association was specific for aspirin and non-steroidal anti-inflammatory drugs there being no association with paracetamol or other drugs. Prescribed use of non-steroidal anti-inflammatory drugs for longer than five years was associated with the lowest risk (0.21 (0.1 to 0.8)), although the numbers reporting prolonged prescribed use were small. Conclusions-These findings support the hypothesis that aspirin and non-steroidal anti-inflammatory drug use protects against the development of colorectal neoplasia.	INT AGCY RES CANC,ANALYT EPIDEMIOL UNIT,SEARCH PROGRAMME,F-69372 LYON,FRANCE; UNIV NOTTINGHAM HOSP,DEPT SURG,NOTTINGHAM NG7 2UH,ENGLAND	World Health Organization; International Agency for Research on Cancer (IARC); University of Nottingham	LOGAN, RFA (corresponding author), UNIV NOTTINGHAM,QUEENS MED CTR,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND.			LIttle, Julian/0000-0001-5026-5531				ARMITAGE N, 1985, BRIT J CANCER, V51, P799, DOI 10.1038/bjc.1985.124; BAKER RJ, 1985, GLIM GENERALISED LIN; DERUBERTIS FR, 1985, GASTROENTEROLOGY, V89, P1054, DOI 10.1016/0016-5085(85)90209-4; DORAN J, 1982, BRIT J SURG, V69, P711, DOI 10.1002/bjs.1800691209; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HARDCASTLE JD, 1989, LANCET, V1, P1160; KUNE GA, 1988, CANCER, V48, P399; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LITTLE J, 1993, BRIT J CANCER, V67, P177, DOI 10.1038/bjc.1993.31; MACFARLANE GJ, 1988, SEARCH COMPUTER PACK; METZGER U, 1984, DIS COLON RECTUM, V27, P366, DOI 10.1007/BF02553001; NARISAWA T, 1983, CARCINOGENESIS, V4, P1225, DOI 10.1093/carcin/4.10.1225; NARISAWA T, 1981, CANCER RES, V41, P1954; NORFLEET RG, 1983, J CLIN GASTROENTEROL, V5, P123, DOI 10.1097/00004836-198304000-00006; NUGENT KP, 1992, GUT, V33, pS33; PAGANINIHILL A, 1991, J NATL CANCER I, V83, P1182, DOI 10.1093/jnci/83.16.1182-a; POLLARD M, 1983, CANCER LETT, V21, P57, DOI 10.1016/0304-3835(83)90082-4; POLLARD M, 1980, CANCER TREAT REP, V64, P1323; POLLARD M, 1983, J NATL CANCER I, V70, P1103; POLLARD M, 1981, P SOC EXP BIOL MED, V167, P161; PYE G, 1987, BRIT MED J, V294, P1510, DOI 10.1136/bmj.294.6586.1510; RANSOHOFF DF, 1990, JAMA-J AM MED ASSOC, V264, P76, DOI 10.1001/jama.264.1.76; REDDY BS, 1990, CANCER RES, V50, P2562; REDDY BS, 1987, CANCER RES, V47, P5340; REES WDW, 1980, LANCET, V2, P410; ROSENBERG L, 1991, J NATL CANCER I, V83, P355, DOI 10.1093/jnci/83.5.355; SIMON JB, 1990, JAMA-J AM MED ASSOC, V264, P84, DOI 10.1001/jama.264.1.84; THOMAS WM, 1990, GUT, V31, P1294, DOI 10.1136/gut.31.11.1294; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; 1991, EGRET EPIDEMIOLOGICA	31	230	237	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					285	289		10.1136/bmj.307.6899.285	http://dx.doi.org/10.1136/bmj.307.6899.285			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374373	Green Published, Bronze			2022-12-28	WOS:A1993LQ51600015
J	VASSILAS, CA; MORGAN, HG				VASSILAS, CA; MORGAN, HG			GENERAL-PRACTITIONERS CONTACT WITH VICTIMS OF SUICIDE	BRITISH MEDICAL JOURNAL			English	Article									UNIV BRISTOL,DEPT MENTAL HLTH,BRISTOL BS2 8DZ,ENGLAND	University of Bristol								BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; DUNNELL K, 1991, POPULATION TRENDS, V64, P38; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; SEAGER CP, 1965, BRIT J PSYCHIAT, V111, P919, DOI 10.1192/bjp.111.479.919; 1992, HLTH NATION STRATEGY	5	75	75	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					300	301		10.1136/bmj.307.6899.300	http://dx.doi.org/10.1136/bmj.307.6899.300			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LQ516	8374378	Green Published, Bronze			2022-12-28	WOS:A1993LQ51600020
J	JESSELL, TM; KANDEL, ER				JESSELL, TM; KANDEL, ER			SYNAPTIC TRANSMISSION - A BIDIRECTIONAL AND SELF-MODIFIABLE FORM OF CELL-CELL COMMUNICATION	CELL			English	Review							LONG-TERM POTENTIATION; PIONEER AXON MIGRATIONS; PROTEIN-KINASE-II; ACETYLCHOLINE-RECEPTOR; NITRIC-OXIDE; ADHESION MOLECULES; ION CHANNELS; TRANSMITTER RELEASE; NICOTINIC RECEPTOR; AMINO-ACIDS				JESSELL, TM (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032, USA.							AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ALDER J, 1992, SCIENCE, V257, P657, DOI 10.1126/science.1353905; ALDER J, 1992, NEURON, V9, P759, DOI 10.1016/0896-6273(92)90038-F; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; ARMSTRONG CM, 1992, PHYSIOL REV, V72, pS5, DOI 10.1152/physrev.1992.72.suppl_4.S5; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; Bixby J L, 1992, Curr Opin Neurobiol, V2, P66, DOI 10.1016/0959-4388(92)90164-G; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BOURNE HR, 1993, CELL, V72, P65, DOI 10.1016/S0092-8674(05)80029-7; BRDY ST, 1991, NEURON, V7, P521; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; Brookfield John, 1992, Current Biology, V2, P553, DOI 10.1016/0960-9822(92)90036-A; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; BUCKLEY KM, 1987, J CELL BIOL, V105, P2447, DOI 10.1083/jcb.105.6.2447; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CALOF A L, 1992, Current Biology, V2, P103, DOI 10.1016/0960-9822(92)90235-3; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CHANGEUX JP, 1981, HARVEY LECT, V75, P85; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; CLINE HT, 1990, J NEUROSCI, V10, P1197; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAHM LM, 1988, DEV BIOL, V130, P621, DOI 10.1016/0012-1606(88)90357-0; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; Dodd J, 1992, Curr Opin Neurobiol, V2, P3, DOI 10.1016/0959-4388(92)90153-C; Eccles J. C, 1957, PHYSL NERVE CELLS; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FALLS DL, 1990, COLD SPRING HARB SYM, V55, P397; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; FERNS M, 1992, NEURON, V8, P1079, DOI 10.1016/0896-6273(92)90129-2; FRANCO B, 1991, NATURE, V353, P539; FRANK E, 1993, IN PRESS CURR OPIN N; FREI T, 1992, J CELL BIOL, V118, P177, DOI 10.1083/jcb.118.1.177; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURSHPAN EJ, 1957, NATURE, V180, P342, DOI 10.1038/180342a0; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GIRAUDAT J, 1986, P NATL ACAD SCI USA, V83, P2719, DOI 10.1073/pnas.83.8.2719; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HE X, 1991, NEURON, V7, P183, DOI 10.1016/0896-6273(91)90257-Z; HEBB DO, 1949, ORG BEHAVIOR; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; Hille B., 1992, IONIC CHANNELS EXCIT; Hodgkin A. L., 1992, CHANCE DESIGN; Hodgkin AL., 1964, CONDUCTION NERVOUS I; HUNT RK, 1990, BRAIN CIRCUITS FUNCT, P19; HUXLEY AF, 1964, SCIENCE, V145, P1154, DOI 10.1126/science.145.3637.1154; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IMOTO K, 1988, NATURE, V335, P645, DOI 10.1038/335645a0; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KARLIN A, 1991, HARVEY LECT, V85, P71; Katz B., 1969, RELEASE NEURAL TRANS; Katz B., 1966, NERVE MUSCLE SYNAPSE; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; Keynes R J, 1992, Curr Opin Neurobiol, V2, P55, DOI 10.1016/0959-4388(92)90162-E; LANDIS SC, 1980, DEV BIOL, V77, P349, DOI 10.1016/0012-1606(80)90480-7; LEGOUIS R, 1991, CELL, V67, P423, DOI 10.1016/0092-8674(91)90193-3; LEONARD RJ, 1988, SCIENCE, V242, P1578, DOI 10.1126/science.2462281; LETOURNEAU PC, 1991, NERVE GROWTH CONE, P535; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Liem RKH, 1990, CURR OPIN CELL BIOL, V2, P86, DOI 10.1016/S0955-0674(05)80036-5; Linstedt A D, 1991, Curr Opin Neurobiol, V1, P382, DOI 10.1016/0959-4388(91)90057-E; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; MILLER C, 1992, SCIENCE, V258, P240, DOI 10.1126/science.1384128; Miller Christopher, 1992, Current Biology, V2, P573, DOI 10.1016/0960-9822(92)90146-2; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NATHANS J, 1987, ANNU REV NEUROSCI, V10, P163; NEHER E, 1992, NEURON, V8, P605, DOI 10.1016/0896-6273(92)90083-P; Nestler E. J, 1983, PROTEIN PHOSPHORYLAT; NICHOLLS JG, 1992, NEURON BRAIN; NICOLL RA, 1988, NEURON, V1, P97, DOI 10.1016/0896-6273(88)90193-6; OCONNOR TP, 1990, J NEUROSCI, V10, P3935, DOI 10.1523/JNEUROSCI.10-12-03935.1990; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAPALOPULU N, 1992, SEMIN NEUROSCI, V4, P295; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; Pongs O, 1992, PHYSL REV S, V72, pS69; Rathjen F. G, 1991, SEMIN NEUROSCI, V3, P297, DOI 10.1016/1044-5765(91)90047-R; REH TA, 1985, J NEUROSCI, V5, P1132; REICHARDT LF, 1991, ANNU REV NEUROSCI, V14, P531, DOI 10.1146/annurev.neuro.14.1.531; REIST NE, 1992, NEURON, V8, P865, DOI 10.1016/0896-6273(92)90200-W; REVAH F, 1990, P NATL ACAD SCI USA, V87, P4675, DOI 10.1073/pnas.87.12.4675; ROBITAILLE R, 1990, NEURON, V5, P773, DOI 10.1016/0896-6273(90)90336-E; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SABRY JH, 1991, J CELL BIOL, V115, P381, DOI 10.1083/jcb.115.2.381; SAGA Y, 1992, GENE DEV, V6, P1821, DOI 10.1101/gad.6.10.1821; SAKMANN B, 1992, NEURON, V8, P613, DOI 10.1016/0896-6273(92)90084-Q; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Schroer T A, 1992, Curr Opin Neurobiol, V2, P618, DOI 10.1016/0959-4388(92)90028-J; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Solomon F, 1992, Curr Opin Neurobiol, V2, P613, DOI 10.1016/0959-4388(92)90027-I; SOSSIN WS, 1989, NEURON, V2, P1407, DOI 10.1016/0896-6273(89)90186-4; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; TESSIERLAVIGNE M, 1991, TRENDS NEUROSCI, V14, P303, DOI 10.1016/0166-2236(91)90142-H; THOMAS L, 1988, SCIENCE, V242, P1050, DOI 10.1126/science.2461586; THOMAS L, 1990, J CELL BIOL, V111, P2041, DOI 10.1083/jcb.111.5.2041; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WEISS P, 1947, YALE J BIOL MED, V9, P235; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WIGSTROM H, 1986, ACTA PHYSIOL SCAND, V126, P317, DOI 10.1111/j.1748-1716.1986.tb07822.x; ZISCH AH, 1992, J CELL BIOL, V119, P203, DOI 10.1083/jcb.119.1.203	134	197	199	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN	1993	72			S			1	30		10.1016/S0092-8674(05)80025-X	http://dx.doi.org/10.1016/S0092-8674(05)80025-X			30	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KL707	8381334				2022-12-28	WOS:A1993KL70700001
J	NACHMAN, RL; SILVERSTEIN, R				NACHMAN, RL; SILVERSTEIN, R			HYPERCOAGULABLE STATES	ANNALS OF INTERNAL MEDICINE			English	Review							HEPARIN-ASSOCIATED THROMBOCYTOPENIA; SYSTEMIC LUPUS-ERYTHEMATOSUS; ANTITHROMBIN-III DEFICIENCY; CORONARY-ARTERY DISEASE; ENDOTHELIAL-CELL INJURY; ISCHEMIC HEART-DISEASE; PROTEIN-C DEFICIENCY; DEEP-VEIN THROMBOSIS; ANTIPHOSPHOLIPID ANTIBODIES; ANTICARDIOLIPIN ANTIBODY	Purpose: To describe the major pathophysiologic mechanisms underlying inherited and secondary hypercoagulable states and to evaluate the frequency, natural history, diagnosis, and management of the various clinical disorders. Data Sources and Study Selection: Relevant clinical literature obtained from bibliographies in hematology textbooks and from computerized indexes was reviewed. A hypothesis was formed based on this literature review and on recent developments from a number of experimental studies. Data Synthesis: Hypercoagulable states include various inherited as well as acquired clinical disorders characterized by an increased risk for thromboembolism. Primary hypercoagulable states include relatively rare inherited conditions that lead to disordered endothelial cell thromboregulation. These conditions include decreased thrombomodulin-dependent activation of activated protein C, impaired heparin binding of antithrombin III, or down-regulation of membrane-associated plasmin generation. The major, inherited, inhibitor disease states include antithrombin III deficiency, protein C deficiency, and protein S deficiency and should be considered in patients who have recurrent, familial, or juvenile deep-vein thrombosis or occlusion in an unusual location such as a mesenteric, brachial, or cerebral vessel. Secondary hypercoagulable states may be seen in many heterogeneous disorders. In many of these conditions, endothelial activation by cytokines leads to loss of normal vessel-wall anticoagulant surface functions with conversion to a proinflammatory thrombogenic phenotype. Important clinical syndromes associated with substantial thromboembolic events include the antiphospholipid syndrome, heparin-induced thrombopathy, the myeloproliferative syndromes, and cancer. Conclusions: Physiologic thromboregulation occurs at the vessel-wall surface. Quantitative and qualitative deficiencies of normal, steady-state endothelial anticoagulant activities are associated with primary hypercoagulable states. Activated endothelial cell surfaces express a thrombogenic phenotype and contribute to secondary or acquired hypercoagulability.	CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT MED, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital					NHLBI NIH HHS [R01 HL42540, HL188281] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042540] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMONDHIRY HAB, 1975, BLOOD, V45, P607; AOKI N, 1978, J CLIN INVEST, V61, P1186, DOI 10.1172/JCI109034; BAUER K, 1991, HEMATOLOGY BASIC PRI, P1420; BAUER KA, 1985, J CLIN INVEST, V76, P826, DOI 10.1172/JCI112040; BAUER KA, 1991, HEMATOLOGY BASIC PRI, P1418; BELL WR, 1980, NEW ENGL J MED, V303, P902, DOI 10.1056/NEJM198010163031602; BOCK SC, 1987, BLOOD, V70, P1273; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BRANDT P, 1981, THROMB RES, V22, P15, DOI 10.1016/0049-3848(81)90304-2; CINES DB, 1987, NEW ENGL J MED, V316, P581, DOI 10.1056/NEJM198703053161004; COMP PC, 1991, HEMATOLOGY BASIC PRI, P1247; CONARD J, 1990, THROMB HAEMOSTASIS, V63, P319; COWCHOCK FS, 1992, AM J OBSTET GYNECOL, V166, P1318, DOI 10.1016/0002-9378(92)91596-3; DANGELO A, 1988, J CLIN INVEST, V81, P1445, DOI 10.1172/JCI113475; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; DEMERS C, 1992, ANN INTERN MED, V116, P754, DOI 10.7326/0003-4819-116-9-754; DEMERS C, 1991, BLOOD, V78, P2194; DEVRAJKIZUK R, 1988, BLOOD, V72, P1518; DOLL DC, 1986, J CLIN ONCOL, V4, P1405, DOI 10.1200/JCO.1986.4.9.1405; ENGESSER L, 1987, BRIT J HAEMATOL, V67, P355, DOI 10.1111/j.1365-2141.1987.tb02357.x; ERBAN JK, 1992, J BIOL CHEM, V267, P2451; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; ESMON CT, 1987, SCIENCE, V235, P1348, DOI 10.1126/science.3029867; FISCHER AM, 1987, BRIT J HAEMATOL, V66, P213, DOI 10.1111/j.1365-2141.1987.tb01301.x; FREEDMAN KD, 1986, BLOOD, V68, pA333; FREYSSINET JM, 1986, THROMB HAEMOSTASIS, V55, P309; FURIE B, 1992, NEW ENGL J MED, V326, P800; GENEST JJ, 1991, ARTERIOSCLER THROMB, V11, P1129, DOI 10.1161/01.ATV.11.5.1129; GILLIS S, 1992, INT J GYNECOL OBSTET, V39, P297, DOI 10.1016/0020-7292(92)90261-G; GREAVES M, 1991, BRIT J HAEMATOL, V79, P148, DOI 10.1111/j.1365-2141.1991.tb04514.x; GREISMAN SG, 1991, ARCH INTERN MED, V151, P389, DOI 10.1001/archinte.151.2.389; GUGLIOTTA L, 1990, BRIT J HAEMATOL, V74, P465, DOI 10.1111/j.1365-2141.1990.tb06336.x; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; HARPEL PC, 1990, BLOOD, V76, pA10; HARRIS EN, 1986, ARCH INTERN MED, V146, P2153, DOI 10.1001/archinte.146.11.2153; HARRIS EN, 1991, ARCH INTERN MED, V151, P231, DOI 10.1001/archinte.151.2.231; HAYASHI T, 1992, BLOOD, V79, P2930; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; ISHII H, 1986, BLOOD, V67, P362; ITURBEALESSIO I, 1986, NEW ENGL J MED, V315, P1390, DOI 10.1056/NEJM198611273152205; LEVINE MN, 1988, NEW ENGL J MED, V318, P404, DOI 10.1056/NEJM198802183180703; LOTTENBERG R, 1985, AM J HEMATOL, V19, P181, DOI 10.1002/ajh.2830190211; LOVE PE, 1990, ANN INTERN MED, V112, P682, DOI 10.7326/0003-4819-112-9-682; LOWE GDO, 1980, BRIT MED J, V280, P673, DOI 10.1136/bmj.280.6215.673; MANNUCCI PM, 1992, THROMB HAEMOSTASIS, V67, P200; MARCUM JA, 1984, J CLIN INVEST, V74, P341, DOI 10.1172/JCI111429; MCGEHEE WG, 1984, ANN INTERN MED, V101, P59, DOI 10.7326/0003-4819-101-1-59; MEADE TW, 1985, THROMB RES, V38, P527, DOI 10.1016/0049-3848(85)90185-9; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; MILLER GJ, 1986, ATHEROSCLEROSIS, V60, P269, DOI 10.1016/0021-9150(86)90174-7; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; MUDD SH, 1985, AM J HUM GENET, V37, P1; MUDD SH, 1983, METABOLIC BASIS INHE, P522; Nemerson Y, 1987, Adv Exp Med Biol, V214, P83; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; PABRINGER I, 1992, BLOOD COAGUL FIBRIN, V3, P547; PAGLIUCA A, 1990, Q J MED, V76, P981; PETERS C, 1988, PEDIATRICS, V81, P272; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51, DOI 10.1111/j.1749-6632.1991.tb43691.x; Rosenberg R D, 1975, Adv Exp Med Biol, V52, P217; SCULLY MF, 1981, BRIT J HAEMATOL, V47, P235, DOI 10.1111/j.1365-2141.1981.tb02784.x; STAHL CP, 1993, BLOOD, V81, P1801; TADA K, 1991, SCAND J GASTROENTERO, V26, P1188, DOI 10.3109/00365529108998612; THALER E, 1981, CLIN HAEMATOL, V10, P369; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TRAN TH, 1985, LANCET, V2, P413; VALLA D, 1985, ANN INTERN MED, V103, P329, DOI 10.7326/0003-4819-103-3-329	72	157	165	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					819	827		10.7326/0003-4819-119-8-199310150-00008	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379603				2022-12-28	WOS:A1993MB49600008
J	PAMUK, ER; WILLIAMSON, DF; SERDULA, MK; MADANS, J; BYERS, TE				PAMUK, ER; WILLIAMSON, DF; SERDULA, MK; MADANS, J; BYERS, TE			WEIGHT-LOSS AND SUBSEQUENT DEATH IN A COHORT OF UNITED-STATES ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-WEIGHT; CORONARY-DISEASE; MORTALITY; FRAMINGHAM; LONGEVITY; HEALTH; MEN; VARIABILITY; POPULATION; OBESITY	Objective: Because we previously found that weight loss was associated with increased risk for death in all but very overweight men in a cohort of U.S. adults, we undertook a new analysis to determine whether inadequate control for preexisting illness or cigarette smoking contributed to this association. Design: Cohort study. Setting: The first National Health and Nutrition Examination Survey (NHANES I, 1971 to 1975) collected information on maximum lifetime weight and measured current weight on a probability sample of U.S. adults. The NHANES I Epidemiologic Follow-up Study determined the vital status of participants through 1987. Participants: Men (n = 2453) and women (n = 2739) who were 45 to 74 years old at the time of the NHANES I examination. Results: The effect of excluding persons who died within the first 5 and first 8 years after baseline was examined to limit the influence of weight loss due to preexisting illness. For women, extension of the exclusionary period weakened the association between weight loss and increased risk for death from noncardiovascular disease. However, excluding death for as much as 8 years after baseline did not affect the strong association between weight loss and increased risk for death from cardiovascular disease among men and women with maximum body mass indexes between 26 and 29 (relative risks of up to 2.1 and 3.6 for men and women, respectively, after excluding deaths in the first 8 years). Results were not substantially altered by limiting the analysis to persons who never smoked. Conclusions: Preexisting illness may influence the association between weight loss and death principally through deaths from noncardiovascular disease. For some persons, weight loss is associated with an increased risk for death, even after excluding deaths occurring in the first 8 years.			PAMUK, ER (corresponding author), CTR DIS CONTROL & PREVENT, DIV NUTR K-26, 1600 CLIFTON RD NE, ATLANTA, GA 30333 USA.							[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; ASHLEY FW, 1974, J CHRON DIS, V27, P103, DOI 10.1016/0021-9681(74)90079-4; AVONS P, 1983, LANCET, V1, P1104; BORKAN GA, 1986, AM J EPIDEMIOL, V124, P410, DOI 10.1093/oxfordjournals.aje.a114411; DEEG DJH, 1990, ARCH GERONTOL GERIAT, V10, P97, DOI 10.1016/0167-4943(90)90048-B; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; HOVELL MF, 1982, AM J PUBLIC HEALTH, V72, P359, DOI 10.2105/AJPH.72.4.359; LEAN MEJ, 1990, DIABETIC MED, V7, P228, DOI 10.1111/j.1464-5491.1990.tb01375.x; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LISSNER L, 1990, INT J OBESITY, V14, P373; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; NOPPA H, 1980, AM J EPIDEMIOL, V111, P693, DOI 10.1093/oxfordjournals.aje.a112947; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; RHOADS GG, 1983, LANCET, V1, P492; SCHROLL M, 1981, DAN MED BULL, V28, P106; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WILCOSKY T, 1990, J CLIN EPIDEMIOL, V43, P743, DOI 10.1016/0895-4356(90)90232-E; WILLIAMSON DF, 1992, AM J PUBLIC HEALTH, V82, P1251, DOI 10.2105/AJPH.82.9.1251; 1959, BUILD BLOOD PRESSURE, V0001; [No title captured]	23	130	133	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				744	748		10.7326/0003-4819-119-7_Part_2-199310011-00023	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00023			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363209				2022-12-28	WOS:A1993MA33000023
J	WILLIAMSON, DF				WILLIAMSON, DF			DESCRIPTIVE EPIDEMIOLOGY OF BODY-WEIGHT AND WEIGHT CHANGE IN UNITED-STATES ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article							MASS INDEX; SOCIOECONOMIC-FACTORS; SKINFOLD THICKNESS; SECULAR TRENDS; OBESITY; WOMEN; GAIN; OVERWEIGHT; POPULATION	Data on body weight and weight change collected from nationally representative samples of U.S. adults are reviewed. The body mass index (weight [kg]/height [m2]) has a low correlation with height and is used to compare body weights between persons of differing heights. The BMI varies to a greater degree in women than in men. Below the 75th percentile of the BMI distribution, women have lower BMIs than men, whereas at the 75th percentile and above, women have higher BMIs than men. Overweight is defined as a BMI of 27.8 or more in men and of 27.3 or more in women, corresponding to approximately 20% or more above desirable weight in the 1983 Metropolitan Life Insurance Company tables. For persons of average height (men, 5'9''; women, 5'4'' this definition is equivalent to a body weight above 85 kg (187 pounds) in men and above 72 kg (158 pounds) in women. Among adults 20 to 74 years of age, 24% of men and 27% of women are overweight, yielding an estimated total of 34 million persons in the United States. The prevalence of overweight increases with age, for both men and women but to a greater degree in women. Blacks and Hispanics have a higher prevalence of overweight than do whites, especially among women. Between 1960 and 1980, the prevalence of overweight among whites increased by 3% in women and by 6% in men. In blacks, however, the prevalence of overweight increased by 7% in women and by 28% in men. Longitudinal body weight measurements taken 10 years apart show that adults younger than 55 years tend to gain weight, whereas those 55 years and older tend to lose weight. The youngest adults gain the most weight, and the oldest adults lose the most weight. In all age groups, women have substantially greater variation in their 10-year weight change than do men.			WILLIAMSON, DF (corresponding author), CTR DIS CONTROL & PREVENTION, CTR CHRON DIS PREVENT & HLTH PROMOT, 4770 BUFORD HIGHWAY NE, K-26, ATLANTA, GA 30341 USA.							BOUCHARD C, 1991, NEW ENGL J MED, V324, P1887, DOI 10.1056/NEJM199106273242609; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P544, DOI 10.1093/ajcn/48.3.544; FLEGAL KM, 1988, AM J CLIN NUTR, V48, P535, DOI 10.1093/ajcn/48.3.535; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; KUMANYIKA S, 1987, EPIDEMIOL REV, V9, P31, DOI 10.1093/oxfordjournals.epirev.a036307; KUMANYIKA S K, 1992, Ethnicity and Disease, V2, P166; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; NAJJAR MF, 1989, VITAL HLTH STATIS 11, V239; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; SHAH M, 1991, INT J OBESITY, V15, P499; THOMPSON JK, 1982, PSYCHOL BULL, V91, P55, DOI 10.1037/0033-2909.91.1.55; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON DF, 1991, AM J CLIN NUTR, V53, pS1515, DOI 10.1093/ajcn/53.6.1515S; [No title captured]	14	303	311	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				646	649		10.7326/0003-4819-119-7_Part_2-199310011-00004	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363190				2022-12-28	WOS:A1993MA33000004
J	GASTON, RS; AYRES, I; DOOLEY, LG; DIETHELM, AG				GASTON, RS; AYRES, I; DOOLEY, LG; DIETHELM, AG			RACIAL EQUITY IN RENAL-TRANSPLANTATION - THE DISPARATE IMPACT OF HLA BASED ALLOCATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAFT-SURVIVAL; KIDNEY-TRANSPLANTS; CYCLOSPORINE ERA; RECIPIENTS; BLACKS; RACE; DISEASE; IMMUNOSUPPRESSION; CANDIDATES; EXPERIENCE		UNIV ALABAMA, DEPT SURG, BIRMINGHAM, AL 35294 USA; VALPARAISO UNIV, SCH LAW, VALPARAISO, IN 46383 USA; STANFORD UNIV, SCH LAW, PALO ALTO, CA 94304 USA	University of Alabama System; University of Alabama Birmingham; Valparaiso University; Stanford University	GASTON, RS (corresponding author), UNIV ALABAMA, DEPT MED, 625 TINSLEY HARRISON TOWER, UAB STN, BIRMINGHAM, AL 35294 USA.		Gaston, Robert/AAR-2932-2020					ALEXANDER JW, 1987, TRANSPLANT P, V19, P672; BARGER B, 1992, TRANSPLANTATION, V53, P770, DOI 10.1097/00007890-199204000-00013; Barger B O, 1987, Clin Transpl, P217; BLUMSTEIN JF, 1989, UC DAVIS L REV, V22, P451; BRAUN WE, 1992, NEW ENGL J MED, V327, P883, DOI 10.1056/NEJM199209173271211; BUTKUS DE, 1991, TRANSPLANT REV, V5, P91; Cecka J M, 1991, Clin Transpl, P1; CICCIARELLI J, 1992, CLIN TRANSPLANTS 199, P325; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; EVANS RW, 1991, CLIN TRANSPLANTS 199, P319; FELDMAN HI, 1992, AM J KIDNEY DIS, V19, P397, DOI 10.1016/S0272-6386(12)80945-0; FERGUSON RM, 1988, CLIN TRANSPLANT, V2, P285; FISCHEL RJ, 1991, TRANSPLANTATION, V51, P118, DOI 10.1097/00007890-199101000-00018; GASTON RS, 1992, TRANSPLANTATION, V53, P103, DOI 10.1097/00007890-199201000-00020; GASTON RS, IN PRESS TRANSPLANTA; GJERTSON DW, 1991, NEW ENGL J MED, V324, P1032, DOI 10.1056/NEJM199104113241505; HAUG CE, 1993, TRANSPLANTATION, V55, P766, DOI 10.1097/00007890-199304000-00016; HUNSICKER LG, 1992, SEMIN NEPHROL, V12, P293; JOHNSON AH, 1989, TRANSPLANT P, V21, P3872; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KNIGHT R, 1993, TRANSPLANTATION, V55, P947; Kondo K, 1987, Clin Transpl, P339; KUSSEROW RP, 1991, DISTRIBUTION ORGANS; LAU M, 1993, CLIN TRANSPLANT, P457; LAZDA VA, 1992, TRANSPLANTATION, V53, P352, DOI 10.1097/00007890-199202010-00017; LAZDA VA, 1989, TRANSPLANT P, V21, P1415; LAZDA VA, 1991, TRANSPLANT P, V23, P901; MACLEOD AM, 1991, LANCET, V337, P25, DOI 10.1016/0140-6736(91)93341-6; Mickey M R, 1987, Clin Transpl, P303; MICKEY MR, 1989, TRANSPLANTATIN, V47, P701; MILFORD EL, 1987, TRANSPLANT P, V19, P30; Okun A.M., 2015, EQUALITY EFFICIENCY; OPELZ G, 1989, TRANSPLANT P, V21, P3918; OPELZ G, 1989, CLIN TRANSPLANT, V3, P233; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; OWEN M, 1989, IMMUNOLOGY; PORT FK, 1991, AM J KIDNEY DIS, V17, P519, DOI 10.1016/S0272-6386(12)80492-6; Rettig RA, 1991, BIOMEDICAL POLITICS, P176; SANFILIPPO FP, 1992, JAMA-J AM MED ASSOC, V267, P247, DOI 10.1001/jama.267.2.247; SOLLINGER HW, 1992, TRANSPLANTATION, V53, P428, DOI 10.1097/00007890-199202010-00031; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; STARZL TE, 1987, JAMA-J AM MED ASSOC, V257, P3073, DOI 10.1001/jama.257.22.3073; SUCIUFOCA N, 1983, TRANSPLANTATION, V35, P35, DOI 10.1097/00007890-198301000-00008; TAKEMOTO S, 1992, NEW ENGL J MED, V327, P834, DOI 10.1056/NEJM199209173271202; TAKEMOTO S, 1989, TRANSPLANT P, V21, P3865; TAKEMOTO S, 1993, CLIN TRANSPLANTS 199, P413; TAKEMOTO S, 1991, CLIN TRANSPLANTS 199, P485; TAMURA K, 1991, Journal of the American Society of Nephrology, V2, P819; TERASAKI PI, 1989, CLIN TRANSPLANT, V3, P301; WARD HJ, 1991, TRANSPLANTATION, V51, P359, DOI 10.1097/00007890-199102000-00017; Yuge J, 1989, Clin Transpl, P407; 1990, UNOS POLICY 3 5 10; 1990, UNOS POLICY 3 3 1; 1991, 1990 ANN REPORT; 1989, UNOS UPDATE, V5, P9; 1993, UNOS UPDATE, V9, P28; 1990, UNOS POLICY 3 3 3; 1990, UNOS POLICY 3 5; 1992, 1991 ANN DATA REPORT; 1991, USRDS 1991 ANN DATA	61	131	131	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1352	1356		10.1001/jama.270.11.1352	http://dx.doi.org/10.1001/jama.270.11.1352			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360970				2022-12-28	WOS:A1993LW34500034
J	ARMBRUST, EV; FERRIS, PJ; GOODENOUGH, UW				ARMBRUST, EV; FERRIS, PJ; GOODENOUGH, UW			A MATING-TYPE LINKED GENE-CLUSTER EXPRESSED IN CHLAMYDOMONAS ZYGOTES PARTICIPATES IN THE UNIPARENTAL INHERITANCE OF THE CHLOROPLAST GENOME	CELL			English	Article							MATERNAL INHERITANCE; PREFERENTIAL DESTRUCTION; INTRAGENOMIC CONFLICT; MICROSCOPIC EVIDENCE; REINHARDTII SHARE; PROTEIN-SYNTHESIS; SOMATIC FUSION; MALE ORIGIN; DNA; TRANSMISSION	A characteristic feature of early zygote development in Chlamydomonas is the selective degradation of chloroplast DNA from the mating type minus parent. The zygote-specific gene cluster ezy-1 is linked to the mating type locus and is transcribed almost immediately upon zygote formation. We show here that the acidic Ezy-1 polypeptide is rapidly transported to both the plus and minus chloroplasts, where it interacts with each chloroplast nucleoid. Expression of ezy-1 is selectively inhibited when pius, but not minus, gametes are briefly ultraviolet irradiated just prior to mating, a treatment known to disrupt the uniparental inheritance of chloroplast traits. We propose that the Ezy-1 polypeptide participates in the destruction of the minus chloroplast DNA in zygotes and thus the uniparental inheritance of chloroplast traits. The ezy-1 gene represents a valuable molecular probe for dissecting mechanisms underlying organelle inheritance.			ARMBRUST, EV (corresponding author), WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA.				NCRR NIH HHS [S10-RR04775-01] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ausubel FM, 1988, MOL REPROD DEV; BALDAN B, 1991, J CELL BIOL, V114, P905, DOI 10.1083/jcb.114.5.905; CAVALIERSMITH T, 1970, NATURE, V228, P333, DOI 10.1038/228333a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN AW, 1984, EXP CELL RES, V152, P528, DOI 10.1016/0014-4827(84)90655-4; COSMIDES LM, 1981, J THEOR BIOL, V89, P83, DOI 10.1016/0022-5193(81)90181-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EBERSOLD WT, 1962, GENETICS, V47, P531; FERRIS PJ, 1989, GENETICS, V122, P363; FERRIS PJ, 1987, MOL CELL BIOL, V7, P2360, DOI 10.1128/MCB.7.7.2360; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; FRANZEN LG, 1989, PLANT MOL BIOL, V12, P463, DOI 10.1007/BF00017585; GILLHAM NW, 1974, GENETICS, V78, P439; GILLHAM NW, 1963, NATURE, V200, P294, DOI 10.1038/200294a0; GILLHAM NW, 1987, GENETICS, V115, P677; GILLHAM NW, 1991, CELL CULT SOMATIC A, V7, P55; GILLHAM NW, 1978, ORGANELLE HEREDITY; Goodenough U.W., 1991, MICROBIAL CELL CELL, P71; GOODENOUGH UW, 1987, GENETIC REGULATION D, P171; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; GUO LH, 1984, GENE, V29, P251, DOI 10.1016/0378-1119(84)90186-0; Harris E. H., 1989, CHLAMYDOMONAS SOURCE; HARRIS EH, 1989, GENETICS, V123, P281; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; KIRK MM, 1985, CELL, V41, P419, DOI 10.1016/S0092-8674(85)80015-5; KUROIWA T, 1985, MICROBIOL SCI, V2, P267; KUROIWA T, 1982, NATURE, V298, P481, DOI 10.1038/298481a0; KUROIWA T, 1983, P JPN ACAD B-PHYS, V59, P182, DOI 10.2183/pjab.59.182; KUROIWA T, 1983, P JPN ACAD B-PHYS, V59, P177, DOI 10.2183/pjab.59.177; KUROIWA T, 1991, INT REV CYTOL, V128, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE RP, 1960, ANNU REV MICROBIOL, V14, P197, DOI 10.1146/annurev.mi.14.100160.001213; MARTIN NC, 1975, J CELL BIOL, V67, P587, DOI 10.1083/jcb.67.3.587; MATAGNE RF, 1987, CURR GENET, V12, P251, DOI 10.1007/BF00435286; MATAGNE RF, 1980, CURR GENET, V1, P127, DOI 10.1007/BF00446958; MATAGNE RF, 1983, P NATL ACAD SCI-BIOL, V80, P4780, DOI 10.1073/pnas.80.15.4780; MATAGNE RF, 1981, CURR GENET, V3, P31, DOI 10.1007/BF00419578; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MITCHELL AP, 1986, NATURE, V319, P738, DOI 10.1038/319738a0; MUNAUT C, 1990, CURR GENET, V18, P259, DOI 10.1007/BF00318390; NAKAMURA S, 1988, PLANT SCI, V56, P129, DOI 10.1016/0168-9452(88)90026-X; RIS H, 1962, J CELL BIOL, V13, P383, DOI 10.1083/jcb.13.3.383; ROCHAIX JD, 1978, J MOL BIOL, V126, P597, DOI 10.1016/0022-2836(78)90011-6; ROESLER KR, 1990, PLANT PHYSIOL, V94, P1837, DOI 10.1104/pp.94.4.1837; ROSEN H, 1991, CURR GENET, V19, P35, DOI 10.1007/BF00362085; SAGER R, 1954, P NATL ACAD SCI USA, V40, P356, DOI 10.1073/pnas.40.5.356; SAGER R, 1967, P NATL ACAD SCI USA, V58, P931, DOI 10.1073/pnas.58.3.931; Sager R., 1985, MBL (Marine Biology Laboratory) Lectures in Biology, V7, P113; Sambrook J, 1989, MOL CLONING LABORATO; SMITH GM, 1950, P NATL ACAD SCI USA, V36, P246, DOI 10.1073/pnas.36.4.246; Sprague G F Jr, 1990, Adv Genet, V27, P33; STRATHERN J, 1981, J MOL BIOL, V147, P357, DOI 10.1016/0022-2836(81)90488-5; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUBO Y, 1984, CURR GENET, V8, P223, DOI 10.1007/BF00417820; VANWINKLESWIFT KP, 1988, CURR GENET, V13, P331, DOI 10.1007/BF00424428; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WHATLEY JM, 1982, BIOL REV, V57, P527, DOI 10.1111/j.1469-185X.1982.tb00373.x; WOESSNER JP, 1992, PLANT SCI, V83, P65, DOI 10.1016/0168-9452(92)90063-R; WOESSNER JP, 1989, PLANT CELL, V1, P901	62	56	59	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 10	1993	74	5					801	811		10.1016/0092-8674(93)90460-8	http://dx.doi.org/10.1016/0092-8674(93)90460-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374951				2022-12-28	WOS:A1993LX29200006
J	COZART, JC				COZART, JC			THE LEGACY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1160	1160		10.1001/jama.270.10.1160	http://dx.doi.org/10.1001/jama.270.10.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355366				2022-12-28	WOS:A1993LV64900001
J	SHARP, D; BLINDERMAN, L; COMBS, KA; KIENZLE, B; RICCI, B; WAGERSMITH, K; GIL, CM; TURCK, CW; BOUMA, ME; RADER, DJ; AGGERBECK, LP; GREGG, RE; GORDON, DA; WETTERAU, JR				SHARP, D; BLINDERMAN, L; COMBS, KA; KIENZLE, B; RICCI, B; WAGERSMITH, K; GIL, CM; TURCK, CW; BOUMA, ME; RADER, DJ; AGGERBECK, LP; GREGG, RE; GORDON, DA; WETTERAU, JR			CLONING AND GENE DEFECTS IN MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ASSOCIATED WITH ABETALIPOPROTEINEMIA	NATURE			English	Article							HEP G2 CELLS; APOLIPOPROTEIN-B; INTRACELLULAR DEGRADATION; DISULFIDE ISOMERASE; SECRETION; LIPOPROTEINS; COMPLEX; SITES	THE microsomal triglyceride transfer protein (MTP), which catalyses the transport of triglyceride, cholesteryl ester and phospholipid between phospholipid surfaces, is a heterodimer composed of the multifunctional protein, protein disulphide isomerase, and a unique large subunit with an apparent M(r) of 88K (refs 1-3). It is isolated as a soluble protein from the lumen of the microsomal fraction of liver and intestine4. The large subunit of MTP was not detectable in four unrelated subjects with abetatipoproteinaemia5, a rare autosomal recessive disease characterized by a defect in the assembly or secretion of plasma lipoproteins that contain apolipoprotein B (ref. 6). We report here the isolation and sequencing of complementary DNA encoding the large subunit of MTP. A comparison of this sequence to corresponding genomic sequences from two abetatipoproteinaemic subjects revealed a homozygous frameshift mutation in one subject and a homozygous nonsense mutation in the other. The results indicate that a defect in the gene for die large subunit of MTP is the proximal cause of abetalipoproteinaemia in these two subjects, and that MTP is required for the secretion of plasma lipoproteins that contain apolipoprotein B.	BRISTOL MYERS SQUIBB,DEPT METAB DIS,PRINCETON,NJ 08543; UNIV CINCINNATI,DEPT PHARMACOL & CELL BIOPHYS,CINCINNATI,OH 45267; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT MED,SAN FRANCISCO,CA 94143; UNIV PARIS 07,INSERM,U327,F-75018 PARIS,FRANCE; NHLBI,MOLEC DIS BRANCH,BETHESDA,MD 20892; CNRS,CTR GENET MOLEC,F-91198 GIF SUR YVETTE,FRANCE	Bristol-Myers Squibb; University System of Ohio; University of Cincinnati; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay			Eckhardt, Erik/G-1567-2010					CIANFLONE KM, 1990, J LIPID RES, V31, P2045; DAVIS RA, 1989, J LIPID RES, V30, P1185; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FURUKAWA S, 1992, J BIOL CHEM, V267, P22630; Kane J.B., 1989, METABOLIC BASIS INHE, P1139; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SATO R, 1990, J BIOL CHEM, V265, P11880; SCHAFER BL, 1992, J BIOL CHEM, V267, P13229; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; WHITE AL, 1992, J BIOL CHEM, V267, P15657; 1988, ARCH INTERN MED, V18, P36	17	362	383	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					65	69		10.1038/365065a0	http://dx.doi.org/10.1038/365065a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361539				2022-12-28	WOS:A1993LV64600055
J	FARABAUGH, PJ				FARABAUGH, PJ			ALTERNATIVE READINGS OF THE GENETIC-CODE	CELL			English	Editorial Material							ESCHERICHIA-COLI; RNA PSEUDOKNOT; STOP CODON; SIGNAL; DOWNSTREAM; SEQUENCE; TERMINATION; SUPPRESSION; TRANSLATION; GENE-60				FARABAUGH, PJ (corresponding author), UNIV MARYLAND, DEPT BIOL SCI, CATONSVILLE, MD 21228 USA.			Farabaugh, Philip/0000-0002-5658-7141				ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BJORK GR, 1989, SCIENCE, V244, P986, DOI 10.1126/science.2471265; BOCK A, 1991, TRENDS BIOCHEM SCI, V16, P463, DOI 10.1016/0968-0004(91)90180-4; BRIERLEY I, 1989, CELL, V57, P537, DOI 10.1016/0092-8674(89)90124-4; BROWN CM, 1990, NUCLEIC ACIDS RES, V18, P6339, DOI 10.1093/nar/18.21.6339; BRUCE AG, 1986, P NATL ACAD SCI USA, V83, P5062, DOI 10.1073/pnas.83.14.5062; CURRAN JF, 1993, NUCLEIC ACIDS RES, V21, P1837, DOI 10.1093/nar/21.8.1837; FARABAUGH PJ, 1993, CELL, V74, P93, DOI 10.1016/0092-8674(93)90297-4; FENG YX, 1992, J VIROL, V66, P5127, DOI 10.1128/JVI.66.8.5127-5132.1992; HATFIELD D, 1993, TRENDS GENET, V9, P69, DOI 10.1016/0168-9525(93)90215-4; HATFIELD D, 1989, VIROLOGY, V173, P736, DOI 10.1016/0042-6822(89)90589-8; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; HUANG WM, 1988, SCIENCE, V239, P1005, DOI 10.1126/science.2830666; JORGENSEN F, 1993, J MOL BIOL, V230, P41, DOI 10.1006/jmbi.1993.1124; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; LUSTIG F, 1989, P NATL ACAD SCI USA, V86, P6873, DOI 10.1073/pnas.86.18.6873; NINIO J, 1974, J MOL BIOL, V84, P297, DOI 10.1016/0022-2836(74)90586-5; SKUZESKI JM, 1991, J MOL BIOL, V218, P365, DOI 10.1016/0022-2836(91)90718-L; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; Weiss R B, 1990, Prog Nucleic Acid Res Mol Biol, V39, P159, DOI 10.1016/S0079-6603(08)60626-1; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WILLS NM, 1991, P NATL ACAD SCI USA, V88, P6991, DOI 10.1073/pnas.88.16.6991; WILSON RK, 1989, P NATL ACAD SCI USA, V86, P409, DOI 10.1073/pnas.86.2.409	26	47	47	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					591	596		10.1016/0092-8674(93)90507-M	http://dx.doi.org/10.1016/0092-8674(93)90507-M			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358788	Green Published, Bronze			2022-12-28	WOS:A1993LU59200003
J	LIEBERMAN, DE				LIEBERMAN, DE			LIFE-HISTORY VARIABLES PRESERVED IN DENTAL CEMENTUM MICROSTRUCTURE	SCIENCE			English	Article							BONE	The age and season of death of mammals, as well as other aspects of their life history, can be estimated from seasonal bands in dental cementum that result from variations in microstructure. Scanning electron micrographs of goats fed controlled diets demonstrate that cementum bands preserve variations in the relative orientation of collagen fibers that reflect changes in the magnitude and frequency of occlusal forces from chewing different quality diets. Changes in the rate of tissue growth are also reflected in cementum bands as variations in the degree of mineralization.	HARVARD UNIV,SOC FELLOWS,CAMBRIDGE,MA 02138	Harvard University	LIEBERMAN, DE (corresponding author), HARVARD UNIV,DEPT ANTHROPOL,11 DIVIN AVE,CAMBRIDGE,MA 02138, USA.		Self, Casey J/B-6871-2011					BOURQUE BJ, 1978, SCIENCE, V199, P530, DOI 10.1126/science.199.4328.530; Boyde A, 1972, DEV ASPECTS ORAL BIO, P243; BURGER E, 1991, BONE, V7, pCH2; CASTANET J, 1991, BONE, V7, pCH9; DERICQLES A, 1991, BONE, V3, pCH1; Fancy S.G., 1980, Wildlife Society Bulletin, V8, P242; GLIMCHER M, 1987, NATURE MINERAL COMPO, P49; Grue H., 1979, Danish Review of Game Biology, V11, P1; HYLANDER WL, 1986, ARCH ORAL BIOL, V31, P149, DOI 10.1016/0003-9969(86)90120-2; JONES SJ, 1987, SCANNING MICROSCOPY, V1, P2003; JONES SJ, 1981, DENTAL ANATOMY EMBRY, P66; Klevezal G.A., 1967, AGE DETERMINATION MA; LANYON L, 1991, BONE, V3, pCH2; LAWS RM, 1952, NATURE, V169, P972, DOI 10.1038/169972b0; Lieberman D.E., 1993, THESIS HARVARD U; LIEBERMAN DE, 1992, MAMMAL REV, V22, P57, DOI 10.1111/j.1365-2907.1992.tb00120.x; Lowenstam HA, 1989, BIOMINERALIZATION; MARTIN RB, 1989, STRUCTURE FUNCTION A; PEABODY FE, 1961, J MORPHOL, V108, P11, DOI 10.1002/jmor.1051080103; Portigliatti Barbos M, 1984, Metab Bone Dis Relat Res, V5, P309, DOI 10.1016/0221-8747(84)90018-3; SAXON A, 1969, AM ANTIQUITY, V34, P303, DOI 10.2307/278413; SCHMIDT WJ, 1972, POLARIZING MICROSCOP; Selvig K A, 1965, Acta Odontol Scand, V23, P423, DOI 10.3109/00016356509007523; WEINER S, 1992, FASEB J, V6, P879, DOI 10.1096/fasebj.6.3.1740237; WEINSTOCK M, 1973, J CELL BIOL, V56, P838, DOI 10.1083/jcb.56.3.838	25	94	95	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1162	1164		10.1126/science.8356448	http://dx.doi.org/10.1126/science.8356448			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356448				2022-12-28	WOS:A1993LU58600029
J	KUBO, Y; REUVENY, E; SLESINGER, PA; JAN, YN; JAN, LY				KUBO, Y; REUVENY, E; SLESINGER, PA; JAN, YN; JAN, LY			PRIMARY STRUCTURE AND FUNCTIONAL EXPRESSION OF A RAT G-PROTEIN-COUPLED MUSCARINIC POTASSIUM CHANNEL	NATURE			English	Article							SENSITIVE K+-CHANNEL; GAMMA-SUBUNIT; ION CHANNELS; INWARD RECTIFICATION; XENOPUS OOCYTES; BETA-SUBUNIT; ACTIVATION; RECEPTOR; NEURONS; CONDUCTANCE	PARASYMPATHETIC nerve stimulation causes slowing of the heart rate by activation of muscarinic receptors and the subsequent opening of muscarinic K+ channels in the sinoatrial node and atrium1-4. This inwardly rectifying K- channel is coupled directly with G protein5-10. Based on sequence homology with cloned inwardly rectifying K+ channels, ROMK1 (ref. 11) and IRK1 (ref. 12), we have isolated a complementary DNA for a G-protein-coupled inwardly rectifying K+ channel (GIRK1) from rat heart. The GIRK1 channel probably corresponds to the muscarinic K+ channel because (1) its functional properties resemble those of the atrial muscarinic K+ channel and (2) its messenger RNA is much more abundant in the atrium than in the ventricle. In addition, GIRK1 mRNA is expressed not only in the heart but also in the brain.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco				Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299; Kubo, Yoshihiro/0000-0001-6707-0837				ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BROWN AM, 1990, REV PHYSL, V52, P197; BROWN DA, 1990, REV PHYSL, V52, P215; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GAHWILER BH, 1985, P NATL ACAD SCI USA, V82, P1558, DOI 10.1073/pnas.82.5.1558; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GERBER U, 1991, J NEUROSCI, V11, P3861; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; ITO H, 1991, J GEN PHYSIOL, V98, P517, DOI 10.1085/jgp.98.3.517; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; JONES DT, 1987, J BIOL CHEM, V262, P14241; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KURACHI Y, 1992, PROG NEUROBIOL, V39, P229, DOI 10.1016/0301-0082(92)90017-9; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; MORIE M, 1989, J PHYSL, V408, P313; NOMA A, 1979, PFLUG ARCH EUR J PHY, V381, P255, DOI 10.1007/BF00583257; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1985, NATURE, V315, P498, DOI 10.1038/315498a0; TRAUTWEIN W, 1958, PFLUG ARCH GES PHYS, V266, P324, DOI 10.1007/BF00416781; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; WILLIAMS JT, 1988, J NEUROSCI, V8, P3499; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5; YANG XC, 1989, SCIENCE, V243, P1068, DOI 10.1126/science.2466333; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	35	594	608	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 26	1993	364	6440					802	806		10.1038/364802a0	http://dx.doi.org/10.1038/364802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU581	8355805				2022-12-28	WOS:A1993LU58100056
J	ORCI, L; PALMER, DJ; AMHERDT, M; ROTHMAN, JE				ORCI, L; PALMER, DJ; AMHERDT, M; ROTHMAN, JE			COATED VESICLE ASSEMBLY IN THE GOLGI REQUIRES ONLY COATOMER AND ARF PROTEINS FROM THE CYTOSOL	NATURE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; BETA-COP; CLATHRIN; TRANSPORT; STACK; PITS; ENDOCYTOSIS; DISSECTION; MEMBRANES	TRANSPORT vesicles derived from the Golgi apparatus are thought to mediate biosynthetic transport across the Golgi stack1-3. These vesicles are surrounded by a protein coat4 whose principal constituents are coatomer (a complex of seven distinct subunits or COPs)5 and ADP-ribosylation factor (ARF, an N-myristylated small GTP-binding protein). The coat proteins of the COP-coated vesicles were originally defined by ultrastructural criteria4-9, however, and it is possible that important but minor coat proteins or cytoplasmic proteins needed for coat assembly may have been overlooked. Here we show that coatomer and ARF are the only cytoplasmic proteins needed for the assembly and budding of COP-coated vesicles. COP-coated buds may therefore form essentially by self-assembly from Golgi cisternae after an initial step in which GTP is used to allow ARF binding.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	ORCI, L (corresponding author), UNIV GENEVA, MED CTR, DEPT MORPHOL, 1 RUE MICHEL SERVET, CH-1211 GENEVA, SWITZERLAND.							CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; KAHN RA, 1992, J BIOL CHEM, V267, P13039; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P16514; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MOORE MS, 1987, SCIENCE, V236, P558, DOI 10.1126/science.2883727; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PALMER DJ, 1993, J BIOL CHEM, V268, P12083; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; WATERS MG, 1992, METHOD ENZYMOL, V219, P331; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	26	203	208	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	1993	364	6439					732	734		10.1038/364732a0	http://dx.doi.org/10.1038/364732a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355790				2022-12-28	WOS:A1993LT67700063
J	GODFREY, KM; BARKER, DJP; PEACE, J; CLOKE, J; OSMOND, C				GODFREY, KM; BARKER, DJP; PEACE, J; CLOKE, J; OSMOND, C			RELATION OF FINGERPRINTS AND SHAPE OF THE PALM TO FETAL GROWTH AND ADULT-BLOOD PRESSURE	BRITISH MEDICAL JOURNAL			English	Article							LIFE	Objective-To examine how finger and palm prints are related to fetal growth and adult blood pressure. Design-Follow up study of babies born around 50 years ago whose birth weight, placental weight, head circumference, and length at birth were recorded. Setting-Preston, Lancashire. Subjects-139 men and women born in Sharoe Green Hospital in Preston during 1935-43 and still living in Lancashire. Main outcome measures-Finger and palm prints and current blood pressure. Results-People who were thin at birth had more whorl patterns on their fingers. People who were short at birth in relation to their head circumference had longer hands and a narrower palmar angle. Mean systolic blood presure was 8 mmHg higher (95% confidence interval 2 to 13; p=0.01) in the 93 men and women with a whorl pattern on one or more fingers compared with the 46 who had no whorls. The greater the number of fingers with whorls the higher the systolic blood pressure. Whorls on the right hand were more strongly associated with higher systolic pressure than whorls on the left, mean systolic pressure rising by 2.2 mmHg (0.2 to 4.1; p = 0.03) for each additional whorl on the right hand. People with long hands and a narrow palmar angle also had higher systolic pressure. Again, these associations were stronger for the right hand. Mean systolic pressure rose by 0-49 mm Hg (-0.03 to 1.01; p = 0.06) for each degree decrease in palmar angle on the right hand. Conclusions-Fingertip whorls and a narrow palmar angle are indelible markers of impaired fetal development at different stages in pregnancy. Both are associated with raised blood pressure in adult life.	SCENES CRIME DEPT,FINGERPRINT SECT,LONDON SW1,ENGLAND		GODFREY, KM (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655; Godfrey, Keith/0000-0002-4643-0618				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BARRY A, 1951, ANAT RECORD, V111, P221, DOI 10.1002/ar.1091110207; CHERRILL FR, 1954, FINGERPRINT SYSTEM S; DAWES GS, 1990, FETAL AUTONOMY ADAPT, P27; Jain P K, 1984, J Assoc Physicians India, V32, P335; KINMONTH JB, 1974, J CARDIOVASC SURG, V15, P447; LACROIX B, 1984, EARLY HUM DEV, V9, P127, DOI 10.1016/0378-3782(84)90093-8; LAW CM, 1991, ARCH DIS CHILD, V66, P1291, DOI 10.1136/adc.66.11.1291; MULVIHIL.JJ, 1969, J PEDIATR, V75, P579, DOI 10.1016/S0022-3476(69)80453-1; PENROSE LS, 1968, BRIT MED J, V2, P321, DOI 10.1136/bmj.2.5601.321; Pursnani M L, 1989, Indian Heart J, V41, P119; PURVISSMITH SG, 1968, LANCET, V2, P141; RASHAD MN, 1975, AM J PHYS ANTHROPOL, V42, P281, DOI 10.1002/ajpa.1330420218; REED T, 1978, AM J HUM GENET, V30, P383; ROBINSON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1223, DOI 10.1111/j.1471-0528.1991.tb15393.x; RUDOLPH AM, 1984, J DEV PHYSIOL, V6, P11; YOUNG AE, 1983, CIBA F SYMP, V100, P222	21	51	52	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1993	307	6901					405	409		10.1136/bmj.307.6901.405	http://dx.doi.org/10.1136/bmj.307.6901.405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374451	Green Published, Bronze			2022-12-28	WOS:A1993LR89500013
J	PORTER, DR; STURROCK, RD				PORTER, DR; STURROCK, RD			FORTNIGHTLY REVIEW - MEDICAL-MANAGEMENT OF RHEUMATOID-ARTHRITIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONTROLLED CLINICAL-TRIAL; DOUBLE-BLIND TRIAL; ANTIRHEUMATIC DRUGS; PEPTIC-ULCER; FOLLOW-UP; METHOTREXATE; AURANOFIN; GOLD; PROGRESSION; TOXICITY		UNIV GLASGOW, GLASGOW ROYAL INFIRM, CTR RHEUMAT DIS, DEPT MED, GLASGOW G4 0SF, SCOTLAND	University of Glasgow				Porter, Duncan/0000-0001-8481-5204				[Anonymous], 1959, ANN RHEUM DIS, V18, P173; CAPELL HA, 1991, Q J MED, V79, P461; CAPELL HA, 1992, ANN RHEUM DIS, V51, P424, DOI 10.1136/ard.51.3.424; COLLIER DS, 1985, GUT, V26, P359, DOI 10.1136/gut.26.4.359; ELLIOTT M, 1993, BR J RHEUMATOL S1, V32, P107; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FRIES JF, 1993, ARTHRITIS RHEUM, V36, P297, DOI 10.1002/art.1780360303; GARTON MJ, 1993, ARTHRITIS RHEUM, V36, P222, DOI 10.1002/art.1780360213; HANRAHAN PS, 1989, BRIT J RHEUMATOL, V28, P147; JEURISSEN MEC, 1991, ARTHRITIS RHEUM-US, V34, P961, DOI 10.1002/art.1780340805; JEURISSEN MEC, 1991, ANN INTERN MED, V114, P999, DOI 10.7326/0003-4819-114-12-999; MCCARTY DJ, 1990, J RHEUMATOL, V17, P1115; PAULUS HE, 1990, ARTHRITIS RHEUM, V33, P113, DOI 10.1002/art.1780330116; PORTER D, 1992, ANN RHEUM DIS, V51, P461, DOI 10.1136/ard.51.4.461; PORTER DR, 1993, J RHEUMATOL, V20, P645; PULLAR T, 1985, ANN RHEUM DIS, V44, P134, DOI 10.1136/ard.44.2.134; SCOTT DL, 1987, LANCET, V1, P1108; SCOTT DL, 1989, BRIT J RHEUMATOL, V28, P128; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; SINGH G, 1991, J RHEUMATOL, V18, P188; SITUNAYAKE RD, 1987, ANN RHEUM DIS, V46, P177, DOI 10.1136/ard.46.3.177; TUGWELL P, 1990, LANCET, V335, P1051, DOI 10.1016/0140-6736(90)92630-Z; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANDERHEIJDE DMFM, 1992, ARTHRITIS RHEUM-US, V35, P26; WALT RP, 1992, NEW ENGL J MED, V327, P1575; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WATTS RA, 1993, CLIN EXP RHEUMATOL, V11, pS165; WEINBLATT ME, 1992, ARTHRITIS RHEUM, V35, P129, DOI 10.1002/art.1780350202; WEINBLATT ME, 1990, ARTHRITIS RHEUM, V33, P330, DOI 10.1002/art.1780330305; WILLIAMS HJ, 1992, ARTHRITIS RHEUM, V35, P259, DOI 10.1002/art.1780350304; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLFE F, 1990, J RHEUMATOL, V17, P994; 1970, NEW ENGL J MED, V283, P883	33	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	1993	307	6901					425	428		10.1136/bmj.307.6901.425	http://dx.doi.org/10.1136/bmj.307.6901.425			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR895	8374456	Green Published, Bronze			2022-12-28	WOS:A1993LR89500021
J	WILKINSON, R; MILLEDGE, JS; LANDON, MJ				WILKINSON, R; MILLEDGE, JS; LANDON, MJ			MICROALBUMINURIA IN CHRONIC OBSTRUCTIVE LUNG-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							HYPOXIC COR-PULMONALE; PROTEINURIA		NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND; MRC,CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London; Medical Research Council Clinical Trials Unit				Wilkinson, Robert/0000-0002-2753-1800				CAMPBELL JL, 1982, THORAX, V37, P607, DOI 10.1136/thx.37.8.607; DAGGETT P, 1977, POSTGRAD MED J, V53, P24, DOI 10.1136/pgmj.53.615.24; SKLAR AH, 1988, ARCH INTERN MED, V148, P87; STEWART AG, 1991, THORAX, V46, P829, DOI 10.1136/thx.46.11.829; WINTERBORN MH, 1987, POSTGRAD MED J, V63, P179, DOI 10.1136/pgmj.63.737.179	5	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					239	239		10.1136/bmj.307.6898.239	http://dx.doi.org/10.1136/bmj.307.6898.239			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369685	Green Published, Bronze			2022-12-28	WOS:A1993LP31400023
J	ROBERTS, I				ROBERTS, I			WHY HAVE CHILD PEDESTRIAN DEATH RATES FALLEN	BRITISH MEDICAL JOURNAL			English	Article							TRAFFIC INJURIES; ACCIDENTS	Pedestrian injuries are a leading cause of childhood mortality and disability. Over the past two decades in Britain child pedestrian death rates have fallen despite large increases in traffic volume. In this paper Roberts examines the likely reasons for this decline. He argues that neither prevention programmes nor improvements in medical care are a plausible explanation and that the decline is most likely the result of a substantial reduction in children's traffic exposure. He believes, however, that restricting children's traffic exposure exacerbates socioeconomic differentials in childhood mortality and denies children their right to mobility. Roberts is convinced that one answer is for British transport policy to be aimed at providing mobility equitably rather than struggling to meet the ever increasing demands of car travel.			ROBERTS, I (corresponding author), UNIV AUCKLAND,DEPT COMMUNITY HLTH,INJURY PREVENT RES CTR,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.							ADAMS JGU, 1988, ERGONOMICS, V31, P407, DOI 10.1080/00140138808966688; BEAGLEHOLE R, 1991, Journal of Public Health Policy, V12, P175, DOI 10.2307/3342502; DOUGHERTY G, 1990, CAN J PUBLIC HEALTH, V81, P204; FORTENBERRY JC, 1982, ACCIDENT ANAL PREV, V14, P315, DOI 10.1016/0001-4575(82)90044-6; GODLEE F, 1991, BRIT MED J, V303, P329; HILLMAN M, 1991, ONE FALSE MOVE STUDY; MAAS MW, 1984, ACCIDENT ANAL PREV, V16, P167, DOI 10.1016/0001-4575(84)90011-3; MUELLER BA, 1990, AM J EPIDEMIOL, V132, P550, DOI 10.1093/oxfordjournals.aje.a115691; PITT R, 1990, ACCIDENT ANAL PREV, V22, P549, DOI 10.1016/0001-4575(90)90027-I; PLESS IB, 1989, AM J PUBLIC HEALTH, V79, P995, DOI 10.2105/AJPH.79.8.995; PLESS IB, 1987, AM J PUBLIC HEALTH, V77, P358, DOI 10.2105/AJPH.77.3.358; PLESS IB, 1989, J PEDIATR-US, V115, P932, DOI 10.1016/S0022-3476(89)80745-0; PRESTON B, 1989, ACCIDENT ANAL PREV, V21, P291, DOI 10.1016/0001-4575(89)90020-1; PREUSSER DF, 1984, J SAFETY RES, V15, P47, DOI 10.1016/0022-4375(84)90001-X; QUICK A, 1991, UNEQUAL RISKS ACCIDE; RIVARA FP, 1990, AM J DIS CHILD, V144, P692, DOI 10.1001/archpedi.1990.02150300090023; RIVARA FP, 1991, PEDIATRICS, V88, P770; ROBERTS I, 1992, BRIT MED J, V305, P283, DOI 10.1136/bmj.305.6848.283; ROBERTS I, 1992, NEW ZEAL MED J, V105, P51; ROBERTS I, 1991, NEW ZEAL MED J, V104, P247; ROBERTS I, 1992, J PAEDIATR CHILD H, V28, P438, DOI 10.1111/j.1440-1754.1992.tb02713.x; ROBERTS IG, 1993, ARCH DIS CHILD, V68, P190, DOI 10.1136/adc.68.2.190; ROSE G, 1990, BRIT MED J, V301, P683, DOI 10.1136/bmj.301.6754.683; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; SPENCER NJ, 1991, ARCH DIS CHILD, V66, P1255, DOI 10.1136/adc.66.10.1255; Trinca G. W., 1988, REDUCING TRAFFIC INJ; 1992, 3RD NATIONAL INJURY; 1983, TRAFFIC SAFETY CHILD; 1988, OFFICE POPULATION DS, V8	30	62	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1737	1739		10.1136/bmj.306.6894.1737	http://dx.doi.org/10.1136/bmj.306.6894.1737			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LK367	8363665	Green Published, Bronze			2022-12-28	WOS:A1993LK36700027
J	MEHLER, MF; ROZENTAL, R; DOUGHERTY, M; SPRAY, DC; KESSLER, JA				MEHLER, MF; ROZENTAL, R; DOUGHERTY, M; SPRAY, DC; KESSLER, JA			CYTOKINE REGULATION OF NEURONAL DIFFERENTIATION OF HIPPOCAMPAL PROGENITOR CELLS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; CHOLINERGIC NEURONS; NERVOUS-SYSTEM; GROWTH; INTERLEUKIN-11; NEUROFILAMENTS; INVITRO; INSITU; INVIVO; LINE	THE signalling mechanisms governing haematolymphopoiesis and those regulating neural development may be closely related, as indicated by similarities of higher-order structure and function of the cytokines involved1, of the regional and temporal regulation of their transcription and translation2-6, and of their bioactivity7-10. Here we investigate this possible evolutionary connection using retroviral transduction of a temperature-sensitive mutant form of the SV40 large T antigen to develop conditionally immortalized murine embryonic hippocampal progenitor cell lines11-14. Treatment of these cells with cytokines that are thought to participate in progressive lymphoid maturation, immunoglobulin synthesis15-18 and erythropoiesis19,20 causes progressive neuronal differentiation, as defined by morphological criteria, successive expression of increasingly mature neurofilament proteins21-23, and the generation of inward currents and action potentials. The cytokine interleukin(IL)-11 induces expression of action potentials that are insensitive to tetrodotoxin, which is indicative of developmentally immature sodium channels24. By contrast, for expression of more mature action potentials24 (tetrodotoxin-sensitive) one of the interleukins IL-5, IL-7 or IL-9 must be applied in association with transforming growth factor-alpha after pretreatment with basic fibroblast growth factor. Our results suggest that the mechanisms regulating lineage commitment and cellular differentiation in the neural and haematopoietic systems are similar. Further, they define an in vitro model system that may facilitate molecular analysis of graded stages of mammalian neuronal differentiation.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROSCI,BRONX,NY 10461; FED UNIV RIO DE JANEIRO,INST BIOPHYS CARLOS CHAGAS FILHO,BR-21941 RIO JANEIRO,BRAZIL	Yeshiva University; Albert Einstein College of Medicine	MEHLER, MF (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461, USA.		Rozental, Renato/D-5302-2012	Spray, David/0000-0001-8368-5073				BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; CATTANEO E, 1990, NATURE, V347, P762, DOI 10.1038/347762a0; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CUNNINGHAM ET, 1992, J NEUROSCI, V12, P1101; DAHL D, 1988, J NEUROSCI RES, V20, P431, DOI 10.1002/jnr.490200405; EVES EM, 1992, P NATL ACAD SCI USA, V89, P4373, DOI 10.1073/pnas.89.10.4373; FARRAR WL, 1989, BLOOD, V73, P137; FREDERIKSEN K, 1988, NEURON, V1, P439, DOI 10.1016/0896-6273(88)90175-4; GALINOVICSCHWARTZ V, 1991, J NEUROSCI RES, V30, P124, DOI 10.1002/jnr.490300114; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HEUER JG, 1990, NEURON, V5, P283, DOI 10.1016/0896-6273(90)90165-C; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; KAMEGAI M, 1990, NEURON, V2, P429; LAZAR LM, 1992, J NEUROSCI, V12, P1688; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; MUSASHI M, 1991, P NATL ACAD SCI USA, V88, P765, DOI 10.1073/pnas.88.3.765; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PIETSCH T, 1990, KLIN PADIATR, V202, P235, DOI 10.1055/s-2007-1025526; QUESNIAUX VFJ, 1992, BLOOD, V80, P1218; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; SPITZER NC, 1991, J NEUROBIOL, V22, P659, DOI 10.1002/neu.480220702; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519	30	229	232	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					62	65		10.1038/362062a0	http://dx.doi.org/10.1038/362062a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8383296				2022-12-28	WOS:A1993KP97600060
J	DAWSON, TM; ARRIZA, JL; JAWORSKY, DE; BORISY, FF; ATTRAMADAL, H; LEFKOWITZ, RJ; RONNETT, GV				DAWSON, TM; ARRIZA, JL; JAWORSKY, DE; BORISY, FF; ATTRAMADAL, H; LEFKOWITZ, RJ; RONNETT, GV			BETA-ADRENERGIC-RECEPTOR KINASE-2 AND BETA-ARRESTIN-2 AS MEDIATORS OF ODORANT-INDUCED DESENSITIZATION	SCIENCE			English	Article							SENSITIVE ADENYLATE-CYCLASE; OLFACTORY NEURONS; MULTIGENE FAMILY; PROTEIN; CHANNEL; PHOSPHORYLATION; TRANSDUCTION; ACTIVATION; EXPRESSION; ARRESTIN	Beta-adrenergic receptor kinase (betaARK) and beta-arrestin function in the homologous or agonist-activated desensitization of G protein-coupled receptors. The isoforms betaARK-2 and beta-arrestin-2 are highly enriched in and localized to the dendritic knobs and cilia of the olfactory receptor neurons where the initial events of olfactory signal transduction occur. Odorants induce a rapid and transient elevation of adenosine 3',5'-monophosphate (cAMP), which activates a nonspecific cation channel and produces membrane depolarization. Preincubation of rat olfactory cilia with antibodies raised against betaARK-2 and beta-arrestin-2 increased the odorant-induced elevation of cAMP and attenuated desensitization. These results suggest that betaARK-2 and beta-arrestin-2 mediate agonist-dependent desensitization in olfaction.	JOHNS HOPKINS MED INST,DEPT NEUROSCI,725 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT NEUROL,BALTIMORE,MD 21205; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DEPT MED & BIOCHEM,DURHAM,NC 27710	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Attramadal, Havard/0000-0001-9506-0687	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002131, K08NS001578] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 01578-01, NS-02131] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIZA JL, IN PRESS J NEUROSCI; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; BENOVIC JL, 1988, ANNU REV CELL BIOL, V4, P405, DOI 10.1146/annurev.cb.04.110188.002201; BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582; BENOVIC JL, 1987, P NATL ACAD SCI USA, V84, P8879, DOI 10.1073/pnas.84.24.8879; BOEKHOFF I, 1992, P NATL ACAD SCI USA, V89, P471, DOI 10.1073/pnas.89.2.471; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CUNNIGHAM AC, 1991, SOC NEUR ABSTR, V17, P754; CUNNINGHAM A, UNPUB; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FIRESTEIN S, 1991, J NEUROSCI, V11, P3565; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HUGANIR RL, 1990, NEURON, V5, P555, DOI 10.1016/0896-6273(90)90211-W; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEIN WL, 1989, FASEB J, V3, P2132, DOI 10.1096/fasebj.3.10.2546848; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; LORENZ W, 1991, P NATL ACAD SCI USA, V88, P8715, DOI 10.1073/pnas.88.19.8715; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MARGOLIS FL, 1974, BRAIN RES, V81, P469, DOI 10.1016/0006-8993(74)90844-0; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; PARMENTIER M, 1992, NATURE, V355, P453, DOI 10.1038/355453a0; RESTREPO D, 1990, SCIENCE, V249, P1166, DOI 10.1126/science.2168580; RONNETT GV, 1991, P NATL ACAD SCI USA, V88, P2366, DOI 10.1073/pnas.88.6.2366; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6974; SIBLEY DR, 1987, CELL, V48, P913, DOI 10.1016/0092-8674(87)90700-8; SKLAR PB, 1986, J BIOL CHEM, V261, P5538	33	179	183	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 5	1993	259	5096					825	829		10.1126/science.8381559	http://dx.doi.org/10.1126/science.8381559			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KL110	8381559				2022-12-28	WOS:A1993KL11000037
J	DERR, LK; STRATHERN, JN				DERR, LK; STRATHERN, JN			A ROLE FOR REVERSE TRANSCRIPTS IN GENE CONVERSION	NATURE			English	Article							MITOTIC RECOMBINATION; YEAST; SELECTION	RECOMBINATION between a diffusible reverse transcript and its homologous chromosomal allele has been proposed as a mechanism for the precise removal of introns from DNA and gene conversion of dispersed repeated sequences1,2. We have reported that RNA-mediated recombination occurs in the yeast Saccharomyces cerevisiae3. This recombination requires expression of the retro-transposon Ty, and results in intron loss from a plasmid-borne marker gene and the formation of pseudogenes. Because the pseudogenes are embedded in Ty sequences, chromosomal insertion could have been mediated by Ty integrase or by homologous recombination with endogenous Ty sequences. The structure of the chromosomal recombinants and the fact that plasmid and chromosomal recombination can have different requirements demanded a direct demonstration of RNA-mediated gene conversion of a chromosomal allele. Here we report the first demonstration, to our knowledge, of recombination between a reverse transcript and its chromosomal homologue and describe an assay that specifically detects this novel recombination pathway.			DERR, LK (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,EUKARYOT GENE EXPRESS LAB,FREDERICK,MD 21701, USA.							ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BALTIMORE D, 1985, CELL, V40, P481, DOI 10.1016/0092-8674(85)90190-4; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; DERR LK, 1991, CELL, V67, P355, DOI 10.1016/0092-8674(91)90187-4; DORNBURG R, 1988, MOL CELL BIOL, V8, P2328, DOI 10.1128/MCB.8.6.2328; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LINIAL M, 1987, CELL, V49, P93, DOI 10.1016/0092-8674(87)90759-8; MALONE RE, 1988, CURR GENET, V14, P211, DOI 10.1007/BF00376741; MCGILL CB, 1990, CURR GENET, V18, P29, DOI 10.1007/BF00321112; MELAMED C, 1992, MOL CELL BIOL, V4, P1613; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587	13	125	128	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 14	1993	361	6408					170	173		10.1038/361170a0	http://dx.doi.org/10.1038/361170a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG466	8380627	Green Published			2022-12-28	WOS:A1993KG46600065
J	HAGERMAN, DA; WILLIAMS, GP				HAGERMAN, DA; WILLIAMS, GP			SOME FEATURES OF FANCONI-ANEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											HAGERMAN, DA (corresponding author), UNIV WISCONSIN,SCH MED,MADISON,WI 53792, USA.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1168	1168						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377781				2022-12-28	WOS:A1993MA66700006
J	WILLIAMSON, DF; PAMUK, ER				WILLIAMSON, DF; PAMUK, ER			THE ASSOCIATION BETWEEN WEIGHT-LOSS AND INCREASED LONGEVITY - A REVIEW OF THE EVIDENCE	ANNALS OF INTERNAL MEDICINE			English	Article								Six published observational epidemiologic studies have reported evidence of reduced mortality rates in persons who have lost weight. In two studies, the reported protective effects of weight loss on mortality could not be justified by the data. In two other studies, weight loss was associated with both increased and decreased longevity in different subgroups. Only one study provided information on whether the weight loss was voluntary, but this study found similar effects of weight loss regardless of volition. These studies provided only limited information on the magnitude of weight loss associated with changes in longevity and no information on the types of methods used to achieve weight loss. Because of difficulties in studying long-term health outcomes related to obesity treatment, randomized, controlled trials are unlikely to provide a practical study design for this issue. Properly designed observational studies will probably provide the most useful information on the effects of voluntary weight loss on longevity.			WILLIAMSON, DF (corresponding author), CTR DIS CONTROL & PREVENT, DIV NUTR, CHRON DIS PREVENT BRANCH, K-26, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA.							DUBLIN L I, 1951, Trans Assoc Life Insur Med Dir Am, V35, P235; DUBLIN LI, 1953, NEW ENGL J MED, V248, P971, DOI 10.1056/NEJM195306042482304; HAMMOND EC, 1969, ARCH ENVIRON HEALTH, V19, P167, DOI 10.1080/00039896.1969.10666825; LEAN MEJ, 1990, DIABETIC MED, V7, P228, DOI 10.1111/j.1464-5491.1990.tb01375.x; MARTON KI, 1981, ANN INTERN MED, V95, P568, DOI 10.7326/0003-4819-95-5-568; SERDULA MK, 1993, ANN INTERN MED, V119, P667, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00008; SJOSTROM L, 1992, INT J OBESITY, V16, P465; WANNAMETHEE G, 1990, EUR J CLIN NUTR, V44, P133; WILLIAMSON DF, 1991, NEW ENGL J MED, V324, P739, DOI 10.1056/NEJM199103143241106; [No title captured]; 1980, BUILD STUDY 1979	11	73	74	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				731	736		10.7326/0003-4819-119-7_Part_2-199310011-00021	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00021			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363207				2022-12-28	WOS:A1993MA33000021
J	WILSON, GT				WILSON, GT			RELATION OF DIETING AND VOLUNTARY WEIGHT-LOSS TO PSYCHOLOGICAL FUNCTIONING AND BINGE-EATING	ANNALS OF INTERNAL MEDICINE			English	Article							DIETARY RESTRAINT; BULIMIA-NERVOSA; FOLLOW-UP; OBESITY; DEPRESSION; BEHAVIOR; FAILURE; EPIDEMIOLOGY; ADOLESCENTS; RESPONSES	Voluntary weight loss in obese patients consistently reduces negative emotions such as depression and anxiety in the short term. Dieting by persons of normal weight is associated with low self-esteem and depressive symptoms. Dieting is linked to the development and maintenance of eating disorders such as anorexia nervosa and bulimia nervosa, although the precise nature of this association is unclear. Dieting cannot be a sufficient causal condition and must combine with other still undetermined vulnerabilities to cause eating disorders. Identification of these risk factors must precede the development of effective programs to prevent eating disorders.			WILSON, GT (corresponding author), RUTGERS UNIV, GSAPP, BOX 819, PISCATAWAY, NJ 08854 USA.							ABRAHAM SF, 1982, PSYCHOL MED, V12, P625, DOI 10.1017/S0033291700055732; BLUNDELL JE, 1990, APPETITE, V14, P113, DOI 10.1016/0195-6663(90)90006-T; BOOTH DA, 1990, APPETITE, V14, P116, DOI 10.1016/0195-6663(90)90007-U; BRODY M, 1992, 5TH INT C EAT DIS NE; BROWNELL KD, 1991, BEHAV THER, V22, P153, DOI 10.1016/S0005-7894(05)80174-1; COWAN PJ, 1992, BIOL FEAST FAMINE; DUBBERT PM, 1984, BEHAV RES THER, V22, P227, DOI 10.1016/0005-7967(84)90003-2; EBERT MH, 1984, PSYCHOBIOLOGY ANOREX; ELDREDGE K, 1990, INT J EAT DISORDER, V9, P37, DOI 10.1002/1098-108X(199001)9:1<37::AID-EAT2260090105>3.0.CO;2-3; FAIRBURN CG, 1990, AM J PSYCHIAT, V147, P401; FAIRBURN CG, 1982, BRIT MED J, V284, P1153, DOI 10.1136/bmj.284.6323.1153; FAIRBURN CG, IN PRESS BINGE EATIN; GARNER DM, 1987, PSYCHOTHER PSYCHOSOM, V48, P170, DOI 10.1159/000288049; GARNER DM, 1991, CLIN PSYCHOL REV, V11, P729, DOI 10.1016/0272-7358(91)90128-H; GOLDFEIN J, 1992, APR INT C EAT DIS NE; HALMI KA, 1980, AM J CLIN NUTR, V33, P446, DOI 10.1093/ajcn/33.2.446; HERMAN CP, 1988, PSYCHOL BULIMIA NERV; Hsu L. K. G., 1990, EATING DISORDERS; KAGAN DM, 1983, INT J EAT DISORDER, V3, P15, DOI 10.1002/1098-108X(198323)3:1<15::AID-EAT2260030103>3.0.CO;2-0; KENDLER KS, 1991, AM J PSYCHIAT, V148, P1627; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; LOWE MR, 1988, APPETITE, V10, P159, DOI 10.1016/0195-6663(88)90009-8; MARCUS MD, 1992, INT J EAT DISORDER, V12, P249, DOI 10.1002/1098-108X(199211)12:3&lt;249::AID-EAT2260120304&gt;3.0.CO;2-W; Marlatt GA., 1985, RELAPSE PREVENTION; OHNO M, 1991, PROGR OBESITY RES; ONEILL PM, 1992, TREATMENT OBESITY RE; PATTON GC, 1990, PSYCHOL MED, V20, P383, DOI 10.1017/S0033291700017700; PERRI MG, 1988, J CONSULT CLIN PSYCH, V56, P529, DOI 10.1037/0022-006X.56.4.529; POLIVY J, 1985, AM PSYCHOL, V40, P193, DOI 10.1037/0003-066X.40.2.193; RODIN J, 1990, INT J OBESITY, V14, P303; ROSEN JC, 1990, INT J EAT DISORDER, V9, P17, DOI 10.1002/1098-108X(199001)9:1&lt;17::AID-EAT2260090103&gt;3.0.CO;2-F; ROSEN JC, 1987, J CONSULT CLIN PSYCH, V55, P742; ROSEN JC, 1990, ADV PSYCHOL ASSESSME, V7; ROSSITER EM, 1992, INT J EAT DISORDER, V11, P111, DOI 10.1002/1098-108X(199203)11:2&lt;111::AID-EAT2260110203&gt;3.0.CO;2-J; RUDERMAN AJ, 1986, PSYCHOL BULL, V99, P247, DOI 10.1037/0033-2909.99.2.247; SMOLLER JW, 1987, J PSYCHOSOM RES, V31, P429, DOI 10.1016/0022-3999(87)90001-8; SPITZER RL, 1992, INT J EAT DISORDER, V11, P191, DOI 10.1002/1098-108X(199204)11:3&lt;191::AID-EAT2260110302&gt;3.0.CO;2-S; STUNKARD AJ, 1974, ANN INTERN MED, V81, P526, DOI 10.7326/0003-4819-81-4-526; STUNKARD AJ, 1986, AM J PSYCHIAT, V143, P417; STUNKARD AJ, 1985, J PSYCHOSOM RES, V29, P71, DOI 10.1016/0022-3999(85)90010-8; TELCH CF, 1993, IN PRESS BEHAV THER; TUSCHL RJ, 1990, APPETITE, V14, P105, DOI 10.1016/0195-6663(90)90004-R; TUSCHL RJ, 1990, APPETITE, V14, P9, DOI 10.1016/0195-6663(90)90050-I; WADDEN TA, 1988, J CONSULT CLIN PSYCH, V56, P925, DOI 10.1037/0022-006X.56.6.925; WADDEN TA, 1986, J CONSULT CLIN PSYCH, V54, P869, DOI 10.1037/0022-006X.54.6.869; WARDLE J, 1990, ADDICT BEHAV, V15, P387, DOI 10.1016/0306-4603(90)90047-2; WARDLE J, 1987, BRIT J CLIN PSYCHOL, V26, P47, DOI 10.1111/j.2044-8260.1987.tb00722.x; WILSON GT, 1993, INT J EAT DISORDER, V13, P25, DOI 10.1002/1098-108X(199301)13:1&lt;25::AID-EAT2260130104&gt;3.0.CO;2-T; WILSON GT, 1992, EATING BODY WEIGHT P; WING RR, 1992, TREATMENT OBESITY RE; WOOLEY SC, 1991, J AM DIET ASSOC, V91, P1248; IN PRESS DIAGNOSTIC	53	86	88	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				727	730		10.7326/0003-4819-119-7_Part_2-199310011-00020	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00020			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363206				2022-12-28	WOS:A1993MA33000020
J	BROENE, RD; BUCHWALD, SL				BROENE, RD; BUCHWALD, SL			ZIRCONOCENE COMPLEXES OF UNSATURATED ORGANIC-MOLECULES - NEW VEHICLES FOR ORGANIC-SYNTHESIS	SCIENCE			English	Article							ANSA-METALLOCENE DERIVATIVES; BRIDGED TETRAHYDROINDENYL LIGANDS; METAL-COMPLEXES; POLYSUBSTITUTED NAPHTHALENES; REGIOSPECIFIC SYNTHESIS; MAGNESIUM REAGENTS; MEDIATED SYNTHESIS; CRYSTAL-STRUCTURE; ALLYLIC AMINES; ZIRCONIUM	Transition metals are known to stabilize high-energy species and to activate otherwise unreactive ones. The zirconocene unit stabilizes highly strained alkynes and alkenes, allowing their use in selective carbon-carbon bond-forming reactions. This unit also increases the reactivity of unactivated molecules, enabling them to participate in nontraditional transformations. A general route has been developed that allows a wider variety of unsaturated fragments to participate in these reactions. The use of these zirconocene complexes in organic synthesis has led to the development of novel routes to a number of polyfunctionalized organic molecules.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034917] Funding Source: NIH RePORTER; NCI NIH HHS [CA 09112] Funding Source: Medline; NIGMS NIH HHS [GM 34917] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENDER BR, 1992, ORGANOMETALLICS, V11, P3427, DOI 10.1021/om00046a049; BENNETT MA, 1989, ANGEW CHEM INT EDIT, V28, P1296, DOI 10.1002/anie.198912961; BERK SC, 1993, J AM CHEM SOC, V115, P4912, DOI 10.1021/ja00064a071; BUCHWALD SL, 1988, CHEM REV, V88, P1047, DOI 10.1021/cr00089a004; BUCHWALD SL, 1987, J AM CHEM SOC, V109, P4396, DOI 10.1021/ja00248a046; BUCHWALD SL, 1991, J AM CHEM SOC, V113, P258, DOI 10.1021/ja00001a037; BUCHWALD SL, 1986, J AM CHEM SOC, V108, P7411, DOI 10.1021/ja00283a048; BUCHWALD SL, 1990, ANGEW CHEM INT EDIT, V29, P771, DOI 10.1002/anie.199007711; BUCHWALD SL, 1989, J AM CHEM SOC, V111, P2870, DOI 10.1021/ja00190a021; BUCHWALD SL, 1989, J ORG CHEM, V54, P2793, DOI 10.1021/jo00273a006; BUCHWALD SL, 1989, J AM CHEM SOC, V111, P4486, DOI 10.1021/ja00194a052; BUCHWALD SL, 1988, J AM CHEM SOC, V110, P3171, DOI 10.1021/ja00218a027; BUCHWALD SL, 1989, CHEM SCRIPTA, V29, P417; Cardin D. J., 1986, CHEM ORGANOZIRCONIUM; COLEMAN RS, 1989, STUDIES NATURAL PROD, V3, P301; COLES N, 1992, SYNLETT, P143; COLES N, 1990, SYNLETT, P271; COLLMAN JP, 1987, PRINCIPLES APPLICATI; Curran DP, 1991, COMPREHENSIVE ORGANI, P714; DZHEMILEV VM, 1989, IZV AKAD NAUK KAZ K, V38, P207; ERKER G, 1977, J ORGANOMET CHEM, V134, P189, DOI 10.1016/S0022-328X(00)81419-9; ERKER G, 1979, J AM CHEM SOC, V101, P3659, DOI 10.1021/ja00507a043; FAGAN PJ, 1988, J AM CHEM SOC, V110, P2310, DOI 10.1021/ja00215a057; FANG Q, UNPUB; GANT TG, 1992, J AM CHEM SOC, V114, P1010, DOI 10.1021/ja00029a032; GROSSMAN RB, 1991, J AM CHEM SOC, V113, P2321, DOI 10.1021/ja00006a071; HALTERMAN RL, 1992, CHEM REV, V92, P965, DOI 10.1021/cr00013a011; HEGEDUS LS, 1988, ANGEW CHEM INT EDIT, V27, P1113, DOI 10.1002/anie.198811133; HOVEYDA AH, 1992, J AM CHEM SOC, V114, P6692, DOI 10.1021/ja00043a012; HSU DP, 1990, TETRAHEDRON LETT, V31, P5563, DOI 10.1016/S0040-4039(00)97897-3; JENSEN M, 1989, J AM CHEM SOC, V111, P4495, DOI 10.1021/ja00194a053; JORDAN RF, 1989, J AM CHEM SOC, V111, P778, DOI 10.1021/ja00184a081; KNIGHT KS, 1991, J AM CHEM SOC, V113, P6268, DOI 10.1021/ja00016a052; LAUHER JW, 1976, J AM CHEM SOC, V98, P1729, DOI 10.1021/ja00423a017; LEWIS DP, 1991, TETRAHEDRON LETT, V32, P6797, DOI 10.1016/S0040-4039(00)93606-2; MASUI H, 1968, B CHEM SOC JPN, V41, P750; NEGISHI, 1989, J ORG CHEM, V54, P3521; NEGISHI E, 1989, CHEM SCRIPTA, V29, P457; NEGISHI EI, 1991, COMPREHENSIVE ORGANI, V5, P1163; NOYORI R, 1990, SCIENCE, V248, P1194, DOI 10.1126/science.248.4960.1194; NUGENT WA, 1989, CHEM SCRIPTA, V29, P439; NUGENT WA, 1993, SCIENCE, V259, P479, DOI 10.1126/science.259.5094.479; NUGENT WA, 1989, J AM CHEM SOC, V111, P6435, DOI 10.1021/ja00198a073; RADOM L, 1986, PURE APPL CHEM, V58, P75, DOI 10.1351/pac198658010075; SCHAFER A, 1987, J ORGANOMET CHEM, V328, P87, DOI 10.1016/S0022-328X(00)99770-5; Schore N. E., 1991, COMPREHENSIVE ORGANI, V5, P1037; SHUR VB, 1985, J ORGANOMET CHEM, V288, pC36; SPENCE REV, 1992, ORGANOMETALLICS, V11, P3492, DOI 10.1021/om00059a003; TAKAHASHI T, 1991, J AM CHEM SOC, V113, P6266, DOI 10.1021/ja00016a051; TIDWELL JH, 1992, J ORG CHEM, V57, P6380, DOI 10.1021/jo00050a003; TIDWELL JH, 1991, J AM CHEM SOC, V113, P4685, DOI 10.1021/ja00012a050; TIDWELL JH, UNPUB; Trost B M, 1991, COMPREHENSIVE ORGANI, V1-9; Trost B. M., 1991, COMPREHENSIVE ORGANI, V4; Trost B. M., 1991, COMPREHENSIVE ORGANI, V2; VOLPIN ME, 1971, J CHEM SOC CHEM COMM, P972; WILD FRWP, 1982, J ORGANOMET CHEM, V232, P233; WILD FRWP, 1985, J ORGANOMET CHEM, V288, P63, DOI 10.1016/0022-328X(85)80104-2; WISCHMEYER U, 1992, TETRAHEDRON LETT, V33, P7735, DOI 10.1016/0040-4039(93)88032-E; WULFF WD, 1988, J AM CHEM SOC, V110, P2312, DOI 10.1021/ja00215a058	60	168	169	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1696	1701		10.1126/science.8378769	http://dx.doi.org/10.1126/science.8378769			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378769				2022-12-28	WOS:A1993LY58400016
J	DRISCOLL, J; BROWN, MG; FINLEY, D; MONACO, JJ				DRISCOLL, J; BROWN, MG; FINLEY, D; MONACO, JJ			MHC-LINKED LMP GENE-PRODUCTS SPECIFICALLY ALTER PEPTIDASE ACTIVITIES OF THE PROTEASOME	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II REGION; MULTICATALYTIC PROTEINASE; ANTIGEN PRESENTATION; SUBUNITS; PATHWAY; CELLS	PROTEASOMES are highly conserved macromolecular structures which function as endopeptidases1-3. They are found in the cytoplasm and nucleus of eukaryotic tissues and consist of at least 14 non-identical subunits with molecular masses ranging from approximately 20 to 32K. Proteasomes are essential in the selective degradation of ubiquitinated and certain non-ubiquitinated proteins, acting as the proteolytic core of an energy-dependent 26S (1,500K) proteolytic complex. Two proteasome subunits, LMP2 and LMP7 (refs 4-7), are encoded within the major histocompatibility complex (MHC), implicating proteasomes in antigen processing8-9. Here we determine the function of these two MHC-linked subunits by comparing the proteolytic activities of purified proteasomes containing (LMP+) or lacking (LMP-) these components. We find that proteasomes of both types have endopeptidase activity against substrates bearing hydrophobic, basic or acidic residues immediately preceding the cleavage site (the P1 position) and at sites following asparagine, glycine and proline residues. The activity of LMP+ proteasomes is much higher than that of LMP- proteasomes against substrates with hydrophobic, basic or asparagine residues at P1, whereas their activities are comparable when acidic and glycine residues are present at P1. The MHC-linked LMP2 and LMP7 subunits therefore function to amplify specific endopeptidase activities of the proteasome.	HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MICROBIOL & IMMUNOL,RICHMOND,VA 23298	Harvard University; Harvard Medical School; Virginia Commonwealth University			Brown, Michael G/AAX-5569-2021	Brown, Michael G/0000-0003-2872-7685; Driscoll, James/0000-0001-8364-0617				ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; BROWN MG, 1993, J IMMUNOL, V151, P1193; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; MARTINEZ CK, 1991, NATURE, V353, P664, DOI 10.1038/353664a0; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; ORINO E, 1991, FEBS LETT, V284, P206, DOI 10.1016/0014-5793(91)80686-W; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; ROTZSCHKE O, 1991, IMMUNOL TODAY, V12, P447, DOI 10.1016/0167-5699(91)90018-O; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928	21	431	441	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					262	264		10.1038/365262a0	http://dx.doi.org/10.1038/365262a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371781				2022-12-28	WOS:A1993LX47100057
J	PARK, HO; CHANT, J; HERSKOWITZ, I				PARK, HO; CHANT, J; HERSKOWITZ, I			BUD2 ENCODES A GTPASE-ACTIVATING PROTEIN FOR BUD1/RSR1 NECESSARY FOR PROPER BUD-SITE SELECTION IN YEAST	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; RAS GTPASE; CELL POLARITY; GENE; PATHWAY; IRA2; GAP; PURIFICATION; REGULATOR; EXCHANGE	CELLS of the budding yeast Saccharomyces cerevisiae bud at either axial or bipolar sites depending on their cell type1. Bud-site selection directs both cell polarity and the cytoskeletal orientation during budding and is determined by at least five genes: BUD1/RSR1, BUD2, BUD3, BUD4 and BUD52-4. Mutants defective in BUD1, BUD2 or BUD5 choose bud sites randomly. Bud1 protein (Bud1p) has sequence similarity to Ras, a small GTP-binding protein, and Bud5p is similar to Cdc25p (refs 4, 5), a GDP-GTP exchange factor6. Here we report that Bud2p is a GTPase-activating protein (GAP) for Bud1p with a sequence similar to the catalytic domain of rasGAPs, and that Bud2p purified from yeast stimulates GTP hydrolysis by Bud1p. Chromosomal deletion of BUD2 causes a random budding pattern but no obvious growth defect. Overexpression of BUD2 also causes a random budding pattern by wild-type cells11.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, PROGRAM GENET, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, PROGRAM CELL BIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco				Park, Hay-Oak/0000-0001-5782-2257				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENDER A, IN PRESS P NATN ACAD; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; POWERS S, 1991, CELL, V65, P1225, DOI 10.1016/0092-8674(91)90017-S; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	27	149	152	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 16	1993	365	6443					269	274		10.1038/365269a0	http://dx.doi.org/10.1038/365269a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371782				2022-12-28	WOS:A1993LX47100060
J	CZAJA, AJ				CZAJA, AJ			CHRONIC ACTIVE HEPATITIS - THE CHALLENGE FOR A NEW NOMENCLATURE	ANNALS OF INTERNAL MEDICINE			English	Review							CHRONIC LIVER-DISEASE; PRIMARY SCLEROSING CHOLANGITIS; C VIRUS-INFECTION; CHRONIC PERSISTENT HEPATITIS; CHRONIC ULCERATIVE-COLITIS; MICROSOME ANTIBODY TYPE-1; AUTOIMMUNE HEPATITIS; ANTIMITOCHONDRIAL ANTIBODIES; CLINICAL-FEATURES; VIRAL-HEPATITIS	Objectives: To review the etiologic agents and pathogenic mechanisms of chronic active hepatitis, to describe the current nomenclature for this disease and highlight its shortcomings, and to propose guidelines for change. Data Sources: Relevant references were identified through a MEDLINE search (1982 to 1992), through prominent review articles and texts, and through a personal library of journals and reprints. Additional references were selected from the bibliographies of identified articles. Study Selection: All pertinent articles on the etiologic agents, pathogenic mechanisms, and nomenclature of chronic active hepatitis were studied. Data Synthesis: Subtypes of chronic active hepatitis can be defined by etiologic agent or immunoserologic marker, and these subtypes may have different clinical features, prognoses, pathogenic mechanisms, and treatments. An unauthorized jargon has evolved to accommodate these subtypes, and it may wrongly or prematurely connote their validity. Patients with cryptogenic disease, mixed viral and immunologic features, and atypical findings lack a formal designation. No established mechanism exists for modification of the nomenclature. Conclusions: Chronic hepatitis can be subclassified into different subtypes that are defined by etiologic agent or by predominate pathogenic mechanism. A new nomenclature must be based on this knowledge. Formal mechanisms must be established to revise the nomenclature and to promulgate change.			CZAJA, AJ (corresponding author), MAYO CLIN & MAYO FDN, 200 1ST ST SW, ROCHESTER, MN 55905 USA.							ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; [Anonymous], 1977, LANCET, V2, P914; BAGGENSTOSS AH, 1972, HUM PATHOL, V3, P183, DOI 10.1016/S0046-8177(72)80072-8; BEARN AG, 1956, AM J MED, V21, P3, DOI 10.1016/0002-9343(56)90003-1; BECKER MD, 1970, LANCET, V1, P53; BERG PA, 1980, LANCET, V2, P1329; BONGIOVANNI AM, 1951, J CLIN ENDOCRINOL, V11, P152, DOI 10.1210/jcem-11-2-152; BOYER JL, 1970, NEW ENGL J MED, V283, P1063, DOI 10.1056/NEJM197011122832001; BOYER JL, 1976, GASTROENTEROLOGY, V70, P1161; BULKLEY BH, 1970, LANCET, V2, P1323; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHRISTOFFERSEN P, 1972, ACTA PATH MICRO IM A, VA 80, P294; COHEN S, 1960, J EXP MED, V111, P285, DOI 10.1084/jem.111.2.285; Cullinan ER, 1936, ST BARTHOLOMEW HOSP, V69, P55; CZAJA AJ, 1990, MAYO CLIN PROC, V65, P1303, DOI 10.1016/S0025-6196(12)62141-7; CZAJA AJ, 1979, MAYO CLIN PROC, V54, P721; CZAJA AJ, 1993, GASTROENTEROLOGY, V104, P1755, DOI 10.1016/0016-5085(93)90656-W; CZAJA AJ, 1984, SEMIN LIVER DIS, V4, P1, DOI 10.1055/s-2008-1040641; CZAJA AJ, 1992, GASTROENTEROLOGY, V103, P1290, DOI 10.1016/0016-5085(92)91518-9; CZAJA AJ, 1981, MAYO CLIN PROC, V56, P311; CZAJA AJ, 1992, J HEPATOL, V14, P88, DOI 10.1016/0168-8278(92)90135-C; CZAJA AJ, 1990, J GASTROEN HEPATOL, V5, P343, DOI 10.1111/j.1440-1746.1990.tb01636.x; CZAJA AJ, 1984, HEPATOLOGY, V4, P622, DOI 10.1002/hep.1840040409; CZAJA AJ, 1981, NEW ENGL J MED, V304, P5, DOI 10.1056/NEJM198101013040102; CZAJA AJ, 1983, GASTROENTEROLOGY, V85, P713; CZAJA AJ, 1992, GASTROENTEROLOGY, V102, P1675, DOI 10.1016/0016-5085(92)91729-N; CZAJA AJ, 1990, MAYO CLIN PROC, V65, P23, DOI 10.1016/S0025-6196(12)62106-5; CZAJA AJ, 1991, MAYO CLIN PROC, V66, P572, DOI 10.1016/S0025-6196(12)60515-1; CZAJA AJ, IN PRESS GASTROENTER; DEGROOTE J, 1968, LANCET, V2, P626; Doniach D, 1966, Clin Exp Immunol, V1, P237; EDDLESTON ALWF, 1976, ANN CLIN RES, V8, P162; ESTEBAN JI, 1989, LANCET, V2, P294; FRAZER IH, 1983, CLIN EXP IMMUNOL, V54, P213; GERBER MA, 1992, HEPATOLOGY, V15, P733, DOI 10.1002/hep.1840150430; GEUBEL AP, 1976, GASTROENTEROLOGY, V71, P444; GOLDSTEIN GB, 1973, AM J DIG DIS, V18, P177, DOI 10.1007/BF01071970; GREEVE M, 1993, HEPATOLOGY, V17, P593, DOI 10.1002/hep.1840170411; GUDAT F, 1975, LAB INVEST, V32, P1; HOMBERG JC, 1987, HEPATOLOGY, V7, P1333, DOI 10.1002/hep.1840070626; HOPF U, 1976, NEW ENGL J MED, V294, P578, DOI 10.1056/NEJM197603112941103; JENSEN DM, 1978, NEW ENGL J MED, V299, P1, DOI 10.1056/NEJM197807062990101; JOSKE RA, 1955, LANCET, V2, P477; KATKOV WN, 1991, ARCH INTERN MED, V151, P1548, DOI 10.1001/archinte.151.8.1548; KENNY RP, 1986, DIGEST DIS SCI, V31, P705, DOI 10.1007/BF01296447; KLATSKIN G, 1958, AM J MED, V25, P333, DOI 10.1016/0002-9343(58)90072-X; KLOPPEL G, 1977, VIRCHOWS ARCH A, V373, P143, DOI 10.1007/BF00432159; KUNKEL HG, 1951, J CLIN INVEST, V30, P654; Leevy CM, 1976, FOGARTY INT CTR P, V22, P1; LENZI M, 1990, LANCET, V335, P258, DOI 10.1016/0140-6736(90)90070-L; LIDMAN K, 1976, CLIN EXP IMMUNOL, V24, P266; LOEPER J, 1993, GASTROENTEROLOGY, V104, P203, DOI 10.1016/0016-5085(93)90853-5; LOEPER J, 1990, HEPATOLOGY, V11, P850, DOI 10.1002/hep.1840110521; LUDWIG J, 1984, LIVER, V4, P105; LUNEL F, 1992, HEPATOLOGY, V16, P630, DOI 10.1002/hep.1840160304; MACKAY IR, 1956, LANCET, V271, P1323; MADDREY WC, 1975, GASTROENTEROLOGY, V68, P351; MADDREY WC, 1977, GASTROENTEROLOGY, V72, P1348; MADDREY WC, 1987, HEPATOLOGY, V7, P1372, DOI 10.1002/hep.1840070631; MAGRIN S, 1991, J HEPATOL, V13, P56, DOI 10.1016/0168-8278(91)90864-8; MANNS M, 1990, HEPATOLOGY, V12, P127, DOI 10.1002/hep.1840120120; MANNS M, 1987, LANCET, V1, P292; MANNS MP, 1991, SEMIN LIVER DIS, V11, P205, DOI 10.1055/s-2008-1040438; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MANNS MP, 1991, J CLIN INVEST, V88, P1370, DOI 10.1172/JCI115443; MCFARLANE BM, 1986, J HEPATOL, V3, P196, DOI 10.1016/S0168-8278(86)80026-5; MCFARLANE IG, 1990, LANCET, V335, P754, DOI 10.1016/0140-6736(90)90870-B; MEYERZUM.KH, 1972, CLIN EXP IMMUNOL, V11, P99; MICHEL G, 1992, LANCET, V339, P267, DOI 10.1016/0140-6736(92)91332-3; NISHIGUCHI S, 1992, ANN INTERN MED, V116, P21, DOI 10.7326/0003-4819-116-1-21; PAGE AR, 1964, AM J MED, V36, P200, DOI 10.1016/0002-9343(64)90083-X; PAPO T, 1992, ANN INTERN MED, V116, P51, DOI 10.7326/0003-4819-116-1-51; PARONETTO F, 1962, LAB INVEST, V11, P150; PERDIGOTO R, 1992, J HEPATOL, V14, P325, DOI 10.1016/0168-8278(92)90178-R; RABINOVITZ M, 1992, DIGEST DIS SCI, V37, P1606, DOI 10.1007/BF01296509; READ AE, 1963, GUT, V4, P378, DOI 10.1136/gut.4.4.378; SAINT E G, 1953, Australas Ann Med, V2, P113; SANCHEZTAPIAS JM, 1990, ANN INTERN MED, V112, P921, DOI 10.7326/0003-4819-112-12-921; SCHALM SW, 1976, GUT, V17, P781, DOI 10.1136/gut.17.10.781; SCHALM SW, 1977, AM J DIG DIS, V22, P973, DOI 10.1007/BF01076196; Seeff L B, 1981, Semin Liver Dis, V1, P104, DOI 10.1055/s-2008-1040723; Shulman N R, 1970, Ann Intern Med, V72, P257; SOLOWAY RD, 1972, GASTROENTEROLOGY, V63, P458; SOLOWAY RD, 1971, AM J DIG DIS, V16, P1082, DOI 10.1007/BF02235164; SUMMERSKILL WH, 1974, GASTROENTEROLOGY, V66, P450; THEODOSSI A, 1980, GASTROENTEROLOGY, V79, P232; TODROS L, 1991, J HEPATOL, V13, P128, DOI 10.1016/0168-8278(91)90874-B; VENTO S, 1989, LANCET, V2, P926; VERGANI GM, 1981, CLIN IMMUNOL ALLERGY, V1, P181; WARE AJ, 1975, GASTROENTEROLOGY, V68, P519; WEE A, 1985, ANN INTERN MED, V102, P581, DOI 10.7326/0003-4819-102-5-581; WHITTINGHAM S, 1966, GASTROENTEROLOGY, V51, P499; WIESNER RH, 1980, GASTROENTEROLOGY, V79, P200; WILLIAMS R, 1979, ISRAEL J MED SCI, V15, P261; WILLOCX RG, 1961, AM J MED, V30, P185, DOI 10.1016/0002-9343(61)90090-0; ZANGER UM, 1988, P NATL ACAD SCI USA, V85, P8256, DOI 10.1073/pnas.85.21.8256; ZUMBUSCHENFELDE KH, 1974, BRIT J EXP PATHOL, V55, P498; 1971, LANCET, V1, P333	98	59	61	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					510	517		10.7326/0003-4819-119-6-199309150-00011	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00011			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357118				2022-12-28	WOS:A1993LZ27500011
J	GORE, RM				GORE, RM			CHOLECYSTOKININ-ENHANCED CHOLESCINTIGRAPHY IN THE DIAGNOSIS OF GALLBLADDER-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ACALCULOUS BILIARY PAIN; CHOLECYSTECTOMY				GORE, RM (corresponding author), NORTHWESTERN UNIV,SCH MED,EVANSTON,IL 60201, USA.							Achord J L, 1992, Gastroenterology, V103, P1985; FINKBENNETT D, 1991, J NUCL MED, V32, P1695; HALVERSON JD, 1992, ARCH INTERN MED, V152, P1305, DOI 10.1001/archinte.152.6.1305; SHAFFER EA, 1992, HEPATOLOGY, V15, P737, DOI 10.1002/hep.1840150432; WESTLAKE PJ, 1990, AM J GASTROENTEROL, V85, P986; YAP L, 1991, GASTROENTEROLOGY, V101, P786, DOI 10.1016/0016-5085(91)90540-2; ZIESSMAN HA, 1992, J NUCL MED, V33, P537	7	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1370	1370		10.1001/jama.270.11.1370	http://dx.doi.org/10.1001/jama.270.11.1370			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360976				2022-12-28	WOS:A1993LW34500040
J	BERCHTOLD, H; RESHETNIKOVA, L; REISER, COA; SCHIRMER, NK; SPRINZL, M; HILGENFELD, R				BERCHTOLD, H; RESHETNIKOVA, L; REISER, COA; SCHIRMER, NK; SPRINZL, M; HILGENFELD, R			CRYSTAL-STRUCTURE OF ACTIVE ELONGATION-FACTOR TU REVEALS MAJOR DOMAIN REARRANGEMENTS	NATURE			English	Article							POLYPEPTIDE-CHAIN-ELONGATION; AMINOACYL-TRANSFER RNA; FACTOR-EF-TU; THERMUS-THERMOPHILUS HB8; ESCHERICHIA-COLI; BINDING-SITE; PROTEIN-BIOSYNTHESIS; EXTREME THERMOPHILE; NUCLEOTIDE BINDING; GTP HYDROLYSIS	The crystal structure of intact elongation factor Tu (EF-Tu) from Thermus thermophilus has been determined and refined at an effective resolution of 1.7 angstrom, with incorporation of data extending to 1.45 angstrom. The effector region, including interaction sites for the ribosome and for transfer RNA, is well defined. Molecular mechanisms are proposed for transduction and amplification of the signal induced by GTP binding as well as for the intrinsic and effector-enhanced GTPase activity of EF-Tu. Comparison of the structure with that of EF-Tu-GDP reveals major mutual rearrangements of the three domains of the molecule.	HOECHST AKT GESELL,CENT RES G865A,PROT CRYSTALLOG,D-65926 FRANKFURT,GERMANY; UNIV BAYREUTH,BIOCHEM LAB,D-95440 BAYREUTH,GERMANY; VA ENGELHARDT MOLEC BIOL INST,MOSCOW 117984,RUSSIA	Sanofi-Aventis; University of Bayreuth; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS			Hilgenfeld, Rolf/C-9675-2011					ANBORGH PH, 1991, EMBO J, V10, P779, DOI 10.1002/j.1460-2075.1991.tb08009.x; ARAI KI, 1978, EUR J BIOCHEM, V92, P521, DOI 10.1111/j.1432-1033.1978.tb12774.x; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BLUMENTHAL T, 1972, P NATL ACAD SCI USA, V69, P1313, DOI 10.1073/pnas.69.5.1313; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, XPLOR 2 1 MANUAL, P240; COOL RH, 1991, BIOCHEMISTRY-US, V30, P362, DOI 10.1021/bi00216a008; DUFFY LK, 1981, BIOCHEMISTRY-US, V20, P4663, DOI 10.1021/bi00519a022; ECCLESTON JF, 1985, J BIOL CHEM, V260, P6237; ECCLESTON JF, 1982, J BIOL CHEM, V257, P5046; GAST WH, 1977, FEBS LETT, V74, P88, DOI 10.1016/0014-5793(77)80759-X; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HWANG YW, 1989, GUANINE NUCLEOTIDE B, P77; JACQUET E, 1988, EMBO J, V7, P2861, DOI 10.1002/j.1460-2075.1988.tb03142.x; JONAK J, 1984, EUR J BIOCHEM, V144, P295, DOI 10.1111/j.1432-1033.1984.tb08463.x; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1977, J MOL BIOL, V117, P999, DOI 10.1016/S0022-2836(77)80009-0; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KINZY TG, 1992, J BIOL CHEM, V267, P1623; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSHIRO A, 1987, EUR J BIOCHEM, V170, P93, DOI 10.1111/j.1432-1033.1987.tb13671.x; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LIMMER S, 1992, BIOCHEMISTRY-US, V31, P2970, DOI 10.1021/bi00126a018; LUCASLEN.J, 1966, P NATL ACAD SCI USA, V55, P1562, DOI 10.1073/pnas.55.6.1562; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER DL, 1970, ARCH BIOCHEM BIOPHYS, V141, P26, DOI 10.1016/0003-9861(70)90102-5; Miller DL, 1977, MOL MECH PROTEIN BIO, P323; NAKAMURA S, 1978, EUR J BIOCHEM, V92, P533, DOI 10.1111/j.1432-1033.1978.tb12775.x; OTT G, 1990, NUCLEIC ACIDS RES, V18, P437, DOI 10.1093/nar/18.3.437; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PARMEGGIANI A, 1987, P NATL ACAD SCI USA, V84, P3141, DOI 10.1073/pnas.84.10.3141; PETER ME, 1990, NUCLEIC ACIDS RES, V18, P6889, DOI 10.1093/nar/18.23.6889; PETER ME, 1990, BIOCHEMISTRY-US, V29, P2876, DOI 10.1021/bi00463a033; PINGOUD A, 1982, EUR J BIOCHEM, V123, P261, DOI 10.1111/j.1432-1033.1982.tb19762.x; RESHETNIKOVA LS, 1991, J MOL BIOL, V221, P375, DOI 10.1016/0022-2836(91)80058-3; RESHETNIKOVA LS, 1992, J CRYST GROWTH, V122, P360, DOI 10.1016/0022-0248(92)90270-S; SEIDLER L, 1987, NUCLEIC ACIDS RES, V15, P9263, DOI 10.1093/nar/15.22.9263; THOMPSON RC, 1982, P NATL ACAD SCI-BIOL, V79, P4922, DOI 10.1073/pnas.79.16.4922; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; 1979, SERC4 DAR LAB COLL C	50	511	518	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 9	1993	365	6442					126	132		10.1038/365126a0	http://dx.doi.org/10.1038/365126a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW442	8371755				2022-12-28	WOS:A1993LW44200038
J	WEAVER, WD; CERQUEIRA, M; HALLSTROM, AP; LITWIN, PE; MARTIN, JS; KUDENCHUK, PJ; EISENBERG, M				WEAVER, WD; CERQUEIRA, M; HALLSTROM, AP; LITWIN, PE; MARTIN, JS; KUDENCHUK, PJ; EISENBERG, M			PREHOSPITAL-INITIATED VS HOSPITAL-INITIATED THROMBOLYTIC THERAPY - THE MYOCARDIAL-INFARCTION TRIAGE AND INTERVENTION TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; TIME DELAYS; STREPTOKINASE; PROJECT; FEASIBILITY; PERFUSION; DIAGNOSIS; ACCURACY; PHASE	Objective.- To determine the effect of prehospital-initiated vs hospital-initiated treatment of myocardial infarction on clinical outcome. Design.- Randomized, controlled clinical trial. Setting.- Multicenter study involving 19 hospitals and all paramedic systems in the Seattle, Wash, metropolitan area. Patients.- A total of 360 patients with symptoms for 6 hours or less, no risk factors for serious bleeding, and ST-segment elevation were selected by paramedics and a remote physician for inclusion into the trial. They represented 4% of patients with chest pain who were screened and 21% of those with acute infarction. Interventions.- Patients were allocated to have aspirin and alteplase treatment initiated before or after hospital arrival. Intravenous sodium heparin was administered to both groups in the hospital. Main Outcome Measure.- The primary endpoint was a ranked composite score (combining death, stroke, serious bleeding, and infarct size). The relation between time to treatment and outcome (composite score, infarct size, ejection fraction, and mortality) was also assessed. Results.- Initiating treatment before hospital arrival decreased the interval from symptom onset to treatment from 110 to 77 minutes (P<.001). Although more patients whose therapy was initiated before hospital arrival had resolution of pain by admission (23% vs 7%; P<.001), there were no significant differences in the composite score (P=.64), mortality (5.7% vs 8.1%), ejection fraction (53% vs 54%), or infarct size (6.1% vs 6.5%). A secondary analysis of time to treatment and outcome showed that treatment initiated within 70 minutes of symptom onset was associated with better outcome (composite score, P=.009; mortality, 1.2% vs 8.7%, P=.04; infarct size, 4.9% vs 11.2%, P<.001; and ejection fraction, 53% vs 49%, P=.03) than later treatment. Identification of patients eligible for thrombolysis by paramedics reduced the hospital treatment time from 60 minutes (for patients not in the study) to 20 minutes (for study patients allocated to begin treatment in the hospital). Conclusion.- There was no improvement in outcome associated with initiating treatment before hospital arrival; however, treatment within 70 minutes of symptom onset-whether in the hospital or in the field-minimized the infarct process and its complications.	UNIV WASHINGTON, SCH MED, DEPT MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT RADIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, SCH MED, DEPT BIOSTAT, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NHLBI NIH HHS [R01HL38454] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038454] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; AUFDERHEIDE TP, 1992, AM J CARDIOL, V69, P991, DOI 10.1016/0002-9149(92)90852-P; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BOSSAERT LL, 1988, CRIT CARE MED, V16, P823, DOI 10.1097/00003246-198809000-00001; BOUTEN MJM, 1990, NED TIJDSCHR GENEES, V50, P2434; BRUGEMANN J, 1992, EUR HEART J, V13, P787; CALDWELL JH, 1984, CIRCULATION, V70, P1048, DOI 10.1161/01.CIR.70.6.1048; CERQUEIRA MD, 1991, CIRCULATION, V84, pI100; FINE DG, 1986, AM J CARDIOL, V58, P411, DOI 10.1016/0002-9149(86)90005-6; GIBLER WB, 1991, AM HEART J, V121, P1, DOI 10.1016/0002-8703(91)90948-H; HALLSTROM AP, 1992, CONTROL CLIN TRIALS, V13, P148, DOI 10.1016/0197-2456(92)90020-Z; HOLMBERG S, 1990, AM J CARDIOL, V65, P401; KEREIAKES DJ, 1990, AM HEART J, V120, P773, DOI 10.1016/0002-8703(90)90192-Z; KUDENCHUK PJ, 1991, J AM COLL CARDIOL, V17, P1486, DOI 10.1016/0735-1097(91)90636-N; MCNEILL AJ, 1989, BRIT HEART J, V61, P316; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; RITCHIE JL, 1984, CIRCULATION, V70, P867, DOI 10.1161/01.CIR.70.5.867; ROTH A, 1990, J AM COLL CARDIOL, V15, P932, DOI 10.1016/0735-1097(90)90219-F; SCHMIDT SB, 1990, AM J CARDIOL, V65, P1411, DOI 10.1016/0002-9149(90)91345-7; SCHOFER J, 1990, AM J CARDIOL, V66, P1429, DOI 10.1016/0002-9149(90)90528-9; SHARKEY SW, 1989, JAMA-J AM MED ASSOC, V262, P3171, DOI 10.1001/jama.262.22.3171; VARSHAVSKY SY, 1992, PREHOSPITAL DISASTER, V7, P57; VILLEMANT D, 1987, LANCET, V1, P228; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WEAVER WD, 1992, THROMBOSIS CARDIOVAS, P275; WEISS AT, 1987, CHEST, V92, P124, DOI 10.1378/chest.92.1.124; WILCOX RG, 1988, LANCET, V2, P525; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; 1985, NEW ENGL J MED, V313, P1384	30	513	527	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	1993	270	10					1211	1216		10.1001/jama.270.10.1211	http://dx.doi.org/10.1001/jama.270.10.1211			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV649	8355383				2022-12-28	WOS:A1993LV64900026
J	KINDIG, DA; CULTICE, JM; MULLAN, F				KINDIG, DA; CULTICE, JM; MULLAN, F			THE ELUSIVE GENERALIST PHYSICIAN - CAN WE REACH A 50-PERCENT GOAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-EDUCATION; PRIMARY CARE; SPECIALISTS; REFORM	National attention has focused on the goal of attaining 50% primary care practitioners to facilitate patient access and cost-effectiveness. To determine how long it might take to achieve this goal, we used the Bureau of Health Professions' aggregate physician supply model to forecast the generalist-specialist balance. Assuming that 30% of graduates will enter generalist practice after 1993 (the percentage in the mid-1980s), the number of generalists would increase from 174940 in 1990 to 232000 in 2040 (77 per 100 000 population), but the percentage would remain at about 30%; specialists would continue to make up about 70% of all active physicians, but their total number would grow from 345 600 to 537 000 (178 per 100 000 population). If 50% of graduates were to enter generalist practices, by the year 2040 the number of generalists would grow to 373 000, or 124 per 100 000 (48.4% of all physicians). If entry into generalist practice falls to 20%, as suggested by recent medical student preferences, the number of generalists would peak at 192 000 (26.4%) in 2010 and would fall to 160 000 (21%) by 2040, resulting in 53 generalists and 201 specialists per 100 000 population. We discuss the implications of these findings on aggregate physician supply and on policy initiative affecting the ratio of generalists to specialists. Reform proposals affecting the specialty mix should clearly identify the desired future ratio of generalists and specialists per capita.	US BUR HLTH PROFESS,WASHINGTON,DC		KINDIG, DA (corresponding author), UNIV WISCONSIN,SCH MED,PROGRAMS HLTH MANAGEMENT,229 BRANDLEY MEM,MADISON,WI 53706, USA.				NHLBI NIH HHS [HRSA-92-288-P] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; Bowman M A, 1982, Health Aff (Millwood), V1, P55, DOI 10.1377/hlthaff.1.4.55; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; GINZBERG E, 1992, JAMA-J AM MED ASSOC, V268, P3115, DOI 10.1001/jama.268.21.3115; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GRUMBACH K, 1991, JAMA-J AM MED ASSOC, V265, P2369; HODGES D, 1991, HMO IND PROFILE PHYS; KASSEBAUM DG, 1992, ACAD MED, V67, P800, DOI 10.1097/00001888-199211000-00020; KINDIG DA, 1987, INQUIRY-J HEALTH CAR, V24, P136; KINDIG DA, 1985, J MED EDUC, V60, P558; KINDIG DA, 1989, HLTH AFF, V81, P61; MARTINI CJM, 1992, JAMA-J AM MED ASSOC, V268, P1097, DOI 10.1001/jama.268.9.1097; MENKEN M, 1985, JAMA-J AM MED ASSOC, V253, P1926; MOORE FD, 1982, SURG CLIN N AM, V62, P579; PETERSDORF RG, 1992, ACAD MED, V67, P377; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; REINHARDT U, 1981, AM J PUBLIC HEALTH, V1, P1149; RIPORTELLAMULLE.R, 1993, JAN AHCPR PRIM CAR R; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1165; SCHROEDER SA, 1993, ACAD MED, V68, P118, DOI 10.1097/00001888-199302000-00002; SCHROEDER SA, 1987, ANN INTERN MED, V106, P768, DOI 10.7326/0003-4819-106-5-768; SCHROEDER SA, 1984, JAMA-J AM MED ASSOC, V252, P373, DOI 10.1001/jama.252.3.373; SCHWARTZ WB, 1988, JAMA-J AM MED ASSOC, V259, P233, DOI 10.1001/jama.259.2.233; SPENCER G, 1989, CURRENT POPULATI P25; STERN RS, 1986, ARCH DERMATOL, V122, P675, DOI 10.1001/archderm.122.6.675; Tarlov A R, 1986, Health Aff (Millwood), V5, P23, DOI 10.1377/hlthaff.5.1.23; TODD JS, 1992, JAMA-J AM MED ASSOC, V268, P1133, DOI 10.1001/jama.268.9.1133; 1993, PHYSICIAN CHARACTERI; 1980, HRA81651 US DEP HLTH; 1980, HRA81657 US DEP HLTH; 1980, HRA81655 US DEP HLTH; 1980, HRA81654 US DEP HLTH; 1992, COUNCIL GRADUATE MED; 1993, ACAD MED, V68, P1; 1992, SELECTED STATISTICS; 1980, HRA81653 US DEP HLTH; 1980, HRA81656 US DEP HLTH; 1980, HRA81652 US DEP HLTH	38	77	77	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1069	1073						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350449				2022-12-28	WOS:A1993LU51200007
J	OLTVAI, ZN; MILLIMAN, CL; KORSMEYER, SJ				OLTVAI, ZN; MILLIMAN, CL; KORSMEYER, SJ			BCL-2 HETERODIMERIZES IN-VIVO WITH A CONSERVED HOMOLOG, BAX, THAT ACCELERATES PROGRAMMED CELL-DEATH	CELL			English	Article							FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; MEMBRANE PROTEIN; GENE; SURVIVAL; EXPRESSION; SEQUENCE; APOPTOSIS; MYC; LINEAGE	Bcl-2 protein is able to repress a number of apoptotic death programs. To investigate the mechanism of Bcl-2's effect, we examined whether Bcl-2 interacted with other proteins. We identified an associated 21 kd protein partner, Bax, that has extensive amino acid homology with Bcl-2, focused within highly conserved domains I and II. Bax is encoded by six exons and demonstrates a complex pattern of alternative RNA splicing that predicts a 21 kd membrane (alpha) and two forms of cytosolic protein (beta and gamma). Bax homodimerizes and forms heterodimers with Bcl-2 in vivo. Overexpressed Bax accelerates apoptotic death induced by cytokine deprivation in an IL-3-dependent cell line. Overexpressed Bax also counters the death repressor activity of Bcl-2. These data suggest a model in which the ratio of Bcl-2 to Bax determines survival or death following an apoptotic stimulus.	WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT PATHOL, ST LOUIS, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL)	OLTVAI, ZN (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, DEPT MED, ST LOUIS, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07088] Funding Source: Medline; PHS HHS [49712-05] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMBRUS JL, 1993, P NATL ACAD SCI USA, V90, P6330, DOI 10.1073/pnas.90.13.6330; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BAIM SB, 1991, P NATL ACAD SCI USA, V88, P5072, DOI 10.1073/pnas.88.12.5072; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BATISTATOU A, 1993, IN PRESS J NEUROSCI; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Freeman Robert S., 1993, Current Opinion in Neurobiology, V3, P25, DOI 10.1016/0959-4388(93)90031-S; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; HARLOW E, 1988, ANTIBODIES LABORATOR; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE JC, 1982, J IMMUNOL, V128, P2393; LEWIN B, 1990, GENES, V4; LIPFORD E, 1987, BLOOD, V70, P1816; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO JKM, 1986, BIOCHIM BIOPHYS ACTA, V869, P197, DOI 10.1016/0167-4838(86)90295-5; Sambrook J, 1989, MOL CLONING LABORATO; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, IN PRESS J IMMUNOL; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; [No title captured]	61	5390	5783	10	310	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					609	619		10.1016/0092-8674(93)90509-O	http://dx.doi.org/10.1016/0092-8674(93)90509-O			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358790				2022-12-28	WOS:A1993LU59200005
J	SCOTTRAM, N				SCOTTRAM, N			MAKING MORE OF ACADEMIC ASSETS	NATURE			English	Editorial Material											SCOTTRAM, N (corresponding author), BRITISH BIOTECHNOL LTD,WATLINGTON RD,OXFORD OX4 5LY,ENGLAND.							1991, NATURE, V353, P485	1	2	2	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					666	668		10.1038/364666a0	http://dx.doi.org/10.1038/364666a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355778				2022-12-28	WOS:A1993LT67700022
J	PHILLIPS, DM				PHILLIPS, DM			IMAGES IN CLINICAL MEDICINE - STREPTOCOCCUS-PNEUMONIAE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,NEW YORK,NY 10021, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					477	477						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8355767				2022-12-28	WOS:A1993LR44300006
J	BELKHADIR, J; ELGHOMARI, H; KLOCKER, N; MIKOU, A; NASCIRI, M; SABRI, M				BELKHADIR, J; ELGHOMARI, H; KLOCKER, N; MIKOU, A; NASCIRI, M; SABRI, M			MUSLIMS WITH NON-INSULIN-DEPENDENT DIABETES FASTING DURING RAMADAN - TREATMENT WITH GLIBENCLAMIDE	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the efficacy of two glibenclamide regimens in patients with non-insulin dependent diabetes who were fasting during Ramadan and regular glibenclamide treatment in the non-fasting group. Design-Non-randomised control group of patients who did not fast during Ramadan and two groups of patients who fasted randomised equally to one of two regimens: to take their usual morning dose of glibenclamide in the evening and their usual evening dose before dawn; or to follow this pattern but to reduce the total dose by a quarter. Setting-Two university hospitals, one private hospital, and two private clinics in Casablanca and Rabat, Morocco. Subjects-591 diabetic patients (198 men, 391 women, two unspecified) with similar duration of diabetes and length and amount of glibenclamide treatment, of whom 542 completed the study. Main outcome measures-Serum fructosamine and total glycated haemoglobin concentrations and number of hypoglycaemic events. Results-At the end of Ramadan there were no significant differences between the groups in fructosamine concentration (400 mumol/l in controls and 381 mumol/l and 376 mumol/l in the fasting groups); percentage of glycated haemoglobin (14.7%, 14.0%, and 13.6%); or number of hypoglycaemic events during Ramadan (11, 14, and 10). Conclusion-Glibenclamide is effective and safe for patients with non-insulin dependent diabetes who fast during Ramadan. The easiest regimen is to take the normal morning dose (together with any midday dose) at sunset and any evening dose before dawn.	HOECHST AG,MED SERV CORP,K607,W-6230 FRANKFURT,GERMANY; UNIV HOSP IBN SINA,DEPT MED E,RABAT,MOROCCO; UNIV HOSP IBN ROCHD,DEPT ENDOCRINOL & METAB DIS,CASABLANCA,MOROCCO; CLIN ENDOCRINOL & DIABETOL,CASABLANCA,MOROCCO; POLYCLIN CNSS ZIRAOUI,DEPT ENDOCRINOL & METAB DIS,CASABLANCA,MOROCCO	Sanofi-Aventis; Mohammed V University in Rabat; Ibn sina University Hospital Center of Rabat; Hassan II University of Casablanca; Ibn Rochd University Hospital Center of Casablanca								ABUJAYYAB A, 1989, MED PRIN PRACT, V1, P214; ARMITAGE P, 1987, STATISTICAL METHODS; CHAMAKHI S, 1991, MEDICOGRAPHIA S1, V13, P27; Chandalia HB, 1987, PRAC DIABETES INT, V4, P287, DOI DOI 10.1002/PDI.1960040610; CHEAH SH, 1990, BRIT J NUTR, V63, P329, DOI 10.1079/BJN19900119; ELHAMY R, 1993, GUIDLINES FASTING DI; ELHAZMI MAF, 1987, SAUDI MED J, V8, P171; Hochberg Y., 1987, MULTIPLE COMP PROCED; Kruse-Jarres JD, 1989, LAB MED, V13, P245; RASHED AH, 1989, LANCET, V1, P1396; RASHED AH, 1992, BRIT MED J, V302, P521; Schmahl F W, 1991, Pol J Occup Med Environ Health, V4, P219; SIMMONS D, 1991, Q J MED, V81, P1021, DOI 10.1093/qjmed/81.3.1021; SULIMANI RA, 1991, NUTR RES, V11, P261, DOI 10.1016/S0271-5317(05)80126-5; SULIMANI RA, 1988, DIABETIC MED, V5, P589, DOI 10.1111/j.1464-5491.1988.tb01057.x; TEUPE B, 1987, QUANTITATIVE DETERMI; 1991, IDF DIRECTORY 1991	17	62	63	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					292	295		10.1136/bmj.307.6899.292	http://dx.doi.org/10.1136/bmj.307.6899.292			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374375	Green Published, Bronze			2022-12-28	WOS:A1993LQ51600017
J	WHEAT, J; HAFNER, R; WULFSOHN, M; SPENCER, P; SQUIRES, K; POWDERLY, W; WONG, B; RINALDI, M; SAAG, M; HAMILL, R; MURPHY, R; CONNOLLYSTRINGFIELD, P; BRIGGS, N; OWENS, S				WHEAT, J; HAFNER, R; WULFSOHN, M; SPENCER, P; SQUIRES, K; POWDERLY, W; WONG, B; RINALDI, M; SAAG, M; HAMILL, R; MURPHY, R; CONNOLLYSTRINGFIELD, P; BRIGGS, N; OWENS, S			PREVENTION OF RELAPSE OF HISTOPLASMOSIS WITH ITRACONAZOLE IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						ACQUIRED IMMUNODEFICIENCY SYNDROME; HISTOPLASMOSIS; ASTERISK-ITRACONAZOLE; AMPHOTERICIN-B; HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS	CAPSULATUM ANTIGEN; AMPHOTERICIN-B; AIDS; DIAGNOSIS; FLUCONAZOLE; THERAPY	Objective: To assess the efficacy and safety of itraconazole in preventing relapse of histoplasmosis after induction therapy with amphotericin B in patients with the acquired immunodeficiency syndrome (AIDS) and disseminated histoplasmosis. Design: A prospective, multicenter, open-label clinical trial, with follow-up for at least 52 weeks. Setting: Tertiary care hospitals participating in a clinical investigation sponsored by the National Institutes of Allergy and Infectious Diseases (AIDS Clinical Trial Group and Mycoses Study Group). Patients: Forty-two patients with AIDS who had successfully completed induction therapy for disseminated histoplasmosis amphotericin B, at least 15 mg/kg body weight given over 4 to 12 weeks. Interventions: Itraconazole, 200 mg given orally twice daily. Main Outcome Measures: Response to therapy, specifically prevention of histoplasmosis relapse, was the main outcome measure. Secondary end points were survival and the effect of therapy on Histoplasma capsulatum variety capsulatum antigen levels in urine and serum. Plasma itraconazole concentrations were measured to document drug absorption and compliance with therapy. Results: The median follow-up was 109 weeks, and median survival was 98 weeks. Two relapses occurred (5%; 95% CI, 0.5% to 16%), one in a patient withdrawn from the study 18 weeks earlier and one in a patient who did not comply with the study therapy. Patients with elevated antigen levels at study entry showed clearance of antigen from urine and serum; urine specimens became negative in 43% of patients (CI, 26% to 59%), and serum specimens became negative in 75% of patients (CI, 56% to 94%). Only one patient discontinued treatment because of itraconazole toxicity (hypokalemia). Conclusions: Itraconazole, 200 mg twice daily, is safe and effective in preventing relapse of disseminated histoplasmosis in patients with AIDS. Antigen clearance from blood and urine correlates with clinical efficacy.	UNIV CINCINNATI, COLL MED, DEPT INTERNAL MED, CINCINNATI, OH 45221 USA; UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, SAN ANTONIO, TX 78284 USA; RICHARD L ROUDEBUSH VET AFFAIRS HOSP, INDIANAPOLIS, IN USA; DEPT VET AFFAIRS MED CTR, BIRMINGHAM, AL 35233 USA; DEPT VET AFFAIRS MED CTR, DIV INFECT DIS 111G, HOUSTON, TX 77030 USA; FRONTIER SCI & TECH RES FDN, AMHERST, NY 14226 USA; WASHINGTON UNIV, CLIN TRIALS UNIT, ST LOUIS, MO 63130 USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; INDIANA UNIV, SCH MED, IDRC, INDIANAPOLIS, IN 46202 USA; CORNELL UNIV, ITHACA, NY 14853 USA; RICHARD L ROUDEBUSH VET ADM MED CTR, INDIANAPOLIS, IN 46202 USA; NIH, DIV AIDS, BETHESDA, MD 20892 USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL 60611 USA	University System of Ohio; University of Cincinnati; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Michael E DeBakey VA Medical Center; Frontier Science Foundation; Washington University (WUSTL); Harvard University; Harvard T.H. Chan School of Public Health; Indiana University System; Indiana University-Purdue University Indianapolis; Cornell University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Richard L. Roudebush VA Medical Center; National Institutes of Health (NIH) - USA; Northwestern University				Murphy, Robert/0000-0003-3936-2052; Powderly, William/0000-0001-7808-3086	NIAID NIH HHS [1-AI-15082] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015082] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHUCK SL, 1989, NEW ENGL J MED, V321, P794, DOI 10.1056/NEJM198909213211205; GRAYBILL JR, 1986, AM REV RESPIR DIS, V134, P768; JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401; JOHNSON PC, 1988, AM J MED, V85, P152, DOI 10.1016/S0002-9343(88)80334-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOBAYASHI GS, 1990, REV INFECT DIS, V12, pS291; MCKINSEY DS, 1989, ANN INTERN MED, V111, P655, DOI 10.7326/0003-4819-111-8-655; MCKINSEY DS, 1992, AM J MED, V92, P225, DOI 10.1016/0002-9343(92)90121-Q; MURPHY RL, 1991, AM J MED, V90, P418, DOI 10.1016/0002-9343(91)80080-6; NEGRONI R, 1989, MYCOSES, V32, P123, DOI 10.1111/j.1439-0507.1989.tb02219.x; NIGHTINGALE SD, 1990, SOUTHERN MED J, V83, P624, DOI 10.1097/00007611-199006000-00007; SAAG MS, 1988, ANTIMICROB AGENTS CH, V32, P1, DOI 10.1128/AAC.32.1.1; TUCKER RM, 1990, J ANTIMICROB CHEMOTH, V26, P561, DOI 10.1093/jac/26.4.561; TUCKER RM, 1992, CLIN INFECT DIS, V14, P165, DOI 10.1093/clinids/14.1.165; WHEAT LJ, 1992, AM J MED, V92, P153, DOI 10.1016/0002-9343(92)90106-L; WHEAT LJ, 1991, ANN INTERN MED, V115, P936, DOI 10.7326/0003-4819-115-12-936; WHEAT LJ, 1986, NEW ENGL J MED, V314, P83, DOI 10.1056/NEJM198601093140205; WHEAT LJ, 1990, MEDICINE, V69, P361, DOI 10.1097/00005792-199011000-00004; WHEAT LJ, 1989, AM J MED, V87, P396, DOI 10.1016/S0002-9343(89)80820-4	19	157	162	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1993	118	8					610	616		10.7326/0003-4819-118-8-199304150-00006	http://dx.doi.org/10.7326/0003-4819-118-8-199304150-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW470	8383934				2022-12-28	WOS:A1993KW47000006
J	LUTTRELL, LM; OSTROWSKI, J; COTECCHIA, S; KENDALL, H; LEFKOWITZ, RJ				LUTTRELL, LM; OSTROWSKI, J; COTECCHIA, S; KENDALL, H; LEFKOWITZ, RJ			ANTAGONISM OF CATECHOLAMINE RECEPTOR SIGNALING BY EXPRESSION OF CYTOPLASMIC DOMAINS OF THE RECEPTORS	SCIENCE			English	Article							BETA-ADRENERGIC-RECEPTOR; LIGAND-BINDING PROPERTIES; ALPHA-1-ADRENERGIC RECEPTOR; MOLECULAR-CLONING; BETA-2-ADRENERGIC RECEPTOR; GS; TRANSDUCIN; ACTIVATION; AFFINITY; DOPAMINE	The actions of many hormones and neurotransmitters are mediated by the members of a superfamily of receptors coupled to heterotrimeric guanine nucleotide-binding proteins (G proteins). These receptors are characterized by a highly conserved topographical arrangement in which seven transmembrane domains are connected by intracellular and extracellular loops. The interaction between these receptors and G proteins is mediated in large part by the third intracellular loop of the receptor. Coexpression of the third intracellular loop of the alpha1B-adrenergic receptor with its parent receptor inhibited receptor-mediated activation of phospholipase C. The inhibition extended to the closely related alpha1C-adrenergic receptor subtype, but not the phospholipase C-coupled M1 muscarinic acetylcholine receptor nor the adenylate cyclase-coupled D1A dopamine receptor. These results suggest that the receptor-G protein interface may represent a target for receptor antagonist drugs.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Duke University; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021	Luttrell, Louis/0000-0003-2805-6949	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; COTECCHIA S, UNPUB; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DEARRY A, 1990, NATURE, V347, P72, DOI 10.1038/347072a0; DELEAN A, 1980, J BIOL CHEM, V255, P7108; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; DIXON RAF, 1988, COLD SPRING HARB SYM, V53, P487, DOI 10.1101/SQB.1988.053.01.056; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; KEBABIAN JW, 1979, NATURE, V277, P93, DOI 10.1038/277093a0; KENT RS, 1980, MOL PHARMACOL, V17, P14; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LUTTRELL LM, UNPUB; LYNCH CJ, 1986, MOL PHARMACOL, V29, P196; Maguire M E, 1977, Adv Cyclic Nucleotide Res, V8, P1; MUKAI H, 1992, J BIOL CHEM, V267, P16237; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1991, CELL, V67, P723, DOI 10.1016/0092-8674(91)90067-9; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SALOMON Y, 1991, METHOD ENZYMOL, V195, P22; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWINN DA, 1990, J BIOL CHEM, V265, P8183; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STRADER CD, 1987, J BIOL CHEM, V262, P16439; WU D, IN PRESS J BIOL CHEM	37	104	109	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1453	1457		10.1126/science.8383880	http://dx.doi.org/10.1126/science.8383880			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8383880				2022-12-28	WOS:A1993KP97800036
J	HENDERSON, BE; ROSS, RK; PIKE, MC				HENDERSON, BE; ROSS, RK; PIKE, MC			HORMONAL CHEMOPREVENTION OF CANCER IN WOMEN	SCIENCE			English	Article							ESTROGEN REPLACEMENT THERAPY; NEGATIVE BREAST-CANCER; POSTMENOPAUSAL WOMEN; ENDOMETRIAL CANCER; ADJUVANT TAMOXIFEN; EXOGENOUS ESTROGEN; CONTRACEPTIVE AGENTS; CONJUGATED ESTROGENS; ORAL-CONTRACEPTIVES; INCESSANT OVULATION	The use of oral contraceptives in the United States during the past three decades has led to a dramatic decline in the incidence of cancers of the ovary and endometrium. The magnitude of these declines was predictable both from epidemiologic data and from the biologic effects of oral contraceptives on these tissues. Although the incidence of breast cancer has not been substantially affected by current oral contraceptives, it may be possible to develop alternative forms of contraception that provide protection against all three cancers. The major goal of hormonal chemoprevention of cancer is to reduce cell proliferation in the relevant epithelial tissue. New chemopreventive agents such as tamoxifen exemplify the application of this principle.	UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA; UNIV SO CALIF, SCH MED, KENNETH NORRIS JR COMPREHENS CANC CTR, LOS ANGELES, CA 90033 USA	University of Southern California; University of Southern California					NCI NIH HHS [CA-17054] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA017054] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; [Anonymous], 1988, NEW ENGL J MED, V319, P1681; [Anonymous], 1987, JAMA, V257, P796; BAUM M, 1988, BRIT J CANCER, V57, P608; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CASAGRANDE JT, 1979, LANCET, V2, P170; CHERKOWSKI R, 1986, NEW ENGL J MED, V314, P1615; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; Cummings F J, 1986, NCI Monogr, P119; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FALKSON HC, 1990, J CLIN ONCOL, V8, P599, DOI 10.1200/JCO.1990.8.4.599; FATHALLA MF, 1971, LANCET, V2, P163; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1989, LANCET, V1, P117; GAL D, 1983, AM J OBSTET GYNECOL, V146, P316, DOI 10.1016/0002-9378(83)90754-8; GAMBRELL RD, 1982, J REPROD MED, V27, P531; HENDERSON BE, 1982, CANCER RES, V42, P3232; HENDERSON BE, 1991, SCIENCE, V254, P1131, DOI 10.1126/science.1957166; HENDERSON BE, 1983, BRIT J CANCER, V47, P749, DOI 10.1038/bjc.1983.127; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1988, CANCER RES, V48, P246; HIATT RA, 1984, CANCER, V54, P139, DOI 10.1002/1097-0142(19840701)54:1<139::AID-CNCR2820540128>3.0.CO;2-X; HOOVER R, 1981, J NATL CANCER I, V67, P815; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; JORDAN VC, 1987, CANCER RES, V47, P4517; JORDAN VC, 1990, CANCER PREVENTION, P1; KAISERKUPFER MI, 1978, CANCER TREAT REP, V62, P315; KEY TJA, 1988, BRIT J CANCER, V57, P205, DOI 10.1038/bjc.1988.44; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LIPTON A, 1984, CANCER TREAT REP, V68, P887; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; LONGSTAFF S, 1989, EUR J CANCER CLIN ON, V25, P1805, DOI 10.1016/0277-5379(89)90351-9; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; LOVE RR, 1990, JNCI-J NATL CANCER I, V82, P1327, DOI 10.1093/jnci/82.16.1327; MACK TM, 1976, NEW ENGL J MED, V294, P1262, DOI 10.1056/NEJM197606032942304; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; NAYFIELD SG, 1991, J NATL CANCER I, V83, P1450, DOI 10.1093/jnci/83.20.1450; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; NOTELOVITZ M, 1987, OBSTET GYNECOL, V70, P749; Palshof T., 1985, REV ENDOCR REL CAN S, V17, P43; PARLIDIS NA, 1992, CANCER, V60, P2961; PERSSON I, 1992, LANCET, V340, P1044, DOI 10.1016/0140-6736(92)93064-T; PHARRISS BB, 1978, J REPROD MED, V20, P155; PIKE MC, 1987, J CHRON DIS, V40, pS59, DOI 10.1016/S0021-9681(87)80009-7; PIKE MC, 1986, LANCET, V1, P264; PIKE MC, IN PRESS CONTRACEPTI; PIKE MC, 1983, CURRENT THERAPY ONCO, P292; PIPER JM, 1987, INT J EPIDEMIOL, V16, P215, DOI 10.1093/ije/16.2.215; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PRITCHARD KI, 1987, ADJUVANT THERAPY CAN, P391; RIES LA, 1990, CANCER STATISTICS RE; RILEY D, 1988, BRIT J CANCER, V57, P604; ROHAN TE, 1988, MED J AUSTRALIA, V148, P217; ROSS RK, 1980, JAMA-J AM MED ASSOC, V243, P1635, DOI 10.1001/jama.243.16.1635; ROSS RK, 1988, AM J PUBLIC HEALTH, V78, P516, DOI 10.2105/AJPH.78.5.516; RUTQVIST LE, 1991, J NATL CANCER I, V83, P1299, DOI 10.1093/jnci/83.18.1299; SCHIFF I, 1982, FERTIL STERIL, V37, P79; SHARF M, 1985, GYNECOL OBSTET INVES, V19, P207, DOI 10.1159/000299035; SILVERBERG SG, 1975, OBSTET GYNECOL, V46, P503; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; Spicer D, 1990, Oncology (Williston Park), V4, P49; SPICER DV, 1991, LANCET, V337, P1414, DOI 10.1016/0140-6736(91)93096-R; SPICER DV, 1991, CONTRACEPTION, V44, P289, DOI 10.1016/0010-7824(91)90019-C; STANCZYK FZ, 1988, AM J OBSTET GYNECOL, V159, P1540, DOI 10.1016/0002-9378(88)90591-1; STEWART HJ, 1987, LANCET, V2, P171; STUDD JWW, 1980, MENOPAUSE POSTMENOPA, P127; TARONE RE, 1992, J NATL CANCER I, V84, P1402, DOI 10.1093/jnci/84.18.1402; TURKEN S, 1989, J NATL CANCER I, V81, P1086, DOI 10.1093/jnci/81.14.1086; VOIGT LF, 1991, LANCET, V338, P274, DOI 10.1016/0140-6736(91)90417-N; WATERHOUSE J, 1976, CANCER INCIDENCE 5 C; WEISS NS, 1980, NEW ENGL J MED, V302, P551, DOI 10.1056/NEJM198003063021004; WEN EJO, 1992, BRIT J OBSTET GYNAEC, V99, P671; WHITEHEAD M, 1983, SEMIN REPROD ENDOCR, V1, P41, DOI 10.1055/s-2007-1022574; WHITTEMORE AS, 1992, AM J EPIDEMIOL, V136, P1184, DOI 10.1093/oxfordjournals.aje.a116427; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YAGER JD, 1980, CANCER RES, V40, P3680; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303; 1983, JAMA-J AM MED ASSOC, V249, P1600; 1987, JAMA-J AM MED ASSOC, V249, P796; 1989, PHS891232 US DEP HLT, P52	82	233	238	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 29	1993	259	5095					633	638		10.1126/science.8381558	http://dx.doi.org/10.1126/science.8381558			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ688	8381558				2022-12-28	WOS:A1993KJ68800031
J	CLINTON, JJ				CLINTON, JJ			PRIMARY-CARE RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AHCPR,DIV PRIMARY CARE,EOC 502,2101 E JEFFERSON ST,ROCKVILLE,MD 20852, USA.								0	1	1	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1405	1405		10.1001/jama.270.12.1405	http://dx.doi.org/10.1001/jama.270.12.1405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371426				2022-12-28	WOS:A1993LX17300004
J	BRENNAN, RG				BRENNAN, RG			THE WINGED-HELIX DNA-BINDING MOTIF - ANOTHER HELIX-TURN-HELIX TAKEOFF	CELL			English	Review							REPRESSOR-OPERATOR COMPLEX; CRYSTAL-STRUCTURE; LAMBDA-REPRESSOR; CRO REPRESSOR; PROTEIN; RESOLUTION; CONTACTS; DOMAIN; RECOGNITION; SUGGESTS				BRENNAN, RG (corresponding author), OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201, USA.			Brennan, Richard/0000-0001-7647-485X				ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BALDWIN JP, 1992, CURRENT OPINION STRU, V2, P78; BRENNAN R, 1992, CURR OPIN STRUC BIOL, V2, P100; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; CAREY J, 1989, J BIOL CHEM, V264, P1941; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DODD IB, 1990, NUCLEIC ACIDS RES, V18, P5019, DOI 10.1093/nar/18.17.5019; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HUBBARD AJ, 1990, BIOCHEMISTRY-US, V29, P9241, DOI 10.1021/bi00491a019; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LEITING B, 1993, EMBO J, V12, P1797, DOI 10.1002/j.1460-2075.1993.tb05827.x; LUISI BF, 1990, BIOCHIM BIOPHYS ACTA, V1048, P113, DOI 10.1016/0167-4781(90)90047-6; MCKAY DB, 1981, NATURE, V290, P744, DOI 10.1038/290744a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1990, SCIENCE, V247, P1210, DOI 10.1126/science.2315694; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PABO CO, 1982, NATURE, V298, P443, DOI 10.1038/298443a0; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Widom J, 1991, CURR OPIN STRUC BIOL, V1, P245, DOI 10.1016/0959-440X(91)90069-6; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOLBERGER C, 1993, CURR OPIN STRUC BIOL, V3, P3, DOI 10.1016/0959-440X(93)90194-P	31	216	222	1	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					773	776		10.1016/0092-8674(93)90456-Z	http://dx.doi.org/10.1016/0092-8674(93)90456-Z			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374950				2022-12-28	WOS:A1993LX29200002
J	DU, W; THANOS, D; MANIATIS, T				DU, W; THANOS, D; MANIATIS, T			MECHANISMS OF TRANSCRIPTIONAL SYNERGISM BETWEEN DISTINCT VIRUS-INDUCIBLE ENHANCER ELEMENTS	CELL			English	Article							NF-KAPPA-B; INTERFERON-BETA GENE; LEUCINE ZIPPER PROTEINS; ATF CDNA CLONES; DNA-BINDING; IFN-BETA; C-JUN; NUCLEOPROTEIN STRUCTURES; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM	The high mobility group protein HMG I(Y) and the transcription factor NF-kappaB are required for the activity of positive regulatory domain II (PRDII), a virus-inducible regulatory element of the human interferon-beta gene promoter. In this paper we provide evidence that HMG I(Y) is also required for the activity of PRDIV, a regulatory element that synergizes with PRDII. In this case, HMG I(Y) stimulates binding of activating transcription factor 2 (ATF-2) and the assembly of inducible complexes containing ATF-2 and c-Jun. Remarkably, HMG I(Y) also specifically interacts with the leucine zipper/basic region of ATF-2, and ATF-2 in turn interacts with NF-kappaB. We therefore propose that the HMG I(Y) plays a critical structural role in establishing transcriptional synergy between PRDII and PRDIV by promoting the activities and/or binding of NF-kappaB and ATF-2 and by facilitating their interaction.			DU, W (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Thanos, Dimitris/AAE-5720-2019		NIAID NIH HHS [AI20642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020642, R01AI020642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; Demaeyer E., 1988, INTERFERONS OTHER RE; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DU W, 1992, P NATL ACAD SCI USA, V89, P2150, DOI 10.1073/pnas.89.6.2150; ECHOLS H, 1984, COLD SPRING HARB SYM, V49, P727, DOI 10.1101/SQB.1984.049.01.082; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FAN CM, 1989, EMBO J, V8, P101, DOI 10.1002/j.1460-2075.1989.tb03353.x; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FUJITA T, 1989, NUCLEIC ACIDS RES, V17, P3335, DOI 10.1093/nar/17.9.3335; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; JONAT G, 1990, CELL, V62, P1189; JVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609; KERPPOLA TK, 1991, SCIENCE, V254, P1210, DOI 10.1126/science.1957173; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LEBLANC JF, 1990, MOL CELL BIOL, V10, P3987, DOI 10.1128/MCB.10.8.3987; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1193; McKnight S.L., 1992, TRANSCRIPTIONAL REGU; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; NASH HA, 1990, TRENDS BIOCHEM SCI, V15, P222, DOI 10.1016/0968-0004(90)90034-9; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PTASHNE M, 1992, GENETIC SWITCH GENE; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VILCEK J, 1990, HDB EXPT PHARM, V95, P1; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	51	438	444	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 10	1993	74	5					887	898		10.1016/0092-8674(93)90468-6	http://dx.doi.org/10.1016/0092-8674(93)90468-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374955				2022-12-28	WOS:A1993LX29200014
J	MORSE, LJ				MORSE, LJ			A DECLARATION-OF-INDEPENDENCE FOR HEALTH SYSTEM REFORM	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											MORSE, LJ (corresponding author), MASSACHUSETTS MED SOC,WALTHAM,MA 02154, USA.							ANGELL M, 1993, NEW ENGL J MED, V328, P1778, DOI 10.1056/NEJM199306173282409; ENTHOVEN AC, 1990, 1990 HARV COMM HLTH, P25; JOHNSON RA, 1970, WORCESTER MED NEWS, V34, P9; LETSCH SW, 1993, HEALTH AFFAIR, V12, P94, DOI 10.1377/hlthaff.12.1.94; MORSE LJ, 1989, CONSIDERATIONS OTHER, P13; TORREY BB, 1993, HEALTH AFFAIR, V12, P126, DOI 10.1377/hlthaff.12.1.126; 1992, HLTH ACCESS AM AMA P; 1993, HLTH CARE POLICY REP, V1, P721	8	6	6	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					804	805		10.1056/NEJM199309093291112	http://dx.doi.org/10.1056/NEJM199309093291112			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350892				2022-12-28	WOS:A1993LV64200012
J	JONAS, HS; ETZEL, SI; BARZANSKY, B				JONAS, HS; ETZEL, SI; BARZANSKY, B			EDUCATIONAL-PROGRAMS IN UNITED-STATES MEDICAL-SCHOOLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									AMER MED ASSOC,DEPT DATA SYST,CHICAGO,IL 60610	American Medical Association	JONAS, HS (corresponding author), AMER MED ASSOC,DIV UNDERGRAD MED EDUC,515 N STATE ST,CHICAGO,IL 60610, USA.							JONAS HS, 1991, JAMA-J AM MED ASSOC, V266, P913, DOI 10.1001/jama.266.7.913; 1992, 3RD US DEP HLTH HUM; 1993, ANN REPORT C; 1992, JAMA-J AM MED ASSOC, V268, P1092	4	28	29	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1061	1068		10.1001/jama.270.9.1061	http://dx.doi.org/10.1001/jama.270.9.1061			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LU512	8350448				2022-12-28	WOS:A1993LU51200006
J	ZHOU, J; MOCHIZUKI, T; SMEETS, H; ANTIGNAC, C; LAURILA, P; DEPAEPE, A; TRYGGVASON, K; REEDERS, ST				ZHOU, J; MOCHIZUKI, T; SMEETS, H; ANTIGNAC, C; LAURILA, P; DEPAEPE, A; TRYGGVASON, K; REEDERS, ST			DELETION OF THE PAIRED ALPHA-5(IV) AND ALPHA-6(IV) COLLAGEN GENES IN INHERITED SMOOTH-MUSCLE TUMORS	SCIENCE			English	Article							BASEMENT-MEMBRANE COLLAGEN; IV COLLAGEN; ALPORT SYNDROME; BIDIRECTIONAL PROMOTER; DIFFUSE LEIOMYOMATOSIS; CELL-ADHESION; CHAIN; IDENTIFICATION; DOMAIN; LOCALIZATION	The gene encoding alpha6(IV) collagen, COL4A6, was identified on the human X chromosome in a head-to-head arrangement and within 452 base pairs of the alpha5(IV) collagen gene, COL4A5. In earlier studies, intragenic deletions of COL4A5 were detected in a subset of patients with Alport syndrome (AS), a hereditary defect of basement membranes. In some families, AS cosegregates with diffuse leiomyomatosis (DL), a benign smooth muscle tumor diathesis. Here it is shown that patients with AS-DL harbor deletions that disrupt both COL4A5 and COL4A6. Thus, type IV collagen may regulate smooth muscle differentiation and morphogenesis.	UNIV HOSP NIJMEGEN,CTR CLIN GENET,NIJMEGEN,NETHERLANDS; HOP NECKER ENFANTS MALAD,INSERM,U192,PARIS,FRANCE; UNIV HELSINKI,DEPT PATHOL,SF-00100 HELSINKI 10,FINLAND; STATE UNIV GHENT HOSP,DEPT HUMAN GENET,B-9000 GHENT,BELGIUM; UNIV OULU,BIOCTR,SF-90100 OULU 10,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90100 OULU 10,FINLAND	Radboud University Nijmegen; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Helsinki; Ghent University; Ghent University Hospital; University of Oulu; Finland National Institute for Health & Welfare; University of Oulu	ZHOU, J (corresponding author), YALE UNIV,SCH MED,HOWARD HUGHES MED INST,295 CONGRESS AVE,NEW HAVEN,CT 06510, USA.		ANTIGNAC, Corinne/H-8945-2017	ANTIGNAC, Corinne/0000-0002-9934-4940				ANTIGNAC C, 1992, KIDNEY INT, V42, P1178, DOI 10.1038/ki.1992.402; AUMAILLEY M, 1986, J CELL BIOL, V103, P1569, DOI 10.1083/jcb.103.4.1569; AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; BORG TK, 1984, DEV BIOL, V104, P86, DOI 10.1016/0012-1606(84)90038-1; BRUNNER H, 1988, KIDNEY INT, V34, P507, DOI 10.1038/ki.1988.210; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1987, J BIOL CHEM, V262, P7874; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; CHELBERG MK, 1989, CANCER RES, V49, P4796; COCHAT P, 1988, J PEDIATR-US, V113, P339, DOI 10.1016/S0022-3476(88)80280-4; DESJARDINS M, 1990, LAB INVEST, V63, P637; FLINTER FA, 1988, LANCET, V2, P1005, DOI 10.1016/S0140-6736(88)90753-2; GUNWAR S, 1990, J BIOL CHEM, V265, P5466; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; HOSTIKKA SL, 1987, FEBS LETT, V216, P281, DOI 10.1016/0014-5793(87)80706-8; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAMAGATA Y, 1992, J BIOL CHEM, V267, P23753; MARIYAMA M, 1992, GENOMICS, V13, P809, DOI 10.1016/0888-7543(92)90157-N; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MARIYAMA M, UNPUB; MARSHALL JB, 1990, AM J GASTROENTEROL, V85, P303; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NETZER KO, 1992, KIDNEY INT, V42, P1336, DOI 10.1038/ki.1992.425; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P13758; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SHEN GQ, 1990, CONNECT TISSUE RES, V24, P289, DOI 10.3109/03008209009152156; SOININEN R, 1988, J BIOL CHEM, V263, P17217; SOININEN R, 1987, FEBS LETT, V225, P188; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; VANDENBERG P, 1991, J CELL BIOL, V113, P1475, DOI 10.1083/jcb.113.6.1475; ZHOU J, 1991, GENOMICS, V9, P10, DOI 10.1016/0888-7543(91)90215-Z; ZHOU J, 1992, J BIOL CHEM, V267, P12475	38	248	262	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1167	1169		10.1126/science.8356449	http://dx.doi.org/10.1126/science.8356449			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356449				2022-12-28	WOS:A1993LU58600031
J	GREENE, S				GREENE, S			SCIENCE RESEARCH AND PHILANTHROPY	NATURE			English	Editorial Material																			0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					741	742		10.1038/364741a0	http://dx.doi.org/10.1038/364741a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355791				2022-12-28	WOS:A1993LT67700069
J	BALKAU, B; ESCHWEGE, E; PAPOZ, L; RICHARD, JL; CLAUDE, JR; WARNET, JM; DUCIMETIERE, P				BALKAU, B; ESCHWEGE, E; PAPOZ, L; RICHARD, JL; CLAUDE, JR; WARNET, JM; DUCIMETIERE, P			RISK-FACTORS FOR EARLY DEATH IN NON-INSULIN-DEPENDENT DIABETES AND MEN WITH KNOWN GLUCOSE-TOLERANCE STATUS	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; FOLLOW-UP; ALCOHOL-CONSUMPTION; MORTALITY; POPULATION; MELLITUS	Objective-To identify risk factors for all cause mortality according to glucose tolerance status. Design-Cohort study with an average 15.6 years' follow up. Setting-Paris, France. Subjects-7166 working men aged 44-55 in 1968-72 in the Paris prospective study cohort, with non-insulin dependent diabetes or known result of two hour 75 g oral glucose tolerance test. Main outcome measure-Risk factors for death from all causes. Results-128 men were known to be diabetic, 180 had diabetes diagnosed, and 697 had impaired glucose tolerance diagnosed. Compared with normoglycaemic men the relative risks of death in these groups were 2.0 (95% confidence interval 1.4 to 3.0), 2.7 (2.0 to 3.6), and 1.6 (1.3 to 2.0) respectively. Obesity, smoking, high blood pressure, and high non-esterified fatty acid concentration were risk factors for death in all subjects and were unaffected by glucose tolerance. The risks for fasting and two hour insulin concentrations and mean corpuscular volume were two times higher in known diabetic men than in men not known to be diabetic. Central obesity was significant only in men not known to be diabetic (1.6 (1.4 to 1.9)). In known diabetic men a two hour glucose concentration higher than 11.1 mmol/l carried a relative risk of death of 3.8 (1.4 to 9.4). Conclusions-Diabetic men have similar risk factors for early mortality to other men but are at higher risk from hyperinsulinaemia, hyperglycaemia, and high mean corpuscular volume.	HOP BROUSSAIS,INSERM,U258,F-75674 PARIS 14,FRANCE; CTR MEDICO SOCIAL,DIRECT ACT SOCIALE ENFANCE & SANTE LAB,F-75013 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	BALKAU, B (corresponding author), HOP PAUL BROUSSE,INSERM,U21,F-94807 VILLEJUIF,FRANCE.							ANDERSON P, 1988, BRIT MED J, V297, P824, DOI 10.1136/bmj.297.6652.824; ANTONIS A, 1965, J LIPID RES, V6, P307; BALKAU B, 1991, J CLIN EPIDEMIOL, V44, P465, DOI 10.1016/0895-4356(91)90209-R; BALKAU B, 1992, DIABETOLOGIA, V35, P39, DOI 10.1007/BF00400850; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BJORNTORP P, 1990, DIABETES ANN, V5, P373; CLAUDE JR, 1968, ANN BIOL CLIN-PARIS, V26, P451; COPPACK SW, 1990, Q J MED, V75, P451; COX DR, 1972, J R STAT SOC B, V34, P187; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; DUCIMETIERE P, 1989, INT J OBESITY, V13, P111; DUCIMETIERE P, 1980, DIABETOLOGIA, V19, P205, DOI 10.1007/BF00275270; DUCIMETIERE P, 1981, CARDIOPATHIES ISCHEM, P9; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; ETIENNE G, 1963, ANN BIOL CLIN, V21, P851; FITZGERALD AP, 1991, DIABETIC MED, V8, P475, DOI 10.1111/j.1464-5491.1991.tb01635.x; FORD ES, 1991, AM J EPIDEMIOL, V133, P1220, DOI 10.1093/oxfordjournals.aje.a115834; JARRETT J, 1990, Q J MED, V75, P413; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; KNUIMAN MW, 1992, AM J EPIDEMIOL, V135, P638, DOI 10.1093/oxfordjournals.aje.a116343; KOHL HW, 1992, DIABETES CARE, V15, P184, DOI 10.2337/diacare.15.2.184; MORRISH NJ, 1990, DIABETOLOGIA, V33, P542, DOI 10.1007/BF00404142; PANZRAM G, 1987, DIABETOLOGIA, V30, P123, DOI 10.1007/BF00274216; PAPOZ L, 1981, JAMA-J AM MED ASSOC, V245, P1748; ROSENGREN A, 1989, BRIT MED J, V299, P1127, DOI 10.1136/bmj.299.6708.1127; ROSSELIN G, 1966, NATURE, V212, P355, DOI 10.1038/212355a0; SASAKI A, 1989, DIABETES RES CLIN PR, V7, P33, DOI 10.1016/0168-8227(89)90042-9; SCHMITZ A, 1988, DIABETES METAB, V14, P193; TOUNTAS C, 1987, DIABETOLOGIA, V330, pA589; 1968, MANUAL INT CLASSIFIC; 1963, METHODOLOGIE TECHNIC; 1985, WHO TECH REP SERIES, V727	32	89	89	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					295	299		10.1136/bmj.307.6899.295	http://dx.doi.org/10.1136/bmj.307.6899.295			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374376	Green Published, Bronze			2022-12-28	WOS:A1993LQ51600018
J	FOLTZ, KR; PARTIN, JS; LENNARZ, WJ				FOLTZ, KR; PARTIN, JS; LENNARZ, WJ			SEA-URCHIN EGG RECEPTOR FOR SPERM - SEQUENCE SIMILARITY OF BINDING DOMAIN AND HSP70	SCIENCE			English	Article							HEAT-SHOCK; GLYCOSYLATION SITES; PROTEIN; FERTILIZATION; PURIFICATION; SURFACE; IDENTIFICATION; CALCIUM; FRAGMENT; RELEASE	Fertilization depends on cell surface recognition proteins that interact and thereby mediate binding and subsequent fusion of the sperm and egg. Overlapping complementary DNA's encoding the egg plasma membrane receptor for sperm from the sea urchin Strongylocentrotus purpuratus were cloned and sequenced. Analysis of the deduced primary structure suggests that the receptor is a transmembrane protein with a short cytoplasmic domain. This domain showed no sequence similarity to known protein sequences. In contrast, the extracellular, sperm binding domain of the receptor did show sequence similarity to the heat shock protein 70 (hsp70) family of proteins. Recombinant protein representing this portion of the receptor bound to the sperm protein, bindin, and also inhibited fertilization in a species-specific manner; beads coated with the protein became specifically bound to acrosome-reacted sperm. These data provide a basis for detailed investigations of molecular interactions that occur in gamete recognition and egg activation.	SUNY STONY BROOK, DEPT BIOCHEM & CELL BIOL, STONY BROOK, NY 11794 USA; UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA; UNIV CALIF SANTA BARBARA, INST MARINE SCI, SANTA BARBARA, CA 93106 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara					NICHD NIH HHS [HD18590] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018590] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BACHVAROVA RF, 1992, CELL, V69, P895, DOI 10.1016/0092-8674(92)90606-D; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BLOCH RJ, 1986, J CELL BIOL, V102, P1447, DOI 10.1083/jcb.102.4.1447; BOURGUIGNON LYW, 1984, INT REV CYTOL, V87, P195, DOI 10.1016/S0074-7696(08)62443-2; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHANDLER DE, 1991, J ELECTRON MICR TECH, V17, P266, DOI 10.1002/jemt.1060170304; DECKER GL, 1979, J CELL BIOL, V81, P92, DOI 10.1083/jcb.81.1.92; DOOLITTLE RF, 1986, URFS ORFS, P1; FASMAN GD, 1990, TRENDS BIOCHEM SCI, V15, P89, DOI 10.1016/0968-0004(90)90187-G; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FOLTZ KR, 1990, J CELL BIOL, V111, P2951, DOI 10.1083/jcb.111.6.2951; FOLTZ KR, 1992, J CELL BIOL, V116, P647, DOI 10.1083/jcb.116.3.647; FOLTZ KR, UNPUB; FRIEDERICH E, 1992, CELL, V70, P81, DOI 10.1016/0092-8674(92)90535-K; FROHMAN MA, 1989, TECHNIQUE, V1, P165; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GLABE CG, 1978, P NATL ACAD SCI USA, V75, P881, DOI 10.1073/pnas.75.2.881; GOOLEY AA, 1991, BIOCHEM BIOPH RES CO, V178, P1194, DOI 10.1016/0006-291X(91)91019-9; GUPTA RS, 1992, J BACTERIOL, V174, P4594, DOI 10.1128/JB.174.14.4594-4605.1992; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; JAFFE LA, 1976, NATURE, V261, P68, DOI 10.1038/261068a0; JAHNIG F, 1990, TRENDS BIOCHEM SCI, V15, P93, DOI 10.1016/0968-0004(90)90188-H; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KINSEY WH, 1986, METHOD CELL BIOL, V27, P139, DOI 10.1016/S0091-679X(08)60346-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARABELL C, 1991, J ELECTRON MICR TECH, V17, P294, DOI 10.1002/jemt.1060170305; LAROSA M, 1990, GENE, V96, P295, DOI 10.1016/0378-1119(90)90267-U; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MATSUDAIRA P, 1989, PRACTICAL GUIDE TO PROTEIN AND PEPTIDE PURIFICATION FOR MICROSEQUENCING, P1; MCCULLOH DH, 1986, J GEN PHYSIOL, V88, pA38; MINOR JE, 1989, MOL BIOL FERTILIZATI, P773; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; POENIE M, 1987, J HISTOCHEM CYTOCHEM, V35, P939, DOI 10.1177/35.9.3611737; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; RAKOW TL, 1990, P NATL ACAD SCI USA, V87, P9285, DOI 10.1073/pnas.87.23.9285; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; ROBINSON KR, 1978, DEV BIOL, V62, P215; ROSSIGNOL DP, 1981, J SUPRAMOL STR CELL, V15, P347, DOI 10.1002/jsscb.1981.380150405; ROSSIGNOL DP, 1984, DEV BIOL, V104, P308, DOI 10.1016/0012-1606(84)90086-1; Ruiz-Bravo N., 1989, P21; RUIZBRAVO N, 1986, DEV BIOL, V118, P202, DOI 10.1016/0012-1606(86)90088-6; Sambrook J, 1989, MOL CLONING LABORATO; SCHMELL E, 1977, J CELL BIOL, V72, P35, DOI 10.1083/jcb.72.1.35; SCONZO G, 1988, CELL DIFFER DEV, V24, P97, DOI 10.1016/0045-6039(88)90061-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TERASAKI M, 1991, J CELL BIOL, V115, P1031, DOI 10.1083/jcb.115.4.1031; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMMER JS, 1986, ANNU REV CELL BIOL, V2, P1; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; Turner P. R., 1989, Cell biology of fertilization., P297; VACQUIER VD, 1977, P NATL ACAD SCI USA, V74, P2456, DOI 10.1073/pnas.74.6.2456; Vandekerckhove J, 1990, CURR OPIN CELL BIOL, V2, P41, DOI 10.1016/S0955-0674(05)80029-8; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG YC, 1992, J BIOL CHEM, V267, P2728; WASSARMAN PM, 1990, DEVELOPMENT, V108, P1; WASSARMAN PM, 1987, SCIENCE, V235, P553, DOI 10.1126/science.3027891; WILSON IBH, 1991, BIOCHEM J, V275, P529, DOI 10.1042/bj2750529; [No title captured]	65	153	156	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 5	1993	259	5100					1421	1425		10.1126/science.8383878	http://dx.doi.org/10.1126/science.8383878			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8383878				2022-12-28	WOS:A1993KP97800026
J	GU, W; SCHNEIDER, JW; CONDORELLI, G; KAUSHAL, S; MAHDAVI, V; NADALGINARD, B				GU, W; SCHNEIDER, JW; CONDORELLI, G; KAUSHAL, S; MAHDAVI, V; NADALGINARD, B			INTERACTION OF MYOGENIC FACTORS AND THE RETINOBLASTOMA PROTEIN MEDIATES MUSCLE-CELL COMMITMENT AND DIFFERENTIATION	CELL			English	Article							LARGE T-ANTIGEN; SUSCEPTIBILITY GENE-PRODUCT; SV40 LARGE-T; TUMOR SUPPRESSOR GENES; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; C-MYC; E1A PROTEINS; RB PROTEIN; MYOD	The experiments reported here document that the tumor suppressor retinoblastoma protein (pRB) plays an important role in the production and maintenance of the terminally differentiated phenotype of muscle cells. We show that pRB inactivation, through either phosphorylation, binding to T antigen, or genetic alteration, inhibits myogenesis. Moreover, inactivation of pRB in terminally differentiated cells allows them to reenter the cell cycle. In addition to its involvement in the myogenic activities of MyoD, pRB is also required for the cell growth-inhibitory activity of this myogenic factor. We also show that pRB and MyoD directly bind to each other, both in vivo and in vitro, through a region that involves the pocket and the basic-helix-loop-helix domains, respectively. All the results obtained are consistent with the proposal that the effects of MyoD on the cell cycle and of pRB on the myogenic pathway result from the direct binding of the two molecules.	CHILDRENS HOSP MED CTR,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	GU, W (corresponding author), CHILDRENS HOSP MED CTR,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.		Condorelli, Gianluigi/Q-6736-2017	Condorelli, Gianluigi/0000-0003-0481-6843				BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BRENNAN TJ, 1990, J CELL BIOL, V110, P929, DOI 10.1083/jcb.110.4.929; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ENDO T, 1986, MOL CELL BIOL, V6, P1412, DOI 10.1128/MCB.6.5.1412; Endo T., 1989, CELLULAR MOL BIOL MU, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAESSMANN A, 1973, DEV BIOL, V35, P180, DOI 10.1016/0012-1606(73)90016-X; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KONIGSBERG IR, 1960, J BIOPHYS BIOCHEM CY, V8, P333, DOI 10.1083/jcb.8.2.333; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE W, 1987, SCIENCE, V235, P1395; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NGUYEN HT, 1983, CELL, V34, P281, DOI 10.1016/0092-8674(83)90159-9; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEARLE PF, 1984, MOL CELL BIOL, V4, P1221, DOI 10.1128/MCB.4.7.1221; SHEW JY, 1990, CELL GROWTH DIFFER, V1, P17; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; STOCKDALE F, 1961, EXP CELL RES, V24, P508, DOI 10.1016/0014-4827(61)90450-5; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; TAUBMAN MB, 1989, J CELL BIOL, V108, P1799, DOI 10.1083/jcb.108.5.1799; TEGTMEYE.P, 1971, J VIROL, V8, P516, DOI 10.1128/JVI.8.4.516-524.1971; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WELLINGTON EL, 1992, P NATL ACAD SCI USA, V89, P1755; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	98	705	713	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 12	1993	72	3					309	324		10.1016/0092-8674(93)90110-C	http://dx.doi.org/10.1016/0092-8674(93)90110-C			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KM162	8381715				2022-12-28	WOS:A1993KM16200003
J	PEREZVELAZQUEZ, JL; ANGELIDES, KJ				PEREZVELAZQUEZ, JL; ANGELIDES, KJ			ASSEMBLY OF GABA(A) RECEPTOR SUBUNITS DETERMINES SORTING AND LOCALIZATION IN POLARIZED CELLS	NATURE			English	Article							HIPPOCAMPAL-NEURONS; FUNCTIONAL EXPRESSION; MEMBRANE GLYCOPROTEIN; EPITHELIAL-CELLS; MESSENGER-RNA; PROTEINS; RAT; HETEROGENEITY; BIOGENESIS; DOMAINS	THE GABA(A) receptor, the principal inhibitory receptor in the CNS, is distributed on cell bodies, dendrites, and in some cells at axon hillocks and presynaptic terminals1-6. The dendritic distribution is crucial for shunting of excitatory synaptic inputs7,8. Molecular cloning has revealed that the GABA(A) receptor can be formed by a diverse set of subunits and by separately encoded subunit isoforms9,10, the expression of each of which differs in distinct areas of the central nervous system11-13 and during development14,15. Why different genes exist to encode these isoforms is not clear, but may be linked to functional differences16-19. Here we show that assembly of specific isoforms also codes for sorting and localization of the receptor complex. Confocal microscopy and immunoblot analysis of epithelial cells transfected with the complementary DNAs encoding the alpha1 and beta1 GABA(A) receptor subunits and probed with subunit isoform-specific antibodies show that the alpha1 subunit is targeted to the basolateral surface, and that the beta1 subunit is sorted to the apical membrane. In cells where alpha1 and beta1 isoforms are co-expressed, assembly of the beta1 with the alpha1 subunit isoform re-routes the alpha1 subunit to the apical surface. The ability to assemble complexes of different isoform composition and to target these to specific regions of the cell surface would enable neurons to modulate GABA(A) receptor distribution and possibly alter the composition of its synapses in response to transcriptional levels of specific subunit isoforms.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT NEUROSCI,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine								AYOUB GS, 1991, NEUROREPORT, V2, P809, DOI 10.1097/00001756-199112000-00020; BARTLES JR, 1987, J CELL BIOL, V105, P1241, DOI 10.1083/jcb.105.3.1241; BENKE D, 1991, J BIOL CHEM, V266, P4478; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; DOTTI CG, 1991, NATURE, V349, P158, DOI 10.1038/349158a0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; FEGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413; GAMBARANA C, 1990, J NEUROBIOL, V21, P1169, DOI 10.1002/neu.480210803; GU Q, 1992, NEUROREPORT, V3, P169, DOI 10.1097/00001756-199202000-00012; HERZ RE, 1989, J BIOL CHEM, V264, P4605; HOUSER CR, 1988, J NEUROSCI, V8, P1370; HUBBARD AL, 1989, ANNU REV PHYSIOL, V51, P755, DOI 10.1146/annurev.physiol.51.1.755; KILLISCH I, 1991, NEURON, V7, P927, DOI 10.1016/0896-6273(91)90338-Z; KLAUSNER R D, 1989, New Biologist, V1, P3; KOCH C, 1983, P NATL ACAD SCI-BIOL, V80, P2799, DOI 10.1073/pnas.80.9.2799; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1992, J NEUROSCI, V12, P4151; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; LEVITAN ES, 1988, NATURE, V335, P76, DOI 10.1038/335076a0; MERLIE JP, 1986, J MEMBRANE BIOL, V91, P1, DOI 10.1007/BF01870209; MONYER A, 1992, SCIENCE, V256, P1217; NELSON WJ, 1986, J CELL BIOL, V103, P1751, DOI 10.1083/jcb.103.5.1751; PADILLA MM, 1990, J COGNITIVE NEUROSCI, V2, P180; PEREZVELAZQUEZ JL, 1989, J NEUROSCI, V9, P2163; POWELL SK, 1991, NATURE, V353, P76, DOI 10.1038/353076a0; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; SCHOCH P, 1986, GABAERGIC TRANSMISSI, P11; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SOMOGYI P, 1989, J NEUROSCI, V9, P2197; STEPHENSON FA, 1990, J BIOL CHEM, V265, P21160; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; VU ET, 1992, SCIENCE, V255, P1710, DOI 10.1126/science.1553559; WADINGERNESS A, 1990, J CELL BIOL, V111, P987; WISDEN W, 1992, NEUROSCIENCE, V12, P1040; YMER S, 1989, EMBO J, V8, P1665, DOI 10.1002/j.1460-2075.1989.tb03557.x	43	67	68	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 4	1993	361	6411					457	460		10.1038/361457a0	http://dx.doi.org/10.1038/361457a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KK713	8381522				2022-12-28	WOS:A1993KK71300063
J	FINCH, NJ; LEMAN, RB; KRATZ, JM; GILLETTE, PC				FINCH, NJ; LEMAN, RB; KRATZ, JM; GILLETTE, PC			DRIVING SAFETY AMONG PATIENTS WITH AUTOMATIC IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							VENTRICULAR TACHYARRHYTHMIAS; ANXIETY	Objective.-To determine the driving behavior of patients following the placement of automatic implantable cardioverter defibrillators (AICDs). Subjects and Design.-Forty patients with AICDs (33 men, seven women; mean age, 62.7 years) responded to a questionnaire designed to ascertain driving behavior after hospital discharge. Results.-Despite medical advice never to drive again, 28 patients (70%) resumed driving, with the majority doing so by 8 months after AICD implantation. Of these, 11 (40%) identified themselves as the primary driver in their household. Fourteen (50%) drove daily. Two (7%) were driving and continued to drive during discharge of their AICDs. Twenty-five (91%) reported that they felt comfortable and safe while driving. Conclusion.-A majority of patients with AICDs continue to drive after a proscription of this activity by health care workers.	MED UNIV S CAROLINA,DEPT MED,DIV CARDIOL,171 ASHLEY AVE,CHARLESTON,SC 29425; MED UNIV S CAROLINA,GAZES CARDIAC RES INST,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT SURG,DIV CARDIOTHORAC SURG,CHARLESTON,SC 29425; MED UNIV S CAROLINA,DEPT PEDIAT,DIV PEDIAT CARDIOL,CHARLESTON,SC 29425	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina								[Anonymous], 1992, CAN J CARDIOL, V8, P406; DOEGE TC, 1989, MED CONDITIONS AFFEC, V21, P88; DOEGE TC, 1986, MED CONDITIONS AFFEC, P41; GOLD R, 1989, HLTH TRENDS, V21, P88; KALBFLEISCH KR, 1989, AM J CARDIOL, V64, P199, DOI 10.1016/0002-9149(89)90457-8; KEREN R, 1991, PACE, V14, P181, DOI 10.1111/j.1540-8159.1991.tb05088.x; KOU W, 1991, PACE PACING CLIN E 2, V14, P721; LARSEN GC, 1990, CIRCULATION, V82, P83; STRICKBERGER SA, 1991, ANN INTERN MED, V115, P560, DOI 10.7326/0003-4819-115-7-560; TROUP PJ, 1991, PACE, V14, P267, DOI 10.1111/j.1540-8159.1991.tb05105.x; VLAY SC, 1989, PACE, V12, P366, DOI 10.1111/j.1540-8159.1989.tb02670.x	11	24	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1587	1588		10.1001/jama.270.13.1587	http://dx.doi.org/10.1001/jama.270.13.1587			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ334	8371470				2022-12-28	WOS:A1993LZ33400033
J	FOREYT, JP; GOODRICK, GK				FOREYT, JP; GOODRICK, GK			EVIDENCE FOR SUCCESS OF BEHAVIOR-MODIFICATION IN WEIGHT-LOSS AND CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article							MULTICOMPONENT MAINTENANCE PROGRAM; OBESITY; RELAPSE; THERAPY; MANAGEMENT; CONTACT	Behavior modification applied to the treatment of obesity has evolved from the environmental control of eating behavior to a broader approach characterized by systematic manipulation of all factors associated with eating and exercise patterns. This approach has shown success in helping obese persons lose modest amounts of weight. The average length of treatment is 18 weeks, and the average weight loss is 9.9 kg. About 66% of these weight losses are maintained at 52 weeks of follow-up. Because obesity is a chronic condition with a substantial potential for relapse, longer-term treatments are needed. In the future, behavioral modification is likely to be further combined with other treatment methods.			FOREYT, JP (corresponding author), BAYLOR COLL MED, NUTR RES CTR, 6535 FANNIN, MS-F700, HOUSTON, TX 77030 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043109] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43109] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BJORVELL H, 1992, INT J OBESITY, V16, P623; BROWNELL KD, 1989, MED CLIN N AM, V73, P185, DOI 10.1016/S0025-7125(16)30698-8; BROWNELL KD, 1987, BEHAV THER, V18, P353, DOI 10.1016/S0005-7894(87)80004-7; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; Brownell KD, 1990, LEARN PROGRAM WEIGHT; BROWNELL KD, 1992, TREATMENT SERIOUSLY, P437; DUBBERT PM, 1984, BEHAV RES THER, V22, P227, DOI 10.1016/0005-7967(84)90003-2; Ferster C. B., 1962, J MATHETICS, V1, P87; FOREYT J P, 1981, Journal of Behavioral Medicine, V4, P159, DOI 10.1007/BF00844268; FOREYT JP, 1987, J CONSULT CLIN PSYCH, V55, P677; FOREYT JP, 1991, MED SCI SPORT EXER, V23, P292, DOI 10.1249/00005768-199103000-00005; FOREYT JP, 1992, LIVING DIETING; GOODRICK GK, 1991, J AM DIET ASSOC, V91, P1243; HARTMAN W, 1990, 24TH ANN C ASS ADV B; KAYMAN S, 1990, AM J CLIN NUTR, V52, P800, DOI 10.1093/ajcn/52.5.800; LEBOW MD, 1989, ADULT OBESITY THERAP; Marlatt GA., 1985, RELAPSE PREVENTION; Perri M. G., 1992, IMPROVING LONG TERM; PERRI MG, 1989, J CONSULT CLIN PSYCH, V57, P450, DOI 10.1037/0022-006X.57.3.450; PERRI MG, 1988, J CONSULT CLIN PSYCH, V56, P529, DOI 10.1037/0022-006X.56.4.529; PERRI MG, 1984, J CONSULT CLIN PSYCH, V52, P404, DOI 10.1037/0022-006X.52.3.404; PERRI MG, 1987, J CONSULT CLIN PSYCH, V55, P615, DOI 10.1037/0022-006X.55.4.615; PERRI MG, 1984, J CONSULT CLIN PSYCH, V52, P480; PERRI MG, 1986, J CONSULT CLIN PSYCH, V54, P670, DOI 10.1037/0022-006X.54.5.670; POLIVY J, 1992, INT J EAT DISORDER, V11, P261, DOI 10.1002/1098-108X(199204)11:3&lt;261::AID-EAT2260110309&gt;3.0.CO;2-F; RODIN J, 1981, AM PSYCHOL, V36, P361, DOI 10.1037/0003-066X.36.4.361; RODIN J, 1978, PSYCHIATR CLIN N AM, V1, P581; RODIN J, 1974, OBESE HUMANS RATS, P89; SCHACHTER S, 1971, AM PSYCHOL, V26, P129, DOI 10.1037/h0030817; SCHLUNDT DG, 1989, INT J OBESITY, V13, P223; SPIEGEL TA, 1991, BEHAV THER, V22, P61, DOI 10.1016/S0005-7894(05)80244-8; SPITZER RL, 1993, IN PRESS INT J EATIN; TELCH CF, 1990, J CONSULT CLIN PSYCH, V58, P629, DOI 10.1037/0022-006X.58.5.629; Wadden T. A., 1992, INT HDB BEHAV MODIFI, V2, P449; WADDEN TA, 1989, INT J OBESITY, V13, P39; WADDEN TA, 1992, TREATMENT SERIOUSLY, P290; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76	37	102	102	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				698	701		10.7326/0003-4819-119-7_Part_2-199310011-00014	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00014			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363200				2022-12-28	WOS:A1993MA33000014
J	MOFFAT, AS				MOFFAT, AS			CHEMISTS AT WORK	SCIENCE			English	Article																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1791	1791		10.1126/science.8378780	http://dx.doi.org/10.1126/science.8378780			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378780				2022-12-28	WOS:A1993LY58400042
J	RUFFJAMISON, S; CHEN, K; COHEN, S				RUFFJAMISON, S; CHEN, K; COHEN, S			INDUCTION BY EGF AND INTERFERON-GAMMA OF TYROSINE-PHOSPHORYLATED DNA-BINDING PROTEINS IN MOUSE-LIVER NUCLEI	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATOR; IFN-GAMMA; ALPHA; RECEPTOR; KINASES; DOMAINS	Intraperitoneal injection of epidermal growth factor (EGF) into mice resulted in the appearance in liver nuclei of three tyrosine phosphorylated proteins (84, 91, and 92 kilodaltons) within minutes after administration of EGF. Administration of interferon-gamma (IFN-gamma) resulted in the appearance in liver nuclei of two tyrosine phosphorylated proteins (84 and 91 kilodaltons). The 84- and 91-kilodalton proteins detected after either EGF or IFN-gamma administration were identified as the IFN-gamma activation factors (GAF). Furthermore, gel shift analysis revealed that these GAF proteins, detected after either EGF or IFN-gamma administration, specifically bound to the sis-inducible element of the c-fos promoter. Thus, GAF proteins participate in nuclear signaling in both IFN-gamma and EGF pathways.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232	Vanderbilt University					NICHD NIH HHS [HD-00700] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CARPENTER G, 1992, FASEB J, V6, P3283, DOI 10.1096/fasebj.6.14.1385243; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CARPENTER G, 1990, PEPTIDE GROWTH FACTO, P69; DAVID M, 1993, J BIOL CHEM, V268, P6593; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; FISHER DA, 1990, ENDOCR REV, V11, P418, DOI 10.1210/edrv-11-3-418; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; GLENNEY JR, 1992, BIOCHIM BIOPHYS ACTA, V1134, P113, DOI 10.1016/0167-4889(92)90034-9; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; IGARASHI K, 1993, MOL CELL BIOL, V13, P1634, DOI 10.1128/MCB.13.3.1634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENCE DJR, 1990, TUMOR BIOL, V11, P229, DOI 10.1159/000217659; LEVY D, 1990, New Biologist, V2, P923; MASMOUDI A, 1989, J BIOL CHEM, V264, P1172; RUFFJAMISON S, 1993, J BIOL CHEM, V268, P7610; RUFFJAMISON S, 1993, PROTEIN ENG, V6, P661, DOI 10.1093/protein/6.6.661; RUFFJAMISON S, UNPUB; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	28	296	303	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1733	1736		10.1126/science.8378774	http://dx.doi.org/10.1126/science.8378774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378774				2022-12-28	WOS:A1993LY58400026
J	NIGHTINGALE, SL				NIGHTINGALE, SL			LEVOMETHADYL APPROVED FOR THE TREATMENT OF OPIATE DEPENDENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1290	1290		10.1001/jama.270.11.1290	http://dx.doi.org/10.1001/jama.270.11.1290			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360956				2022-12-28	WOS:A1993LW34500007
J	PORT, FK; WOLFE, RA; MAUGER, EA; BERLING, DP; JIANG, KH				PORT, FK; WOLFE, RA; MAUGER, EA; BERLING, DP; JIANG, KH			COMPARISON OF SURVIVAL PROBABILITIES FOR DIALYSIS PATIENTS VS CADAVERIC RENAL-TRANSPLANT RECIPIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DISEASE; LIFE; HEMODIALYSIS; SELECTION	Objective.-To compare mortality risk among cadaveric renal transplant recipients vs transplant candidates on dialysis in the cyclosporine era. Setting.-Patient mortality risk was analyzed by treatment modality for a completed statewide patient population. Patients.-All Michigan residents younger than age 65 years who started end-stage renal disease (ESRD) therapy between January 1, 1984, and December 31, 1989, were included. Patients were followed up from ESRD onset (n=5020), to wait-listing for renal transplant (n=1569), to receiving a cadaveric first transplant (n=799), and to December 31, 1989. Main Outcome Measure.-Mortality rates. Results.-Using a time-dependent variable based on the waiting time from date of wait-listing to transplantation and adjusting for age, sex, race, and primary cause of ESRD, the relative risk (RR) of dying was increased early after transplantation and then decreased to a beneficial long-term effect, given survival to 365 days after transplantation (RR, 0.36; P<.001). This lower long-term risk was most pronounced (RR, 0.25) among diabetic transplant recipients compared with diabetic wait-listed dialysis patients (P<.001) and not observed among patients with glomerulonephritis as cause of ESRD (P>.05). Overall, the estimated times from transplantation to equal mortality risk was 117+/-28 days and to equal cumulative mortality was 325+/-91 days. Conclusions.-The overall mortality risk following renal transplantation was initially increased, but there was a long-term survival benefit compared with similar patients on dialysis. These analyses allow improved description of comparative mortality risks for dialysis and transplant patients and allow advising patients regarding comparative survival outcomes.	UNIV MICHIGAN, SCH PUBL HLTH, DEPT EPIDEMIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH PUBL HLTH, DEPT BIOSTAT, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT INTERNAL MED, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, SCH MED, DEPT EPIDEMIOL, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, SCH MED, DEPT BIOSTAT, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	PORT, FK (corresponding author), MICHIGAN KIDNEY REGISTRY, 315 W HURON, SUITE 340, ANN ARBOR, MI 48103 USA.							BURTON PR, 1987, LANCET, V1, P1115; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; COX DR, 1972, J R STAT SOC B, V34, P187; COX DR, 1984, ANAL SURVIVAL DATA, P137; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GARCIAGARCIA G, 1985, AM J KIDNEY DIS, V5, P10, DOI 10.1016/S0272-6386(85)80129-3; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HENARI FZ, 1977, BRIT MED J, V1, P409, DOI 10.1136/bmj.1.6058.409; HIGGINS MR, 1977, CAN MED ASSOC J, V117, P880; HUTCHINSON TA, 1984, KIDNEY INT, V26, P44, DOI 10.1038/ki.1984.132; KRAKAUER H, 1983, NEW ENGL J MED, V308, P1558, DOI 10.1056/NEJM198306303082603; LOWRIE EG, 1973, NEW ENGL J MED, V288, P863, DOI 10.1056/NEJM197304262881701; MINETTI L, 1985, TRANSPLANT P, V17, P28; PORT FK, 1983, NEW ENGL J MED, V309, P1520; PORT FK, 1993, KIDNEY INT S, V43, pS1; PRICE JDE, 1978, CAN MED ASSOC J, V118, P263; VAUPEL JW, 1985, AM STAT, V39, P176, DOI 10.2307/2683925; VOLLMER WM, 1983, NEW ENGL J MED, V308, P1553, DOI 10.1056/NEJM198306303082602; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; 1991, AM J KIDNEY DIS S2, V18, P1	20	606	616	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1339	1343		10.1001/jama.270.11.1339	http://dx.doi.org/10.1001/jama.270.11.1339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360969				2022-12-28	WOS:A1993LW34500032
J	SHENG, M; LIAO, YJ; JAN, YN; JAN, LY				SHENG, M; LIAO, YJ; JAN, YN; JAN, LY			PRESYNAPTIC A-CURRENT BASED ON HETEROMULTIMERIC K+ CHANNELS DETECTED IN-VIVO	NATURE			English	Article							POTASSIUM CHANNELS; XENOPUS-OOCYTES; RAT-BRAIN; DIVERSITY; SHAKER; HIPPOCAMPUS; SUBUNITS; PROTEINS; NEURONS; APLYSIA	A WIDE variety of voltage-gated K+ channels are involved in the regulation of neuronal excitability and synaptic transmission. Their heterogeneity arises in part from the large number of genes encoding different K+ channel subunits (reviewed in ref. 1). In addition, heterologous expression studies indicate that assembly of distinct subunits into heteromultimeric channels may contribute further to K+ channel diversity2-6. A question has been whether heteromeric K+ channels actually form in vivo, and if so, whether specific combinations of subunits could account for major K+ currents identified in neurons. We present here biochemical evidence that Kv1.4 and Kv1.2, two K+ channel subunits of the Shaker subfamily, co-assemble in rat brain. The Kv1.4/Kv1.2 heteromultimer combines features of both parent subunits, resulting in an A-type K+ channel6. Immunocytochemical evidence suggests that the heteromultimers are localized in axons and nerve terminals. We propose that Kv1.4/Kv1.2 heteromultimers may form the molecular basis of a presynaptic A-type K+ channel involved in the regulation of neurotransmitter release.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT BIOCHEM,SAN FRANCISCO,CA 94143	Howard Hughes Medical Institute; University of California System; University of California San Francisco	SHENG, M (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Sheng, Morgan/0000-0002-8703-5366; Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				BALDWIN TJ, 1991, NEURON, V7, P471, DOI 10.1016/0896-6273(91)90299-F; CHRISTIE MJ, 1990, NEURON, V4, P405, DOI 10.1016/0896-6273(90)90052-H; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; JAN YN, 1977, PROC R SOC SER B-BIO, V198, P87, DOI 10.1098/rspb.1977.0087; KAANG BK, 1992, P NATL ACAD SCI USA, V89, P1133, DOI 10.1073/pnas.89.3.1133; MCCORMACK K, 1990, BIOCHEM BIOPH RES CO, V171, P1361, DOI 10.1016/0006-291X(90)90836-C; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; ROGAWSKI MA, 1985, TRENDS NEUROSCI, V8, P214, DOI 10.1016/0166-2236(85)90082-7; RUDY B, 1988, NEUROSCIENCE, V25, P729, DOI 10.1016/0306-4522(88)90033-4; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SHENG M, 1992, NEURON, V9, P271, DOI 10.1016/0896-6273(92)90166-B; SHIMAHARA T, 1981, NEUROSCI LETT, V24, P139, DOI 10.1016/0304-3940(81)90237-8; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TIBBS GR, 1989, J NEUROCHEM, V52, P201, DOI 10.1111/j.1471-4159.1989.tb10917.x; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y	18	313	318	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					72	75		10.1038/365072a0	http://dx.doi.org/10.1038/365072a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361540				2022-12-28	WOS:A1993LV64600057
J	SUTNICK, AI; STILLMAN, PL; NORCINI, JJ; FRIEDMAN, M; REGAN, MB; WILLIAMS, RG; KACHUR, EK; HAGGERTY, MA; WILSON, MP				SUTNICK, AI; STILLMAN, PL; NORCINI, JJ; FRIEDMAN, M; REGAN, MB; WILLIAMS, RG; KACHUR, EK; HAGGERTY, MA; WILSON, MP			ECFMG ASSESSMENT OF CLINICAL COMPETENCE OF GRADUATES OF FOREIGN MEDICAL-SCHOOLS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; TEST SECURITY; EVALUATE; SKILLS	Objective.-To develop an assessment of clinical competence of graduates of foreign medical schools and to determine the reliability and validity of the assessment and the feasibility of large-scale administration. Design.-The Educational Commission for Foreign Medical Graduates (ECFMG) clinical competence study included (1) clinical encounters with standardized patients to assess history taking, physical examination, and communication skills; (2) laser videodisk pictorials to assess identification and interpretation of diagnostic procedures; (3) written clinical vignettes to assess diagnosis and management skills; and (4) assessment of spoken English. A uniform method of operating the test centers and of training the standardized patients was developed. Setting.-Medical schools and their primary teaching hospitals and affiliated hospitals. Participants.-Six hundred twenty-four first-year residents, of whom 525 are graduates of foreign medical schools. Main Outcome Measures.-Scores, reliability coefficients, validity measures, feasibility of multisite administration, trends of scores over time, and acceptability by examinees. Results.-The ECFMG clinical competence assessment was conducted at four geographically separate test centers. Reliability coefficients were high (.85) for the integrated clinical encounter and were in a reasonable range (.71 to.82) for all test components. The assessment adds to the predictability of the residents' performance in the hospital over that of current ECFMG certification examinations. Test security was addressed by demonstrating no consistent pattern of change in scores over testing dates. Virtually all examinees thought the assessment was appropriate. Standardized patients were able to assess spoken English accurately. Conclusion.-The feasibility of conducting a reliable and valid test of clinical competence for graduates of foreign medical schools was demonstrated for this test population.	UNIV MASSACHUSETTS,MED CTR,WORCESTER,MA 01605; AMER BOARD INTERNAL MED,PHILADELPHIA,PA; UNIV ILLINOIS,CHICAGO,IL 60680; INTERFAITH MED CTR,BROOKLYN,NY; UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,NEWARK,NJ 07103	University of Massachusetts System; University of Massachusetts Worcester; American Board of Internal Medicine; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center	SUTNICK, AI (corresponding author), EDUC COMMISS FOREIGN MED GRAD,3624 MARKET ST,PHILADELPHIA,PA 19104, USA.			Norcini, John/0000-0002-8464-4115				BARROWS HS, 1964, J MED EDUC, V39, P802; BORMANIS J, 1989, 4TH U TENN ANN C MEM; CLARK JLD, 1980, TOEFL7 ED TEST SERV; COLLIVER JA, 1991, ACAD MED, V66, P279, DOI 10.1097/00001888-199105000-00011; CONN HL, 1986, J MED EDUC, V61, P863; CONN HL, 1987, ACAD MED, V62, P448; Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297; ETZEL SI, 1989, JAMA-J AM MED ASSOC, V262, P1029, DOI 10.1001/jama.262.8.1029; FRIEDMAN M, 1991, ACAD MED, V66, pS61, DOI 10.1097/00001888-199109000-00042; FRIEDMAN M, 1992, APPROACHES ASSESSMEN, P305; MCGIRE C, 1987, FURHTER DEV ASSESSIN, P46; Norcini J J, 1984, Eval Health Prof, V7, P485, DOI 10.1177/016327878400700409; NORCINI JJ, IN PRESS EVAL HLTH P; POWERS DE, 1983, TOEFL13 ED TEST SERV; STILLMAN PL, 1991, ACAD MED, V66, pS25, DOI 10.1097/00001888-199109000-00030; STILLMAN PL, 1992, ACAD MED, V67, pS57, DOI 10.1097/00001888-199210000-00039; STILLMAN PL, 1976, PEDIATRICS, V57, P766; SUTNICK AI, 1993, ACAD MED, V68, P150, DOI 10.1097/00001888-199302000-00012; SUTNICK AI, 1992, INT J DERMATOL, V31, P798, DOI 10.1111/j.1365-4362.1992.tb04250.x; SUTNICK AI, 1970, J AMER MED ASSOC, V213, P2241, DOI 10.1001/jama.213.13.2241; SUTNICK AI, 1972, J MED EDUC, V47, P434; SUTNICK AI, 1968, ANN INTERN MED, V68, P1127, DOI 10.7326/0003-4819-68-5-1127; Sutnick AI, 1992, TEACH LEARN MED, V4, P150; SUTNICK AI, 1992, APPROACHES ASSESSMEN, P78; SUTNICK AI, 1971, INT ED CULT EXCHANGE, V6, P91; SWANSON D, 1987, ASSESS EVAL HIGH EDU, V12, P220, DOI DOI 10.1080/0260293870120307; Williams RG, 1991, CURRENT DEV ASSESSIN, P363	27	36	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1041	1045		10.1001/jama.270.9.1041	http://dx.doi.org/10.1001/jama.270.9.1041			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350445				2022-12-28	WOS:A1993LU51200003
J	EDELMAN, RR; WARACH, S				EDELMAN, RR; WARACH, S			MEDICAL PROGRESS .2. MAGNETIC-RESONANCE-IMAGING	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DIAGNOSTIC-ONCOLOGY-GROUP; PROSTATE-CANCER; MR-ANGIOGRAPHY; TISSUE CHARACTERIZATION; CAVERNOUS HEMANGIOMA; CRUCIATE LIGAMENT; IRON OVERLOAD; KNEE-JOINT; GD-DTPA; LIVER		HARVARD UNIV,SCH MED,BOSTON,MA 02115; BETH ISRAEL HOSP,DEPT NEUROL,BOSTON,MA 02215	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	EDELMAN, RR (corresponding author), BETH ISRAEL HOSP,DEPT RADIOL,330 BROOKLINE AVE,BOSTON,MA 02215, USA.		Warach, Steven/R-5074-2019					ADAM G, 1991, AM J ROENTGENOL, V156, P125, DOI 10.2214/ajr.156.1.1898545; AMENDOLA MA, 1990, CANCER, V66, P40, DOI 10.1002/1097-0142(19900701)66:1<40::AID-CNCR2820660109>3.0.CO;2-5; ANDERSON CM, 1992, AM J NEURORADIOL, V13, P989; ARACH S, 1992, NEUROLOGY, V42, P1717; ARRIVE L, 1989, RADIOLOGY, V171, P687, DOI 10.1148/radiology.171.3.2717739; BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; BARAKOS JA, 1989, AM J ROENTGENOL, V153, P47, DOI 10.2214/ajr.153.1.47; BELLIVEAU JW, 1990, MAGNET RESON MED, V14, P538, DOI 10.1002/mrm.1910140311; BERNARDINO ME, 1992, RADIOLOGY, V183, P53, DOI 10.1148/radiology.183.1.1549694; BERQUIST TH, 1989, CLIN ORTHOP RELAT R, V244, P101; BRAHME SK, 1991, RHEUM DIS CLIN N AM, V17, P721; BURK DL, 1988, AM J ROENTGENOL, V150, P331, DOI 10.2214/ajr.150.2.331; COUMAS JM, 1992, AM J ROENTGENOL, V158, P591, DOI 10.2214/ajr.158.3.1739001; CRISTIANI G, 1990, J HAND SURG-BRIT EUR, V15B, P249, DOI 10.1016/0266-7681(90)90132-N; CRUES JV, 1987, RADIOLOGY, V164, P445, DOI 10.1148/radiology.164.2.3602385; DUBOULAY GH, 1990, NEURORADIOLOGY, V32, P124, DOI 10.1007/BF00588562; EBERT T, 1991, UROL CLIN N AM, V18, P453; EDELMAN RR, 1990, STROKE, V21, P56, DOI 10.1161/01.STR.21.1.56; EDELMAN RR, 1989, AM J ROENTGENOL, V153, P1213, DOI 10.2214/ajr.153.6.1213; EDELMAN RR, 1989, RADIOLOGY, V173, P831, DOI 10.1148/radiology.173.3.2813794; EDELMAN RR, 1990, RADIOLOGY, V176, P211, DOI 10.1148/radiology.176.1.2353094; EVENS RG, 1991, AM J ROENTGENOL, V157, P603, DOI 10.2214/ajr.157.3.1872246; FERRUCCI JT, 1990, AM J ROENTGENOL, V155, P473, DOI 10.2214/ajr.155.3.2117343; FERRUCCI JT, 1990, AM J ROENTGENOL, V155, P943, DOI 10.2214/ajr.155.5.2120963; FINN J P, 1992, Magnetic Resonance Quarterly, V8, P1; FISCHER SP, 1991, J BONE JOINT SURG AM, V73A, P2, DOI 10.2106/00004623-199173010-00002; FRANCIS IR, 1992, RADIOLOGY, V184, P1; FRITZSCHE PJ, 1989, SEMIN ULTRASOUND CT, V10, P11; GATSONIS C, 1990, RADIOLOGY, V175, P571, DOI 10.1148/radiology.175.2.2183290; GEFTER WB, 1988, RADIOL CLIN N AM, V26, P573; GLAZER GM, 1986, RADIOLOGY, V158, P73, DOI 10.1148/radiology.158.1.3940402; GLICKSTEIN MF, 1988, RADIOLOGY, V169, P213, DOI 10.1148/radiology.169.1.3420260; GROVER JS, 1990, RADIOLOGY, V174, P527, DOI 10.1148/radiology.174.2.2296661; HANKEY GJ, 1990, STROKE, V21, P209, DOI 10.1161/01.STR.21.2.209; HAUZEUR JP, 1991, J RHEUMATOL, V18, P1211; HEISERMAN JE, 1992, RADIOLOGY, V182, P761, DOI 10.1148/radiology.182.3.1535891; HIEHLE JF, 1991, RHEUM DIS CLIN N AM, V17, P669; HIGGINS CB, 1988, AM J ROENTGENOL, V151, P239, DOI 10.2214/ajr.151.2.239; HRICAK H, 1991, RADIOLOGY, V179, P829, DOI 10.1148/radiology.179.3.2028000; JOHNSTON DL, 1989, AM J MED, V87, P40; KAISER WA, 1989, RADIOLOGY, V170, P681, DOI 10.1148/radiology.170.3.2916021; KAMHOLTZ R, 1991, SEMIN ONCOL, V18, P158; KANG HS, 1991, RADIOLOGY, V181, P401, DOI 10.1148/radiology.181.2.1924779; KANZER GK, 1991, RADIOL CLIN N AM, V29, P1259; KARASICK S, 1992, AM J ROENTGENOL, V158, P799, DOI 10.2214/ajr.158.4.1546595; KNEELAND J B, 1992, Magnetic Resonance Quarterly, V8, P97; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LANG P, 1992, CLIN ORTHOP RELAT R, V274, P135; Le Bihan D, 1991, Magn Reson Q, V7, P1; LEVINE RA, 1986, J AM COLL CARDIOL, V7, P688, DOI 10.1016/S0735-1097(86)80481-8; LIEN HH, 1991, AM J ROENTGENOL, V157, P1221, DOI 10.2214/ajr.157.6.1950869; LINK K M, 1991, Magnetic Resonance Quarterly, V7, P173; LUND JT, 1989, AM J ROENTGENOL, V152, P469, DOI 10.2214/ajr.152.3.469; MANNING WJ, 1991, J AM COLL CARDIOL, V18, P959, DOI 10.1016/0735-1097(91)90754-W; MANNING WJ, IN PESS N ENGL J MED; MANSFIELD P, 1978, J MAGN RESON, V29, P355, DOI 10.1016/0022-2364(78)90159-2; MASARYK AM, 1991, RADIOLOGY, V179, P797, DOI 10.1148/radiology.179.3.2027995; MASUI T, 1992, RADIOLOGY, V182, P369, DOI 10.1148/radiology.182.2.1732952; MATTLE HP, 1991, J VASC SURG, V13, P838; MESGARZADEH M, 1989, RADIOLOGY, V171, P749, DOI 10.1148/radiology.171.3.2541464; MINK JH, 1988, RADIOLOGY, V167, P769, DOI 10.1148/radiology.167.3.3363138; MINTZ MC, 1988, SEMIN ULTRASOUND CT, V9, P167; MIROWITZ SA, 1990, J COMPUT ASSIST TOMO, V14, P223, DOI 10.1097/00004728-199003000-00011; MOORE SG, 1991, RADIOLOGY, V179, P345, DOI 10.1148/radiology.179.2.2014274; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; OHTOMO K, 1990, AM J ROENTGENOL, V154, P505, DOI 10.2214/ajr.154.3.2154911; OWEN RS, 1992, NEW ENGL J MED, V326, P1577, DOI 10.1056/NEJM199206113262428; PETTIGREW RI, 1991, SEMIN ULTRASOUND CT, V12, P61; PIERCE WB, 1991, RADIOLOGY, V181, P757, DOI 10.1148/radiology.181.3.1947093; PORTER BA, 1986, RADIOL CLIN N AM, V24, P269; REICHER MA, 1985, AM J ROENTGENOL, V145, P895, DOI 10.2214/ajr.145.5.895; REICHER MA, 1985, AM J ROENTGENOL, V145, P903, DOI 10.2214/ajr.145.5.903; RIFKIN MD, 1990, NEW ENGL J MED, V323, P621, DOI 10.1056/NEJM199009063231001; ROSEN B R, 1989, Magnetic Resonance Quarterly, V5, P263; ROSS JS, 1990, AM J NEURORADIOL, V11, P449; RUWE PA, 1992, RADIOLOGY, V183, P335, DOI 10.1148/radiology.183.2.1561332; RZEDZIAN RR, 1987, AM J ROENTGENOL, V149, P245, DOI 10.2214/ajr.149.2.245; SCHMIEDL U, 1990, J COMPUT ASSIST TOMO, V14, P600, DOI 10.1097/00004728-199007000-00017; SCHNALL MD, 1991, RADIOLOGY, V178, P797, DOI 10.1148/radiology.178.3.1994421; SEEGER LL, 1988, RADIOLOGY, V168, P695, DOI 10.1148/radiology.168.3.3406398; SIEGELMAN ES, 1991, RADIOLOGY, V179, P361, DOI 10.1148/radiology.179.2.2014275; SKAHEN JR, 1990, J HAND SURG-AM, V15A, P552, DOI 10.1016/S0363-5023(09)90014-4; SMITH HJ, 1988, AM J NEURORADIOL, V9, P225; STARK DD, 1985, AM J ROENTGENOL, V145, P213, DOI 10.2214/ajr.145.2.213; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; STEINER R M, 1990, Magnetic Resonance Quarterly, V6, P17; TOGASHI K, 1989, RADIOLOGY, V171, P245, DOI 10.1148/radiology.171.1.2928532; VANGILS APG, 1991, RADIOGRAPHICS, V11, P37, DOI 10.1148/radiographics.11.1.1671719; WARACH S, 1992, RADIOLOGY, V182, P41, DOI 10.1148/radiology.182.1.1727307; WEBB WR, 1991, RADIOLOGY, V178, P705, DOI 10.1148/radiology.178.3.1847239; YAO L, 1988, RADIOLOGY, V167, P749, DOI 10.1148/radiology.167.3.3363134; ZLATKIN M B, 1992, Magnetic Resonance Quarterly, V8, P65; ZLATKIN M B, 1989, Magnetic Resonance Quarterly, V5, P3; 1991, NEW ENGL J MED, V325, P445	95	35	38	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 18	1993	328	11					785	791		10.1056/NEJM199303183281109	http://dx.doi.org/10.1056/NEJM199303183281109			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KR848	8369029				2022-12-28	WOS:A1993KR84800009
J	PACE, J; HAYMAN, MJ; GALAN, JE				PACE, J; HAYMAN, MJ; GALAN, JE			SIGNAL TRANSDUCTION AND INVASION OF EPITHELIAL-CELLS BY SALMONELLA-TYPHIMURIUM	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; MAMMALIAN-CELLS; SALMONELLA-TYPHIMURIUM; FACTOR RECEPTOR; PHOSPHOLIPASE-A2 ACTIVITY; MOLECULAR-CLONING; ESCHERICHIA-COLI; PROTEIN; CALCIUM; ENTRY	Invasion of host cells is essential for the pathogenicity of Salmonella. We have recently shown that invasion of cultured epithelial cells by S. typhimurium is accompanied by activation of the epidermal growth factor receptor. In this report we show that S. typhimurium invasion stimulated a rapid increase in the levels of free intracellular calcium ([Ca2+]i) in cultured epithelial cells. Mutants defective in invasion were unable to induce these calcium fluxes, and addition of calcium antagonists blocked wild-type S. typhimurium entry. These results indicate that [Ca2+]i increase is required for bacterial entry. Further analysis demonstrated that phospholipase A2 and 5-lipoxygenase activities resulting in production of leukotrienes are required for bacterial entry. Addition of the leukotriene D4 to Henle-407 cells caused both an increase in [Ca2+]i and the internalization of an invasion-defective mutant of S. typhimurium. Furthermore, S. typhimurium caused the activation of mitogen-activated protein (also known as extracellular signal-regulated protein) kinase in infected cells.			PACE, J (corresponding author), SUNY STONY BROOK, SCH MED, DEPT MICROBIOL, STONY BROOK, NY 11794 USA.				NIAID NIH HHS [AI30492] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030492, R01AI030492, R29AI030492] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGELSON JM, 1992, SCIENCE, V255, P1718, DOI 10.1126/science.1553561; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BRUGGE JS, 1986, CELL, V46, P149, DOI 10.1016/0092-8674(86)90729-4; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; BUKHOLM G, 1984, ACTA PATH MICRO IM B, V92, P145; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CLARK S, 1991, BIOCHEM J, V274, P715, DOI 10.1042/bj2740715; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; ELSINGHORST EA, 1989, P NATL ACAD SCI USA, V86, P5173, DOI 10.1073/pnas.86.13.5173; FALKOW S, 1991, CELL, V65, P1099, DOI 10.1016/0092-8674(91)90003-H; FINLAY BB, 1990, J INFECT DIS, V162, P1096, DOI 10.1093/infdis/162.5.1096; FINLAY BB, 1991, J CELL SCI, V99, P283; FINLAY BB, 1988, MOL MICROBIOL, V2, P757, DOI 10.1111/j.1365-2958.1988.tb00087.x; GAILLARD JL, 1991, CELL, V65, P1127, DOI 10.1016/0092-8674(91)90009-N; GALAN JE, 1991, INFECT IMMUN, V59, P2901; GALAN JE, 1990, INFECT IMMUN, V58, P1879; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GALAN JE, 1992, J BACTERIOL, V174, P4338; GALAN JE, 1989, P NATL ACAD SCI USA, V86, P6383, DOI 10.1073/pnas.86.16.6383; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GOULD KL, 1986, J CELL BIOL, V102, P660, DOI 10.1083/jcb.102.2.660; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAGIWARA S, 1981, ANNU REV NEUROSCI, V4, P69, DOI 10.1146/annurev.ne.04.030181.000441; HIRATA F, 1984, P NATL ACAD SCI-BIOL, V81, P4717, DOI 10.1073/pnas.81.15.4717; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; ISBERG RR, 1991, SCIENCE, V252, P934, DOI 10.1126/science.1674624; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; ISBERG RR, 1985, NATURE, V317, P262, DOI 10.1038/317262a0; KIHLSTROM E, 1977, ACTA PATH MICRO IM B, V85, P322; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; LANSMAN JB, 1986, J GEN PHYSIOL, V88, P321, DOI 10.1085/jgp.88.3.321; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LEONG JM, 1990, EMBO J, V9, P1979, DOI 10.1002/j.1460-2075.1990.tb08326.x; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; MARGOLIS BL, 1988, BIOCHEM J, V256, P469, DOI 10.1042/bj2560469; MARKS PW, 1990, CELL CALCIUM, V11, P18, DOI 10.1016/0143-4160(90)90069-7; MENDELSOHN CL, 1989, CELL, V56, P855, DOI 10.1016/0092-8674(89)90690-9; MILLER VL, 1988, INFECT IMMUN, V56, P1242, DOI 10.1128/IAI.56.5.1242-1248.1988; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; MOULDER JW, 1985, MICROBIOL REV, V49, P298, DOI 10.1128/MMBR.49.3.298-337.1985; NHIEU GTV, 1991, J BIOL CHEM, V266, P24367; ORNING L, 1980, J BIOL CHEM, V255, P8023; ORTEGABARRIA E, 1991, CELL, V67, P411, DOI 10.1016/0092-8674(91)90192-2; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; PIPER PJ, 1983, BRIT MED BULL, V39, P255, DOI 10.1093/oxfordjournals.bmb.a071829; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; ROUZER CA, 1986, P NATL ACAD SCI USA, V83, P857, DOI 10.1073/pnas.83.4.857; SANSONETTI PJ, 1991, REV INFECT DIS, V13, pS285; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; STONE BJ, 1992, J BACTERIOL, V174, P3945, DOI 10.1128/jb.174.12.3945-3952.1992; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; TAYLOR DL, 1980, J CELL BIOL, V86, P599, DOI 10.1083/jcb.86.2.599; TEITELBAUM I, 1990, J BIOL CHEM, V265, P4218; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TYLER KL, 1990, VIROLOGY, P191; WEISS GB, 1974, ANNU REV PHARMACOL, V14, P343, DOI 10.1146/annurev.pa.14.040174.002015; WONG A, 1991, BIOCHEMISTRY-US, V30, P9346, DOI 10.1021/bi00102a030	69	235	241	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 26	1993	72	4					505	514		10.1016/0092-8674(93)90070-7	http://dx.doi.org/10.1016/0092-8674(93)90070-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KP165	8382566				2022-12-28	WOS:A1993KP16500006
J	SEABRA, MC; BROWN, MS; GOLDSTEIN, JL				SEABRA, MC; BROWN, MS; GOLDSTEIN, JL			RETINAL DEGENERATION IN CHOROIDEREMIA - DEFICIENCY OF RAB GERANYLGERANYL TRANSFERASE	SCIENCE			English	Article							GTP-BINDING PROTEIN; SYNDROME TYPE-II; RETINITIS-PIGMENTOSA; SMG P25A; GENE; CHROMOSOME-1Q; CLONING	Rab geranylgeranyl transferase (GG transferase) is a two-component enzyme that attaches 20-carbon isoprenoid groups to cysteine residues in Rab proteins, a family of guanosine triphosphate-binding proteins that regulate vesicular traffic. The mutant gene in human choroideremia, an X-linked form of retinal degeneration, encodes a protein that resembles component A of rat Rab GG transferase. Lymphoblasts from choroideremia subjects showed a marked deficiency in the activity of component A, but not component B, of Rab GG transferase. The deficiency was more pronounced when the substrate was Rab3A, a synaptic vesicle protein, than it was when the substrate was Rab1A, a protein of the endoplasmic reticulum. The data imply the existence of multiple component A proteins, one of which is missing in choroideremia.			SEABRA, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Seabra, Miguel C/M-3280-2013; Seabra, Miguel/AAC-3099-2019	Seabra, Miguel C/0000-0002-6404-4892; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SK, UNPUB; BALCH WE, 1990, TRENDS BIOCHEM SCI, V15, P473, DOI 10.1016/0968-0004(90)90301-Q; BERMAN ER, 1991, BIOCH EYE, P1; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0; FODOR E, 1991, NATURE, V351, P614, DOI 10.1038/351614b0; HALLGREN B, 1959, ACTA PSYCHIAT N S138, V34, P9; Heckenlively JR, 1988, RETINITIS PIGMENTOSA, P176; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KIMBERLING WJ, 1990, GENOMICS, V7, P245, DOI 10.1016/0888-7543(90)90546-7; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; LEWIS RA, 1990, GENOMICS, V7, P250, DOI 10.1016/0888-7543(90)90547-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MERRY DE, 1992, P NATL ACAD SCI USA, V89, P2135, DOI 10.1073/pnas.89.6.2135; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P159; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VALLE D, 1989, METABOLIC BASIS INHE, P599; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0	29	281	287	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 15	1993	259	5093					377	381		10.1126/science.8380507	http://dx.doi.org/10.1126/science.8380507			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KG624	8380507				2022-12-28	WOS:A1993KG62400037
J	SOCIE, G; HENRYAMAR, M; BACIGALUPO, A; HOWS, J; TICHELLI, A; LJUNGMAN, P; MCCANN, SR; FRICKHOFEN, N; VANTVEERKORTHOF, E; GLUCKMAN, E				SOCIE, G; HENRYAMAR, M; BACIGALUPO, A; HOWS, J; TICHELLI, A; LJUNGMAN, P; MCCANN, SR; FRICKHOFEN, N; VANTVEERKORTHOF, E; GLUCKMAN, E			MALIGNANT-TUMORS OCCURRING AFTER TREATMENT OF APLASTIC-ANEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; TERM FOLLOW-UP; IMMUNOSUPPRESSIVE THERAPY; ANTITHYMOCYTE GLOBULIN; HODGKINS-DISEASE; LEUKEMIA; MYELODYSPLASIA; CLASSIFICATION; EVOLUTION; PROPOSALS	Background and Methods. Recent studies have shown that long-term survivors of acquired aplastic anemia may be at high risk for malignant diseases. We assessed the risk of cancer after aplastic anemia was treated with immunosuppression or bone marrow transplantation and sought to identify risk factors according to treatment. The study population consisted of 860 patients treated by immunosuppression and 748 patients who had received bone marrow transplants for the treatment of severe aplastic anemia. The risk of cancer was analyzed overall and according to treatment relative to the risk in the general population. In calculating relative risk, we excluded patients with myelodysplastic syndromes or acute leukemias arising less than 6 months after treatment, and solid cancers arising less than 12 months after treatment, because of a possible association with aplastic anemia itself rather than with the treatment received. Results. Forty-two malignant conditions were reported in the 860 patients who received immunosuppressive therapy: 19 cases of myelodysplastic syndrome, 15 cases of acute leukemia, 1 case of non-Hodgkin's lymphoma, and 7 solid tumors. Nine were reported in the 748 patients who received bone marrow transplants: two cases of acute leukemia and seven solid tumors. After the exclusions listed above, the overall relative risk of cancer was 5.50 (P<0.001) as compared with that in the general European population; the risk was 5.15 (P<0.001) after immunosuppressive therapy and 6.67 (P<0.001) after transplantation. The 10-year cumulative incidence rate of cancer was 18.8 percent after immunosuppressive therapy and 3.1 percent after transplantation. The risk factors for myelodysplastic syndrome or acute leukemia after immunosuppressive therapy included the addition of androgens to the immunosuppressive treatment (relative risk = 0.28), older age (relative risk = 1.03), treatment in 1982 or later, as compared with 1981 or earlier (relative risk = 3.01), splenectomy (relative risk = 3.65), and treatment with multiple courses of immunosuppression (relative risk = 2.26). Risk factors for solid tumors after bone marrow transplantation were age (relative risk = 1.11 per year) and the use of radiation as a conditioning regimen before transplantation (relative risk = 9.56); such tumors occurred only in male patients. Conclusions. Survivors of aplastic anemia are at high risk for subsequent malignant conditions. Myelodysplastic syndrome and acute leukemia tend to follow immunosuppressive therapy, whereas the incidence of solid tumors is similar after immunosuppression and after bone marrow transplantation.	INST GUSTAVE ROUSSY,F-94805 VILLEJUIF,FRANCE; OSPED SAN MARTINO GENOVA,GENOA,ITALY; SOUTHMEAD GEN HOSP,BRISTOL BS10 5NB,AVON,ENGLAND; KANTONSSPITAL,BASEL,SWITZERLAND; KAROLINSKA INST,HUDDINGE UNIV HOSP,S-14186 HUDDINGE,SWEDEN; ST JAMES HOSP,DUBLIN 8,IRELAND; UNIV ULM,MED KLIN & POLIKLIN,W-7900 ULM,GERMANY; ACAD ZIEKENHUIS LEIDEN,LEIDEN,NETHERLANDS	UNICANCER; Gustave Roussy; University of Genoa; IRCCS AOU San Martino IST; Southmead Hospital; Kantonsspital Aarau AG (KSA); University of Basel; Karolinska Institutet; Trinity College Dublin; Ulm University; Leiden University; Leiden University Medical Center (LUMC)	SOCIE, G (corresponding author), HOP ST LOUIS,SERV GREFFE MOELLE,1 AVE CLAUDE VELLEFAUX,F-75010 PARIS,FRANCE.		eliane, Gluckman/AAA-5024-2021; Ljungman, Per/M-4946-2019; Henry-Amar, Michel/S-9358-2019	Henry-Amar, Michel/0000-0002-9357-6476				[Anonymous], 1982, CANCER, V49, P2112; APPELBAUM FR, 1987, EXP HEMATOL, V15, P1134; BACIGALUPO A, 1989, CLIN HAEMATOL, V2, P19; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BLOHME I, 1985, TRANSPLANTATION, V39, P23; BROWNE PV, 1991, NEW ENGL J MED, V325, P710, DOI 10.1056/NEJM199109053251007; CAMITTA BM, 1976, BLOOD, V48, P63; CAMITTA BM, 1990, AM J PEDIAT HEMATOL, V12, P411; COX DR, 1972, J R STAT SOC B, V34, P187; DEPLANQUE MM, 1988, BRIT J HAEMATOL, V70, P55; DEPLANQUE MM, 1989, BRIT J HAEMATOL, V73, P121; DONEY K, 1992, BLOOD, V79, P2566; DONEY K, 1990, APLASTIC ANEMIA AND OTHER BONE MARROW FAILURE SYNDROMES, P104; HENRYAMAR M, 1992, ANN ONCOL, V3, pS117, DOI 10.1093/annonc/3.suppl_4.S117; HENRYAMAR M, 1993, HEMATOL ONCOL CLIN N, V7, P369, DOI 10.1016/S0889-8588(18)30246-6; HUGHES RT, 1988, BRIT J HAEMATOL, V68, P391, DOI 10.1111/j.1365-2141.1988.tb04220.x; KALDOR JM, 1987, INT J CANCER, V39, P571, DOI 10.1002/ijc.2910390506; KALDOR JM, 1990, NEW ENGL J MED, V322, P7, DOI 10.1056/NEJM199001043220102; KLINGEMANN HG, 1986, BRIT J HAEMATOL, V63, P47, DOI 10.1111/j.1365-2141.1986.tb07493.x; KOJIMA S, 1992, NEW ENGL J MED, V326, P1294; LOUGHRAN TP, 1990, HEMATOL ONCOL CLIN N, V4, P559, DOI 10.1016/S0889-8588(18)30478-7; MARSH JCW, 1991, BRIT J HAEMATOL, V77, P447; MARY JY, 1990, BLOOD, V75, P1646; MIKE V, 1982, LANCET, V2, P1326; MURI C, 1987, IARC SCI PUBLICATION, V88; NAJEAN Y, 1990, BLOOD, V76, P2222; NISSEN C, 1991, SEMIN HEMATOL, V28, P313; SOCIE G, 1992, BRIT J HAEMATOL, V80, P427, DOI 10.1111/j.1365-2141.1992.tb04553.x; SOCIE G, 1991, BLOOD, V78, P277; SOCIE G, 1992, BRIT J HAEMATOL, V80, P391, DOI 10.1111/j.1365-2141.1992.tb08150.x; SPECK B, 1986, EXP HEMATOL, V14, P126; STORB R, 1989, BRIT J HAEMATOL, V72, P567, DOI 10.1111/j.1365-2141.1989.tb04325.x; TICHELLI A, 1988, BRIT J HAEMATOL, V69, P413, DOI 10.1111/j.1365-2141.1988.tb02382.x; WITHERSPOON RP, 1992, BLOOD, V79, P289; YOUNG NS, 1992, BLOOD, V79, P1385, DOI 10.1182/blood.V79.6.1385.bloodjournal7961385; 1989, LANCET, V1, P1425; [No title captured]; 1992, STATA REFERENCE MANU; 1977, MANUAL INT STATISTIC, V1	40	386	397	1	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1152	1157		10.1056/NEJM199310143291603	http://dx.doi.org/10.1056/NEJM199310143291603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377778				2022-12-28	WOS:A1993MA66700003
J	JEFFERY, RW				JEFFERY, RW			MINNESOTA STUDIES ON COMMUNITY-BASED APPROACHES TO WEIGHT-LOSS AND CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article							HEART HEALTH-PROGRAM; BODY-MASS INDEX; SMOKING CESSATION; LOSS COMPETITIONS; BEHAVIOR-CHANGE; REDUCTION; EDUCATION; STRATEGIES; WORKSITE; PROJECT	Community-based approaches to weight control including worksite interventions, intervention by home correspondence, and multimodal community strategies are reviewed. Community-based programs have shown the ability to treat large numbers of obese persons, many of whom probably would not spontaneously seek professional care. Community-based approaches produce modest weight losses at lower costs than do clinical interventions. Although no community program has yet to reduce the prevalence of obesity in the general population, this area is relatively new and deserves further study. Recommended areas for future research include strategies for recruitment to community programs and primary prevention of weight gain.			JEFFERY, RW (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL025523, R01HL034740] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL25523, R01-HL34740] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM S, 1979, ADVANCEDATA, V51, P1; BROWNELL KD, 1984, AM J PUBLIC HEALTH, V74, P1283, DOI 10.2105/AJPH.74.11.1283; CAMERON R, 1990, CAN J PUBLIC HEALTH, V81, P275; Erfurt J C, 1991, Am J Health Promot, V5, P438; FEINLEIB M, 1985, ANN INTERN MED, V103, P1019, DOI 10.7326/0003-4819-103-6-1019; Fielding J. E., 1990, Health Promotion International, V5, P75, DOI 10.1093/heapro/5.1.75; FORSTER JL, 1988, PREV MED, V17, P129, DOI 10.1016/0091-7435(88)90078-3; FORTMANN SP, 1981, AM J CLIN NUTR, V34, P2030, DOI 10.1093/ajcn/34.10.2030; JEFFERY RW, 1993, AM J PUBLIC HEALTH, V83, P395, DOI 10.2105/AJPH.83.3.395; JEFFERY RW, 1990, HEALTH PSYCHOL, V9, P585, DOI 10.1037/0278-6133.9.5.585; JEFFERY RW, 1982, BEHAV THER, V13, P24, DOI 10.1016/S0005-7894(82)80047-6; JEFFERY RW, 1982, ADDICT BEHAV, V7, P57, DOI 10.1016/0306-4603(82)90025-9; LASATER T, 1984, BEHAVIORAL HLTH HDB, P1166; MARSTON AR, 1977, OBESITY BARIAT MED, V6, P140; MCALISTER A, 1982, AM J PUBLIC HEALTH, V72, P43, DOI 10.2105/AJPH.72.1.43; MITTELMARK MB, 1986, PREV MED, V15, P1, DOI 10.1016/0091-7435(86)90031-9; SHAH M, 1991, INT J OBESITY, V15, P499; STUNKARD AJ, 1989, PREV MED, V18, P460, DOI 10.1016/0091-7435(89)90006-6; TAYLOR CB, 1991, AM J EPIDEMIOL, V134, P235, DOI 10.1093/oxfordjournals.aje.a116077	19	25	25	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				719	721		10.7326/0003-4819-119-7_Part_2-199310011-00018	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00018			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363204				2022-12-28	WOS:A1993MA33000018
J	SCHWARTZ, A; GINSBURG, PB; LEROY, LB				SCHWARTZ, A; GINSBURG, PB; LEROY, LB			REFORMING GRADUATE MEDICAL-EDUCATION - SUMMARY REPORT OF THE PHYSICIAN-PAYMENT-REVIEW-COMMISSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOUSE STAFF				SCHWARTZ, A (corresponding author), PHYSICIAN PAYMENT REVIEW COMMISS,WASHINGTON,DC, USA.							ANDERSON GF, 1990, PROIVIDING HOSPITAL; BARNETT PG, 1989, JAMA-J AM MED ASSOC, V262, P2864, DOI 10.1001/jama.262.20.2864; CAWLEY JF, 1992, 1992 P NAT PRIM CAR; FALLON HJ, 1992, ANN INTERN MED, V116, P1103, DOI 10.7326/0003-4819-116-12-1103; KLETKE PR, 1987, DEMOGRAPHICS PHYSICI; MAUDSLEY RF, 1988, CAN MED ASSOC J, V139, P1134; SILVER HK, 1988, AM J NURS, V88, P1671; THORPE KE, 1990, JAMA-J AM MED ASSOC, V263, P3177, DOI 10.1001/jama.263.23.3177; WHITCOMB M, 1992, JAMA-J AM MED ASSOC, V268, P1106, DOI 10.1001/jama.268.9.1106; 1990, OTAH434 PUBL; 1993, ANN REPORT C 1993; 1991, SURVEY HOUSESTAFF ST; 1992, GENERAL CENSUS DATA; 1992, 4TH ANN REPORT 1991; 1991, ANN REPORT 1991; 1992, ANN REPORT C 1992	16	33	33	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1079	1082		10.1001/jama.270.9.1079	http://dx.doi.org/10.1001/jama.270.9.1079			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350451				2022-12-28	WOS:A1993LU51200009
J	WILSON, MA; MCNAUGHTON, BL				WILSON, MA; MCNAUGHTON, BL			DYNAMICS OF THE HIPPOCAMPAL ENSEMBLE CODE FOR SPACE	SCIENCE			English	Article							LONG-LASTING POTENTIATION; SINGLE UNIT-ACTIVITY; SYNAPTIC ENHANCEMENT; RAT HIPPOCAMPUS; CELLS; STIMULATION; ENVIRONMENT; NEURONS; SYSTEM	Ensemble recordings of 73 to 148 rat hippocampal neurons were used to predict accurately the animals' movement through their environment, which confirms that the hippocampus transmits an ensemble code for location. In a novel space, the ensemble code was initially less robust but improved rapidly with exploration. During this period, the activity of many inhibitory cells was suppressed, which suggests that new spatial information creates conditions in the hippocampal circuitry that are conducive to the synaptic modification presumed to be involved in learning. Development of a new population code for a novel environment did not substantially alter the code for a familiar one, which suggests that the interference between the two spatial representations was very small. The parallel recording methods outlined here make possible the study of the dynamics of neuronal interactions during unique behavioral events.	UNIV ARIZONA, DIV NEURAL SYST MEMORY & AGING, TUCSON, AZ 85724 USA	University of Arizona	WILSON, MA (corresponding author), UNIV ARIZONA, DEPT PSYCHOL, TUCSON, AZ 85724 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046823, R37MH046823] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46823] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELES M, 1977, P IEEE, V65, P762, DOI 10.1109/PROC.1977.10559; AHISSAR E, 1992, SCIENCE, V257, P1412, DOI 10.1126/science.1529342; BARNES CA, 1990, PROG BRAIN RES, V83, P287; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; DIAMOND DM, 1988, J NEUROSCI, V8, P4079; EICHENBAUM H, 1988, TRENDS NEUROSCI, V11, P244, DOI 10.1016/0166-2236(88)90100-2; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; GARDNERMEDWIN AR, 1976, PROC R SOC SER B-BIO, V194, P375, DOI 10.1098/rspb.1976.0084; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; HILL AJ, 1978, EXP NEUROL, V62, P282, DOI 10.1016/0014-4886(78)90058-4; KUPERSTEIN M, 1986, EXP BRAIN RES, V61, P438; LARSON J, 1988, NEUROL NEUR, V46, P411; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCNAUGHTON BL, 1978, BRAIN RES, V157, P277, DOI 10.1016/0006-8993(78)90030-6; MCNAUGHTON BL, 1983, J NEUROSCI METH, V8, P391, DOI 10.1016/0165-0270(83)90097-3; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; McNaughton BL, 1990, NEUROSCIENCE CONNECT, P1; MOUNTCASTLE VB, 1991, J NEUROSCI METH, V36, P77, DOI 10.1016/0165-0270(91)90140-U; MULLER RU, 1987, J NEUROSCI, V7, P1935; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; OKEEFE J, 1976, EXP NEUROL, V51, P78, DOI 10.1016/0014-4886(76)90055-8; OLTON DS, 1978, EXP NEUROL, V58, P387, DOI 10.1016/0014-4886(78)90096-1; PAVLIDES C, 1989, J NEUROSCI, V9, P2907; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; RECCE M K, 1989, Society for Neuroscience Abstracts, V15, P1250; Rolls E.T., 1989, NEURAL MODELS PLASTI, P240; SCHARFMAN HE, 1985, BRAIN RES, V331, P267, DOI 10.1016/0006-8993(85)91552-5; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SEGAL M, 1972, J NEUROPHYSIOL, V35, P680, DOI 10.1152/jn.1972.35.5.680; Skaggs WE, 1993, ADV NEURAL INFORM PR, V5, P1030, DOI DOI 10.1109/PROC.1977.10559; SQUIRE LR, 1989, NEURAL MODELS PLASTI, P208; SWANSON LW, 1987, HDB CHEM NEUROANATOM, V5, pCH2; THOMPSON LT, 1989, J NEUROSCI, V9, P2382; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WILSON M A, 1991, Society for Neuroscience Abstracts, V17, P1395; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	40	1496	1519	2	112	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1055	1058		10.1126/science.8351520	http://dx.doi.org/10.1126/science.8351520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351520				2022-12-28	WOS:A1993LT74700037
J	QIAN, YW; WANG, YCJ; HOLLINGSWORTH, RE; JONES, D; LING, N; LEE, EYHP				QIAN, YW; WANG, YCJ; HOLLINGSWORTH, RE; JONES, D; LING, N; LEE, EYHP			A RETINOBLASTOMA-BINDING PROTEIN RELATED TO A NEGATIVE REGULATOR OF RAS IN YEAST	NATURE			English	Article							SV40 T-ANTIGEN; GENE-PRODUCT; SUSCEPTIBILITY GENE; CELLULAR PROTEINS; MESSENGER-RNAS; IDENTIFICATION; TRANSCRIPTION; CLONING; TRANSLATION; REGION	THE growth suppression function of the retinoblastoma protein (Rb) is thought to be mediated by Rb binding to cellular proteins1. p48 is one of the major proteins that binds to a putative functional domain at the carboxy terminus of the Rb protein2. Here we report the isolation of a full-length complementary DNA (RbAp48) encoding p48. Complex formation between p48 and Rb occurs in vitro and in vivo, and apparently involves direct interaction between the proteins. Like Rb, p48 is a ubiquitously expressed nuclear protein. RbAp48 share sequence homology with MSI1, a negative regulator of the Ras-cyclic AMP pathway in the yeast Saccharomyces cerevisiae3. Furthermore, like MSI1, human RbAp48 suppresses the heat-shock sensitivity of the yeast ira1 strains and RAS2val19 strains. Interaction with p48 may be one of the mechanisms for suppression of growth mediated by Rb.	UNIV TEXAS,HLTH SCI CTR,INST BIOTECHNOL,CTR MOLEC MED,15355 LAMBDA DR,SAN ANTONIO,TX 78245; WHITTIER INST,LA JOLLA,CA 92037	University of Texas System; University of Texas Health San Antonio								Barbacid M., 1987, REV BIOCH, V56, P779; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; GODRICH DW, IN PRESS BIOCH BIOPH; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LEE WH, 1991, COLD SPRING HARB SYM, V5, P211; Matsudaira P, 1989, PRACTICAL GUIDE PROT; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHERMAN F, 1986, LABORATORY COURSE MA; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233	22	250	267	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					648	652		10.1038/364648a0	http://dx.doi.org/10.1038/364648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350924				2022-12-28	WOS:A1993LR77100059
J	MCCARTHY, M; LAYZELL, S				MCCARTHY, M; LAYZELL, S			FUNDING POLICIES FOR HIV AND AIDS - TIME FOR CHANGE	BRITISH MEDICAL JOURNAL			English	Article								Funding for HIV and AIDS in England has been allocated to regions by a formula based on the number of cases of AIDS and HIV infection and on population size. Regions have distributed the resources directly to hospitals and community services. A survey of staff and managers in North East Thames region showed that funding arrangements have led to unsatisfactory development of services for HIV and AIDS. Firstly, because hospitals are funded according to current numbers of patients services are highly developed at the central London hospitals and underdeveloped in outer districts. Secondly, specialised community care teams have been established rather than integrating care for HIV and AIDS into generic primary care. Thirdly, the information on district of residence of infected patients is inaccurate, limiting allocation of funds according to population needs. Fourthly, prevention of infection has been given far less attention than treatment and care despite the lack of effective treatment. In future allocations for HIV and AIDS should be made to purchasers rather than directly to providers.	UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND	University of London; University College London	MCCARTHY, M (corresponding author), CAMDEN & ISLINGTON HLTH AUTHOR, LONDON NW1 2LJ, ENGLAND.		McCarthy, Mark/C-1117-2009					ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; LAYZELL S, 1992, COMMUNITY BASED HLTH; LAYZELL S, 1992, AIDS CARE, V4, P205; 1992, AIDS HIV Q SURVEILLA; 1993, AIDS HIV INFECTED HL; 1992, EL9218 NHS MAN EX DE; 1992, EL9216 NHS MAN EX DE; 1991, HIV AIDS RELATED HLT; 1993, CAMDEN ISLINGTON HIV; 1993, EL9319 NHS MAN EX DE	10	10	10	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					367	369		10.1136/bmj.307.6900.367	http://dx.doi.org/10.1136/bmj.307.6900.367			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374421	Green Published, Bronze			2022-12-28	WOS:A1993LR76800024
J	THORNICROFT, G; HALPERN, A				THORNICROFT, G; HALPERN, A			LEGAL LANDMARK FOR COMMUNITY CARE OF FORMER PSYCHIATRIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								A recent judgment of the Lands Tribunal has set an important precedent which should decrease the potential for restrictive covenants to thwart the development of the government's care in the community programme. In 1989 a Worthing couple were permitted to convert their own house into a residential care home for former psychiatric patients. Judge B Marder, QC, ruled on 12 January 1993 that the ''public interest'' outweighed a contractual stipulation that the property should be used only for residential, non-business purposes. This is a radical change in the Lands Tribunal's view of mental illness.	NATL ASSOC MENTAL HLTH,MIND,LONDON W1N 4ED,ENGLAND		THORNICROFT, G (corresponding author), INST PSYCHIAT,PSYCHIAT RES SERV MEASUREMENT,LONDON SE5 8AF,ENGLAND.		Thornicroft, Graham/B-4027-2010	Thornicroft, Graham/0000-0003-0662-0879				HIRSCH SR, 1988, PSYCHIATRIC BEDS RES; LINDQVIST P, 1990, BRIT J PSYCHIAT, V157, P345, DOI 10.1192/bjp.157.3.345; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; TEPLIN LA, 1985, AM J PSYCHIAT, V142, P593; WILKINSON G, 1986, PROVISION MENTAL HLT; 1992, HOUSE COMMONS OFFICI, P595; 1987, MODEL COMPREHENSIVE; 1985, 2ND SOC SERV COMM RE; 1991, IMPLICATIONS FIELD M; 1993, W SUSSEX COMMUNITY C; 1991, HLTH NATION; 1991, TEAM ASSESSMENT PSYC	12	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					248	250		10.1136/bmj.307.6898.248	http://dx.doi.org/10.1136/bmj.307.6898.248			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP314	8369693	Bronze, Green Published			2022-12-28	WOS:A1993LP31400032
J	SOLOMON, EI; LOWERY, MD				SOLOMON, EI; LOWERY, MD			ELECTRONIC-STRUCTURE CONTRIBUTIONS TO FUNCTION IN BIOINORGANIC CHEMISTRY	SCIENCE			English	Article							COPPER ACTIVE-SITE; PLASTOCYANIN SINGLE-CRYSTALS; MAGNETIC CIRCULAR-DICHROISM; RESONANCE RAMAN; NATIVE LACCASE; OXYGEN-BINDING; MODEL COMPLEX; RHUS LACCASE; HEMOCYANIN; TYROSINASE	Many metalloenzymes exhibit distinctive spectral features that are now becoming well understood. These reflect active site electronic structures that can make significant contributions to catalysis. Copper proteins provide well-characterized examples in which the unusual electronic structures of their active sites contribute to rapid, long-range electron transfer reactivity, oxygen binding and activation, and the multielectron reduction of dioxygen to water.			SOLOMON, EI (corresponding author), STANFORD UNIV, DEPT CHEM, STANFORD, CA 94305 USA.			Solomon, Edward/0000-0003-0291-3199	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031450, R01DK031450] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-31450] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADMAN ET, 1991, ADV PROTEIN CHEM, V42, P145; ALLENDORF MD, 1985, P NATL ACAD SCI USA, V82, P3063, DOI 10.1073/pnas.82.10.3063; BALDWIN MJ, 1991, J AM CHEM SOC, V113, P8671, DOI 10.1021/ja00023a014; BALDWIN MJ, 1992, J AM CHEM SOC, V114, P10421, DOI 10.1021/ja00052a043; BATES CA, 1962, P PHYS SOC LOND, V79, P73, DOI 10.1088/0370-1328/79/1/311; BRILL AS, 1968, J CHEM PHYS, V48, P4398, DOI 10.1063/1.1668007; BROWN JM, 1980, J AM CHEM SOC, V102, P4210, DOI 10.1021/ja00532a037; CO MS, 1981, J AM CHEM SOC, V103, P984, DOI 10.1021/ja00394a066; COLE JL, 1991, J AM CHEM SOC, V113, P8544, DOI 10.1021/ja00022a064; COLE JL, 1990, J AM CHEM SOC, V112, P9534, DOI 10.1021/ja00182a013; COLE JL, 1990, J AM CHEM SOC, V112, P2243, DOI 10.1021/ja00162a025; COLE JR, UNPUB; COLMAN PM, 1978, NATURE, V272, P319, DOI 10.1038/272319a0; DOOLEY DM, 1978, P NATL ACAD SCI USA, V75, P3019, DOI 10.1073/pnas.75.7.3019; EICKMAN NC, 1979, P NATL ACAD SCI USA, V76, P2094, DOI 10.1073/pnas.76.5.2094; EICKMAN NC, 1978, J AM CHEM SOC, V100, P6529, DOI 10.1021/ja00488a059; FARVER O, 1978, FEBS LETT, V94, P383, DOI 10.1016/0014-5793(78)80983-1; FEE JA, 1975, STRUCT BONDING BERLI, V23, P1; FREEDMAN TB, 1976, J AM CHEM SOC, V98, P2809, DOI 10.1021/ja00426a023; GEORGE SJ, IN PRESS J AM CHEM S; GEWIRTH AA, 1988, J AM CHEM SOC, V110, P3811, DOI 10.1021/ja00220a015; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; GRAZIANI MT, 1976, FEBS LETT, V70, P87, DOI 10.1016/0014-5793(76)80732-6; GUSS JM, 1983, J MOL BIOL, V169, P521; HAY PJ, 1975, J AM CHEM SOC, V97, P4884, DOI 10.1021/ja00850a018; HIMMELWRIGHT RS, 1980, J AM CHEM SOC, V102, P7339, DOI 10.1021/ja00544a031; HUGHEY JL, 1979, J AM CHEM SOC, V101, P2617, DOI 10.1021/ja00504a020; JACOBSON RR, 1988, J AM CHEM SOC, V110, P3690, DOI 10.1021/ja00219a071; JOLLEY RL, 1974, J BIOL CHEM, V249, P335; KARLIN KD, 1988, J AM CHEM SOC, V110, P6769, DOI 10.1021/ja00228a027; KARLIN KD, 1987, J AM CHEM SOC, V109, P2668, DOI 10.1021/ja00243a019; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; LARRABEE JA, 1980, J AM CHEM SOC, V102, P4217, DOI 10.1021/ja00532a038; LARRABEE JA, 1977, J AM CHEM SOC, V99, P1979, DOI 10.1021/ja00448a053; LOWERY MD, IN PRESS J AM CHEM S; MAGNUS K, 1992, Journal of Inorganic Biochemistry, V47, P20, DOI 10.1016/0162-0134(92)84091-Z; MAGNUS KA, COMMUNICATION; MALKIN R, 1970, ADV ENZYMOL REL S BI, V33, P177; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MORIEBEBEL MM, 1984, J AM CHEM SOC, V106, P3677, DOI 10.1021/ja00324a048; NAKAGAWA KH, UNPUB; NEWTON MD, 1991, CHEM REV, V91, P767, DOI 10.1021/cr00005a007; NIEDERHOFFER EC, 1984, CHEM REV, V84, P137, DOI 10.1021/cr00060a003; PALMER GA, 1991, STRUCT BOND, V75, P1; PATE JE, 1987, J AM CHEM SOC, V109, P2624, DOI 10.1021/ja00243a013; PENFIELD KW, 1981, J AM CHEM SOC, V103, P4382, DOI 10.1021/ja00405a016; PENFIELD KW, 1985, J AM CHEM SOC, V107, P4519, DOI 10.1021/ja00301a024; REINHAMMAR B, 1981, J INORG BIOCHEM, V15, P27, DOI 10.1016/S0162-0134(00)80133-6; Rheinhammar B., 1984, COPPER PROTEINS COPP, V3, P1; ROBERTS JE, 1980, J AM CHEM SOC, V102, P825, DOI 10.1021/ja00522a063; ROSS PK, 1991, J AM CHEM SOC, V113, P3246, DOI 10.1021/ja00009a005; SCOTT RA, 1982, J AM CHEM SOC, V104, P5364, DOI 10.1021/ja00384a020; SHADLE SE, 1993, J AM CHEM SOC, V115, P767, DOI 10.1021/ja00055a057; Solomon E. I., 1984, COMMENTS INORG CHEM, V3, P227; SOLOMON EI, 1976, P NATL ACAD SCI USA, V73, P1389, DOI 10.1073/pnas.73.5.1389; SOLOMON EI, 1992, CHEM REV, V92, P521, DOI 10.1021/cr00012a003; SOLOMON EI, 1992, ACCOUNTS CHEM RES, V25, P343, DOI 10.1021/ar00020a004; SOLOMON EI, 1976, J AM CHEM SOC, V98, P1029, DOI 10.1021/ja00420a035; SOLOMON EI, IN PRESS METHODS ENZ; SOLOMON EI, 1988, STRUCT BOND, V53, P1; SPIRASOLOMON DJ, 1987, J AM CHEM SOC, V109, P6421, DOI 10.1021/ja00255a031; SPIRASOLOMON DJ, 1986, J AM CHEM SOC, V108, P5318, DOI 10.1021/ja00277a043; SPIRO T, 1981, METAL IONS BIOL, V3; SYKES AG, 1991, ADV INORG CHEM, V36, P377, DOI 10.1016/S0898-8838(08)60044-6; SYKES AG, 1991, STRUCT BOND, V75, P175; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; WILCOX DE, 1985, J AM CHEM SOC, V107, P4015, DOI 10.1021/ja00299a043; WILCOX DE, 1984, J AM CHEM SOC, V106, P2186, DOI 10.1021/ja00319a046; WINKLER ME, 1981, J AM CHEM SOC, V103, P7001, DOI 10.1021/ja00413a055; WOOLERY GL, 1984, J AM CHEM SOC, V106, P86, DOI 10.1021/ja00313a019	72	400	407	1	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 12	1993	259	5101					1575	1581		10.1126/science.8384374	http://dx.doi.org/10.1126/science.8384374			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KR543	8384374				2022-12-28	WOS:A1993KR54300029
J	TAPSCOTT, SJ; THAYER, MJ; WEINTRAUB, H				TAPSCOTT, SJ; THAYER, MJ; WEINTRAUB, H			DEFICIENCY IN RHABDOMYOSARCOMAS OF A FACTOR REQUIRED FOR MYOD ACTIVITY AND MYOGENESIS	SCIENCE			English	Article							CELL-LINES; MUSCLE; EXPRESSION; ACTIVATION; DIFFERENTIATION; FIBROBLASTS; PROTEINS; MYOBLASTS; FAMILY; GENES	Rhabdomyosarcoma cells express the myogenic helix-loop-helix proteins of the MyoD family but do not differentiate into skeletal muscle cells. Gel shift and transient transfection assays revealed that MyoD in the rhabdomyosarcoma cells was capable of binding DNA but was relatively nonfunctional as a transcriptional activator. Heterokaryon formation with fibroblasts resulted in the restoration of transcriptional activation by MyoD and the differentiation of the rhabdomyosarcoma cells into skeletal muscle cells. These results suggest that rhabdomyosarcomas are deficient in a factor required for MyoD activity.			TAPSCOTT, SJ (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; CHOI J, 1990, P NATL ACAD SCI USA, V87, P7988, DOI 10.1073/pnas.87.20.7988; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DIAS P, 1990, AM J PATHOL, V137, P1283; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; HAZELTON BJ, 1987, CANCER RES, V47, P4501; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HOUGHTON P, COMMUNICATION; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; MCALLISTER RM, 1969, CANCER-AM CANCER SOC, V24, P520, DOI 10.1002/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TAPSCOTT S, UNPUB; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; THAYER MJ, 1990, CELL, V63, P23, DOI 10.1016/0092-8674(90)90285-M; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YALE J, 1992, GENE DEV, V6, P1466	23	164	166	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 5	1993	259	5100					1450	1453		10.1126/science.8383879	http://dx.doi.org/10.1126/science.8383879			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP978	8383879				2022-12-28	WOS:A1993KP97800035
J	MENNEMEYER, ST; WINKELMAN, JW				MENNEMEYER, ST; WINKELMAN, JW			SEARCHING FOR INACCURACY IN CLINICAL LABORATORY TESTING USING MEDICARE DATA - EVIDENCE FOR PROTHROMBIN TIME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS OFFICE LABORATORIES; ORAL ANTICOAGULANT-THERAPY; MYOCARDIAL-INFARCTION; WARFARIN	Objective.-To determine if the occurrence of health outcomes following clinical laboratory testing can be used to identify types of laboratories that may be having higher than expected error rates. Design.-Retrospective analysis of Medicare Part B outpatient claims, Part A hospitalization bills, and death records using a case-control study Setting.-Medicare records from six carrier territories were sampled during the period 1985 through 1987. Patients.-A total of 14 755 Medicare patients receiving a prothrombin time test in either a physician office laboratory or a commercial laboratory. Outcome Measures.-Occurrence of a hospitalization for stroke or acute myocardial infarction, death, or no adverse outcome within 6 days of a prothrombin time. Results.-In physician office laboratories where prothrombin time test volume is below 40 per month, the odds that a tested patient will experience a stroke or an acute myocardial infarction are up to 1.96 and 3.43 times greater, respectively, than for a similar patient tested in a commercial laboratory. Switching from one laboratory to another between successive prothrombin time tests increased the odds of a stroke or an acute myocardial infarction by 1.57 and 1.32, respectively. Patients in two states with strong laboratory regulatory programs had fewer adverse outcomes. Conclusion.-Examining patient outcomes subsequent to clinical laboratory testing may be a useful tool for clinical laboratory quality assurance.	ABT ASSOCIATES INC, CAMBRIDGE, MA USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PATHOL, BOSTON, MA 02115 USA	ABT Associates; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	MENNEMEYER, ST (corresponding author), UNIV ALABAMA, SCH PUBL HLTH, DEPT HLTH CARE ORG & POLICY, 118 PICKWICK PL, UAB STN, BIRMINGHAM, AL 35294 USA.				AHRQ HHS [HHS-100-89-0017] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLOCH MJ, 1988, JAMA-J AM MED ASSOC, V260, P230, DOI 10.1001/jama.260.2.230; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; CRAWLEY R, 1986, JAMA-J AM MED ASSOC, V255, P374, DOI 10.1001/jama.255.3.374; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HIRSH J, 1987, JAMA-J AM MED ASSOC, V258, P2723, DOI 10.1001/jama.258.19.2723; HIRSH J, 1989, CHEST, V95, pS5, DOI 10.1378/chest.95.2.5S; HOSMER DW, 1989, APPL LOGISTIC REGRES, P178; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KEELER EB, 1992, JAMA-J AM MED ASSOC, V268, P1709, DOI 10.1001/jama.268.13.1709; KENNEY ML, 1987, CLIN CHEM, V33, P725; KENNEY ML, 1984, THESIS U CALIFORNIA; Mennemeyer S T, 1991, QRB Qual Rev Bull, V17, P194; MENNEMEYER ST, 1992, HHS100890017 ABT ASS; PAULY MV, 1991, HHS100890017 ABT ASS; PEDDECORD KM, 1989, CLIN CHEM, V35, P691; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; SCHREIBER TL, 1990, AM HEART J, V119, P1238, DOI 10.1016/S0002-8703(05)80170-X; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; Steinberg D., 1991, LOGIT SUPPLEMENTARY; TURPIE AGG, 1988, LANCET, V1, P1242; 1992, RFP200920567P CTR DI; 1991, CIRCULATION, V84, P527; 1991, RES ACTIVITIES   FEB; 1985, J CLIN PATHOL, V38, P133; 1991, FRP200910959 CTR DIS	26	16	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1993	269	8					1030	1033		10.1001/jama.269.8.1030	http://dx.doi.org/10.1001/jama.269.8.1030			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KM603	8369028				2022-12-28	WOS:A1993KM60300033
J	RACINE, A; JOYCE, T; ANDERSON, R				RACINE, A; JOYCE, T; ANDERSON, R			THE ASSOCIATION BETWEEN PRENATAL-CARE AND BIRTH-WEIGHT AMONG WOMEN EXPOSED TO COCAINE IN NEW-YORK-CITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERINATAL COCAINE; PREGNANCY; DRUG; ABUSE; TERATOGENICITY; PREVALENCE; POPULATION; COHORT; IMPACT	Objectives.-Although the association between antenatal cocaine use and adverse birth outcomes has been well documented, relatively little is known about interventions that may ameliorate these consequences. We therefore examined the relationship between prenatal care and birth weight among a population of prenatal cocaine users. Design.-Population-based retrospective analysis. Patients.-All single-gestation live births to white non-Hispanic, black non-Hispanic, and Hispanic residents of New York City who gave birth between 1988 and 1990 with a positive indication for cocaine recorded on birth certificates (N=7923). Main Outcome Measures.-We contrasted mean birth weight and rates of low birth weight (<2500 g) among cocaine users with one to three prenatal care visits, four or more visits, and unknown numbers of visits with users who reported no prenatal care. We used ordinary least squares and logistic regression to control for age, parity, smoking, alcohol, other drugs, weight gain, prepregnancy weight, employment, marital status, participation in the Supplemental Food Program for Women, Infants and Children, and method of finance. Main Results.-Adjusted odds ratios of low birth weight for cocaine users with four prenatal care visits or more as compared with those who had none were 0.51 for blacks (95% confidence interval [CI], 0.44 to 0.59), 0.39 for whites (95% CI, 0.23 to 0.66), and 0.37 for Hispanics (95% CI, 0.28 to 0.48). Adjusted mean birth weight differences between users with four visits or more and those with none were 262 g for blacks (P<.001), 247 g for whites (P<.001), and 317 g for Hispanics (P<.001). Conclusions.-The receipt of prenatal care among cocaine users is associated with significant improvements in birth weight. Enrollment of cocaine users in prenatal care may be an effective start to a more comprehensive approach to this problem.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10461; CUNY,BARUCH COLL,DEPT ECON & FINANCE,NEW YORK,NY 10021; SUNY COLL FARMINGDALE,DEPT ECON,FARMINGDALE,NY 11735	Yeshiva University; Albert Einstein College of Medicine; City University of New York (CUNY) System; Baruch College (CUNY); State University of New York (SUNY) System	RACINE, A (corresponding author), NATL BUR ECON RES,269 MERCER ST,8TH FLOOR,NEW YORK,NY 10003, USA.							BATEMAN DA, 1993, AM J PUBLIC HEALTH, V83, P190, DOI 10.2105/AJPH.83.2.190; BINGOL N, 1987, J PEDIATR-US, V110, P93, DOI 10.1016/S0022-3476(87)80297-4; BURKETT G, 1990, J REPROD MED, V35, P35; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CHASNOFF IJ, 1985, NEW ENGL J MED, V313, P666, DOI 10.1056/NEJM198509123131105; CHASNOFF IJ, 1989, JAMA-J AM MED ASSOC, V261, P1741, DOI 10.1001/jama.261.12.1741; CHAVEZ GF, 1989, JAMA-J AM MED ASSOC, V262, P795, DOI 10.1001/jama.262.6.795; CHAVKIN W, 1990, AM J PUBLIC HEALTH, V80, P483, DOI 10.2105/AJPH.80.4.483; CHERUKURI R, 1988, OBSTET GYNECOL, V72, P147; CHOUTEAU M, 1988, OBSTET GYNECOL, V72, P351; FANTEL AG, 1982, TERATOLOGY, V26, P17, DOI 10.1002/tera.1420260104; FELDMAN JG, 1992, AM J PUBLIC HEALTH, V82, P726, DOI 10.2105/AJPH.82.5.726; FINGERHUT MA, 1985, VITAL HLTH STAT 99, V2; FRANK DA, 1988, PEDIATRICS, V82, P888; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; HADEED AJ, 1989, PEDIATRICS, V84, P205; HANDLER A, 1991, AM J EPIDEMIOL, V133, P812; KAYE K, 1989, NEW YORK STATE J MED, V89, P256; LITTLE BB, 1989, OBSTET GYNECOL, V73, P157; MACGREGOR SN, 1989, OBSTET GYNECOL, V74, P882; MACGREGOR SN, 1987, AM J OBSTET GYNECOL, V157, P686, DOI 10.1016/S0002-9378(87)80029-7; MCCALLA S, 1991, AM J OBSTET GYNECOL, V164, P625, DOI 10.1016/S0002-9378(11)80036-0; McLachlan G. J., 1992, DISCRIMINANT ANAL ST, DOI DOI 10.1002/0471725293; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; OSTREA EM, 1992, PEDIATRICS, V89, P107; PHIBBS CS, 1991, JAMA-J AM MED ASSOC, V266, P1521, DOI 10.1001/jama.266.11.1521; SCHUTZMAN DL, 1991, PEDIATRICS, V88, P825; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1990, MMWR MORB MORTAL WKL, V39, P225; 1973, CONTRASTS HLTH STATU, P1; 1991, DEP HLTH HUMAN SERV	31	58	58	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	1993	270	13					1581	1586		10.1001/jama.270.13.1581	http://dx.doi.org/10.1001/jama.270.13.1581			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ334	8371469				2022-12-28	WOS:A1993LZ33400032
J	LACOMBE, MA				LACOMBE, MA			A CONFLICT-OF-INTEREST	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											LACOMBE, MA (corresponding author), OXFORD HILLS INTERNAL MED GRP, 23 WINTER ST, NORWAY, ME 04268 USA.								0	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				623	626		10.7326/0003-4819-119-7_Part_1-199310010-00012	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363173				2022-12-28	WOS:A1993MA29100012
J	CALNE, DB				CALNE, DB			DRUG-THERAPY - TREATMENT OF PARKINSONS-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DOPAMINE AGONIST THERAPY; SINEMET CR; PHARMACOLOGICAL PROPERTIES; DOPAMINOMIMETIC PSYCHOSIS; PLEUROPULMONARY DISEASE; BROMOCRIPTINE TREATMENT; MOLECULAR-BIOLOGY; ANTAGONIST NBQX; LEVODOPA; PHARMACOKINETICS				CALNE, DB (corresponding author), UNIV BRITISH COLUMBIA HOSP, DEPT MED, DIV NEUROL, CTR NEURODEGENERAT DISORDERS, 2211 WESBROOK MALL, VANCOUVER V6T 2B5, BC, CANADA.							APPEL SH, 1992, ANN NEUROL, V32, P494, DOI 10.1002/ana.410320403; BARONTI F, 1992, NEUROLOGY, V42, P1241, DOI 10.1212/WNL.42.6.1241; BHATT MH, 1991, ANN NEUROL, V30, P613, DOI 10.1002/ana.410300416; BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; BURN D J, 1991, Neurology, V41, P399; BURNS RS, 1983, LISURIDE OTHER DOPAM, P153; CALNE DB, 1992, ANN NEUROL, V32, P799, DOI 10.1002/ana.410320615; CEDARBAUM JM, 1990, CLIN NEUROPHARMACOL, V13, P544, DOI 10.1097/00002826-199012000-00006; CHASE TN, 1989, NEUROLOGY, V39, P7; CIVELLI O, 1991, EUR J PHARM-MOLEC PH, V207, P277, DOI 10.1016/0922-4106(91)90001-X; COHEN G, 1993, ANN NEUROL, V32, P804; EISLER T, 1981, NEUROLOGY, V31, P1368, DOI 10.1212/WNL.31.10.1368; Fahn S., 1989, DRUGS TREATMENT PARK, P385, DOI [10.1007/978-3-642-73899-9_14, DOI 10.1007/978-3-642-73899-9_14]; FARIELLO RG, 1991, ANN NEUROL, V30, P257; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; FRIEDMAN JH, 1989, NEUROLOGY, V39, P1219, DOI 10.1212/WNL.39.9.1219; GANCHER ST, 1987, NEUROLOGY, V37, P940, DOI 10.1212/WNL.37.6.940; GOETZ CG, 1989, NEUROLOGY, V39, P63; GOETZ CG, 1993, NEUROLOGY, V43, P1; GOETZ CG, 1990, NEUROLOGY, V40, P50; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HURWITZ TA, 1988, CAN J NEUROL SCI, V15, P32, DOI 10.1017/S0317167100027141; HUTTON J T, 1992, Neurology, V42, P443; HUTTON JT, 1989, NEUROLOGY, V39, P67; KLOCKGETHER T, 1991, ANN NEUROL, V30, P717, DOI 10.1002/ana.410300513; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LANGTRY HD, 1990, DRUGS, V39, P491, DOI 10.2165/00003495-199039030-00009; LEWITT PA, 1983, NEUROLOGY, V33, P1009, DOI 10.1212/WNL.33.8.1009; LEWITT PA, 1982, NEUROLOGY, V32, P69, DOI 10.1212/WNL.32.1.69; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; LINDVALL O, 1991, RESTORATIVE NEUROLOG, V4, P1; LOSCHMANN PA, 1991, J NEURAL TRANSM-PARK, V3, P203, DOI 10.1007/BF02259538; MCELVANEY NG, 1988, ARCH INTERN MED, V148, P2231, DOI 10.1001/archinte.148.10.2231; MCTAVISH D, 1989, DRUGS, V38, P757, DOI 10.2165/00003495-198938050-00004; MCTAVISH D, 1990, DRUGS, V39; MIZUNO Y, 1992, MOV DISORD S, V7, P98; MIZUNO Y, 1991, PARKINSONS DIS BASIC, P314; NUTT JG, 1989, J NEUROL NEUROSUR PS, V52, P481, DOI 10.1136/jnnp.52.4.481; OERTEL WH, 1991, PARKINSONS DISEASE P, P375; OLANOW CW, 1992, NEUROLOGY, V42, P13; OLANOW CW, 1990, NEUROLOGY, V40, P32; OLANOW CW, 1987, RECENT DEV PARKINSON, V2, P201; PRZUNTEK H, 1992, EUR J CLIN PHARMACOL, V43, P357, DOI 10.1007/BF02220609; RINNE UK, 1985, NEUROLOGY, V35, P1196, DOI 10.1212/WNL.35.8.1196; SALO PT, 1992, J NEUROSCI RES, V31, P394, DOI 10.1002/jnr.490310223; SCHNEIDER JS, 1992, SCIENCE, V256, P843, DOI 10.1126/science.1350379; SCHOLZ E, 1985, EUR ARCH PSY CLIN N, V235, P60, DOI 10.1007/BF00380972; SCHULZER M, 1992, ANN NEUROL, V32, P795, DOI 10.1002/ana.410320614; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SIBLEY DR, 1992, TRENDS PHARMACOL SCI, V13, P61, DOI 10.1016/0165-6147(92)90025-2; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; STIBE CMH, 1988, LANCET, V1, P403; STOCCHI F, 1991, PARKINSONS DISEASE P, P296; STOOF JC, 1983, ACS SYM SER, V224, P117; TSUI JK, 1989, NEUROLOGY, V39, P549, DOI 10.1212/WNL.39.4.549; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; VANLAAR T, 1992, MOV DISORD S1, V7, P92; VANLOON GR, 1979, NEUROENDOCRINOLOGY, V28, P425, DOI 10.1159/000122891; WEINER WJ, 1993, NEUROLOGY, V43, P21, DOI 10.1212/WNL.43.1_Part_1.21; WIDNER H, 1992, NEW ENGL J MED, V327, P1556, DOI 10.1056/NEJM199211263272203; WOLTERS EC, 1990, NEUROLOGY, V40, P832, DOI 10.1212/WNL.40.5.832; YEH KC, 1989, NEUROLOGY, V39, P25; ZURCHER G, 1990, ADV NEUROL, V53, P497	65	199	205	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1021	1027						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366903				2022-12-28	WOS:A1993LY58700008
J	GORTMAKER, SL; MUST, A; PERRIN, JM; SOBOL, AM; DIETZ, WH				GORTMAKER, SL; MUST, A; PERRIN, JM; SOBOL, AM; DIETZ, WH			SOCIAL AND ECONOMIC CONSEQUENCES OF OVERWEIGHT IN ADOLESCENCE AND YOUNG ADULTHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBESITY; TRANSITION; ATTAINMENT	Background and Methods. Overweight in adolescents may have deleterious effects on their subsequent self-esteem, social and economic characteristics, and physical health. We studied the relation between overweight and subsequent educational attainment, marital status, household income, and self-esteem in a nationally representative sample of 10,039 randomly selected young people who were 16 to 24 years old in 1981. Follow-up data were obtained in 1988 for 65 to 79 percent of the original cohort, depending on the variable studied. The characteristics of the subjects who had been overweight in 1981 were compared with those for young people with asthma, musculoskeletal abnormalities, and other chronic health conditions. Overweight was defined as a body-mass index above the 95th percentile for age and sex. Results. ln 1981, 370 of the subjects were overweight. Seven years later, women who had been overweight had completed fewer years of school (0.3 year less; 95 percent confidence interval, 0.1 to 0.6; P = 0.009), were less likely to be married (20 percent less likely; 95 percent confidence interval, 13 to 27 percent; P<0.001), had lower household incomes ($6,71 0 less per year; 95 percent confidence interval, $3,942 to $9,478; P<0.001), and had higher rates of household poverty (10 percent higher; 95 percent confidence interval, 4 to 16 percent; P<0.001) than the women who had not been overweight, independent of their base-line socioeconomic status and aptitude-test scores. Men who had been overweight were less likely to be married (11 percent less likely; 95 percent confidence interval, 3 to 18 percent; P = 0.005). In contrast, people with the other chronic conditions we studied did not differ in these ways from the nonoverweight subjects. We found no evidence of an effect of overweight on self-esteem. Conclusions. Overweight during adolescence has important social and economic consequences, which are greater than those of many other chronic physical conditions. Discrimination against overweight persons may account for these results.	TUFTS UNIV NEW ENGLAND MED CTR,DEPT PEDIAT GASTROENTEROL & NUTR,BOSTON,MA 02111; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Tufts Medical Center; Harvard University; Harvard Medical School	GORTMAKER, SL (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Fahimifar, Sepideh/M-5303-2019	Perrin, James/0000-0002-1810-3708				Baker P. C., 1989, NLSY CHILD HDB 1989; Berscheid E., 1974, ADV EXPT SOCIAL PSYC, V7, P157, DOI DOI 10.1016/S0065-2601(08)60037-4; CANNING H, 1966, NEW ENGL J MED, V275, P1172, DOI 10.1056/NEJM196611242752107; CANNING H, 1967, AM J CLIN NUTR, V20, P352, DOI 10.1093/ajcn/20.4.352; DEJONG W, 1980, J HEALTH SOC BEHAV, V21, P75, DOI 10.2307/2136696; GOLDBLATT PB, 1965, J AMER MED ASSOC, V192, P1039, DOI 10.1001/jama.1965.03080250017004; GORTMAKER SL, 1987, AM J DIS CHILD, V141, P535, DOI 10.1001/archpedi.1987.04460050077035; GORTMAKER SL, 1990, J AM DIET ASSOC, V90, P1247; GORTMAKER SL, 1993, J RES ADOLESCENCE, V0003; HOGAN DP, 1986, ANNU REV SOCIOL, V12, P109, DOI 10.1146/annurev.so.12.080186.000545; MADDOX GL, 1968, J HEALTH SOC BEHAV, V9, P287, DOI 10.2307/2948537; MARINI MM, 1978, AM SOCIOL REV, V43, P483, DOI 10.2307/2094774; Martel LF., 1987, STATURE STIGMA BIOPS; MONELLO LF, 1972, J PEDIATR, V13, P35; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; MUST A, 1991, AM J CLIN NUTR, V54, P773, DOI 10.1093/ajcn/54.5.773; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; PLESS IB, 1989, CARING FOR CHILDREN WITH CHRONIC ILLNESS : ISSUES AND STRATEGIES, P147; REVICKI DA, 1986, AM J PUBLIC HEALTH, V76, P992, DOI 10.2105/AJPH.76.8.992; Roe D A, 1976, J Am Med Womens Assoc (1972), V31, P193; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; ROSS JG, 1987, J PHYSICAL ED RECREA, V58, P74; ROTHBLUM ED, IN PRESS FEMINIST PE; Rowland M L, 1989, Stat Bull Metrop Insur Co, V70, P2; Sewell W. H., 1975, ED OCCUPATION EARNIN; SHEAR CL, 1988, AM J PUBLIC HEALTH, V78, P75, DOI 10.2105/AJPH.78.1.75; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; SONNEHOLM S, 1986, BRIT MED J, V292, P586, DOI 10.1136/bmj.292.6520.586; STEIN REK, 1987, LANCET, V2, P1506; STUNKARD A J, 1992, American Journal of Clinical Nutrition, V55, p524S, DOI 10.1093/ajcn/55.2.524s; STUNKARD AJ, 1981, AM J CLIN NUTR, V34, P1593, DOI 10.1093/ajcn/34.8.1593; TANNER JM, 1990, FETUS MAN PHYSICAL G; WADDEN TA, 1987, ANN NY ACAD SCI, V499, P55, DOI 10.1111/j.1749-6632.1987.tb36197.x; WEST J, 1991, MILBANK Q S, V69; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P731, DOI 10.1093/oxfordjournals.aje.a114156; 1992, NLS USERS GUIDE 1992	36	1032	1043	1	84	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1008	1012		10.1056/NEJM199309303291406	http://dx.doi.org/10.1056/NEJM199309303291406			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LY587	8366901	Green Published			2022-12-28	WOS:A1993LY58700006
J	LUFT, BJ; HAFNER, R; KORZUN, AH; LEPORT, C; ANTONISKIS, D; BOSLER, EM; BOURLAND, DD; UTTAMCHANDANI, R; FUHRER, J; JACOBSON, J; MORLAT, P; VILDE, JL; REMINGTON, JS				LUFT, BJ; HAFNER, R; KORZUN, AH; LEPORT, C; ANTONISKIS, D; BOSLER, EM; BOURLAND, DD; UTTAMCHANDANI, R; FUHRER, J; JACOBSON, J; MORLAT, P; VILDE, JL; REMINGTON, JS			TOXOPLASMIC ENCEPHALITIS IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; AIDS; PYRIMETHAMINE; THERAPY; LESIONS; SULFADIAZINE; CLINDAMYCIN; EFFICACY	Background. In patients with the acquired immunodeficiency syndrome (AIDS), toxoplasmic encephalitis is usually a presumptive diagnosis based on the clinical manifestations, a positive antitoxoplasma-antibody titer, and characteristic neuroradiologic abnormalities. A response to specific therapy helps to confirm the diagnosis, but it is unclear how rapid the response should be. We studied the course of patients treated for acute toxoplasmic encephalitis and evaluated objective clinical criteria for this empirical diagnosis. Methods. A quantifiable neurologic assessment was used prospectively to evaluate the clinical outcome of patients with AIDS and toxoplasmic encephalitis who were treated with oral clindamycin (600 mg four times a day) and pyrimethamine (75 mg every day) for six weeks. Results. Thirty-five of 49 patients (71 percent) responded to therapy, and 30 of these (86 percent) had improvement by day 7. Thirty-two of those with a response (91 percent) improved with respect to at least half of their base-line abnormalities by day 14. Improvement in neurologic abnormalities within 7 to 14 days after the start of therapy was strongly associated with the neurologic response at 6 weeks. The four patients in whom treatment failed and the two patients with lymphoma had progressing neurologic abnormalities or new abnormalities during the first 12 days of therapy. Nonlocalizing abnormalities (headache and seizure) improved regardless of the clinical outcome. Conclusions. Oral clindamycin and pyrimethamine are an effective treatment for toxoplasmic encephalitis. Patients who have early neurologic deterioration despite treatment or who do not improve neurologically after 10 to 14 days of appropriate antitoxoplasma therapy should be considered candidates for brain biopsy.	NIAID,DIV AIDS,BETHESDA,MD 20892; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115; GRP HOSP BICHAT CLAUDE BERNARD,PARIS,FRANCE; UNIV SO CALIF,LOS ANGELES CTY MED CTR,LOS ANGELES,CA 90033; UNIV MIAMI,MIAMI,FL 33152; MT SINAI MED CTR,NEW YORK,NY 10029; HOP PELLEGRIN,F-33076 BORDEAUX,FRANCE; PALO ALTO MED RES FDN,PALO ALTO,CA 94301	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Harvard T.H. Chan School of Public Health; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Southern California; University of Miami; Icahn School of Medicine at Mount Sinai; CHU Bordeaux; Palo Alto Medical Foundation Research Institute	LUFT, BJ (corresponding author), SUNY,DIV INFECT DIS,STONY BROOK,NY 11794, USA.			Luft, Benjamin/0000-0001-9008-7004	NIAID NIH HHS [AI-04717, UO1AI-131808] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI004717, R01AI004717] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BISHBURG E, 1989, ARCH INTERN MED, V149, P941, DOI 10.1001/archinte.149.4.941; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CIRICILLO SF, 1990, J NEUROSURG, V73, P720, DOI 10.3171/jns.1990.73.5.0720; CIRICILLO SF, 1991, J NEUROSURG, V74, P1029; COHN JA, 1989, AM J MED, V86, P521, DOI 10.1016/0002-9343(89)90378-1; DANNEMANN B, 1992, ANN INTERN MED, V116, P33, DOI 10.7326/0003-4819-116-1-33; HAVERKOS HW, 1987, AM J MED, V82, P907, DOI 10.1016/0002-9343(87)90151-3; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KATLAMA C, 1991, EUR J CLIN MICROBIOL, V10, P189, DOI 10.1007/BF01964459; LEPORT C, 1988, AM J MED, V84, P94, DOI 10.1016/0002-9343(88)90014-9; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306	12	329	340	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					995	1000		10.1056/NEJM199309303291403	http://dx.doi.org/10.1056/NEJM199309303291403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366923				2022-12-28	WOS:A1993LY58700003
J	CULOTTA, E				CULOTTA, E			JOBS IN BIO-MED .1. DOCTOR-DOCTOR - GROWING DEMAND FOR MD-PHDS	SCIENCE			English	Article																		MARTIN J, 1991, ACADEMIC MED; WYNGAARDEN J, 1979, NEW ENGLAND J MED	2	7	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1784	&		10.1126/science.8378777	http://dx.doi.org/10.1126/science.8378777			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378777				2022-12-28	WOS:A1993LY58400039
J	DUTTA, A; RUPPERT, JM; ASTER, JC; WINCHESTER, E				DUTTA, A; RUPPERT, JM; ASTER, JC; WINCHESTER, E			INHIBITION OF DNA-REPLICATION FACTOR RPA BY P53	NATURE			English	Article							PROTEIN-A; SV40 ORIGIN; T-ANTIGEN; INVITRO; BINDING; INITIATION; MUTATIONS; SUBUNIT; GENE	THE tumour suppressor p53 specifically interferes with the onset of S phase. The mechanism of the growth suppression action of the protein is unclear, though recent evidence points to transcriptional activation and repression functions of the protein1. A competing hypothesis suggests that p53 interacts with the DNA replication apparatus and directly interferes with DNA replication. The major evidence for this hypothesis is that p53 interacts with the simian virus 40 (SV40)-encoded protein T antigen and interferes with the ability of T antigen to unwind the SV40 origin of DNA replication, and recruit DNA polymerase alpha to the replication initiation complex2,3. Here we report that p53 physically interacts with and inhibits the function of a cellular DNA replication factor, the single-stranded DNA-binding protein complex RPA.	JOHNS HOPKINS UNIV,SCH MED,DEPT OTOLARYNGOL & HEAD & NECK SURG,BALTIMORE,MD 21205	Johns Hopkins University	DUTTA, A (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOLEC ONCOL,20 SHATTUCK ST,BOSTON,MA 02115, USA.		Dutta, Anindya/P-3203-2016; Aster, Jon C/B-6857-2009	Dutta, Anindya/0000-0002-4319-0073				BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; ERDILE LF, 1990, J BIOL CHEM, V265, P3177; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GANNON J V, 1990, New Biologist, V2, P84; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6	22	378	378	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					79	82		10.1038/365079a0	http://dx.doi.org/10.1038/365079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361542				2022-12-28	WOS:A1993LV64600059
J	SHIDARA, M; KAWANO, K; GOMI, H; KAWATO, M				SHIDARA, M; KAWANO, K; GOMI, H; KAWATO, M			INVERSE-DYNAMICS MODEL EYE-MOVEMENT CONTROL BY PURKINJE-CELLS IN THE CEREBELLUM	NATURE			English	Article							OCULAR FOLLOWING RESPONSES; VESTIBULOOCULAR REFLEX; PRIMATE FLOCCULUS; ALERT MONKEY	MANY lines of evidence suggest that the cerebellum is involved in motor control1. But what features of these movements are encoded by cerebellar neurons? For slow-tracking eye movements, the activity of Purkinje cells in the ventral paraflocculus of the cerebellum is known to be correlated with eye velocity2-5 and acceleration5. Here we show that the complex temporal pattern of the firing frequency that occurs during the ocular following response elicited by movements of a large visual scene6-8 can be reconstructed by an inverse-dynamics representation, which uses the position, velocity and acceleration of eye movements. Further analysis reveals that the velocity and acceleration components can provide appropriate dynamic drive signals to ocular motor neurons, whereas the position component often has the wrong polarity. We conclude that these Purkinje cells primarily contribute dynamic command signals.	ATR,HUMAN INFORMAT PROC RES LAB,KYOTO 61902,JAPAN; HOKKAIDO UNIV,ELECTR SCI RES INST,PARALLEL DISTRIBUTED PROC LAB,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	SHIDARA, M (corresponding author), ELECTROTECH LAB,NEUROSCI SECT,1-1-4 UMEZONO,TSUKUBA,IBARAKI 305,JAPAN.		Gomi, Hiroaki/AEL-2645-2022; Gomi, Hiroaki/C-5269-2013	Gomi, Hiroaki/0000-0003-3541-2251				ATKESON CG, 1989, ANNU REV NEUROSCI, V12, P157, DOI 10.1146/annurev.neuro.12.1.157; Barto A. G., 1990, NEURAL NETWORKS CONT, P5; BETHIER NE, 1991, BIOL CYBERN, V65, P99; GOMI H, 1992, BIOL CYBERN, V68, P105, DOI 10.1007/BF00201432; HOLLERBACH JM, 1982, ROBOT MOTION; Ito M, 1984, CEREBELLUM NEURAL CO; JUDGE SJ, 1980, VISION RES, V20, P535, DOI 10.1016/0042-6989(80)90128-5; KAWANO K, 1992, J NEUROPHYSIOL, V67, P680, DOI 10.1152/jn.1992.67.3.680; KAWATO M, 1987, BIOL CYBERN, V57, P169, DOI 10.1007/BF00364149; KAWATO M, 1992, TRENDS NEUROSCI, V15, P445, DOI 10.1016/0166-2236(92)90008-V; KAWATO M, 1992, BIOL CYBERN, V68, P95, DOI 10.1007/BF00201431; KAWATO M, 1993, TRENDS NEUROSCI, V18, P177; KELLER EL, 1973, VISION RES, V13, P1565, DOI 10.1016/0042-6989(73)90015-1; LISBERGER SG, 1978, J NEUROPHYSIOL, V41, P733, DOI 10.1152/jn.1978.41.3.733; MILES FA, 1975, SCIENCE, V189, P1000, DOI 10.1126/science.1083068; MILES FA, 1986, J NEUROPHYSIOL, V56, P1321, DOI 10.1152/jn.1986.56.5.1321; MILES FA, 1980, J NEUROPHYSIOL, V43, P1437, DOI 10.1152/jn.1980.43.5.1437; Robinson DA., 1981, HDB PHYSL AM PHYSL 1, V2, P1275; SHIDARA M, 1993, EXP BRAIN RES, V93, P185; STONE LS, 1990, J NEUROPHYSIOL, V63, P1241, DOI 10.1152/jn.1990.63.5.1241; WALPOLE RE, 1978, PROBABILITY STATISTI	21	243	243	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 2	1993	365	6441					50	52		10.1038/365050a0	http://dx.doi.org/10.1038/365050a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361536				2022-12-28	WOS:A1993LV64600051
J	BRODY, H; SPARKS, HV; ABBETT, WS; WOOD, DL; WADLAND, WC; SMITH, RC				BRODY, H; SPARKS, HV; ABBETT, WS; WOOD, DL; WADLAND, WC; SMITH, RC			THE MAMMALIAN MEDICAL-CENTER FOR THE 21ST-CENTURY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ORIENTED PRIMARY CARE; FAMILY-PRACTICE; HUMAN GENOME; HEALTH; PATIENT; PHYSICIANS; POPULATION; CHALLENGE		MICHIGAN STATE UNIV,OFF VICE PROVOST HUMAN HLTH PROGRAMS,E LANSING,MI 48824; MICHIGAN STATE UNIV,COLL HUMAN MED,OFF DEAN,E LANSING,MI 48824; MICHIGAN STATE UNIV,COLL OSTEOPATH MED,OFF DEAN,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT MED,DIV GEN MED,E LANSING,MI 48824	Michigan State University; Michigan State University; Michigan State University College of Human Medicine; Michigan State University; Michigan State University College of Osteopathic Medicine; Michigan State University	BRODY, H (corresponding author), MICHIGAN STATE UNIV,DEPT FAMILY PRACTICE,B100 CLIN CTR,E LANSING,MI 48824, USA.		Brody, Howard/GQA-6310-2022	Smith, Robert/0000-0001-6996-9037				Brody H, 1990, Fam Med, V22, P42; BROOK RH, 1987, ANN INTERN MED, V107, P392, DOI 10.7326/0003-4819-107-2-392; Brown E. Richard, 1979, ROCKEFELLER MED MEN; COLWILL JM, 1992, NEW ENGL J MED, V326, P387, DOI 10.1056/NEJM199202063260606; DAVIS BD, 1990, SCIENCE, V249, P342, DOI 10.1126/science.2377887; Duffy J., 1979, HEALERS HIST AM MED; EDDY DM, 1990, JAMA-J AM MED ASSOC, V264, P1737, DOI 10.1001/jama.264.13.1737; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P287, DOI 10.1001/jama.263.2.287; Flexner A., 1910, FLEXNER REPORT; Fox Daniel M., 1986, HLTH POLICIES HLTH P; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FROOM P, 1987, J FAM PRACTICE, V24, P80; GEYMAN C, 1984, J FAM PRACTICE, V18, P911; GEYMAN JP, 1990, J FAM PRACTICE, V31, P297; GOLD MR, 1990, J FAM PRACTICE, V30, P639; HUNT AD, 1991, MED ED ACCREDITATION; KUES JR, 1991, J FAM PRACTICE, V32, P571; LUDMERER KM, 1985, LEARNING HEAL; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MULLAN F, 1982, NEW ENGL J MED, V307, P1076, DOI 10.1056/NEJM198210213071710; NOBLE J, 1989, J GEN INTERN MED, V4, P555, DOI 10.1007/BF02599560; NORTON PG, 1991, PRIMARY CARE RES TRA; Nutting P A, 1991, Fam Med, V23, P218; NUTTING PA, 1987, J FAM PRACTICE, V24, P83; NUTTING PA, 1991, J FAM PRACTICE, V32, P27; ODEGAARD CE, 1992, PHAROS           SUM, P2; POLITZER RM, 1991, JAMA-J AM MED ASSOC, V266, P104, DOI 10.1001/jama.266.1.104; RELMAN AS, 1989, NEW ENGL J MED, V320, P1411, DOI 10.1056/NEJM198905253202109; ROSENBLATT RA, 1992, JAMA-J AM MED ASSOC, V267, P1665, DOI 10.1001/jama.267.12.1665; SCHIEBER GJ, 1991, HEALTH AFFAIR, V10, P22, DOI 10.1377/hlthaff.10.3.22; SCHWENK TL, 1986, J FAM PRACTICE, V23, P489; STARFIELD B, 1991, JAMA-J AM MED ASSOC, V266, P2268, DOI 10.1001/jama.266.16.2268; Starr P, 1982, SOCIAL TRANSFORMATIO; STEINWACHS DM, 1986, NEW ENGL J MED, V314, P217, DOI 10.1056/NEJM198601233140406; STIMMEL B, 1992, JAMA-J AM MED ASSOC, V268, P2060, DOI 10.1001/jama.268.15.2060; VERBY JE, 1991, JAMA-J AM MED ASSOC, V266, P110, DOI 10.1001/jama.266.1.110; Wennberg J E, 1991, J Am Board Fam Pract, V4, P365; White K.L., 1988, TASK MED DIALOGUE WI; WHITE KC, 1992, MED SCH MISSION POPU; WIKLER D, 1992, J AM GERIATR SOC, V40, P398, DOI 10.1111/j.1532-5415.1992.tb02143.x; 1991, RES AGENDA PRIMARY C; 1984, PHYSICIANS 21 CENTUR; 1992, JAMA-J AM MED ASSOC, V268, P2420; 1988, CLIN ED DOCTOR TOMOR; 1982, FUTUE DIRECTIONS MED; 1992, POLICY POSITION GENE	46	12	12	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1097	1100		10.1001/jama.270.9.1097	http://dx.doi.org/10.1001/jama.270.9.1097			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350457				2022-12-28	WOS:A1993LU51200015
J	DICKSON, D				DICKSON, D			CHARITIES TAKING THE STRAIN	NATURE			English	Editorial Material																		1992, NATURE, V360, P519	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					742	744		10.1038/364742a0	http://dx.doi.org/10.1038/364742a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355792				2022-12-28	WOS:A1993LT67700070
J	CHAMBERLAIN, J; MOSS, SM; KIRKPATRICK, AE; MICHELL, M; JOHNS, L				CHAMBERLAIN, J; MOSS, SM; KIRKPATRICK, AE; MICHELL, M; JOHNS, L			NATIONAL-HEALTH-SERVICE BREAST SCREENING-PROGRAM RESULTS FOR 1991-2	BRITISH MEDICAL JOURNAL			English	Article							TRIAL	Objectives-To report the results of the NHS breast screening programme for the year March 1991 to April 1992. Design-A report of statistics was derived from Korner (K62) returns and from the radiology quality assurance programme. Main outcome measures-Detection rates for breast cancer and small (less-than-or-equal-to 10 mm diameter) invasive cancer, benign biopsy rates, and recall and acceptance rates. Results-The acceptance rate for screening across the United Kingdom was 71.3%. The referral rate for further investigation was 6.2% (regional 4.3-9.0%). The breast cancer detection rate was 6.2 cancers per 1000 women screened (5.1-9.0) and the detection rate of invasive cancers less-than-or-equal-to 10 mm was 1.4/1000 (1.0-2.3). 72% of screening programmes reached the target 70% acceptance rate, and 95% of programmes achieved a recall rate of less than 10%. 75% of programmes had a cancer detection rate of more than 5/1000, but only 32% had a detection rate for invasive cancers less-than-or-equal-to 10 mm of more than 1.5/1000. Conclusions-Overall, the results of the screening programme for the year 1991-2 can be regarded as extremely satisfactory, given the size and complexity of the operation.	SE SCOTLAND BREAST SCREENING PROGRAM,ARDMILLAN TERRACE,EDINBURGH EH11 2JL,SCOTLAND; INST CANC RES,CANC SCREENING EVALUAT UNIT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV LONDON KINGS COLL HOSP,BREAST SCREENING UNIT,LONDON SE5 9RS,ENGLAND	University of London; Institute of Cancer Research - UK; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London								FORREST APM, 1986, BREAST CANCER SCREEN; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; TABAR L, 1987, BRIT J CANCER, V55, P547, DOI 10.1038/bjc.1987.112; 1992, HLTH NATION STRATEGY; 1988, NHSBSP PUBLICATIONS; 1993, BREAST, V2, P13; IN PRESS UKCCCRN NHS	7	78	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1993	307	6900					353	356		10.1136/bmj.307.6900.353	http://dx.doi.org/10.1136/bmj.307.6900.353			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374416	Bronze, Green Published			2022-12-28	WOS:A1993LR76800017
J	STEVENSON, R; RANJADAYALAN, K; WILKINSON, P; ROBERTS, R; TIMMIS, AD				STEVENSON, R; RANJADAYALAN, K; WILKINSON, P; ROBERTS, R; TIMMIS, AD			SHORT AND LONG-TERM PROGNOSIS OF ACUTE MYOCARDIAL-INFARCTION SINCE INTRODUCTION OF THROMBOLYSIS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; MINNESOTA-HEART-SURVEY; FOLLOW-UP; SURVIVAL; TRIAL; MORTALITY; THERAPY; RECOVERY; STRATIFICATION; STREPTOKINASE	Objective-To record prognosis and determinants of outcome in patients with acute myocardial infarction since thrombolysis was introduced. Design-Observational study. Setting-London district general hospital. Patients-608 consecutive patients admitted to the coronary care unit with acute myocardial infarction between 1 January 1988 and 31 December 1991. Main outcome measure-All cause mortality, non-fatal ischaemic events (myocardial infarction, unstable angina), and revascularisation. Results-Of the 608 patients, 89 (14.6%) died in hospital. 596 patients were followed up after discharge from hospital. Mortality (95% confidence interval) at 30 days, one year, and three years was 16.0% (13.4% to 19.2%), 21.7% (18.6% to 25.2%), and 29.4% (25.3% to 33.9%) respectively. Event free survival (survival without a non-fatal ischaemic event) was 80.4% (77.0% to 83.4%) at 30 days, 66.8% (62.8% to 70.5%) at one year, and 56.1% (51.3% to 60.6%) at three years. Survival in patients treated with thrombolysis was considerably higher than in those not given thrombolysis (three year survival: 76.7% v 54.3%), although the incidence of non-fatal ischaemic events was the same in the two groups. Multivariate determinants of six month survival were left ventricular failure, treatment with thrombolysis and aspirin, smoking history, bundle branch block, and age. For patients who survived six months, age was the only factor related to long term survival. Conclusions-Although patients treated by thrombolysis had a relatively good prognosis, long term mortality and the incidence of non-fatal recurrent ischaemic events remained high. Effective strategies for the identification and treatment of high risk patients need to be reassessed.	NEWHAM DIST GEN HOSP, DEPT CARDIOL, LONDON E13, ENGLAND; LONDON CHEST HOSP, EPIDEMIOL RES UNIT, LONDON E2, ENGLAND		STEVENSON, R (corresponding author), LONDON CHEST HOSP, DEPT CARDIOL, LONDON E2, ENGLAND.			Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1987, LANCET, V2, P871; BARBASH GI, 1992, J AM COLL CARDIOL, V20, P36, DOI 10.1016/0735-1097(92)90134-9; CHAMBERLAIN DA, 1990, LANCET, V335, P427; CLEEMPOEL H, 1988, BRIT HEART J, V60, P98; COX DR, 1972, J R STAT SOC B, V34, P187; DECKERS JW, 1987, AM HEART J, V113, P90, DOI 10.1016/0002-8703(87)90014-7; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; DUBOIS C, 1988, AM J CARDIOL, V61, P216, DOI 10.1016/0002-9149(88)90918-6; ELLIS SG, 1989, CIRCULATION, V80, P1159, DOI 10.1161/01.CIR.80.5.1159; FRABICIUSBJERRE N, 1979, AM J MED, V66, P986; GOMEZMARIN O, 1987, NEW ENGL J MED, V316, P1353, DOI 10.1056/NEJM198705283162201; HARRISON DG, 1984, CIRCULATION, V69, P991, DOI 10.1161/01.CIR.69.5.991; HENNING H, 1979, CIRCULATION, V59, P1124, DOI 10.1161/01.CIR.59.6.1124; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P10; KRONE RJ, 1983, AM J CARDIOL, V52, P234, DOI 10.1016/0002-9149(83)90114-5; MARTIN CA, 1983, CIRCULATION, V68, P961, DOI 10.1161/01.CIR.68.5.961; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; MUELLER HS, 1992, CIRCULATION, V85, P1254, DOI 10.1161/01.CIR.85.4.1254; MURRAY DP, 1987, BRIT HEART J, V57, P313; NORRIS RM, 1984, AM J CARDIOL, V53, P408, DOI 10.1016/0002-9149(84)90003-1; POHJOLA S, 1980, BRIT HEART J, V43, P176, DOI 10.1136/hrt.43.2.176; RIVERS JT, 1990, J AM COLL CARDIOL, V16, P340, DOI 10.1016/0735-1097(90)90583-B; SANZ G, 1982, NEW ENGL J MED, V306, P1065, DOI 10.1056/NEJM198205063061801; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1985, LANCET, V2, P578; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525; WILLIAMS DO, 1986, CIRCULATION, V73, P338, DOI 10.1161/01.CIR.73.2.338; WOLFFENBUTTEL BHR, 1983, BRIT HEART J, V50, P266; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1990, LANCET, V335, P545; 1968, LANCET, V2, P349	33	147	150	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	1993	307	6900					349	353		10.1136/bmj.307.6900.349	http://dx.doi.org/10.1136/bmj.307.6900.349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR768	8374415	Bronze, Green Published			2022-12-28	WOS:A1993LR76800016
J	SURANA, R; QUINN, F; PURI, P				SURANA, R; QUINN, F; PURI, P			IS IT NECESSARY TO PERFORM APPENDECTOMY IN THE MIDDLE OF THE NIGHT IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							APPENDICITIS		OUR LADYS HOSP SICK CHILDREN,DUBLIN 12,IRELAND	Our Ladys Children Hospital Crumlin								Buck N, 1987, REPORT CONFIDENTIAL; MAXWELL JM, 1991, AM SURGEON, V57, P282; NEILSON IR, 1990, J PEDIATR SURG, V25, P1113, DOI 10.1016/0022-3468(90)90742-R; WILLIAMS N, 1991, ARCH DIS CHILD, V66, P1270, DOI 10.1136/adc.66.11.1270; WYATT MG, 1990, ANN ROY COLL SURG, V72, P236	5	84	84	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1993	306	6886					1168	1168		10.1136/bmj.306.6886.1168	http://dx.doi.org/10.1136/bmj.306.6886.1168			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LA685	8369045	Green Published, Bronze			2022-12-28	WOS:A1993LA68500022
J	RASTINEJAD, F; BLAU, HM				RASTINEJAD, F; BLAU, HM			GENETIC COMPLEMENTATION REVEALS A NOVEL REGULATORY ROLE FOR 3' UNTRANSLATED REGIONS IN GROWTH AND DIFFERENTIATION	CELL			English	Article							NF-KAPPA-B; DNA-BINDING PROTEINS; TRANSCRIPTION FACTOR; ACTIN GENE; MESSENGER-RNAS; MUSCLE-CELLS; ALPHA-ACTIN; TRANSIENT HETEROKARYONS; MOLECULAR-CLONING; MAMMALIAN-CELLS	Differentiated skeletal muscle cells cease dividing and sustain expression of a battery of tissue-specific genes. To identify regulators of growth and differentiation, we used a genetic complementation approach. Following introduction of a cDNA expression library into a differentiation-defective myoblast mutant (NMU2), cDNAs were isolated that activated muscle-specific promoters. The complementing cDNAs were identified as muscle structural genes, troponin I, tropomyosin, and alpha-cardiac actin, and their activity was mapped to the 3' untranslated region (3'UTR). The 3'UTRs augmented the differentiation of wild-type muscle cells. Upon expression in 10T1/2 fibroblasts, proliferation was suppressed, indicating that the effects of the 3'UTRs are not limited to myogenic cells. These data suggest that 3'UTRs of certain differentiation-specific RNAs are trans-acting regulators in a feedback loop that inhibits cell division and promotes differentiation.			RASTINEJAD, F (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT PHARMACOL, STANFORD, CA 94305 USA.				NICHD NIH HHS [HD-07249, HD-20203] Funding Source: Medline; NIGMS NIH HHS [GM-14588] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014588] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; BELOTE JM, 1987, P NATL ACAD SCI USA, V84, P8026, DOI 10.1073/pnas.84.22.8026; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACK RA, 1985, P NATL ACAD SCI USA, V82, P124, DOI 10.1073/pnas.82.1.124; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLAU HM, 1988, CELL, V53, P673, DOI 10.1016/0092-8674(88)90082-7; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BLAU HM, 1981, P NATL ACAD SCI-BIOL, V78, P5623, DOI 10.1073/pnas.78.9.5623; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; BOUCK N, 1982, MOL CELL BIOL, V2, P97, DOI 10.1128/MCB.2.2.97; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CASTRILLO JL, 1989, SCIENCE, V243, P814, DOI 10.1126/science.2563596; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DELALUNA S, 1988, GENE, V62, P121; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; EDMONDSON DG, 1992, MOL CELL BIOL, V12, P3665, DOI 10.1128/MCB.12.9.3665; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRECO A, 1987, P NATL ACAD SCI USA, V84, P1565, DOI 10.1073/pnas.84.6.1565; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNNING P, 1984, J MOL EVOL, V20, P202, DOI 10.1007/BF02104727; GUSTAFSON TA, 1989, MOL CELL BIOL, V9, P3269, DOI 10.1128/MCB.9.8.3269; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; HARDEMAN EC, 1988, J CELL BIOL, V106, P1027, DOI 10.1083/jcb.106.4.1027; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HERSKOWITZ I, 1985, COLD SPRING HARB SYM, V50, P565, DOI 10.1101/SQB.1985.050.01.069; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOELLER DM, 1991, P NATL ACAD SCI USA, V88, P7778, DOI 10.1073/pnas.88.17.7778; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LESSARD JL, 1988, CELL MOTIL CYTOSKEL, V10, P349, DOI 10.1002/cm.970100302; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LIN CS, 1988, MOL CELL BIOL, V8, P160, DOI 10.1128/MCB.8.1.160; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; PAN LC, 1992, SOMAT CELL MOLEC GEN, V18, P163, DOI 10.1007/BF01233162; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PETERSON CA, 1992, DEV BIOL, V151, P626, DOI 10.1016/0012-1606(92)90201-Q; PINSET C, 1988, DIFFERENTIATION, V38, P28, DOI 10.1111/j.1432-0436.1988.tb00588.x; RICHARDSON KK, 1987, P NATL ACAD SCI USA, V84, P344, DOI 10.1073/pnas.84.2.344; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SANTORO IM, 1991, MOL CELL BIOL, V11, P1944, DOI 10.1128/MCB.11.4.1944; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHATZ DG, 1988, CELL, V53, P107, DOI 10.1016/0092-8674(88)90492-8; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHARP SB, 1989, GENE, V80, P293, DOI 10.1016/0378-1119(89)90293-X; SILBERSTEIN L, 1986, CELL, V46, P1075, DOI 10.1016/0092-8674(86)90707-5; SIMMONS DL, 1992, J IMMUNOL, V148, P267; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPEAR BT, 1990, MOL CELL BIOL, V10, P5047, DOI 10.1128/MCB.10.10.5047; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; VAIDYA TB, 1991, J CELL BIOL, V114, P809, DOI 10.1083/jcb.114.4.809; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WADE R, 1990, GENOMICS, V7, P346, DOI 10.1016/0888-7543(90)90168-T; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; WELLS D, 1987, NUCLEIC ACIDS RES, V15, P2871, DOI 10.1093/nar/15.7.2871; WRIGHT WE, 1984, J CELL BIOL, V98, P436, DOI 10.1083/jcb.98.2.436; WU KJ, 1991, MOL CELL BIOL, V11, P4423, DOI 10.1128/MCB.11.9.4423; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X	86	246	255	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 26	1993	72	6					903	917		10.1016/0092-8674(93)90579-F	http://dx.doi.org/10.1016/0092-8674(93)90579-F			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KU175	8384533				2022-12-28	WOS:A1993KU17500011
J	ROBERTSON, HM				ROBERTSON, HM			THE MARINER TRANSPOSABLE ELEMENT IS WIDESPREAD IN INSECTS	NATURE			English	Article							DROSOPHILA-MELANOGASTER; DNA	THE mariner transposable element is a small member of the short inverted terminal repeat class thought to transpose through a DNA intermediate1. Originally described in Drosophila mauritiana2, it is now known in several species of the family Drosophilidae3,4, and in a moth Hyalophora cecropia5. Here I use primers designed to represent regions of amino-acid conservation between the putative transposase genes of the D. mauritiana and H. cecropia elements to amplify equivalent regions of presumed mariner elements from ten other insects representing six additional orders, including the malaria-vector mosquito, Anopheles gambiae. Sequences of multiple clones from each species reveal a diverse array of mariner elements, with multiple subfamilies in the genomes of some insects, indicating both vertical inheritance and horizontal transfers. An intact open reading frame in at least one clone from each species suggests each may carry functional transposable elements. Therefore the mariner element is an excellent candidate for development of genetic transformation systems for non-drosophilid insects, and possibly other arthropods.			ROBERTSON, HM (corresponding author), UNIV ILLINOIS,DEPT ENTOMOL,505 S GOODWIN AVE,URBANA,IL 61801, USA.							CARPENTER F M, 1976, Psyche (Cambridge), V83, P336; DANIELS SB, 1990, GENETICS, V129, P399; Eckert K A, 1991, PCR Methods Appl, V1, P17; GARZA D, 1991, GENETICS, V128, P303; Hartl DL., 1989, MOBILE DNA, P5531; Hennig W., 1981, INSECT PHYLOGENY; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HOLTON TA, 1991, NUCLEIC ACIDS RES, V19, P1156, DOI 10.1093/nar/19.5.1156; HOUCK MA, 1991, SCIENCE, V253, P1125, DOI 10.1126/science.1653453; HURST GDD, 1992, NATURE, V356, P659, DOI 10.1038/356659a0; JACOBSON JW, 1986, P NATL ACAD SCI USA, V83, P8684, DOI 10.1073/pnas.83.22.8684; Kristensen N.P., 1991, P125; LIDHOLM DA, 1991, J BIOL CHEM, V266, P11518; MARUYAMA K, 1991, J MOL EVOL, V33, P514, DOI 10.1007/BF02102804; MARUYAMA K, 1991, GENETICS, V128, P319; MEDHORA M, 1991, GENETICS, V128, P311; ONEILL SL, 1992, P NATL ACAD SCI USA, V89, P2699, DOI 10.1073/pnas.89.7.2699; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; QIAN L, 1991, BIOTECHNIQUES, V10, P736; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONELIG M, 1991, P NATL ACAD SCI USA, V88, P6102, DOI 10.1073/pnas.88.14.6102; SWOFFORD DL, 1991, PAUP PHYLOGENETIC AN	25	340	358	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 18	1993	362	6417					241	245		10.1038/362241a0	http://dx.doi.org/10.1038/362241a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KT026	8384700				2022-12-28	WOS:A1993KT02600055
J	FRIEDEN, TR; STERLING, T; PABLOSMENDEZ, A; KILBURN, JO; CAUTHEN, GM; DOOLEY, SW				FRIEDEN, TR; STERLING, T; PABLOSMENDEZ, A; KILBURN, JO; CAUTHEN, GM; DOOLEY, SW			THE EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED PATIENTS; MYCOBACTERIUM-TUBERCULOSIS; UNITED-STATES	Background. in the past decade the incidence of tuberculosis has increased nationwide and more than doubled in New York City, where there have been recent nosocomial outbreaks of multidrug-resistant tuberculosis. Methods. We collected information on every patient in New York City with a positive culture for Mycobacterium tuberculosis during April 1991. Drug-susceptibility testing was performed at the Centers for Disease Control and Prevention. Results. Of the 518 patients with positive cultures, 466 (90 percent) had isolates available for testing. Overall, 33 percent of these patients had isolates resistant to one or more antituberculosis drugs, 26 percent had isolates resistant to at least isoniazid, and 19 percent had isolates resistant to both isoniazid and rifampin. Of the 239 patients who had received antituberculosis therapy, 44 percent had isolates resistant to one or more drugs and 30 percent had isolates resistant to both isoniazid and rifampin. Among the patients who had never been treated, the proportion with resistance to one or more drugs increased from 10 percent in 1982 through 1984 to 23 percent in 1991 (P = 0.003). Patients who had never been treated and who were infected with the human immunodeficiency virus (HIV) or reported injection-drug use were more likely to have resistant isolates. Among patients with the acquired immunodeficiency syndrome, those with resistant isolates were more likely to die during follow-up through January 1992 (80 percent vs. 47 percent, P = 0.02). A history of antituberculosis therapy was the strongest predictor of the presence of resistant organisms (odds ratio, 2.7; P < 0.001). Conclusions. There has been a marked increase in drug-resistant tuberculosis in New York City. Previously treated patients, those infected with HIV, and injection-drug users are at increased risk for drug resistance. Measures to control and prevent drug-resistant tuberculosis are urgently needed.	CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,PROGRAM OFF,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV MYCOT & BACTERIAL DIS,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR PREVENT SERV,DIV TB ELIMINAT,ATLANTA,GA; NEW YORK CITY DEPT HLTH,DIV DIS INTERVENT,NEW YORK,NY 10013; COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; New York City Department of Health & Mental Hygiene; Columbia University; NewYork-Presbyterian Hospital								ADDINGTON WW, 1979, CHEST, V76, P741, DOI 10.1378/chest.76.6_Supplement.741; BARNES PF, 1987, AM REV RESPIR DIS, V136, P325, DOI 10.1164/ajrccm/136.2.325; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BENDOV I, 1987, AM REV RESPIR DIS, V135, P1307; BERLINER DS, 1987, AVIAT SPACE ENVIR MD, V58, P83; BLOCH AB, 1989, CLIN CHEST MED, V10, P297; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; BUTLER WR, 1991, J CLIN MICROBIOL, V29, P2468, DOI 10.1128/JCM.29.11.2468-2472.1991; COSTELLO HD, 1980, AM REV RESPIR DIS, V121, P313; Dean A. G., 1990, EPI INFO VERSION 5 W; DIPERRI G, 1989, LANCET, V2, P1502; DOSTER B, 1976, AM REV RESPIR DIS, V113, P419; GIBSON J, 1986, TUBERCLE, V67, P119, DOI 10.1016/0041-3879(86)90005-X; Goble M, 1986, Semin Respir Infect, V1, P220; Grange J M, 1990, Bull Int Union Tuberc Lung Dis, V65, P57; HOBBY GL, 1964, AM REV RESPIR DIS, V89, P337; ISEMAN MD, 1989, CLIN CHEST MED, V10, P341; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; Kent PT, 1985, GUIDE LEVEL 3 LAB; KOPANOFF DE, 1978, AM REV RESPIR DIS, V118, P835; KOPLAN JP, 1980, JAMA-J AM MED ASSOC, V244, P2736, DOI 10.1001/jama.244.24.2736; MITCHISON DA, 1986, AM REV RESPIR DIS, V133, P423; MONNO L, 1991, LANCET, V337, P852, DOI 10.1016/0140-6736(91)92559-K; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; RILEY LW, 1989, AM REV RESPIR DIS, V139, P1282, DOI 10.1164/ajrccm/139.5.1282; Safi M I, 1988, J Pak Med Assoc, V38, P73; SALOMON N, 1991, 31ST INT C ANT AG CH, P152; SBARBARO JA, 1985, AM J MED, V79, P34, DOI 10.1016/0002-9343(85)90085-3; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SHAFER RW, 1991, AIDS, V5, P399, DOI 10.1097/00002030-199104000-00007; SHENNAN D H, 1964, Tubercle, V45, P1, DOI 10.1016/S0041-3879(64)80080-5; STEINER P, 1986, AM REV RESPIR DIS, V134, P446; Valenzuela P, 1988, Bull Pan Am Health Organ, V22, P175; VILLARINO M E, 1992, Morbidity and Mortality Weekly Report, V41, P59; 1991, MMWR MORB MORTAL WKL, V40, P585; 1983, MMWR MORB MORTAL WKL, V32, P521; 1989, HIVCID990006 CTR DIS; 1990, SAS LANGUAGE VERSION; 1991, MMWR MORB MORTAL WKL, V40, P129; 1987, MMWR MORB MORTAL WKL, V36, P785; 1989, MMWR MORB MORTAL WKL, V38, P313; 1991, TUBERCULOSIS NEW YOR; 1990, MMWR MORB MORTAL WKL, V39, P718	43	776	806	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					521	526		10.1056/NEJM199302253280801	http://dx.doi.org/10.1056/NEJM199302253280801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8381207				2022-12-28	WOS:A1993KP05300001
J	NATARAJAN, S; KAUL, S; MIRON, A; BASTIA, D				NATARAJAN, S; KAUL, S; MIRON, A; BASTIA, D			A 27 KD PROTEIN OF ESCHERICHIA-COLI PROMOTES ANTITERMINATION OF REPLICATION INVITRO AT A SEQUENCE-SPECIFIC REPLICATION TERMINUS	CELL			English	Article							DNA-BINDING PROTEIN; ESCHERICHIA-COLI; CHROMOSOME-REPLICATION; PLASMID REPLICATION; TERMINATION PROTEIN; BACILLUS-SUBTILIS; IDENTIFICATION; HELICASE; SITES; R6K	We have discovered a 27 kd protein of E. coli that binds to a terminator site (tau)-terminator protein (ter) complex and abrogates the replication fork-arresting activity of ter protein in vitro. The 27 kd protein also neutralizes the contrahelicase activity of ter protein, allowing dnaB helicase to unwind DNA past a tau-ter complex. The stimulatory activity of low levels of ter protein on helicase II is also abolished by the 27 kd protein. The binding of the 27 kd protein to a tau-ter complex does not appear to dissociate the ter protein from the DNA. Although the in vivo function of the 27 kd protein is unknown at this time, it has the major attributes of a novel replication antiterminator in vitro.			NATARAJAN, S (corresponding author), DUKE UNIV,MED CTR,DEPT MICROBIOL,DURHAM,NC 27710, USA.							BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BASTIA D, 1981, GENE, V41, P81; BEDROSIAN CL, 1991, P NATL ACAD SCI USA, V88, P2618, DOI 10.1073/pnas.88.7.2618; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; CROSA JH, 1976, J BACTERIOL, V126, P454, DOI 10.1128/JB.126.1.454-466.1976; GAHN TA, 1989, CELL, V58, P527, DOI 10.1016/0092-8674(89)90433-9; GERMINO J, 1981, CELL, V23, P681, DOI 10.1016/0092-8674(81)90431-1; GREENBLATT J, 1981, J MOL BIOL, V147, P11, DOI 10.1016/0022-2836(81)90076-0; HIASA H, 1992, J BIOL CHEM, V267, P11379; HILL TM, 1989, P NATL ACAD SCI USA, V86, P1593, DOI 10.1073/pnas.86.5.1593; HILL TM, 1988, CELL, V55, P459, DOI 10.1016/0092-8674(88)90032-3; HORIUCHI T, 1988, CELL, V54, P515, DOI 10.1016/0092-8674(88)90073-6; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KOLTER R, 1978, J MOL BIOL, V124, P425, DOI 10.1016/0022-2836(78)90180-8; KUEMPEL PL, 1977, P NATL ACAD SCI USA, V73, P3927; LEBOWITZ JO, 1976, J BIOL CHEM, V261, P4738; LEE EH, 1992, J BIOL CHEM, V267, P8778; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LEWIS PJ, 1990, J MOL BIOL, V214, P73, DOI 10.1016/0022-2836(90)90147-E; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LOUARN J, 1977, J MOL BIOL, V115, P295, DOI 10.1016/0022-2836(77)90156-5; LOVETT MA, 1975, P NATL ACAD SCI USA, V72, P2905, DOI 10.1073/pnas.72.8.2905; MACALLISTER T, 1990, P NATL ACAD SCI USA, V87, P2828, DOI 10.1073/pnas.87.7.2828; MATSON SW, 1986, J BIOL CHEM, V261, P169; MEHTA PP, 1992, J BIOL CHEM, V267, P18885; NATARAJAN S, 1991, P NATL ACAD SCI USA, V88, P3867, DOI 10.1073/pnas.88.9.3867; SISTA PR, 1991, GENE DEV, V5, P74, DOI 10.1101/gad.5.1.74; SISTA PR, 1989, P NATL ACAD SCI USA, V86, P3026, DOI 10.1073/pnas.86.9.3026; WEISS AS, 1984, CELL, V39, P683, DOI 10.1016/0092-8674(84)90475-6	29	11	11	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 15	1993	72	1					113	120		10.1016/0092-8674(93)90055-U	http://dx.doi.org/10.1016/0092-8674(93)90055-U			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	KG955	8380756				2022-12-28	WOS:A1993KG95500015
J	CASEY, LC; BALK, RA; BONE, RC				CASEY, LC; BALK, RA; BONE, RC			PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						SEPSIS SYNDROME; TUMOR NECROSIS FACTORS; LIPOPOLYSACCHARIDES; INTERLEUKIN-1; INTERLEUKIN-6	TUMOR-NECROSIS-FACTOR; CONTROLLED CLINICAL-TRIAL; HUMAN SEPTIC SHOCK; MONOCLONAL-ANTIBODY; SERUM LEVELS; INTERLEUKIN-1; CACHECTIN; INJURY; ASSOCIATION; BACTEREMIA	Objective: To determine whether plasma tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), interleukin-6 (IL-6), and lipopolysaccharide are detectable in patients when they first present with the sepsis syndrome and to determine whether levels correlate with patient survival. Design: Prospective study comparing patients with the sepsis syndrome, critically ill patients without sepsis, and normal healthy volunteers. Setting: Tertiary care hospital affiliated with a medical school. Patients: The study included 97 consecutive patients on a medical service who met the criteria for the sepsis syndrome; 20 critically ill patients without sepsis who were in the medical intensive care unit; and 20 healthy volunteers who served as comparison groups. Measurements: Plasma tumor necrosis factor-alpha, IL-1beta, interleukin-6, and endotoxin (lipopolysaccharide) levels were measured when a patient was first identified as having the sepsis syndrome. Survival was defined as being alive 30 days after the sepsis syndrome was diagnosed. Results. Fifty-four percent of patients with the sepsis syndrome had detectable levels of TNF-alpha (median, 26 pg/mL; range, nondetectable to 1000 pg/mL); 37% had detectable levels of IL-1 (median, 20 pg/mL; range, nondetectable to 2850 pg/mL); 80% had detectable levels of IL-6 (median, 415 pg/mL; range, nondetectable to 2380 pg/mL); and 89% had detectable levels of lipopolysaccharide (median, 2.6; range, nondetectable to 12.5 endotoxin units [EU]/mL). In all cases, levels were higher than those in critically ill patients without sepsis and normal healthy controls (P < 0.001 for all comparisons). Plasma levels of TNF-alpha, IL-1beta, IL-6, and lipopolysaccharide were detectable in patients regardless of culture status. The IL-6 level was 69%. (95% CI, 30% to 108%) higher in patients who died compared with those who survived. The scores for the individual levels of TNF-alpha IL-1beta, IL-6, and lipopolysaccharide were summed to arrive at a total lipopolysaccharide-cytokine score, and mortality increased with lipopolysaccharide-cytokine score (P < 0.001). Conclusions: Patients with the sepsis syndrome have detectable levels of circulating TNF-alpha, IL-1, IL-6, and lipopolysaccharide independent of culture-documented infection. Lipopolysaccharide and cytokines may play a pathogenic role in sepsis, and the combination of several elevated factors may be important in determining patient survival.			CASEY, LC (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT PULM & CRIT CARE MED, 1725 W HARRISON ST, SUITE 306, CHICAGO, IL 60612 USA.		Fahimifar, Sepideh/M-5303-2019					ABRAMOWICZ D, 1989, TRANSPLANTATION, V47, P606, DOI 10.1097/00007890-198904000-00008; AYALA A, 1991, AM J PHYSIOL, V260, pR167, DOI 10.1152/ajpregu.1991.260.1.R167; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, 1987, NEW ENGL J MED, V316, P379; BEUTLER BA, 1985, J IMMUNOL, V135, P3972; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; DAMAS P, 1989, CRIT CARE MED, V17, P975, DOI 10.1097/00003246-198910000-00001; DANNER RL, 1991, CHEST, V99, P169, DOI 10.1378/chest.99.1.169; DAVIDSON M, 1976, JAMA-J AM MED ASSOC, V235, P158, DOI 10.1001/jama.235.2.158; DEITCH EA, 1987, ARCH SURG-CHICAGO, V122, P185; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153, DOI [10.1016/s0065-2776(08)60642-2, 10.1016/S0065-2776(08)60642-2, DOI 10.1016/S0065-2776(08)60642-2]; ELIAS JA, 1987, J IMMUNOL, V138, P3812; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; GUICE KS, 1989, ANN SURG, V210, P740, DOI 10.1097/00000658-198912000-00008; HACK CE, 1989, BLOOD, V74, P1704; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LUGER A, 1986, CRIT CARE MED, V14, P458, DOI 10.1097/00003246-198605000-00004; MARANO MA, 1988, ARCH SURG-CHICAGO, V123, P1383; MATHISON JC, 1988, J CLIN INVEST, V81, P1925, DOI 10.1172/JCI113540; MAURY CPJ, 1987, J EXP MED, V166, P1132, DOI 10.1084/jem.166.4.1132; MAURY CPJ, 1989, ARTHRITIS RHEUM, V32, P146, DOI 10.1002/anr.1780320206; MICHIE HR, 1988, SURGERY, V104, P280; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MORRISON DC, 1978, AM J PATHOL, V93, P526; NATANSON C, 1989, J CLIN INVEST, V83, P243, DOI 10.1172/JCI113866; OFFNER F, 1990, J LAB CLIN MED, V116, P100; OHLSSON K, 1990, NATURE, V348, P550, DOI 10.1038/348550a0; OKUSAWA S, 1988, J EXP MED, V168, P443, DOI 10.1084/jem.168.1.443; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PREISER JC, 1991, CYTOKINE, V3, P1, DOI 10.1016/1043-4666(91)90002-U; ROTH RI, 1990, J LAB CLIN MED, V116, P153; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; WAAGE A, 1987, LANCET, V1, P355; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WHITE CW, 1987, J CLIN INVEST, V79, P1868, DOI 10.1172/JCI113029; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701; 1990, MMWR, V39, P31	44	880	922	0	23	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					771	778		10.7326/0003-4819-119-8-199310150-00001	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379598				2022-12-28	WOS:A1993MB49600001
J	HILL, JO; DROUGAS, H; PETERS, JC				HILL, JO; DROUGAS, H; PETERS, JC			OBESITY TREATMENT - CAN DIET COMPOSITION PLAY A ROLE	ANNALS OF INTERNAL MEDICINE			English	Article							RESTRICTED HYPOCALORIC DIETS; LIBITUM FED MICE; ENERGY-EXPENDITURE; FAT OXIDATION; NUTRIENT BALANCE; BODY-WEIGHT; FOOD-INTAKE; CARBOHYDRATE; HUMANS; EXERCISE	Diet composition can play a role in obesity treatment because it can influence energy intake and nutrient balance. The greatest potential effect of diet composition occurs not during weight reduction but during maintenance of a reduced body weight. During weight reduction, the extent of negative energy balance is the greatest determinant of the amount and rate of weight loss, and any effects of diet composition are likely to be very small. Conversely, during the maintenance period after weight reduction, maintenance energy requirements are reduced and the rate of fat oxidation may be low. Prevention of fat storage and regain of body weight can be achieved either by increasing fat oxidation (for example, by increasing exercise) or by reducing the fat content of the habitual diet. The treatment with the greatest chance for success combines a reduced-fat diet with aerobic exercise.	PROCTER & GAMBLE CO, ROSS, OH USA; VANDERBILT UNIV, NASHVILLE, TN 37240 USA	Procter & Gamble; Vanderbilt University	HILL, JO (corresponding author), UNIV COLORADO, HLTH SCI CTR, CTR HUMAN NUTR, CAMPUS BOX C225, 4200 E 9TH AVE, DENVER, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038088, R01DK042549, R37DK042549] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38088, DK42549] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHESON KJ, 1988, AM J CLIN NUTR, V48, P240, DOI 10.1093/ajcn/48.2.240; BENNETT C, 1992, AM J CLIN NUTR, V55, P1071, DOI 10.1093/ajcn/55.6.1071; BOGARDUS C, 1981, J CLIN INVEST, V68, P399, DOI 10.1172/JCI110268; BOOTH DA, 1970, PHYSIOL BEHAV, V5, P1299, DOI 10.1016/0031-9384(70)90044-2; DAUNCEY MJ, 1990, CAN J PHYSIOL PHARM, V68, P17, DOI 10.1139/y90-002; Flatt J., 1978, REC ADV OBES RES, V2, P211; Flatt J. P, 1985, SUBSTRATE ENERGY MET, P58; FLATT JP, 1991, J NUTR BIOCHEM, V2, P186, DOI 10.1016/0955-2863(91)90015-W; FLATT JP, 1985, J CLIN INVEST, V76, P1019, DOI 10.1172/JCI112054; FLATT JP, 1987, ANN NY ACAD SCI, V499, P104, DOI 10.1111/j.1749-6632.1987.tb36202.x; FLATT JP, 1988, DIABETES METAB REV, V4, P571, DOI 10.1002/dmr.5610040603; FLETCHER SW, 1992, ANN INTERN MED, V116, P942, DOI 10.7326/0003-4819-116-11-951; HILL JO, 1991, AM J CLIN NUTR, V54, P10, DOI 10.1093/ajcn/54.1.10; HILL JO, 1987, AM J CLIN NUTR, V46, P622, DOI 10.1093/ajcn/46.4.622; HILL JO, 1984, METABOLISM, V33, P743, DOI 10.1016/0026-0495(84)90216-6; HORTON TJ, 1993, OBESITY RES S1, V1, P115; KENDALL A, 1991, AM J CLIN NUTR, V53, P1124, DOI 10.1093/ajcn/53.5.1124; PETERS JC, 1985, J NUTR, V115, P382, DOI 10.1093/jn/115.3.382; RAMIREZ I, 1990, PHYSIOL BEHAV, V47, P1157, DOI 10.1016/0031-9384(90)90367-D; RAVUSSIN E, 1986, J CLIN INVEST, V78, P1568, DOI 10.1172/JCI112749; ROSEN JC, 1982, AM J CLIN NUTR, V36, P463, DOI 10.1093/ajcn/36.3.463; SALMON DMW, 1985, INT J OBESITY, V9, P443; SCHUTZ Y, 1992, AM J CLIN NUTR, V55, P670, DOI 10.1093/ajcn/55.3.670; SCHUTZ Y, 1989, AM J CLIN NUTR, V50, P307, DOI 10.1093/ajcn/50.2.307; THOMAS CD, 1992, AM J CLIN NUTR, V55, P934, DOI 10.1093/ajcn/55.5.934; TREMBLAY A, 1989, AM J CLIN NUTR, V49, P799, DOI 10.1093/ajcn/49.5.799; WEIGLE DS, 1988, INT J OBESITY, V12, P567; 1985, USDA CSFII853 HUM NU	28	51	51	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				694	697		10.7326/0003-4819-119-7_Part_2-199310011-00013	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00013			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363199				2022-12-28	WOS:A1993MA33000013
J	KRAMER, F; SASSE, SA; SIMMS, JC; LEEDOM, JM				KRAMER, F; SASSE, SA; SIMMS, JC; LEEDOM, JM			PRIMARY CUTANEOUS TUBERCULOSIS AFTER A NEEDLESTICK INJURY FROM A PATIENT WITH AIDS AND UNDIAGNOSED TUBERCULOSIS	ANNALS OF INTERNAL MEDICINE			English	Note											KRAMER, F (corresponding author), UNIV SO CALIF, LOS ANGELES CTY MED CTR, INFECT DIS SECT, ROOM 6442, 1200 N STATE ST, LOS ANGELES, CA 90033 USA.							CANBY JP, 1963, PEDIATRICS, V63, P331; DENNIE CC, 1945, ARCH DERMATOL SYPHIL, V51, P316; GERBERDING JL, 1985, NEW ENGL J MED, V312, P56; GLASER JB, 1985, NEW ENGL J MED, V313, P266; GOETTE DK, 1978, ARCH DERMATOL, V114, P567, DOI 10.1001/archderm.114.4.567; HEILMAN KM, 1965, NEW ENGL J MED, V273, P1035, DOI 10.1056/NEJM196511042731908; HEYCOCK J B, 1961, Tubercle, V42, P25, DOI 10.1016/S0041-3879(61)80014-7; Holt LE, 1913, J AMER MED ASSOC, V61, P99, DOI 10.1001/jama.1913.04350020025011; Michelson HE, 1935, ARCH DERMATOL SYPH, V32, P589, DOI 10.1001/archderm.1935.01470040046010; O' Leary PA, 1941, ARCH DERMATOL SYPH, V44, P371, DOI 10.1001/archderm.1941.01500030053006; [No title captured]	11	33	34	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				594	595		10.7326/0003-4819-119-7_Part_1-199310010-00007	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363170				2022-12-28	WOS:A1993MA29100007
J	KOVACS, RG; AGUAYO, SM				KOVACS, RG; AGUAYO, SM			SUPERIOR VENA-CAVA SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											KOVACS, RG (corresponding author), ATLANTA VET AFFAIRS MED CTR, DECATUR, GA 30033 USA.								0	3	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1007	1007						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366900				2022-12-28	WOS:A1993LY58700005
J	HOLDEN, C				HOLDEN, C			JOBS IN SOCIAL-SCIENCE .1. NEW LIFE AHEAD FOR SOCIAL-SCIENCES	SCIENCE			English	Article																			0	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1796	1798		10.1126/science.8378781	http://dx.doi.org/10.1126/science.8378781			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LY584	8378781				2022-12-28	WOS:A1993LY58400043
J	SILVENNOINEN, O; SCHINDLER, C; SCHLESSINGER, J; LEVY, DE				SILVENNOINEN, O; SCHINDLER, C; SCHLESSINGER, J; LEVY, DE			RAS-INDEPENDENT GROWTH-FACTOR SIGNALING BY TRANSCRIPTION FACTOR TYROSINE PHOSPHORYLATION	SCIENCE			English	Article							DNA-BINDING PROTEIN; C-FOS PROMOTER; INTERFERON-ALPHA; STIMULATED TRANSCRIPTION; KINASE-ACTIVITY; SH3 DOMAINS; ACTIVATION; RECEPTOR; CELLS; REQUIREMENT	Interferons induce transcriptional activation through tyrosine phosphorylation of the latent, cytoplasmic transcription factor interferon-stimulated gene factor-3 (ISGF-3). Growth factors and cytokines were found to use a similar pathway: The 91-kilodalton subunit of ISGF-3 was activated and tyrosine phosphorylated in response to epidermal growth factor (EGF), platelet-derived growth factor, and colony stimulating factor-1. The tyrosine phosphorylated factor acquired DNA binding activity and accumulated in nuclei. Activation required the major sites for autophosphorylation on the EGF receptor that bind Src homology region 2 domain-containing proteins implicated in Ras activation. However, activation of this factor was independent of the normal functioning of Ras.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN COMPREHENS CANC CTR,NEW YORK,NY 10016; NYU,SCH MED,DEPT PHARMACOL,NEW YORK,NY 10016; COLUMBIA UNIV COLL PHYS & SURG,NEW YORK,NY 10032	New York University; New York University; New York University; Columbia University			Levy, David/GPS-4945-2022; Levy, David/AAG-6202-2019	Levy, David/0000-0002-7320-7788	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-28900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOU CK, 1987, J BIOL CHEM, V262, P1842; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DECKER SJ, 1993, J BIOL CHEM, V268, P9176; DENHERTOG J, 1991, CELL GROWTH DIFFER, V2, P155; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI N, UNPUB; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; ROZAKISADCOCK M, 1993, NATURE, V363, P45; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SILVENNOINEN O, UNPUB; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STACEY DW, 1991, ONCOGENE, V6, P2297; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x	47	357	364	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1736	1739		10.1126/science.8378775	http://dx.doi.org/10.1126/science.8378775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378775				2022-12-28	WOS:A1993LY58400027
J	WATSON, JD				WATSON, JD			REFLECTIONS - SUCCEEDING IN SCIENCE - SOME RULES OF THUMB	SCIENCE			English	Editorial Material																			0	11	11	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 24	1993	261	5129					1812	1813		10.1126/science.8378784	http://dx.doi.org/10.1126/science.8378784			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY584	8378784				2022-12-28	WOS:A1993LY58400046
J	KLEBANOFF, MA; READ, JS; MILLS, JL; SHIONO, PH				KLEBANOFF, MA; READ, JS; MILLS, JL; SHIONO, PH			THE RISK OF CHILDHOOD-CANCER AFTER NEONATAL EXPOSURE TO VITAMIN-K	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Two recent studies have found that infants who received intramuscular vitamin K were at twice the expected risk tor cancer during childhood. Since nearly all newborns in the United States receive this drug, the public health implications ot this association, it confirmed, would be substantial. Methods. We examined the relation between vitamin K and cancer in a nested case-control study that used data from the Collaborative Perinatal Project, a multicenter, prospective study of pregnancy, delivery, and childhood. Among 54,795 children born from 1959 through 1966, 48 cases ot cancer were diagnosed after the first day ot lite and before the eighth birthday. Each case child was matched with five randomly selected controls whose last study visit occurred at or after the age when the case child's cancer was diagnosed. Exposure to vitamin K was determined from study forms and medical records. Results. Vitamin K had been administered to 68 percent of the 44 case children and 71 percent of the 226 controls for whom data were available (matched odds ratio, 0.84; 95 percent confidence interval, 0.41 to 1.71). The odds ratio was 0.47 (95 percent confidence interval, 0.14 to 1.55) for leukemia and 1.08 (95 percent confidence interval, 0.45 to 2.61) for other cancers. Sequential adjustment for potential confounding factors did not change the results substantially. Conclusions. We found no association between exposure to vitamin K and an increased risk of any childhood cancer or of all childhood cancers combined, although a slightly increased risk could not be ruled out. The benefits of neonatal vitamin K prophylaxis against hemorrhagic disease have been well described. Unless other evidence supporting an association between vitamin K and cancer appears, there is no reason to abandon the routine administration of vitamin K to newborns.	DAVID & LUCILE PACKARD FDN,CTR FUTURE CHILDREN,LOS ALTOS,CA		KLEBANOFF, MA (corresponding author), NICHHD,DIV EPIDEMIOL STAT & PREVENT RES,6100 BLDG,RM 7B03,BETHESDA,MD 20892, USA.			Mills, James/0000-0003-4496-332X				Berendes HW, 1966, RESEARCH METHODOLOGY, P118; CHAYEN J, 1992, BRIT MED J, V305, P710, DOI 10.1136/bmj.305.6855.710-c; DAVIS MK, 1988, LANCET, V2, P365; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; LABENZ PJ, 1980, EARLY CORRELATES SPE, P37; MILLER RW, 1992, BMJ-BRIT MED J, V305, P1016, DOI 10.1136/bmj.305.6860.1016-c; MISER JS, 1993, PRINCIPLES PRACTICE, P823; Myrianthopoulos NC; Collaborative Perinatal Project (U.S.), 1985, MALFORMATIONS CHILDR; NEGLIA JP, 1988, PEDIATR CLIN N AM, V35, P675; Poplack D.G, 1993, PRINCIPLES PRACTICE, V2nd, P3; SHIONO PH, 1980, JNCI-J NATL CANCER I, V65, P681, DOI 10.1093/jnci/65.4.681; 1985, SAS USERS GUIDE STAT, P529; 1961, PEDIATRICS, V28, P501; 1986, SUGI LIBRARYS USER S, P307; 1993, PHYICIANS DESK REFER; 1993, PEDIATRICS, V91, P1001	17	95	101	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					905	908		10.1056/NEJM199309233291301	http://dx.doi.org/10.1056/NEJM199309233291301			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361503				2022-12-28	WOS:A1993LX75100001
J	ROY, AL; MALIK, S; MEISTERERNST, M; ROEDER, RG				ROY, AL; MALIK, S; MEISTERERNST, M; ROEDER, RG			AN ALTERNATIVE PATHWAY FOR TRANSCRIPTION INITIATION INVOLVING TFII-I	NATURE			English	Article							RNA POLYMERASE-II; TATA-BINDING PROTEIN; GENE-TRANSCRIPTION; COMPLEX; ACTIVATION; PROMOTER	THE minimal promoter elements required for initiation by RNA polymerase II include the TATA box and/or an initiator element (Inr) at or near the transcription start site1-4. Studies of the adeno-virus major late core promoter (containing both elements) have demonstrated an initiation pathway that involves binding of the transcription factor TFIID (or the derived subunit, the TATA-binding protein TBP (TFIIDtau)) to the TATA element, which is facilitated by transcription factor TFIIA, followed by sequential interactions of other general factors4-8. Here we describe a novel pathway that requires an intact Inr and the Inr-binding factor TFII-I (ref. 3). Sequential addition of the general factors generated TFII-I-dependent preinitiation complexes different from those formed with TFIIA. Furthermore, TBP bound cooperatively (with only TFII-I) to an Inr-containing TATA-less promoter, suggesting a means for activation of TATA-less promoters, which nonetheless require TFIID (refs 9-11). These observations provide support for functionally distinct pathways which could be subject to differential regulation by specific activators or repressors.			ROY, AL (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.							BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P9999; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; GROSSCHEDL R, 1980, P NATL ACAD SCI-BIOL, V77, P1432, DOI 10.1073/pnas.77.3.1432; INOSTROZA JA, 1992, CELL, V70, P477; KILLEEN M, 1992, J BIOL CHEM, V267, P9463; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEITERERNST M, 1991, CELL, V67, P557; OLSEN HS, 1992, J VIROL, V66, P5594, DOI 10.1128/JVI.66.9.5594-5597.1992; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	20	151	153	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					355	359		10.1038/365355a0	http://dx.doi.org/10.1038/365355a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377828				2022-12-28	WOS:A1993LY49600057
J	FRANKS, P; NUTTING, PA; CLANCY, CM				FRANKS, P; NUTTING, PA; CLANCY, CM			HEALTH-CARE REFORM, PRIMARY-CARE, AND THE NEED FOR RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICARE PHYSICIAN EXPENDITURES; LOW-BACK-PAIN; FAMILY PHYSICIANS; RANDOMIZED TRIAL; AMBULATORY CARE; RESOURCE USE; QUALITY; SERVICES; COST; INTERNISTS	Health care reform proposals that seek to increase access for almost 40 million uninsured Americans will require an expansion of primary care. Simply expanding available primary care services is likely to be prohibitively expensive. Developing a rational and efficient strategy for the provision of primary care to all Americans will require understanding of the relationships among primary care and access, costs, and quality-relationships that are often obscured by the complexity of the US health care system. Those relationships are examined to identify some key areas of research needed to inform policy development and improve primary care services. Despite significant gaps in our knowledge, the evidence strongly suggests that restructuring and strengthening the role of primary care practitioners in the health care system will facilitate access to affordable, high-quality health care for all Americans.	AGCY HLTH CARE POLICY & RES, DIV PRIMARY CARE, ROCKVILLE, MD USA	Agency for Healthcare Research & Quality	FRANKS, P (corresponding author), UNIV ROCHESTER, DEPT FAMILY MED, 885 SOUTH AVE, ROCHESTER, NY 14620 USA.							AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; ALPERT JJ, 1976, PEDIATRICS, V57, P917; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; BERENSON R, 1992, JAMA-J AM MED ASSOC, V267, P687, DOI 10.1001/jama.267.5.687; BERNARD AM, 1990, MED CARE, V28, P170, DOI 10.1097/00005650-199002000-00007; BERNSTEIN AB, 1991, MED CARE, V29, P196; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BLUMENTHAL D, 1991, MED CARE, V29, P502, DOI 10.1097/00005650-199106000-00010; BROOK RH, 1990, MED CARE, V28, P392, DOI 10.1097/00005650-199005000-00002; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; CLARK RA, 1983, J AM ACAD DERMATOL, V9, P787, DOI 10.1016/S0190-9622(83)70193-3; CLEARY PD, 1988, INQUIRY, V25, P51; CORNELIUS L, 1991, PHS910042 AG HLTH CA; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; Crombie D L, 1988, Health Trends, V20, P53; DALEY J, 1988, HEALTH AFFAIR, V7, P107, DOI 10.1377/hlthaff.7.1.107; DAVIES AR, 1986, HEALTH SERV RES, V21, P429; DEYO RA, 1991, ANNU REV PUBL HEALTH, V12, P141, DOI 10.1146/annurev.pu.12.050191.001041; DEYO RA, 1987, ARCH INTERN MED, V147, P141, DOI 10.1001/archinte.147.1.141; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; DOR A, 1990, INQUIRY-J HEALTH CAR, V27, P307; Eddy D M, 1984, Health Aff (Millwood), V3, P74, DOI 10.1377/hlthaff.3.2.74; ENGEL W, 1989, MED CARE, V27, P306, DOI 10.1097/00005650-198903000-00009; Farmer F L, 1991, J Rural Health, V7, P153; FARMER FL, 1991, NEW ENGL J MED, V7, P153; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; FISHBANE M, 1981, NEW ENGL J MED, V305, P552, DOI 10.1056/NEJM198109033051004; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FRANKS P, 1987, J FAM PRACTICE, V24, P152; FRANKS P, 1986, MED CARE, V24, P941, DOI 10.1097/00005650-198610000-00007; GARG ML, 1979, SOC SCI MED-MED ECON, V13, P187, DOI 10.1016/0160-7995(79)90043-1; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAYWARD RA, 1991, AM J PUBLIC HEALTH, V81, P434, DOI 10.2105/AJPH.81.4.434; HURLEY RE, 1989, AM J PUBLIC HEALTH, V79, P843, DOI 10.2105/AJPH.79.7.843; KINDIG DA, 1987, INQUIRY-J HEALTH CAR, V24, P136; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; Levit K R, 1991, Health Care Financ Rev, V13, P29; LOHR KN, 1992, MED CARE, V30, pMS1, DOI 10.1097/00005650-199205001-00001; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MANU P, 1983, SOC SCI MED, V17, P1339, DOI 10.1016/0277-9536(83)90193-4; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; MCLAUGHLIN FJ, 1992, PEDIATRICS, V89, P128; MURRAY JP, 1992, MED CARE, V30, P252, DOI 10.1097/00005650-199203000-00007; NOBLE J, 1987, NTIS HRP0907161 HLTH; NOREN J, 1980, NEW ENGL J MED, V302, P11, DOI 10.1056/NEJM198001033020103; NUTTING PA, 1992, J FAM PRACTICE, V35, P21; OHSFELDT RL, 1985, MED CARE, V23, P1338, DOI 10.1097/00005650-198512000-00003; ORNSTEIN SM, 1988, MED CARE, V26, P536, DOI 10.1097/00005650-198806000-00002; ROBACK G, 1991, PHYSICIAN CHARACTERI; Roos N P, 1979, Inquiry, V16, P73; ROSENBLATT RA, 1983, NEW ENGL J MED, V309, P892, DOI 10.1056/NEJM198310133091505; ROSSITER LF, 1989, JAMA-J AM MED ASSOC, V262, P57, DOI 10.1001/jama.262.1.57; SAFRIET BJ, 1992, YALE J REGUL, V9, P149; Schappert SM, 1992, ADV DATA VITAL HLTH, V213; SCHNEEWEISS R, 1989, JAMA-J AM MED ASSOC, V262, P370; SCHROTH WS, 1992, J GEN INTERN MED, V7, P486, DOI 10.1007/BF02599449; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SHEAR CL, 1983, MED CARE, V21, P1204, DOI 10.1097/00005650-198312000-00007; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; SPIEGEL JS, 1983, NEW ENGL J MED, V308, P1208, DOI 10.1056/NEJM198305193082007; Starfield B., 1992, PRIMARY CARE CONCEPT; STRAUSS MJ, 1986, MED CARE, V24, P915, DOI 10.1097/00005650-198610000-00005; WARE JE, 1986, LANCET, V1, P1017; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; WEINER JP, 1983, AM J PUBLIC HEALTH, V73, P666, DOI 10.2105/AJPH.73.6.666; ZEIGER RS, 1991, J ALLERGY CLIN IMMUN, V87, P1160, DOI 10.1016/0091-6749(91)92162-T; 1978, IOM PUBLICATION, V7802; 1986, OTAHCS37 US C OFF TE	72	61	61	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1449	1453		10.1001/jama.270.12.1449	http://dx.doi.org/10.1001/jama.270.12.1449			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371445				2022-12-28	WOS:A1993LX17300029
J	ZHU, TF; MO, HM; WANG, N; NAM, DS; CAO, YZ; KOUP, RA; HO, DD				ZHU, TF; MO, HM; WANG, N; NAM, DS; CAO, YZ; KOUP, RA; HO, DD			GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF HIV-1 IN PATIENTS WITH PRIMARY INFECTION	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL TROPISM; SOLUBLE CD4; GP120; TRANSMISSION; DEFINITION; MACROPHAGE; VARIANTS; DISEASE; REGIONS	Better characterization of human immunodeficiency virus-type 1 (HIV-1) in patients with primary infection has important implications for the development of an acquired immunodeficiency syndrome (AIDS) vaccine because vaccine strategies should target viral isolates with the properties of transmitted viruses. In five HIV-1 seroconverters, the viral phenotype was found to be uniformly macrophage-tropic and non-syncytium-inducing. Furthermore, the viruses were genotypically homogeneous within each patient, but a common signature sequence was not discernible among transmitted viruses. In the two cases where the sexual partners were also studied, the sequences of the transmitted viruses matched best with minor variants in the blood of the transmitters. There was also a stronger pressure to conserve sequences in gp120 than in gp41, nef, and p17, suggesting that a selective mechanism is involved in transmission.	NYU,SCH MED,AARON DIAMOND AIDS RES CTR,455 1ST AVE,NEW YORK,NY 10016	New York University			Zhu, Tuofu/G-6158-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027742, R01AI025541, R01AI024030] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24030, AI25541, AI27742] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CHESEBRO B, 1992, J VIROL, V66, P6547, DOI 10.1128/JVI.66.11.6547-6554.1992; CICHUTEK K, 1992, P NATL ACAD SCI USA, V89, P7365, DOI 10.1073/pnas.89.16.7365; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COOPER DA, 1985, LANCET, V1, P537; DAAR ES, 1990, P NATL ACAD SCI USA, V87, P6574, DOI 10.1073/pnas.87.17.6574; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; HO DD, 1985, ANN INTERN MED, V103, P880, DOI 10.7326/0003-4819-103-6-880; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; KOUP RA, UNPUB; MCNEARNEY T, 1992, P NATL ACAD SCI USA, V89, P10247, DOI 10.1073/pnas.89.21.10247; MEYERHANS A, 1989, CELL, V58, P901, DOI 10.1016/0092-8674(89)90942-2; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; OBRIEN WA, 1990, NATURE, V348, P69, DOI 10.1038/348069a0; PANG S, 1992, AIDS, V6, P453, DOI 10.1097/00002030-199205000-00003; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; ROOS MTL, 1992, J INFECT DIS, V165, P427, DOI 10.1093/infdis/165.3.427; SAAG MS, 1988, NATURE, V334, P440, DOI 10.1038/334440a0; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHIODA T, 1991, NATURE, V349, P167, DOI 10.1038/349167a0; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU T, UNPUB	28	1110	1144	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 27	1993	261	5125					1179	1181		10.1126/science.8356453	http://dx.doi.org/10.1126/science.8356453			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LU586	8356453				2022-12-28	WOS:A1993LU58600035
J	STEIN, CA; CHENG, YC				STEIN, CA; CHENG, YC			ANTISENSE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS - IS THE BULLET REALLY MAGICAL	SCIENCE			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; CHRONICALLY INFECTED-CELLS; FIBROBLAST GROWTH-FACTOR; SOLID-PHASE SYNTHESIS; RAS P21 EXPRESSION; MYC MESSENGER-RNA; NF-KAPPA-B; GENE-EXPRESSION; PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES; CELLULAR UPTAKE	Because of the specificity of Watson-Crick base pairing, attempts are now being made to use oligodeoxynucleotides (oligos) in the therapy of human disease. However, for a successful outcome, the oligo must meet at least six criteria: (i) the oligos can be synthesized easily and in bulk; (ii) the oligos must be stable in vivo; (iii) the oligos must be able to enter the target cell; (iv) the oligos must be retained by the target cell; (v) the oligos must be able to interact with their cellular targets; and (vi) the oligos should not interact in a non-sequence-specific manner with other macromolecules. Phosphorothioate oligos are examples of oligos that are being considered for clinical therapeutic trials and meet some, but not all, of these criteria. The potential use of phosphorothioate oligos as inhibitors of viral replication is highlighted.	YALE UNIV, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Yale University	STEIN, CA (corresponding author), COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA.				NCI NIH HHS [CA 44538] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; AGRAWAL S, 1989, P NATL ACAD SCI USA, V86, P7790, DOI 10.1073/pnas.86.20.7790; AGRAWAL S, 1988, P NATL ACAD SCI USA, V85, P7079, DOI 10.1073/pnas.85.19.7079; AGRAWAL S, COMMUNICATION; AO A, 1991, ANTISENSE RES DEV, V1, P1; ARSURA M, 1992, BLOOD, V79, P2708; BABA M, 1988, ANTIVIR RES, V9, P335, DOI 10.1016/0166-3542(88)90035-6; BACON TA, 1991, ONCOGENE RES, V6, P13; BAVISOTTO L, 1991, J EXP MED, V174, P1097, DOI 10.1084/jem.174.5.1097; Bayever E, 1992, Antisense Res Dev, V2, P109; BEAUCAGE S, 1981, TETRAHEDRON LETT, V37, P3557; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; BENNETT RM, 1985, J CLIN INVEST, V76, P2182, DOI 10.1172/JCI112226; BIRCHENALLROBERTS MC, 1990, J IMMUNOL, V145, P3290; BLOCK A, 1991, PROSPECTS ANTISENSE, P63; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BOUTORIN AS, 1989, FEBS LETT, V254, P129, DOI 10.1016/0014-5793(89)81023-3; BRUNETTI A, 1990, J BIOL CHEM, V265, P13435; BRYANT FR, 1979, BIOCHEMISTRY-US, V18, P2825, DOI 10.1021/bi00580a022; Budker V G, 1992, Antisense Res Dev, V2, P177; CACERES A, 1991, J NEUROSCI, V11, P1515; CAZENAVE C, 1989, NUCLEIC ACIDS RES, V17, P4255, DOI 10.1093/nar/17.11.4255; CHANG EH, 1991, BIOCHEMISTRY-US, V30, P8283, DOI 10.1021/bi00098a001; CHENG YC, 1991, NUCLEOS NUCLEOT, V10, P155, DOI 10.1080/07328319108046443; CHIANG MY, 1991, J BIOL CHEM, V266, P18162; CHIN D J, 1990, New Biologist, V2, P1091; CITRO G, 1992, P NATL ACAD SCI USA, V89, P7031, DOI 10.1073/pnas.89.15.7031; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; Cook J L, 1992, Antisense Res Dev, V2, P199; COONEY M, 1988, SCIENCE, V241, P456, DOI 10.1126/science.3293213; COPE FO, 1989, P NATL ACAD SCI USA, V86, P5590, DOI 10.1073/pnas.86.14.5590; COPE FO, 1991, PROSPECTS ANTISENSE, P125; COSSTICK R, 1985, BIOCHEMISTRY-US, V24, P3630, DOI 10.1021/bi00335a035; CROOKE RM, 1991, ANTI-CANCER DRUG DES, V6, P609; CROOKE ST, 1992, ANNU REV PHARMACOL, V32, P329; DAAKA Y, 1990, ONCOGENE RES, V5, P267; DASH P, 1987, P NATL ACAD SCI USA, V84, P7896, DOI 10.1073/pnas.84.22.7896; DESMIDT PC, 1991, NUCLEIC ACIDS RES, V19, P4695, DOI 10.1093/nar/19.17.4695; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Eder P S, 1991, Antisense Res Dev, V1, P141; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; FERRARI S, 1992, ANN NY ACAD SCI, V660, P11, DOI 10.1111/j.1749-6632.1992.tb21053.x; FIELDS AP, 1988, NATURE, V333, P278, DOI 10.1038/333278a0; FROEHLER BC, 1986, NUCLEIC ACIDS RES, V14, P5399, DOI 10.1093/nar/14.13.5399; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; GAO W, 1989, J BIOL CHEM, V264, P11521; GAO W, UNPUB; GAO WY, 1990, J BIOL CHEM, V265, P20172; GAO WY, 1992, MOL PHARMACOL, V41, P223; GAO WY, 1993, MOL PHARMACOL, V43, P45; GAO WY, 1990, ANTIMICROB AGENTS CH, V34, P808, DOI 10.1128/AAC.34.5.808; GHOSH MK, 1992, PROG NUCLEIC ACID RE, V42, P79, DOI 10.1016/S0079-6603(08)60574-7; GOODARZI G, 1991, BIOCHEM BIOPH RES CO, V181, P1343, DOI 10.1016/0006-291X(91)92086-Y; GOODCHILD J, 1989, OLIGODEOXYNUCLEOTIDE, V12, P53; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; HATZFELD J, 1991, J EXP MED, V174, P925, DOI 10.1084/jem.174.4.925; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; HERMINE O, 1991, BLOOD, V78, P2253; Ho P T, 1991, Antisense Res Dev, V1, P329; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; IVERSEN P, 1991, ANTI-CANCER DRUG DES, V6, P531; Iversen P L, 1992, Antisense Res Dev, V2, P211; IVERSON P, UNPUB; IYER RP, 1990, J AM CHEM SOC, V112, P1253, DOI 10.1021/ja00159a059; KANBE M, 1992, ANTI-CANCER DRUG DES, V7, P341; KINCHINGTON D, 1992, ANTIVIR RES, V17, P53, DOI 10.1016/0166-3542(92)90090-R; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; Krieg A M, 1991, Antisense Res Dev, V1, P161; KRIEG AM, 1993, P NATL ACAD SCI USA, V90, P1048, DOI 10.1073/pnas.90.3.1048; KRIEG AM, 1992, IMMUNOMETHODS, V1, P191; KRONMILLER JE, 1991, DEV BIOL, V147, P485, DOI 10.1016/0012-1606(91)90307-O; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LAPLANCHE LA, 1986, NUCLEIC ACIDS RES, V14, P9081, DOI 10.1093/nar/14.22.9081; LATIMER LJP, 1989, NUCLEIC ACIDS RES, V17, P1549, DOI 10.1093/nar/17.4.1549; LEDERMAN S, 1989, J IMMUNOL, V143, P1149; LEITER JME, 1990, P NATL ACAD SCI USA, V87, P3430, DOI 10.1073/pnas.87.9.3430; Leonetti JP, 1990, BIOCONJUGATE CHEM, V1, P149, DOI 10.1021/bc00002a010; LETSINGER RL, 1989, P NATL ACAD SCI USA, V86, P6553, DOI 10.1073/pnas.86.17.6553; LIMA WF, 1992, BIOCHEMISTRY-US, V31, P12055, DOI 10.1021/bi00163a013; LISTERUD M, 1991, SCIENCE, V254, P1518, DOI 10.1126/science.1720573; LISZIEWICZ J, 1993, P NATL ACAD SCI USA, V90, P3860, DOI 10.1073/pnas.90.9.3860; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MAJUMDAR C, 1989, BIOCHEMISTRY-US, V28, P1340, DOI 10.1021/bi00429a060; MANSON J, 1990, LYMPHOKINE RES, V9, P35; Marti G, 1992, Antisense Res Dev, V2, P27; MATSUKURA M, 1989, P NATL ACAD SCI USA, V86, P4244, DOI 10.1073/pnas.86.11.4244; MATSUKURA M, 1987, P NATL ACAD SCI USA, V84, P7706, DOI 10.1073/pnas.84.21.7706; MATSUKURA M, 1991, PROSPECTS ANTISENSE, P159; MILLER PS, 1991, BIO-TECHNOL, V9, P358, DOI 10.1038/nbt0491-358; MILLER PS, 1987, ANTI-CANCER DRUG DES, V2, P117; MORI K, 1989, NUCLEIC ACIDS RES, V17, P8207, DOI 10.1093/nar/17.20.8207; MORRISON RS, 1991, J BIOL CHEM, V266, P728; NARAYANAN R, 1992, ONCOGENE, V7, P553; NEYSES L, 1991, BIOCHEM BIOPH RES CO, V181, P22, DOI 10.1016/S0006-291X(05)81376-2; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; PEPPERKOK R, 1991, EXP CELL RES, V197, P245, DOI 10.1016/0014-4827(91)90429-X; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; POSTEL EH, 1991, P NATL ACAD SCI USA, V88, P8227, DOI 10.1073/pnas.88.18.8227; POTTER BVL, 1983, J BIOL CHEM, V258, P1758; POTTS JD, 1991, P NATL ACAD SCI USA, V88, P1516, DOI 10.1073/pnas.88.4.1516; RATAJCZAK MZ, 1992, P NATL ACAD SCI USA, V89, P11823, DOI 10.1073/pnas.89.24.11823; Reynolds T, 1992, J Natl Cancer Inst, V84, P288, DOI 10.1093/jnci/84.5.288; RITTNER K, 1993, NUCLEIC ACIDS RES, V21, P1381, DOI 10.1093/nar/21.6.1381; RIVOLTINI L, 1990, INT J CANCER, V46, P727, DOI 10.1002/ijc.2910460429; SAISONBEHMOARAS T, 1991, EMBO J, V10, P1111, DOI 10.1002/j.1460-2075.1991.tb08051.x; SARIOLA H, 1991, SCIENCE, V254, P571, DOI 10.1126/science.1658930; Saxon M, 1992, Antisense Res Dev, V2, P243; SCHOLS D, 1989, P NATL ACAD SCI USA, V86, P3322, DOI 10.1073/pnas.86.9.3322; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SHOEMAKER MO, 1990, J CELL BIOL, V111, P1107, DOI 10.1083/jcb.111.3.1107; SHOJI Y, 1991, NUCLEIC ACIDS RES, V19, P5543, DOI 10.1093/nar/19.20.5543; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SKORSKI T, 1992, J EXP MED, V175, P743, DOI 10.1084/jem.175.3.743; SODROSKI J, 1986, NATURE, V321, P412, DOI 10.1038/321412a0; SORSCHER EJ, 1991, P NATL ACAD SCI USA, V88, P7759, DOI 10.1073/pnas.88.17.7759; STEC WJ, 1984, J AM CHEM SOC, V106, P6077, DOI 10.1021/ja00332a054; STEC WJ, 1991, NUCLEIC ACIDS RES, V19, P5883, DOI 10.1093/nar/19.21.5883; Stein C A, 1993, Antisense Res Dev, V3, P19; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; STEIN CA, 1990, ANAL BIOCHEM, V188, P11; STEIN CA, 1993, BIOCHEMISTRY-US, V32, P4855, DOI 10.1021/bi00069a022; STEIN CA, 1988, GENE, V72, P333, DOI 10.1016/0378-1119(88)90160-6; STEIN CA, 1988, CANCER RES, V48, P2659; STEIN CA, 1991, J ACQ IMMUN DEF SYND, V4, P686; STEIN CA, 1991, BIOCHEMISTRY-US, V30, P2439, DOI 10.1021/bi00223a020; STEIN CA, 1991, PHARMACOL THERAPEUT, V52, P365, DOI 10.1016/0163-7258(91)90032-H; STEIN CA, UNPUB; TANAKA T, 1992, J EXP MED, V175, P597, DOI 10.1084/jem.175.2.597; TEICHMANWEINBERG A, 1988, GENE, V72, P297, DOI 10.1016/0378-1119(88)90155-2; THINAKARAN G, 1991, EXP CELL RES, V192, P227, DOI 10.1016/0014-4827(91)90180-3; TOULME JJ, 1988, GENE, V72, P51, DOI 10.1016/0378-1119(88)90127-8; VICKERS T, 1991, NUCLEIC ACIDS RES, V19, P3359, DOI 10.1093/nar/19.12.3359; VU H, 1991, TETRAHEDRON LETT, V32, P3005, DOI 10.1016/0040-4039(91)80672-S; WALDER RY, 1988, P NATL ACAD SCI USA, V85, P5011, DOI 10.1073/pnas.85.14.5011; WEAVER JL, 1992, ANTIVIR CHEM CHEMOTH, V3, P147, DOI 10.1177/095632029200300303; WEIGENT DA, 1991, ENDOCRINOLOGY, V128, P2053, DOI 10.1210/endo-128-4-2053; WEST AP, 1991, MOL CELL ENDOCRINOL, V79, pR9, DOI 10.1016/0303-7207(91)90111-5; WICKSTROM E, 1992, CANCER RES, V52, P6741; WITSELL AL, 1992, P NATL ACAD SCI USA, V89, P4754, DOI 10.1073/pnas.89.10.4754; WOOLF TM, 1992, P NATL ACAD SCI USA, V89, P7305, DOI 10.1073/pnas.89.16.7305; WU J, 1990, ONCOGENE, V5, P873; YAKUBOV L, IN PRESS BIOKHIMIYA; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; Yaswen P, 1993, Antisense Res Dev, V3, P67; Yeoman L C, 1992, Antisense Res Dev, V2, P51; Zhou J.-S., UNPUB; ZON G, 1991, ANTI-CANCER DRUG DES, V6, P539	150	1322	1711	4	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 20	1993	261	5124					1004	1012		10.1126/science.8351515	http://dx.doi.org/10.1126/science.8351515			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351515				2022-12-28	WOS:A1993LT74700022
J	SHELDON, TA; SMITH, GD; BEVAN, G				SHELDON, TA; SMITH, GD; BEVAN, G			WEIGHTING IN THE DARK - RESOURCE-ALLOCATION IN THE NEW NHS	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL-CARE; JARMAN INDEX; HEALTH-CARE; DEPRIVATION; MORBIDITY; RAWP	National allocation of resources to regional health authorities and by them to districts is now determined by a weighted capitation formula. The national formula was derived from regression analysis, with hospital utilisation as an index of need for health care-a method which has fundamental limitations. This paper argues that the search for an empirically based resource allocation formula of high precision in the name of promotion of equity is largely fruitless given the impossibility of measuring the true need for, and costs of, providing health care, especially with the limited data available. The inclusion of measures of social deprivation is also poorly thought out. The availability of data from the 1991 census, which included a question regarding long-standing illness, together with the intention of the Department of Health to review the weighted capitation formula using this information may stimulate much work but little light. It is essential that the impact of resource allocation formulas is justifiable on grounds other than the composition of any particular formula.	UNIV GLASGOW,DEPT PUBL HLTH,GLASGOW G12 8QQ,SCOTLAND; LONDON ECON,LONDON W1M 7SS,ENGLAND	University of Glasgow	SHELDON, TA (corresponding author), UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND.		Davey Smith, George/A-7407-2013; Sheldon, Trevor/AAK-7088-2021	Davey Smith, George/0000-0002-1407-8314; Sheldon, Trevor/0000-0002-7479-5913				BALARAJAN R, 1987, J EPIDEMIOL COMMUN H, V41, P196, DOI 10.1136/jech.41.3.196; BALARAJAN R, 1990, SOCIAL DEPRIVATION A; BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; BLANE D, 1990, BRIT MED J, V301, P429, DOI 10.1136/bmj.301.6749.429; CAMPBELL DA, 1991, BMJ-BRIT MED J, V303, P750, DOI 10.1136/bmj.303.6805.750; CARRHILL R, 1992, J PUBLIC HEALTH MED, V14, P117; CARRHILL RA, 1990, J EPIDEMIOL COMMUN H, V44, P271, DOI 10.1136/jech.44.4.271; CARRHILL RA, IN PRESS DEPRIVATION; CARSTAIRS V, 1989, COMMUNITY MED, V11, P364; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; FRANKEL S, 1991, J EPIDEMIOL COMMUN H, V45, P257, DOI 10.1136/jech.45.4.257; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; Gallie W.B., 1955, P ARISTOTELIAN SOC, V56, P167; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; HUTCHINSON A, 1989, BRIT MED J, V299, P1142, DOI 10.1136/bmj.299.6708.1142; JARMAN B, 1990, PAPERS SCI TECHNOLOG, V22; JESSOP EG, 1992, J EPIDEMIOL COMMUN H, V46, P543, DOI 10.1136/jech.46.5.543; KNOX EG, 1978, J EPIDEMIOL COMMUN H, V32, P3, DOI 10.1136/jech.32.1.3; LECK I, 1989, COMMUNITY MED, V11, P102; Long A F, 1992, Qual Health Care, V1, P74, DOI 10.1136/qshc.1.1.74; Lubitz J, 1984, Health Care Financ Rev, V5, P117; MAYS N, 1989, COMMUNITY MED, V11, P173; MAYS N, 1987, OCCASIONAL PAPERS SO, V81; MOORE W, 1992, HLTH SERVICE J, V102, P6; MORGAN M, 1987, J EPIDEMIOL COMMUN H, V41, P269, DOI 10.1136/jech.41.4.269; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; Palmer S, 1979, Community Med, V1, P275, DOI 10.1007/BF02549239; ROYSTON GHD, 1992, SOCIO ECON PLAN SCI, V26, P169, DOI 10.1016/0038-0121(92)90008-S; SHELDON TA, 1992, J ROY STAT SOC A STA, V155, P403, DOI 10.2307/2982891; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; TOWNSEND P, 1990, DEPRIVATION ILL HLTH; VICTOR CR, 1992, BRIT MED J, V305, P387, DOI 10.1136/bmj.305.6850.387; WATT I, 1993, IN PRESS BMJ; 1976, SHARING RESOURCES HL; 1989, 2 DEP HLTH WORK PAP; 1992, WEIGHTED CAPITATION; 1988, INTEGRATED ANAL REV; 1988, REV RESOURCE ALLOCAT	39	36	37	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 27	1993	306	6881					835	839		10.1136/bmj.306.6881.835	http://dx.doi.org/10.1136/bmj.306.6881.835			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KV348	8357370	Bronze, Green Published			2022-12-28	WOS:A1993KV34800024
J	SABATE, J; FRASER, GE; BURKE, K; KNUTSEN, SF; BENNETT, H; LINDSTED, KD				SABATE, J; FRASER, GE; BURKE, K; KNUTSEN, SF; BENNETT, H; LINDSTED, KD			EFFECTS OF WALNUTS ON SERUM-LIPID LEVELS AND BLOOD-PRESSURE IN NORMAL MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; LINOLEIC-ACID; FATTY-ACIDS; DIETARY FATS	Background. In a recent six-year follow-up study, we found that frequent consumption of nuts was associated with a reduced risk of ischemic heart disease. To explore possible explanations for this finding, we studied the effects of nut consumption on serum lipids and blood pressure. Methods. We randomly placed 18 healthy men on two mixed natural diets, each diet to be followed for four weeks. Both diets conformed to the National Cholesterol Education Program Step 1 diet and contained identical foods and macronutrients, except that 20 percent of the calories of one diet (the walnut diet) were derived from walnuts (offset by lesser amounts of fatty foods, meat, and visible fat [oils, margarine, and butter]). Results. With the reference diet, the mean (+/-SD) serum values for total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol were, respectively, 182+/-23, 112+/-16, and 47+/-11 mg per deciliter (4.71+/-0.59, 2.90+/-0.41, and 1.22+/-0.28 mmol per liter). With the walnut diet, the mean total cholesterol level was 22.4 mg per deciliter (0.58 mmol per liter) lower than the mean level with the reference diet (95 percent confidence interval, 28 to 17 mg per deciliter [0.72 to 0.44 mmol per liter]); the LDL and HDL cholesterol levels were, respectively, 18.2 mg per deciliter (0.47 mmol per liter) (P<0.001) and 2.3 mg per deciliter (0.06 mmol per liter) (P = 0.01) lower. These lower values represented reductions of 12.4, 16.3, and 4.9 percent in the levels of total, LDL, and HDL cholesterol, respectively. The ratio of LDL cholesterol to HDL cholesterol was also lowered (P<0.001) by the walnut diet. Mean blood-pressure values did not change during either dietary period. Conclusions. Incorporating moderate quantities of walnuts into the recommended cholesterol-lowering diet while maintaining the intake of total dietary fat and calories decreases serum levels of total cholesterol and favorably modifies the lipoprotein profile in normal men. The long-term effects of walnut consumption and the extension of this finding to other population groups deserve further study.	LOMA LINDA UNIV,SCH ALLIED HLTH PROFESS,DEPT NUTR & DIETET,LOMA LINDA,CA 92350; LOMA LINDA UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,LOMA LINDA,CA 92350; LOMA LINDA UNIV,SCH PUBL HLTH,DEPT NUTR,LOMA LINDA,CA 92350	Loma Linda University; Loma Linda University; Loma Linda University	SABATE, J (corresponding author), LOMA LINDA UNIV,SCH PUBL HLTH,CTR HLTH RES,NICHOL HALL,RM 2016,LOMA LINDA,CA 92350, USA.			Sabate, Joan/0000-0002-9063-9785				AHRENS EH, 1957, LANCET, V1, P943; ALLAIN CC, 1974, CLIN CHEM, V20, P470; [Anonymous], 1987, OFFICIAL METHODS ANA; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CHAN JK, 1991, AM J CLIN NUTR, V53, P1230, DOI 10.1093/ajcn/53.5.1230; Fleiss J.L., 1986, DESIGN ANAL CLIN EXP; FRASER G, 1986, PREVENTIVE CARDIOLOG; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; FRASER GE, 1992, ARCH INTERN MED, V152, P2507, DOI 10.1001/archinte.1992.00400240119026; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GLATZ JFC, 1989, AM J CLIN NUTR, V49, P269, DOI 10.1093/ajcn/49.2.269; HEPBURN FN, 1986, J AM DIET ASSOC, V86, P788; HOPKINS GJ, 1981, J NATL CANCER I, V66, P517; KESTIN M, 1990, AM J CLIN NUTR, V51, P1028, DOI 10.1093/ajcn/51.6.1028; KEYS A, 1965, METABOLIS, V14, P747, DOI 10.1016/0026-0495(65)90001-6; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1965, METABOLIS, V14, P759, DOI 10.1016/0026-0495(65)90002-8; KEYS A, 1957, LANCET, V2, P959; KEYS A, 1965, METABOLIS, V14, P766, DOI 10.1016/0026-0495(65)90003-X; KRITCHEVSKY D, 1982, ATHEROSCLEROSIS, V41, P429, DOI 10.1016/0021-9150(82)90208-8; KRITCHEVSKY D, 1988, ARCH PATHOL LAB MED, V112, P1041; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P15; OSTER P, 1980, PROG FOOD NUTR SCI, V4, P39; SACKS FM, 1989, NUTR REV, V47, P291, DOI 10.1111/j.1753-4887.1989.tb02753.x; SALONEN JT, 1988, AM J CLIN NUTR, V48, P1226, DOI 10.1093/ajcn/48.5.1226; SPILLER GA, 1992, J AM COLL NUTR, V11, P126; SPILLER GA, 1991, AM J CLIN NUTR, V54, P615, DOI 10.1093/ajcn/54.4.615; WARNICK GR, 1985, CLIN CHEM, V31, P217; WEINER MA, 1986, NEW ENGL J MED, V315, P883; 1988, ARCH INTERN MED, V148, P36; 1984, DEP AGR AGR HDB, V812; 1980, NIH801527 PUBL, V1; 1990, TFS254 DEPT AGR; 1983, CLIN TRIALS PRACTICA, P80	34	292	312	2	25	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 4	1993	328	9					603	607		10.1056/NEJM199303043280902	http://dx.doi.org/10.1056/NEJM199303043280902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP680	8357360				2022-12-28	WOS:A1993KP68000002
J	PISUNYER, FX				PISUNYER, FX			SHORT-TERM MEDICAL BENEFITS AND ADVERSE-EFFECTS OF WEIGHT-LOSS	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-CALORIE DIET; OVERWEIGHT HYPERTENSIVE PATIENTS; OBESITY-HYPOVENTILATION-SYNDROME; RANDOMIZED CONTROLLED TRIAL; HIGH-DENSITY LIPOPROTEIN; ONSET DIABETES-MELLITUS; OBSTRUCTIVE SLEEP-APNEA; CORONARY HEART-DISEASE; SPARING MODIFIED FAST; BLOOD-PRESSURE	Weight loss reduces many of the health hazards associated with obesity including insulin resistance, diabetes mellitus, hypertension, dyslipidemia, sleep apnea, hypoxemia and hypercarbia, and osteoarthritis. Potential adverse effects of weight loss include a greater risk for gallstone formation and cholecystitis, excessive loss of lean body mass, water and electrolyte problems, mild liver dysfunction, and elevated uric acid levels. Less consequential problems such as diarrhea, constipation, hair loss, and cold intolerance may also occur. The short-term adverse effects are not severe enough to contraindicate weight loss, nor do they outweigh its short-term benefits.			PISUNYER, FX (corresponding author), ST LUKES ROOSEVELT HOSP, OBES RES CTR, 111 AMSTERDAM AVE, NEW YORK, NY 10025 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R55DK035911, R01DK040414, P30DK026687] Funding Source: NIH RePORTER; NIDDK NIH HHS [R55-DK35911, DK40414, P30-DK26687] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBU J, 1992, METABOLISM, V41, P1068, DOI 10.1016/0026-0495(92)90287-K; ALEXANDER JK, 1962, AM J MED, V32, P512, DOI 10.1016/0002-9343(62)90052-9; AMATRUDA JM, 1988, ARCH INTERN MED, V148, P873, DOI 10.1001/archinte.148.4.873; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; ANDERSON JW, 1992, AM J GASTROENTEROL, V87, P6; ANDERSON JW, 1990, INT J OBESITY S2, V14, P67; [Anonymous], 1984, ARCH INTERN MED, V144, P1045; ATKINSON RL, 1985, J AM COLL NUTR, V4, P411, DOI 10.1080/07315724.1985.10720084; ATKINSON RL, 1992, TREATMENT SERIOUSLY, P273; BARRETTCONNOR EL, 1985, ANN INTERN MED, V103, P1010, DOI 10.7326/0003-4819-103-6-1010; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BICKELMANN A G, 1956, Am J Med, V21, P811; BISTRIAN BR, 1976, DIABETES, V25, P494, DOI 10.2337/diabetes.25.6.494; BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; BOGARDUS C, 1984, J CLIN INVEST, V73, P800, DOI 10.1172/JCI111274; BOGARDUS C, 1984, DIABETES, V33, P311, DOI 10.2337/diabetes.33.4.311; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; BROWNELL KD, 1982, CIRCULATION, V65, P477, DOI 10.1161/01.CIR.65.3.477; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DEYO RA, 1989, SPINE, V14, P501, DOI 10.1097/00007632-198905000-00005; DOAR JWH, 1975, LANCET, V1, P1263, DOI 10.1016/S0140-6736(75)92550-7; ECKEL RH, 1987, J CLIN INVEST, V80, P992, DOI 10.1172/JCI113193; ELAHI D, 1982, NEW ENGL J MED, V306, P1196, DOI 10.1056/NEJM198205203062002; ELIAHOU HE, 1981, INT J OBESITY, V5, P157; FISHER A, 1975, ANAESTHESIA, V30, P633, DOI 10.1111/j.1365-2044.1975.tb00924.x; FITZ JD, 1983, DIABETES CARE, V6, P328, DOI 10.2337/diacare.6.4.328; FRIIS R, 1987, J CLIN GASTROENTEROL, V9, P204, DOI 10.1097/00004836-198704000-00019; GARAY SM, 1981, AM REV RESPIR DIS, V124, P451; GELFAND RA, 1989, DIABETES METAB REV, V5, P17, DOI 10.1002/dmr.5610050103; GENUTH SM, 1974, JAMA-J AM MED ASSOC, V230, P987, DOI 10.1001/jama.230.7.987; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HADDEN DR, 1975, BMJ-BRIT MED J, V3, P276, DOI 10.1136/bmj.3.5978.276; HENRY RR, 1986, DIABETES, V35, P155, DOI 10.2337/diabetes.35.2.155; HEYMSFIELD SB, 1992, TREATMENT SERIOUSLY, P136; HUGHES TA, 1984, AM J MED, V77, P7, DOI 10.1016/0002-9343(84)90429-7; ISNER JM, 1979, CIRCULATION, V60, P1401, DOI 10.1161/01.CIR.60.6.1401; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KIRSCHNER MA, 1988, INT J OBESITY, V12, P69; KOPELMAN PG, 1986, INT J OBESITY, V10, P211; Kopelman PG., 1992, OBESITY, P568; LICATA AA, 1981, AM J MED, V71, P767, DOI 10.1016/0002-9343(81)90362-4; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MACMAHON SW, 1986, NEW ENGL J MED, V314, P334, DOI 10.1056/NEJM198602063140602; MACMAHON SW, 1985, CLIN EXP PHARMACOL P, V12, P267, DOI 10.1111/j.1440-1681.1985.tb02645.x; MANCINI M, 1981, INT J OBESITY, V5, P341; MARZIO L, 1988, DIGEST DIS SCI, V33, P4, DOI 10.1007/BF01536623; MAXWELL MH, 1984, ARCH INTERN MED, V144, P1581, DOI 10.1001/archinte.144.8.1581; MESSERLI FH, 1986, NEW ENGL J MED, V314, P378, DOI 10.1056/NEJM198602063140608; MILLER NE, 1977, LANCET, V1, P965, DOI 10.1016/S0140-6736(77)92274-7; MONTOYE HJ, 1966, AM J CLIN NUTR, V18, P397, DOI 10.1093/ajcn/18.6.397; NUNEZ C, 1992, FASEB J, V6, pA1674; OLEFSKY JM, 1982, AM J PHYSIOL, V243, pE15, DOI 10.1152/ajpendo.1982.243.1.E15; PALGI A, 1985, AM J PUBLIC HEALTH, V75, P1190, DOI 10.2105/AJPH.75.10.1190; PASULKA PS, 1986, ANN INTERN MED, V104, P540, DOI 10.7326/0003-4819-104-4-540; PISUNYER FX, 1992, AM J CLIN NUTR, V56, P240, DOI 10.1093/ajcn/56.1.240S; RAMSAY LE, 1978, BRIT MED J, V2, P244, DOI 10.1136/bmj.2.6132.244; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REISIN E, 1978, NEW ENGL J MED, V298, P1, DOI 10.1056/NEJM197801052980101; ROCHESTER DF, 1974, AM J MED, V57, P402, DOI 10.1016/0002-9343(74)90135-1; SALZANO J. V., 1958, JOUR AMER DIETETIC ASSOC, V34, P1309; SCHWARTZ RS, 1987, METABOLISM, V36, P165, DOI 10.1016/0026-0495(87)90012-6; SORBRIS R, 1981, EUR J CLIN INVEST, V11, P491, DOI 10.1111/j.1365-2362.1981.tb02019.x; SOURS HE, 1981, AM J CLIN NUTR, V34, P453, DOI 10.1093/ajcn/34.4.453; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; SUGERMAN HJ, 1988, ANN SURG, V207, P604, DOI 10.1097/00000658-198805000-00015; SURATT PM, 1987, CHEST, V92, P631, DOI 10.1378/chest.92.4.631; TUCK ML, 1981, NEW ENGL J MED, V304, P930, DOI 10.1056/NEJM198104163041602; TYROLER HA, 1975, EPIDEMIOLOGY CONTROL, P177; VANITALLIE TB, 1984, AM J CLIN NUTR, V39, P695, DOI 10.1093/ajcn/39.5.695; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1983, ANN INTERN MED, V99, P675, DOI 10.7326/0003-4819-99-5-675; WARD W K, 1986, Diabetes Metabolism Reviews, V2, P297; WATTCHOW DA, 1983, BRIT MED J, V286, P763, DOI 10.1136/bmj.286.6367.763; WING RR, 1991, ARCH INTERN MED, V151, P1334, DOI 10.1001/archinte.151.7.1334; WOLF RN, 1983, ARTERIOSCLEROSIS, V3, P160, DOI 10.1161/01.ATV.3.2.160; WOOD PD, 1988, NEW ENGL J MED, V319, P1173, DOI 10.1056/NEJM198811033191801; YANG H Y, 1990, Gastroenterology, V98, pA266; YANG MU, 1981, INT J OBESITY, V5, P231; [No title captured]; [No title captured]	84	114	115	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				722	726		10.7326/0003-4819-119-7_Part_2-199310011-00019	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00019			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363205				2022-12-28	WOS:A1993MA33000019
J	ROY, AL; CARRUTHERS, C; GUTJAHR, T; ROEDER, RG				ROY, AL; CARRUTHERS, C; GUTJAHR, T; ROEDER, RG			DIRECT ROLE FOR MYC IN TRANSCRIPTION INITIATION MEDIATED BY INTERACTIONS WITH TFII-I	NATURE			English	Article							C-MYC; DNA-BINDING; PROTEINS; MAX; DIMERIZATION; ACTIVATION; ONCOGENE; SEQUENCE; MYOD; USF	THE nuclear proto-oncoprotein Myc has been implicated in the control of cell proliferation and differentiation1-3. Myc participates in transcription4,5 and belongs to the basic-helix-loop-helix (bHLH) family of regulatory proteins2,3. Here we show that Myc interacts with TFII-I, a transcription initiation factor that activates core promoters through an initiator element (Inr)6. As previously observed for the bHLH activator USF6, Myc was found to interact cooperatively with TFII-I at both Inr and upstream E-box promoter elements. However, in this case Myc interactions with TFII-I at the Inr lead to an inhibition of transcription initiation. This inhibition is selective for a TFII-I-dependent (as opposed to TFIIA-dependent) initiation pathway and correlates with the prevention of complex formation between the TATA-binding protein TBP (TFIIDtau), TFII-I and the promoter. TBP probably interacts with Myc, but only slowly. These observations indicate that Myc has the potential to interact physically and functionally with components of the general transcription machinery.			ROY, AL (corresponding author), ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.			Gutjahr, Thomas/0000-0002-8395-5464				AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PENDERGAST GC, 1991, CELL, V65, P395; PENDERGAST GC, 1992, TIGS, V8, P91; POGNONEC P, 1991, MOL CELL BIOL, V11, P5125, DOI 10.1128/MCB.11.10.5125; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; VANANTWERP ME, 1992, P NATL ACAD SCI USA, V89, P9010, DOI 10.1073/pnas.89.19.9010; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	27	249	250	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					359	361		10.1038/365359a0	http://dx.doi.org/10.1038/365359a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377829				2022-12-28	WOS:A1993LY49600058
J	KELLERMANN, AL; HACKMAN, BB; SOMES, G				KELLERMANN, AL; HACKMAN, BB; SOMES, G			PREDICTING THE OUTCOME OF UNSUCCESSFUL PREHOSPITAL ADVANCED CARDIAC LIFE-SUPPORT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY MEDICAL TECHNICIANS; CARDIOPULMONARY-RESUSCITATION; VENTRICULAR-FIBRILLATION; IMPROVING SURVIVAL; ARREST; DEFIBRILLATION; FIELD; MANAGEMENT; SERVICES	Objective.-To determine if failure to achieve return of spontaneous circulation following prehospital advanced cardiac life support (ACLS) warrants termination of efforts at the scene. Design.-Retrospective case series. Setting.-Memphis, Tenn, a city of 610337 people that is served by a fire department-based emergency medical service system. All city ambulances provide ACLS. Patients.-Adult victims of out-of-hospital cardiac arrest due to heart disease. Intervention.-All patients received prehospital ACLS according to the 1986 American Heart Association guidelines. Following prehospital ACLS, all patients were transported to the nearest hospital emergency department whether or not a pulse was restored in the field. Main Outcome Measures.-Survival to hospital admission, survival to hospital discharge, and neurological status at discharge. Results.-Over the 39-month study interval, the Memphis Fire Department treated 1068 victims of out-of-hospital cardiac arrest. Three hundred ten of these (29%) had return of spontaneous circulation prior to transport for some period. The remaining 758 patients (71%) never regained a pulse and were transported with ongoing cardiopulmonary resuscitation. Patients who had return of spontaneous circulation prior to transport were more likely to be admitted (69% vs 7.0%) and far more likely to be discharged alive (26.5% vs 0.4%) than patients who failed to respond to prehospital ACLS. Three patients who survived to hospital discharge despite failure to achieve return of spontaneous circulation prior to emergency medical service transport sustained their cardiac arrest after paramedic arrival. All three were discharged with moderate to severe cerebral disability. Conclusion.-Rapid transport of adults who fail to respond to an adequate trial of prehospital ACLS does not result in meaningful rates of survival. In such cases, on-line emergency medical service physicians should authorize paramedics to cease efforts in the field.	UNIV TENNESSEE CTR HLTH SCI,DIV CARDIOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT INTERNAL MED,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DEPT BIOSTAT & EPIDEMIOL,MEMPHIS,TN 38163; UNIV TENNESSEE CTR HLTH SCI,DIV EMERGENCY MED,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center					AHRQ HHS [HS 06094] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BONNIN MJ, 1989, ANN EMERG MED, V18, P507, DOI 10.1016/S0196-0644(89)80834-0; COBB LA, 1980, MOD CONC CARDIOV DIS, V49, P31; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; EISENBERG MS, 1980, JAMA-J AM MED ASSOC, V243, P1049, DOI 10.1001/jama.243.10.1049; EISENBERG MS, 1985, ANN EMERG MED, V14, P1106, DOI 10.1016/S0196-0644(85)80932-X; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH; FRANK M, 1989, ANN EMERG MED, V18, P594, DOI 10.1016/S0196-0644(89)80853-4; GRAY WA, 1991, NEW ENGL J MED, V325, P1393, DOI 10.1056/NEJM199111143252001; HACKMAN BB, 1992, CONNS CURRENT THERAP, P209; KELLERMANN AL, 1993, ANN EMERG MED, V22, P47, DOI 10.1016/S0196-0644(05)80249-5; KELLERMANN AL, 1988, ANN EMERG MED, V17, P589, DOI 10.1016/S0196-0644(88)80398-6; KELLERMANN AL, 1987, AM J EMERG MED, V5, P548, DOI 10.1016/0735-6757(87)90197-5; KERBER RE, 1991, STATEMENT EARLY DEFI; LEWIS LM, 1990, AM J EMERG MED, V8, P118, DOI 10.1016/0735-6757(90)90196-7; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; PARADIS NA, 1990, JAMA-J AM MED ASSOC, V263, P1106, DOI 10.1001/jama.263.8.1106; SANDERS AB, 1989, JAMA-J AM MED ASSOC, V262, P1347, DOI 10.1001/jama.262.10.1347; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; WEAVER WD, 1988, NEW ENGL J MED, V319, P661, DOI 10.1056/NEJM198809153191101; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1992, JAMA-J AM MED ASSOC, V268, P2171	26	132	134	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1433	1436		10.1001/jama.270.12.1433	http://dx.doi.org/10.1001/jama.270.12.1433			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX173	8371442				2022-12-28	WOS:A1993LX17300026
J	ROSENZWEIG, BP; GUARNERI, E; KRONZON, I				ROSENZWEIG, BP; GUARNERI, E; KRONZON, I			ECHOCARDIOGRAPHIC MANIFESTATIONS IN A PATIENT WITH PSEUDOXANTHOMA ELASTICUM	ANNALS OF INTERNAL MEDICINE			English	Note									NYU MED CTR, 560 1ST AVE, ROOM HW228, SUITE 7B, NEW YORK, NY 10016 USA	New York University								CHALLENOR VF, 1988, BRIT HEART J, V59, P266; FANG ML, 1988, ARCH DERMATOL, V124, P1959; FREUNDLICH I M, 1975, Critical Reviews in Clinical Radiology and Nuclear Medicine, V6, P171; KAPLAN L, 1954, ARCH INTERN MED, V94, P489, DOI 10.1001/archinte.1954.00250030159019; LEBWOHL MG, 1982, NEW ENGL J MED, V307, P228, DOI 10.1056/NEJM198207223070406; LEONARD JJ, 1957, NEW ENGL J MED, V256, P629, DOI 10.1056/NEJM195704042561402; MENDELSOHN G, 1978, ARCH PATHOL LAB MED, V102, P298; MESSIS CP, 1970, NEUROLOGY, V20, P703, DOI 10.1212/WNL.20.7.703; NAVARROLOPEZ F, 1980, CHEST, V78, P113, DOI 10.1378/chest.78.1.113; NELDNER KH, 1988, CLIN DERMATOLOGY PSE, P45; PYERITZ RE, 1982, NEW ENGL J MED, V307, P1451; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; UITTO J, 1985, CECIL TXB MED, P1152	13	14	14	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					487	491		10.7326/0003-4819-119-6-199309150-00007	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357114				2022-12-28	WOS:A1993LZ27500007
J	KEMP, CJ; DONEHOWER, LA; BRADLEY, A; BALMAIN, A				KEMP, CJ; DONEHOWER, LA; BRADLEY, A; BALMAIN, A			REDUCTION OF P53 GENE DOSAGE DOES NOT INCREASE INITIATION OR PROMOTION BUT ENHANCES MALIGNANT PROGRESSION OF CHEMICALLY-INDUCED SKIN TUMORS	CELL			English	Article							WILD-TYPE P53; CELL-CYCLE CONTROL; MOUSE SKIN; RAS GENE; HA-RAS; COLORECTAL TUMORIGENESIS; MULTISTEP CARCINOGENESIS; CANCER; MUTATIONS; ONCOGENE	The availability of p53 knockout mice generated by gene targeting has enabled us to investigate the functional role of the p53 tumor suppressor gene in initiation, promotion, and progression of carcinogenesis in vivo, using mouse skin as a model system. The number, size, and growth rate of benign papillomas were not increased in the p53 heterozygous mice in comparison with wild type. The p53 null mice showed a reduced yield of papillomas, but these underwent much more rapid malignant progression, with some poorly differentiated carcinomas developing after only 10 weeks of promotion. Progression rate was also greater in heterozygous than in wild-type mice and was associated with loss of the remaining wild-type allele. Most tumors from all groups had activating mutations in the H-ras gene. Absence of p53, therefore, does not augment the frequency of initiation or the rate of promotion but greatly enhances malignant progression.	BAYLOR COLL MED, HOWARD HUGHES MED INST, INST MOLEC VIROL, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DIV MOLEC VIROL, HOUSTON, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine	KEMP, CJ (corresponding author), BEATSON INST CANC RES, CANC RES CAMPAIGN BEATSON LABS, GARSCUBE ESTATE, SWITCHBACK RD, GLASGOW G61 1BD, SCOTLAND.			Bradley, Allan/0000-0002-2349-8839				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BALMAIN A, 1988, ADV CANCER RES, V51, P147, DOI 10.1016/S0065-230X(08)60222-5; BALMAIN A, 1992, PRINCESS TAKAMATSU S, V22, P97; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENNETT WP, 1992, CANCER RES, V52, P6092; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1990, P NATL ACAD SCI USA, V87, P538, DOI 10.1073/pnas.87.2.538; BURNS PA, 1991, ONCOGENE, V6, P2363; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINSTEIN E, 1992, ONCOGENE, V7, P1853; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FULTS D, 1992, CANCER RES, V52, P674; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P749, DOI 10.1093/carcin/10.4.749; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; HARVEY M, 1993, IN PRESS ONCOGENE; HECKER E, 1982, CARCINOGENESIS COMPR, V7; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klein-Szanto A J, 1989, Carcinog Compr Surv, V11, P19; KLINEDINST DK, 1991, MUTAT RES, V250, P365, DOI 10.1016/0027-5107(91)90193-R; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; LI FP, 1988, CANCER RES, V48, P5358; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOEB LA, 1991, CANCER RES, V51, P3075; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; NOWELL PC, 1989, CANCER CELL-MON REV, V1, P29; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; RUGGERI B, 1991, CANCER RES, V51, P6615; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENMAN G, 1987, P NATL ACAD SCI USA, V84, P184, DOI 10.1073/pnas.84.1.184; SUKUMAR S, 1990, CANCER CELL-MON REV, V2, P199; TEMIN HM, 1988, CANCER RES, V48, P1697; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONDEIMLING A, 1992, CANCER RES, V52, P2987; WEINBERG RA, 1989, CANCER RES, V49, P3713; YANDELL DW, 1986, SOMAT CELL MOLEC GEN, V12, P255, DOI 10.1007/BF01570784; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YUSPA SH, 1983, CANCER RES, V43, P6021	64	449	452	1	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 10	1993	74	5					813	822		10.1016/0092-8674(93)90461-X	http://dx.doi.org/10.1016/0092-8674(93)90461-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LX292	8374952				2022-12-28	WOS:A1993LX29200007
J	BRETSCHER, MS; MUNRO, S				BRETSCHER, MS; MUNRO, S			CHOLESTEROL AND THE GOLGI-APPARATUS	SCIENCE			English	Editorial Material							MEMBRANE-SPANNING DOMAIN; PHASE-EQUILIBRIA; RETENTION; PROTEIN; SIGNAL; ALPHA-2,6-SIALYLTRANSFERASE; PHOSPHATIDYLCHOLINE; MECHANISM; SEQUENCES; CISTERNAE				BRETSCHER, MS (corresponding author), MRC,MOLEC BIOL LAB,HILLS RD,CAMBRIDGE CB2 2QH,ENGLAND.			Munro, Sean/0000-0001-6160-5773				BACKER JM, 1981, BIOCHEMISTRY-US, V20, P3805, DOI 10.1021/bi00516a021; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; COLLEY KJ, 1992, J BIOL CHEM, V267, P7784; ENGLEMAN DM, 1986, ANN REV BIOPHYS CHEM, V15, P321; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; JECKEL D, 1992, J CELL BIOL, V117, P259, DOI 10.1083/jcb.117.2.259; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LANGE Y, 1977, BIOCHEMISTRY-US, V16, P4339, DOI 10.1021/bi00639a002; LEVINE YK, 1971, NATURE-NEW BIOL, V230, P69, DOI 10.1038/newbio230069a0; LEWIS BA, 1983, J MOL BIOL, V166, P203, DOI 10.1016/S0022-2836(83)80006-0; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; MOURITSEN OG, 1984, BIOPHYS J, V46, P141, DOI 10.1016/S0006-3495(84)84007-2; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1991, EMBO J, V10, P3577, DOI 10.1002/j.1460-2075.1991.tb04924.x; NEZIL FA, 1992, BIOPHYS J, V61, P1176, DOI 10.1016/S0006-3495(92)81926-4; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; NILSSON T, 1991, EMBO J, V10, P3567, DOI 10.1002/j.1460-2075.1991.tb04923.x; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; RECKTENWALD DJ, 1981, BIOCHEMISTRY-US, V20, P4505, DOI 10.1021/bi00518a042; REISSHUS.F, 1967, J MOL BIOL, V25, P363, DOI 10.1016/0022-2836(67)90192-1; ROTH J, 1987, BIOCHIM BIOPHYS ACTA, V906, P405, DOI 10.1016/0304-4157(87)90018-9; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10670, DOI 10.1021/bi00499a014; SWIFT AM, 1991, J CELL BIOL, V115, P19, DOI 10.1083/jcb.115.1.19; VIST MR, 1990, BIOCHEMISTRY-US, V29, P451, DOI 10.1021/bi00454a021	30	717	730	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1280	1281		10.1126/science.8362242	http://dx.doi.org/10.1126/science.8362242			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8362242				2022-12-28	WOS:A1993LV65600016
J	DOVER, JS; JOHNSON, RA				DOVER, JS; JOHNSON, RA			BASAL-CELL CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											DOVER, JS (corresponding author), NEW ENGLAND DEACONESS HOSP,BOSTON,MA 02215, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					545	545						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8355768				2022-12-28	WOS:A1993LR89200006
J	SHU, ZJ; SWINDALE, NV; CYNADER, MS				SHU, ZJ; SWINDALE, NV; CYNADER, MS			SPECTRAL MOTION PRODUCES AN AUDITORY AFTER-EFFECT	NATURE			English	Article							MOVEMENT AFTEREFFECTS CONTINGENT; FREQUENCY-MODULATED TONES; DIRECTION; CHANNELS; PATTERN; COLOR	DISTORTIONS of perception following prolonged exposure to an unvarying sensory stimulus have been observed since at least the third century BC1. The motion after-effect is a familiar experience2 in which, after a few minutes of viewing objects moving in a single direction, a stationary object appears to move in the opposite direction. Similar after-effects have been observed for many visual stimuli, including tilted lines, colours, stereoscopic depth, curvature, spatial frequency, contrast, rotation and motion in depth3-9. In contrast to the rich variety of visual after-effects reported since the 1960s, reports of analogous auditory adaptation effects only appeared in the 1970s10-12, but have continued since then13,14. Some effects of sound source spatial movement perception after adaptation to a spatially moving sound source have been reported15. Here we report an auditory perceptual after-effect analogous to the visual motion after-effect, which is caused by adaptation to auditory spectral (frequency) motion. After a few minutes of listening to a simple spectral pattern moving upwards or downwards in frequency space, the same pattern sounds as though it is drifting in the opposite direction when it is stationary. The effect shows binaural transfer, implying that it is generated at the level after binaural interaction. After-effects produced by the motion of spectral peaks are independent of those produced by spectral notches, suggesting separate processing channels for spectral peaks and notches.	UNIV BRITISH COLUMBIA,DEPT ELECT ENGN,VANCOUVER V6T 1Z4,BC,CANADA	University of British Columbia	SHU, ZJ (corresponding author), UNIV BRITISH COLUMBIA,DEPT OPHTHALMOL,2550 WILLOW ST,VANCOUVER V5Z 3N9,BC,CANADA.							ANSTIS SM, 1967, SCIENCE, V155, P710, DOI 10.1126/science.155.3763.710; BARLOW HB, 1963, NATURE, V200, P1345, DOI 10.1038/2001345a0; Blauert J., 1983, SPATIAL HEARING; BLOOM PJ, 1977, J AUDIO ENG SOC, V25, P560; BUTLER RA, 1983, AM J OTOLARYNG, V4, P165, DOI 10.1016/S0196-0709(83)80039-8; FAVREAU OE, 1976, VISION RES, V16, P181, DOI 10.1016/0042-6989(76)90096-1; Finney D.J., 1971, PROBIT ANAL; GARDNER RB, 1979, J ACOUST SOC AM, V66, P704, DOI 10.1121/1.383220; GRANTHAM DW, 1989, PERCEPT PSYCHOPHYS, V45, P129, DOI 10.3758/BF03208047; GREN GGR, 1976, J PHYSIOL-LONDON, V260, pP49; KAY RH, 1972, J PHYSIOL-LONDON, V225, P657, DOI 10.1113/jphysiol.1972.sp009962; KAY RH, 1982, PHYSIOL REV, V62, P894, DOI 10.1152/physrev.1982.62.3.894; MAYHEW JEW, 1972, PERCEPT PSYCHOPHYS, V12, P77, DOI 10.3758/BF03212847; MENDELSON JR, 1985, BRAIN RES, V327, P331, DOI 10.1016/0006-8993(85)91530-6; MOORE BCJ, 1989, J ACOUST SOC AM, V85, P820, DOI 10.1121/1.397554; POTTS MJ, 1975, VISION RES, V15, P1225, DOI 10.1016/0042-6989(75)90166-2; REGAN D, 1979, J ACOUST SOC AM, V65, P1249, DOI 10.1121/1.382792; SEKULER RW, 1963, SCIENCE, V139, P419, DOI 10.1126/science.139.3553.419; WALKER JT, 1972, PSYCHON SCI, V28, P333; WILSON JP, 1992, BRIT J AUDIOL, V26, P188; Wohlgemuth A., 1911, AFTER EFFECT SEEN MO, V1; ARISTOTLE PARVA NATU	22	58	63	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 19	1993	364	6439					721	723		10.1038/364721a0	http://dx.doi.org/10.1038/364721a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT677	8355786				2022-12-28	WOS:A1993LT67700059
J	DEAR, SP; SIMMONS, JA; FRITZ, J				DEAR, SP; SIMMONS, JA; FRITZ, J			A POSSIBLE NEURONAL BASIS FOR REPRESENTATION OF ACOUSTIC SCENES IN AUDITORY-CORTEX OF THE BIG BROWN BAT	NATURE			English	Article							CORTICAL COMPUTATIONAL MAPS; TARGET RANGE; ECHOLOCATING BATS; MYOTIS-LUCIFUGUS; MUSTACHE BAT	BEHAVIOURAL studies1-4 and field observations5-7 demonstrate that echolocating bats simultaneously perceive range, direction and shape of multiple objects in the environment as acoustic images derived from echoes. Cortical echo delay-tuned neurons contribute to the perception of object range, because focal inactivation of these neurons disrupts behavioural discrimination of range8. We report here that response properties of delay-tuned neurons in the cortical tonotopic area of the bat, Eptesicus, transform the sequential arrival times of echoes with different delays into a concurrent, accumulating neural representation of multiple objects at different ranges. The sharpness of delay tuning systematically increases at each best delay in a subpopulation of these neurons while responses to echoes at different delays are accumulated. The resulting concurrent, multiresolution representation of echo delay corresponds to neural implementation of a common representation of images used in computational vision9-11 and may provide the basis for representing acoustic images of multiple objects as acoustic 'scenes'.	BROWN UNIV,DEPT PSYCHOL,PROVIDENCE,RI 02912	Brown University	DEAR, SP (corresponding author), BROWN UNIV,DEPT NEUROSCI,BOX 1853,PROVIDENCE,RI 02912, USA.			Fritz, Jonathan/0000-0002-0625-172X				Akansu AN, 1992, MULTIRESOLUTION SIGN; BERKOWITZ A, 1989, HEARING RES, V41, P255, DOI 10.1016/0378-5955(89)90017-8; BURT PJ, 1981, IEEE T SYST MAN CYB, V11, P802, DOI 10.1109/TSMC.1981.4308619; DEAR SP, IN PRESS J NEUROPHYS; FENG AS, 1978, SCIENCE, V202, P645, DOI 10.1126/science.705350; GRIFFIN DR, 1965, J EXP ZOOL, V158, P155, DOI 10.1002/jez.1401580204; Griffin DR, 1958, LISTENING DARK; HONG TH, 1984, IEEE T PATTERN ANAL, V6, P229, DOI 10.1109/TPAMI.1984.4767506; HONG TH, 1984, IEEE T PATTERN ANAL, V6, P222, DOI 10.1109/TPAMI.1984.4767505; KICK SA, 1984, J NEUROSCI, V4, P2725; MALLAT SG, 1989, IEEE T ACOUST SPEECH, V37, P2019; MARR D, 1979, PROC R SOC SER B-BIO, V204, P301, DOI 10.1098/rspb.1979.0029; MARR D, 1980, PROC R SOC SER B-BIO, V207, P187, DOI 10.1098/rspb.1980.0020; Marr D., 1982, VISION; NEUWEILER G, 1990, PHYSIOL REV, V70, P615, DOI 10.1152/physrev.1990.70.3.615; ONEILL WE, 1979, SCIENCE, V203, P69, DOI 10.1126/science.758681; RIQUIMAROUX H, 1991, SCIENCE, V251, P565, DOI 10.1126/science.1990432; ROSENFELD A, 1971, IEEE T COMPUT, VC 20, P562, DOI 10.1109/T-C.1971.223290; Schnitzler H., 1980, ANIMAL SONAR SYSTEMS, V28, P109, DOI [10.10007/978-1-4684-7254-7_6, DOI 10.1007/978-1-4684-7254-7_6]; SCHULLER G, 1991, EUR J NEUROSCI, V3, P1165, DOI 10.1111/j.1460-9568.1991.tb00051.x; SIMMONS JA, 1973, J ACOUST SOC AM, V54, P157, DOI 10.1121/1.1913559; SIMMONS JA, 1971, SCIENCE, V171, P925, DOI 10.1126/science.171.3974.925; SUGA N, 1990, NEURAL NETWORKS, V3, P3, DOI 10.1016/0893-6080(90)90043-K; SUGA N, 1978, SCIENCE, V200, P778, DOI 10.1126/science.644320; SULLIVAN WE, 1982, J NEUROPHYSIOL, V48, P1011, DOI 10.1152/jn.1982.48.4.1011; WEBSTER FA, 1968, AMRLTR67192 TECHN RE; WITKIN AP, 1984, IEEE ICASSP P, V39; WONG D, 1988, BRAIN RES, V453, P349, DOI 10.1016/0006-8993(88)90176-X	28	93	93	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					620	623		10.1038/364620a0	http://dx.doi.org/10.1038/364620a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350920				2022-12-28	WOS:A1993LR77100051
J	ARIEFF, AI				ARIEFF, AI			FORTNIGHTLY REVIEW - MANAGEMENT OF HYPONATREMIA	BRITISH MEDICAL JOURNAL			English	Article							SEVERE SYMPTOMATIC HYPONATREMIA; IMMUNE-DEFICIENCY-SYNDROME; PERMANENT BRAIN-DAMAGE; RAPID CORRECTION; HYPERTONIC SALINE; WATER; CHILDREN; SEIZURES; DRINKERS; DEATH		UNIV CALIF SAN FRANCISCO,SCH MED,SAN FRANCISCO,CA 94121	University of California System; University of California San Francisco	ARIEFF, AI (corresponding author), VET AFFAIRS MED CTR,DEPT MED 111G,DIV GERIATR,SAN FRANCISCO,CA 94121, USA.							ADAMS RD, 1959, ARCH NEURO PSYCHIATR, V81, P154, DOI 10.1001/archneurpsyc.1959.02340140020004; ANDREOLI TE, 1992, CECIL TXB MED, V1, P499; ARIEFF AI, 1992, BRIT MED J, V304, P1218, DOI 10.1136/bmj.304.6836.1218; ARIEFF AI, 1976, MEDICINE, V55, P121, DOI 10.1097/00005792-197603000-00002; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; ARIEFF AI, IN PRESS JAMA; ASHRAF N, 1981, AM J MED, V70, P1163, DOI 10.1016/0002-9343(81)90822-6; AUYS JC, 1992, ANN INTERN MED, V117, P891; AYUS JC, 1985, AM J PHYSIOL, V248, pF711, DOI 10.1152/ajprenal.1985.248.5.F711; AYUS JC, 1987, NEW ENGL J MED, V317, P1190, DOI 10.1056/NEJM198711053171905; AYUS JC, 1982, AM J MED, V72, P43, DOI 10.1016/0002-9343(82)90575-7; AYUS JC, 1993, ENDOCRIN METAB CLIN, V22, P425; AYUS JC, 1989, AM J PHYSIOL, V257, pF18, DOI 10.1152/ajprenal.1989.257.1.F18; BEAL JL, 1989, CAN J ANAESTH, V36, P278, DOI 10.1007/BF03010765; CHENG JC, 1990, AM J MED, V88, P561, DOI 10.1016/0002-9343(90)90518-I; CHUNG HM, 1986, ARCH INTERN MED, V146, P333, DOI 10.1001/archinte.146.2.333; Coller FA, 1944, ANN SURG, V119, P533, DOI 10.1097/00000658-194404000-00007; CUSANO AJ, 1990, J ACQ IMMUN DEF SYND, V3, P949; DEMANET JC, 1971, LANCET, V2, P1115; FRASER CL, 1990, ANN INTERN MED, V112, P113, DOI 10.7326/0003-4819-112-2-113; FRASER CL, 1990, METABOLIC MOL BASIS, V1, P1002; GOLDMAN MB, 1988, NEW ENGL J MED, V318, P397, DOI 10.1056/NEJM198802183180702; HANTMAN D, 1973, ANN INTERN MED, V78, P870, DOI 10.7326/0003-4819-78-6-870; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; Matas R, 1924, ANN SURG, V79, P643, DOI 10.1097/00000658-192405000-00001; SARNAIK AP, 1991, CRIT CARE MED, V19, P758, DOI 10.1097/00003246-199106000-00005; STERNS RH, 1987, ANN INTERN MED, V107, P656, DOI 10.7326/0003-4819-107-5-656; TIEN R, 1992, AM J MED, V92, P513, DOI 10.1016/0002-9343(92)90748-Z; Trout HM, 1913, SURG GYNECOL OBSTET, V16, P560; VITTING KE, 1990, JAMA-J AM MED ASSOC, V263, P973, DOI 10.1001/jama.263.7.973; WORTHLEY LIG, 1986, BRIT MED J, V292, P168, DOI 10.1136/bmj.292.6514.168	31	98	101	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					305	308		10.1136/bmj.307.6899.305	http://dx.doi.org/10.1136/bmj.307.6899.305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374381	Bronze, Green Published			2022-12-28	WOS:A1993LQ51600024
J	FARMER, A				FARMER, A			MEDICAL-PRACTICE GUIDELINES - LESSONS FROM THE UNITED-STATES	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT; DECISION; QUALITY	Clinical guidelines, or protocols, have been devised by many different groups, often with differing aims. Some aim to reduce variations in care by using guidelines, while others seek to improve outcomes. Guidelines have long been used in the United States to try to control the behaviour of the medical profession-and the cost of health care. The ''effectiveness initiative,'' run by the Agency for Health Care Policy and Research spawned much activity among other groups, including the American Medical Association and the American College of Physicians. The experience of the Americans in analysing data to gauge effectiveness and then in disseminating good practice may help British moves in this direction. In particular, it is often hard to get guidelines adopted in practice; doctors have to be exposed to the same message in different forms. Also guidelines must not be unrealistic: those devised by senior doctors away from the realities of day to day practice are likely to fail.			FARMER, A (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND.							AUDET AM, 1990, ANN INTERN MED, V113, P709, DOI 10.7326/0003-4819-113-9-709; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; BERWICK DM, 1992, BRIT MED J, V304, P235, DOI 10.1136/bmj.304.6821.235; BROWN LD, 1992, HEALTH AFFAIR, V11, P17, DOI 10.1377/hlthaff.11.4.17; BROWN MM, 1992, BMJ-BRIT MED J, V305, P1071, DOI 10.1136/bmj.305.6861.1071; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P1839, DOI 10.1001/jama.263.13.1839; EDDY DM, 1992, ASSESSING HLTH CARE; Field MJ, 1990, CLIN PRACTICE GUIDEL; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; GRAY BH, 1992, HEALTH AFFAIR, V11, P38, DOI 10.1377/hlthaff.11.4.38; LITTLEJOHNS P, 1992, BRIT MED J, V305, P1098, DOI 10.1136/bmj.305.6861.1098-a; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MANT D, 1990, BRIT MED J, V300, P916, DOI 10.1136/bmj.300.6729.916; MCGINN P, 1988, AM MED NEWS     1202, P1; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; PURVES I, 1992, BRIT MED J, V305, P1364, DOI 10.1136/bmj.305.6865.1364-b; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; Russell IT GJ, 1992, HOSP REFERRALS, P179; SCHOENBAUM SC, 1990, BMJ-BRIT MED J, V301, P1374, DOI 10.1136/bmj.301.6765.1374; SCHWARTZ JS, 1982, ANN INTERN MED, V96, P246, DOI 10.7326/0003-4819-96-2-246; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; WADE DT, 1992, EPIDEMIOLOGICALLY BA; WENNBERG JE, 1987, LANCET, V1, P1185, DOI 10.1016/s0140-6736(87)92152-0; WOOLF SH, 1991, AHCPR INTERIM MANUAL; 1989, GENERAL PRACTICE NAT; 1991, RES HLTH RES DEV STR; 1991, FEASIBILITY LINKING; 1992, ASSESSING EFFECTS HL; 1992, LANCET, V340, P1324; 1992, LANCET, V340, P1131	31	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1993	307	6899					313	317		10.1136/bmj.307.6899.313	http://dx.doi.org/10.1136/bmj.307.6899.313			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ516	8374384	Green Published, Bronze			2022-12-28	WOS:A1993LQ51600029
J	RADEMAKER, J; SEVERS, M				RADEMAKER, J; SEVERS, M			OPIATE RELATED COLLAPSE IN AN OCTOGENARIAN	BRITISH MEDICAL JOURNAL			English	Letter							OBSTRUCTIVE LUNG-DISEASE				RADEMAKER, J (corresponding author), QUEEN ALEXANDRA HOSP,PORTSMOUTH,HANTS,ENGLAND.							CARADOCDAVIS TH, 1981, BMJ, V283, P91; KAIKO RF, 1982, MED CLIN N AM, V66, P1081; MUNCK LK, 1990, PHARMACOL TOXICOL, V66, P335, DOI 10.1111/j.1600-0773.1990.tb00759.x; THOMPSON JW, 1990, OPIOIDS TREATMENT CA, P17; VENTAFRIDDA V, 1987, LANCET, V1, P1204; WOODCOCK AA, 1981, NEW ENGL J MED, V305, P1611, DOI 10.1056/NEJM198112313052703	6	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					241	241		10.1136/bmj.307.6898.241	http://dx.doi.org/10.1136/bmj.307.6898.241			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369690	Green Published, Bronze			2022-12-28	WOS:A1993LP31400025
J	NABULSI, AA; FOLSOM, AR; WHITE, A; PATSCH, W; HEISS, G; WU, KK; SZKLO, M				NABULSI, AA; FOLSOM, AR; WHITE, A; PATSCH, W; HEISS, G; WU, KK; SZKLO, M			ASSOCIATION OF HORMONE-REPLACEMENT THERAPY WITH VARIOUS CARDIOVASCULAR RISK-FACTORS IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DENSITY LIPOPROTEIN CHOLESTEROL; IMPROVED LIPOLYTIC EFFICIENCY; CORONARY HEART-DISEASE; ESTROGEN REPLACEMENT; BLOOD COLLECTION; PROTEIN-C; ENZYMATIC DETERMINATION; ANTITHROMBIN-III; HEPATIC LIPASE; SERUM-LIPIDS	Background. Most epidemiologic studies of cardiovascular disease in postmenopausal women suggest that estrogen-replacement therapy has a protective effect. The effects of the use of estrogen combined with progestin are less well studied. Methods. To examine the associations of hormone-replacement therapy with concentrations of plasma lipids and hemostatic factors, fasting serum concentrations of glucose and insulin, and blood pressure, we studied 4958 postmenopausal women participating in a population-based investigation. Using cross-sectional data, we classified the women into four groups according to their use of hormone-replacement therapy: current users of estrogen alone, current users of estrogen with progestin, nonusers who had formerly used these hormones, and nonusers who had never used them. Results. Current users had higher mean levels of high-density lipoprotein cholesterol, its subfractions high-density lipoprotein2 and high-density lipoprotein3, and apolipoprotein A-1 than nonusers, and lower mean levels of low-density lipoprotein cholesterol, apolipoprotein B, lipoprotein(a), fibrinogen, antithrombin III, and fasting serum glucose and insulin. However, current users of estrogen alone had higher triglyceride, factor VII, and protein C levels than either nonusers or current users of estrogen with progestin. After making certain assumptions, we estimated that the findings, if causal, would translate into a reduction of 42 percent in the risk of coronary heart disease in users of hormones as compared with nonusers. Women using estrogen with progestin would have an even greater estimated benefit. Conclusions. A randomized trial is needed to eliminate possible selection biases in our observational study that are related to the prescription of replacement hormones. Nevertheless, hormone-replacement therapy appears to be associated with a favorable physiologic profile, which probably mediates its protective effects on cardiovascular disease. The use of estrogen combined with progestin appears to be associated with a better profile than the use of estrogen alone.	UNIV MINNESOTA, SCH PUBL HLTH,DIV EPIDEMIOL,1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA; BURROUGHS WELLCOME CO, DIV ESP, RES TRIANGLE PK, NC 27709 USA; METHODIST HOSP, ATHEROSCLEROSIS CLIN LAB, HOUSTON, TX 77030 USA; UNIV N CAROLINA, SCH PUBL HLTH, DEPT EPIDEMIOL, CHAPEL HILL, NC 27514 USA; UNIV TEXAS, SCH MED, DIV HEMATOL ONCOL, HOUSTON, TX 77025 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD 21218 USA	University of Minnesota System; University of Minnesota Twin Cities; Burroughs Wellcome Fund; The Methodist Hospital System; The Methodist Hospital - Houston; University of North Carolina; University of North Carolina Chapel Hill; University of Texas System; Johns Hopkins University			Wu, Kenneth Kun-Yu/B-1070-2010	Szklo, Moyses/0000-0001-9433-6266	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055016, N01HC055015, N01HC055018] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1989, AM J EPIDEMIOL, V129, P687; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BALLEISEN L, 1987, LANCET, V2, P461; Barrett-Connor E L, 1989, Public Health Rep, V104 Suppl, P62; BARRETTCONNOR E, 1989, JAMA-J AM MED ASSOC, V261, P2095, DOI 10.1001/jama.261.14.2095; BARRETTCONNOR E, 1990, ARTERIOSCLEROSIS, V10, P531, DOI 10.1161/01.ATV.10.4.531; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BROWN SA, 1988, CLIN CHEM, V34, P920; BROWN SA, 1990, CLIN CHEM, V36, P1662; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; ESMON CT, 1983, BLOOD, V62, P1155; FARISH E, 1986, ACTA ENDOCRINOL-COP, V113, P123, DOI 10.1530/acta.0.1130123; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON EM, 1988, J LAB CLIN MED, V111, P52; HEGELE RA, 1989, CAN J CARDIOL, V5, P263; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KENNEDY DL, 1985, OBSTET GYNECOL, V65, P441; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LINDBERG UB, 1989, THROMB HAEMOSTASIS, V61, P65; LOBO RA, 1987, POSTGRAD MED    0914, P48; Lobo RA, 1990, ANN NY ACAD SCI, V592, P334; LOBO RA, 1990, ANN NY ACAD SCI, V592, P286; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MEADE TW, 1985, THROMB HAEMOSTASIS, V53, P198; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MEADE TW, 1984, ANTICOAGULANTS MYOCA, P91; NAGELE U, 1984, J CLIN CHEM CLIN BIO, V22, P165; NIKKILA EA, 1983, PROGESTERONE PROGEST, P411; NOTELOVITZ M, 1989, AM J OBSTET GYNECOL, V161, P1832, DOI 10.1016/S0002-9378(89)80003-1; NOTELOVITZ M, 1983, OBSTET GYNECOL, V62, P596; NOTELOVITZ M, 1984, OBSTET GYNECOL, V63, P621; PAPP AC, 1989, THROMB HAEMOSTASIS, V61, P15; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SACKS FM, 1990, ANN NY ACAD SCI, V592, P334; SACKS FM, 1990, ANN NY ACAD SCI, V592, P272; SIEDEL J, 1983, CLIN CHEM, V29, P1075; SILFVERSTOLPE G, 1982, MATURITAS, V4, P103, DOI 10.1016/0378-5122(82)90036-6; SKARTLIEN AH, 1989, ARTERIOSCLEROSIS, V9, P798, DOI 10.1161/01.ATV.9.6.798; SOMA M, 1991, LANCET, V337, P612, DOI 10.1016/0140-6736(91)91674-J; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; THALER E, 1981, CLIN HAEMATOL, V10, P369; TIKKANEN MJ, 1982, J CLIN ENDOCR METAB, V54, P1113, DOI 10.1210/jcem-54-6-1113; TIKKANEN MJ, 1981, ATHEROSCLEROSIS, V40, P365, DOI 10.1016/0021-9150(81)90147-7; TIKKANEN MJ, 1986, MATURITAS, V8, P7, DOI 10.1016/0378-5122(86)90003-4; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; WARNICK GR, 1982, CLIN CHEM, V28, P1574; WEINSTEIN L, 1987, OBSTET GYNECOL, V69, P929; 1987, ARIC ATHEROSCLEROSIS, V8; [No title captured]; 1988, SAS USERS GUIDE STAT; 1987, VITAL HLTH STATIS 11, V238	52	858	874	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 15	1993	328	15					1069	1075		10.1056/NEJM199304153281501	http://dx.doi.org/10.1056/NEJM199304153281501			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KX178	8384316	Bronze			2022-12-28	WOS:A1993KX17800001
J	FUNDER, JW				FUNDER, JW			MINERALOCORTICOIDS, GLUCOCORTICOIDS, RECEPTORS AND RESPONSE ELEMENTS	SCIENCE			English	Editorial Material											FUNDER, JW (corresponding author), BAKER MED RES INST,POB 348,PRAHRAN,VIC 3181,AUSTRALIA.							ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; BINDER HJ, 1989, J CLIN INVEST, V84, P1924; EDWARDS CRW, 1988, LANCET, V2, P986, DOI 10.1016/S0140-6736(88)90742-8; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1990, FASEB J, V4, P3234, DOI 10.1096/fasebj.4.14.2172062; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; NARAYFEJESTOTH A, 1990, AM J PHYSIOL, V259, pF672, DOI 10.1152/ajprenal.1990.259.4.F672; PEARCE D, 1993, SCIENCE, V259, P1161, DOI 10.1126/science.8382376; WEHLING M, IN PRESS MOL CELL EN; WEHLING M, 1991, BIOCHEM BIOPH RES CO, V181, P1305; WEHLING M, IN PRESS ENDOCRINOLO; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	12	159	160	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1132	1133		10.1126/science.8382375	http://dx.doi.org/10.1126/science.8382375			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8382375				2022-12-28	WOS:A1993KM91700030
J	KESSLER, DA; SIEGEL, JP; NOGUCHI, PD; ZOON, KC; FEIDEN, KL; WOODCOCK, J				KESSLER, DA; SIEGEL, JP; NOGUCHI, PD; ZOON, KC; FEIDEN, KL; WOODCOCK, J			REGULATION OF SOMATIC-CELL THERAPY AND GENE-THERAPY BY THE FOOD-AND-DRUG-ADMINISTRATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; IMMUNOTHERAPY; MELANOMA; HUMANS		US FDA,OFF COMMISSIONER,ROCKVILLE,MD 20857; US FDA,CTR BIOL EVALUAT & RES,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)								AEBERSOLD P, 1990, HUM GENE THER, V1, P373, DOI 10.1089/hum.1990.1.4-373; ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; CULVER K W, 1992, Pediatric Research, V31, p149A; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; CULVER KW, 1991, HUM GENE THER, V2, P107, DOI 10.1089/hum.1991.2.2-107; EPSTEIN SL, 1991, HUM GENE THER, V2, P243, DOI 10.1089/hum.1991.2.3-243; PITMAN M, 1987, NATIONAL I ALLERGY I, P61; RIDDELL SR, 1992, SCIENCE, V257, P238; ROSENBERG SA, 1990, NEW ENGL J MED, V323, P570, DOI 10.1056/NEJM199008303230904; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; 1991, POINTS CONSIDER HUMA	11	100	102	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1169	1173		10.1056/NEJM199310143291607	http://dx.doi.org/10.1056/NEJM199310143291607			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377782				2022-12-28	WOS:A1993MA66700007
J	BLACKBURN, GL				BLACKBURN, GL			COMPARISON OF MEDICALLY SUPERVISED AND UNSUPERVISED APPROACHES TO WEIGHT-LOSS AND CONTROL	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-CALORIE DIETS; CONTROLLED TRIAL; BLOOD-PRESSURE; OBESITY; HYPERTENSION; REDUCTION; PROGRAMS	The rising incidence of obesity in the United States has given physicians an increased role in its treatment. Although unsupervised programs can produce significant weight losses, the lack of medical supervision increases the potential for health problems. As with other lifestyle changes (for example, smoking cessation and blood pressure control), even minimal physician involvement may enhance outcome. In published clinical trials, the absence of contact with health professionals among control group participants may account in part for their poor success at weight loss or for their weight gain. Smaller trials examining the value of physician advice and encouragement among dieting patients have shown promising results. Physicians should monitor the health of obese and overweight patients during and after weight loss as is appropriate for the patient, depending on caloric levels, rate of weight loss, weight-loss goals, and intercurrent health events. Medical supervision is necessary for patients on very-low-calorie diets, for severely obese patients (body mass index >35), and for patients with other health problems.			BLACKBURN, GL (corresponding author), HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, 194 PILGRIM RD, BOSTON, MA 02215 USA.							ANDERSON JW, 1992, AM J GASTROENTEROL, V87, P6; BLACKBURN GL, 1988, CIRCULATION, V78, P568; Bray, 1985, MANAGEMENT OBESITY S; BRAY GA, 1989, MED CLIN N AM, V73, P161, DOI 10.1016/S0025-7125(16)30697-6; BRAY GA, 1992, AM J CLIN NUTR, V55, P488, DOI 10.1093/ajcn/55.2.488s; Cohen M D, 1991, Fam Med, V23, P25; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; DAVIS PG, 1990, INT J OBESITY, V14, P779; GOLDSTEIN DJ, 1992, INT J OBESITY, V16, P397; GREEN LW, 1986, PUBLIC HLTH PREVENTI; HENDEE WR, 1988, JAMA-J AM MED ASSOC, V260, P2547; HOLMES MD, 1989, J FAM PRACTICE, V28, P610; INUI TS, 1976, ANN INTERN MED, V84, P646, DOI 10.7326/0003-4819-84-6-646; KANDERS BS, 1992, TREATMENT SERIOUSLY, P213; KANDERS BS, 1991, CONNS CURRENT THERAP; KAPLAN RM, 1985, DIABETES CARE, V8, P343, DOI 10.2337/diacare.8.4.343; KLAWANSKY S, 1992, JAMA-J AM MED ASSOC, V268, P873, DOI 10.1001/jama.1992.03490070051035; LI VC, 1987, AM J PREV MED, V3, P81; PALGI A, 1985, AM J PUBLIC HEALTH, V75, P1190, DOI 10.2105/AJPH.75.10.1190; RAMSAY LE, 1978, BRIT MED J, V2, P244, DOI 10.1136/bmj.2.6132.244; ROCCHINI AP, 1987, HYPERTENSION, V10, P267, DOI 10.1161/01.HYP.10.3.267; SICHIERI R, 1991, AM J PUBLIC HEALTH, V81, P880, DOI 10.2105/AJPH.81.7.880; STAMLER R, 1989, JAMA-J AM MED ASSOC, V262, P1801, DOI 10.1001/jama.262.13.1801; WADDEN TA, 1990, JAMA-J AM MED ASSOC, V263, P83, DOI 10.1001/jama.263.1.83; WADDEN TA, 1992, ARCH INTERN MED, V152, P961, DOI 10.1001/archinte.152.5.961; WADDEN TA, 1983, ANN INTERN MED, V99, P675, DOI 10.7326/0003-4819-99-5-675; WADDEN TA, 1992, METHODS VOLUNTARY WE, P64; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; WEINSIER RL, 1984, AM J CLIN NUTR, V40, P865, DOI 10.1093/ajcn/40.4.865; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WILLIAMSON DF, 1990, ARCH INTERN MED, V150, P665, DOI 10.1001/archinte.150.3.665; WILLIAMSON PS, 1988, J FAM PRACTICE, V27, P187; 1989, MED LETT DRUGS THER, V31, P22; 1991, REPORT TASK FORCE TR; 1990, SAFE WEIGHT LOSS E L; 1990, DIETARY GUIDELINES A	36	29	29	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				714	718		10.7326/0003-4819-119-7_Part_2-199310011-00017	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00017			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363203				2022-12-28	WOS:A1993MA33000017
J	WARSHAFSKY, S; KAMER, RS; SIVAK, SL				WARSHAFSKY, S; KAMER, RS; SIVAK, SL			EFFECT OF GARLIC ON TOTAL SERUM-CHOLESTEROL - A METAANALYSIS	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; ALLIUM-SATIVUM; BLOOD-LIPIDS; ATHEROSCLEROSIS; ONION; RISK	Objective: To assess the size and consistency of garlic's effect on total serum cholesterol in persons with cholesterol levels greater than 5.17 mmol/L (200 mg/dL). Data Sources: Clinical trials were identified by a computerized literature search of MEDLINE and by an assessment of the bibliographies of published studies and reviews. Study Selection: Trials were selected if they were randomized and placebo-controlled and if at least 75% of their patients had cholesterol levels greater than 5.17 mmol/L (200 mg/dL). Studies were excluded if they did not provide enough data to compute effect size. Five of 28 studies were selected for review. Data Extraction: Details of study design, patient characteristics, interventions, duration of therapy, and cholesterol measurements were extracted by one author and were verified by another. Data Synthesis: Study quality was evaluated by multiple reviewers using a closed-ended questionnaire. Patients treated with garlic consistently showed a greater decrease in total cholesterol levels compared with those receiving placebo. Meta-analysis of homogeneous trials estimated a net cholesterol decrease attributable to garlic of 0.59 mmol/L (95% CI, 0.44 to 0.74) (23 mg/dL [CI, 17 to 29]) (P < 0.001). Conclusions: Meta-analysis of the controlled trials of garlic to reduce hypercholesterolemia showed a significant reduction in total cholesterol levels. The best available evidence suggests that garlic, in an amount approximating one half to one clove per day, decreased total serum cholesterol levels by about 9% in the groups of patients studied.			WARSHAFSKY, S (corresponding author), NEW YORK MED COLL, DEPT MED, GEN INTERNAL MED SECT, VALHALLA, NY 10595 USA.							ARORA RC, 1981, ATHEROSCLEROSIS, V39, P447, DOI 10.1016/0021-9150(81)90002-2; ARORA RC, 1981, ATHEROSCLEROSIS, V40, P175, DOI 10.1016/0021-9150(81)90036-8; Auer W, 1990, Br J Clin Pract Suppl, V69, P3; AUGUSTI KT, 1977, INDIAN J EXP BIOL, V15, P489; BAKHSH R, 1984, NAHRUNG, V28, P159; BHUSHAN S, 1979, Indian Journal of Physiology and Pharmacology, V23, P211; BIMMERMANN A, 1988, THERAPIEWOCHE, V38, P3885; BORDIA A, 1975, ATHEROSCLEROSIS, V21, P15, DOI 10.1016/0021-9150(75)90091-X; BORDIA A, 1973, LANCET, V2, P1491; BORDIA A, 1981, AM J CLIN NUTR, V34, P2100, DOI 10.1093/ajcn/34.10.2100; Bordia A, 1982, Indian Heart J, V34, P86; BROSCHE T, 1989, MED WELT, V40, P1233; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CHI MS, 1982, J NUTR, V112, P241, DOI 10.1093/jn/112.2.241; CHI MS, 1982, P SOC EXP BIOL MED, V171, P174, DOI 10.3181/00379727-171-41494; ERNST E, 1985, BRIT MED J, V291, P139, DOI 10.1136/bmj.291.6488.139-b; ERNST E, 1987, PHARMATHERAPEUTICA, V5, P83; ERNST E, 1986, ARZTLICHE PRAXIS ZEI, V51, P1748; FENWICK GR, 1985, CRC CR REV FOOD SCI, V23, P1; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; Glass G.V., 1981, META ANAL SOCIAL RES; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HARENBERG J, 1988, ATHEROSCLEROSIS, V74, P247, DOI 10.1016/0021-9150(88)90244-4; JAIN RC, 1977, AM J CLIN NUTR, V30, P1380, DOI 10.1093/ajcn/30.9.1380; KAMANNA VS, 1982, LIPIDS, V17, P483, DOI 10.1007/BF02535329; Kandziora J., 1988, ARZTL FORSCH, V35, P3; KANDZIORA J, 1988, AERZTLICHE FORSCHUNG, V35, P3; KENDLER BS, 1987, PREV MED, V16, P670, DOI 10.1016/0091-7435(87)90050-8; KLEIJNEN J, 1989, BRIT J CLIN PHARMACO, V28, P535, DOI 10.1111/j.1365-2125.1989.tb03539.x; KONIG FK, 1986, ARZTLICHE PRAXIS, V15, P1; LAU BHS, 1983, NUTR RES, V3, P119, DOI 10.1016/S0271-5317(83)80128-6; LAU BHS, 1987, NUTR RES, V7, P139, DOI 10.1016/S0271-5317(87)80026-X; LULEY C, 1986, ARZNEIMITTEL-FORSCH, V36-1, P766; Lutomski J, 1984, Z PHYTOTHER, V5, P938; MADER FH, 1990, ARZNEIMITTEL-FORSCH, V40-2, P1111; NITIYANANT W, 1987, Journal of the Medical Association of Thailand, V70, P646; PLENGVIDHYA C, 1988, Journal of the Medical Association of Thailand, V71, P248; QURESHI AA, 1983, LIPIDS, V18, P343, DOI 10.1007/BF02537229; QURESHI AA, 1983, J NUTR, V113, P1746, DOI 10.1093/jn/113.9.1746; ROSSOUW JE, 1990, ENDOCRIN METAB CLIN, V19, P279, DOI 10.1016/S0889-8529(18)30325-6; SAINANI GS, 1979, INDIAN J MED RES, V69, P776; SITPRIJA S, 1987, Journal of the Medical Association of Thailand, V70, P223; SUCUR M, 1980, Diabetologia Croatica, V9, P323; TURNER M, 1990, J ROY SOC HEALTH, V110, P90, DOI 10.1177/146642409011000306; Vorberg G, 1990, Br J Clin Pract Suppl, V69, P7; ZIEGLER VS, 1989, DTSCH APOTHEKER ZEIT, V129, P318; Zimmermann W, 1990, Br J Clin Pract Suppl, V69, P20; 1986, J TRADIT CHIN MED, V6, P117	48	244	254	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				599	605		10.7326/0003-4819-119-7_Part_1-199310010-00009	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363171				2022-12-28	WOS:A1993MA29100009
J	THIRMAN, MJ; GILL, HJ; BURNETT, RC; MBANGKOLLO, D; MCCABE, NR; KOBAYASHI, H; ZIEMINVANDERPOEL, S; KANEKO, Y; MORGAN, R; SANDBERG, AA; CHAGANTI, RSK; LARSON, RA; LEBEAU, MM; DIAZ, MO; ROWLEY, JD				THIRMAN, MJ; GILL, HJ; BURNETT, RC; MBANGKOLLO, D; MCCABE, NR; KOBAYASHI, H; ZIEMINVANDERPOEL, S; KANEKO, Y; MORGAN, R; SANDBERG, AA; CHAGANTI, RSK; LARSON, RA; LEBEAU, MM; DIAZ, MO; ROWLEY, JD			REARRANGEMENT OF THE MLL GENE IN ACUTE LYMPHOBLASTIC AND ACUTE MYELOID LEUKEMIAS WITH 11Q23 CHROMOSOMAL TRANSLOCATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-CELL LYMPHOMA; CLINICAL CHARACTERISTICS; DROSOPHILA-TRITHORAX; T(4-11); BREAKPOINT; BAND-11Q23; T(11-19)(Q23-P13); T(4-11)(Q21-Q23); NEOPLASIA; INVITRO	Background. Translocations involving chromosome band 11q23 are very frequent in both acute lymphoblastic and acute myeloid leukemias and are the most common genetic alteration in infants with leukemia, In all age groups and all phenotypes of leukemia, an 11q23 translocation carries a poor prognosis. A major question has been whether one or several genes on band 11q23 are implicated in these leukemias. Previously, we identified the chromosomal breakpoint region in leukemias with the common 11q23 translocations and subsequently cloned a gene named MLL that spans the 11q23 breakpoint. Methods. We isolated a 0.74-kb BamHI fragment from a complementary DNA (cDNA) clone of the MLL gene. To determine the incidence of MLL rearrangements in patients with 11q23 abnormalities, we analyzed DNA from 61 patients with acute leukemia, 3 cell lines derived from such patients, and 20 patients with non-Hodgkin's lymphoma and 11q23 aberrations. Results. The 0.74-kb cDNA probe detected DNA rearrangements in the MLL gene in 58 of the patients with leukemia, in the 3 cell lines, and in 3 of the patients with lymphoma. All the breaks occurred in an 8.3-kb breakpoint cluster region within the MLL gene. The probe identified DNA rearrangements in all 48 patients with the five common 11q23 translocations involving chromosomes 4, 6,9, and 19, as well as in 16 patients with uncommon 11q23 aberrations. Twenty-one different chromosomal breakpoints involving the MLL gene were detected. Conclusions. MLL gene rearrangements were detected with a single probe and a single restriction-enzyme digest in all DNA samples from patients with the common 11q23 translocations as well as in 16 patients or cell lines with other 11q23 anomalies. The ability to detect an MLL gene rearrangement rapidly and reliably, especially in patients with limited material for cytogenetic analysis, should make it possible to identify patients who have a poor prognosis and therefore require aggressive chemotherapy or marrow transplantation.	UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PEDIAT,CHICAGO,IL 60637; SAITAMA CANC CTR,INA,SAITAMA 362,JAPAN; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; SW BIOMED RES INST,SCOTTSDALE,AZ; GENETRIX INC,SCOTTSDALE,AZ	University of Chicago; University of Chicago; Memorial Sloan Kettering Cancer Center	THIRMAN, MJ (corresponding author), UNIV CHICAGO,DEPT MED,HEMATOL & ONCOL SECT,CHICAGO,IL 60637, USA.			Larson, Richard/0000-0001-9168-3203	NCI NIH HHS [CA42557, CA40046, CA38725] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA038725, R35CA042557, R01CA038725] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAO Y, 1991, CANCER RES, V51, P1574; AKAO Y, 1990, CANCER RES, V50, P4856; ARTHUR DC, 1982, BLOOD, V59, P96; BLOOMFIELD CD, 1992, LEUKEMIA, V6, P65; BURNETT RC, 1993, GENE CHROMOSOME CANC, V7, P38, DOI 10.1002/gcc.2870070107; CHEN CS, 1993, BLOOD, V81, P2386; CHEN CS, 1991, BLOOD, V78, P2498; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHERIF D, 1992, GENE CHROMOSOME CANC, V4, P107, DOI 10.1002/gcc.2870040202; CIMINO G, 1992, CANCER RES, V52, P3811; CIMINO G, 1991, CANCER RES, V51, P6712; CUNEO A, 1992, BLOOD, V79, P720; DAS S, 1991, GENE CHROMOSOME CANC, V3, P44, DOI 10.1002/gcc.2870030108; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DREXLER HG, 1991, LEUKEMIA, V5, P637; FENAUX P, 1992, BLOOD, V80, P2176; GIBBONS B, 1990, BRIT J HAEMATOL, V74, P264, DOI 10.1111/j.1365-2141.1990.tb02581.x; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HUDSON MM, 1991, LEUKEMIA, V5, P1064; HURET JL, 1993, LEUKEMIA, V7, P152; KANEKO Y, 1988, LEUKEMIA, V2, P672; KARPAS A, 1977, LEUKEMIA RES, V1, P35, DOI 10.1016/0145-2126(77)90063-7; KOBAYASHI H, 1993, BLOOD, V82, P547; MCCABE NR, 1992, P NATL ACAD SCI USA, V89, P11794, DOI 10.1073/pnas.89.24.11794; MITELMAN F, 1991, CYTOGENET CELL GENET, V58, P1053, DOI 10.1159/000133721; MITELMAN F, 1991, INT SYSTEM HUMAN C S, V6; MITELMAN F, 1991, CATALOG CHROMOSOME A; NICHOLS J, 1992, BLOOD, V80, P2953; NUCIFORA G, 1993, BLOOD, V81, P2728; PUI CH, 1991, BLOOD, V77, P440; RADICE P, 1992, GENE CHROMOSOME CANC, V5, P50, DOI 10.1002/gcc.2870050108; ROWLEY JD, 1990, SEMIN HEMATOL, V27, P122; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA; SAVAGE PD, 1988, CYTOGENET CELL GENET, V49, P289, DOI 10.1159/000132680; SAVAGE PD, 1991, CYTOGENET CELL GENET, V56, P112, DOI 10.1159/000133062; SMITH SD, 1989, BLOOD, V73, P2182; STONG RC, 1985, BLOOD, V66, P439; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TUNNACLIFFE A, 1990, GENOMICS, V8, P447, DOI 10.1016/0888-7543(90)90030-X; VANDERPOEL SZ, 1992, P NATL ACAD SCI USA, V89, P4220; WESTBROOK CA, 1992, BLOOD, V80, P2983; YUNIS JJ, 1989, GENOMICS, V5, P84, DOI 10.1016/0888-7543(89)90090-6; 1984, CANCER GENET CYTOGEN, V11, P332; 1989, CANCER GENET CYTOGEN, V40, P171	46	480	488	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					909	914		10.1056/NEJM199309233291302	http://dx.doi.org/10.1056/NEJM199309233291302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361504				2022-12-28	WOS:A1993LX75100002
J	LASKEY, RA; DINGWALL, C				LASKEY, RA; DINGWALL, C			NUCLEAR SHUTTLING - THE DEFAULT PATHWAY FOR NUCLEAR PROTEINS	CELL			English	Review							CYTOPLASM; NUCLEOPLASMIN; BINDING		UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND	University of Cambridge	LASKEY, RA (corresponding author), UNIV CAMBRIDGE,WELLCOME CANC RES COUNCIL INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1988, J CELL BIOL, V107, P841, DOI 10.1083/jcb.107.3.841; GOLDFARB D S, 1991, Current Biology, V1, P212, DOI 10.1016/0960-9822(91)90059-6; GOLDSTEIN L, 1958, EXP CELL RES, V15, P635, DOI 10.1016/0014-4827(58)90118-6; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; KAMBACH C, 1992, J CELL BIOL, V118, P11, DOI 10.1083/jcb.118.1.11; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; MEIER UT, 1992, CELL, V70, P127; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; SCHMDITZACHMANN MS, 1993, IN PRESS J CELL SCI; SCHMIDTZACHMANN MS, 1993, CELL, V74, P494; SCHULZ B, 1987, BIOCHIM BIOPHYS ACTA, V930, P419, DOI 10.1016/0167-4889(87)90015-2	14	66	67	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 27	1993	74	4					585	586		10.1016/0092-8674(93)90505-K	http://dx.doi.org/10.1016/0092-8674(93)90505-K			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358787				2022-12-28	WOS:A1993LU59200001
J	DENG, HX; HENTATI, A; TAINER, JA; IQBAL, Z; CAYABYAB, A; HUNG, WY; GETZOFF, ED; HU, P; HERZFELDT, B; ROOS, RP; WARNER, C; DENG, G; SORIANO, E; SMYTH, C; PARGE, HE; AHMED, A; ROSES, AD; HALLEWELL, RA; PERICAKVANCE, MA; SIDDIQUE, T				DENG, HX; HENTATI, A; TAINER, JA; IQBAL, Z; CAYABYAB, A; HUNG, WY; GETZOFF, ED; HU, P; HERZFELDT, B; ROOS, RP; WARNER, C; DENG, G; SORIANO, E; SMYTH, C; PARGE, HE; AHMED, A; ROSES, AD; HALLEWELL, RA; PERICAKVANCE, MA; SIDDIQUE, T			AMYOTROPHIC-LATERAL-SCLEROSIS AND STRUCTURAL DEFECTS IN CU,ZN SUPEROXIDE-DISMUTASE	SCIENCE			English	Article							MANGANESE; PROTEIN; ENZYME; MUTATIONS; INTERFACE; STABILITY; DISEASE; LINKAGE	Single-site mutants in the Cu,Zn superoxide dismutase (SOD) gene (SOD1) occur in patients with the fatal neurodegenerative disorder familial amyotrophic lateral sclerosis (FALS). Complete screening of the SOD1 coding region revealed that the mutation Ala4 to Val in exon 1 was the most frequent one; mutations were identified in exons 2, 4, and 5 but not in the active site region formed by exon 3. The 2.4 angstrom crystal structure of human SOD, along with two other SOD structures, established that all 12 observed FALS mutant sites alter conserved interactions critical to the beta-barrel fold and dimer contact, rather than catalysis. Red cells from heterozygotes had less than 50 percent normal SOD activity, consistent with a structurally defective SOD dimer. Thus, defective SOD is linked to motor neuron death and carries implications for understanding and possible treatment of FALS.	NORTHWESTERN UNIV, SCH MED, DEPT NEUROL, 300 E SUPER ST, CHICAGO, IL 60611 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; NORTHWESTERN UNIV, INST NEUROSCI, CHICAGO, IL 60611 USA; UNIV CHICAGO, DEPT NEUROL, CHICAGO, IL 60637 USA; DENT NEUROL INST, DEPT NEUROL, BUFFALO, NY 14209 USA; DUKE UNIV, MED CTR, DEPT MED NEUROL, DURHAM, NC 27710 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOCHEM, LONDON SW7 2AZ, ENGLAND; NORTHWESTERN UNIV, SCH MED, DEPT CELL MOLEC & STRUCT BIOL, CHICAGO, IL 60611 USA	Northwestern University; Scripps Research Institute; Northwestern University; University of Chicago; Duke University; Imperial College London; Northwestern University			Siddique, Teepu/AAT-8166-2021; Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Deng, Han-Xiang/0000-0002-0030-8465; Siddique, Teepu/0000-0001-7293-9146				ANTONARAKIS SE, 1992, GENOMICS, V14, P1126, DOI 10.1016/S0888-7543(05)80148-X; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BORGSTAHL GEO, 1992, CELL, V71, P107, DOI 10.1016/0092-8674(92)90270-M; BRACCO F, 1991, P SOC EXP BIOL MED, V196, P36; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CEBALLOS I, 1991, FREE RADICAL RES COM, V12-3, P571; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; GETZOFF ED, 1989, PROTEINS, V5, P322, DOI 10.1002/prot.340050408; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; HALLEWELL RA, 1985, NUCLEIC ACIDS RES, V13, P2017, DOI 10.1093/nar/13.6.2017; HALLEWELL RA, UNPUB; HALLEWELL RA, 1986, SUPEROXIDE DISMUTASE, P249; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hirano A., 1979, AMYOTROPHIC LATERAL, P107; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; IQBAL Z, UNPUB; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P634; KUO CF, 1987, J BIOL CHEM, V262, P4724; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCNAMARA JO, 1993, NATURE, V362, P20, DOI 10.1038/362020a0; MCREE DE, 1990, J BIOL CHEM, V265, P14234; MENDEL D, 1992, SCIENCE, V256, P1798, DOI 10.1126/science.1615324; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; NISHIYAMA M, 1992, PROTEIN ENG, V5, P177, DOI 10.1093/protein/5.2.177; Oberley L.W., 1985, HDB METHODS OXYGEN R, P217; OLANOW CW, 1990, NEUROLOGY, V40, P32; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; OTT J, 1991, ANAL HUMAN GENETIC L, P203; PARGE HE, 1992, P NATL ACAD SCI USA, V89, P6109, DOI 10.1073/pnas.89.13.6109; PARGE HE, 1986, J BIOL CHEM, V261, P6215; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; REDFORD S, UNPUB; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sambrook J., 1989, MOL CLONING; SANDBERG WS, 1989, SCIENCE, V245, P54, DOI 10.1126/science.2787053; SCRUTTON NS, 1992, SCIENCE, V258, P1140, DOI 10.1126/science.1439821; SIDDIQUE T, 1989, NEUROLOGY, V39, P919, DOI 10.1212/WNL.39.7.919; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; SIDDIQUE T, IN PRESSS IN TJ NEUR; SIDDIQUE T, UNPUB; SPITZ DR, 1989, ANAL BIOCHEM, V179, P8, DOI 10.1016/0003-2697(89)90192-9; TANDAN R, 1979, ANN NEUROL, V36, P271; TANDAN R, 1979, ANN NEUROL, V36, P419; WILLIAMS DB, 1993, PERIPHERAL NEUROPATH, P1028; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; YONEDA T, 1992, BRAIN RES, V582, P342, DOI 10.1016/0006-8993(92)90153-Z	51	1383	1428	3	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					1047	1051		10.1126/science.8351519	http://dx.doi.org/10.1126/science.8351519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351519				2022-12-28	WOS:A1993LT74700035
J	PAWLOWSKI, T; ELLIOTT, JD; LOH, DY; STAERZ, UD				PAWLOWSKI, T; ELLIOTT, JD; LOH, DY; STAERZ, UD			POSITIVE SELECTION OF T-LYMPHOCYTES ON FIBROBLASTS	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CELL RECEPTOR; HEMATOPOIETIC-CELLS; MONOCLONAL-ANTIBODY; ANTIGEN RECEPTOR; MICE; THYMUS; LINE; DIFFERENTIATION; SPECIFICITY	THYMOCYTES are selected for expression of alphabeta T-cell antigen receptors (TCR) which recognize antigen in conjunction with self-major histocompatibility complex (MHC) molecules1,2. In the thymus the restriction element is imprinted on radioresistant stromal elements3-7 and on cells of haematopoietic origin8-10. In mice negative for beta2-microglobulin that are devoid of mature cytotoxic T lymphocytes11, we find that intrathymic injection of different fibroblasts causes the maturation of CD4-CD8+TCR(high) thymocytes with distinct patterns of TCR Vbeta distribution. Here we show that in TCR-transgenic mice, intrathymic injection of L cells expressing the selecting H-2K(b) molecule (L-K(b) cells) reconstitutes the maturation of thymocytes bearing the- transgenic TCR, and that in normal B10.BR (H-2k) mice, H-2K(b) Molecules expressed on L-K(b) cells lead to the development of T lymphocytes with recognition restricted to H-2K(b). A class I MHC restriction element can thus be selected by interaction with fibroblasts, that is, cells of other than epithelial or haematopoietic origin3-10.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT IMMUNOL,ST LOUIS,MO 63110; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80262	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	PAWLOWSKI, T (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DEPT MED,1400 JACKSON ST,DENVER,CO 80206, USA.							ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BERNSTEIN ID, 1980, SCIENCE, V207, P68, DOI 10.1126/science.6965328; BEVAN MJ, 1978, IMMUNOL REV, V42, P3, DOI 10.1111/j.1600-065X.1978.tb00256.x; BILL J, 1988, P NATL ACAD SCI USA, V85, P9184, DOI 10.1073/pnas.85.23.9184; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; BIX M, 1992, NATURE, V359, P330, DOI 10.1038/359330a0; CRISPE IN, 1985, NATURE, V317, P627, DOI 10.1038/317627a0; DEBRICK JE, 1991, J IMMUNOL, V147, P2846; HUGO P, 1992, NATURE, V360, P679, DOI 10.1038/360679a0; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; KAYE J, 1992, CELL, V71, P423, DOI 10.1016/0092-8674(92)90512-B; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUBO RT, 1989, J IMMUNOL, V142, P2736; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; LONGO DL, 1985, P NATL ACAD SCI USA, V82, P5900, DOI 10.1073/pnas.82.17.5900; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OHKI H, 1987, SCIENCE, V237, P1032, DOI 10.1126/science.3616623; PULLEN AM, 1990, J EXP MED, V171, P49, DOI 10.1084/jem.171.1.49; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHAW WC, 1990, P NATL ACAD SCI USA, V87, P6186; SHAW WC, 1988, NATURE, V333, P742; SPEISER DE, 1992, NATURE, V355, P170, DOI 10.1038/355170a0; SPRENT J, 1978, J EXP MED, V147, P1159, DOI 10.1084/jem.147.4.1159; STAERZ UD, 1986, EUR J IMMUNOL, V16, P263, DOI 10.1002/eji.1830160310; VUKMANOVIC S, 1992, NATURE, V359, P729, DOI 10.1038/359729a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	28	92	92	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					642	645		10.1038/364642a0	http://dx.doi.org/10.1038/364642a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350923				2022-12-28	WOS:A1993LR77100057
J	FONG, TM; CASCIERI, MA; YU, H; BANSAL, A; SWAIN, C; STRADER, CD				FONG, TM; CASCIERI, MA; YU, H; BANSAL, A; SWAIN, C; STRADER, CD			AMINO AROMATIC INTERACTION BETWEEN HISTIDINE-197 OF THE NEUROKININ-1 RECEPTOR AND CP-96345	NATURE			English	Article							SUBSTANCE-P RECEPTOR; MOLECULAR CHARACTERIZATION; FUNCTIONAL CDNA; ANTAGONIST; PEPTIDES; PROTEINS; NEURONS; BINDING; POTENT; RINGS	SUBSTANCE P is a peptide neurotransmitter that binds to the neurokinin-1 receptor and is involved in pain transmission and neurogenic inflammation1-4. Recently, a non-peptide substance P antagonist (CP 96345) has been shown to be effective in animal models of pain and inflammation5,6. An understanding of the molecular interactions responsible for ligand binding will be critical for the development of more specific and selective antagonists for the neurokinin-I receptor and for the discovery of new antagonists for related G-protein-coupled receptors. Here we report that histidine at position 197 in the fifth transmembrane helix of the human neurokinin-1 receptor binds specifically to CP 96345 but not to peptide agonists. Substitution of His 197 by different amino acids and analysis of structural analogues of antagonists suggest that His 197 is involved in an amino-aromatic interaction with the benzhydryl moiety of CP 96345.	MERCK SHARP & DOHME LTD, NEUROSCI RES CTR, HARLOW CM20 2PT, ESSEX, ENGLAND	Merck & Company	FONG, TM (corresponding author), MERCK RES LABS, DEPT MOLEC PHARMACOL & BIOCHEM 80M213, POB 2000, RAHWAY, NJ 07065 USA.							BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; DE KONINCK Y, 1991, P NATL ACAD SCI USA, V88, P11344, DOI 10.1073/pnas.88.24.11344; DEAKYNE CA, 1985, J AM CHEM SOC, V107, P474; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, MOL PHARMACOL, V41, P24; GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; HELKE CJ, 1990, FASEB J, V4, P1606, DOI 10.1096/fasebj.4.6.1969374; HERSHEY AD, 1990, SCIENCE, V247, P958, DOI 10.1126/science.2154852; IVERSEN LL, 1987, TOP MED CHEM, V65, P1; KHORANA HG, 1992, J BIOL CHEM, V267, P1; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LOWE JA, 1992, J MED CHEM, V35, P2591, DOI 10.1021/jm00092a009; NAKANISHI S, 1991, REV NEUROSCI, V14, P123; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; REES DC, 1989, SCIENCE, V245, P510, DOI 10.1126/science.2667138; REGOLI D, 1989, PHARMACOLOGY, V38, P1, DOI 10.1159/000138512; SINGH J, 1990, J MOL BIOL, V211, P595, DOI 10.1016/0022-2836(90)90268-Q; SINGH J, 1985, FEBS LETT, V191, P1, DOI 10.1016/0014-5793(85)80982-0; SNIDER RM, 1991, SCIENCE, V251, P435, DOI 10.1126/science.1703323; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; YOKOTA Y, 1989, J BIOL CHEM, V264, P17649	25	212	213	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 25	1993	362	6418					350	353						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KU176	8384323				2022-12-28	WOS:A1993KU17600063
J	WAHLESTEDT, C; PICH, EM; KOOB, GF; YEE, F; HEILIG, M				WAHLESTEDT, C; PICH, EM; KOOB, GF; YEE, F; HEILIG, M			MODULATION OF ANXIETY AND NEUROPEPTIDE-Y-Y1 RECEPTORS BY ANTISENSE OLIGODEOXYNUCLEOTIDES	SCIENCE			English	Article							PANCREATIC-POLYPEPTIDE; FEEDING-BEHAVIOR; PEPTIDE-YY; RAT-BRAIN; NPY; HETEROGENEITY; INVOLVEMENT; EXPRESSION; CELLS; MAZE	The function of neuropeptide Y, one of the most abundant peptide transmitters of the mammalian brain, remains unclear because of a lack of specific receptor antagonists. An antisense oligodeoxynucleotide corresponding to the NH2-terminus of the rat Y1 receptor was constructed and added to cultures of rat cortical neurons. This treatment resulted in a reduced density of Y1 (but not Y2) receptors and diminished the decrease in adenosine 3',5'-monophosphate (cAMP) usually seen after Y1 receptor activation. Repeated injection of the same oligodeoxynucleotide into the lateral cerebral ventricle of rats was followed by a similar reduction of cortical Y1 (but not Y2) receptors. Such antisense-treated animals displayed behavioral signs of anxiety. Thus, specific inhibition of neurotransmitter receptor expression can be accomplished in the living brain and demonstrates that altered central, neuropeptide Y transmission produces an anxiety-like state.	CORNELL UNIV, MED CTR,COLL MED,DEPT NEUROL & NEUROSCI, DIV NEUROBIOL, NEW YORK, NY 10021 USA; Scripps Res Inst, RES INST, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA	Cornell University; Scripps Research Institute			Wahlestedt, Claes/A-7039-2009					ADRIAN TE, 1983, NATURE, V306, P584, DOI 10.1038/306584a0; AICHER SA, 1991, NEUROSCI LETT, V130, P32, DOI 10.1016/0304-3940(91)90220-N; Akhtar S, 1992, Trends Cell Biol, V2, P139, DOI 10.1016/0962-8924(92)90100-2; BURCH RM, 1991, J CLIN INVEST, V88, P1190, DOI 10.1172/JCI115421; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; HANDLEY SL, 1984, N-S ARCH PHARMACOL, V327, P1, DOI 10.1007/BF00504983; HEILIG M, 1991, EUR J PHARMACOL, V209, P27, DOI 10.1016/0014-2999(91)90006-C; HEILIG M, 1988, EUR J PHARMACOL, V157, P205, DOI 10.1016/0014-2999(88)90384-6; HEILIG M, 1990, ACTA PSYCHIAT SCAND, V82, P95, DOI 10.1111/j.1600-0447.1990.tb01366.x; HEILIG M, 1989, PSYCHOPHARMACOLOGY, V98, P524, DOI 10.1007/BF00441953; HEILIG M, IN PRESS NEUROPSYCHO; HELENE C, 1990, BIOCHIM BIOPHYS ACTA, V1049, P99, DOI 10.1016/0167-4781(90)90031-V; JIRIKOWSKI GF, 1992, SCIENCE, V255, P996, DOI 10.1126/science.1546298; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; LARHAMMAR D, 1992, J BIOL CHEM, V267, P10935; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LEVY Y, 1991, J CLIN INVEST, V88, P696, DOI 10.1172/JCI115355; LOKE SL, 1989, P NATL ACAD SCI USA, V86, P3474, DOI 10.1073/pnas.86.10.3474; MCDONALD JK, 1988, CRIT REV NEUROBIOL, V4, P97; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; STANLEY BG, 1985, P NATL ACAD SCI USA, V82, P3940, DOI 10.1073/pnas.82.11.3940; STANLEY BG, 1992, PEPTIDES, V13, P581, DOI 10.1016/0196-9781(92)90093-I; TATEMOTO K, 1982, NATURE, V296, P659, DOI 10.1038/296659a0; WAHLESTEDT C, 1992, LIFE SCI, V50, pPL7, DOI 10.1016/0024-3205(92)90342-M; WAHLESTEDT C, IN PRESS ANN REV PHA; WAHLESTEDT C, 1990, ANN NY ACAD SCI, V611, P7; WALKER MW, 1988, MOL PHARMACOL, V34, P779; WEST AP, 1991, MOL CELL ENDOCRINOL, V79, pR9, DOI 10.1016/0303-7207(91)90111-5; YAKUBOV LA, 1989, P NATL ACAD SCI USA, V86, P6454, DOI 10.1073/pnas.86.17.6454; ZHENG HG, 1989, P NATL ACAD SCI USA, V86, P3758, DOI 10.1073/pnas.86.10.3758	31	507	535	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 22	1993	259	5094					528	531		10.1126/science.8380941	http://dx.doi.org/10.1126/science.8380941			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KJ079	8380941				2022-12-28	WOS:A1993KJ07900039
J	POHJOLASINTONEN, S; VIITASALO, M; TOIVONEN, L; NEUVONEN, P				POHJOLASINTONEN, S; VIITASALO, M; TOIVONEN, L; NEUVONEN, P			TORSADES-DE-POINTES AFTER TERFENADINE-ITRACONAZOLE INTERACTION	BRITISH MEDICAL JOURNAL			English	Letter											POHJOLASINTONEN, S (corresponding author), UNIV HELSINKI,CENT HOSP,SF-00100 HELSINKI 10,FINLAND.		Neuvonen, Pertti J/G-4675-2011; Neuvonen, Pertti/Z-4818-2019	Neuvonen, Pertti/0000-0003-3631-9411				DAVIES AJ, 1989, BRIT MED J, V298, P325, DOI 10.1136/bmj.298.6669.325; MACCONNELL TJ, 1991, BRIT MED J, V302, P1469, DOI 10.1136/bmj.302.6790.1469-b; MATTHEWS DR, 1991, JAMA-J AM MED ASSOC, V266, P2375; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; ZIMMERMANN M, 1992, EUR HEART J, V13, P1002	5	49	49	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					186	186		10.1136/bmj.306.6871.186	http://dx.doi.org/10.1136/bmj.306.6871.186			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8382980	Bronze, Green Published			2022-12-28	WOS:A1993KH51300024
J	BOND, JH				BOND, JH			POLYP GUIDELINE - DIAGNOSIS, TREATMENT, AND SURVEILLANCE FOR PATIENTS WITH NONFAMILIAL COLORECTAL POLYPS	ANNALS OF INTERNAL MEDICINE			English	Article							CONTRAST BARIUM ENEMA; ADENOMATOUS COLONIC POLYPS; FLEXIBLE SIGMOIDOSCOPY; INVASIVE-CARCINOMA; MALIGNANT POLYPS; LARGE BOWEL; FIBEROPTIC SIGMOIDOSCOPY; COLONOSCOPIC POLYPECTOMY; ENDOSCOPIC POLYPECTOMY; CLINICAL-SIGNIFICANCE	Objective: To outline the preferable approach to the management of patients with nonfamilial colorectal polyps. Data Sources: The human subject English language literature for the past 15 years, searched using MEDLINE and the terms ''poly-,'' ''adenoma-,'' and ''polypectomy-colorectal.'' Study Selection: The titles and abstracts of all pertinent articles were reviewed. All randomized controlled trials and large case-control and cohort studies related to colorectal polyps were reviewed in depth. Data Synthesis: Evidence was evaluated along a hierarchy with randomized controlled trials receiving the greatest weight. Conclusions and recommendations were reviewed by a large group of experts in gastroenterology, radiology, and pathology and were circulated for comment to primary care medical societies. Conclusions: Most patients with polyps should undergo colonoscopy to excise the polyp and search for synchronous neoplasms. Small polyps (<0.5 cm) require individualization. A hyperplastic polyp found during proctosigmoidoscopy is not an indication for colonoscopy. Large sessile polyps require careful follow-up to ensure complete resection. The need for further treatment of a resected polyp with invasive carcinoma depends on several well-defined clinical and pathologic criteria. Follow-up surveillance after polypectomy should be tailored to the individual risk assessment for each patient. Initial follow-up should be performed at 3 years for most postpolypectomy patients. After one negative result of a 3-year examination, the interval can be increased to 5 years. Patients with one small tubular adenoma do not have an increased risk for cancer, and therefore follow-up surveillance may not be indicated. Adoption of these recommendations should substantially reduce the cost of postpolypectomy surveillance and of screening for colorectal cancer.			BOND, JH (corresponding author), AMER COLL GASTROENTEROL, 4900 B S 31ST ST, ARLINGTON, VA 22206 USA.							ACHKAR E, 1988, ANN INTERN MED, V109, P880, DOI 10.7326/0003-4819-109-11-880; ANSHER AF, 1989, AM J GASTROENTEROL, V84, P113; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BARRY MJ, 1987, GASTROENTEROLOGY, V93, P301, DOI 10.1016/0016-5085(87)91019-5; BOND JH, 1979, GASTROENTEROLOGY, V77, P1349; Bussey H.J.R., 1975, FAMILIAL POLYPOSIS C; CANNONALBRIGHT LA, 1988, NEW ENGL J MED, V319, P533, DOI 10.1056/NEJM198809013190902; CHRISTIE JP, 1988, AM SURGEON, V54, P93; CHU DZJ, 1986, CANCER, V57, P445, DOI 10.1002/1097-0142(19860201)57:3<445::AID-CNCR2820570307>3.0.CO;2-D; COHEN LB, 1986, CLIN GASTROENTEROL, V15, P359; COHEN LB, 1989, DIFFICULT DECISIONS, P528; COOPER HS, 1983, AM J SURG PATHOL, V7, P613, DOI 10.1097/00000478-198310000-00002; CORREA P, 1979, GASTROENTEROLOGY, V77, P1245; COUTSOFTIDES T, 1978, ANN SURG, V188, P638, DOI 10.1097/00000658-197811000-00009; COVERLIZZA S, 1989, CANCER-AM CANCER SOC, V64, P1937, DOI 10.1002/1097-0142(19891101)64:9<1937::AID-CNCR2820640929>3.0.CO;2-X; CRANLEY JP, 1986, GASTROENTEROLOGY, V91, P419, DOI 10.1016/0016-5085(86)90577-9; DAY DW, 1978, MAJOR PROBLEMS PATHO, P43; DEROOS A, 1985, RADIOLOGY, V154, P11, DOI 10.1148/radiology.154.1.3964926; DODD GD, 1981, GASTROINTESTINAL CAN, P327; ECKARDT VF, 1988, CANCER, V61, P2552, DOI 10.1002/1097-0142(19880615)61:12<2552::AID-CNCR2820611227>3.0.CO;2-6; EIDE TJ, 1986, HISTOPATHOLOGY, V10, P111, DOI 10.1111/j.1365-2559.1986.tb02467.x; FARRANDS PA, 1983, DIS COLON RECTUM, V26, P727; FECZKO PJ, 1986, AM J ROENTGENOL, V146, P697, DOI 10.2214/ajr.146.4.697; FENOGLIO CM, 1982, CANCER, V50, P2601; FENOGLIO CM, 1973, GASTROENTEROLOGY, V64, P51; FENOGLIOPREISER CM, 1985, CA-CANCER J CLIN, V35, P322, DOI 10.3322/canjclin.35.6.322; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; FOUTCH PG, 1990, GASTROINTEST ENDOSC, V36, P212; FOWLER DL, 1980, GASTROINTEST ENDOSC, V26, P67; FUCINI C, 1986, MAYO CLIN PROC, V61, P123, DOI 10.1016/S0025-6196(12)65198-2; GILBERTSEN VA, 1978, CANCER, V41, P1137, DOI 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G; GILBERTSEN VA, 1979, SURG GYNECOL OBSTET, V149, P877; GILLESPIE PE, 1979, GUT, V20, P240, DOI 10.1136/gut.20.3.240; GRANQVIST S, 1981, SCAND J GASTROENTERO, V16, P1025, DOI 10.3109/00365528109181023; GREENBURG AG, 1981, ARCH SURG-CHICAGO, V116, P788; HAGGITT RC, 1985, GASTROENTEROLOGY, V89, P326; HENRY LG, 1975, ANN SURG, V182, P511, DOI 10.1097/00000658-197510000-00017; HIXSON LJ, 1991, GASTROINTEST ENDOSC, V37, P125, DOI 10.1016/S0016-5107(91)70668-8; HOGAN WJ, 1977, GASTROINTEST ENDOSC, V23, P230; IRVINE EJ, 1988, GUT, V29, P1188, DOI 10.1136/gut.29.9.1188; JENSEN J, 1990, BRIT J SURG, V77, P270, DOI 10.1002/bjs.1800770311; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KIRSNER JB, 1960, GASTROENTEROLOGY, V39, P178; KNUTSON CO, 1979, ARCH SURG-CHICAGO, V114, P430; KONISHI F, 1982, J CLIN PATHOL, V35, P830, DOI 10.1136/jcp.35.8.830; LANGER JC, 1984, DIS COLON RECTUM, V27, P6, DOI 10.1007/BF02554062; LIPPER S, 1983, CANCER, V52, P1691, DOI 10.1002/1097-0142(19831101)52:9<1691::AID-CNCR2820520924>3.0.CO;2-P; LOTFI AM, 1986, MAYO CLIN PROC, V61, P337, DOI 10.1016/S0025-6196(12)61950-8; MATEK W, 1985, ENDOSCOPY, V17, P175, DOI 10.1055/s-2007-1018494; MILLER RE, 1974, JAMA-J AM MED ASSOC, V230, P1195, DOI 10.1001/jama.230.8.1195; MORSON BC, 1966, P ROY SOC MED, V59, P607, DOI 10.1177/003591576605900710; MORSON BC, 1984, GUT, V25, P437, DOI 10.1136/gut.25.5.437; MORSON BC, 1974, CANCER, V34, P845, DOI 10.1002/1097-0142(197409)34:3+<845::AID-CNCR2820340710>3.0.CO;2-H; MORSON BC, 1982, GASTROINTEST RADIOL, V7, P275, DOI 10.1007/BF01887653; MORSON BC, 1976, INT HISTOLOGICAL CLA, V15; MORSON BC, 1986, GENESIS COLORECTAL C, P505; MUTO T, 1977, DIS COLON RECTUM, V20, P11, DOI 10.1007/BF02587445; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; PROVENZALE D, 1990, ANN INTERN MED, V113, P760, DOI 10.7326/0003-4819-113-10-760; RANKIN GB, 1987, GASTROINTEST ENDOSC, P873; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; REX DK, 1992, GASTROENTEROLOGY, V102, P317, DOI 10.1016/0016-5085(92)91817-N; REX DK, 1990, GASTROENTEROLOGY, V98, P855, DOI 10.1016/0016-5085(90)90007-N; RICHARDS WO, 1987, ANN SURG, V205, P665, DOI 10.1097/00000658-198706000-00008; ROSSINI FP, 1982, ENDOSCOPY, V14, P124, DOI 10.1055/s-2007-1021598; SCHOTTENFELD D, 1982, CANCER EPIDEMIOL, P703; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SHATNEY CH, 1974, SURG GYNECOL OBSTET, V139, P845; SHINYA H, 1979, ANN SURG, V190, P679, DOI 10.1097/00000658-197912000-00001; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; STOLTENBERG PH, 1988, GASTROINTEST ENDOSC, V34, P172; TEDESCO FJ, 1982, GASTROINTEST ENDOSC, V28, P1, DOI 10.1016/S0016-5107(82)72954-2; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; VELLACOTT KD, 1981, BRIT MED J, V283, P1583, DOI 10.1136/bmj.283.6306.1583; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAYE JD, 1988, AM J GASTROENTEROL, V83, P120; WAYE JD, 1982, ENDOSCOPY, V14, P79, DOI 10.1055/s-2007-1021585; WAYE JD, 1991, GASTROINTEST ENDOSC, V37, P152, DOI 10.1016/S0016-5107(91)70674-3; WILCOX GM, 1987, GASTROENTEROLOGY, V92, P1159, DOI 10.1016/S0016-5085(87)91072-9; WILLIAMS AR, 1982, GUT, V23, P835, DOI 10.1136/gut.23.10.835; WINAWER S J, 1991, Gastroenterology, V100, pA410; WINAWER SJ, 1987, GASTROINTEST ENDOSC, V33, P167; WINAWER SJ, 1979, DIGEST DIS SCI, V24, P277, DOI 10.1007/BF01296540; WINAWER SJ, 1990, B WORLD HEALTH ORGAN, V68, P789; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINNAN G, 1980, NEW ENGL J MED, V302, P1011, DOI 10.1056/NEJM198005013021806; WOLFF WI, 1975, ANN SURG, V182, P516, DOI 10.1097/00000658-197510000-00018; ZAUBER A, 1988, AM J GASTROENTEROL, V83, P1060	90	206	208	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					836	843		10.7326/0003-4819-119-8-199310150-00010	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379605				2022-12-28	WOS:A1993MB49600010
J	FELSON, DT; ZHANG, YQ; HANNAN, MT; KIEL, DP; WILSON, PWF; ANDERSON, JJ				FELSON, DT; ZHANG, YQ; HANNAN, MT; KIEL, DP; WILSON, PWF; ANDERSON, JJ			THE EFFECT OF POSTMENOPAUSAL ESTROGEN THERAPY ON BONE-DENSITY IN ELDERLY WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIP FRACTURE; CIGARETTE-SMOKING; OSTEOPOROSIS; RISK; MENOPAUSE; CALCIUM	Background. Estrogen therapy prevents bone loss in postmenopausal women who take it early in the postmenopausal period. The risk of fracture is highest much later in life, however. We studied whether bone mass in elderly women was affected by earlier estrogen use and how long women needed to take estrogen for it to have a beneficial effect on bone density later in life. Methods. In 1988 and 1989, we measured bone mineral density at the femur, spine, shaft of the radius, and ultradistal radius in 670 white women in the Framingham Study cohort (mean age, 76 years; range, 68 to 96). These women had been followed prospectively through menopause and had been asked repeatedly about estrogen therapy. After excluding women who began taking estrogen after a fracture, we investigated whether postmenopausal estrogen therapy affected bone density; in these analyses we adjusted for age, weight, height, cigarette smoking, physical activity, and age at menopause. Results. A total of 212 women (31.6 percent) had received estrogen therapy (mean estimated duration of treatment, 5 years). Only women who had taken estrogen for 7 to 9 years or for 10 or more years had significantly higher bone mineral density than women who had not taken estrogen (7 to 9 years of treatment, P<0.05 at sites in the femur and the spine; greater-than-or-equal-to 10 years, P<0.05 at all sites except the spine). In the women less than 75 years of age who had taken estrogen for seven or more years, the bone density was, averaging all sites, 11.2 percent greater than in women who had never received estrogen. Among women 75 years of age and older in whom the duration of therapy was comparable, bone density was only 3.2 percent higher than in women who had never taken estrogen. Conclusions. For long-term preservation of bone mineral density, women should take estrogen for at least seven years after menopause. Even this duration of therapy may have little residual effect on bone density among women 75 years of age and older, who have the highest risk of fracture.	HEBREW REHABIL CTR AGED, BOSTON, MA USA; BOSTON CITY HOSP, DEPT MED, BOSTON, MA 02118 USA; UNIV HOSP BOSTON, DEPT MED, BOSTON, MA 02118 USA; FRAMINGHAM STUDY, FRAMINGHAM, MA USA	Boston Medical Center	FELSON, DT (corresponding author), BOSTON UNIV, SCH MED, CTR ARTHRITIS, 80 E CONCORD ST, A203, BOSTON, MA 02118 USA.		Wilson, Peter W.F./J-2455-2016	Felson, David/0000-0002-2668-2447; Zhang, Yuqing/0000-0001-7954-1149; Kiel, Douglas/0000-0001-8474-0310; Hannan, Marian/0000-0002-9586-6928	NIAMS NIH HHS [AR20613] Funding Source: Medline; NIA NIH HHS [R01AG09300] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009300] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARZEL US, 1988, AM J MED, V85, P847; BENGNER U, 1988, CLIN ORTHOP RELAT R, V231, P179; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; ETTINGER B, 1985, ANN INTERN MED, V102, P319, DOI 10.7326/0003-4819-102-3-319; FARMER ME, 1984, AM J PUBLIC HEALTH, V74, P1374, DOI 10.2105/AJPH.74.12.1374; HANNAN MT, 1992, J BONE MINER RES, V7, P547; HEANEY RP, 1990, BONE MINER, V11, P67, DOI 10.1016/0169-6009(90)90016-9; HUTCHINSON TA, 1979, LANCET, V2, P705; JENSEN GF, 1982, CLIN ENDOCRINOL, V16, P515, DOI 10.1111/j.1365-2265.1982.tb02769.x; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; JENSEN JS, 1979, ACTA ORTHOP SCAND, V50, P161, DOI 10.3109/17453677908989751; JOHNSON RE, 1981, AM J PUBLIC HEALTH, V71, P138, DOI 10.2105/AJPH.71.2.138; KANIS JA, 1992, BRIT MED J, V305, P1124, DOI 10.1136/bmj.305.6862.1124; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KEY TJA, 1991, J STEROID BIOCHEM, V39, P529, DOI 10.1016/0960-0760(91)90247-3; KIEL DP, 1992, ANN INTERN MED, V116, P716, DOI 10.7326/0003-4819-116-9-716; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; LINDSAY R, 1991, BAILLIERE CLIN OB GY, V5, P837, DOI 10.1016/S0950-3552(05)80291-3; MELTON LJ, 1987, CALCIFIED TISSUE INT, V41, P57; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MICHNOVICZ JJ, 1986, NEW ENGL J MED, V315, P1305, DOI 10.1056/NEJM198611203152101; NORDIN BEC, 1990, J CLIN ENDOCR METAB, V70, P83, DOI 10.1210/jcem-70-1-83; Paganini-Hill A, 1991, Epidemiology, V2, P16; PAGANINIHILL A, 1981, ANN INTERN MED, V95, P28, DOI 10.7326/0003-4819-95-1-28; PETITTI DB, 1989, CLIN ORTHOP RELAT R, P150; SERNBO I, 1988, ACTA ORTHOP SCAND, V59, P382, DOI 10.3109/17453678809149386; WEISS NS, 1980, NEW ENGL J MED, V303, P1195, DOI 10.1056/NEJM198011203032102	27	520	531	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 14	1993	329	16					1141	1146		10.1056/NEJM199310143291601	http://dx.doi.org/10.1056/NEJM199310143291601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA667	8377776				2022-12-28	WOS:A1993MA66700001
J	NEWBURGER, JW; JONAS, RA; WERNOVSKY, G; WYPIJ, D; HICKEY, PR; KUBAN, KCK; FARRELL, DM; HOLMES, GL; HELMERS, SL; CONSTANTINOU, J; CARRAZANA, E; BARLOW, JK; WALSH, AZ; LUCIUS, KC; SHARE, JC; WESSEL, DL; HANLEY, FL; MAYER, JE; CASTANEDA, AR; WARE, JH				NEWBURGER, JW; JONAS, RA; WERNOVSKY, G; WYPIJ, D; HICKEY, PR; KUBAN, KCK; FARRELL, DM; HOLMES, GL; HELMERS, SL; CONSTANTINOU, J; CARRAZANA, E; BARLOW, JK; WALSH, AZ; LUCIUS, KC; SHARE, JC; WESSEL, DL; HANLEY, FL; MAYER, JE; CASTANEDA, AR; WARE, JH			A COMPARISON OF THE PERIOPERATIVE NEUROLOGIC EFFECTS OF HYPOTHERMIC CIRCULATORY ARREST VERSUS LOW-FLOW CARDIOPULMONARY BYPASS IN INFANT HEART-SURGERY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMINO-ACID RECEPTORS; PROFOUND HYPOTHERMIA; CARDIAC-SURGERY; GREAT-ARTERIES; NERVOUS-SYSTEM; BRAIN-DAMAGE; EXTRACORPOREAL-CIRCULATION; OXYGEN-CONSUMPTION; CEREBRAL FUNCTION; DEEP HYPOTHERMIA	Background. Hypothermic circulatory arrest is a widely used support technique during heart surgery in infants, but its effects on neurologic outcome have been controversial. An alternative method, low-flow cardiopulmonary bypass, maintains continuous cerebral circulation but may increase exposure to known pump-related sources of brain injury, such as embolism or inadequate cerebral perfusion. Methods. We compared the incidence of perioperative brain injury after deep hypothermia and support consisting predominantly of total circulatory arrest with the incidence after deep hypothermia and support consisting predominantly of low-flow cardiopulmonary bypass in a randomized, single-center trial. The criteria for eligibility included a diagnosis of transposition of the great arteries with an intact ventricular septum or a ventricular septal defect and a planned arterial-switch operation before the age of three months. Results. Of 171 patients with D-transposition of the great arteries, 129 (66 of whom were assigned to circulatory arrest and 63 to low-flow bypass) had an intact ventricular septum, and 42 (21 assigned to circulatory arrest and 21 to low-flow bypass) had a ventricular septal defect. After adjustment for diagnosis, assignment to circulatory arrest as compared with low-flow bypass was associated with a higher risk of clinical seizures (odds ratio, 11.4; 95 percent confidence interval, 1.4 to 93.0), a tendency to a higher risk of ictal activity on continuous electroencephalographic (EEG) monitoring during the first 48 hours after surgery (odds ratio, 2.5; 95 percent confidence interval, 1.0 to 6.4), a longer recovery time to the first reappearance of EEG activity (only in the group with an intact ventricular septum, P<0.001), and greater release of the brain isoenzyme of creatine kinase in the first 6 hours after surgery (P = 0.046). Analyses comparing durations of circulatory arrest produced results similar to those of analyses comparing treatments. Conclusions. In heart surgery in infants, a strategy consisting predominantly of circulatory arrest is associated with greater central nervous system perturbation in the early postoperative period than a strategy consisting predominantly of low-flow cardiopulmonary bypass. Assessment of the effect of these findings on later outcomes awaits follow-up of this cohort.	CHILDRENS HOSP MED CTR,DEPT CARDIOVASC SURG,300 LONGWOOD AVE,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT CARDIOL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT ANESTHESIA,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT NEUROL,BOSTON,MA 02115; CHILDRENS HOSP MED CTR,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT SURG,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT RADIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Carvalho, Lidiane/P-8446-2019; Hickey, Paul/GYV-3947-2022	Carvalho, Lidiane/0000-0002-2290-329X; Wypij, David/0000-0001-8367-8711; Kuban, Karl/0000-0001-5299-3567	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041786] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 02172] Funding Source: Medline; NHLBI NIH HHS [HL 41786] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRE M, 1990, NEONATAL SEIZURES, P61; BARRATTBOYES BG, 1971, CIRCULATION, V44, P924, DOI 10.1161/01.CIR.44.5.924; BERTHRONG M, 1951, B JOHNS HOPKINS HOSP, V89, P384; BRUNBERG JA, 1974, CIRCULATION, V50, P60; CASTANEDA AR, 1984, ANN THORAC SURG, V38, P438, DOI 10.1016/S0003-4975(10)64181-1; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CLARKSON PM, 1980, CIRCULATION, V62, P855, DOI 10.1161/01.CIR.62.4.855; COLES JG, 1984, CIRCULATION, V70, P96; COTTRILL CM, 1973, AM J DIS CHILD, V125, P484, DOI 10.1001/archpedi.1973.04160040010003; Dubowitz L., 1981, NEUROLOGICAL ASSESSM; EHYAI A, 1984, JAMA-J AM MED ASSOC, V252, P3165, DOI 10.1001/jama.252.22.3165; FERRY PC, 1990, AM J DIS CHILD, V144, P369, DOI 10.1001/archpedi.1990.02150270119040; FISK G C, 1976, Anaesthesia and Intensive Care, V4, P126; FISK GC, 1974, ANAESTH INTENS CARE, V2, P33, DOI 10.1177/0310057X7400200104; Folkerth T L, 1975, Recent Adv Stud Cardiac Struct Metab, V10, P411; FOX LS, 1982, J THORAC CARDIOV SUR, V83, P239; FOX LS, 1984, J THORAC CARDIOV SUR, V87, P658; GILLES FH, 1973, J NEUROPATH EXP NEUR, V32, P179; GREELEY WJ, 1989, J THORAC CARDIOV SUR, V97, P737; GREELEY WJ, 1991, ANN THORAC SURG, V52, P417, DOI 10.1016/0003-4975(91)90900-B; HAMMEKE TA, 1988, J THORAC CARDIOV SUR, V96, P326; INSEL TR, 1990, NEUROSCIENCE, V35, P31, DOI 10.1016/0306-4522(90)90117-M; JAVID H, 1969, J THORAC CARDIOV SUR, V58, P502, DOI 10.1016/S0022-5223(19)42564-6; JOHNSTON WE, 1991, ANN THORAC SURG, V52, P479, DOI 10.1016/0003-4975(91)90909-A; KECK EW, 1981, MONATSSCHR KINDERH, V129, P45; KIRKLIN JW, 1961, ANN SURG, V154, P769; KIRKLIN JW, 1993, HYPOTHERMIA CIRCULAT, P62; KRAMER RS, 1968, J THORAC CARDIOV SUR, V56, P699, DOI 10.1016/S0022-5223(19)42797-9; LEE WH, 1971, ANN SURG, V173, P1013, DOI 10.1097/00000658-197106010-00020; LEGIDO A, 1991, PEDIATRICS, V88, P583; LINDE LM, 1970, ACTA PAEDIATR SCAND, V59, P169, DOI 10.1111/j.1651-2227.1970.tb08984.x; LINDE LM, 1967, J PEDIATR-US, V71, P198, DOI 10.1016/S0022-3476(67)80072-6; LINDERKAMP O, 1979, J PEDIATR-US, V95, P567, DOI 10.1016/S0022-3476(79)80770-2; LOMBROSO CT, 1985, J CLIN NEUROPHYSIOL, V2, P105, DOI 10.1097/00004691-198504000-00002; Mayer J E Jr, 1986, J Card Surg, V1, P97, DOI 10.1111/j.1540-8191.1986.tb00700.x; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MILLER LP, 1990, NEUROSCIENCE, V35, P45, DOI 10.1016/0306-4522(90)90118-N; MOLINA JE, 1984, J THORAC CARDIOV SUR, V87, P596; MOSHE SL, 1981, BRAIN RES, V211, P190, DOI 10.1016/0006-8993(81)90082-2; NEWBURGER JW, 1984, NEW ENGL J MED, V310, P1495, DOI 10.1056/NEJM198406073102303; ODOHERTY N, 1986, NEUROLOGICAL EXAMINA; ODOUGHERTY M, 1983, CHILD DEV, V54, P1129, DOI 10.1111/j.1467-8624.1983.tb00534.x; PAINE RS, 1966, NEUROLOGICAL EXAMINA; PHORNPHUTKUL C, 1973, AM J CARDIOL, V32, P329, DOI 10.1016/S0002-9149(73)80142-0; Prechtl H. F. R., 1977, NEUROLOGICAL EXAMINA, V2nd; REBEYKA IM, 1987, ANN THORAC SURG, V43, P391, DOI 10.1016/S0003-4975(10)62812-3; ROSE AL, 1970, PEDIATRICS, V45, P404; ROSSI R, 1986, AM J CARDIOL, V58, P1236, DOI 10.1016/0002-9149(86)90389-9; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SHAW PJ, 1987, STROKE, V18, P700, DOI 10.1161/01.STR.18.4.700; SOTANIEMI KA, 1981, ARCH NEUROL-CHICAGO, V38, P2, DOI 10.1001/archneur.1981.00510010028003; SOTANIEMI KA, 1983, ARCH NEUROL-CHICAGO, V40, P75, DOI 10.1001/archneur.1983.04050020037006; SWAIN JA, 1991, J THORAC CARDIOV SUR, V102, P76; TERPLAN KL, 1973, AM J DIS CHILD, V125, P175, DOI 10.1001/archpedi.1973.04160020011003; TREASURE T, 1983, J THORAC CARDIOV SUR, V86, P761; TYLER HR, 1957, ARCH NEURO PSYCHIATR, V77, P17, DOI 10.1001/archneurpsyc.1957.02330310027003; TYLER HR, 1957, ARCH NEURO PSYCHIATR, V77, P483, DOI 10.1001/archneurpsyc.1957.02330350049004; VOLPE JJ, 1987, NEUROLOGY NEWBORN, P129; WEISS M, 1975, J THORAC CARDIOV SUR, V70, P316; WEISS M, 1960, T AM SOC ART INT ORG, V6, P227; WILSON GJ, 1988, ANN THORAC SURG, V45, P206, DOI 10.1016/S0003-4975(10)62439-3; WOLIN LR, 1973, EXP NEUROL, V39, P336, DOI 10.1016/0014-4886(73)90235-5; 1992, STATISTICAL SOFTWARE	63	493	501	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1057	1064		10.1056/NEJM199310073291501	http://dx.doi.org/10.1056/NEJM199310073291501			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371727				2022-12-28	WOS:A1993LZ64000001
J	VONDEROHE, MR; CAMILLERI, M; KVOLS, LK; THOMFORDE, GM				VONDEROHE, MR; CAMILLERI, M; KVOLS, LK; THOMFORDE, GM			MOTOR DYSFUNCTION OF THE SMALL-BOWEL AND COLON IN PATIENTS WITH THE CARCINOID-SYNDROME AND DIARRHEA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBSTANCE-P; TRANSIT; MOTILITY; TUMORS; FLUID; POLYPEPTIDE; SOLIDS; DOG	Background and Methods. The pathophysiology of diarrhea in patients with the carcinoid syndrome is not understood. Possible causes include tumor production of neurohumoral substances, such as serotonin and substance P, which stimulate small-bowel and colonic motility, and intestinal abnormalities, such as lymphangiectasia and bacterial overgrowth. We undertook this study to determine whether carcinoid diarrhea is associated with abnormal motor function in the small intestine and colon. We measured the gastric, small-bowel, and colonic transit of radiolabeled solid residue and estimated the volume of the ascending colon in 16 patients with the carcinoid syndrome and diarrhea and 16 normal subjects. We also measured colonic tone and phasic pressure activity by intracolonic multilumen manometry and with an electronic barostat in seven patients and six normal subjects. Results. The patients with the carcinoid syndrome had elevated 24-hour urinary excretion of 5-hydroxyindoleacetic acid and elevated fasting plasma serotonin concentrations. Transit times in the small bowel and colon were two times (P<0.001) and six times (P = 0.001) faster in the patients than in the normal subjects. The volume of the ascending colon was approximately 50 percent smaller in the patients than in the normal subjects (P<0.001). The patients had normal fasting colonic tone; their mean post-prandial colonic tone was markedly increased as compared with the values in the normal subjects (mean increase, 41 percent vs. 24 percent; P = 0.03). Conclusions. Patients with the carcinoid syndrome who have diarrhea have major alterations in gut motor function that affect both the small intestine and colon.	MAYO CLIN & MAYO FDN,GASTROENTEROL RES UNIT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DIV MED ONCOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic					NCRR NIH HHS [RR00585] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000585] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BADLEY AD, 1993, NUCL MED COMMUN, V14, P485; BARTHO L, 1985, NEUROSCIENCE, V16, P1, DOI 10.1016/0306-4522(85)90043-0; BULBRING E, 1958, J PHYSIOL-LONDON, V140, P381; CAMILLERI M, 1992, GASTROENTEROLOGY, V103, P36, DOI 10.1016/0016-5085(92)91092-I; CAMILLERI M, 1989, AM J PHYSIOL, V257, pG284, DOI 10.1152/ajpgi.1989.257.2.G284; COWLES VE, 1959, AM J PHYSIOL, V38, P2119; DANIEL EE, 1982, CAN J PHYSIOL PHARM, V60, P830, DOI 10.1139/y82-116; DEBONGNIE JC, 1978, GASTROENTEROLOGY, V74, P698; DONOWITZ M, 1975, AM J DIG DIS, V20, P1115, DOI 10.1007/BF01070754; EMSON PC, 1984, CANCER, V54, P715, DOI 10.1002/1097-0142(1984)54:4<715::AID-CNCR2820540420>3.0.CO;2-6; FELDMAN JM, 1977, AM J MED SCI, V273, P43, DOI 10.1097/00000441-197701000-00004; GREYDANUS MP, 1990, GASTROENTEROLOGY, V99, P158, DOI 10.1016/0016-5085(90)91243-Y; HAMMER J, 1992, Gastroenterology, V102, pA456; HAMMER J, 1992, J GASTROINTEST MOTIL, V4, P221; HENDRIX TR, 1957, AM J MED, V23, P886, DOI 10.1016/0002-9343(57)90298-X; KOSTERLITZ HW, 1957, J PHYSIOL-LONDON, V136, P249, DOI 10.1113/jphysiol.1957.sp005757; KOWLESSAR OD, 1959, AM J MED, V27, P673, DOI 10.1016/0002-9343(59)90051-8; LABAYLE D, 1977, GASTROEN CLIN BIOL, V1, P231; Malagelada JRCM, 1986, MANOMETRIC DIAGNOSIS; MISIEWICZ JJ, 1966, GUT, V7, P208, DOI 10.1136/gut.7.3.208; Moertel C G, 1987, J Clin Oncol, V5, P1502; OCONNOR MK, 1988, EUR J NUCL MED, V14, P562; PEARSE AGE, 1974, VIRCHOWS ARCH B, V16, P95, DOI 10.1007/BF02894068; PROANO M, 1990, AM J PHYSIOL, V258, pG856, DOI 10.1152/ajpgi.1990.258.6.G856; RAMBAUD JC, 1988, GUT, V29, P537, DOI 10.1136/gut.29.4.537; RAMBAUD JC, 1986, CLIN GASTROENTEROL, V15, P603; RICHTER G, 1986, SCAND J GASTROENTERO, V21, P193, DOI 10.3109/00365528609087452; SMITH AN, 1965, GASTROENTEROLOGY, V48, P738; SPILLER RC, 1986, GASTROENTEROLOGY, V91, P100, DOI 10.1016/0016-5085(86)90445-2; STEADMAN CJ, 1991, GASTROENTEROLOGY, V101, P373, DOI 10.1016/0016-5085(91)90014-C; STIVLAND T, 1991, GASTROENTEROLOGY, V101, P107, DOI 10.1016/0016-5085(91)90466-X; TYCE GM, 1981, ANAL BIOCHEM, V112, P143, DOI 10.1016/0003-2697(81)90271-2; VONDEROHE M, 1992, GASTROENTEROLOGY, V103, P1378; YAKSH TL, 1988, PEPTIDES, V9, P357, DOI 10.1016/0196-9781(88)90272-0; YANG K, 1983, CANCER, V51, P1918, DOI 10.1002/1097-0142(19830515)51:10<1918::AID-CNCR2820511027>3.0.CO;2-Y	35	146	147	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1073	1078		10.1056/NEJM199310073291503	http://dx.doi.org/10.1056/NEJM199310073291503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371728				2022-12-28	WOS:A1993LZ64000003
J	DAVIS, PA; PLATON, JF; GERSHWIN, ME; HALPERN, GM; KEEN, CL; DIPAOLO, D; ALEXANDER, J; ZIBOH, VA				DAVIS, PA; PLATON, JF; GERSHWIN, ME; HALPERN, GM; KEEN, CL; DIPAOLO, D; ALEXANDER, J; ZIBOH, VA			A LINOLEATE-ENRICHED CHEESE PRODUCT REDUCES LOW-DENSITY-LIPOPROTEIN IN MODERATELY HYPERCHOLESTEROLEMIC ADULTS	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERCHOLESTEROLEMIA; CHEESE; LIPOPROTEINS, LDL CHOLESTEROL; LINOLEIC ACIDS; CHOLESTEROL, DIETARY	CORONARY HEART-DISEASE; CHOLESTEROL LEVELS; FATTY-ACIDS; DIET; MEN	Objective: To test the effect of substituting a modified-fat cheese product into the diets of hypercholesterolemic adults. Design: A 4-month, randomized, double-blind, crossover substitution trial. Setting: General community outpatient study. Participants: Twenty-six healthy adult volunteers (17 men, 9 women) with moderate hypercholesterolemia (total cholesterol >5.69 mmol/L but <7.24 mmol/L). Intervention: Daily substitution of 100 g of cheese, either partial skim-milk mozzarella or modified-fat (vegetable oil) mozzarella cheese product, into participants' normal diets. Participants consumed an assigned cheese for 2 months, at which time they crossed over to consume the other study cheese. Main Outcome Measures: Plasma lipid and apolipoprotein levels were measured at baseline and at 2 and 4 months after initiation of the study. Compliance was assessed by body weight and by biweekly dietary records and interviews. Results: No differences in weight or in the amount or type of calories consumed were found during the study. No statistically significant changes in lipid values resulted from consumption of mozzarella cheese. Modified-fat cheese substitution resulted in a decreased low-density lipoprotein cholesterol level when compared with levels at both baseline (-0.28 mmol/L; 95% CI, -0.14 to -0.42 mmol/L) and during consumption of the skim-milk mozzarella cheese (-0.38 mmol/L; 95% CI, -0.2 to -0.70 mmol/L). Findings for total cholesterol were similar. High-density lipoprotein cholesterol, plasma triglyceride, and apolipoprotein A-I and B-100 levels were unaltered. Both sexes responded similarly. Conclusions: A linoleate-enriched cheese product, in the absence of any other changes in diet or habits, substituted into the normal diets of hypercholesterolemic adults reduced low-density lipoprotein and plasma cholesterol levels.	ACTIOTECH, F-75015 PARIS, FRANCE		DAVIS, PA (corresponding author), UNIV CALIF DAVIS, DEPT INTERNAL MED, TB 156, DAVIS, CA 95616 USA.				NIDDK NIH HHS [DK 35747] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035747] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHRENS EH, 1957, LANCET, V1, P943; [Anonymous], 1988, CLIN CHEM, V34, P193; BOBERG J, 1984, EFFECTS DIET FAT CHA; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; DAVIDSON MH, 1991, JAMA-J AM MED ASSOC, V265, P1833, DOI 10.1001/jama.265.14.1833; FLYNN MA, 1986, J AM DIET ASSOC, V86, P1541; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GINSBERG HN, 1990, NEW ENGL J MED, V322, P574, DOI 10.1056/NEJM199003013220902; GRUNDY SM, 1986, JAMA-J AM MED ASSOC, V256, P2351, DOI 10.1001/jama.256.17.2351; HEISS G, 1980, CIRCULATION, V62, P116; JACKSON B, 1986, J AM DIET ASSOC, V86, P1531; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; MCNAMARA DJ, 1987, J CLIN INVEST, V79, P1729, DOI 10.1172/JCI113013; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1989, NEW ENGL J MED, V321, P436, DOI 10.1056/NEJM198908173210705; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; RISPIN CM, 1992, JAMA-J AM MED ASSOC, V267, P3317; SCHAEFER EJ, 1981, AM J CLIN NUTR, V34, P1758, DOI 10.1093/ajcn/34.9.1758; THOMPSON PD, 1979, AM J CLIN NUTR, V32, P2016, DOI 10.1093/ajcn/32.10.2016; 1988, FOOD FATS OILS; 1988, SURGEON GENERALS REP	22	11	12	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	1				555	559		10.7326/0003-4819-119-7_Part_1-199310010-00002	http://dx.doi.org/10.7326/0003-4819-119-7_Part_1-199310010-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA291	8363165				2022-12-28	WOS:A1993MA29100002
J	DOUGLASS, JK; WILKENS, L; PANTAZELOU, E; MOSS, F				DOUGLASS, JK; WILKENS, L; PANTAZELOU, E; MOSS, F			NOISE ENHANCEMENT OF INFORMATION-TRANSFER IN CRAYFISH MECHANORECEPTORS BY STOCHASTIC RESONANCE	NATURE			English	Article							BISTABLE SYSTEMS; PHASE LOCKING; DYNAMICS; NEURONS; POPULATION	IN linear information theory, electrical engineering and neurobiology, random noise has traditionally been viewed as a detriment to information transmission. Stochastic resonance (SR) is a nonlinear, statistical dynamics whereby information flow in a multistate system is enhanced by the presence of optimized, random noise1-4. A major consequence of SR for signal reception is that it makes possible substantial improvements in the detection of weak periodic signals. Although SR has recently been demonstrated in several artificial physical systems5,6, it may also occur naturally, and an intriguing possibility is that biological systems have evolved the capability to exploit SR by optimizing endogenous sources of noise. Sensory systems are an obvious place to look for SR, as they excel at detecting weak signals in a noisy environment. Here we demonstrate SR using external noise applied to crayfish mechanoreceptor cells. Our results show that individual neurons can provide a physiological substrate for SR in sensory systems.	UNIV MISSOURI, DEPT BIOL, ST LOUIS, MO 63121 USA; UNIV MISSOURI, DEPT PHYS, ST LOUIS, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis; University of Missouri System; University of Missouri Saint Louis								BANO W, 1978, BIOL CYBERN, V31, P99; BENZI R, 1982, TELLUS, V34, P10, DOI 10.1111/j.2153-3490.1982.tb01787.x; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; BULSARA A, 1993, J STAT PHYS, V70, P1, DOI 10.1007/BF01053949; Bush B.M.H., 1982, P399; CHIALVO DR, 1993, J STAT PHYS, V70, P375, DOI 10.1007/BF01053974; CRONER LJ, 1993, P NATL ACAD SCI USA, V90, P8128, DOI 10.1073/pnas.90.17.8128; DITZINGER T, 1990, BIOL CYBERN, V63, P453, DOI 10.1007/BF00199577; FAUVE S, 1983, PHYS LETT A, V97, P5, DOI 10.1016/0375-9601(83)90086-5; GAMMAITONI L, 1989, PHYS REV LETT, V62, P349, DOI 10.1103/PhysRevLett.62.349; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GLASS L, 1979, J MATH BIOL, V7, P339, DOI 10.1007/BF00275153; GLASS L, 1980, J THEOR BIOL, V86, P455, DOI 10.1016/0022-5193(80)90345-8; JUNG P, 1989, EUROPHYS LETT, V8, P505, DOI 10.1209/0295-5075/8/6/003; KAPLAN E, 1980, NATURE, V286, P393, DOI 10.1038/286393a0; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P767, DOI 10.1085/jgp.59.6.767; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; MCNAMARA B, 1989, PHYS REV A, V39, P4854, DOI 10.1103/PhysRevA.39.4854; MELLON D, 1963, J EXP BIOL, V40, P137; MOORE GP, 1966, ANNU REV PHYSIOL, V28, P493, DOI 10.1146/annurev.ph.28.030166.002425; MOSS F, IN PRESS INTRO SOME; NARINS PM, 1989, J ACOUST SOC AM, V85, P1255, DOI 10.1121/1.397456; ROSE JE, 1967, J NEUROPHYSIOL, V30, P769, DOI 10.1152/jn.1967.30.4.769; STEIN RB, 1965, BIOPHYS J, V5, P173, DOI 10.1016/S0006-3495(65)86709-1; Van Harreveld A, 1936, P SOC EXP BIOL MED, V34, P428; WIESE K, 1976, J NEUROPHYSIOL, V39, P816, DOI 10.1152/jn.1976.39.4.816; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255	29	1210	1235	0	100	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 23	1993	365	6444					337	340		10.1038/365337a0	http://dx.doi.org/10.1038/365337a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LY496	8377824				2022-12-28	WOS:A1993LY49600051
J	FRIEDMAN, E				FRIEDMAN, E			WHITHER MEDICAL-EDUCATION - A SOMETIMES INFLEXIBLE SYSTEM FACES CHANGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		MARDER WD, 1993, 1993 M ASS HLTH SERV; 1992, 1992 GRADUATING STUD; 1993, AAMC DATA BOOK	3	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	1993	270	12					1473	1476		10.1001/jama.270.12.1473	http://dx.doi.org/10.1001/jama.270.12.1473			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LX173	8371450				2022-12-28	WOS:A1993LX17300035
J	STRAND, M; PROLLA, TA; LISKAY, RM; PETES, TD				STRAND, M; PROLLA, TA; LISKAY, RM; PETES, TD			DESTABILIZATION OF TRACTS OF SIMPLE REPETITIVE DNA IN YEAST BY MUTATIONS AFFECTING DNA MISMATCH REPAIR	NATURE			English	Article							5' EXONUCLEASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SEQUENCE; MUTANTS	The genomes of all eukaryotes contain tracts of DNA in which a single base or a small number of bases is repeated. Expansions of such tracts have been associated with several human disorders including the fragile X syndrome1. In addition, simple repeats are unstable in certain forms of colorectal cancer, suggesting a defect in DNA replication or repair2-4. We show here that mutations in any three yeast genes involved in DNA mismatch repair (PMS1, MLH1 and MSH2) lead to 100- to 700-fold increases in tract instability, whereas mutations that eliminate the proof-reading function of DNA polymerases have little effect. The meiotic stability of the tracts is similar to the mitotic stability. Th results suggest that tract instability is associated with DNA polymerases slipping during replication, and that some types of colorectal cancer may reflect mutations in genes involved in DNA mismatch repair.	UNIV N CAROLINA,CURRICULUM GENET & MOLEC BIOL,CHAPEL HILL,NC 27599; YALE UNIV,SCH MED,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT THERAPEUT RADIOL,NEW HAVEN,CT 06510	University of North Carolina; University of North Carolina Chapel Hill; Yale University; Yale University	STRAND, M (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P6465, DOI 10.1073/pnas.79.21.6465; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KLEIN HL, 1984, MOL CELL BIOL, V4, P329, DOI 10.1128/MCB.4.2.329; KRAMER W, 1989, J BACTERIOL, V171, P5339, DOI 10.1128/jb.171.10.5339-5346.1989; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; Luria SE, 1943, GENETICS, V28, P491; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PETES TD, 1991, MOL CELLULAR BIOL YE, V1, P407; REENAN RAG, 1992, GENETICS, V132, P963; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SMITH GP, 1973, COLD SPRING HARB SYM, V38, P507, DOI 10.1101/SQB.1974.038.01.055; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; THIBODEAU SN, 1993, SCIENCE, V260, P818; WILLIAMSON MS, 1985, GENETICS, V110, P609	21	949	1001	2	78	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 16	1993	365	6443					274	276		10.1038/365274a0	http://dx.doi.org/10.1038/365274a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LX471	8371783				2022-12-28	WOS:A1993LX47100061
J	LYNN, JT				LYNN, JT			A MAGNIFICENT WHOLE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1993	119	6					527	527		10.7326/0003-4819-119-6-199309150-00015	http://dx.doi.org/10.7326/0003-4819-119-6-199309150-00015			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ275	8357122				2022-12-28	WOS:A1993LZ27500015
J	BOISE, LH; GONZALEZGARCIA, M; POSTEMA, CE; DING, LY; LINDSTEN, T; TURKA, LA; MAO, XH; NUNEZ, G; THOMPSON, CB				BOISE, LH; GONZALEZGARCIA, M; POSTEMA, CE; DING, LY; LINDSTEN, T; TURKA, LA; MAO, XH; NUNEZ, G; THOMPSON, CB			BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH	CELL			English	Article							PRE-B-CELLS; PROTO-ONCOGENE; T-CELLS; FOLLICULAR LYMPHOMA; NEGATIVE SELECTION; MEMBRANE PROTEIN; TRANSGENIC MICE; EXPRESSION; SURVIVAL; PROLIFERATION	We report the isolation of bcl-x, a bcl-2-related gene that can function as a bcl-2-independent regulator of programed cell death (apoptosis). Alternative splicing results in two distinct bcl-x mRNAs. The protein product of the larger mRNA, bcl-x(L), is similar in size and predicted structure to Bcl-2. When stably transfected into an IL-3-dependent cell line, bcl-x(L) inhibits cell death upon growth factor with drawal at least as well as bcl-2. Surprisingly, the second mRNA species, bcl-x(s), encodes a protein that inhibits the ability of bcl-2 to enhance the survival of growth factor-deprived cells. In vivo, bcl-x(s) mRNA is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. In contrast, bcl-x(L) is found in tissues containing long-lived postmitotic cells, such as adult brain. Together these data suggest that bcl-x plays an important role in both positive and negative regulation of programed cell death.	UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV MICHIGAN, SCH MED, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT MED, ANN ARBOR, MI 48109 USA	Howard Hughes Medical Institute; University of Chicago; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	BOISE, LH (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA.		Nuñez, Gabriel/A-7160-2014; Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020557] Funding Source: NIH RePORTER; NIAMS NIH HHS [P60-AR20557] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BORZILLO GV, 1992, ONCOGENE, V7, P869; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COOPER MD, 1991, ADV IMMUNOL, V50, P87; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DAVIES AM, 1987, DEVELOPMENT, V101, P185; EGUCHI Y, 1992, NUCLEIC ACIDS RES, V20, P4187, DOI 10.1093/nar/20.16.4187; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIEGEL RM, 1992, P NATL ACAD SCI USA, V89, P7003, DOI 10.1073/pnas.89.15.7003; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TURKA LA, 1991, J IMMUNOL, V146, P1428; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929	43	2935	3078	5	101	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					597	608		10.1016/0092-8674(93)90508-N	http://dx.doi.org/10.1016/0092-8674(93)90508-N			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358789	Green Published			2022-12-28	WOS:A1993LU59200004
J	DJERASSI, C				DJERASSI, C			BASIC RESEARCH - THE GRAY ZONE	SCIENCE			English	Editorial Material											DJERASSI, C (corresponding author), STANFORD UNIV,STANFORD,CA 94305, USA.							ANDERSON C, 1993, SCIENCE, V259, P300, DOI 10.1126/science.8419997; ANDERSON C, 1993, SCIENCE, V259, P884, DOI 10.1126/science.8438146; BRAUMAN JI, 1993, SCIENCE, V259, P1519, DOI 10.1126/science.259.5101.1519; DJERASSI C, 1992, PILL PYGMY CHIMPS DE; KOSHLAND DE, 1993, SCIENCE, V259, P1379, DOI 10.1126/science.8451629	5	5	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 20	1993	261	5124					972	973		10.1126/science.8351521	http://dx.doi.org/10.1126/science.8351521			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LT747	8351521				2022-12-28	WOS:A1993LT74700007
J	BEWLEY, AP; FEHER, MD; STAUGHTON, RCD				BEWLEY, AP; FEHER, MD; STAUGHTON, RCD			ERYTHEMA MULTIFORME FOLLOWING SUBSTITUTION OF AMLODIPINE FOR NIFEDIPINE	BRITISH MEDICAL JOURNAL			English	Letter											BEWLEY, AP (corresponding author), WESTMINSTER MED SCH & HOSP,LONDON SW10 9TH,ENGLAND.							CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; HOSIE J, 1992, CARDIOLOGY, V80, P54, DOI 10.1159/000175048; MURDOCH D, 1991, DRUGS, V41, P478, DOI 10.2165/00003495-199141030-00009	3	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1993	307	6898					241	241		10.1136/bmj.307.6898.241-a	http://dx.doi.org/10.1136/bmj.307.6898.241-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP314	8369687	Green Published, Bronze			2022-12-28	WOS:A1993LP31400026
J	BOLAN, CD; KRISHNAMURTI, C; TANG, DB; CARRINGTON, LR; ALVING, BM				BOLAN, CD; KRISHNAMURTI, C; TANG, DB; CARRINGTON, LR; ALVING, BM			ASSOCIATION OF PROTEIN-S DEFICIENCY WITH THROMBOSIS IN A KINDRED WITH INCREASED LEVELS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1	ANNALS OF INTERNAL MEDICINE			English	Article						PLASMINOGEN ACTIVATOR INHIBITOR-1; PROTEIN-S; THROMBOSIS; PROTEIN DEFICIENCY; HEREDITARY DISEASES	FAST-ACTING INHIBITOR; DEEP-VEIN THROMBOSIS; VENOUS THROMBOSIS; THROMBOEMBOLIC DISEASE; FIBRINOLYTIC-ACTIVITY; C4B-BINDING PROTEIN; HUMAN-PLASMA; FAMILY; RELEASE; ASSAY	Objective: A single kindred in North America with venous thrombosis was described as having defective fibrinolysis because of increased levels of plasminogen activator inhibitor-1 (PAI-1). Our study describes the discovery of protein S deficiency in this kindred and its association with venous thromboembolism. Design: A family study. Setting: Community. Participants: Twenty-eight adults (ages 21 to 71 years) from three generations of the kindred; seven had a history of venous thromboembolism. Measurements: Plasma levels of total and free protein S antigen, as well as the activities of protein S, protein C, PAI-1, and antithrombin III. Results: Six of 7 persons (86%) with a history of venous thromboembolism were deficient in total and free protein S; of 21 asymptomatic members, 9 were deficient in protein S (P = 0.08). When compared with these 9 asymptomatic family members, the 6 persons with protein S deficiency and a history of thrombosis tended to smoke (P = 0.01) and to have higher triglyceride levels (P = 0.001). Overall, the mean PAI-1 activity in the 7 persons who had thrombosis was 7.9 kAU/L (AU/mL) and was 9.3 kAU/L (AU/mL) in the 21 persons who did not have thrombosis (95% CI, -9.9 to 7.0). Conclusions: In this kindred, a deficiency of total and free or functional protein S is the cause of thrombosis. Measurement of PAI-1 activity was not useful in the evaluation of familial thrombosis. The utility of the routine measurement of PAI-1 activity in the evaluation of familial thrombosis has not been established.	WALTER REED ARMY INST RES, DEPT BIOMETR, WASHINGTON, DC 20307 USA; WALTER REED ARMY INST RES, DEPT HEMATOL, WASHINGTON, DC 20307 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	BOLAN, CD (corresponding author), WALTER REED ARMY MED CTR, DEPT HEMATOL ONCOL, WARD 78, WASHINGTON, DC 20307 USA.							ALVING BM, 1992, THROMB HAEMOSTASIS, V67, P672; BUCOLO G, 1973, CLIN CHEM, V19, P476; CHANDLER WL, 1989, CLIN CHEM, V35, P787; CHMIELEWSKA J, 1983, THROMB RES, V31, P427, DOI 10.1016/0049-3848(83)90407-3; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; COLUCCI M, 1985, J CLIN INVEST, V75, P818, DOI 10.1172/JCI111777; COMP PC, 1986, BLOOD, V67, P504; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; ENGEBRETSEN LF, 1986, THROMB RES, V42, P713, DOI 10.1016/0049-3848(86)90351-8; ENGESSER L, 1989, THROMB HAEMOSTASIS, V62, P673; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; ENGESSER L, 1988, Fibrinolysis, V2, P55; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1992, BLOOD, V79, P3203; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; Jespersen J., 1983, CLIN ASPECTS FIBRINO, P273; JOHANSSON L, 1978, ACTA MED SCAND, V203, P477; JORGENSEN M, 1987, THROMB HAEMOSTASIS, V58, P872; JORGENSEN M, 1987, BRIT J HAEMATOL, V65, P175, DOI 10.1111/j.1365-2141.1987.tb02261.x; JORGENSEN M, 1982, SCAND J HAEMATOL, V29, P217; KLUFT C, 1988, Fibrinolysis, V2, P93; KRISHNAMURTI C, 1988, AM J CLIN PATHOL, V89, P747, DOI 10.1093/ajcp/89.6.747; LAUER CG, 1990, J VASC SURG, V12, P541, DOI 10.1067/mva.1990.23531; MALM J, 1992, THROMB HAEMOSTASIS, V68, P7; MARTINOLI JL, 1986, THROMB RES, V43, P253, DOI 10.1016/0049-3848(86)90145-3; PARAMO JA, 1985, THROMB HAEMOSTASIS, V54, P713; PIZZO SV, 1986, ARCH INTERN MED, V146, P188, DOI 10.1001/archinte.146.1.188; PRINS MH, 1991, ARCH INTERN MED, V151, P1721, DOI 10.1001/archinte.151.9.1721; REMINGTON RD, 1985, STATISTICS APPLICATI; SCHMIDEL DK, 1991, BLOOD, V77, P551; STEAD NW, 1983, AM J MED, V74, P33, DOI 10.1016/0002-9343(83)91115-4; SUFFREDINI AF, 1989, NEW ENGL J MED, V320, P1165, DOI 10.1056/NEJM198905043201802; VANAMSTEL HKP, 1989, BLOOD, V73, P479; WIMAN B, 1983, CLIN CHIM ACTA, V127, P279, DOI 10.1016/S0009-8981(83)80012-6; WOLF M, 1989, THROMB HAEMOSTASIS, V62, P1144; 1991, ATATXACT USER MANUAL	36	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1993	119	8					779	785		10.7326/0003-4819-119-8-199310150-00002	http://dx.doi.org/10.7326/0003-4819-119-8-199310150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB496	8379599				2022-12-28	WOS:A1993MB49600002
J	IGARASHI, M				IGARASHI, M			IMAGES IN CLINICAL MEDICINE - MULTIPLE BRAIN ABSCESSES	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											IGARASHI, M (corresponding author), UNIV TENNESSEE,MEMPHIS,TN 38105, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 7	1993	329	15					1083	1083						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ640	8371730				2022-12-28	WOS:A1993LZ64000005
J	HORM, J; ANDERSON, K				HORM, J; ANDERSON, K			WHO IN AMERICA IS TRYING TO LOSE WEIGHT	ANNALS OF INTERNAL MEDICINE			English	Article								Objectives: To describe the characteristics and weight-loss methods of persons who are trying to lose weight; to compare the knowledges and practices regarding weight loss between those persons trying to lose weight and those not trying to lose weight; and to evaluate trends in these knowledges and practices between 1985 and 1990. Design: Large (approximately 120 000 persons per year), nationally representative random sample of the U.S. population. Setting: The 1985 and 1990 Health Promotion Disease Prevention Current Health Topics Supplements to the National Health Interview Survey. Participants: Random sample of the U.S. population. Measurements: Proportions of the NHIS sample with characteristics of interest weighted to be representative of the U.S. population. Results: Approximately 44 million persons 25 years or older were trying to lose weight in 1990; 61.8% of men and 59.6% of women were doing so by increasing their physical activity. Both proportions are significantly increased compared to the 1985 proportions of 56.9% and 56.2%, respectively. Twenty-seven percent of those persons who saw themselves as overweight were not trying to lose weight. Conclusions: More than one third of Americans see themselves as overweight, but fewer than two thirds of these persons are trying to lose weight. About 4% of self-perceived underweight persons and 11.4% of persons who think their weight was about right are also trying to lose weight. Most persons who are trying to lose weight are doing so by eating less, by increasing their physical activity, or by a combination of these methods.			HORM, J (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, DIV HLTH INTERVIEW STAT, 6525 BELCREST RD, ROOM 850, HYATTSVILLE, MD 20782 USA.							ADAMS PF, 1991, VITAL HLTH STATIS 10, V181; BENNETT EM, 1991, AM J CLIN NUTR, V53, pS1519, DOI 10.1093/ajcn/53.6.1519S; Levy P., 1991, SAMPLING POPULATIONS; MASSEY JT, 1989, DHHS PHS891384 NAT C; MILES DS, 1991, CLIN SPORT MED, V10, P157; MILLAR WJ, 1986, J EPIDEMIOL COMMUN H, V40, P319, DOI 10.1136/jech.40.4.319; SCHOENBORN CA, 1988, VITAL HLTH STATIS 10, V163; 1989, SUDAAN PROFESSIONAL; 1991, DHHS PHS9150212 PUB; [No title captured]	10	127	127	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				672	676		10.7326/0003-4819-119-7_Part_2-199310011-00009	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363195				2022-12-28	WOS:A1993MA33000009
J	PISUNYER, FX				PISUNYER, FX			MEDICAL HAZARDS OF OBESITY	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; BODY-FAT DISTRIBUTION; ADIPOSE-TISSUE DISTRIBUTION; HIGH-DENSITY LIPOPROTEIN; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; RISK-FACTORS; FOLLOW-UP; MEN BORN	The medical hazards of obesity are discussed. Risks include insulin resistance, diabetes mellitus, hypertriglyceridemia, decreased levels of high-density lipoprotein cholesterol, and increased levels of low-density lipoprotein cholesterol. Obesity is also associated with gallbladder disease and some forms of cancer as well as sleep apnea, chronic hypoxia and hypercapnia, and degenerative joint disease. Obesity is an independent risk factor for death from coronary heart disease. A central distribution of body fat enhances the risk for most of these conditions.	COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA	Columbia University	PISUNYER, FX (corresponding author), ST LUKES ROOSEVELT HOSP, OBES RES CTR, NEW YORK, NY 10025 USA.				NIDDK NIH HHS [DK40414, R55-DK35911, P30-DK26687] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026687, R01DK040414, R55DK035911] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBRINK MJ, 1962, NEW ENGL J MED, V266, P484, DOI 10.1056/NEJM196203082661003; USA Pooling Project Research Group, 1978, Journal of Chronic Diseases, V31, P201; BARRERA F, 1973, AM REV RESPIR DIS, V108, P819; BARROCAS M, 1975, CHEST, V68, P401; Bennett P H, 1976, Recent Prog Horm Res, V32, P333; BIERMAN EL, 1968, AM J CLIN NUTR, V21, P1434, DOI 10.1093/ajcn/21.12.1434; BJORNTORP P, 1990, NUTRITION, V6, P131; BJORNTORP P, 1990, ARTERIOSCLEROSIS, V10, P493, DOI 10.1161/01.ATV.10.4.493; BRAY GA, 1985, ANN INTERN MED, V103, P1052, DOI 10.7326/0003-4819-103-6-1052; BRENNER BM, 1988, AM J HYPERTENS, V1, P335, DOI 10.1093/ajh/1.4.335; Burnett W, 1971, Tijdschr Gastroenterol, V14, P79; BURTON BT, 1985, INT J OBESITY, V9, P155; CHAPMAN JM, 1971, J CHRON DIS, V23, P631, DOI 10.1016/0021-9681(71)90159-7; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; DESPRES JP, 1985, METABOLISM, V34, P967, DOI 10.1016/0026-0495(85)90147-7; DESPRES JP, 1988, J CLIN EPIDEMIOL, V41, P889, DOI 10.1016/0895-4356(88)90106-0; DONAHUE RP, 1987, LANCET, V1, P821; DORNFELD LP, 1987, KIDNEY INT, V32, pS254; DOUGLAS FG, 1972, J APPL PHYSIOL, V33, P559, DOI 10.1152/jappl.1972.33.5.559; DUCIMETIERE P, 1989, INT J OBESITY, V13, P111; DUSTAN HP, 1985, ANN INTERN MED, V103, P1047, DOI 10.7326/0003-4819-103-6-1047; ECKEL RH, 1987, J CLIN INVEST, V80, P992, DOI 10.1172/JCI113193; EPSTEIN FH, 1965, AM J EPIDEMIOL, V81, P307, DOI 10.1093/oxfordjournals.aje.a120517; FEINLEIB M, 1985, ANN INTERN MED, V103, P1019, DOI 10.7326/0003-4819-103-6-1019; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GARFINKEL L, 1985, ANN INTERN MED, V103, P1034, DOI 10.7326/0003-4819-103-6-1034; GARRISON RJ, 1985, ANN INTERN MED, V103, P1006, DOI 10.7326/0003-4819-103-6-1006; GILLUM RF, 1987, J CHRON DIS, V40, P421, DOI 10.1016/0021-9681(87)90175-5; GLUECK CJ, 1980, CIRCULATION, V62, P62; GOLDIN RH, 1976, ANN RHEUM DIS, V35, P349, DOI 10.1136/ard.35.4.349; GORDON T, 1988, INT J EPIDEMIOL, V17, P77, DOI 10.1093/ije/17.1.77; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GRUNDY SM, 1974, METABOLISM, V23, P67, DOI 10.1016/0026-0495(74)90105-X; GRUNDY SM, 1972, J CLIN INVEST, V51, P3026, DOI 10.1172/JCI107130; HAFFNER SM, 1986, DIABETES CARE, V9, P153, DOI 10.2337/diacare.9.2.153; HAFFNER SM, 1989, AM J EPIDEMIOL, V129, P587, DOI 10.1093/oxfordjournals.aje.a115171; HARTZ AJ, 1983, PREV MED, V12, P351, DOI 10.1016/0091-7435(83)90244-X; HAVLIK RJ, 1983, ANN INTERN MED, V98, P855, DOI 10.7326/0003-4819-98-5-855; Higgins M, 1988, Acta Med Scand Suppl, V723, P23; HOLLEY HS, 1967, J CLIN INVEST, V46, P475, DOI 10.1172/JCI105549; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; KALKHOFF RK, 1983, J LAB CLIN MED, V102, P621; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KANNEL WB, 1969, ANN INTERN MED, V71, P89, DOI 10.7326/0003-4819-71-1-89; KANNEL WB, 1979, OBESITY AM, P125; KEEN H, 1974, RECENT ADV OBESITY R, V1, P116; KISSEBAH AH, 1986, RECENT ADV OBESITY R, P54; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; KOPELMAN PG, 1986, INT J OBESITY, V10, P211; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LARSSON B, 1984, BRIT MED J, V288, P1401, DOI 10.1136/bmj.288.6428.1401; LEACH RE, 1973, CLIN ORTHOP RELAT R, V93, P271; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; LINDSTED K, 1991, INT J OBESITY, V15, P397; LUBIN F, 1985, AM J EPIDEMIOL, V122, P579, DOI 10.1093/oxfordjournals.aje.a114137; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MacMahon S W, 1984, J Hypertens, V2, P85, DOI 10.1097/00004872-198402000-00015; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MARINOVIC I, 1972, REV MED CHILE, V100, P1320; MONTOYE HJ, 1966, AM J CLIN NUTR, V18, P397, DOI 10.1093/ajcn/18.6.397; NAIMARK A, 1960, J APPL PHYSIOL, V15, P377, DOI 10.1152/jappl.1960.15.3.377; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PAFFENBARGER RS, 1980, AM J EPIDEMIOL, V112, P258, DOI 10.1093/oxfordjournals.aje.a112992; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; RABKIN SW, 1977, AM J CARDIOL, V39, P452, DOI 10.1016/S0002-9149(77)80104-5; RADIN EL, 1972, SEMIN ARTHRITIS RHEU, V73, P245; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; RIMM AA, 1975, PUBLIC HEALTH REP, V90, P44; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; SHARP JT, 1980, CLIN CHEST MED, V1, P103; SIDNEY S, 1987, AM J PUBLIC HEALTH, V77, P317, DOI 10.2105/AJPH.77.3.317; SOWERS JR, 1982, J CLIN ENDOCR METAB, V54, P1181, DOI 10.1210/jcem-54-6-1181; STALLONES RA, 1985, ANN INTERN MED, V103, P1003, DOI 10.7326/0003-4819-103-6-1003; Stamler J., 1979, MED COMPLICATIONS OB, P191; STAMLER R, 1978, JAMA-J AM MED ASSOC, V240, P1607, DOI 10.1001/jama.240.15.1607; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; TYROLER HA, 1975, EPIDEMIOLOGY CONTROL, P177; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; VANITALLIE TB, 1992, TREATMENT SERIOUSLY, P3; WAARD FD, 1975, CANCER RES, V35, P3351; WALTEMATH CL, 1974, ANESTHESIOLOGY, V41, P84, DOI 10.1097/00000542-197407000-00022; WEBER ML, 1939, MED B VET ADM, V2, P43; WEINSIER RL, 1985, HYPERTENSION, V7, P578, DOI 10.1161/01.HYP.7.4.578; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; ZIMMET P, 1981, DIABETES, V30, P45, DOI 10.2337/diabetes.30.1.45; ZIMMET P, 1977, DIABETOLOGIA, V13, P111, DOI 10.1007/BF00745137; 1988, CANADIAN GUIDELINES; 1978, CANADA HLTH SURVEY; [No title captured]; [No title captured]; 1975, US DHEW761021 NAT CO, V1; [No title captured]; 1980, TECHNICAL REPORT SER, V646	98	1004	1032	0	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1993	119	7	2				655	660		10.7326/0003-4819-119-7_Part_2-199310011-00006	http://dx.doi.org/10.7326/0003-4819-119-7_Part_2-199310011-00006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MA330	8363192				2022-12-28	WOS:A1993MA33000006
J	OWEN, WF; LEW, NL; LIU, Y; LOWRIE, EG; LAZARUS, JM				OWEN, WF; LEW, NL; LIU, Y; LOWRIE, EG; LAZARUS, JM			THE UREA REDUCTION RATIO AND SERUM-ALBUMIN CONCENTRATION AS PREDICTORS OF MORTALITY IN PATIENTS UNDERGOING HEMODIALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEATH RISK; DIALYSIS; VARIABLES	Background. Among patients with end-stage renal disease who are treated with hemodialysis, solute clearance during dialysis and nutritional adequacy are determinants of mortality. We determined the effects of reductions in blood urea nitrogen concentrations during dialysis and changes in serum albumin concentrations, as an indicator of nutritional status, on mortality in a large group of patients treated with hemodialysis. Methods. We analyzed retrospectively the demographic characteristics, mortality rate, duration of hemodialysis, serum albumin concentration, and urea reduction ratio (defined as the percent reduction in blood urea nitrogen concentration during a single dialysis treatment) in 13,473 patients treated from October 1, 1990, through March 31, 1991. The risk of death was determined as a function of the urea reduction ratio and serum albumin concentration. Results. As compared with patients with urea reduction ratios of 65 to 69 percent, patients with values below 60 percent had a higher risk of death during follow-up (odds ratio, 1.28 for urea reduction ratios of 55 to 59 percent and 1.39 for ratios below 55 percent). Fifty-five percent of the patients had urea reduction ratios below 60 percent. The duration of dialysis was not predictive of mortality. The serum albumin concentration was a more powerful (21 times greater) predictor of death than the urea reduction ratio, and 60 percent of the patients had serum albumin concentrations predictive of an increased risk of death (values below 4.0 g per deciliter). The odds ratio for death was 1.48 for serum albumin concentrations of 3.5 to 3.9 g per deciliter and 3.13 for concentrations of 3.0 to 3.4 g per deciliter. Diabetic patients had lower serum albumin concentrations and urea reduction ratios than nondiabetic patients. Conclusions. Low urea reduction ratios during dialysis are associated with increased odds ratios for death. These risks are worsened by inadequate nutrition.	HARVARD UNIV,SCH MED,BOSTON,MA 02115; NATL MED CARE INC,WALTHAM,MA	Harvard University; Harvard Medical School	OWEN, WF (corresponding author), BRIGHAM & WOMENS HOSP,SEELEY MUDD BLDG,250 LONGWOOD AVE,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045656] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45656-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1989, SAS STAT USERS GUIDE, V2, P1071; BASILE C, 1990, AM J KIDNEY DIS, V15, P40, DOI 10.1016/S0272-6386(12)80590-7; Daugirdas J T, 1989, ASAIO Trans, V35, P336, DOI 10.1097/00002480-198907000-00052; FLANIGAN MJ, 1991, AM J KIDNEY DIS, V17, P295, DOI 10.1016/S0272-6386(12)80477-X; FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P156; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; HARTER HR, 1983, KIDNEY INT S13, V23, pS107; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1990, AM J KIDNEY DIS, V15, P451, DOI 10.1016/S0272-6386(12)70363-3; HERRMANN FR, 1992, ARCH INTERN MED, V152, P125, DOI 10.1001/archinte.152.1.125; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HULL AR, 1990, AM J KIDNEY DIS, V15, P375, DOI 10.1016/S0272-6386(12)70354-2; JINDAL KK, 1987, T AM SOC ART INT ORG, V33, P286; LAIRD NM, 1983, KIDNEY INT, pS101; LINDSAY RM, 1992, KIDNEY INT, V42, pS32; LINDSAY RM, 1989, AM J KIDNEY DIS, V13, P382, DOI 10.1016/S0272-6386(89)80021-6; Lowrie E.G., 1991, CONTEMP DIAL NEPHROL, V12, P11; LOWRIE EG, 1992, KIDNEY INT, V42, pS22; LOWRIE EG, 1992, SEMIN NEPHROL, V12, P276; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 1983, KIDNEY INT S, V13, pS11; MURRAY MJ, 1988, MAYO CLIN PROC, V63, P1106, DOI 10.1016/S0025-6196(12)65505-0; PARKER TF, 1983, KIDNEY INT S13, V23, pS42; PARKER TF, 1983, KIDNEY INT S, V13, pS37; 1992, US RENAL DATA SYSTEM	25	1152	1181	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1001	1006		10.1056/NEJM199309303291404	http://dx.doi.org/10.1056/NEJM199309303291404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	8366899				2022-12-28	WOS:A1993LY58700004
J	ASSAF, AR; LAPANE, KL; MCKENNEY, JL; CARLETON, RA				ASSAF, AR; LAPANE, KL; MCKENNEY, JL; CARLETON, RA			POSSIBLE INFLUENCE OF THE PROSPECTIVE PAYMENT SYSTEM ON THE ASSIGNMENT OF DISCHARGE DIAGNOSES FOR CORONARY HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; DRG	Background. The prospective payment system, under which diagnosis-related groups (DRGs) are used to reimburse hospitals for the care of Medicare patients, replaced the fee-for-service method of payment in Rhode Island in 1983 and in Massachusetts in 1985. Changes in financial incentives resulting from the use of the DRG system may have influenced the assignment of discharge diagnostic codes away from those with lower reimbursement toward codes with higher reimbursement. Methods. We collected data from the hospital records of patients 35 through 74 years of age who were discharged with codes 41 0 through 414 (representing various categories of coronary heart disease) of the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM). The patients were discharged from seven hospitals in two New England communities (one in Rhode Island and one in Massachusetts) between 1980 and 1988. The rates of diagnosis of various forms of coronary heart disease were determined by studying ICD-9CM hospital discharge codes (codes 410 and 411 for acute forms of coronary heart disease and codes 412, 413, and 414 for chronic forms) and by using a computerized diagnostic algorithm designed to detect definite myocardial infarction and fatal coronary heart disease. Results. The rates of definite coronary events diagnosed by the algorithm and by the study of ICD-9-CM codes 410 through 414 were constant or increased slightly during the study period. However, the frequency of assignment of codes for the acute forms of coronary heart disease (which entail higher reimbursement) rose from 35.2 percent to 48.4 percent among discharged patients with cardiac disease after the institution of DRGs. The majority of this increase was associated with the code for unstable angina pectoris. The frequency of assignment of codes for the chronic forms of coronary heart-disease (which entail lower reimbursement) decreased reciprocally, from 64.8 percent to 51.6 percent (P<0.001). Conclusions. Our data are consistent with the hypothesis that the prospective reimbursement system has influenced the assignment of hospital discharge codes in a way that would increase payment to hospitals. However, the data do not permit us to distinguish whether hospitals began to assign more precise diagnoses with the advent of the DRG system, or whether they began to favor diagnoses of acute conditions solely for financial reasons.	MEM HOSP RHODE ISL, DEPT MED, PAWTUCKET, RI USA; BROWN UNIV, SCH MED, DEPT COMMUNITY HLTH, PROVIDENCE, RI 02912 USA; BROWN UNIV, SCH MED, DEPT MED, PROVIDENCE, RI 02912 USA	Brown University; Brown University	ASSAF, AR (corresponding author), MEM HOSP RHODE ISL, PAWTUCKET HEART HLTH PROGRAM, PAWTUCKET, RI USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL023629] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL23629] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Assaf A R, 1987, R I Med J, V70, P541; BLACKBURN H, 1984, BEHAVIORAL HLTH HDB, P1171; Carleton R A, 1987, R I Med J, V70, P533; COHEN BB, 1987, AM J EPIDEMIOL, V126, P1; FARQUHAR JW, 1985, AM J EPIDEMIOL, V122, P323, DOI 10.1093/oxfordjournals.aje.a114104; FEINLEIB M, 1989, CIRCULATION, V79, P13; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; MAY JJ, 1985, AM J CARDIOL, V56, pC16, DOI 10.1016/S0002-9149(85)80004-7; MCKINLAY SM, 1989, INT J EPIDEMIOL, V18, P67, DOI 10.1093/ije/18.1.67; MULLIN RL, 1982, JAMA-J AM MED ASSOC, V254, P1208; MUNOZ E, 1990, ACAD MED, V65, P533, DOI 10.1097/00001888-199008000-00011; ROGERS WH, 1990, JAMA-J AM MED ASSOC, V264, P1989, DOI 10.1001/jama.264.15.1989; SIMBORG DW, 1981, NEW ENGL J MED, V304, P1602, DOI 10.1056/NEJM198106253042611; SYTKOWSKI P A, 1991, Comprehensive Therapy, V17, P39; 1983, FED REGISTER, V48, P39752; 1980, MASSACHUSETTS PATIEN; 1986, 31 RHOD ISL DEP HLTH; 1980, DHHS PHS801260 DEP H	18	107	108	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 23	1993	329	13					931	935		10.1056/NEJM199309233291307	http://dx.doi.org/10.1056/NEJM199309233291307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LX751	8361508				2022-12-28	WOS:A1993LX75100007
J	VEGA, WA; KOLODY, B; HWANG, J; NOBLE, A				VEGA, WA; KOLODY, B; HWANG, J; NOBLE, A			PREVALENCE AND MAGNITUDE OF PERINATAL SUBSTANCE EXPOSURES IN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COCAINE USE; DRUG; METHAMPHETAMINE; PREGNANCY; WOMEN	Background. Perinatal substance exposure has been linked to many neonatal and obstetrical complications. There have been few population-based epidemiologic studies to identify the prevalence and demographic profiles associated with drugs, alcohol, and smoking during pregnancy. Methods. We studied a population sample selected according to a multistage probability sampling design to estimate the prevalence of perinatal substance exposures in California in 1992. Urine samples from 29,494 women presenting for delivery in 202 hospitals were coded and screened for toxins; the results of toxicology screening were later linked by code number to the subjects' demographic variables and their reported use of tobacco and prescribed drugs. Urinary toxicologic tests provide conservative estimates because they can detect only very recent substance use. Results. The weighted prevalence for perinatal substance exposure was 5.16 percent for the use of one or more drugs, 6.72 Percent for alcohol (analyzed independently), and 8.82 percent for self-reported smoking. The percentage of women testing positive for any drug, including alcohol, was 11.35 percent. Estimates for racial and ethnic groups varied widely. Black women had the highest prevalence of total drug use (14.22 percent), alcohol use (11.58 percent), cocaine use (7.79 percent), and tobacco use (20.12 percent). Most drug exposures occurred among white non-Hispanic and Hispanic women. White non-Hispanic women had the second highest prevalence rate for the use of one or more drugs (6.79 percent) and self-reported tobacco use (14.82 percent). Hispanic women had the second highest prevalence rate for alcohol (6.87 percent). Conclusions. In California in 1992, there were 67,361 estimated perinatal exposures to one or more drugs, including alcohol, and 52,346 self-reported exposures to tobacco. These findings have clinical and public health implications.	SAN DIEGO STATE UNIV, SAN DIEGO, CA 92182 USA; CALIF STATE COLL SAN BERNARDINO, SAN BERNARDINO, CA 92407 USA; WESTERN CONSORTIUM PUBL HLTH, BERKELEY, CA USA	California State University System; San Diego State University; California State University System; California State University San Bernardino	VEGA, WA (corresponding author), UNIV CALIF BERKELEY, SCH PUBL HLTH, CTR COMMUNITY HLTH, WARREN HALL, BERKELEY, CA 94720 USA.							CHASNOFF IJ, 1989, ANN NY ACAD SCI, V562, P208, DOI 10.1111/j.1749-6632.1989.tb21019.x; CHASNOFF IJ, 1990, NEW ENGL J MED, V322, P1202, DOI 10.1056/NEJM199004263221706; CHASNOFF IJ, 1986, J PEDIATR-US, V108, P456, DOI 10.1016/S0022-3476(86)80896-4; DIXON SD, 1989, WESTERN J MED, V150, P436; FINNEGAN LP, 1988, DRUGS ALCOHOL PREGNA, P59; FRANK DA, 1988, PEDIATRICS, V82, P888; GILLOGLEY KM, 1990, AM J OBSTET GYNECOL, V163, P1535, DOI 10.1016/0002-9378(90)90621-D; HOLLINSHEAD WH, 1990, MMWR-MORBID MORTAL W, V39, P225; KHALSA JH, 1991, SEMIN PERINATOL, V15, P265; NALTY DF, 1991, 1991 S CAROLINA PREV; ORO AS, 1987, J PEDIATR-US, V111, P571, DOI 10.1016/S0022-3476(87)80125-7; OSTREA EM, 1992, PEDIATRICS, V89, P107; SCHYDLOWER M, 1993, PEDIATRICS, V91, P1004; VEGA WA, 1993, AM J PUBLIC HEALTH, V83, P185, DOI 10.2105/AJPH.83.2.185; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; 1992, CALIFORNIA VITAL STA	16	147	150	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 16	1993	329	12					850	854		10.1056/NEJM199309163291207	http://dx.doi.org/10.1056/NEJM199309163291207			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW551	8355744				2022-12-28	WOS:A1993LW55100007
J	HENKIN, RI				HENKIN, RI			METALLIC TASTE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HENKIN, RI (corresponding author), TASTE & SMELL CLIN,WASHINGTON,DC, USA.							[Anonymous], 1813, Med Chir Trans, V4, P48; HENKIN R I, 1989, FASEB Journal, V3, pA338; HENKIN RI, 1991, JAMA-J AM MED ASSOC, V265, P2253; HENKIN RI, 1971, J AMER MED ASSOC, V218, P1946, DOI 10.1001/jama.218.13.1946; HENKIN RI, 1986, DRUG EFFECTS TASTE S, P748; HENKIN RI, 1991, PHATONGEUSIA DIFFICU, V2, P348; Noordenbos W., 1959, PAIN PROBLEMS PERTAI	7	3	3	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	1993	270	11					1369	1370						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LW345	8360975				2022-12-28	WOS:A1993LW34500039
J	RAZ, R; STAMM, WE				RAZ, R; STAMM, WE			A CONTROLLED TRIAL OF INTRAVAGINAL ESTRIOL IN POSTMENOPAUSAL WOMEN WITH RECURRENT URINARY-TRACT INFECTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BACTERIAL VAGINOSIS; PROPHYLAXIS; FLORA; CELLS	Background. Recurrent urinary tract infections are a problem for many postmenopausal women. Estrogen replacement restores atrophic mucosa, lowers vaginal pH, and may prevent urinary tract infections. Methods. We enrolled 93 postmenopausal women with a history of recurrent urinary tract infections in a randomized, double-blind, placebo-controlled trial of a topically applied intravaginal estriol cream. Midstream urine cultures were obtained at enrollment, monthly for eight months, and whenever urinary symptoms occurred. Vaginal cultures and pH measurements were obtained at entry and after one and eight months. The women were assigned to receive either estriol (n = 50) or placebo (n = 43), both administered intravaginally; 36 and 24, respectively, completed the eight months of follow-up. Results. The incidence of urinary tract infection in the group given estriol was significantly reduced as compared with that in the group given placebo (0.5 vs. 5.9 episodes per patient-year, P<0.001). Survival analysis showed that more of the women in the estriol group than in the placebo group remained free of urinary tract infection (P<0.001). Lactobacilli were absent in all vaginal cultures before treatment and reappeared after one month in 22 of 36 estriol-treated women (61 percent) but in none of the 24 placebo recipients (P<0.001). With estriol the mean vaginal pH declined from 5.5 to 3.8 (P<0.001), whereas there was no significant change with placebo. The rate of vaginal colonization with Enterobacteriaceae fell from 67 percent to 31 percent in estriol recipients but was virtually unchanged (from 67 to 63 percent) in the placebo recipients (P<0.005). Side effects were minor, but caused 10 estriol recipients (28 percent) and 4 placebo recipients (17 percent) to discontinue treatment. Conclusions. The intravaginal administration of estriol prevents recurrent urinary tract infections in postmenopausal women, probably by modifying the vaginal flora.	TECHNION ISRAEL INST TECHNOL, FAC MED, HAIFA, ISRAEL; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Washington; University of Washington Seattle	RAZ, R (corresponding author), CENT EMEK HOSP, INFECT DIS UNIT, IL-18101 AFULA, ISRAEL.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040045] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40045] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRANDBERG A, 1987, ACTA OBSTET GYN SCAN, P33; CHAN RCY, 1985, INFECT IMMUN, V47, P84, DOI 10.1128/IAI.47.1.84-89.1985; ESCHENBACH DA, 1989, J CLIN MICROBIOL, V27, P251, DOI 10.1128/JCM.27.2.251-256.1989; HARDING GKM, 1974, NEW ENGL J MED, V291, P597, DOI 10.1056/NEJM197409192911203; HOOTON TM, 1991, JAMA-J AM MED ASSOC, V265, P64, DOI 10.1001/jama.265.1.64; HOOTON TM, 1989, ARCH INTERN MED, V149, P1932, DOI 10.1001/archinte.149.9.1932; HOOTON TM, 1991, J INFECT DIS, V164, P1216, DOI 10.1093/infdis/164.6.1216; KIRKENGEN A L, 1992, Scandinavian Journal of Primary Health Care, V10, P139, DOI 10.3109/02813439209014051; KLEBANOFF SJ, 1991, J INFECT DIS, V164, P94, DOI 10.1093/infdis/164.1.94; LANG W R, 1955, Obstet Gynecol Surv, V10, P546; MATTSSON LA, 1983, ACTA OBSTET GYN SCAN, V62, P393, DOI 10.3109/00016348309154208; MOLANDER U, 1990, MATURITAS, V12, P113, DOI 10.1016/0378-5122(90)90089-O; NICOLLE LE, 1988, J INFECT DIS, V157, P1239, DOI 10.1093/infdis/157.6.1239; ORLANDER JD, 1992, J AM GERIATR SOC, V40, P817, DOI 10.1111/j.1532-5415.1992.tb01855.x; PARSONS CL, 1982, J UROLOGY, V128, P1224, DOI 10.1016/S0022-5347(17)53434-5; PRIVETTE M, 1988, NEPHRON, V50, P24, DOI 10.1159/000185111; RAZ R, 1991, ANTIMICROB AGENTS CH, V35, P1241, DOI 10.1128/AAC.35.6.1241; ROMANO JM, 1981, GERIATRICS, V36, P113; STAMEY TA, 1975, J UROLOGY, V113, P214, DOI 10.1016/S0022-5347(17)59447-1; STAMEY TA, 1971, CALIF MED, V115, P1; STAMM WE, 1991, REV INFECT DIS, V13, P77; STAMM WE, 1980, ANN INTERN MED, V92, P770, DOI 10.7326/0003-4819-92-6-770; TREVOUX R, 1982, Reproduccion, V6, P101	23	524	551	1	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 9	1993	329	11					753	756		10.1056/NEJM199309093291102	http://dx.doi.org/10.1056/NEJM199309093291102			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV642	8350884				2022-12-28	WOS:A1993LV64200002
J	CONCHA, NO; HEAD, JF; KAETZEL, MA; DEDMAN, JR; SEATON, BA				CONCHA, NO; HEAD, JF; KAETZEL, MA; DEDMAN, JR; SEATON, BA			RAT ANNEXIN-V CRYSTAL-STRUCTURE - CA2+-INDUCED CONFORMATIONAL-CHANGES	SCIENCE			English	Article							PHOSPHOLIPID-BINDING PROTEIN; MEMBRANE-BINDING; CALCIUM-BINDING; ANTICOAGULANT PROTEIN; MOLECULAR-STRUCTURE; LIPOCORTIN-I; FAMILY; REFINEMENT; LOCATION	Annexins are a family of calcium- and phospholipid-binding proteins implicated in mediating membrane-related processes such as secretion, signal transduction, and ion channel activity. The crystal structure of rat annexin V was solved to 1.9 angstrom resolution by multiple isomorphous replacement. Unlike previously solved annexin V structures, all four domains bound calcium in this structure. Calcium binding in the third domain induced a large relocation of the calcium-binding loop regions, exposing the single tryptophan residue to the solvent. These alterations in annexin V suggest a role for domain 3 in calcium-triggered interaction with phospholipid membranes.	BOSTON UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02118; UNIV CINCINNATI,COLL MED,DEPT PHYSIOL & BIOPHYS,CINCINNATI,OH 45267	Boston University; University System of Ohio; University of Cincinnati				Seaton, Barbara/0000-0003-4654-7709; Head, James/0000-0002-6226-4146	NIDDK NIH HHS [R01-DK-41740] Funding Source: Medline; NIGMS NIH HHS [R29-GM-44554] Funding Source: Medline; NINDS NIH HHS [R01-NS-20357] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020357] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P971, DOI 10.1021/bi00218a013; BEWLEY MC, 1993, BIOCHEMISTRY-US, V32, P393; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BURGOYNE RD, 1989, CELL CALCIUM, V10, P1, DOI 10.1016/0143-4160(89)90038-9; CONCHA NO, UNPUB; CREUTZ CE, 1992, SCIENCE, V258, P924, DOI 10.1126/science.1439804; CRUMPTON MJ, 1990, NATURE, V345, P212, DOI 10.1038/345212a0; GEISOW MJ, 1986, NATURE, V320, P636, DOI 10.1038/320636a0; GEISOW MJ, 1986, FEBS LETT, V203, P99, DOI 10.1016/0014-5793(86)81445-4; HAIGLER HT, 1987, J BIOL CHEM, V262, P6921; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HU W, 1993, BIOCHEMISTRY-US, V32, P7035, DOI 10.1021/bi00078a032; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; HUBER R, 1990, FEBS LETT, V275, P15, DOI 10.1016/0014-5793(90)81428-Q; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEE CB, 1988, BIOCHEMISTRY-US, V27, P6645, DOI 10.1021/bi00418a001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEWITBENTLEY A, 1992, EUR J BIOCHEM, V210, P73, DOI 10.1111/j.1432-1033.1992.tb17392.x; MEERS P, 1993, BIOCHEMISTRY-US, V32, P5411, DOI 10.1021/bi00071a016; MEERS P, 1990, BIOCHEMISTRY-US, V29, P3325, DOI 10.1021/bi00465a025; MOSSER G, 1991, J MOL BIOL, V217, P241, DOI 10.1016/0022-2836(91)90538-H; PEPINSKY RB, 1988, J BIOL CHEM, V263, P10799; SCHLAEPFER DD, 1987, P NATL ACAD SCI USA, V84, P6078, DOI 10.1073/pnas.84.17.6078; SEATON BA, 1990, J BIOL CHEM, V265, P4567; SHADLE PJ, 1985, J BIOL CHEM, V260, P6354; SWAIRJO MA, IN PRESS ANN REV BIO; TAIT JF, 1989, J BIOL CHEM, V264, P7944; WENG XW, 1993, PROTEIN SCI, V2, P448	29	173	179	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 3	1993	261	5126					1321	1324		10.1126/science.8362244	http://dx.doi.org/10.1126/science.8362244			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV656	8362244				2022-12-28	WOS:A1993LV65600028
J	JACENKO, O; LUVALLE, PA; OLSEN, BR				JACENKO, O; LUVALLE, PA; OLSEN, BR			SPONDYLOMETAPHYSEAL DYSPLASIA IN MICE CARRYING A DOMINANT-NEGATIVE MUTATION IN A MATRIX PROTEIN-SPECIFIC FOR CARTILAGE-TO-BONE TRANSITION	NATURE			English	Article							X COLLAGEN GENE; REGIONS; DOMAIN; VIII	THE vertebrate skeleton is formed primarily by endochondral ossification, starting during embryogenesis when cartilage anlagens develop central regions of hypertrophic cartilage which are replaced by bony trabeculae and bone marrow1,2. During this process chondrocytes express a unique matrix molecule, type X collagen3. We report here that mice carrying a mutated collagen X transgene develop skeletal deformities including compression of hypertrophic growth plate cartilage and a decrease in newly formed bone, as well as leukocyte deficiency in bone marrow, reduction in size of thymus and spleen, and lymphopenia. The defects indicate that collagen X is required for normal skeletal morphogenesis and suggest that mutations in COL10A1 are responsible for certain human chondrodysplasias, such as spondylometaphyseal dysplasias and metaphyseal chondrodysplasias4.			JACENKO, O (corresponding author), HARVARD UNIV, SCH MED, DEPT ANAT & CELLULAR BIOL, 220 LONGWOOD AVE, BOSTON, MA 02115 USA.							APTE SS, 1992, EUR J BIOCHEM, V206, P217, DOI 10.1111/j.1432-1033.1992.tb16919.x; ARMAN ML, IN PRESS NATURE GENE; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Caplan AI, 1987, BONE MINERAL RES, P117; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; HAM AW, 1965, HISTOLOGY, P384; IYAMA K, 1991, ANAT RECORD, V229, P462, DOI 10.1002/ar.1092290405; JACENKO O, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P327; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; LUVALLE P, J CELL BIOL, V121, P1173; MCKUSICK VA, 1992, MENDELIAN INHERITANC, V2; MCKUSICK VA, 1992, MENDELIAN INHERITANC, V1; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; SAWADA H, 1990, J CELL BIOL, V110, P219, DOI 10.1083/jcb.110.1.219; SCHMID TM, 1990, ANN NY ACAD SCI, V580, P64, DOI 10.1111/j.1749-6632.1990.tb17918.x; SUMMERS TA, 1988, J BIOL CHEM, V263, P581	20	179	183	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 2	1993	365	6441					56	61		10.1038/365056a0	http://dx.doi.org/10.1038/365056a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LV646	8361538				2022-12-28	WOS:A1993LV64600053
J	NORMAN, GR; DAVIS, DA; LAMB, S; HANNA, E; CAULFORD, P; KAIGAS, T				NORMAN, GR; DAVIS, DA; LAMB, S; HANNA, E; CAULFORD, P; KAIGAS, T			COMPETENCE ASSESSMENT OF PRIMARY-CARE PHYSICIANS AS PART OF A PEER-REVIEW PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRUCTURED CLINICAL EXAMINATION; RELIABILITY; RESIDENTS	Objective.-To design and test a program that assesses clinical competence as a second stage in a peer review process and to determine the program's reliability. Design and Setting.-A three-cohort study of Ontario primary care physicians. Participants.-Reference physicians (n=26) randomly drawn from the Hamilton, Ontario, area; volunteer, self-referred physicians (n=20); and physicians referred by the licensing body (n=37) as a result of a disciplinary hearing or peer review. Main Outcome Measures.-Standardized patients, structured oral examinations, chart-stimulated recall, objective structured clinical examination, and multiple-choice examination. Results.-Test reliability was high, ranging from 0.73 to 0.91, and all tests discriminated among subgroups. Demographic variables relating to the final category were age, Canadian or foreign graduates, and whether or not participants were certified in family medicine. Conclusions.-The study demonstrated the feasibility, reliability, and validity of a multicomponent examination in the peer review process.	UNIV TORONTO,TORONTO M5S 1A1,ONTARIO,CANADA; COLL PHYSICIANS & SURGEONS ONTARIO,TORONTO,ON,CANADA	University of Toronto	NORMAN, GR (corresponding author), MCMASTER UNIV,HLTH SCI CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,ROOM 2C14,HAMILTON L8N 3Z5,ONTARIO,CANADA.							BARROWS H, 1971, SIMULATED PATIENTS; COHEN R, 1990, AM J SURG, V160, P302, DOI 10.1016/S0002-9610(06)80029-2; CRONBACH LJ, 1972, DEPENDABILITY BEHAVI; FARNSWORTH PB, 1990, NEW YORK STATE J MED, V90, P531; HARDEN RM, 1979, MED EDUC, V13, P41; LST JM, 1991, ANN RCPSC, V24, P7; MAATSCH J, 1978, 17TH C RES MED ED NE; MCAULEY RG, 1984, CAN MED ASSOC J, V131, P557; STILLMAN P, 1991, ANN INTERN MED, V114, P393, DOI 10.7326/0003-4819-114-5-393; SWANSON DB, 1990, TEACH LEARN MED, V2, P58; TUGWELL P, 1985, ASSESSING CLIN COMPE; VANDERVLEUTEN CPM, 1991, MED EDUC, V25, P110	12	75	75	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 1	1993	270	9					1046	1051						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU512	8350446				2022-12-28	WOS:A1993LU51200004
J	XU, H; LITTMAN, DR				XU, H; LITTMAN, DR			A KINASE-INDEPENDENT FUNCTION OF LCK IN POTENTIATING ANTIGEN-SPECIFIC T-CELL ACTIVATION	CELL			English	Review							PROTEIN-TYROSINE KINASE; AMINO-TERMINAL DOMAIN; RECEPTOR ZETA-CHAIN; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; LYMPHOCYTES-T; MICE LACKING; PHYSICAL ASSOCIATION; CYTOPLASMIC DOMAINS; NEGATIVE SELECTION	The lymphocyte-specific cytoplasmic protein-tyrosine kinase p56lck (Lck) is essential for T cell development and activation. Its association with the coreceptor molecules, CD4 and CD8, is required for potentiation of antigen-specific signals through the T cell antigen receptor. To study the mechanism of action of Lck, hybrid molecules consisting of the extracellular and transmembrane domains of CD4 fused to Lck or other Src family kinases were analyzed in an antigen-specific, CD4-dependent T cell hybridoma. Surprisingly, a chimera with a deletion of the Lck kinase domain was more active than the full-length protein. In contrast, point mutations in residues required for SH2 or kinase function resulted in moderately decreased activity, while a combination of these mutations rendered the chimera largely inactive. Different domains of CD4-associated Lck therefore have distinct functions that can independently contribute to T cell activation.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	XU, H (corresponding author), UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BOLEN JB, 1991, ADV CANCER RES, V57, P103; CARON L, 1992, MOL CELL BIOL, V12, P2720, DOI 10.1128/MCB.12.6.2720; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CLAYTON LK, 1989, NATURE, V339, P548, DOI 10.1038/339548a0; COLLINS TL, 1992, J IMMUNOL, V148, P2159; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; EMMRICH F, 1988, IMMUNOL TODAY, V9, P296, DOI 10.1016/0167-5699(88)91320-5; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; INGOLD AL, 1991, NATURE, V352, P721, DOI 10.1038/352721a0; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KILLEEN N, 1992, J EXP MED, V176, P89, DOI 10.1084/jem.176.1.89; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KILLEEN N, 1993, IN PRESS NATURE; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; LAMARRE D, 1989, SCIENCE, V245, P743, DOI 10.1126/science.2549633; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LITTMAN DR, 1987, NATURE, V325, P453, DOI 10.1038/325453a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MITTLER RS, 1989, P NATL ACAD SCI USA, V86, P8531, DOI 10.1073/pnas.86.21.8531; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; OROURKE AM, 1992, NATURE, V358, P253, DOI 10.1038/358253a0; OROURKE AM, 1990, NATURE, V346, P187, DOI 10.1038/346187a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P1741, DOI 10.1073/pnas.88.5.1741; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; OWENS T, 1987, P NATL ACAD SCI USA, V84, P9209, DOI 10.1073/pnas.84.24.9209; QUINTRELL N, 1987, MOL CELL BIOL, V7, P2267, DOI 10.1128/MCB.7.6.2267; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROJO JM, 1989, P NATL ACAD SCI USA, V86, P3311, DOI 10.1073/pnas.86.9.3311; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; RONCHESE F, 1987, J IMMUNOL, V139, P629; RUDD CE, 1990, IMMUNOL TODAY, V11, P400, DOI 10.1016/0167-5699(90)90159-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; TURNER JM, 1991, ADV REG CELL GROWTH, V2, P181; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; ZAMOYSKA R, 1989, NATURE, V342, P278, DOI 10.1038/342278a0	70	222	225	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 27	1993	74	4					633	643		10.1016/0092-8674(93)90511-N	http://dx.doi.org/10.1016/0092-8674(93)90511-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LU592	8358792				2022-12-28	WOS:A1993LU59200007
J	FRANCIS, CL; RYAN, TA; JONES, BD; SMITH, SJ; FALKOW, S				FRANCIS, CL; RYAN, TA; JONES, BD; SMITH, SJ; FALKOW, S			RUFFLES INDUCED BY SALMONELLA AND OTHER STIMULI DIRECT MACROPINOCYTOSIS OF BACTERIA	NATURE			English	Article							EPIDERMAL GROWTH-FACTOR; CARCINOMA-CELLS A-431; CULTURED-MAMMALIAN-CELLS; FACTOR RECEPTOR; CYTOSKELETAL CHANGES; EPITHELIAL-CELLS; TYROSINE KINASE; KB-CELLS; MEMBRANE; TYPHIMURIUM	RUFFLES are specialized plasma membrane ultrastructures of mammalian cells thought to be integral to growth, development and locomotion1-4. Induced by growth factors5-8, mitogens9 or oncogene expression10,11, ruffles are sites of filamentous actin rearrangement7,8 and are temporally associated with enhanced pinocytosis10,12. But the function of ruffles, their mechanism of induction and their role in pinocytosis are not understood. We have observed formation of structures resembling ruffles associated with the site of entry of invasive Salmonella typhimurium13. Here we report that ruffles elicited by invasive Salmonella directly mediate internalization of non-invasive bacteria in a macropinocytotic fashion, a phenomenon we term 'passive entry'. Furthermore, ruffles induced in the absence of Salmonella also facilitate passive entry. We present evidence that ruffles, common to many signalling events, comprise the macropinocytotic machinery mediating pinocytosis and are subverted by Salmonella so as to enter mammalian cells.	STANFORD UNIV,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305; NIH,ROCKY MT LAB,HAMILTON,MT 59840	Stanford University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	FRANCIS, CL (corresponding author), STANFORD UNIV,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305, USA.		Ryan, Timothy/AAO-8286-2020	Jones, Brad/0000-0002-2698-8251; Ryan, Timothy/0000-0003-2533-9548				ABERCROMBIE M., 1961, EXPTL CELL RES SUPPL, V8, P188, DOI 10.1016/0014-4827(61)90348-2; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; FINLAY BB, 1988, BIOCHIMIE, V70, P1089, DOI 10.1016/0300-9084(88)90271-4; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; GALAN JE, 1992, NATURE, V357, P588, DOI 10.1038/357588a0; GINOCCHIO C, 1992, P NATL ACAD SCI USA, V89, P5976, DOI 10.1073/pnas.89.13.5976; GOSHIMA K, 1984, J CELL BIOL, V98, P801, DOI 10.1083/jcb.98.3.801; HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; ISBERG RR, 1987, CELL, V50, P769, DOI 10.1016/0092-8674(87)90335-7; JACKOWSKI MM, 1990, J CELL PHYSIOL, V142, P458, DOI 10.1002/jcp.1041420304; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; LABIGNEROUSSEL AF, 1984, INFECT IMMUN, V46, P251, DOI 10.1128/IAI.46.1.251-259.1984; LEE CA, 1992, P NATL ACAD SCI USA, V89, P1847, DOI 10.1073/pnas.89.5.1847; LEE CA, 1990, P NATL ACAD SCI USA, V87, P4304, DOI 10.1073/pnas.87.11.4304; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; MISUMI Y, 1991, AM J ANAT, V191, P419, DOI 10.1002/aja.1001910409; MIYATA Y, 1988, EXP CELL RES, V175, P286, DOI 10.1016/0014-4827(88)90193-0; PFEIFFER JR, 1985, J CELL BIOL, V101, P2145, DOI 10.1083/jcb.101.6.2145; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; SCHNEIDER CA, 1986, P NATL ACAD SCI USA, V83, P333, DOI 10.1073/pnas.83.2.333; SIRAGANIAN RP, 1982, FED PROC, V41, P30; SPAARGAREN M, 1991, J BIOL CHEM, V266, P1733; Trinkaus J.P., 1985, EXPL BIOL MED, V10, P130; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YAHARA I, 1982, J CELL BIOL, V92, P69, DOI 10.1083/jcb.92.1.69	30	365	368	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 12	1993	364	6438					639	642		10.1038/364639a0	http://dx.doi.org/10.1038/364639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR771	8350922				2022-12-28	WOS:A1993LR77100056
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERIM METHADONE-MAINTENANCE TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	8	8	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1993	269	11					1361	1361		10.1001/jama.269.11.1361	http://dx.doi.org/10.1001/jama.269.11.1361			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KQ857	8382752				2022-12-28	WOS:A1993KQ85700006
J	DRESSLER, GR; WILKINSON, JE; ROTHENPIELER, UW; PATTERSON, LT; WILLIAMSSIMONS, L; WESTPHAL, H				DRESSLER, GR; WILKINSON, JE; ROTHENPIELER, UW; PATTERSON, LT; WILLIAMSSIMONS, L; WESTPHAL, H			DEREGULATION OF PAX-2 EXPRESSION IN TRANSGENIC MICE GENERATES SEVERE KIDNEY ABNORMALITIES	NATURE			English	Article							PROMOTER; GENE	THE Pax genes comprise a family of transcription factors active in specific tissues during embryonic development and are associated with at least three developmental mutations in mouse and man1,2. In the developing kidney, Pax-2 is expressed in the induced mesenchyme, in the ureter epithelium, and in early epithelial structures derived from the mesenchyme3. Pax-2 expression is repressed upon terminal differentiation of the renal tubule epithelium, but persists in the undifferentiated epithelium of human Wilms' tumours4,5. We have produced a dominant gain-of-function mutation in transgenic mice by deregulating the expression of the mouse Pax-2 gene. The data obtained with four independently derived transgenic embryos and with one transgenic line demonstrate that deregulated Pax-2 expression results in histologically abnormal and dysfunctional renal epithelium with properties similar to congenital nephrotic syndrome. Thus, repression of Pax-2 is required for normal kidney development and persistent expression of Pax-2 may restrict the differentiation potential of renal epithelial cells.	UNIV TENNESSEE,COLL VET MED,DEPT PATHOBIOL,KNOXVILLE,TN 37901	University of Tennessee System; University of Tennessee Knoxville; UT Institute of Agriculture	DRESSLER, GR (corresponding author), NICHHD,MAMMALIAN GENES & DEV LAB,BETHESDA,MD 20892, USA.							DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; ECCLES MR, 1992, CELL GROWTH DIFFER, V3, P279; FOECKING MK, 1986, GENE, V45, P101, DOI 10.1016/0378-1119(86)90137-X; FURTH PA, 1991, NUCLEIC ACIDS RES, V19, P6205, DOI 10.1093/nar/19.22.6205; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HOGAN B, 1986, MANIPULATING MOUSE E; MAHAN JD, 1987, PEDIATRIC NEPHROLOGY; NORNES HO, 1990, DEVELOPMENT, V109, P7907; OVERBEEK PA, 1985, P NATL ACAD SCI USA, V82, P7815, DOI 10.1073/pnas.82.23.7815; PUESCHEL AW, 1992, MECH DEVELOP, V38, P197; Sambrook J, 1989, MOL CLONING LABORATO; Saxen L., 1987, ORGANOGENESIS KIDNEY; VESTWEBER D, 1985, EMBO J, V4, P3393, DOI 10.1002/j.1460-2075.1985.tb04095.x; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4	16	258	263	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 4	1993	362	6415					65	67		10.1038/362065a0	http://dx.doi.org/10.1038/362065a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KP976	8383297				2022-12-28	WOS:A1993KP97600061
J	FOLLI, F; SOLIMENA, M; COFIELL, R; AUSTONI, M; TALLINI, G; FASSETTA, G; BATES, D; CARTLIDGE, N; BOTTAZZO, GF; PICCOLO, G; DECAMILLI, P				FOLLI, F; SOLIMENA, M; COFIELL, R; AUSTONI, M; TALLINI, G; FASSETTA, G; BATES, D; CARTLIDGE, N; BOTTAZZO, GF; PICCOLO, G; DECAMILLI, P			AUTOANTIBODIES TO A 128-KD SYNAPTIC PROTEIN IN 3 WOMEN WITH THE STIFF-MAN SYNDROME AND BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUTAMIC-ACID DECARBOXYLASE; PANCREATIC BETA-CELLS; CEREBELLAR DEGENERATION; NERVOUS-SYSTEM; DIABETES-MELLITUS; GABA; ANTIBODIES; LOCALIZATION; EXPRESSION; DISORDER	Background. The stiff-man syndrome is a rare disease of the central nervous system characterized by progressive rigidity of the body musculature. Autoantibodies directed against glutamic acid decarboxylase are present in about 60 percent of patients with the syndrome. in this group, there is a striking association of the stiff-man syndrome with organ-specific autoimmune diseases, primarily insulin-dependent diabetes mellitus. Methods. We studied three women with the stiff-man syndrome and breast cancer, seeking autoantibodies directed against nervous system antigens in serum and cerebrospinal fluid by immunocytochemical techniques, Western blotting, and immunoprecipitation. Results. Autoantibodies directed against a 128-kd brain protein were found in two of the women with the stiff-man syndrome and breast cancer. These results led to a search for breast cancer in the third patient with the stiff-man syndrome, who also had autoantibodies. A small invasive ductal carcinoma was detected by ultrasonography and removed. Serum samples from all three patients were negative for autoantibodies directed against glutamic acid decarboxylase. Autoantibodies against the 128-kd antigen were not detected in control patients with the stiff-man syndrome without breast cancer or in patients with cancer who did not have the syndrome. Within the nervous system, the 128-kd autoantigen was localized in neurons and concentrated at synapses. Conclusions. In a subgroup of patients with the stiff-man syndrome, the condition is likely to have an autoimmune paraneoplastic origin. The detection of autoantibodies against the 128-kd antigen in patients with this syndrome should be considered an indication to search for an occult breast cancer.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; UNIV PADUA,IST SEMEIOT MED,I-35100 PADUA,ITALY; OSPED BELLUNO,DIV NEUROL,BELLUNO,ITALY; ROYAL VICTORIA INFIRM,DEPT NEUROL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND; LONDON HOSP,COLL MED,DEPT IMMUNOL,LONDON E1 1BB,ENGLAND; UNIV PAVIA,IST NEUROL MONDINO,I-27100 PAVIA,ITALY	Yale University; Yale University; Howard Hughes Medical Institute; Yale University; University of Padua; ULSS 1 Dolomiti; Ospedale di Belluno; Newcastle University - UK; University of London; Queen Mary University London; IRCCS Fondazione Casimiro Mondino; University of Pavia			Solimena, Michele/GVS-5990-2022; Tallini, Giovanni/F-7850-2013; Solimena, Michele/E-1275-2011; folli, franco/J-2795-2018	Tallini, Giovanni/0000-0003-0113-6682; folli, franco/0000-0001-9824-5222	NIAID NIH HHS [AI 30248-01] Funding Source: Medline; NIDDK NIH HHS [DK 43078-01] Funding Source: Medline; NIMH NIH HHS [MH 45191-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK043078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045191] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ACKERMAN RJ, 1989, SURGICAL PATHOLOGY, V2, P1140; BAEKKESKOV S, 1990, NATURE, V347, P151, DOI 10.1038/347151a0; BATEMAN DE, 1990, J NEUROL NEUROSUR PS, V53, P695, DOI 10.1136/jnnp.53.8.695; DALMAU J, 1991, NEUROLOGY, V41, P1757, DOI 10.1212/WNL.41.11.1757; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; ENGLEHARDT JI, 1990, ARCH NEUROL-CHICAGO, V47, P1210; ERDO SL, 1989, CELL TISSUE RES, V255, P431; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; FERRARI P, 1990, HAEMATOLOGICA, V75, P570; FURNEAUX HM, 1990, NEW ENGL J MED, V322, P1844, DOI 10.1056/NEJM199006283222604; GORIN F, 1990, ANN NEUROL, V28, P7; GREENLEE JE, 1983, ANN NEUROL, V14, P609, DOI 10.1002/ana.410140603; HETZEL DJ, 1990, MAYO CLIN PROC, V65, P1558, DOI 10.1016/S0025-6196(12)62189-2; LORISH TR, 1989, MAYO CLIN PROC, V64, P629, DOI 10.1016/S0025-6196(12)65339-7; MASSON C, 1987, ANN MED INTERNE, V138, P502; MOERSCH FP, 1956, P STAFF M MAYO CLIN, V31, P421; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; OERTEL WH, 1981, NEUROSCIENCE, V6, P2715, DOI 10.1016/0306-4522(81)90115-9; Palay S. L., 1974, CEREBELLAR CORTEX CY; PERSSON H, 1990, MOL CELL BIOL, V10, P4701, DOI 10.1128/MCB.10.9.4701; PICCOLO G, 1988, ITAL J NEUROL SCI, V9, P559, DOI 10.1007/BF02337009; PICCOLO G, 1989, ANN NEUROL, V26, P105, DOI 10.1002/ana.410260118; POSNER JB, 1990, RES P ARNMD, V68, P187; REETZ A, 1991, EMBO J, V10, P1275, DOI 10.1002/j.1460-2075.1991.tb08069.x; SCHERBAUM WA, 1986, IMMUNOCYTOCHEMISTRY, P456; SOLIMENA M, 1988, NEW ENGL J MED, V318, P1012, DOI 10.1056/NEJM198804213181602; SOLIMENA M, 1991, TRENDS NEUROSCI, V14, P452, DOI 10.1016/0166-2236(91)90044-U; SOLIMENA M, 1990, NEW ENGL J MED, V322, P1555, DOI 10.1056/NEJM199005313222202; THIRKILL CE, 1989, NEW ENGL J MED, V321, P1589, DOI 10.1056/NEJM198912073212307; TOURTELLOTTE WW, 1980, NEUROLOGY, V30, P240, DOI 10.1212/WNL.30.3.240; VINCENT SR, 1983, NEUROENDOCRINOLOGY, V36, P197, DOI 10.1159/000123456	31	226	232	1	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 25	1993	328	8					546	551		10.1056/NEJM199302253280805	http://dx.doi.org/10.1056/NEJM199302253280805			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KP053	8381208				2022-12-28	WOS:A1993KP05300005
J	NIGHTINGALE, SL				NIGHTINGALE, SL			SUMATRIPTAN APPROVED FOR MIGRAINE HEADACHE PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1776	1776						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8384667				2022-12-28	WOS:A1993KW25000008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			USER FRIENDLY REPORTING OF PROBLEMS WITH MEDICATIONS AND MEDICAL DEVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1993, FED REGISTER, V26, P11768	1	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 14	1993	269	14					1776	1776						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW250	8384667				2022-12-28	WOS:A1993KW25000006
